<SEC-DOCUMENT>0001104506-18-000011.txt : 20181030
<SEC-HEADER>0001104506-18-000011.hdr.sgml : 20181030
<ACCEPTANCE-DATETIME>20181030072959
ACCESSION NUMBER:		0001104506-18-000011
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		62
CONFORMED PERIOD OF REPORT:	20180930
FILED AS OF DATE:		20181030
DATE AS OF CHANGE:		20181030

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INSMED Inc
		CENTRAL INDEX KEY:			0001104506
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				541972729
		STATE OF INCORPORATION:			VA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30739
		FILM NUMBER:		181145518

	BUSINESS ADDRESS:	
		STREET 1:		10 FINDERNE AVENUE
		STREET 2:		BUILDING 10
		CITY:			BRIDGEWATER
		STATE:			NJ
		ZIP:			08807
		BUSINESS PHONE:		908-977-9900

	MAIL ADDRESS:	
		STREET 1:		10 FINDERNE AVENUE
		STREET 2:		BUILDING 10
		CITY:			BRIDGEWATER
		STATE:			NJ
		ZIP:			08807

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INSMED INC
		DATE OF NAME CHANGE:	20000128
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>insm-20180930x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:4522BFCECDE757BA9B0822EDFA58C426,x:02b6c4f7851448a389435866803f1c0d-->
<!-- Document created using Wdesk  -->
<!-- Copyright 2018 Workiva -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:exch="http://xbrl.sec.gov/exch/2017-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:insm="http://www.insmed.com/20180930" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2017-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<head>
		<meta http-equiv="Content-Type" content="text/html" />
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="FD2018Q3YTD" name="dei:AmendmentFlag" id="Fact-543F3E0B5837592781A8F14A08E21347-wk-Fact-543F3E0B5837592781A8F14A08E21347" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric contextRef="FD2018Q3YTD" name="dei:CurrentFiscalYearEndDate" id="Fact-CC10964958695483A39C99C87BD983DA-wk-Fact-CC10964958695483A39C99C87BD983DA">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="FD2018Q3YTD" name="dei:DocumentFiscalPeriodFocus" id="Fact-A18F8FD64E0D5BDCA7D710A93D51B3E4-wk-Fact-A18F8FD64E0D5BDCA7D710A93D51B3E4">Q3</ix:nonNumeric><ix:nonNumeric contextRef="FD2018Q3YTD" name="dei:DocumentFiscalYearFocus" id="Fact-A1C899A3F7D659D8A08DE3ABB9F1FD83-wk-Fact-A1C899A3F7D659D8A08DE3ABB9F1FD83">2018</ix:nonNumeric><ix:nonNumeric contextRef="FD2018Q3YTD" name="dei:DocumentPeriodEndDate" id="Fact-3A5ED426961258329C99D45289710BB5-wk-Fact-3A5ED426961258329C99D45289710BB5">2018-09-30</ix:nonNumeric><ix:nonNumeric contextRef="FD2018Q3YTD" name="dei:EntityCentralIndexKey" id="Fact-17C53AFAA4B15BB4A330C0DB7036C011-wk-Fact-17C53AFAA4B15BB4A330C0DB7036C011">0001104506</ix:nonNumeric><ix:nonNumeric contextRef="FD2018Q3YTD" name="dei:EntityCurrentReportingStatus" id="Fact-DE29AFFA4E9C5EAE8024595FF092CACA-wk-Fact-DE29AFFA4E9C5EAE8024595FF092CACA">Yes</ix:nonNumeric><ix:nonNumeric contextRef="FD2018Q3YTD" name="dei:EntityFilerCategory" id="Fact-8CCD433BE5F25D4E9F942B77F63466DE-wk-Fact-8CCD433BE5F25D4E9F942B77F63466DE">Large Accelerated Filer</ix:nonNumeric><ix:nonNumeric contextRef="FD2018Q3YTD" name="dei:EntityRegistrantName" id="Fact-CF2A5C6B5669B06A89E3821902D2019B-wk-Fact-CF2A5C6B5669B06A89E3821902D2019B">INSMED INC</ix:nonNumeric><ix:nonFraction decimals="INF" unitRef="security" contextRef="FI2017Q4" name="insm:AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities" id="Fact-11A40782930A582E92AACCD41378BB31-wk-Fact-11A40782930A582E92AACCD41378BB31">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usd" contextRef="FD2017Q3YTD" name="insm:FairValueLevel1Level2Level3TransfersAmount" id="Fact-F14C860551DA53BB856ACC0B53020162-wk-Fact-F14C860551DA53BB856ACC0B53020162">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2017Q4" name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact-2CD2012CF84559E88D2932DA0F65CDA4-wk-Fact-2CD2012CF84559E88D2932DA0F65CDA4">0.01</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2017Q4" name="us-gaap:CommonStockSharesAuthorized" id="Fact-CAE4BEFC077056BCBFE65619D04273F0-wk-Fact-CAE4BEFC077056BCBFE65619D04273F0">500000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2017Q4" name="us-gaap:CommonStockSharesIssued" id="Fact-1C675F1059225E248F007A9591DCCA7E-wk-Fact-1C675F1059225E248F007A9591DCCA7E">76610508</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2017Q4" name="us-gaap:CommonStockSharesOutstanding" id="Fact-D5D07AA52D5550259B028B5D1A0C1C29-wk-Fact-D5D07AA52D5550259B028B5D1A0C1C29">76610508</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q3" name="us-gaap:CommonStockSharesOutstanding" id="Fact-374CE66BBB7953838E975C2421E20727-wk-Fact-374CE66BBB7953838E975C2421E20727">77085715</ix:nonFraction><ix:nonFraction decimals="7" unitRef="number" contextRef="D2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" id="Fact-BA08EA6723775C3EA27D3C7D4F8A0ADA-wk-Fact-BA08EA6723775C3EA27D3C7D4F8A0ADA">0.0255384</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usd" contextRef="FI2018Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" name="us-gaap:DebtInstrumentFaceAmount" id="Fact-89107A10925F5D6096107CCFBC490452-wk-Fact-89107A10925F5D6096107CCFBC490452">450000000.0</ix:nonFraction><ix:nonFraction decimals="-5" unitRef="usd" contextRef="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" name="us-gaap:FiniteLivedIntangibleAssetsGross" id="Fact-C8567F8D1E3C9530211B824AD8DD1FFC-wk-Fact-C8567F8D1E3C9530211B824AD8DD1FFC">58200000</ix:nonFraction><ix:nonNumeric contextRef="D2018Q3Sept2018_us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_insm_BridgewaterNewJerseyOfficeSpaceMember" name="us-gaap:LesseeLeasingArrangementsOperatingLeasesRenewalTerm" id="Fact-C41D4D0D9308FFC84366835924AFACEE-wk-Fact-C41D4D0D9308FFC84366835924AFACEE">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="D2018Q3Sept2018_us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_insm_BridgewaterNewJerseyOfficeSpaceMember" name="us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract" id="Fact-7001F6E2EE3786E9A5C4A14C770B7518-wk-Fact-7001F6E2EE3786E9A5C4A14C770B7518">P130M</ix:nonNumeric><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q3" name="us-gaap:PreferredStockSharesOutstanding" id="Fact-4CD592D6B98D590491D358AD48B35942-wk-Fact-4CD592D6B98D590491D358AD48B35942">0</ix:nonFraction><ix:nonFraction decimals="2" unitRef="number" contextRef="FD2017Q3QTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember_us-gaap_RangeAxis_us-gaap_MaximumMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact-D12148CC3AB66FCB81723BB4F8F55EB6-wk-Fact-D12148CC3AB66FCB81723BB4F8F55EB6">0.73</ix:nonFraction><ix:nonFraction decimals="2" unitRef="number" contextRef="FD2017Q3QTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember_us-gaap_RangeAxis_us-gaap_MinimumMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact-927A05914930E246271C3BB5075D187C-wk-Fact-927A05914930E246271C3BB5075D187C">0.72</ix:nonFraction><ix:nonFraction decimals="2" unitRef="number" contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember_us-gaap_RangeAxis_us-gaap_MaximumMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact-C3C4E8934DEA57CC85898ADD083E6171-wk-Fact-C3C4E8934DEA57CC85898ADD083E6171">0.74</ix:nonFraction><ix:nonFraction decimals="2" unitRef="number" contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember_us-gaap_RangeAxis_us-gaap_MinimumMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact-73F6C01DE9935E6FA5B60FF997845FF9-wk-Fact-73F6C01DE9935E6FA5B60FF997845FF9">0.72</ix:nonFraction><ix:nonFraction decimals="2" unitRef="number" contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember_us-gaap_RangeAxis_us-gaap_MaximumMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact-4FDC96981958593DA3F1F474AF4C57EC-wk-Fact-4FDC96981958593DA3F1F474AF4C57EC">0.67</ix:nonFraction><ix:nonFraction decimals="2" unitRef="number" contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember_us-gaap_RangeAxis_us-gaap_MinimumMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact-C21756C45D635F84B1CCF0FA4183D792-wk-Fact-C21756C45D635F84B1CCF0FA4183D792">0.66</ix:nonFraction><ix:nonFraction decimals="2" unitRef="number" contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember_us-gaap_RangeAxis_us-gaap_MaximumMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact-C34223AFCCB95389B52F2D705A4E4D76-wk-Fact-C34223AFCCB95389B52F2D705A4E4D76">0.68</ix:nonFraction><ix:nonFraction decimals="2" unitRef="number" contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember_us-gaap_RangeAxis_us-gaap_MinimumMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact-20D6D76E96A1580BA310C99B5D37A764-wk-Fact-20D6D76E96A1580BA310C99B5D37A764">0.66</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2017Q3QTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember_us-gaap_RangeAxis_us-gaap_MaximumMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact-7063A5EEE56C54F49B9C01086E85DE69-wk-Fact-7063A5EEE56C54F49B9C01086E85DE69">0.0193</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2017Q3QTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember_us-gaap_RangeAxis_us-gaap_MinimumMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact-0EB21FF5544E5A8AAE10005F91E25388-wk-Fact-0EB21FF5544E5A8AAE10005F91E25388">0.0173</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember_us-gaap_RangeAxis_us-gaap_MaximumMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact-980E832750B65DA8A010F9A72B74F27D-wk-Fact-980E832750B65DA8A010F9A72B74F27D">0.0199</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember_us-gaap_RangeAxis_us-gaap_MinimumMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact-5834BA2E4C5E5C559FF6BC637F8C0346-wk-Fact-5834BA2E4C5E5C559FF6BC637F8C0346">0.0173</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember_us-gaap_RangeAxis_us-gaap_MaximumMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact-B12F50C6DB2F5C46AB0F9FA0461FB669-wk-Fact-B12F50C6DB2F5C46AB0F9FA0461FB669">0.0287</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember_us-gaap_RangeAxis_us-gaap_MinimumMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact-0C97547B79615897800A62828116E661-wk-Fact-0C97547B79615897800A62828116E661">0.0275</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember_us-gaap_RangeAxis_us-gaap_MaximumMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact-F743CC836A1756199B244396AC526299-wk-Fact-F743CC836A1756199B244396AC526299">0.0287</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember_us-gaap_RangeAxis_us-gaap_MinimumMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact-BE5608E429985D96B5D4F9BC1ED78E1D-wk-Fact-BE5608E429985D96B5D4F9BC1ED78E1D">0.0225</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usd" contextRef="FI2017Q4" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" id="Fact-A280AAFE9638552388A749DD3402F950-wk-Fact-A280AAFE9638552388A749DD3402F950">0</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:href="insm-20180930.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="FD2018Q3YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q4Oct26">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-10-26</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q3">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_us-gaap_CashAndCashEquivalentsAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q1YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_insm_EmployeeAndDirectorsStockOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_insm_EmployeeAndDirectorsStockOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q3Sept28">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_DebtInstrumentConversionTermOneMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:DebtInstrumentConversionTermOneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_DebtInstrumentConversionTermFourMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:DebtInstrumentConversionTermFourMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_DebtInstrumentConversionTermTwoMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:DebtInstrumentConversionTermTwoMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q1Feb2018_us-gaap_DebtInstrumentAxis_us-gaap_LineOfCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-02-01</xbrli:startDate>
			<xbrli:endDate>2018-02-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q1Feb28-Feb28_us-gaap_DebtInstrumentAxis_us-gaap_LineOfCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-02-28</xbrli:startDate>
			<xbrli:endDate>2018-02-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_DebtInstrumentConversionTermThreeMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:DebtInstrumentConversionTermThreeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q3Sept17">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-09-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range5Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range5Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range6Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range6Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range6Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range6Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range7Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range7Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range5Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range5Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range7Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range7Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range4Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range4Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range9Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range9Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range10Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range10Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range10Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range10Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range8Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range8Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range4Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range4Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range9Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range9Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range8Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range8Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2May15_us-gaap_PlanNameAxis_insm_EmployeeStockPurchasePlan2018Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">insm:EmployeeStockPurchasePlan2018Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-05-15</xbrli:startDate>
			<xbrli:endDate>2018-05-15</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q2May15_us-gaap_PlanNameAxis_insm_EmployeeStockPurchasePlan2018Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">insm:EmployeeStockPurchasePlan2018Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-05-15</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q2May18">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-05-18</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_AwardTypeAxis_insm_RestrictedStockAndRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:RestrictedStockAndRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3QTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q3YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_insm_BridgewaterNewJerseyOfficeSpaceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">insm:BridgewaterNewJerseyOfficeSpaceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_insm_BridgewaterNewJerseyFacilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">insm:BridgewaterNewJerseyFacilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3Sept2018_us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_insm_BridgewaterNewJerseyOfficeSpaceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">insm:BridgewaterNewJerseyOfficeSpaceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-09-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit><xbrli:unit id="security">
		<xbrli:measure>insm:security</xbrli:measure>
	</xbrli:unit><xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit><xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit><xbrli:unit id="day">
		<xbrli:measure>insm:day</xbrli:measure>
	</xbrli:unit><xbrli:unit id="renewal">
		<xbrli:measure>insm:renewal</xbrli:measure>
	</xbrli:unit><xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit></ix:resources></ix:header></div><div><a id="s96A0B003464F50AABBE72D30208C3B1E"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.42184557438794%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:18pt;"><span style="font-family:inherit;font-size:18pt;font-weight:bold;">UNITED STATES</span></div><div style="line-height:120%;text-align:center;font-size:18pt;"><span style="font-family:inherit;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Washington, D.C. 20549</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:18pt;"><span style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM&#160;</span><span><ix:nonNumeric id="d37580207e332-wk-Fact-F4B36C32C5D0E4BCB96B3BBF183AAA89" name="dei:DocumentType" contextRef="FD2018Q3YTD"><span style="font-size:18pt;font-weight:bold;">10-Q</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:18pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Mark One)</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><span style="font-family:Wingdings;font-size:12pt;">x</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">For the quarterly period ended </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">OR</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><span style="font-family:Wingdings;font-size:10pt;">o</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Commission File Number 0-30739</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:18pt;"><span style="font-size:18pt;font-weight:bold;">INSMED INCORPORATED</span><span style="font-family:inherit;font-size:18pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Exact name of registrant as specified in its charter)</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.42184557438794%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Virginia</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">54-1972729</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(State or other jurisdiction of incorporation or organization)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(I.R.S. employer identification no.)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">10 Finderne Avenue, Building 10</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Bridgewater, New Jersey</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">08807</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Address of principal executive offices)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Zip Code)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(908) 977-9900</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Registrant&#8217;s telephone number including area code)</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Not Applicable</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Former name, former address and former fiscal year, if changed since last report)</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;Yes&#160;</span><span style="font-family:Wingdings;font-size:10pt;">x</span><span style="font-family:inherit;font-size:10pt;">&#160;No&#160;</span><span style="font-family:Wingdings;font-size:10pt;">o</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;Yes&#160;</span><span style="font-family:Wingdings;font-size:10pt;">x</span><span style="font-family:inherit;font-size:10pt;">&#160;No&#160;</span><span style="font-family:Wingdings;font-size:10pt;">o</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.42184557438794%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Large accelerated filer&#160;</span><span style="font-family:Wingdings;font-size:10pt;">x</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accelerated filer&#160;</span><span style="font-family:Wingdings;font-size:10pt;">o</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-accelerated filer&#160;</span><span style="font-family:Wingdings;font-size:10pt;">o</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Smaller reporting company&#160;</span><span style="font-family:Wingdings;font-size:10pt;">o</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Emerging growth company </span><span style="font-family:Wingdings;font-size:10pt;">o</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;</span><span style="font-family:Wingdings;font-size:10pt;">o</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;Yes&#160;</span><span style="font-family:Wingdings;font-size:10pt;">o</span><span style="font-family:inherit;font-size:10pt;">&#160;No&#160;</span><span style="font-family:Wingdings;font-size:10pt;">x</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">October&#160;26, 2018</span><span style="font-family:inherit;font-size:10pt;">, there were </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37580207e625-wk-Fact-C49EE1B59FEC5B03BF8BE8B903C25788" name="dei:EntityCommonStockSharesOutstanding" contextRef="I2018Q4Oct26" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">77,090,229</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of the registrant&#8217;s common stock, $0.01 par value, outstanding.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.42184557438794%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div><br/></div><hr style="page-break-after:always"></hr><div><a id="s0D0886DA1D655A85ACDCD91D659042CA"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D0886DA1D655A85ACDCD91D659042CA"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">INSMED INCORPORATED</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">FORM&#160;10-Q</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">FOR THE QUARTER ENDED </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">SEPTEMBER&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">INDEX</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:13%;"></td><td style="width:80%;"></td><td style="width:7%;"></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s6B7B72CA58F55E6283921F1113664904"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART&#160;I.&#160;&#160;FINANCIAL&#160;INFORMATION</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s73B422D8BE235AAE88EAA5103A4FEF10"><span style="font-family:inherit;font-size:10pt;">ITEM 1</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s49DE57C6F44E5327AF34C3EA870EFBD6"><span style="font-family:inherit;font-size:10pt;">Consolidated Financial Statements</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s49DE57C6F44E5327AF34C3EA870EFBD6"><span style="font-family:inherit;font-size:10pt;">Consolidated Balance Sheets as of September 30, 2018 (unaudited) and December&#160;31, 2017</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s49DE57C6F44E5327AF34C3EA870EFBD6">3</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sCDB91E7E943052538E90ADBCC1E2B190"><span style="font-family:inherit;font-size:10pt;">Consolidated Statements of Comprehensive Loss (unaudited) for the three and nine months ended September 30, 2018 and&#160;2017</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sCDB91E7E943052538E90ADBCC1E2B190">4</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF9B35DC73E1854ECA9F08A0D53DE7F17"><span style="font-family:inherit;font-size:10pt;">Consolidated Statements of Cash Flows (unaudited) for the nine months ended September 30, 2018 and&#160;2017</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF9B35DC73E1854ECA9F08A0D53DE7F17">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2201FF608CC250D78E8623E24AF6B96C"><span style="font-family:inherit;font-size:10pt;">Notes to Consolidated Financial Statements (unaudited)</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2201FF608CC250D78E8623E24AF6B96C">6</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF453A4FEE38C516AA3FCC4DC08499590"><span style="font-family:inherit;font-size:10pt;">ITEM 2</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF453A4FEE38C516AA3FCC4DC08499590"><span style="font-family:inherit;font-size:10pt;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF453A4FEE38C516AA3FCC4DC08499590">16</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF9A32EDDC41C547998DF3BDDB3720D65"><span style="font-family:inherit;font-size:10pt;">ITEM 3</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF9A32EDDC41C547998DF3BDDB3720D65"><span style="font-family:inherit;font-size:10pt;">Quantitative and Qualitative Disclosures about Market Risk</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF9A32EDDC41C547998DF3BDDB3720D65">27</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8A3FB1CF1A855FF98E0433FF7F27EDDF"><span style="font-family:inherit;font-size:10pt;">ITEM 4</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8A3FB1CF1A855FF98E0433FF7F27EDDF"><span style="font-family:inherit;font-size:10pt;">Controls and Procedures</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8A3FB1CF1A855FF98E0433FF7F27EDDF">27</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s6E000465425558DAB4685170933EA4F0"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART&#160;II.&#160;&#160;OTHER INFORMATION</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE864CC014B7D598086F04CFC80023E08"><span style="font-family:inherit;font-size:10pt;">ITEM 1</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE864CC014B7D598086F04CFC80023E08"><span style="font-family:inherit;font-size:10pt;">Legal Proceedings</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE864CC014B7D598086F04CFC80023E08">27</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC29E9ADDE37A501485A271960F960ECC"><span style="font-family:inherit;font-size:10pt;">ITEM 1A</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC29E9ADDE37A501485A271960F960ECC"><span style="font-family:inherit;font-size:10pt;">Risk Factors</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC29E9ADDE37A501485A271960F960ECC">27</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s44EC2A4B6C11540FBC65A797093F13FE"><span style="font-family:inherit;font-size:10pt;">ITEM 2</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s44EC2A4B6C11540FBC65A797093F13FE"><span style="font-family:inherit;font-size:10pt;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s44EC2A4B6C11540FBC65A797093F13FE">47</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0145384789C05C12BD063B6EAE19DBC3"><span style="font-family:inherit;font-size:10pt;">ITEM 6</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0145384789C05C12BD063B6EAE19DBC3"><span style="font-family:inherit;font-size:10pt;">Exhibits</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0145384789C05C12BD063B6EAE19DBC3">48</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sDCE75C8A9D1F502ABF2C5509E72C0443"><span style="font-family:inherit;font-size:10pt;">SIGNATURE</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sDCE75C8A9D1F502ABF2C5509E72C0443">49</a></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unless the context otherwise indicates, references in this Form&#160;10-Q to &#8220;Insmed Incorporated&#8221; refers to Insmed Incorporated, a Virginia corporation, and &#8220;Company,&#8221; &#8220;Insmed,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Insmed Incorporated together with its consolidated subsidiaries. INSMED, ARIKAYCE, and CONVERT are trademarks of Insmed Incorporated. This Form&#160;10-Q also contains trademarks of third parties. Each trademark of another company appearing in this Form&#160;10-Q is the property of its owner.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2</span></div></div><hr style="page-break-after:always"></hr><div><a id="s6B7B72CA58F55E6283921F1113664904"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D0886DA1D655A85ACDCD91D659042CA"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART&#160;I.&#160; FINANCIAL INFORMATION</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div><a id="s73B422D8BE235AAE88EAA5103A4FEF10"></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 1.&#160;CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div><a id="s49DE57C6F44E5327AF34C3EA870EFBD6"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">INSMED INCORPORATED</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Balance Sheets</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except par value and share data)</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:69%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(unaudited)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current assets:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37583484e548-wk-Fact-1BE6FE185E03589087FAB308105B46AE" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">567,574</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37583484e567-wk-Fact-7D13774CB56B50F691CFDF9E0DC702CA" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">381,165</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37583484e582-wk-Fact-D47441EDA0585ADE97F115D0940BC64D" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,921</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37583484e601-wk-Fact-EF54DAF161805C2AA6FD9ED09E742FCE" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,279</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total current assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37583484e621-wk-Fact-C25B303449F755A49D250CC3C6741DE4" name="us-gaap:AssetsCurrent" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">577,495</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37583484e640-wk-Fact-BCE7AD2ECB7054B696F5FE2DCA5BBF1A" name="us-gaap:AssetsCurrent" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">389,444</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37583484e701-wk-Fact-4F558109777F5EF1B435D05517A69E5D" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">59,941</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37583484e720-wk-Fact-228FB3CE6C5A54FEB27E748DEE513810" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">58,200</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fixed assets, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37583484e740-wk-Fact-DC88FE0A5313545BB8465E20A121D7FB" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">19,526</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37583484e759-wk-Fact-156D85310A4B52B1A8E6337BE4AF64C3" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,432</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37583484e780-wk-Fact-E59EDB06600C53A8A153DF114AAD5B22" name="us-gaap:OtherAssets" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,551</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37583484e799-wk-Fact-5D9AE20127855D33B0CC637FB85439B5" name="us-gaap:OtherAssets" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,971</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37583484e824-wk-Fact-F81963E8F7C950C69217B1B80C545E54" name="us-gaap:Assets" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">661,513</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37583484e843-wk-Fact-24873CE6AEAB52C58826775DE5AA8DBA" name="us-gaap:Assets" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">462,047</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities and shareholders&#8217; equity</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current liabilities:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37583484e982-wk-Fact-BA82280C790853F88E587CC1BEEB2CCE" name="us-gaap:AccountsPayableCurrent" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,579</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37583484e1001-wk-Fact-966E10614E66513B962D2D82804C4E4F" name="us-gaap:AccountsPayableCurrent" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,671</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37583484e1016-wk-Fact-E7A53E4292C3507FAAB562842E428728" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">40,368</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37583484e1035-wk-Fact-1C594FB75856593F8B96A3EA9DEA6C7E" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">29,339</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37583484e1055-wk-Fact-7C0A9C8F75FD55B69CBFC0C58C872963" name="us-gaap:OtherLiabilitiesCurrent" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">472</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37583484e1074-wk-Fact-78326A3073545EE6B19D1D245B98D7F3" name="us-gaap:OtherLiabilitiesCurrent" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">646</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37583484e1094-wk-Fact-41616F63FF475BB08916FA9BCD82ED7C" name="us-gaap:LiabilitiesCurrent" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">57,419</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37583484e1113-wk-Fact-1580018AC4AF5E28978B3A5E59DF9D61" name="us-gaap:LiabilitiesCurrent" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">44,656</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term debt, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37583484e1174-wk-Fact-04AAF8399F7F50089D01A23C0F563455" name="us-gaap:LongTermDebtNoncurrent" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">311,861</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37583484e1193-wk-Fact-9577E81E82835150BD2F46CA10306CF9" name="us-gaap:LongTermDebtNoncurrent" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">55,567</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37583484e1214-wk-Fact-D81997447C3C5A77AC609DCC733E7525" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">826</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37583484e1233-wk-Fact-99865EE4A16956BBB42442A6B5582E15" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">765</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37583484e1253-wk-Fact-5E51F8D8956E589AA9D8A85C310318A9" name="us-gaap:Liabilities" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">370,106</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37583484e1272-wk-Fact-C6C9340214765FFC8EF695D7AC4AE2BD" name="us-gaap:Liabilities" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">100,988</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shareholders&#8217; equity:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock, $0.01 par value; 500,000,000 authorized shares, 77,085,715 and 76,610,508 issued and outstanding shares at September 30, 2018 and December&#160;31,&#160;2017,&#160;respectively</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37583484e1372-wk-Fact-484D376419005F36A7CEF2173700892F" name="us-gaap:CommonStockValue" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">771</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37583484e1391-wk-Fact-61D3CD136480528EB2DF81797EF839DE" name="us-gaap:CommonStockValue" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">766</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additional paid-in capital</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37583484e1411-wk-Fact-45658F35E7ED501187EA19BAC08B5996" name="us-gaap:AdditionalPaidInCapital" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,481,205</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37583484e1430-wk-Fact-C0E9D6D306695EAB8C9DF8E07E9B8A85" name="us-gaap:AdditionalPaidInCapital" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,318,181</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated deficit</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37583484e1450-wk-Fact-CCD314E789965563ADE88BF94D40AD89" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,190,589</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37583484e1470-wk-Fact-6561564BB8325502904169C95BF65F8E" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">957,885</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37583484e1491-wk-Fact-69E699855907599A9338BBF5A72A4CA8" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37583484e1510-wk-Fact-56CA53231A8F59FA9C8DCD0D0DED5678" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total shareholders&#8217; equity</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37583484e1531-wk-Fact-ACB053F2369A5B66BE981E31DC8D38E2" name="us-gaap:StockholdersEquity" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">291,407</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37583484e1550-wk-Fact-5115DD7C33225595A9655F911DF6011A" name="us-gaap:StockholdersEquity" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">361,059</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities and shareholders&#8217; equity</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37583484e1575-wk-Fact-4AFEC3B136AA509BA110354EDDD0EE33" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">661,513</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37583484e1594-wk-Fact-D810C1897EBA5AD1B381F61680DD0492" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">462,047</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">See accompanying notes to consolidated financial statements</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3</span></div></div><hr style="page-break-after:always"></hr><div><a id="sCDB91E7E943052538E90ADBCC1E2B190"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D0886DA1D655A85ACDCD91D659042CA"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">INSMED INCORPORATED</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Statements of Comprehensive Loss (unaudited)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except per share data)</span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.015625%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:51%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585990e598-wk-Fact-B064ED96C98058ADB3E4E526BBB142F6" name="us-gaap:Revenues" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585990e617-wk-Fact-B5463B46287F503EA7212507B016D886" name="us-gaap:Revenues" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585990e636-wk-Fact-4A241F7DC38C57A5B1315FBEEAB0A867" name="us-gaap:Revenues" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585990e656-wk-Fact-38C0125A41FB5826A7A165748ACE9DAB" name="us-gaap:Revenues" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating expenses:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585990e831-wk-Fact-CEF7523E10E755FA98744C92480FFF83" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">39,538</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585990e850-wk-Fact-D877494A358A595B95F1EA041193CFEE" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">26,675</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585990e869-wk-Fact-22DF3451332B59D5949236B046D8431E" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">105,358</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585990e889-wk-Fact-325322EADD9F5EC2B0777B4B99483E0A" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">75,800</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585990e909-wk-Fact-E6365763DCC055A5AAD948C79CAC1579" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">44,445</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585990e928-wk-Fact-B481D2585D75561EB430E823359932ED" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,408</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585990e947-wk-Fact-1A44B26777715D349880DBD55C3E78A7" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">114,258</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585990e967-wk-Fact-A6F76D9758D15055B225021A84055620" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">47,767</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585990e987-wk-Fact-31150344694E5A879C9AD0A0738C20AE" name="us-gaap:OperatingExpenses" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">83,983</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585990e1006-wk-Fact-0B466BDE4F1B59AE89F50C1964C4C424" name="us-gaap:OperatingExpenses" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">44,083</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585990e1025-wk-Fact-23E0C78CE32B521B814627BA22DD3EE6" name="us-gaap:OperatingExpenses" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">219,616</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585990e1045-wk-Fact-3CC32A48A0CD5B319D68CEF6035B1650" name="us-gaap:OperatingExpenses" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">123,567</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating loss</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37585990e1147-wk-Fact-6AE039E33D9C5CDEAE1012967F96DFBD" name="us-gaap:OperatingIncomeLoss" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">83,983</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37585990e1167-wk-Fact-40677A16031B540E973B20BBF5C9DE82" name="us-gaap:OperatingIncomeLoss" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">44,083</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37585990e1187-wk-Fact-0DB77577FC045D58A94069007BC33552" name="us-gaap:OperatingIncomeLoss" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">219,616</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37585990e1208-wk-Fact-8E43775313085116A5CA0A7EEFE9CEBF" name="us-gaap:OperatingIncomeLoss" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">123,567</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Investment income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585990e1312-wk-Fact-F76E8021626558E88A3085C079EB3E80" name="us-gaap:InvestmentIncomeNonoperating" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,741</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585990e1331-wk-Fact-B0578478606E59C6B48D35C4676179F5" name="us-gaap:InvestmentIncomeNonoperating" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">326</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585990e1350-wk-Fact-5F89EE90EA5456EAB6F8B5C5CA302BD8" name="us-gaap:InvestmentIncomeNonoperating" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,510</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585990e1370-wk-Fact-6EB92D84DD4A54DB83D8E2833231A3FD" name="us-gaap:InvestmentIncomeNonoperating" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">649</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37585990e1390-wk-Fact-5298773546E956B2A476B4D00B0CC953" name="us-gaap:InterestExpense" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,675</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37585990e1410-wk-Fact-46AD3F5FEC25521788BB47B9D992E8D5" name="us-gaap:InterestExpense" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,496</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37585990e1430-wk-Fact-0261293D4CE557119BC44A95C1CB75EE" name="us-gaap:InterestExpense" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,805</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37585990e1451-wk-Fact-1E85C2C8082B598EB0AA11002F15739B" name="us-gaap:InterestExpense" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,459</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss on extinguishment of debt</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585990e1472-wk-Fact-EAB8C2DD87AF53349CE1BB115E64CFC6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585990e1491-wk-Fact-78EDC684840D5BCEA35159C6FEF06B8C" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37585990e1510-wk-Fact-796B77D246935C489EF999DC75EF64A2" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,209</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585990e1531-wk-Fact-A0E4D1FE0A705237AF09DD43A976115F" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Other income, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585990e1551-wk-Fact-B43EE1099717593BB7B456D1D863E4ED" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">220</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585990e1570-wk-Fact-8B3723818D2252BA9443479D1C2F4A30" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">101</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585990e1589-wk-Fact-667E1B0D901654C39AF62E0D6074DB77" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">550</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585990e1609-wk-Fact-284A37198851572EA1C9050AEA57AFDA" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">206</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss before income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37585990e1629-wk-Fact-27E44007A5375504ADEE6AF20ABF6227" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">87,697</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37585990e1649-wk-Fact-C81801AAE97D58C396E2A7B78B5EF32A" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">45,152</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37585990e1669-wk-Fact-4A79887409225F2BA0603FD9145B50A8" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">232,570</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37585990e1690-wk-Fact-8E6ADF844FD257E89EE14B6395F3CB32" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">127,171</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Provision for income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585990e1793-wk-Fact-69971A3E7D3F57BAAF3705F5AD80D4F4" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">46</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585990e1812-wk-Fact-35D2D40AA43F5C9D9B5934F32E20F1BA" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">27</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585990e1831-wk-Fact-C45D6E334FD15D42A9DA0E8FAE4EA341" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">134</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585990e1851-wk-Fact-1FD78E5302455C94BB9DC295F0C61BE6" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">94</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37585990e1958-wk-Fact-140F3BA91E2256A5BF9E0BE306FB0BF7" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">87,743</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37585990e1978-wk-Fact-943BC7301A8358DDB78350FA470D31A1" name="us-gaap:NetIncomeLoss" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">45,179</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37585990e1998-wk-Fact-B45A0729B05C59668CED7875FF86978E" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">232,704</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37585990e2019-wk-Fact-E7598833183958F9826A9C7E045F8A51" name="us-gaap:NetIncomeLoss" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">127,265</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted net loss per share</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37585990e2123-wk-Fact-9B35FCB3B7EB583994D0E1C89E3CB22A" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2018Q3QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">1.14</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37585990e2143-wk-Fact-9951475A6A9F50B7B0578A1952AF668A" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2017Q3QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.69</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37585990e2163-wk-Fact-6C2CDE809B045C2FA0991187295B38A6" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2018Q3YTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">3.03</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37585990e2184-wk-Fact-07424B054FE3587D9AE84C3BB0C6517A" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2017Q3YTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">2.01</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average basic and diluted common shares&#160;outstanding</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585990e2282-wk-Fact-2E4D3BAA30465324A79605758B5C141E" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2018Q3QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">77,066</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585990e2301-wk-Fact-EC588876091D5D438C89DFAEAC2F2059" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2017Q3QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">65,312</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585990e2320-wk-Fact-173C030FB9C754C0A58729C30EB60806" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2018Q3YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">76,819</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585990e2340-wk-Fact-461B720DDB4B5D3384EEF5D36885D351" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2017Q3YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">63,199</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37585990e2447-wk-Fact-140F3BA91E2256A5BF9E0BE306FB0BF7" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">87,743</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37585990e2467-wk-Fact-943BC7301A8358DDB78350FA470D31A1" name="us-gaap:NetIncomeLoss" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">45,179</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37585990e2487-wk-Fact-B45A0729B05C59668CED7875FF86978E" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">232,704</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37585990e2508-wk-Fact-E7598833183958F9826A9C7E045F8A51" name="us-gaap:NetIncomeLoss" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">127,265</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency translation gains</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585990e2602-wk-Fact-7828C1CEF9975AB38D6278420B92CEF9" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585990e2621-wk-Fact-94F335F6955557C0B0720F6F0E0E7909" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">76</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585990e2640-wk-Fact-39AC78B296FA55BA8F3AB1B66723D287" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585990e2660-wk-Fact-04A2F27FFC0A5DAEBFD11DDE6BE34845" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">99</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total comprehensive loss</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37585990e2685-wk-Fact-F317265E3B6755FBBB8BC2470F1CCE9E" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">87,741</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37585990e2705-wk-Fact-0EBB8D7ABC9B50DBBDEA6F6945F9F1EE" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">45,103</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37585990e2725-wk-Fact-8B7F65D180075E55952DD3AAE4B311B0" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">232,681</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37585990e2746-wk-Fact-08B649D205FB559BA2FC47D553EC8BC5" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">127,166</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">See accompanying notes to consolidated financial statements</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4</span></div></div><hr style="page-break-after:always"></hr><div><a id="sF9B35DC73E1854ECA9F08A0D53DE7F17"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D0886DA1D655A85ACDCD91D659042CA"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">INSMED INCORPORATED</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Statements of Cash Flows (unaudited)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating activities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37585999e464-wk-Fact-B45A0729B05C59668CED7875FF86978E" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">232,704</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37585999e484-wk-Fact-E7598833183958F9826A9C7E045F8A51" name="us-gaap:NetIncomeLoss" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">127,265</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjustments to reconcile net loss to net cash used in operating activities:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585999e539-wk-Fact-821EA4960E3B59DE80B070E6D3EDC4DA" name="us-gaap:Depreciation" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,652</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585999e558-wk-Fact-68AD4DFD2A5E54E88E0FAE6998D7D857" name="us-gaap:Depreciation" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,168</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585999e578-wk-Fact-42DEFC89C84C5EA9BB4530260E2E97D1" name="us-gaap:ShareBasedCompensation" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,205</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585999e597-wk-Fact-2194940E11ED5CD1A3AC537A9BB4FDF5" name="us-gaap:ShareBasedCompensation" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,332</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of debt issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585999e617-wk-Fact-2DCBC22CAE23561D8C8137E0A74483C2" name="us-gaap:AmortizationOfFinancingCosts" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585999e636-wk-Fact-5288C234F50F548E9EB138AA0CE2764E" name="us-gaap:AmortizationOfFinancingCosts" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">91</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accretion of debt discount</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585999e656-wk-Fact-9F140DB9CAD55F8A82F57323DE07C7D4" name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,541</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585999e675-wk-Fact-E7408D702B955003AD3C8811576D0C16" name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accretion of back-end fee on debt</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585999e695-wk-Fact-FFA531B819255E8DBE34E9085DB5F0F4" name="us-gaap:AccretionExpense" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">50</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585999e714-wk-Fact-0B815E0BF6A3502EB1CCF4823C6F02AA" name="us-gaap:AccretionExpense" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">506</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Changes in operating assets and liabilities:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses and other assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37585999e774-wk-Fact-FFD637D42AA85FE1B9A9D287D1FDAF28" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,315</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37585999e794-wk-Fact-262892DB6746582692B79919FE229CEF" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,052</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585999e815-wk-Fact-2F18932E9E6B54D4A4BE63FA708C8AB2" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,536</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37585999e834-wk-Fact-F94F34F8B19D558687869483F8E5D6EF" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">921</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses and other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585999e855-wk-Fact-9567954D18F45B6A9CB178B3D041DD25" name="insm:IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,596</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585999e874-wk-Fact-F6073B5D5BDF520B8F901C3AB8F9106B" name="insm:IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,745</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash used in operating activities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37585999e894-wk-Fact-2B0AC5D865105ABA82CF4C22998ABF04" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">188,439</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37585999e914-wk-Fact-71F9B8FABD1F54C18B8CC23D297B4F35" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">111,396</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Investing activities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Purchase of fixed assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37585999e974-wk-Fact-8A348B5E40AB5DF48936C7DA066F301A" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,063</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37585999e994-wk-Fact-B2EE5197455152A99A69B9CD0C9DB840" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,301</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash used in investing activities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37585999e1015-wk-Fact-D274D600333253D89630796D38990604" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">10,063</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37585999e1035-wk-Fact-9498FB4146825B3FA2B2D0D7D4BAA244" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,301</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Financing activities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Proceeds from exercise of stock options</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585999e1095-wk-Fact-CDA468C1448459BFAE8B0DBA1BBA12B9" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,390</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585999e1114-wk-Fact-593FA62967C858529615D6B0A6ED8E62" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,953</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss on extinguishment of debt</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37585999e1134-wk-Fact-FBB052B514595206B29873038BF50CCB" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,209</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585999e1154-wk-Fact-3BAA2EF98BF55EACB6A05DCD12E9474F" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payment of debt </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37585999e1174-wk-Fact-18D9125B85745404916A2107ED70E6F3" name="us-gaap:RepaymentsOfDebt" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">55,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585999e1194-wk-Fact-15AFF01F57D65BB1BF05A81A603DB0C7" name="us-gaap:RepaymentsOfDebt" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Proceeds from issuance of 1.75% convertible senior notes due 2025</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585999e1215-wk-Fact-96F71BE14A4C5E7CA12B89D9803E76FC" name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">450,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585999e1234-wk-Fact-3F1EBFF13FF05728BA62207CA682556A" name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payment of debt issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37585999e1254-wk-Fact-65B6033193DA5876A2261D420C74BE1C" name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,235</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585999e1274-wk-Fact-ACD08068D5A550D2A48F6ADCEAA4FF79" name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Proceeds from issuance of common stock, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585999e1294-wk-Fact-604A61E13AC859908E6585A41F505718" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585999e1313-wk-Fact-8B64CB7C78275771B9423691F7B6958B" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">377,703</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash provided by financing activities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585999e1333-wk-Fact-AA53131971885D349FCCD5A2E4AFE614" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">384,946</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585999e1352-wk-Fact-2209022AB29E5628ADF80B00AE16A896" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">380,656</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of exchange rates on cash and cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37585999e1372-wk-Fact-474DE0A8777B52F38BC2A99912FE40FF" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">35</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585999e1392-wk-Fact-D4542103BF6157BCBE22F138C5324C18" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">128</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net increase in cash and cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585999e1412-wk-Fact-66F2C24A57E159E6B61E347B889AE7E3" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">186,409</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585999e1431-wk-Fact-3B38744A1C535769BA42BA7AC1AD9D81" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">268,087</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents at beginning of period</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585999e1451-wk-Fact-7D13774CB56B50F691CFDF9E0DC702CA" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">381,165</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585999e1470-wk-Fact-E238271D7691568095B282B08F275FAD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2016Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">162,591</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents at end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585999e1495-wk-Fact-1BE6FE185E03589087FAB308105B46AE" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">567,574</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585999e1514-wk-Fact-DE71C8EC598D50E1B813FC06C1BAD600" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2017Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">430,678</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supplemental disclosures of cash flow information:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for interest</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585999e1614-wk-Fact-C590F6852E8B5E71886E699DF042397F" name="us-gaap:InterestPaidNet" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,975</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585999e1633-wk-Fact-216AD199E9655B5D985797FB54052D70" name="us-gaap:InterestPaidNet" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,876</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for income taxes</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585999e1654-wk-Fact-D5AC3E36B91C5482A405C7A6C88524DC" name="us-gaap:IncomeTaxesPaidNet" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">127</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37585999e1673-wk-Fact-C8A1FA92B8DA5B5B852F740DB37E66C6" name="us-gaap:IncomeTaxesPaidNet" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">62</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">See accompanying notes to consolidated financial statements</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5</span></div></div><hr style="page-break-after:always"></hr><div><a id="s2201FF608CC250D78E8623E24AF6B96C"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D0886DA1D655A85ACDCD91D659042CA"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">INSMED INCORPORATED</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div><a id="sCFF65C35AE1E5ED5A642F868D4F9DE45"></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">1.</span><span style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;"> </span><ix:nonNumeric contextRef="FD2018Q3YTD" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="TextSelection-034D62C3CE8957B1B7BF0DD4EE4000D7-0-wk-Fact-24D1DF213843532F98897F2D1FAB6A60" continuedAt="TextSelection-034D62C3CE8957B1B7BF0DD4EE4000D7-1" escape="true"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The Company and Basis of Presentation</span></ix:nonNumeric></div><ix:continuation id="TextSelection-034D62C3CE8957B1B7BF0DD4EE4000D7-1" continuedAt="TextSelection-034D62C3CE8957B1B7BF0DD4EE4000D7-2"><div style="line-height:120%;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), received accelerated approval in the United States (US) on September 28, 2018 for the treatment of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Mycobacterium avium</span><span style="font-family:inherit;font-size:10pt;"> complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. The Company's clinical-stage pipeline includes INS1007 and INS1009. INS1007 is a novel oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1) with therapeutic potential in non-cystic fibrosis (non-CF) bronchiectasis and other inflammatory diseases. INS1009 is an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension (PAH).</span></div><div style="line-height:120%;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company was incorporated in the Commonwealth of Virginia on November&#160;29, 1999 and its principal executive offices are in Bridgewater, New Jersey. The Company has legal entities in the US,&#160;Ireland, Germany, France, the United Kingdom (UK), the Netherlands, and Japan. All intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying unaudited interim consolidated financial statements have been prepared pursuant to the rules&#160;and regulations for reporting on Form&#160;10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the US for complete consolidated financial statements are not included herein. The unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company&#8217;s Annual Report on Form&#160;10-K for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. The unaudited interim consolidated financial information presented herein reflects all normal adjustments that are, in the opinion of management, necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company had </span><span style="font-family:inherit;font-size:10pt;">$567.6 million</span><span style="font-family:inherit;font-size:10pt;"> in cash and cash equivalents as of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and reported a net loss of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d37586247e361-wk-Fact-F0A239BFB7D05E44887AEC2D14180C00" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">232.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">. Historically, the Company has funded its operations through public offerings of equity securities and debt financings. To date, the Company has not generated material revenue from ARIKAYCE. The Company commenced commercial shipments in October 2018. The Company expects to continue to incur operating losses while funding commercial launch efforts for ARIKAYCE, research and development (R&amp;D) activities, regulatory submissions outside the US, and general and administrative expenses. The Company expects its future cash requirements to be substantial, and the Company may need to raise additional capital to fund operations, including the commercialization of ARIKAYCE and additional clinical trials related to ARIKAYCE, to develop INS1007 and INS1009 and to develop, acquire, in-license or co-promote other products that address orphan or rare diseases.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-034D62C3CE8957B1B7BF0DD4EE4000D7-2">The source, timing and availability of any future financing or other transaction will depend principally upon continued progress in the Company&#8217;s commercial, regulatory and development activities. Any equity or debt financing will also be contingent upon equity and debt market conditions and interest rates at the time. If the Company is unable to obtain sufficient additional funds when required, the Company may be forced to delay, restrict or eliminate all or a portion of its development programs or commercialization efforts.</ix:continuation></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div><a id="s8258C34BFF0F53309AC2FF8AA501F92D"></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2.</span><span style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;"> </span><ix:nonNumeric contextRef="FD2018Q3YTD" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="TextSelection-4F1E881A2A775975BD5D364C77D2E618-0-wk-Fact-E0862973C8525EAE8717DA115CF7CC67" continuedAt="TextSelection-4F1E881A2A775975BD5D364C77D2E618-1" escape="true"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Summary of Significant Accounting Policies</span></ix:nonNumeric></div><ix:continuation id="TextSelection-4F1E881A2A775975BD5D364C77D2E618-1" continuedAt="TextSelection-4F1E881A2A775975BD5D364C77D2E618-2"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The following are the required interim disclosure updates to the Company's significant accounting policies described in Note 2 of the notes to the consolidated financial statements in the Company&#8217;s Annual Report on Form&#160;10-K for the year ended </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">December&#160;31, 2017</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"><ix:nonNumeric contextRef="FD2018Q3YTD" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="TextSelection-5A4CAE62761D50CC9C8586B7AC0E38C0-0-wk-Fact-E597CC14C2BB58C08DE14D2E9C5CB8CC" continuedAt="TextSelection-5A4CAE62761D50CC9C8586B7AC0E38C0-1" escape="true">Fair Value Measurements</ix:nonNumeric></span><ix:continuation id="TextSelection-5A4CAE62761D50CC9C8586B7AC0E38C0-1" continuedAt="TextSelection-5A4CAE62761D50CC9C8586B7AC0E38C0-2"><span style="font-family:inherit;font-size:10pt;"> - The Company categorizes its financial assets and liabilities measured and reported at fair value in the financial statements on a recurring basis based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs used to determine the fair value of financial assets and liabilities, are as follows:</span></ix:continuation></div><ix:continuation id="TextSelection-5A4CAE62761D50CC9C8586B7AC0E38C0-2" continuedAt="TextSelection-5A4CAE62761D50CC9C8586B7AC0E38C0-3"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D0886DA1D655A85ACDCD91D659042CA"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-4F1E881A2A775975BD5D364C77D2E618-2" continuedAt="TextSelection-4F1E881A2A775975BD5D364C77D2E618-3"><ix:continuation id="TextSelection-5A4CAE62761D50CC9C8586B7AC0E38C0-3" continuedAt="TextSelection-5A4CAE62761D50CC9C8586B7AC0E38C0-4"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 1 &#8212; Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 2 &#8212; Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the assets or liability through correlation with market data at the measurement date and for the duration of the instrument&#8217;s anticipated life.</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 3 &#8212; Inputs reflect management&#8217;s best estimate of what market participants would use in pricing the asset or liability at the measurement date.&#160;Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Each major category of financial assets and liabilities measured at fair value on a recurring basis is categorized based upon the lowest level of significant input to the valuations. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Financial instruments in Level 1 generally include US treasuries and mutual funds listed in active markets.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s only financial assets and liabilities which were measured at fair value as of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</span><span style="font-family:inherit;font-size:10pt;"> were Level 1 assets comprised of cash and cash equivalents of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d37589112e388-wk-Fact-262A8C3075AB59F6A9434AEB56E78F03" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2018Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">567.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d37589112e392-wk-Fact-4BEC86EEFC125BCD97660C358B830578" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2017Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">381.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. The estimated fair value of the liability component of the </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37589112e396-wk-Fact-755C13FF89B15B2CB9781EF2E9B053C7" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="FI2018Q3_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">1.75</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> convertible senior notes due 2025 (the Convertible Notes) (categorized as a Level 2 liability for fair value measurement purposes) was determined using current market factors and the ability of the Company to obtain debt on comparable terms to the Convertible Notes. <ix:nonNumeric contextRef="FD2018Q3YTD" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="TextSelection-BF9D7701CC7A5E3EB7504546ED8F5DB8-0-wk-Fact-565738CC69E65C35A9CB7FFF9DAF0976" continuedAt="TextSelection-BF9D7701CC7A5E3EB7504546ED8F5DB8-1" escape="true">The following table shows certain assets and liabilities and their carrying values and fair values:</ix:nonNumeric></span></div><ix:continuation id="TextSelection-BF9D7701CC7A5E3EB7504546ED8F5DB8-1" continuedAt="TextSelection-BF9D7701CC7A5E3EB7504546ED8F5DB8-2"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:83.0078125%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:55%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of September 30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Level 1</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37589112e595-wk-Fact-970EEA3A52C751799958B6AFC30E2A59" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">567.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37589112e614-wk-Fact-78C20C0BC2F35EF4BA46C572F3653EE6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">567.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Level 2</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Convertible Notes ($450.0 face value)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37589112e675-wk-Fact-F0C0A9216C1A5F87A2F0C1C891430137" name="us-gaap:ConvertibleDebtFairValueDisclosures" contextRef="FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">311.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37589112e694-wk-Fact-FA39F73B0BF056E2A4157CE28EC82553" name="us-gaap:ConvertibleDebtFairValueDisclosures" contextRef="FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">381.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;font-size:9pt;"><ix:continuation id="TextSelection-BF9D7701CC7A5E3EB7504546ED8F5DB8-2" continuedAt="TextSelection-BF9D7701CC7A5E3EB7504546ED8F5DB8-3"><span style="font-family:inherit;font-size:9pt;">&#160;* The carrying value of the Convertible Notes excludes </span><span style="font-family:inherit;font-size:9pt;"><span>$<ix:nonFraction id="d37589112e705-wk-Fact-4998B9312C95515C9EA11C5B4F3DBFB2" name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="FI2018Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">129.4</ix:nonFraction> million</span></span></ix:continuation><span style="font-family:inherit;font-size:9pt;"><ix:continuation id="TextSelection-BF9D7701CC7A5E3EB7504546ED8F5DB8-3"> of the unamortized portion of the debt discount.</ix:continuation></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s cash and cash equivalents permit daily redemption and the fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions. Cash equivalents consist of liquid investments with an original maturity of three months or less from the date of purchase. As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company's cash and cash equivalents balance included US treasury bills of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d37589112e719-wk-Fact-508D6DEF54345B8CA9F4292E5B48ECF6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2018Q3_us-gaap_CashAndCashEquivalentsAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">399.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter. There were </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37589112e730-wk-Fact-35CC56CB07455FF089D209A8A6DACB69" name="insm:FairValueLevel1Level2Level3TransfersAmount" contextRef="FD2018Q3YTD" unitRef="usd" decimals="INF" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> transfers in or out of Level 1, Level 2 or Level 3 during the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;text-indent:48px;font-size:10pt;"><ix:continuation id="TextSelection-5A4CAE62761D50CC9C8586B7AC0E38C0-4" continuedAt="TextSelection-5A4CAE62761D50CC9C8586B7AC0E38C0-5"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</span><span style="font-family:inherit;font-size:10pt;">, the Company held </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37589112e759-wk-Fact-BC704597F57451B886DA07B6F9F379C2" name="insm:AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities" contextRef="FI2018Q3" unitRef="security" decimals="INF" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-5A4CAE62761D50CC9C8586B7AC0E38C0-5"> securities that were in an unrealized gain or loss position. The Company reviews the status of each security quarterly to determine whether an other-than-temporary impairment has occurred. In making its determination, the Company considers a number of factors, including: (1) the significance of the decline; (2)&#160;whether the securities were rated below investment grade; (3)&#160;how long the securities have been in an unrealized loss position; and (4) the Company&#8217;s ability and intent to retain the investment for a sufficient period of time for it to recover.</ix:continuation></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"><ix:nonNumeric contextRef="FD2018Q3YTD" name="us-gaap:EarningsPerSharePolicyTextBlock" id="TextSelection-73F518D94512557FA5054386AED0870A-0-wk-Fact-B4E22C47503E559982F2F3C982E8FF89" continuedAt="TextSelection-73F518D94512557FA5054386AED0870A-1" escape="true">Net Loss Per Share</ix:nonNumeric></span><ix:continuation id="TextSelection-73F518D94512557FA5054386AED0870A-1" continuedAt="TextSelection-73F518D94512557FA5054386AED0870A-2"><span style="font-family:inherit;font-size:10pt;"> - Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period.&#160;Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares and other dilutive securities outstanding during the period. Potentially dilutive securities from stock options, restricted stock units (RSUs) and convertible debt securities would be anti-dilutive as the Company incurred a net loss. Potentially dilutive common shares resulting from the assumed exercise of outstanding stock options and from the assumed conversion of the Convertible Notes are determined based on the treasury stock method.</span></ix:continuation></div><ix:continuation id="TextSelection-73F518D94512557FA5054386AED0870A-2" continuedAt="TextSelection-73F518D94512557FA5054386AED0870A-3"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D0886DA1D655A85ACDCD91D659042CA"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-4F1E881A2A775975BD5D364C77D2E618-3" continuedAt="TextSelection-4F1E881A2A775975BD5D364C77D2E618-4"><ix:continuation id="TextSelection-73F518D94512557FA5054386AED0870A-3" continuedAt="TextSelection-73F518D94512557FA5054386AED0870A-4"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:nonNumeric contextRef="FD2018Q3YTD" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" id="TextSelection-1FEF68C38DC75760A6899529939F8605-0-wk-Fact-85A75E625E0A556C9B7D4D018EAA786C" continuedAt="TextSelection-1FEF68C38DC75760A6899529939F8605-1" escape="true">The following table sets forth the reconciliation of the weighted average number of common shares used to compute basic and diluted net loss per share for the </ix:nonNumeric></span><ix:continuation id="TextSelection-1FEF68C38DC75760A6899529939F8605-1" continuedAt="TextSelection-1FEF68C38DC75760A6899529939F8605-2"><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">:</span></ix:continuation></div><ix:continuation id="TextSelection-1FEF68C38DC75760A6899529939F8605-2" continuedAt="TextSelection-1FEF68C38DC75760A6899529939F8605-3"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></ix:continuation><div style="line-height:120%;font-size:10pt;"><ix:continuation id="TextSelection-1FEF68C38DC75760A6899529939F8605-3"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in&#160;thousands,&#160;except&#160;per&#160;share&#160;amounts)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Numerator:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37589112e1157-wk-Fact-140F3BA91E2256A5BF9E0BE306FB0BF7" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">87,743</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37589112e1177-wk-Fact-943BC7301A8358DDB78350FA470D31A1" name="us-gaap:NetIncomeLoss" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">45,179</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37589112e1197-wk-Fact-B45A0729B05C59668CED7875FF86978E" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">232,704</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37589112e1218-wk-Fact-E7598833183958F9826A9C7E045F8A51" name="us-gaap:NetIncomeLoss" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">127,265</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Denominator:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average common shares used in calculation of basic net loss per share:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37589112e1312-wk-Fact-4EC56997C8285C5383565676429B7A91" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2018Q3QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">77,066</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37589112e1331-wk-Fact-03944E6867D6537B9F235AEF82777579" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2017Q3QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">65,312</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37589112e1350-wk-Fact-FE4F8D92CAC2575AA3BFFB67AE510E53" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2018Q3YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">76,819</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37589112e1370-wk-Fact-28532D3BB595506AA35E9B66A7C81C4E" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2017Q3YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">63,199</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of dilutive securities:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock options</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37589112e1468-wk-Fact-1467CE3DC3DD5424A5AAC80CC92C4757" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="shares" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37589112e1487-wk-Fact-22BAAB400BEA502C90A72E9677A17720" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2017Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="shares" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37589112e1506-wk-Fact-DED0A91F646B54308A5BC3B1D7BA401B" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="shares" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37589112e1526-wk-Fact-260212FAA27C59DEB974FE0D02CCA3A7" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="shares" xsi:nil="true" scale="3" format="ixt:nocontent"></ix:nonFraction></span><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">RSUs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37589112e1545-wk-Fact-3EC30ED4368E5D1BB016279689B5A139" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37589112e1564-wk-Fact-BE7AFFD406DF5980967FB912E04B368C" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2017Q3QTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37589112e1583-wk-Fact-83FDBA66F3685798BDC0D1F8E9C4957F" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37589112e1603-wk-Fact-F598E555C7805778BAF7B83ED44D6FF0" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" xsi:nil="true" scale="3" format="ixt:nocontent"></ix:nonFraction></span><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Convertible debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37589112e1622-wk-Fact-6E1A8A195F425F3190A6036A681A8F03" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" contextRef="FD2018Q3QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37589112e1641-wk-Fact-E982E47291085B59B56D42427ADC43C3" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" contextRef="FD2017Q3QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37589112e1660-wk-Fact-4E49C286A8D254E09921353B0734B4E3" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" contextRef="FD2018Q3YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37589112e1680-wk-Fact-32CB443CF5745EC9A9108699711D70E8" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" contextRef="FD2017Q3YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average common shares outstanding used&#160;in calculation of diluted net loss per share</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37589112e1701-wk-Fact-ED081918EC395B68A8E74B9F49849B81" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2018Q3QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">77,066</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37589112e1720-wk-Fact-D9D3BF1000E3566FAB3956FD24834197" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2017Q3QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">65,312</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37589112e1739-wk-Fact-230B7F6508B651079FFFDECCECED7982" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2018Q3YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">76,819</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37589112e1759-wk-Fact-3A1288C5C261588E9669FA4F1468373E" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2017Q3YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">63,199</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss per share:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37589112e1862-wk-Fact-9B35FCB3B7EB583994D0E1C89E3CB22A" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2018Q3QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">1.14</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37589112e1882-wk-Fact-9951475A6A9F50B7B0578A1952AF668A" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2017Q3QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.69</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37589112e1902-wk-Fact-6C2CDE809B045C2FA0991187295B38A6" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2018Q3YTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">3.03</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37589112e1923-wk-Fact-07424B054FE3587D9AE84C3BB0C6517A" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2017Q3YTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">2.01</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></ix:continuation><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:nonNumeric contextRef="FD2018Q3YTD" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="TextSelection-66BE67F067115AB391655C180079E493-0-wk-Fact-FFF82E2B3BD55D80B8261A37015F111F" continuedAt="TextSelection-66BE67F067115AB391655C180079E493-1" escape="true">The following potentially dilutive securities have been excluded from the computations of diluted weighted average common shares outstanding as of </ix:nonNumeric></span><ix:continuation id="TextSelection-66BE67F067115AB391655C180079E493-1" continuedAt="TextSelection-66BE67F067115AB391655C180079E493-2"><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> as their effect would have been anti-dilutive (in thousands):</span></ix:continuation></div><ix:continuation id="TextSelection-66BE67F067115AB391655C180079E493-2" continuedAt="TextSelection-66BE67F067115AB391655C180079E493-3"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></ix:continuation></ix:continuation><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><ix:continuation id="TextSelection-66BE67F067115AB391655C180079E493-3"><ix:continuation id="TextSelection-73F518D94512557FA5054386AED0870A-4"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.4140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:69%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock options to purchase common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37589112e2036-wk-Fact-DDE26BFF50665DC5B4E367A0C281D047" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2018Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_insm_EmployeeAndDirectorsStockOptionsMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">9,608</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37589112e2050-wk-Fact-7A4CDD4A23DC5110947F5C310265AC6E" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2017Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_insm_EmployeeAndDirectorsStockOptionsMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">8,601</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unvested RSUs</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37589112e2065-wk-Fact-9950304EFEE150CC9A074A1535EFBB93" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2018Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">245</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37589112e2079-wk-Fact-07F53D264BF65A209CB3E4B8B0912E31" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2017Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">47</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Convertible debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37589112e2094-wk-Fact-9DE2C8E047DD5987B08ECCC0C034A32D" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2018Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">11,492</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37589112e2108-wk-Fact-7669FAB07F8C533992ED1490FEFB356B" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2017Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember" unitRef="shares" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></ix:continuation></ix:continuation><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"><ix:nonNumeric contextRef="FD2018Q3YTD" name="us-gaap:InventoryPolicyTextBlock" id="TextSelection-EF5482DFE4FF844A11788231595E4A37-0-wk-Fact-3398BE7FE1A97174CA778231AA7DB4C2" continuedAt="TextSelection-EF5482DFE4FF844A11788231595E4A37-1" escape="true">Inventory - </ix:nonNumeric></span><ix:continuation id="TextSelection-EF5482DFE4FF844A11788231595E4A37-1" continuedAt="TextSelection-EF5482DFE4FF844A11788231595E4A37-2"><span style="font-family:inherit;font-size:10pt;">Inventory is stated at the lower of cost and net realizable value with cost determined on a standard costing method. The Company began capitalizing inventory costs subsequent to US Food and Drug Administration (FDA) approval of ARIKAYCE on September 28, 2018, when it was determined that the inventory had a probable future economic benefit. Inventory will be sold beginning in the fourth quarter of 2018 based on first-in, first out basis. Manufacturing variances, such as material usage variance and yield variance, will be capitalized in inventory until the respective units are sold at which point the variances will be released in cost of goods sold. The Company will periodically review inventory for expiry and obsolescence and write down accordingly.  The Company performs quality control procedures throughout the manufacturing processes of ARIKAYCE; however, certain batches or units of ARIKAYCE may not meet quality specifications and result in a charge to cost of goods sold.</span></ix:continuation></div><ix:continuation id="TextSelection-EF5482DFE4FF844A11788231595E4A37-2" continuedAt="TextSelection-EF5482DFE4FF844A11788231595E4A37-3"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:48px;font-size:10pt;"><ix:continuation id="TextSelection-EF5482DFE4FF844A11788231595E4A37-3" continuedAt="TextSelection-EF5482DFE4FF844A11788231595E4A37-4"><span style="font-family:inherit;font-size:10pt;">Prior to FDA approval of ARIKAYCE, the Company expensed all inventory related costs in the period incurred; therefore, inventory is not included in the </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-EF5482DFE4FF844A11788231595E4A37-4"> consolidated balance sheet. Inventory used for clinical development purposes is expensed to research and development (R&amp;D) expense when consumed.</ix:continuation></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"><ix:nonNumeric contextRef="FD2018Q3YTD" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="TextSelection-54729AE8417850398774DC3093645532-0-wk-Fact-85E9015FE8D85175A711DD937AC708BE" continuedAt="TextSelection-54729AE8417850398774DC3093645532-1" escape="true">Recently Adopted Accounting Pronouncements</ix:nonNumeric></span><ix:continuation id="TextSelection-54729AE8417850398774DC3093645532-1" continuedAt="TextSelection-54729AE8417850398774DC3093645532-2"><span style="font-family:inherit;font-size:10pt;"> - In August 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standard Update (ASU) 2016-15, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments</span><span style="font-family:inherit;font-size:10pt;">, which addressed eight specific cash flow issues with the objective of reducing the existing diversity in practice. Among the updates, the standard requires debt extinguishment costs to be classified as cash outflows for financing activities. This standard update is effective as of the first quarter of 2018. As a result of the adoption of the standard, in the first quarter of 2018, the Company reported a </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d37589112e2149-wk-Fact-294C9818237154148BE8AA50B2B54BD3" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" contextRef="FD2018Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> loss on extinguishment of debt in the financing activities section of its consolidated statement of cash flows. The Company had no material debt extinguishment costs prior to the first quarter of 2018. The impact of adopting this standard was not material to the Company.</span></ix:continuation></div><ix:continuation id="TextSelection-54729AE8417850398774DC3093645532-2" continuedAt="TextSelection-54729AE8417850398774DC3093645532-3"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D0886DA1D655A85ACDCD91D659042CA"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-54729AE8417850398774DC3093645532-3" continuedAt="TextSelection-54729AE8417850398774DC3093645532-4"><div style="line-height:120%;text-indent:56px;font-size:10pt;"><ix:continuation id="TextSelection-4F1E881A2A775975BD5D364C77D2E618-4" continuedAt="TextSelection-4F1E881A2A775975BD5D364C77D2E618-5"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">New Accounting Pronouncements (Not Yet Adopted)</span><span style="font-family:inherit;font-size:10pt;">&#8212;In February 2016, the FASB issued ASU 2016-2, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</span><span style="font-family:inherit;font-size:10pt;"> in order to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous generally accepted accounting principles. ASU 2016-2 requires a lessee to recognize a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term on the balance sheet. ASU 2016-2 is effective for fiscal years beginning after December&#160;15, 2018 (including interim periods within those periods) and early adoption is permitted. In August 2018, the FASB issued ASU 2018-11, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Targeted Improvements to ASC 842</span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-4F1E881A2A775975BD5D364C77D2E618-5">, which provides a new transition option in which an entity initially applies ASU 2016-2 at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company will use the new transition option and is also utilizing the package of practical expedients that allows it to not reassess: (1) whether any expired or existing contracts are or contain leases, (2) lease classification for any expired or existing leases, and (3) initial direct costs for any expired or existing leases. The Company additionally expects to use the practical expedient that allows it to treat the lease and non-lease components of its leases as a single component. The Company has identified approximately ten leasing arrangements and is currently assessing the financial impact on the consolidated balance sheet. The Company expects to adopt ASU 2016-2 in the first quarter of 2019 and is in the process of evaluating the impact of adoption on its consolidated financial statements.</ix:continuation> </span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-54729AE8417850398774DC3093645532-4">&#160;</ix:continuation></span></div><div><a id="sEC8E0C1A26815DD2B7C5967ED0952A10"></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">3.</span><span style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;"> </span><ix:nonNumeric contextRef="FD2018Q3YTD" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="TextSelection-07483B66448E5C1EAAF5467A69B18EBB-0-wk-Fact-588B7305E6EE5C46AE232851B257F7F5" continuedAt="TextSelection-07483B66448E5C1EAAF5467A69B18EBB-1" escape="true"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Intangible Assets</span></ix:nonNumeric></div><ix:continuation id="TextSelection-07483B66448E5C1EAAF5467A69B18EBB-1" continuedAt="TextSelection-07483B66448E5C1EAAF5467A69B18EBB-2"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of September 30, 2018, the Company's identifiable intangible assets consisted of acquired ARIKAYCE R&amp;D, formerly referred to as in-process research and development, and a milestone payable to PARI Pharma GmbH (PARI) for the license to use PARI's Lamira&#8482; Nebulizer System for the delivery of ARIKAYCE to patients. The total carrying value of the acquired ARIKAYCE R&amp;D was&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d37586553e324-wk-Fact-AD20B71B1B6826A1C1538248F08C6A5D" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2018Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">58.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;as of&#160;</span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</span><span style="font-family:inherit;font-size:10pt;">, resulting from the initial amount recorded at the time of the Company's merger with Transave, Inc. (Transave) in 2010 and subsequent adjustments. On September 28, 2018, as a result of the FDA approval for ARIKAYCE, the Company recorded a milestone payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d37586553e336-wk-Fact-FD81903B8A3D9AD08B2682699717D45B" name="insm:AccruedMilestonePaymentCurrent" contextRef="I2018Q3Sept28" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> due to PARI. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:nonNumeric contextRef="FD2018Q3YTD" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="TextSelection-0E037DA458F05449D593821FDC8841EA-0-wk-Fact-C752B2F0E5813C997F1882218D914ED2" continuedAt="TextSelection-0E037DA458F05449D593821FDC8841EA-1" escape="true">Intangible assets consist of the following:</ix:nonNumeric></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><ix:continuation id="TextSelection-0E037DA458F05449D593821FDC8841EA-1"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:72.4609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:20%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of September 30, <br/>2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of December 31, <br/>2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquired ARIKAYCE R&amp;D</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37586553e457-wk-Fact-1C61BDCDA05AF27723578243D86410B4" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2018Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">58,200</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37586553e476-wk-Fact-E550D66824F4A7ADCA5D8243D857646F" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">58,200</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PARI milestone upon FDA approval</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37586553e491-wk-Fact-5FD26FBADD337F16781C8243D8819991" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2018Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,741</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37586553e510-wk-Fact-177C426B32364CBC24CA8243D86FA182" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Intangible assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37586553e535-wk-Fact-BCE69FE0C62A914B7A8A8243D869478E" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">59,941</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37586553e554-wk-Fact-DCB56C97A1E2B61CB9F78243D876B48C" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">58,200</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></ix:continuation><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</span></div></ix:continuation><div style="line-height:120%;text-indent:48px;font-size:10pt;"><ix:continuation id="TextSelection-07483B66448E5C1EAAF5467A69B18EBB-2" continuedAt="TextSelection-07483B66448E5C1EAAF5467A69B18EBB-3"><span style="font-family:inherit;font-size:10pt;">Intangible assets are measured at their respective fair values on the date they were recorded and, with respect to the Acquired ARIKAYCE milestone, at the date of subsequent adjustments of fair value. Intangible assets will be amortized beginning October 1, 2018 over the initial regulatory exclusivity period for ARIKAYCE (</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d37586553e569-wk-Fact-552349AA3A0164E5C222824793D1CBDC" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="FD2018Q3YTD" format="ixt-sec:duryear">12</ix:nonNumeric> years</span></span><span style="font-family:inherit;font-size:10pt;">). As of&#160;</span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-07483B66448E5C1EAAF5467A69B18EBB-3">, the Company performed a qualitative assessment on the assets. This assessment did not identify any indicators of impairment of the intangible assets and indicated that the implied value of the assets was more than&#160;100%&#160;greater than the book value as of that date.</ix:continuation></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div><a id="s9A7ADDE489F050C79385FD5931F4DA8E"></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">4.</span><span style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;"> </span><ix:nonNumeric contextRef="FD2018Q3YTD" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="TextSelection-F665474877C956D09544A8AC6C140D60-0-wk-Fact-F2D87B8B788B5307B137BB35ED79E931" continuedAt="TextSelection-F665474877C956D09544A8AC6C140D60-1" escape="true"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accrued Expenses</span></ix:nonNumeric></div><ix:continuation id="TextSelection-F665474877C956D09544A8AC6C140D60-1" continuedAt="TextSelection-F665474877C956D09544A8AC6C140D60-2"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:nonNumeric contextRef="FD2018Q3YTD" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="TextSelection-1F5074DD33C85E9F8A5757AF4942A3DD-0-wk-Fact-B2C2EA35F5AF5065B93B778633239490" continuedAt="TextSelection-1F5074DD33C85E9F8A5757AF4942A3DD-1" escape="true">Accrued expenses consist of the following:</ix:nonNumeric></span></div><ix:continuation id="TextSelection-1F5074DD33C85E9F8A5757AF4942A3DD-1" continuedAt="TextSelection-1F5074DD33C85E9F8A5757AF4942A3DD-2"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D0886DA1D655A85ACDCD91D659042CA"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><ix:continuation id="TextSelection-F665474877C956D09544A8AC6C140D60-2"><ix:continuation id="TextSelection-1F5074DD33C85E9F8A5757AF4942A3DD-2"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.96875%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of September&#160;30, <br/>2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of December&#160;31, <br/>2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in&#160;thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued clinical trial expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37588595e438-wk-Fact-66886C3E48C952D680072FCBC36B0AA9" name="insm:AccruedClinicalTrialExpenses" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,576</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37588595e457-wk-Fact-C5AE24FBAE1B5FF494CDC10E4A27E6A2" name="insm:AccruedClinicalTrialExpenses" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,837</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued compensation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37588595e472-wk-Fact-81680FA69D6F5319848DB75AC5FB1755" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,387</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37588595e491-wk-Fact-F105BE16978F5B888879EBC86DC5E548" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,197</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued professional fees</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37588595e511-wk-Fact-28CF2535C82F5F168C38480FFF3A835B" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,746</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37588595e530-wk-Fact-FD091747DC7153ADB6BA9002399E767E" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,500</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued technical operation expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37588595e550-wk-Fact-8CE50102244D593B81657187DE73ED2D" name="insm:AccruedTechnicalOperationExpenses" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,137</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37588595e569-wk-Fact-1A28B7C9EAF853E7A5A4EAF449514C11" name="insm:AccruedTechnicalOperationExpenses" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,182</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued milestone payment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37588595e589-wk-Fact-30DBF05FAB924AADE6C5826D0799865F" name="insm:AccruedMilestonePaymentCurrent" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,741</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37588595e608-wk-Fact-58881E4BFC557B8AF6BB826D07AABA4F" name="insm:AccruedMilestonePaymentCurrent" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued interest payable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37588595e628-wk-Fact-E7EDBAA1A19254E48F527962CA404603" name="us-gaap:InterestPayableCurrent" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,663</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37588595e647-wk-Fact-DF59140E6DB158208117DAF6EDFBD1A0" name="us-gaap:InterestPayableCurrent" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">423</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued construction costs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37588595e667-wk-Fact-8D2CE62F710256C4867627D2673FA135" name="insm:AccruedConstructionLiabilitiesCurrent" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,069</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37588595e686-wk-Fact-3AB1CABE9DEA50A48D81863FBCDE743E" name="insm:AccruedConstructionLiabilitiesCurrent" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,719</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other accrued expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37588595e706-wk-Fact-556B917E54F45BB0BC136644B1CC1AF2" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,049</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37588595e725-wk-Fact-93C99C26AB0059D2A3AEC6BD8093C56C" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">481</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37588595e750-wk-Fact-E7A53E4292C3507FAAB562842E428728" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">40,368</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37588595e769-wk-Fact-1C594FB75856593F8B96A3EA9DEA6C7E" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">29,339</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></ix:continuation></ix:continuation><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div><a id="s710F64B3B6B85342BB87E79454A315CC"></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">5.</span><span style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;"> </span><ix:nonNumeric contextRef="FD2018Q3YTD" name="us-gaap:DebtDisclosureTextBlock" id="TextSelection-92EFBAF97FE3567C966C9F3BCEEBD55C-0-wk-Fact-EE00012398585A3791EAE44FEE5F315E" continuedAt="TextSelection-92EFBAF97FE3567C966C9F3BCEEBD55C-1" escape="true"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Debt</span></ix:nonNumeric></div><ix:continuation id="TextSelection-92EFBAF97FE3567C966C9F3BCEEBD55C-1" continuedAt="TextSelection-92EFBAF97FE3567C966C9F3BCEEBD55C-2"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2018, the Company completed an underwritten public offering of the Convertible Notes, in which the Company sold </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d37590224e324-wk-Fact-7E4A9357C5E15E559A53F43438548641" name="us-gaap:DebtInstrumentFaceAmount" contextRef="I2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">450.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> aggregate principal amount of Convertible Notes, including the exercise in full of the underwriters' option to purchase additional Convertible Notes of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d37590224e328-wk-Fact-345AD2CA179752AA825673E8760EC16E" name="insm:DebtInstrumentOptionToPurchaseAdditionalDebt" contextRef="I2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">50.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. The Company's net proceeds from the offering, after deducting underwriting discounts and commissions and other offering expenses of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d37590224e332-wk-Fact-8DC678152A7652C482C25373DA3D75DB" name="us-gaap:DeferredFinanceCostsNet" contextRef="I2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, were approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d37590224e336-wk-Fact-C7C8C725F0B3500198F89DE37AA0C1B2" name="us-gaap:ProceedsFromConvertibleDebt" contextRef="D2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">435.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. The Convertible Notes bear interest payable semiannually in arrears on January 15 and July 15 of each year, beginning on July 15, 2018. The Convertible Notes mature on January 15, 2025, unless earlier converted, redeemed, or repurchased. </span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On or after October&#160;15, 2024, until the close of business on the second scheduled trading day immediately preceding January 15, 2025, holders may convert their Convertible Notes at any time. Upon conversion, holders may receive cash, shares of the Company's common stock or a combination of cash and shares of the Company's common stock, at the Company's option. The initial conversion rate is </span><span style="font-family:inherit;font-size:10pt;">25.5384</span><span style="font-family:inherit;font-size:10pt;"> shares of common stock per $1,000 principal amount of Convertible Notes (equivalent to an initial conversion price of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d37590224e351-wk-Fact-4D041FB2AF7D5A91A88CDEF5C0721A55" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="I2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">39.16</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share of common stock). The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Holders may convert their Convertible Notes prior to October 15, 2024, only under the following circumstances, subject to the conditions set forth in an indenture, dated as of January 26, 2018, between the Company and Wells Fargo Bank, National Association (Wells Fargo), as trustee, as supplemented by the first supplemental indenture, dated January 26, 2018, between the Company and Wells Fargo (as supplemented, the Indenture): (i) during the </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37590224e361-wk-Fact-1860C51771A85B85994795C837B0C6BE" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" contextRef="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_DebtInstrumentConversionTermOneMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" unitRef="day" decimals="INF" scale="0" format="ixt-sec:numwordsen">five</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> business day period immediately after any </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37590224e365-wk-Fact-3053D2613E905CA5BA1DA5E51C484BFD" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" contextRef="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_DebtInstrumentConversionTermOneMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" unitRef="day" decimals="INF" scale="0" format="ixt-sec:numwordsen">five</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> consecutive trading day period (the measurement period) in which the trading price per $1,000 principal amount of convertible notes, as determined following a request by a holder of the convertible notes, for each trading day of the measurement period was less than </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37590224e369-wk-Fact-9D0E49F95C015086AAE78CF35B2CBBFA" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" contextRef="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_DebtInstrumentConversionTermOneMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">98</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the product of the last reported sale price of the common stock and the conversion rate on such trading day, (ii) the Company elects to distribute to all or substantially all holders of the common stock (a) any rights, options or warrants (other than in connection with a stockholder rights plan for so long as the rights issued under such plan have not detached from the associated shares of common stock) entitling them, for a period of not more than </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37590224e373-wk-Fact-0C2F3580B9B45F7A809BB4BF53118911" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" contextRef="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_DebtInstrumentConversionTermTwoMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" unitRef="day" decimals="INF" scale="0" format="ixt:numdotdecimal">45</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> days from the declaration date for such distribution, to subscribe for or purchase shares of common stock at a price per share that is less than the average of the last reported sale prices of the common stock for the </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37590224e377-wk-Fact-7A3190B8AE84538CB44026DF751D68B6" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" contextRef="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_DebtInstrumentConversionTermTwoMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" unitRef="day" decimals="INF" scale="0" format="ixt:numdotdecimal">10</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> consecutive trading day period ending on, and including, the trading day immediately preceding the declaration date for such distribution, or (b) the Company&#8217;s assets, debt securities or rights to purchase securities of the Company, which distribution has a per share value, as reasonably determined by the board of directors, exceeding </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37590224e382-wk-Fact-482FCC034EB85DDB8BE94373AE6BA8A4" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" contextRef="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_DebtInstrumentConversionTermTwoMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the last reported sale price of the common stock on the trading day immediately preceding the declaration date for such distribution, (iii) if a transaction or event that constitutes a fundamental change or a make-whole fundamental change occurs, or if the Company is a party to (a) a consolidation, merger, combination, statutory or binding share exchange or similar transaction, pursuant to which the common stock would be converted into, or exchanged for, cash, securities or other property or assets, or (b) any sale, conveyance, lease or other transfer or similar transaction in one transaction or a series of transactions of all or substantially all of the consolidated assets of the Company and its subsidiaries, taken as a whole, all or any portion of the Convertible Notes may be surrendered by a holder for conversion at any time from or after the date that is </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37590224e386-wk-Fact-C3022FBDC3E25803BCA97471C7C5A997" name="insm:DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange" contextRef="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_DebtInstrumentConversionTermThreeMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" unitRef="day" decimals="INF" scale="0" format="ixt:numdotdecimal">30</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> scheduled trading days prior to the anticipated effective date of the transaction, (iv) if during any calendar quarter commencing after the calendar quarter ending on March&#160;31, 2018 (and only during such calendar quarter), the last reported sale price of the common stock for at least </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37590224e390-wk-Fact-64DD445CD13653DD9E213D225A4F235C" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" contextRef="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_DebtInstrumentConversionTermFourMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" unitRef="day" decimals="INF" scale="0" format="ixt:numdotdecimal">20</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> trading days (whether or not consecutive) during the period of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37590224e394-wk-Fact-BD23F4F6AC7B5B4AAD209DBA42344B8D" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" contextRef="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_DebtInstrumentConversionTermFourMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" unitRef="day" decimals="INF" scale="0" format="ixt:numdotdecimal">30</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37590224e398-wk-Fact-251126F334385D76BBAA260CC4412FEE" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" contextRef="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_DebtInstrumentConversionTermFourMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">130</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the conversion price on each applicable trading day, or, (v) if the Company sends a notice of redemption, a holder may </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D0886DA1D655A85ACDCD91D659042CA"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-92EFBAF97FE3567C966C9F3BCEEBD55C-2" continuedAt="TextSelection-92EFBAF97FE3567C966C9F3BCEEBD55C-3"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">surrender all or any portion of its Convertible Notes, to which the notice of redemption relates, for conversion at any time on or after the date the applicable notice of redemption was sent until the close of business on (a)&#160;the second business day immediately preceding the related redemption date or (b)&#160;if the Company fails to pay the redemption price on the redemption date as specified in such notice of redemption, such later date on which the redemption price is paid.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Convertible Notes can be settled in cash, common stock, or a combination of cash and common stock at the Company's option, and thus, the Company determined the embedded conversion options in the convertible notes are not required to be separately accounted for as a derivative. However, since the Convertible Notes are within the scope of the accounting guidance for cash convertible instruments, the Company is required to separate the Convertible Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the fair value of a similar liability that does not have an associated equity component. The fair value was based on data from readily available pricing sources which utilize market observable inputs and other characteristics for similar types of instruments. The carrying amount of the equity component representing the embedded conversion option was determined by deducting the fair value of the liability component from the gross proceeds of the Convertible Notes. The excess of the principal amount of the liability component over its carrying amount is amortized to interest expense over the expected life of a similar liability that does not have an associated equity component using the effective interest method. The equity component is not remeasured as long as it continues to meet the conditions for equity classification in the accounting guidance for contracts in an entity&#8217;s own equity.  The fair value of the liability component of the Convertible Notes on the date of issuance was estimated at </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d37590224e412-wk-Fact-6213C958474757D787B50EA834F44A2C" name="us-gaap:ConvertibleDebtFairValueDisclosures" contextRef="I2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">309.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> using an effective interest rate of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37590224e416-wk-Fact-1E1F39EA84AD5BD989A27A3E4DC62E95" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="I2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">7.6</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">, and accordingly, the residual equity component on the date of issuance was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d37590224e420-wk-Fact-FBD59C907D965D3ABD0967FEF6CA4C54" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" contextRef="I2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">140.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. The discount is being amortized to interest expense over the term of the Convertible Notes and has a remaining period of approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d37590224e424-wk-Fact-ACFE8AE29C0E580F8D1D767FDAE7A575" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" contextRef="D2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" format="ixt-sec:duryear">6.28</ix:nonNumeric> years</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, total interest expense related to the Convertible Notes was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d37590224e442-wk-Fact-8600FFB679DD5930AF42ADF360AE9B7A" name="us-gaap:InterestExpense" contextRef="FD2018Q3QTD_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d37590224e446-wk-Fact-5FD0C162FF595C3CA1A93EF2E89E12B4" name="us-gaap:InterestExpense" contextRef="FD2018Q3YTD_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">17.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, which includes the contractual interest coupon payable semi-annually in cash, the amortization of the issuance costs, and accretion of debt discount, as described in the table below. <ix:nonNumeric contextRef="FD2018Q3YTD" name="us-gaap:ScheduleOfDebtTableTextBlock" id="TextSelection-C90F1D5E53BF59F3A5DED3E32085B0C6-0-wk-Fact-278627BB7121577FB530886AD706AF39" continuedAt="TextSelection-C90F1D5E53BF59F3A5DED3E32085B0C6-1" escape="true">The following table presents the carrying value of the Company&#8217;s debt balance as of </ix:nonNumeric></span><ix:continuation id="TextSelection-C90F1D5E53BF59F3A5DED3E32085B0C6-1" continuedAt="TextSelection-C90F1D5E53BF59F3A5DED3E32085B0C6-2"><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span></ix:continuation></div><ix:continuation id="TextSelection-C90F1D5E53BF59F3A5DED3E32085B0C6-2" continuedAt="TextSelection-C90F1D5E53BF59F3A5DED3E32085B0C6-3"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></ix:continuation><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><ix:continuation id="TextSelection-C90F1D5E53BF59F3A5DED3E32085B0C6-3"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.96875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:84%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;1.75% convertible senior notes due 2025</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37590224e485-wk-Fact-63BCB9E07D84541D968DBD78CEF77F5B" name="us-gaap:SecuredDebt" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">450,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;Debt issuance costs, unamortized</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37590224e500-wk-Fact-81BBE5D4E1F652CB8E694D57C3503390" name="us-gaap:DeferredFinanceCostsNet" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,789</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;Discount on debt</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37590224e521-wk-Fact-7C40E6C310BB53459A386372C4754FAE" name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">129,350</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term debt, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37590224e547-wk-Fact-04AAF8399F7F50089D01A23C0F563455" name="us-gaap:LongTermDebtNoncurrent" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">311,861</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></ix:continuation><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:nonNumeric contextRef="FD2018Q3YTD" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="TextSelection-EBF9AF87D8EB585587C302CA9743DE00-0-wk-Fact-6D28D41BFA5B55CBA9C9DB97215C7F56" continuedAt="TextSelection-EBF9AF87D8EB585587C302CA9743DE00-1" escape="true">As of </ix:nonNumeric></span><ix:continuation id="TextSelection-EBF9AF87D8EB585587C302CA9743DE00-1" continuedAt="TextSelection-EBF9AF87D8EB585587C302CA9743DE00-2"><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, future principal repayments of the debt for each of the fiscal years through maturity were as follows (in thousands):</span></ix:continuation></div><ix:continuation id="TextSelection-EBF9AF87D8EB585587C302CA9743DE00-2" continuedAt="TextSelection-EBF9AF87D8EB585587C302CA9743DE00-3"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></ix:continuation><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><ix:continuation id="TextSelection-EBF9AF87D8EB585587C302CA9743DE00-3"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.96875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:84%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ending December&#160;31:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37590224e616-wk-Fact-956C3D4C46755B40A79756A9A9AD817C" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37590224e631-wk-Fact-3FFEB2388F5257258A561EB5777F3AFA" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37590224e651-wk-Fact-7B64441B7EF45330BD8A465EB8F1B93E" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37590224e671-wk-Fact-A7F148E8E77E5A9AADD5EA1E2BE05E9B" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37590224e691-wk-Fact-17E81A5D169E592489166C86109A6A3F" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37590224e711-wk-Fact-D8A23D53CDD8581D9AD83F0A8958B54E" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">450,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37590224e736-wk-Fact-F50B2E0DDBDD5041B2E899A6DDAB035D" name="us-gaap:LongTermDebt" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">450,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></ix:continuation><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2018, the Company used part of the net proceeds from the issuance of the Convertible Notes to pay off its outstanding debt to Hercules Capital (Hercules). The payments to Hercules consisted of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d37590224e754-wk-Fact-D1BA5C40A59F5505BEC996903C978815" name="us-gaap:RepaymentsOfDebt" contextRef="D2018Q1Feb28-Feb28_us-gaap_DebtInstrumentAxis_us-gaap_LineOfCreditMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">55.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for the principal amount and an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d37590224e758-wk-Fact-8B2C149F4D175609AD186D639666A554" name="insm:RepaymentsOfDebtFeesAndOutstandingInterest" contextRef="D2018Q1Feb2018_us-gaap_DebtInstrumentAxis_us-gaap_LineOfCreditMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in back-end fees, outstanding interest, and prepayment penalty fees, which resulted in a </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d37590224e762-wk-Fact-8F99C5D4DAAE5FD89F9B3F727258D6C7" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="FD2018Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> loss on extinguishment of debt in the quarter ended March 31, 2018.&#160;&#160;&#160;&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Interest Expense</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:nonNumeric contextRef="FD2018Q3YTD" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" id="TextSelection-0BFEBE0667735D93A7DAEBA55CE0435E-0-wk-Fact-A7FE7B2B6EF45DE38AE7BB2E927227E6" continuedAt="TextSelection-0BFEBE0667735D93A7DAEBA55CE0435E-1" escape="true">The following table sets forth the total interest expense recognized in the periods presented (in thousands):</ix:nonNumeric></span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">11</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D0886DA1D655A85ACDCD91D659042CA"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><ix:continuation id="TextSelection-92EFBAF97FE3567C966C9F3BCEEBD55C-3"><ix:continuation id="TextSelection-0BFEBE0667735D93A7DAEBA55CE0435E-1"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:82.421875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:37%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contractual interest expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37590224e979-wk-Fact-4378B2392B7E55ECA171B5B6F61C04EF" name="us-gaap:InterestExpenseDebt" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,971</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37590224e998-wk-Fact-25EF54A1EE30544291CD49D1A93A8D95" name="us-gaap:InterestExpenseDebt" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,302</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37590224e1017-wk-Fact-818EE6EB8884530F995A75A2E2B80D3C" name="us-gaap:InterestExpenseDebt" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,214</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37590224e1037-wk-Fact-A9E2E23A780C5F2892A216F76C9B178F" name="us-gaap:InterestExpenseDebt" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,862</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of debt issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37590224e1052-wk-Fact-8775519611E355C5B1CC57ED3A8C0096" name="us-gaap:AmortizationOfFinancingCosts" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">415</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37590224e1071-wk-Fact-2960E48E1CAB55CCB362A519DB56F8DC" name="us-gaap:AmortizationOfFinancingCosts" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">30</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37590224e1090-wk-Fact-2DCBC22CAE23561D8C8137E0A74483C2" name="us-gaap:AmortizationOfFinancingCosts" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37590224e1110-wk-Fact-5288C234F50F548E9EB138AA0CE2764E" name="us-gaap:AmortizationOfFinancingCosts" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">91</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accretion of back-end fee on debt</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37590224e1130-wk-Fact-80B09A4F20715E50B54ECCDCBA869DE7" name="insm:AmortizationOfBackendFee" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37590224e1149-wk-Fact-FCB72504E51459D39150C190C88ABD21" name="insm:AmortizationOfBackendFee" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">164</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37590224e1168-wk-Fact-BF43524D7117515D8A4E3DD3B8BEF22D" name="insm:AmortizationOfBackendFee" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">50</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37590224e1188-wk-Fact-C489ECA8A49C566F92A47918C38B28BD" name="insm:AmortizationOfBackendFee" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">506</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accretion of debt discount</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37590224e1208-wk-Fact-1D33054849665ACA859C363371960D43" name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,289</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37590224e1227-wk-Fact-64BB61762B345F9391ED6DD0A704BB0D" name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-3" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37590224e1246-wk-Fact-9F140DB9CAD55F8A82F57323DE07C7D4" name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,541</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37590224e1266-wk-Fact-E7408D702B955003AD3C8811576D0C16" name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total interest expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37590224e1291-wk-Fact-5298773546E956B2A476B4D00B0CC953" name="us-gaap:InterestExpense" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,675</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37590224e1310-wk-Fact-46AD3F5FEC25521788BB47B9D992E8D5" name="us-gaap:InterestExpense" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,496</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37590224e1329-wk-Fact-0261293D4CE557119BC44A95C1CB75EE" name="us-gaap:InterestExpense" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,805</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37590224e1349-wk-Fact-1E85C2C8082B598EB0AA11002F15739B" name="us-gaap:InterestExpense" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,459</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></ix:continuation></ix:continuation><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div><a id="s5301FCFC8D9E54DEA394524008D03165"></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">6.</span><span style="font-family:inherit;font-size:3pt;font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;"> </span><ix:nonNumeric contextRef="FD2018Q3YTD" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="TextSelection-D5D1788D83865FFEA73440DC4DBDBC06-0-wk-Fact-2FF54B0995B354309640F4D6CE4E14BD" continuedAt="TextSelection-D5D1788D83865FFEA73440DC4DBDBC06-1" escape="true"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Shareholders&#8217; Equity</span></ix:nonNumeric></div><ix:continuation id="TextSelection-D5D1788D83865FFEA73440DC4DBDBC06-1" continuedAt="TextSelection-D5D1788D83865FFEA73440DC4DBDBC06-2"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock</span><span style="font-family:inherit;font-size:10pt;"> &#8212; As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37590573e331-wk-Fact-AC16D73A88E954E697D03E834320F06E" name="us-gaap:CommonStockSharesAuthorized" contextRef="FI2018Q3" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">500,000,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock authorized with a par value of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d37590573e335-wk-Fact-66DD83FC3C975DDDB45E789302396230" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="FI2018Q3" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">0.01</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37590573e339-wk-Fact-EB0E193E026659B496BD06BED17E8E20" name="us-gaap:CommonStockSharesIssued" contextRef="FI2018Q3" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">77,085,715</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock issued and outstanding. In addition, as of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company had reserved </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37590573e348-wk-Fact-A4F9AD54A21E5BC8965C6E02853578EF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="FI2018Q3_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">9,608,344</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock for issuance upon the exercise of outstanding stock options and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37590573e352-wk-Fact-0C531E1106865DACA89C577A153349C5" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="FI2018Q3_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">244,801</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock for issuance upon the vesting of RSUs. The Company has also reserved </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span><ix:nonFraction id="d37590573e356-wk-Fact-53C2B3EAA9425F78AF9AD48149337C83" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="FI2018Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">11,492,280</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">shares of common stock for issuance upon conversion of the Convertible Notes, subject to adjustment in accordance with the Indenture.&#160;&#160;&#160;&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2018, the Company completed an underwritten public offering of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d37590573e368-wk-Fact-7E4A9357C5E15E559A53F43438548641" name="us-gaap:DebtInstrumentFaceAmount" contextRef="I2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">450.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> aggregate principal amount of Convertible Notes, including the exercise in full of the underwriter's option to purchase additional Convertible Notes. The fair value of the liability component of the Convertible Notes on the date of issuance was estimated at </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d37590573e372-wk-Fact-6213C958474757D787B50EA834F44A2C" name="us-gaap:ConvertibleDebtFairValueDisclosures" contextRef="I2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">309.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, and accordingly, the equity component (included in additional paid-in capital) on the date of issuance was calculated as </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d37590573e376-wk-Fact-FBD59C907D965D3ABD0967FEF6CA4C54" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" contextRef="I2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">140.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> using the residual method, as further described in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 5 Debt</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In September 2017, the Company completed an underwritten public offering of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37590573e390-wk-Fact-B9E42C065B8F54C6AB1BB60742CBF249" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="D2017Q3Sept17" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">14,123,150</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s common stock, which included the underwriter&#8217;s exercise in full of its over-allotment option of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37590573e394-wk-Fact-AC6C0C409AF95A3B943ECCE99614530B" name="insm:CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption" contextRef="FI2017Q3" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,842,150</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares, at a price to the public of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d37590573e398-wk-Fact-9CE2A821B041564D8BBCF422983331E7" name="us-gaap:SharePrice" contextRef="FI2017Q3" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">28.50</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share.&#160; The Company&#8217;s net proceeds from the sale of the shares, after deducting the underwriter&#8217;s discount and offering expenses of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d37590573e402-wk-Fact-C5588C77CB9B5FBFB416A1ABEBB5FBA6" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="D2017Q3Sept17" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">24.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, were $</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37590573e406-wk-Fact-0C136B6B2B075856A9D312C7F4FF21C2" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="D2017Q3Sept17" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">377.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Preferred Stock</span><span style="font-family:inherit;font-size:10pt;"> &#8212; As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37590573e422-wk-Fact-8F74BBD921865D81A803DF38E48CC344" name="us-gaap:PreferredStockSharesAuthorized" contextRef="FI2018Q3" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">200,000,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of preferred stock authorized with a par value of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d37590573e426-wk-Fact-493EE2C5118650E882E50A82BEE0095E" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="FI2018Q3" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">0.01</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37590573e430-wk-Fact-9EBC6D072F1C5ED684726953D3AFF37A" name="us-gaap:PreferredStockSharesIssued" contextRef="FI2018Q3" unitRef="shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of preferred stock were issued and outstanding.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:nonNumeric contextRef="FD2018Q3YTD" name="us-gaap:ScheduleOfStockholdersEquityTableTextBlock" id="TextSelection-E1F8F3D2AFE456F3931488F0917D9F1C-0-wk-Fact-04F546C013DF51B48D39C5155AB7FE46" continuedAt="TextSelection-E1F8F3D2AFE456F3931488F0917D9F1C-1" escape="true">The following table summarizes the changes in total shareholders' equity for the </ix:nonNumeric></span><ix:continuation id="TextSelection-E1F8F3D2AFE456F3931488F0917D9F1C-1" continuedAt="TextSelection-E1F8F3D2AFE456F3931488F0917D9F1C-2"><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span></ix:continuation></div></ix:continuation><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><ix:continuation id="TextSelection-D5D1788D83865FFEA73440DC4DBDBC06-2"><ix:continuation id="TextSelection-E1F8F3D2AFE456F3931488F0917D9F1C-2"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:61.328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:82%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37590573e475-wk-Fact-5115DD7C33225595A9655F911DF6011A" name="us-gaap:StockholdersEquity" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">361,059</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss for the period</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37590573e490-wk-Fact-B45A0729B05C59668CED7875FF86978E" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">232,704</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Proceeds from exercise of stock options</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37590573e511-wk-Fact-30EE0C7EC8FDE992CC143B984DFC694C" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,390</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity component of Convertible Notes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37590573e531-wk-Fact-4A3FA2F0B53F8EA9B5BC3B984DF2CCC8" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">136,434</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37590573e551-wk-Fact-257ED560AA631EB44D413B984DFF813C" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,205</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change in cumulative translation adjustment</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37590573e571-wk-Fact-39AC78B296FA55BA8F3AB1B66723D287" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at September 30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37590573e596-wk-Fact-ACB053F2369A5B66BE981E31DC8D38E2" name="us-gaap:StockholdersEquity" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">291,407</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></ix:continuation></ix:continuation><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s37DD9B90AC515FE1AB741F7EF903B943"></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">7.</span><span style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;"> </span><ix:nonNumeric contextRef="FD2018Q3YTD" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="TextSelection-2EF1C0DFA0D65408A6BD3E9996D416DD-0-wk-Fact-3AA6C8A8F72654B3B6D369B9A002E0DB" continuedAt="TextSelection-2EF1C0DFA0D65408A6BD3E9996D416DD-1" escape="true"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-Based Compensation</span></ix:nonNumeric></div><ix:continuation id="TextSelection-2EF1C0DFA0D65408A6BD3E9996D416DD-1" continuedAt="TextSelection-2EF1C0DFA0D65408A6BD3E9996D416DD-2"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s current equity compensation plan, the 2017 Incentive Plan, was approved by shareholders at the Company&#8217;s Annual Meeting of Shareholders on May&#160;18, 2017.&#160;The 2017 Incentive Plan is administered by the Compensation Committee and the Board of Directors of the Company.&#160;Under the terms of the 2017 Incentive Plan, the Company is authorized to grant a variety of incentive awards based on its common stock, including stock options (both incentive stock options and non-qualified stock options), RSUs, performance options/shares and other stock awards, as well as pay incentive bonuses to eligible employees and non-employee directors.&#160;On May&#160;18, 2017, upon the approval of the 2017 Incentive Plan by shareholders, </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e323-wk-Fact-7ECC6221F1F2532AA9421C0BF38526A4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="I2017Q2May18" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">5,000,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares were authorized for issuance thereunder, plus any shares subject to then-outstanding awards under the 2015 Incentive Plan and the 2013 Incentive Plan that subsequently were canceled, terminated unearned, expired, were forfeited, lapsed for any reason or were settled in cash without the delivery of shares. As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D0886DA1D655A85ACDCD91D659042CA"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-2EF1C0DFA0D65408A6BD3E9996D416DD-2" continuedAt="TextSelection-2EF1C0DFA0D65408A6BD3E9996D416DD-3"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e332-wk-Fact-43F67A890AB556A081B4D336712D33D9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="FI2018Q3" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">3,408,995</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares remained for future issuance under the 2017 Incentive Plan. The 2017 Incentive Plan will terminate on April&#160;3, 2027 unless it is extended or terminated earlier pursuant to its terms. In addition, from time to time, the Company makes inducement grants of stock options to new hires, which awards are made pursuant to the NASDAQ inducement grant exception. During the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company granted inducement stock options covering </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e344-wk-Fact-0AA6EE81DFB7511E88A8220D1FDC68A2" name="insm:ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross" contextRef="FD2018Q3YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">236,730</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock to new employees.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On May 15, 2018, the 2018 Employee Stock Purchase Plan (2018 ESPP) was approved by shareholders at the Company&#8217;s Annual Meeting of Shareholders. The Company has reserved the following for issuance under the 2018 ESPP: (i)&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e354-wk-Fact-C652ECC9EE0F331174069DE5B3C7AEF9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="I2018Q2May15_us-gaap_PlanNameAxis_insm_EmployeeStockPurchasePlan2018Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,000,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock,&#160;plus&#160;(ii)&#160;commencing on January&#160;1, 2019 and ending on December&#160;31, 2023, an additional number of shares to be added on the first day of each calendar year equal to the lesser of (A)&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e358-wk-Fact-DA79DFBA19DA36691F4F9DE96F1B5CCC" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="D2018Q2May15_us-gaap_PlanNameAxis_insm_EmployeeStockPurchasePlan2018Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,200,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock, (B)&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e362-wk-Fact-11FFF0C8601F2C8795AE9DEAF9DD1E07" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" contextRef="D2018Q2May15_us-gaap_PlanNameAxis_insm_EmployeeStockPurchasePlan2018Member" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">2</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the number of outstanding shares of common stock on such date and (C)&#160;an amount determined by the administrator.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock Options</span><span style="font-family:inherit;font-size:10pt;"> - The Company calculates the fair value of stock options granted using the Black-Scholes valuation model. <ix:nonNumeric contextRef="FD2018Q3YTD" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="TextSelection-82E23812858D573291FC4C45C019730C-0-wk-Fact-F43EB96BBBD25807848FD3680051A8A5" continuedAt="TextSelection-82E23812858D573291FC4C45C019730C-1" escape="true">The following table summarizes the Company&#8217;s grant date fair value and assumptions used in determining the fair value of all stock options granted during the periods presented:</ix:nonNumeric></span></div><ix:continuation id="TextSelection-82E23812858D573291FC4C45C019730C-1" continuedAt="TextSelection-82E23812858D573291FC4C45C019730C-2"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;font-size:10pt;"><ix:continuation id="TextSelection-82E23812858D573291FC4C45C019730C-2"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.484375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:45%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Volatility</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">66%-67%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">72%-73%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">66%-68%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">72%-74%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.75%-2.87%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.73%-1.93%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.25%-2.87%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.73%-1.99%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Dividend yield</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e566-wk-Fact-A51681E09A37514DB5F3143E09054C59" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">0.0</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e576-wk-Fact-A978281FB63F5536B5FB2B17A0798BA2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="FD2017Q3QTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">0.0</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e586-wk-Fact-4952654B434D5B49AE49D24DED8A0467" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">0.0</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e596-wk-Fact-BE7E067587525369B6F8A78876494803" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">0.0</ix:nonFraction>%</span></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected option term (in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d37594213e607-wk-Fact-894BC61A91315A358714DBBCF282A05D" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember" format="ixt-sec:duryear">5.14</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d37594213e617-wk-Fact-0CD3EDB8D1AE5F37A22E3162D002DF2E" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="FD2017Q3QTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember" format="ixt-sec:duryear">6.25</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d37594213e627-wk-Fact-68AC34C6106650A3B114F5808E96BC3C" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember" format="ixt-sec:duryear">5.09</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d37594213e637-wk-Fact-F13232A56BEC51BEB2F170F9F6C48500" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember" format="ixt-sec:duryear">6.25</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average fair value of stock options granted</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d37594213e648-wk-Fact-46153BC343CB50EE9DB33F8057CCB15B" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">13.62</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d37594213e658-wk-Fact-3FDE8523F97E5614A70FCC3C1EFC9172" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2017Q3QTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">9.59</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d37594213e668-wk-Fact-63F150AC5B5A5BA98787BFA14F2AC304" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">16.56</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d37594213e678-wk-Fact-9B6B3ACA56645783AA53CD95D7118F41" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">10.18</ix:nonFraction></span></span></div></td></tr></table></div></ix:continuation><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For each period presented, the volatility factor was based on the Company&#8217;s historical volatility during the expected option term.&#160;Estimated forfeitures are based on the actual percentage of option forfeitures since the closing of the Company&#8217;s merger with Transave in December&#160;2010. The expected option term for these grants was determined using the Company&#8217;s historical exercise behavior of grantees. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From time to time, the Company has granted performance-condition options to certain of its employees. Vesting of these options was subject to the Company achieving certain performance criteria established at the date of grant and the grantees fulfilling a service condition (continued employment). During the quarter ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, performance-condition options totaling </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d37594213e700-wk-Fact-A7FEB966C382A7D381FE9DE1D6B19337" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e704-wk-Fact-6A5AE218B37A5FDB8495617480F9751F" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">133,334</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares, met their recognition criteria as a result of the FDA approval of ARIKAYCE and vested in full. As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, there were </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e712-wk-Fact-E514305F6B4EF9D907DB827940438FBA" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="FI2018Q3_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> performance-condition options outstanding. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:nonNumeric contextRef="FD2018Q3YTD" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="TextSelection-4DD890629F1B5F9CBB54C688183D3964-0-wk-Fact-6AAFA28D2C795AAD803ADAD1B815D724" continuedAt="TextSelection-4DD890629F1B5F9CBB54C688183D3964-1" escape="true">The following table summarizes the Company&#8217;s aggregate stock option activity for the </ix:nonNumeric></span><ix:continuation id="TextSelection-4DD890629F1B5F9CBB54C688183D3964-1" continuedAt="TextSelection-4DD890629F1B5F9CBB54C688183D3964-2"><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">:&#160;</span></ix:continuation></div><div style="line-height:120%;font-size:10pt;"><ix:continuation id="TextSelection-4DD890629F1B5F9CBB54C688183D3964-2"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:45%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Number&#160;of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Life&#160;in&#160;Years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Intrinsic</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value&#160;(in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options outstanding at December&#160;31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e862-wk-Fact-D8E859F3971E543397E456351E5C50AE" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="FI2017Q4" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">8,608,921</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e881-wk-Fact-8F6D99238C1B50BB89E86204002ABAB4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="FI2017Q4" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">14.08</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e926-wk-Fact-A129EC8410355CF69573B15DB4E1A87E" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="FD2018Q3YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,610,010</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e945-wk-Fact-441D5DA3C6CE5901B9522915B3470157" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="FD2018Q3YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">28.57</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37594213e990-wk-Fact-96B457DEF18D52288580888A0FBBD3E7" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2018Q3YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">427,729</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e1010-wk-Fact-6F3A927911305166A10B5B827EE63C72" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="FD2018Q3YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">14.94</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited or expired</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37594213e1055-wk-Fact-61E6E5A89E67573C9422C86891D3EB25" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="FD2018Q3YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">182,858</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e1075-wk-Fact-E258850E24725DE39658D49473C86B33" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="FD2018Q3YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">19.15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options outstanding at September&#160;30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e1120-wk-Fact-88B35D2EB9B9581FA0289B7336391AE9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="FI2018Q3" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">9,608,344</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e1139-wk-Fact-3D55AF88E4D75F1380B89C916E2D86B6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="FI2018Q3" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">16.37</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d37594213e1153-wk-Fact-9F8F9253042D5F279A47F2D018553342" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="FD2018Q3YTD" format="ixt-sec:duryear">7.08</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e1169-wk-Fact-09606A8F8F7159B380FA395AD0CAF075" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">52,765</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested and expected to vest at September&#160;30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e1184-wk-Fact-79D57883AFFE53618D061D01BC4268B1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="FI2018Q3" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">8,760,828</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e1203-wk-Fact-C439DBE219F9518AB9122B8522525BB1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="FI2018Q3" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">15.90</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d37594213e1217-wk-Fact-C951238361FC5F47B3611DCEC5BD8A2D" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" contextRef="FD2018Q3YTD" format="ixt-sec:duryear">6.92</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e1233-wk-Fact-30F593F6E5815034ABE7966464349666" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">50,354</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercisable at September&#160;30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e1248-wk-Fact-6C0DDD925E03599D83BB6DD6724B4400" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="FI2018Q3" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">5,317,732</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e1267-wk-Fact-55C2C1C8DB795647908936C5F9A70699" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="FI2018Q3" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">13.23</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d37594213e1281-wk-Fact-38BB648AFF3956A7A5DF0ED6C7BF05BE" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="FD2018Q3YTD" format="ixt-sec:duryear">5.96</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e1297-wk-Fact-7F7F08004F6B518293B44139791CB772" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">38,723</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></ix:continuation><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The total intrinsic value of stock options exercised during the three months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d37594213e1320-wk-Fact-29D8296083F95575BC7D174DF7FD070D" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d37594213e1324-wk-Fact-9D47B37AF72C577093D242920E6ECA43" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="FD2017Q3QTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, and during the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d37594213e1341-wk-Fact-49B9117B8BE251C7B68428C64ABC080F" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d37594213e1345-wk-Fact-506544425EC05DB9BFD9A25845721727" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">13</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D0886DA1D655A85ACDCD91D659042CA"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-2EF1C0DFA0D65408A6BD3E9996D416DD-3" continuedAt="TextSelection-2EF1C0DFA0D65408A6BD3E9996D416DD-4"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, there was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d37594213e1359-wk-Fact-3FAE02F463F7514380A21436E302BDC8" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="FI2018Q3_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">34.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted average period of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d37594213e1363-wk-Fact-586730FA0C585667A1E3B42CCBC7DCA3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember" format="ixt-sec:duryear">2.5</ix:nonNumeric> years</span></span><span style="font-family:inherit;font-size:10pt;">. <ix:nonNumeric contextRef="FD2018Q3YTD" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" id="TextSelection-2926B02ECA945782B45A2187E6AB5160-0-wk-Fact-0020DD4F0D6E55CDBBCD0CBBAF477555" continuedAt="TextSelection-2926B02ECA945782B45A2187E6AB5160-1" escape="true">The following table summarizes the range of exercise prices and the number of stock options outstanding and exercisable as of </ix:nonNumeric></span><ix:continuation id="TextSelection-2926B02ECA945782B45A2187E6AB5160-1" continuedAt="TextSelection-2926B02ECA945782B45A2187E6AB5160-2"><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">:</span></ix:continuation></div><ix:continuation id="TextSelection-2926B02ECA945782B45A2187E6AB5160-2" continuedAt="TextSelection-2926B02ECA945782B45A2187E6AB5160-3"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></ix:continuation><div style="line-height:120%;text-align:center;font-size:10pt;"><ix:continuation id="TextSelection-2926B02ECA945782B45A2187E6AB5160-3"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.1328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td colspan="16" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Outstanding as of September&#160;30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercisable as of September&#160;30, 2018</span></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Range of Exercise Prices&#160;($)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of Options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average Remaining Contractual Term (in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average Exercise&#160;Price&#160;($)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of Options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average Exercise&#160;Price&#160;($)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e1652-wk-Fact-42F0833A9C135AFF9CE114E286F09D57" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range1Member" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">3.03</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e1671-wk-Fact-2F85D5919B7350EDA088FDD5795BED51" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range1Member" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">6.90</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e1685-wk-Fact-0D3232FE979A52D2B917D6A3F6F06DA4" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range1Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,087,941</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d37594213e1700-wk-Fact-4514043CCB4553F0A0F68E44844ABF30" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range1Member" format="ixt-sec:duryear">3.94</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e1715-wk-Fact-0BD9EFF14F555BB787FA1A1E2BBFE6B9" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range1Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">3.99</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e1729-wk-Fact-2358F84249AA57FCB336DE23F60D65F4" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range1Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,087,941</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e1748-wk-Fact-D5219E28BA8B54229604E884DC3B42D9" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range1Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">3.99</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e1764-wk-Fact-BFA67709AB6B5F7B8AA0DF97F7D73E93" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range2Member" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">6.96</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e1783-wk-Fact-4723C2395CF9519BA3B77381989B27BF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range2Member" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">10.85</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e1797-wk-Fact-87024A29AFFB5A3D992552E54FD5540F" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range2Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">997,221</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d37594213e1812-wk-Fact-86920ED302FE5006919C0E38ACD79B1F" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range2Member" format="ixt-sec:duryear">7.53</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e1827-wk-Fact-927C79A20C4E5966BC3A17D3C983EBB4" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range2Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">10.77</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e1841-wk-Fact-FF1C466DED965DA9A0994FA1DF724E50" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range2Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">481,574</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e1860-wk-Fact-91F3D9B3E488597F9273360395EDC246" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range2Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">10.68</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e1876-wk-Fact-3832DE4DE23A55A88F2C9E9BD375ADC9" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range3Member" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">11.14</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e1895-wk-Fact-3C0225188E495D3A97C517E87961B2A1" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range3Member" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">12.58</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e1909-wk-Fact-60825299B9A55E1A80A8A76D2CA86201" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range3Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">984,936</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d37594213e1924-wk-Fact-8FCFE7374A0E546A9CD6AAF8ACDF1EA9" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range3Member" format="ixt-sec:duryear">5.49</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e1939-wk-Fact-42960A9B1355533F98D1638C6577F1F8" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range3Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">12.17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e1953-wk-Fact-792BDAC79E3E5A2CBFDDA74822726253" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range3Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">893,989</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e1972-wk-Fact-C8CAE378BE70566881CDB4830EDBDFD0" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range3Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">12.20</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e1988-wk-Fact-FCB756A455D757B0B4B497087B2584AD" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range4Member" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">12.66</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e2007-wk-Fact-77952169A65E580AB56430F59BCF8912" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range4Member" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">13.67</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e2021-wk-Fact-3F6279C6D13451948DB9C314600001BD" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range4Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">984,161</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d37594213e2036-wk-Fact-A287DA45C39D5A1396EADC4DE3A959F6" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range4Member" format="ixt-sec:duryear">7.97</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e2051-wk-Fact-25D051DFDED6527BB08AAC7F666F0358" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range4Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">13.60</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e2065-wk-Fact-5770A88F8D8A5CB7B3865EC5F662B787" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range4Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">428,577</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e2084-wk-Fact-9EA65CC85F905BBFA85AF5B9FE98A965" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range4Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">13.56</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e2100-wk-Fact-CEE2760183C15C93825CFBCF130B8707" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range5Member" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">13.94</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e2119-wk-Fact-705519525ACD531F912AB893CEF6C9C2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range5Member" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">16.07</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e2133-wk-Fact-DCF33F34A963589A8DD047BD9785E165" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range5Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,139,533</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d37594213e2148-wk-Fact-02420044A741557EB61883EAEDAE9333" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range5Member" format="ixt-sec:duryear">6.80</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e2163-wk-Fact-43DA51A416E452DFBAF219FFCCB99FB0" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range5Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">15.26</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e2177-wk-Fact-1FEEA0935B5B579CBBC52B8E17B799B7" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range5Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">765,384</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e2196-wk-Fact-A77BA5E57F6D583D95769E6A0A604059" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range5Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">15.17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e2212-wk-Fact-D7F0D2BA6B19522EA8EEE81C27E8B91F" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range6Member" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">16.09</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e2231-wk-Fact-59F0CAA976BA505DB52756FF57D78275" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range6Member" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">17.16</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e2245-wk-Fact-31FCD1AE49975DFCBB85EE599E2614F0" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range6Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,438,502</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d37594213e2260-wk-Fact-C177B417566A5BB68A391827BB893CB4" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range6Member" format="ixt-sec:duryear">7.95</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e2275-wk-Fact-925669E147B658799229DE9855ABEA1C" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range6Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">16.69</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e2289-wk-Fact-E9C5A168271553B1819040AAC91C935A" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range6Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">602,949</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e2308-wk-Fact-17B081C609B450EDB3E56D17C4DCACA6" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range6Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">16.48</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e2324-wk-Fact-794CBC6A90CA5AC68DAB47FC46C61E1B" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range7Member" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">17.24</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e2343-wk-Fact-38F3841EFD0D5E2A86B4FD8B8D5A8E77" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range7Member" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">22.76</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e2357-wk-Fact-FAFBD7B15896546F974481ABF750FCF0" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range7Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,366,680</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d37594213e2372-wk-Fact-37AAA64834995FF697D2FFAEB21FBF56" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range7Member" format="ixt-sec:duryear">6.56</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e2387-wk-Fact-B7F591D387295CF881CFE2B3D2E2606C" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range7Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">21.20</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e2401-wk-Fact-82EEF6FE87965A0EA64EC43CAC56AF81" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range7Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,017,263</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e2420-wk-Fact-8BCD7C8FD178522F825FAB14925452D8" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range7Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">21.26</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e2436-wk-Fact-7F6E966710975039ACEF9EC9D90D56F7" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range8Member" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">22.84</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e2455-wk-Fact-44745C6633AE5AF7AEE9DD7A4363757D" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range8Member" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">30.46</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e2469-wk-Fact-388D9F32407558C6B28F707C7BACA536" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range8Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,439,910</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d37594213e2484-wk-Fact-BC7F45FB56B8521FA4658F30232D37A5" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range8Member" format="ixt-sec:duryear">9.21</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e2499-wk-Fact-C57844E9F03A5C0F91352AB308A01199" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range8Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">28.61</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e2513-wk-Fact-CC36D05104F954D9A9C86D941860F0A8" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range8Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">40,055</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e2532-wk-Fact-BC9DEDACEA2F577BB06F9D0174DB06CF" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range8Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">24.26</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e2548-wk-Fact-3F03C016F96255E5AF14D83D2072A2CC" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range9Member" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">30.86</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e2567-wk-Fact-91D5DDC70794516F970800CB3776A50B" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range9Member" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">31.78</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e2581-wk-Fact-D041F8F63205579BBC5F459D0F7F7EA0" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range9Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">155,960</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d37594213e2596-wk-Fact-6B70E334A75F57D889717D232BB2FCFE" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range9Member" format="ixt-sec:duryear">9.25</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e2611-wk-Fact-2CB1EC1CB60959B0A54829501506F1BD" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range9Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">31.10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e2625-wk-Fact-6A68AA239916587BAE69181D272404A4" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range9Member" unitRef="shares" decimals="INF" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e2644-wk-Fact-7F7EF982A42F5DCA8C2F660E9C827BD0" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range9Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e2661-wk-Fact-23BA4CACD2B7525EA61CC3834C985D03" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range10Member" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">32.46</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e2680-wk-Fact-22532F065516570285097C8E8853E960" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range10Member" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">32.46</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e2694-wk-Fact-5A93E822189C548EA1B78320F86A646F" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range10Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">13,500</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d37594213e2709-wk-Fact-13BFDF3B61955C7CBB326ECE53779A00" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range10Member" format="ixt-sec:duryear">9.26</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e2724-wk-Fact-43259AD1C5255AEA8DC4FCFFBCEB7221" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range10Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">32.46</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e2738-wk-Fact-61EFFACCB01951348D46752E28C2FCE2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range10Member" unitRef="shares" decimals="INF" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e2757-wk-Fact-8C8C6B7F10C25B00B9D0AA6FA2948794" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range10Member" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></ix:continuation><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Stock and Restricted Stock Units</span><span style="font-family:inherit;font-size:10pt;"> &#8212; Under the 2017 Incentive Plan, the Company may grant restricted stock (RS) and RSUs to eligible participants, including its executives, non-employee directors, and other service providers. Each share of RS vests, and each RSU represents a right to receive </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e2774-wk-Fact-1715F306546C5CB08627E11D83122A50" name="insm:NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit" contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_insm_RestrictedStockAndRestrictedStockUnitsMember" unitRef="shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> share of the Company&#8217;s common stock, upon the completion of a specific period of continued service or achievement of a certain milestone. RS and RSU awards are valued at the market price of the Company&#8217;s common stock on the date of grant. The Company recognizes noncash compensation expense for the fair values of these RS and RSU awards on a straight-line basis over the requisite service period of these awards. As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, there was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d37594213e2782-wk-Fact-67751CBFB6035D91B46F8ABEA0BA0066" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="FI2018Q3_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of unrecognized compensation expense related to unvested RSU awards which is expected to be recognized over a weighted average period of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d37594213e2786-wk-Fact-183CDC7022B45960B929D68177A36A42" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear">2.8</ix:nonNumeric> years</span></span><span style="font-family:inherit;font-size:10pt;">. <ix:nonNumeric contextRef="FD2018Q3YTD" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="TextSelection-54CAD63D01C251BE870E2341B6E8859B-0-wk-Fact-5C463E62A40951A58A64A179E7928773" continuedAt="TextSelection-54CAD63D01C251BE870E2341B6E8859B-1" escape="true">The following table summarizes the Company&#8217;s RSU award activity during the </ix:nonNumeric></span><ix:continuation id="TextSelection-54CAD63D01C251BE870E2341B6E8859B-1" continuedAt="TextSelection-54CAD63D01C251BE870E2341B6E8859B-2"><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">:</span></ix:continuation></div><ix:continuation id="TextSelection-54CAD63D01C251BE870E2341B6E8859B-2" continuedAt="TextSelection-54CAD63D01C251BE870E2341B6E8859B-3"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></ix:continuation><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><ix:continuation id="TextSelection-54CAD63D01C251BE870E2341B6E8859B-3"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.96875%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:67%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Number&#160;of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">RSUs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Grant&#160;Price&#160;($)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at December&#160;31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e2873-wk-Fact-157E1A5783C15A05A3E1C33AF8946F14" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">46,914</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e2892-wk-Fact-7BDBE861F98B5FE1975A6B381588EF8E" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">17.16</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e2907-wk-Fact-E47C68E50C705699950452445FB00E94" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">248,468</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e2926-wk-Fact-40FF1FDCD63956F99537A1FE49A0C85C" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">29.41</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Released</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37594213e2941-wk-Fact-01CB6EFAC9BD55DF98C822C1D6DFFF02" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">47,478</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e2961-wk-Fact-E12EAB76A83B5712BA586877F0736CA1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">17.32</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d37594213e2976-wk-Fact-B6B378A04B105962B219E298CA8A8E69" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">3,103</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e2996-wk-Fact-02222A22BEFA5EBA964F0993F4BA8D17" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">30.46</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at September&#160;30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e3011-wk-Fact-013DAB26E52050D4851CBD309A10786B" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2018Q3_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">244,801</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e3030-wk-Fact-A65C71FB9C5D59CD967D216E99BEAB63" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="FI2018Q3_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">29.40</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></ix:continuation><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:nonNumeric contextRef="FD2018Q3YTD" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="TextSelection-94E34DAAC8A25936A53343267BC252B2-0-wk-Fact-0EBDA34B2CCA554E8CC9B05187720583" continuedAt="TextSelection-94E34DAAC8A25936A53343267BC252B2-1" escape="true">The following table summarizes the aggregate stock-based compensation expense recorded in the consolidated statements of comprehensive loss related to stock options and RSUs during the three and </ix:nonNumeric></span><ix:continuation id="TextSelection-94E34DAAC8A25936A53343267BC252B2-1" continuedAt="TextSelection-94E34DAAC8A25936A53343267BC252B2-2"><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively:</span></ix:continuation></div><ix:continuation id="TextSelection-94E34DAAC8A25936A53343267BC252B2-2" continuedAt="TextSelection-94E34DAAC8A25936A53343267BC252B2-3"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></ix:continuation></ix:continuation><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><ix:continuation id="TextSelection-94E34DAAC8A25936A53343267BC252B2-3"><ix:continuation id="TextSelection-2EF1C0DFA0D65408A6BD3E9996D416DD-4"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in&#160;millions)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e3343-wk-Fact-EE4A3076DD1658B3A107CEE4ECE6E777" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e3362-wk-Fact-D3D216BE593C57BAAC3F074105E07550" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2017Q3QTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e3381-wk-Fact-E9BDE0B5AD37547790E5745C4615F946" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e3401-wk-Fact-E275ED6C602C5AF5BC351BDDD678BC02" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e3416-wk-Fact-A676DCC6D466585DB18F2870A73D44F5" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e3435-wk-Fact-3344763DAE7D5AD1A62D50AB11882519" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2017Q3QTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e3454-wk-Fact-70033FE6959A5A039AB17C9A6EA1461A" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e3474-wk-Fact-FC3E12C8099553BB8B4EAF22982F77F0" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e3499-wk-Fact-0EE854EF16B559C9860D082C60393614" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e3518-wk-Fact-FE61A3350D3752FEAE4F69B0F37DA6D3" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2017Q3QTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e3537-wk-Fact-53BD971A06C55BF6934E3B46D290C361" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">20.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594213e3557-wk-Fact-5C0FC6E616FD570FAF4A461BA561F613" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></ix:continuation></ix:continuation><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div><a id="s8C2D04AC1C18513AAE922731754141B7"></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">8.</span><span style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;"> </span><ix:nonNumeric contextRef="FD2018Q3YTD" name="us-gaap:IncomeTaxDisclosureTextBlock" id="TextSelection-2EC5356E60FB571088C30BCF246BE7CD-0-wk-Fact-CEFE1E6685D45CD79BEC0773F9272749" continuedAt="TextSelection-2EC5356E60FB571088C30BCF246BE7CD-1" escape="true"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</span></ix:nonNumeric></div><ix:continuation id="TextSelection-2EC5356E60FB571088C30BCF246BE7CD-1" continuedAt="TextSelection-2EC5356E60FB571088C30BCF246BE7CD-2"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">14</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D0886DA1D655A85ACDCD91D659042CA"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-2EC5356E60FB571088C30BCF246BE7CD-2" continuedAt="TextSelection-2EC5356E60FB571088C30BCF246BE7CD-3"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s provision for income taxes was $</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594215e323-wk-Fact-69971A3E7D3F57BAAF3705F5AD80D4F4" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">46,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and $</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594215e327-wk-Fact-C45D6E334FD15D42A9DA0E8FAE4EA341" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">134,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, respectively, and $</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594215e339-wk-Fact-35D2D40AA43F5C9D9B5934F32E20F1BA" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">27,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and $</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594215e344-wk-Fact-1FD78E5302455C94BB9DC295F0C61BE6" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">94,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;">, respectively. The provision for income taxes in all periods was a result of certain of the Company&#8217;s subsidiaries in Europe, which had taxable income during the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">. In jurisdictions where the Company has net losses, there was a full valuation allowance recorded against the Company&#8217;s deferred tax assets and therefore </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594215e369-wk-Fact-0FA583432F045200A5AC06F484429E63" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="FD2018Q3YTD" unitRef="usd" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> tax benefit was recorded. </span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Following adoption of the Tax Cuts and Jobs Act during the fourth quarter of 2017, the Company remeasured certain deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future, which is generally 21%. The Company recorded a provisional amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d37594215e378-wk-Fact-E918824083575108A1A82ED71883C41D" name="insm:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" contextRef="FI2017Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">94.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> as of December 31, 2017 related to the re-measurement of certain deferred tax balances, which was completely offset by a full valuation allowance. Upon further analyses, the Company determined in the second quarter of 2018 that the provisional amount would not need to be adjusted.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to local taxes in foreign jurisdictions, the Company is subject to US federal, US state, and US tax on foreign earnings.&#160;In regard to the US tax on foreign earnings, the Company was subject to a one-time transition tax based on its total earnings and profits, which were generally deferred from US income taxes under previous US law.&#160;Due to the aggregate loss position of the Company's foreign subsidiaries, the Company did not record any provisional amount for the one-time transition tax liability at December 31, 2017.&#160;Additionally, the global intangible low-taxed income tax and base erosion provisions in the Tax Cuts and Jobs Act are effective for taxable years beginning after December 31, 2017. The Company does not currently expect these provisions to have a material impact (i) due to the aggregate loss position of its foreign subsidiaries and (ii) because the Company currently expects to be below the gross receipts threshold for purposes of the base erosion provisions. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;text-indent:48px;font-size:10pt;"><ix:continuation id="TextSelection-2EC5356E60FB571088C30BCF246BE7CD-3" continuedAt="TextSelection-2EC5356E60FB571088C30BCF246BE7CD-4"><span style="font-family:inherit;font-size:10pt;">The Company is subject to US federal and state income taxes and the statute of limitations for tax audit is open for the Company's federal tax returns for the years ended 2014 and later, and is generally open for certain states for the years 2013 and later. The Company has incurred net operating losses since inception, except for the year ended December&#160;31, 2009. Such loss carryforwards would be subject to audit in any tax year in which those losses are utilized, notwithstanding the year of origin. As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</span><span style="font-family:inherit;font-size:10pt;">, the Company had recorded </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594215e400-wk-Fact-9265F0928DA955D8907D6E0B3C8A7CA7" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" contextRef="FI2018Q3" unitRef="usd" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-2EC5356E60FB571088C30BCF246BE7CD-4"> reserves for unrecognized income tax benefits, nor had it recorded any accrued interest or penalties related to uncertain tax positions. The Company does not anticipate any material changes in the amount of unrecognized tax positions over the next 12 months.</ix:continuation></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div><a id="s597B08A03FED5418A7CD53755AA3F23F"></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">9.</span><span style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;"> </span><ix:nonNumeric contextRef="FD2018Q3YTD" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="TextSelection-66D61AD7349A586D81984FB8AF590692-0-wk-Fact-B61D104013855BF4A3AC0DF4EFD433F2" continuedAt="TextSelection-66D61AD7349A586D81984FB8AF590692-1" escape="true"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Commitments and Contingencies</span></ix:nonNumeric></div><ix:continuation id="TextSelection-66D61AD7349A586D81984FB8AF590692-1" continuedAt="TextSelection-66D61AD7349A586D81984FB8AF590692-2"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has an operating lease for office and laboratory space located in Bridgewater, NJ, its corporate headquarters, for which the initial lease term expires in November&#160;2019. Future minimum rental payments under this lease are </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d37594520e323-wk-Fact-7B1C43E099F250F596559BDF454E71BF" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" contextRef="FI2018Q3_us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_insm_BridgewaterNewJerseyFacilityMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. In July&#160;2016, the Company signed an operating lease for laboratory space located in Bridgewater, NJ for which the initial lease term expires in December&#160;2021. Future minimum rental payments under this lease are </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d37594520e327-wk-Fact-96E3BFADE2695C879F843B21D61CE3FF" name="insm:AdditionalLaboratorySpaceOperatingLeasesFutureMinimumPaymentsDue" contextRef="FI2018Q3_us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_insm_BridgewaterNewJerseyFacilityMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In September 2018, the Company entered into a lease agreement for office space in Bridgewater, NJ for its future corporate headquarters. The lease provides for a commencement date of the earlier of (1)&#160;September&#160;1, 2019, subject to completion of certain improvements by specified dates, and (2)&#160;the date on which the Company takes possession of the premises to commence its business operations therein (the Commencement Date).&#160;The initial lease term runs </span><span style="font-family:inherit;font-size:10pt;">130 months</span><span style="font-family:inherit;font-size:10pt;"> from the Commencement Date (plus any partial month from the Commencement Date until the first day of the next full calendar month during the term), and the Company has the option to extend that term for up to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594520e341-wk-Fact-7CB87852A83D8157DEB1834EFBEEAC1D" name="insm:LesseeOperatingLeaseNumberOfRenewals" contextRef="D2018Q3Sept2018_us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_insm_BridgewaterNewJerseyOfficeSpaceMember" unitRef="renewal" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> additional </span><span style="font-family:inherit;font-size:10pt;">five</span><span style="font-family:inherit;font-size:10pt;">-year periods. Future minimum rental payments under this lease are </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d37594520e349-wk-Fact-594B02D028E7E162C7B19DF1B02DA817" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" contextRef="FI2018Q3_us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_insm_BridgewaterNewJerseyOfficeSpaceMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">32.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Rent expense charged to operations was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d37594520e359-wk-Fact-538AC9A04BD65180816DE21476FFB01D" name="us-gaap:LeaseAndRentalExpense" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d37594520e363-wk-Fact-DCBDD01FF9515C578561B47F5B8E5CB4" name="us-gaap:LeaseAndRentalExpense" contextRef="FD2017Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for the three months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively, and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d37594520e375-wk-Fact-A800BBBCE61E52CA8D88A0E0028DF35D" name="us-gaap:LeaseAndRentalExpense" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d37594520e380-wk-Fact-A90FB18502E1505988609E848F60280F" name="us-gaap:LeaseAndRentalExpense" contextRef="FD2017Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively. <ix:nonNumeric contextRef="FD2018Q3YTD" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" id="TextSelection-7BC686E6921E5CBC96A734742B382900-0-wk-Fact-15B5A4EE0B0E5DF8ABEF402832AA41EA" continuedAt="TextSelection-7BC686E6921E5CBC96A734742B382900-1" escape="true">Future minimum rental payments required under the Company&#8217;s leases for the period from October 1, 2018 to </ix:nonNumeric></span><ix:continuation id="TextSelection-7BC686E6921E5CBC96A734742B382900-1" continuedAt="TextSelection-7BC686E6921E5CBC96A734742B382900-2"><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and for each of the five years thereafter are as follows (in thousands):</span></ix:continuation></div><ix:continuation id="TextSelection-7BC686E6921E5CBC96A734742B382900-2" continuedAt="TextSelection-7BC686E6921E5CBC96A734742B382900-3"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">15</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D0886DA1D655A85ACDCD91D659042CA"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-66D61AD7349A586D81984FB8AF590692-2" continuedAt="TextSelection-66D61AD7349A586D81984FB8AF590692-3"><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><ix:continuation id="TextSelection-7BC686E6921E5CBC96A734742B382900-3"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.96875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:84%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ending December&#160;31:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018 (remaining)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594520e450-wk-Fact-B370F1D8989556EE88501F6713A77F21" name="us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">490</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594520e465-wk-Fact-A347ECA5EA0D5AC4BAEEB8F9D2A05D05" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,863</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594520e485-wk-Fact-6780772832E85EB187A96CBB4987BDC0" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,185</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594520e505-wk-Fact-49D60C0EB18C5FF9B1B35C59F0913678" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,958</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594520e525-wk-Fact-A0D28E1B01BD5BB7824152F7C4816377" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,281</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594520e545-wk-Fact-A643D0D35E1250EDA5ECB3856A61D83C" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23,261</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d37594520e570-wk-Fact-719C3F077501527EBC95E4493774863F" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">37,038</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></ix:continuation><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Legal Proceedings</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></ix:continuation><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-66D61AD7349A586D81984FB8AF590692-3">From time to time, the Company is a party to various lawsuits, claims and other legal proceedings that arise in the ordinary course of business. While the outcomes of these matters are uncertain, management does not expect that the ultimate costs to resolve these matters will have a material adverse effect on the Company&#8217;s consolidated financial position, results of operations or cash flows.</ix:continuation></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sF453A4FEE38C516AA3FCC4DC08499590"></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 2.&#160; MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cautionary Note Regarding Forward Looking Statements</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">This Quarterly Report on Form&#160;10-Q contains forward-looking statements that involve substantial risks and uncertainties. "Forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995, are statements that are not historical facts and involve a number of risks and uncertainties. Words herein such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," "intends," "potential," "continues," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) identify forward-looking statements.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Forward-looking statements are based on our current expectations and beliefs, and involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance and achievements and the timing of certain events to differ materially from the results, performance, achievements or timing discussed, projected, anticipated or indicated in any forward-looking statements. Such risks, uncertainties and other factors include, among others, the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">failure to successfully commercialize or maintain US approval for ARIKAYCE, our only approved product;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">uncertainties in the degree of market acceptance of ARIKAYCE by physicians, patients, third-party payers and others in the health-care community;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">our inability to obtain full approval of ARIKAYCE from the US Food and Drug Administration (FDA), including the risk that we will not successfully complete the confirmatory post-marketing study required for full approval;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">inability of us, PARI Pharma GmbH (PARI) or our third party manufacturers to comply with regulatory requirements related to ARIKAYCE or the Lamira Nebulizer System;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">our inability to obtain adequate reimbursement from government or third-party payers for ARIKAYCE or acceptable prices for ARIKAYCE;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">development of unexpected safety or efficacy concerns related to ARIKAYCE;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">inaccuracies in our estimates of the size of the potential markets for ARIKAYCE;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">our inability to create an effective direct sales and marketing infrastructure or to partner with third parties that offer such an infrastructure for distribution of ARIKAYCE;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">failure to obtain regulatory approval to expand ARIKAYCE&#8217;s indication to a broader patient population;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">failure to successfully conduct future clinical trials for ARIKAYCE and our product candidates, including due to our limited experience in conducting preclinical development activities and clinical trials necessary for regulatory approval and our inability to enroll or retain sufficient patients to complete the trials or generate data necessary for regulatory approval;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">risks that our clinical studies will be delayed or that serious side effects will be identified during drug development;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">failure to obtain regulatory approvals for ARIKAYCE outside the US or for our product candidates in the US, Europe, Japan or other markets;</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">16</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D0886DA1D655A85ACDCD91D659042CA"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">failure of third parties on which we are dependent to manufacture sufficient quantities of ARIKAYCE or our product candidates for commercial or clinical needs, to conduct our clinical trials, or to comply with our agreements or laws and regulations that impact our business;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">our inability to attract and retain key personnel or to effectively manage our growth; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">our inability to adapt to our highly competitive and changing environment;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">our inability to adequately protect our intellectual property rights or prevent disclosure of our trade secrets and other proprietary information and costs associated with litigation or other proceedings related to such matters;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">restrictions imposed on us by material license agreements, including our license agreements with PARI and AstraZeneca AB (AstraZeneca), and failure to comply with our obligations under such agreements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">the cost and potential reputational damage resulting from litigation to which we are or may become a party, including product liability claims;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">limited experience operating internationally;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">changes in laws and regulations applicable to our business and failure to comply with such laws and regulations; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">inability to repay our existing indebtedness and uncertainties with respect to our ability to access future capital.</span></div></td></tr></table><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Any forward-looking statement is based on information current as of the date of this Quarterly Report on Form 10-Q and speaks only as of the date on which such statement is made. Actual events or results may differ materially from the results, plans, intentions or expectations anticipated in these forward-looking statements as a result of a variety of factors, many of which are beyond our control. More information on factors that could cause actual results to differ materially from those anticipated is included from time to time in our reports filed with the Securities and Exchange Commission (SEC), including, but not limited to, those described in the sections titled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in this Quarterly Report on Form 10-Q and our Annual Report on Form&#160;10-K for the fiscal year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</span><span style="font-family:inherit;font-size:10pt;">. We disclaim any obligation, except as specifically required by law, and the rules&#160;of the SEC, to publicly update or revise any such statements to reflect any change in our expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following discussion should be read in conjunction with our consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report on&#160;Form&#160;10-Q and the consolidated financial statements and related notes thereto in our Annual Report on Form&#160;10-K for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div><a id="sBA914902D79F5BDC9EEDBB4EECBA000B"></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">OVERVIEW</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;We are a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Our first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), received accelerated approval in the United States (US) on September 28, 2018 for the treatment of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Mycobacterium avium</span><span style="font-family:inherit;font-size:10pt;"> complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Our clinical-stage pipeline includes INS1007 and INS1009. INS1007 is a novel oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1) with therapeutic potential in non-cystic fibrosis (non-CF) bronchiectasis and other inflammatory diseases. INS1009 is an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension (PAH).</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below summarizes the current status and anticipated milestones for ARIKAYCE and our product candidates INS1007 and INS1009.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">17</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D0886DA1D655A85ACDCD91D659042CA"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:20%;"></td><td style="width:1%;"></td><td style="width:39%;"></td><td style="width:1%;"></td><td style="width:39%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Principal Product/Product&#160;Candidate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Status</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Next&#160;Expected&#160;Milestones</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">ARIKAYCE for&#160;MAC lung&#160;disease</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8226;We are focused on having a successful commercial launch of ARIKAYCE in the US for appropriate patients. We began commercial shipments of ARIKAYCE in October 2018.</span></div><div style="text-align:left;padding-left:18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/>&#8226; In September 2018, the FDA granted accelerated approval of ARIKAYCE for the treatment of MAC lung disease as part of a combination antibacterial drug regimen for adult patients who have limited or no alternative treatment options.<br/><br/>&#8226; We announced interim data from the CONVERT study and the 312 extension study in January 2018, which we view as consistent with the six-month results of the CONVERT study. The data included interim long-term durability data for the CONVERT study and interim efficacy data for the 312 study. These studies are ongoing.<br/> <br/>&#8226; We announced top-line data for the CONVERT study in September 2017. The CONVERT study met its primary endpoint of culture conversion, which we defined as three consecutive negative monthly sputum cultures by month six with statistical and clinical significance, with 29% of patients in the ARIKAYCE plus current guideline-based therapy (GBT) arm achieving culture conversion, compared to 9% of patients in the GBT-only arm (p&lt;0.0001).</span></div><div style="text-align:left;padding-left:18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br/>&#8226;  The FDA has designated ARIKAYCE as an orphan drug and a qualified infectious disease product (QIDP) for nontuberculous mycobacterial (NTM) lung disease, and the European Commission has granted an orphan designation for ARIKAYCE for the treatment of NTM lung disease. <br/></span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8226; We intend to seek regulatory approvals for ARIKAYCE outside the US, such as in Europe and Japan, when sufficient data are available. If approved, we expect ARIKAYCE would be the first inhaled therapy specifically indicated for the treatment of MAC lung disease in Europe and Japan<br/><br/>&#8226; We intend to collaborate with the FDA on, and invest in, the post-approval confirmatory clinical trial required by the FDA to support full approval and lifecycle management programs.<br/> <br/>&#8226; If approved, we plan to commercialize ARIKAYCE in certain countries in Europe, Japan, and certain other countries.</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">INS1007 (oral reversible&#160;inhibitor of&#160;DPP1)&#160;for non-CF&#160;bronchiectasis and other rare diseases</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8226; We are enrolling patients in the WILLOW study, a global phase 2, randomized, double-blind, placebo-controlled, parallel-group, multi-center clinical study to assess the efficacy, safety and tolerability, and pharmacokinetics of INS1007 administered once daily for 24 weeks in subjects with non-CF bronchiectasis.</span></div><div style="text-align:left;padding-left:18px;text-indent:0px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;<br/>&#8226; We are currently assessing regulatory strategies which could expedite the development and regulatory reviews of INS1007 in the US and the European Union (EU).</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8226; We expect to continue to advance enrollment in the WILLOW clinical study of INS1007 during 2018.</span></div><div style="text-align:left;padding-left:18px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><div style="text-align:left;padding-left:18px;text-indent:-6px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8226; We are exploring the potential of INS1007 in various neutrophil-driven inflammatory conditions.</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">INS1009 (inhaled formulation of a treprostinil prodrug) for rare pulmonary disorders</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#8226; The results of our phase&#160;1 study of INS1009 were presented at the European Respiratory Society international congress in September 2016.</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;&#160;&#8226; We believe INS1009 may offer a differentiated product profile for rare pulmonary disorders, including PAH, and we are currently evaluating our options to advance its development including exploring its use as an inhaled dry powder formulation.</span></div><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our earlier-stage pipeline includes preclinical compounds that we are evaluating in multiple rare diseases of unmet medical need, including gram positive pulmonary infections and NTM lung disease. To complement our internal research and development, we actively evaluate in-licensing and acquisition opportunities for a broad range of rare diseases. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">18</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D0886DA1D655A85ACDCD91D659042CA"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Our Strategy</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our strategy focuses on the needs of patients with rare diseases. We are currently primarily focused on the US commercial launch of ARIKAYCE. We are not aware of any other approved inhaled therapies specifically indicated to treat MAC lung disease in North America, Europe, or Japan. We secured US regulatory approval of ARIKAYCE for the treatment of MAC lung disease in patients with limited or no alternative treatment options. We also believe that ARIKAYCE has the potential to treat a number of different bacterial infections. We are also advancing earlier-stage programs in other rare pulmonary disorders.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our current priorities are as follows:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Launching ARIKAYCE in the US for appropriate patients;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Establishing patient access and providing appropriate support for patients being prescribed ARIKAYCE;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Ensuring our product supply chain will support the commercialization and potential future lifecycle management programs of ARIKAYCE;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Designing and conducting the required confirmatory clinical trial to support full US approval of ARIKAYCE;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Developing the core value dossier to support the reimbursement for ARIKAYCE in the US, Europe and Japan;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Obtaining determinations of coverage and reimbursement in the US for ARIKAYCE from governmental and other third-party payers;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supporting further research and lifecycle management strategies for ARIKAYCE, including exploring the potential use of ARIKAYCE as part of a front-line, multi-drug regimen and as maintenance monotherapy to prevent recurrence (defined as true relapse or reinfection) of MAC lung disease;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Continuing expansion efforts in certain countries in Europe and Japan to prepare for regulatory filings for ARIKAYCE;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Enrolling patients in the WILLOW phase 2 study of INS1007 in non-CF bronchiectasis;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exploring INS1009 for use as an inhaled dry powder formulation and generating preclinical findings from our earlier-stage programs; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expanding our rare disease pipeline through corporate development.</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ARIKAYCE for Patients with MAC Lung Disease</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ARIKAYCE (amikacin liposome inhalation suspension) is our first approved product. ARIKAYCE received accelerated approval in the US on September 28, 2018 for the treatment of MAC lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Amikacin solution for parenteral administration is an established drug that has activity against a variety of NTM; however, its use is limited by the need to administer it intravenously and by toxicity to hearing, balance, and kidney function (Peloquin et al., 2004). Unlike amikacin solution for intravenous administration, our advanced liposome technology uses charge-neutral liposomes to deliver amikacin directly to the lungs where it is taken up by the lung macrophages where the MAC infection resides. This technology prolongs the release of amikacin in the lungs, while minimizing systemic exposure, thereby offering the potential for decreased systemic toxicities. ARIKAYCE&#8217;s ability to deliver high levels of amikacin directly to the lung distinguishes it from intravenous amikacin. ARIKAYCE is administered once-daily, using the Lamira Nebulizer System, an inhalation device developed and manufactured by PARI. Lamira is a portable nebulizer that enables aerosolization of liquid medications, including liposomal formulations such as ARIKAYCE, via a vibrating, perforated membrane.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The FDA has designated ARIKAYCE as an orphan drug and a QIDP for NTM lung disease. Orphan designated drugs are eligible for seven years of exclusivity for the orphan indication. QIDP designation features an additional five years of exclusivity for the designated indication. The FDA granted a total of 12 years exclusivity in the indication for which ARIKAYCE was approved.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Accelerated Approval</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">19</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D0886DA1D655A85ACDCD91D659042CA"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2018, we submitted a new drug application for ARIKAYCE to the FDA pursuant to Section 506(c) of the Federal Food Drug and Cosmetic Act and 21 C.F.R. Part 314 Subpart H (Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses) (Subpart H).  Accelerated approval under Subpart H allows drugs that (i) are being developed to treat a serious or life-threatening disease or condition and (ii) provide a meaningful therapeutic benefit over existing treatments to be approved substantially based on an intermediate endpoint or a surrogate endpoint that is reasonably likely to predict clinical benefit, rather than a clinical endpoint such as survival or irreversible morbidity. The FDA granted our request for a priority review and set a PDUFA action date of September 28, 2018. On August 7, 2018, the FDA advisory committee voted 12-2 in favor of the safety and effectiveness of ARIKAYCE for adults with MAC lung disease who have limited or no treatment options. The committee also voted in favor of the surrogate endpoint of sputum culture conversion used in the Phase 3 CONVERT study being reasonably likely to predict clinical benefit. In a separate vote, the committee voted against the safety and effectiveness of ARIKAYCE in the broadest population of adult patients with MAC lung disease. On September 28, 2018, the FDA granted approval for ARIKAYCE under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) for the treatment of MAC lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options and the accelerated approval pathway. LPAD, which was enacted as part of the 21st Century Cures Act, serves to advance the development of new antibacterial drugs to treat serious or life-threatening infections in limited populations of patients with unmet needs.&#160;As required for drugs approved under the LPAD pathway,&#160;labeling for ARIKAYCE includes certain statements to convey that the drug has been shown to be safe and effective only for use in a limited population. Approval under the LPAD pathway may be supported by a streamlined clinical development program.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a condition of accelerated approval, we must conduct a post-approval confirmatory clinical trial. The required confirmatory trial, which is currently under discussion with FDA, is proposed to be a randomized, double-blind, placebo-controlled clinical trial to assess and describe the clinical benefit of ARIKAYCE in patients with MAC lung disease. The trial will evaluate the effect of ARIKAYCE on a clinically meaningful endpoint, as compared to an appropriate control, in the intended patient population of patients with MAC lung disease. Pursuant to the timetable agreed upon with the FDA, the study protocol is scheduled to be finalized in 2019, with trial results to be reported by 2024. Continued approval of ARIKAYCE will be contingent upon verification and description of clinical benefit in this study.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Further Research and Lifecycle Management for ARIKAYCE</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Along with the post-approval confirmatory clinical study described above, we are currently exploring and supporting research and lifecycle management programs for ARIKAYCE beyond treatment of MAC lung disease as part of a combination antibacterial regimen for adult patients who have limited or no treatment options. Specifically, we are evaluating future study designs focusing on the MAC lung disease treatment pathway, including front-line treatment and monotherapy maintenance to prevent recurrence (defined as true relapse or reinfection) of MAC lung disease. </span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If the data from the CONVERT study are sufficient to support our marketing authorization applications (MAAs) in Europe and Japan and those regulatory bodies approve ARIKAYCE, lifecycle management studies could potentially enable us to reach more patients worldwide. In addition, we are evaluating the use of ARIKAYCE to treat infections caused by non-MAC NTM species, such as </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">M. abscessus</span><span style="font-family:inherit;font-size:10pt;">. These initiatives include investigator-initiated studies, which are clinical studies initiated and sponsored by physicians or research institutions with funding from us, and may also include new clinical studies sponsored by us. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Market Opportunity for ARIKAYCE in MAC Lung Disease in 2018</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NTM lung disease is associated with increased rates of morbidity and mortality, and MAC is the predominant pathogenic species in NTM lung disease in the US, Europe and Japan. The prevalence of NTM lung disease has increased over the past two decades, and we believe it is an emerging public health concern worldwide. Based on currently available information from external sources, including market research funded by us and third parties, and internal analyses and calculations, we estimate potential patient populations in the US, Japan and the EU5 (comprised of France, Germany, Italy, Spain and the United Kingdom) for 2018 as follows:</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">20</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D0886DA1D655A85ACDCD91D659042CA"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:80.6640625%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:19%;"></td><td style="width:9%;"></td><td style="width:24%;"></td><td style="width:24%;"></td><td style="width:24%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Potential Market</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated Number of Patients with Diagnosed NTM Lung Disease</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated Number of Patients Treated for MAC Lung Disease</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated Number of MAC lung disease Patients Refractory to Treatment**</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">75,000-105,000</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">40,000-50,000</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10,000-15,000</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Japan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">125,000-145,000</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">60,000-70,000</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">15,000-18,000</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">EU5</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">14,000</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4,400</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,400</span></div></td></tr></table></div></div><div style="line-height:120%;text-indent:48px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">** ARIKAYCE received accelerated approval for this population in the US in September 2018.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are not aware of any other approved inhaled therapies specifically indicated for NTM lung disease in North America, Europe or Japan. Current guideline-based approaches for NTM lung disease, including those from the American Thoracic Society and Infectious Diseases Society of America, involve multi-drug regimens not approved for the treatment of NTM lung disease and treatment that could last two years or more. Based on a burden of illness study that we conducted in the US with a major medical benefits provider, we previously concluded that patients with NTM lung disease are costly to healthcare plans, while a recent claims-based study in the US has shown that patients with NTM lung disease have higher resource utilization and costs than their age and gender-matched controls. Accordingly, we believe that a significant market opportunity for ARIKAYCE in NTM lung disease exists in the US and internationally.&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are currently exploring the MAC lung disease market opportunity for ARIKAYCE in Japan. The CONVERT study included a comprehensive pharmacokinetic sub-study in Japanese subjects in lieu of a separate local pharmacokinetic study in Japan, as agreed with the PDMA. If the data from the CONVERT study are sufficient to support our MAAs, we expect to submit regulatory filings in Europe and Japan. We established a Japanese subsidiary and, in 2018, began hiring local employees, including a general manager, to closely manage our regulatory and pre-commercial activities.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Product Pipeline</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">INS1007</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">INS1007 is a small molecule, oral, reversible inhibitor of DPP1, which we licensed from AstraZeneca in October 2016. DPP1 is an enzyme responsible for activating neutrophil serine proteases in neutrophils when they are formed in the bone marrow. Neutrophils are the most common type of white blood cell and play an essential role in pathogen destruction and inflammatory mediation. Neutrophils contain the neutrophil serine proteases (including neutrophil elastase, proteinase 3, and cathepsin G) that have been implicated in a variety of inflammatory diseases. In chronic inflammatory lung diseases, neutrophils accumulate in the airways and release active neutrophil serine proteases in excess that cause lung destruction and inflammation. INS1007 may decrease the damaging effects of inflammatory diseases, such as non-CF bronchiectasis, by inhibiting DPP1 and its activation of neutrophil serine proteases. Non-CF bronchiectasis is a progressive pulmonary disorder in which the bronchi become permanently dilated due to chronic inflammation and infection. Currently, there is no cure, and we are not aware of any FDA-approved therapies specifically indicated for non-CF bronchiectasis.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">The WILLOW Study</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The WILLOW study is a global phase 2, randomized, double-blind, placebo-controlled, parallel group, multi-center clinical study to assess the efficacy, safety and tolerability, and pharmacokinetics of&#160;INS1007 administered once daily for 24 weeks in subjects with non-CF bronchiectasis. We commenced enrollment in the WILLOW study in December 2017. In addition, we are exploring the potential of INS1007 in various neutrophil-driven inflammatory conditions.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">INS1009</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">INS1009 is an investigational sustained-release inhaled treprostinil prodrug formulation that has the potential to address certain of the current limitations of existing prostanoid therapies. We believe that INS1009 prolongs duration of effect and may provide PAH patients with greater consistency in pulmonary arterial pressure reduction over time. Current inhaled prostanoid therapies must be dosed four to nine times per day for the treatment of PAH. Reducing dose frequency has the potential to ease patient burden and improve compliance. Additionally, we believe that INS1009 may be associated with fewer side effects, including elevated heart rate, low blood pressure, and severity and/or frequency of cough, associated with high initial drug levels and local upper airway exposure when using current inhaled prostanoid therapies. We believe INS1009 may offer a differentiated product profile for rare pulmonary disorders, including PAH, and we are currently evaluating our options to advance its development, including exploring its use as an inhaled dry powder formulation.&#160;</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">21</span></div></div><hr style="page-break-after:always"></hr><div><a id="s7923451D36CD511E807B7A1B79E85C38"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D0886DA1D655A85ACDCD91D659042CA"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">KEY COMPONENTS OF OUR STATEMENT OF OPERATIONS</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Research and Development (R&amp;D) Expenses</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">R&amp;D expenses consist of salaries, benefits and other related costs, including stock-based compensation, for personnel serving in our research and development functions, including medical affairs. Expenses also include other internal operating expenses, the cost of manufacturing ARIKAYCE and our product candidates&#160;for clinical study, the cost of conducting clinical studies, and the cost of conducting preclinical and research activities. In addition, our R&amp;D expenses include payments to third parties for the license rights to products or components thereof in development prior to regulatory approval, such as the Lamira Nebulizer System and INS1007. Our expenses related to manufacturing ARIKAYCE and our product candidates&#160;for clinical studies and commercial inventory, if any, prior to regulatory approvals are primarily related to activities at contract manufacturing organizations (CMOs) that manufacture ARIKAYCE and our product candidates for our use, including purchases of active pharmaceutical ingredients. R&amp;D expenses also include spending to build-out the CMO facilities to support commercialization of ARIKAYCE in the US and potential future global production requirements. Our expenses related to clinical trials are primarily related to activities at CROs that conduct and manage clinical trials on our behalf.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Since 2011, we have focused our development activities principally on our proprietary, advanced liposomal technology designed specifically for inhaled therapies. Our development efforts since 2015 have principally related to the development of ARIKAYCE in NTM lung disease.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">General and Administrative Expenses</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative expenses consist primarily of salaries, benefits and other related costs, including stock-based compensation, for our non-employee directors and personnel serving in our executive, finance and accounting, legal and compliance, pre-commercial, corporate development, information technology, program management and human resource functions. General and administrative expenses also include professional fees for legal services and patent-related expenses, consulting services including for pre-commercial planning activities such as non-branded disease awareness, insurance, board of director fees, tax and accounting services.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Investment Income and Interest Expense</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Investment income consists of interest income earned on our cash and cash equivalents. Interest expense consists primarily of contractual interest expense, amortization of debt issuance costs and accretion of debt discount. Debt issuance costs are amortized, and the debt discount is accreted to interest expense using the effective interest rate method over the term of the debt. Unamortized debt issuance costs associated with extinguished debt are expensed in the period of the extinguishment.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div><a id="sFD61C25FC85A576D83F5B2C3368C9F61"></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">RESULTS OF OPERATIONS</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Comparison of the </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended September 30, 2018</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> and </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Loss</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss for the quarter ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;">$87.7 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">$1.14</span><span style="font-family:inherit;font-size:10pt;"> per share&#8212;basic and diluted, compared with a net loss of </span><span style="font-family:inherit;font-size:10pt;">$45.2 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">$0.69</span><span style="font-family:inherit;font-size:10pt;"> per share&#8212;basic and diluted, for the quarter ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;">. The </span><span style="font-family:inherit;font-size:10pt;">$42.6 million</span><span style="font-family:inherit;font-size:10pt;"> increase in our net loss for the quarter ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> as compared to the same period in </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> was primarily due to:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Increased R&amp;D expenses of </span><span style="font-family:inherit;font-size:10pt;">$12.9 million</span><span style="font-family:inherit;font-size:10pt;">, primarily resulting from an increase in external manufacturing expenses and higher compensation and related expenses due to an increase in headcount; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Increased general and administrative expenses of </span><span style="font-family:inherit;font-size:10pt;">$27.0 million</span><span style="font-family:inherit;font-size:10pt;">, resulting from higher compensation and related expenses due to an increase in headcount, and an increase in consulting fees relating to pre-commercial planning activities in preparation for the launch of ARIKAYCE.</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, there was a </span><span style="font-family:inherit;font-size:10pt;">$5.2 million</span><span style="font-family:inherit;font-size:10pt;"> increase in interest expense resulting from the issuance of </span><span style="font-family:inherit;font-size:10pt;">$450.0 million</span><span style="font-family:inherit;font-size:10pt;"> aggregate principal amount of 1.75% convertible senior notes due 2025 (the Convertible Notes) in January 2018.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">R&amp;D Expenses</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">22</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D0886DA1D655A85ACDCD91D659042CA"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">R&amp;D expenses for the quarters ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> were comprised of the following components (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.96875%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarters&#160;Ended&#160;September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Increase&#160;(decrease)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">External Expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Clinical development&#160;&amp; research</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8,047</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12,307</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(4,260</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(34.6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Manufacturing</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">13,130</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,884</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10,246</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">355.3</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Regulatory and quality assurance</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,969</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,370</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,599</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">116.7</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Subtotal&#8212;external expenses</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">24,146</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">16,561</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7,585</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">45.8</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Internal Expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Compensation and related expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12,863</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8,373</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4,490</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">53.6</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other internal operating expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,529</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,741</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">788</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">45.3</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Subtotal&#8212;internal expenses</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">15,392</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10,114</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5,278</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">52.2</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">39,538</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">26,675</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12,863</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">48.2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">R&amp;D expenses increased to </span><span style="font-family:inherit;font-size:10pt;">$39.5 million</span><span style="font-family:inherit;font-size:10pt;"> during the quarter ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> from </span><span style="font-family:inherit;font-size:10pt;">$26.7 million</span><span style="font-family:inherit;font-size:10pt;"> in the same period in </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">. The </span><span style="font-family:inherit;font-size:10pt;">$12.9 million</span><span style="font-family:inherit;font-size:10pt;"> increase was primarily due to an increase of </span><span style="font-family:inherit;font-size:10pt;">$10.2 million</span><span style="font-family:inherit;font-size:10pt;"> in external manufacturing expenses, specifically related to purchases of ARIKAYCE raw materials, CMO expenses related to ARIKAYCE commercial inventory production, and construction costs relating to the build-out of a third party CMO production facility. In addition, there was a </span><span style="font-family:inherit;font-size:10pt;">$4.5 million</span><span style="font-family:inherit;font-size:10pt;"> increase in compensation and related expenses due to an increase in headcount in the quarter ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> as compared to the prior year period.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">General and Administrative Expenses</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative expenses for the quarters ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> were comprised of the following (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.96875%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarters&#160;Ended&#160;September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Increase&#160;(decrease)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General&#160;&amp; administrative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">17,290</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9,355</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7,935</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">84.8</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pre-commercial expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">27,155</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8,053</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">19,102</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">237.2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total general&#160;&amp; administrative expenses</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">44,445</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">17,408</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">27,037</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">155.3</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative expenses increased to </span><span style="font-family:inherit;font-size:10pt;">$44.4 million</span><span style="font-family:inherit;font-size:10pt;"> during the quarter ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> from </span><span style="font-family:inherit;font-size:10pt;">$17.4 million</span><span style="font-family:inherit;font-size:10pt;"> in the same period in </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">. The </span><span style="font-family:inherit;font-size:10pt;">$27.0 million</span><span style="font-family:inherit;font-size:10pt;"> increase was primarily due to $11.7 million in higher compensation and related expenses due to an increase in headcount, including the hiring of our field force, and $13.2&#160;million in consulting fees relating to pre-commercial planning activities in preparation for the launch of ARIKAYCE, including non-branded disease awareness, patient support planning, field operations and other professional fees.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest Expense</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense was </span><span style="font-family:inherit;font-size:10pt;">$6.7 million</span><span style="font-family:inherit;font-size:10pt;"> for the quarter ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> as compared to </span><span style="font-family:inherit;font-size:10pt;">$1.5 million</span><span style="font-family:inherit;font-size:10pt;"> in the same period in </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">. The </span><span style="font-family:inherit;font-size:10pt;">$5.2 million</span><span style="font-family:inherit;font-size:10pt;"> increase in interest expense in the quarter ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> as compared to the prior year period relates to the&#160;issuance of </span><span style="font-family:inherit;font-size:10pt;">$450.0 million</span><span style="font-family:inherit;font-size:10pt;"> aggregate principal amount of the Convertible Notes in January 2018. The interest expense on the Convertible Notes is based on an effective interest rate of 7.6%.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Comparison of the </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September 30, 2018</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> and </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Loss</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss for the </span><span style="font-family:inherit;font-size:10pt;">nine months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;">$232.7 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">$3.03</span><span style="font-family:inherit;font-size:10pt;"> per share&#8212;basic and diluted, compared with a net loss of </span><span style="font-family:inherit;font-size:10pt;">$127.3 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">$2.01</span><span style="font-family:inherit;font-size:10pt;"> per share&#8212;basic and diluted, for the </span><span style="font-family:inherit;font-size:10pt;">nine months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">23</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D0886DA1D655A85ACDCD91D659042CA"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">. The </span><span style="font-family:inherit;font-size:10pt;">$105.4 million</span><span style="font-family:inherit;font-size:10pt;"> increase in our net loss for the quarter ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> as compared to the same period in </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> was primarily due to:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Increased R&amp;D expenses of </span><span style="font-family:inherit;font-size:10pt;">$29.6 million</span><span style="font-family:inherit;font-size:10pt;">, primarily resulting from an increase in external manufacturing expenses and higher compensation and related expenses due to an increase in headcount; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Increased general and administrative expenses of </span><span style="font-family:inherit;font-size:10pt;">$66.5 million</span><span style="font-family:inherit;font-size:10pt;">, resulting from higher compensation and related expenses due to an increase in headcount, and an increase in consulting fees relating to pre-commercial planning activities in the preparation for the launch of ARIKAYCE.</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, there was a </span><span style="font-family:inherit;font-size:10pt;">$14.3 million</span><span style="font-family:inherit;font-size:10pt;"> increase in interest expense resulting from the issuance of </span><span style="font-family:inherit;font-size:10pt;">$450.0 million</span><span style="font-family:inherit;font-size:10pt;"> aggregate principal amount of the Convertible Notes in January 2018.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">R&amp;D Expenses</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">R&amp;D expenses for the nine months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> were comprised of the following components (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.96875%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months&#160;Ended&#160;September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Increase&#160;(decrease)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">External Expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Clinical development&#160;&amp; research</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">22,785</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">30,627</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(7,842</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(25.6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Manufacturing</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">32,010</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10,490</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">21,520</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">205.1</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Regulatory and quality assurance</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8,128</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4,863</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,265</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">67.1</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Subtotal&#8212;external expenses</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">62,923</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">45,980</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">16,943</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">36.8</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Internal Expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Compensation and related expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">34,339</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">24,071</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10,268</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">42.7</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other internal operating expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8,096</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5,749</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,347</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">40.8</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Subtotal&#8212;internal expenses</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">42,435</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">29,820</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12,615</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">42.3</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">105,358</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">75,800</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">29,558</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">39.0</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">R&amp;D expenses increased to </span><span style="font-family:inherit;font-size:10pt;">$105.4 million</span><span style="font-family:inherit;font-size:10pt;"> during the </span><span style="font-family:inherit;font-size:10pt;">nine months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> from </span><span style="font-family:inherit;font-size:10pt;">$75.8 million</span><span style="font-family:inherit;font-size:10pt;"> in the same period in </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">. The </span><span style="font-family:inherit;font-size:10pt;">$29.6 million</span><span style="font-family:inherit;font-size:10pt;"> increase was primarily due to an increase of </span><span style="font-family:inherit;font-size:10pt;">$21.5 million</span><span style="font-family:inherit;font-size:10pt;"> in external manufacturing expenses, specifically related to purchases of ARIKAYCE raw materials, CMO expenses related to ARIKAYCE commercial inventory production, and construction costs relating to the build-out of a third party CMO production facility. In addition, there was a </span><span style="font-family:inherit;font-size:10pt;">$10.3 million</span><span style="font-family:inherit;font-size:10pt;"> increase in compensation and related expenses due to an increase in headcount in the </span><span style="font-family:inherit;font-size:10pt;">nine months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> as compared to the prior year period.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">General and Administrative Expenses</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative expenses for the </span><span style="font-family:inherit;font-size:10pt;">nine months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> were comprised of the following (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.96875%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended&#160;September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Increase&#160;(decrease)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General&#160;&amp; administrative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">44,264</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">27,364</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">16,900</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">61.8</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pre-commercial expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">69,994</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">20,403</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">49,591</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">243.1</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total general&#160;&amp; administrative expenses</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">114,258</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">47,767</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">66,491</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">139.2</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative expenses increased to </span><span style="font-family:inherit;font-size:10pt;">$114.3 million</span><span style="font-family:inherit;font-size:10pt;"> during the </span><span style="font-family:inherit;font-size:10pt;">nine months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> from </span><span style="font-family:inherit;font-size:10pt;">$47.8 million</span><span style="font-family:inherit;font-size:10pt;"> in the same period in </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">. The </span><span style="font-family:inherit;font-size:10pt;">$66.5 million</span><span style="font-family:inherit;font-size:10pt;"> increase was primarily due to $31.1 million in higher compensation and related expenses due to an increase in headcount, including the hiring of our field force, and $28.2&#160;million in consulting fees relating to pre-commercial planning activities in preparation for the launch of ARIKAYCE, including non-branded disease awareness, patient support planning, field operations and other professional fees. In addition, there was an </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">24</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D0886DA1D655A85ACDCD91D659042CA"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">increase of $4.3 million related to patient services software licenses and fees, and ongoing training costs for the field force hired in the first quarter of 2018.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest Expense</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense was </span><span style="font-family:inherit;font-size:10pt;">$18.8 million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">nine months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> as compared to </span><span style="font-family:inherit;font-size:10pt;">$4.5 million</span><span style="font-family:inherit;font-size:10pt;"> in the same period in </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">. The </span><span style="font-family:inherit;font-size:10pt;">$14.3 million</span><span style="font-family:inherit;font-size:10pt;"> increase in interest expense in the </span><span style="font-family:inherit;font-size:10pt;">nine months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> as compared to the prior year period relates to the&#160;issuance of </span><span style="font-family:inherit;font-size:10pt;">$450.0 million</span><span style="font-family:inherit;font-size:10pt;"> aggregate principal amount of Convertible Notes in January 2018. The interest expense on the Convertible Notes is based on an effective interest rate of 7.6%.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div><a id="sFC58820B1FE75874A30AAE92C98B97AE"></a></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Overview</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There is considerable time and cost associated with developing a potential pharmaceutical product to the point of regulatory approval and commercialization. To date, we have not generated material revenue from ARIKAYCE. We commenced commercial shipments of ARIKAYCE in October 2018, but we do not expect to generate material revenue in 2018. In recent years, we have funded our operations through public offerings of equity securities and debt financings. We expect to continue to incur operating losses both in our US and certain international entities, as we plan to fund research and development activities and commercial launch activities for ARIKAYCE.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2018, we completed an underwritten public offering of </span><span style="font-family:inherit;font-size:10pt;">$450.0 million</span><span style="font-family:inherit;font-size:10pt;"> aggregate principal amount of Convertible Notes, including the exercise in full of the underwriter's option to purchase additional Convertible Notes. Our net proceeds from the offering, after deducting underwriting discounts and commissions and other offering expenses of </span><span style="font-family:inherit;font-size:10pt;">$14.2 million</span><span style="font-family:inherit;font-size:10pt;">, were </span><span style="font-family:inherit;font-size:10pt;">$435.8 million</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In&#160;September&#160;2017, we completed an underwritten public offering of&#160;</span><span style="font-family:inherit;font-size:10pt;">14,123,150</span><span style="font-family:inherit;font-size:10pt;">&#160;shares of our common stock, which included the underwriter&#8217;s exercise in full of its over-allotment option of&#160;</span><span style="font-family:inherit;font-size:10pt;">1,842,150</span><span style="font-family:inherit;font-size:10pt;"> shares, at a price to the public of&#160;</span><span style="font-family:inherit;font-size:10pt;">$28.50</span><span style="font-family:inherit;font-size:10pt;">&#160;per share.&#160; Our net proceeds from the sale of the shares, after deducting underwriting discounts and offering expenses of&#160;</span><span style="font-family:inherit;font-size:10pt;">$24.8 million</span><span style="font-family:inherit;font-size:10pt;">, were </span><span style="font-family:inherit;font-size:10pt;">$377.7 million</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may need to raise additional capital to fund our operations, including commercialization of ARIKAYCE and future clinical trials related to ARIKAYCE, to develop INS1007 and INS1009, and to develop, acquire, in-license or co-promote other products that address orphan or rare diseases. We believe we currently have sufficient funds to meet our financial needs for at least the next 12&#160;months. We may opportunistically raise additional capital and may do so through equity or debt financing(s), strategic transactions or otherwise. We expect such additional funding, if any, would be used to continue to commercialize ARIKAYCE, to conduct further trials of ARIKAYCE, develop our product candidates, or to pursue the license or purchase of other technologies or products. During the remainder of 2018, we plan to support the commercial launch of ARIKAYCE in the US, to continue to fund further clinical development of ARIKAYCE and INS1007, and support efforts to obtain regulatory approvals for ARIKAYCE outside the US. Our cash requirements for the remainder of 2018 and for 2019 will be impacted by a number of factors, the most significant of which are expenses related to the commercialization efforts for ARIKAYCE, the CONVERT and 312 studies, and to a lesser extent, expenses related to INS1007 and future ARIKAYCE clinical trials. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash Flows</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, we had cash and cash equivalents of $</span><span style="font-family:inherit;font-size:10pt;">567.6 million</span><span style="font-family:inherit;font-size:10pt;">, as compared with $</span><span style="font-family:inherit;font-size:10pt;">381.2 million</span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</span><span style="font-family:inherit;font-size:10pt;">. The $</span><span style="font-family:inherit;font-size:10pt;">186.4 million</span><span style="font-family:inherit;font-size:10pt;"> increase was due primarily to the net cash proceeds from our issuance of Convertible Notes in January 2018, partially offset by cash used in operating activities and, to a lesser extent, cash used in investing activities. Our working capital was $</span><span style="font-family:inherit;font-size:10pt;">520.1 million</span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> as compared with $</span><span style="font-family:inherit;font-size:10pt;">344.8 million</span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash used in operating activities was $</span><span style="font-family:inherit;font-size:10pt;">188.4 million</span><span style="font-family:inherit;font-size:10pt;"> and $</span><span style="font-family:inherit;font-size:10pt;">111.4 million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively. The net cash used in operating activities during the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> was primarily for the pre-commercial, clinical and manufacturing activities related to ARIKAYCE, as well as general and administrative expenses. In addition, net cash used in operating activities during the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> included clinical trial expenses related to INS1007.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">25</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D0886DA1D655A85ACDCD91D659042CA"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash used in investing activities was $</span><span style="font-family:inherit;font-size:10pt;">10.1 million</span><span style="font-family:inherit;font-size:10pt;"> and $</span><span style="font-family:inherit;font-size:10pt;">1.3 million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively. The net cash used in investing activities in 2018 was primarily related to the purchase of fixed assets for our long-term production capacity build-out at one of our CMOs. The net cash used in investing activities in 2017 related to payments for the build-out of our lab facility in Bridgewater, New Jersey.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash provided by financing activities was $</span><span style="font-family:inherit;font-size:10pt;">384.9 million</span><span style="font-family:inherit;font-size:10pt;"> and $</span><span style="font-family:inherit;font-size:10pt;">380.7 million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively. Net cash provided by financing activities for the </span><span style="font-family:inherit;font-size:10pt;">nine months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> included net cash proceeds of </span><span style="font-family:inherit;font-size:10pt;">$435.8 million</span><span style="font-family:inherit;font-size:10pt;"> from our issuance of Convertible Notes in January 2018 and cash proceeds from stock option exercises, partially offset by the February 2018 pay-off of our outstanding debt to Hercules Capital (Hercules) in the amount of $55.0 million. Net cash provided by financing activities for the </span><span style="font-family:inherit;font-size:10pt;">nine months ended</span><span style="font-family:inherit;font-size:10pt;"> September 30, 2017 was primarily due to the issuance of 14.1 million shares of our common stock in September 2017, along with cash proceeds from stock option exercises. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual Obligations</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There were no material changes outside of the ordinary course of business in our contractual obligations during the </span><span style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2018</span><span style="font-family:inherit;font-size:10pt;"> from those disclosed in Item 7, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Liquidity and Capital Resources&#8212;Contractual Obligations&#8221; in our Annual Report on Form&#160;10-K for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</span><span style="font-family:inherit;font-size:10pt;">, except for the following:</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2018, we completed an underwritten public offering of $450.0 million aggregate principal amount of Convertible Notes pursuant to an indenture between the Company and Wells Fargo Bank, National Association, as trustee. Our net proceeds from the offering, after deducting underwriting discounts and commissions and other offering expenses of </span><span style="font-family:inherit;font-size:10pt;">$14.2 million</span><span style="font-family:inherit;font-size:10pt;">, were approximately </span><span style="font-family:inherit;font-size:10pt;">$435.8 million</span><span style="font-family:inherit;font-size:10pt;">. The Convertible Notes bear interest payable semiannually in arrears on January 15 and July 15 of each year, beginning on July 15, 2018. The Convertible Notes mature on January 15, 2025, unless earlier converted, redeemed, or repurchased. The Convertible Notes are convertible into common stock of the Company under certain circumstances described in the indenture. See </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 5 - Debt</span><span style="font-family:inherit;font-size:10pt;"> of our consolidated financial statements for more information. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2018, we used part of the net proceeds from the issuance of the Convertible Notes to pay off the outstanding debt owed to Hercules. The payments consisted of </span><span style="font-family:inherit;font-size:10pt;">$55.0 million</span><span style="font-family:inherit;font-size:10pt;"> for the principal amount and an additional </span><span style="font-family:inherit;font-size:10pt;">$3.2 million</span><span style="font-family:inherit;font-size:10pt;"> in back-end fees, outstanding interest, and prepayment penalties. As a result, we incurred a </span><span style="font-family:inherit;font-size:10pt;">$2.2 million</span><span style="font-family:inherit;font-size:10pt;"> loss on the extinguishment of debt in the quarter ended March 31, 2018.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In September 2018, we entered into an agreement (the Lease) with Exeter 700 Route 202/206, LLC to lease approximately 117,000 rentable square feet of office space located at 700 Route 202/206, Bridgewater, New Jersey for our future headquarters. Subject to certain conditions, we have the one-time option to expand the leased premises by up to 50,000 rentable square feet, exercisable prior to the fifth anniversary of the Commencement Date (as defined below). The Lease provides for a commencement date of the earlier of (1) September 1, 2019, subject to completion of certain improvements by specified dates, and (2) the date on which we take possession of the premises to commence its business operations therein (the Commencement Date). The initial Lease term runs 130 months from the Commencement Date (plus any partial month from the Commencement Date until the first day of the next full calendar month during the term) and we have the option to extend that term for up to three additional five-year periods. In addition, we are also responsible for operating expenses and taxes pursuant to the Lease. Future minimum payments under the Lease during the initial Lease Term are expected to approximate $</span><span style="font-family:inherit;font-size:10pt;">32.3 million</span><span style="font-family:inherit;font-size:10pt;">. The Lease contains customary default provisions, including those relating to payment defaults, performance defaults and events of bankruptcy.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Off-Balance Sheet Arrangements</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We do not have any off-balance sheet arrangements, other than operating leases, that have or are reasonably likely to have a current or future material effect on our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources. We do not have any interest in special purpose entities, structured finance entities or other variable interest entities.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s35FD2821858E5A428C596B96740F7C3B"></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CRITICAL ACCOUNTING POLICIES</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There have been no material changes to our critical accounting policies as disclosed in our Annual Report on Form&#160;10-K for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</span><span style="font-family:inherit;font-size:10pt;">. For the required interim disclosure updates related to our accounting policies, see </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 2 </span><span style="font-family:inherit;font-size:10pt;">to our consolidated financial statements &#8212; </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies</span><span style="font-family:inherit;font-size:10pt;"> in this Quarterly Report on Form&#160;10-Q.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">26</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D0886DA1D655A85ACDCD91D659042CA"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sF9A32EDDC41C547998DF3BDDB3720D65"></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 3.</span><span style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, our cash and cash equivalents were in cash accounts or were invested in US treasury bills and money market funds. Our investments in US treasury bills and money market funds are not insured by the federal government.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, we had $</span><span style="font-family:inherit;font-size:10pt;">450.0 million</span><span style="font-family:inherit;font-size:10pt;"> of Convertible Notes outstanding which bear interest at a coupon rate of </span><span style="font-family:inherit;font-size:10pt;">1.75%</span><span style="font-family:inherit;font-size:10pt;">. If a 10% change in interest rates had occurred on </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, it would not have had a material effect on the fair value of our debt as of that date, nor would it have had a material effect on our future earnings or cash flows.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The majority of our business is conducted in US dollars. However, we do conduct certain transactions in other currencies, including Euros, British Pounds, and Japanese Yen. Historically, fluctuations in foreign currency exchange rates have not materially affected our results of operations and during the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, our results of operations were not materially affected by fluctuations in foreign currency exchange rates.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div><a id="s8A3FB1CF1A855FF98E0433FF7F27EDDF"></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 4.</span><span style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CONTROLS AND PROCEDURES</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Evaluation of Disclosure Controls and Procedures</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our management, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">.&#160;The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Securities and Exchange Act of 1934, as amended (the Exchange Act), means controls and other procedures that are designed to provide reasonable assurance that information required to be disclosed by us in the periodic reports that we file or submit with the SEC is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules&#160;and forms, and to ensure that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.&#160;Based on that evaluation as of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures are effective at the reasonable assurance level.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Changes in Internal Control Over Financial Reporting</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There were no changes in our internal control over financial reporting (as defined in Rule&#160;13a-15(f)&#160;and 15d-15(f)&#160;under the Exchange Act) during the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div><a id="s6E000465425558DAB4685170933EA4F0"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART&#160;II. OTHER INFORMATION</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div><a id="sE864CC014B7D598086F04CFC80023E08"></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 1.</span><span style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">LEGAL PROCEEDINGS</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From time to time, we are party to various lawsuits, claims and other legal proceedings that arise in the ordinary course of our business. While the outcomes of these matters are uncertain, management does not expect that the ultimate costs to resolve these matters will have a material adverse effect on our consolidated financial position, results of operations or cash flows.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sC29E9ADDE37A501485A271960F960ECC"></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 1A.</span><span style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">RISK FACTORS</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Our business is subject to substantial risks and uncertainties. Any of the risks and uncertainties described below, either alone or taken together, could materially and adversely affect our business, financial condition, results of operations, prospects for growth, and the value of an investment in our common stock. In addition, these risks and uncertainties could cause actual results to differ materially from those expressed or implied by forward-looking statements contained in this Form 10-Q (please read the Cautionary Note Regarding Forward-Looking Statements appearing at the beginning of Management&#8217;s Discussion &amp; Analysis in this Form 10-Q). </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to the Commercialization and Continued Approval of ARIKAYCE</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our prospects are highly dependent on the success of our only approved product, ARIKAYCE, which was approved in the United States (US) under the LPAD and accelerated approval pathways. If we are unable to successfully commercialize or maintain approval for ARIKAYCE, our business, financial condition, results of operations and prospects and the value of </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">27</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D0886DA1D655A85ACDCD91D659042CA"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">our common stock will be materially adversely affected.</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our long-term viability and growth depend on the successful commercialization of ARIKAYCE, our only approved product, which has been approved in the US for the treatment of patients with MAC lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.  We have invested and continue to invest significant efforts and financial resources in the launch of ARIKAYCE, and our ability to generate revenue from ARIKAYCE will depend heavily on successfully commercializing and obtaining full regulatory approval for ARIKAYCE by conducting an appropriate confirmatory post-marketing study.  ARIKAYCE is our first commercial launch, and its successful commercialization and our receipt of full regulatory approval for ARIKAYCE in the US are subject to many risks.  </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The commercial success of ARIKAYCE will depend on the degree of market acceptance by physicians, patients, third-party payers and others in the health care community.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Despite receiving US Food and Drug Administration (FDA) approval of ARIKAYCE, the product may not gain market acceptance by physicians, patients, third-party payers or others in the health care community. ARIKAYCE was the first product approved via the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) pathway, and there is limited information on how this approval may impact market acceptance of the product. If ARIKAYCE does not achieve an adequate level of acceptance, it is likely that we will not generate material revenue or become profitable. The degree of market acceptance of ARIKAYCE, which we launched in the US early in the fourth quarter of 2018, is also dependent on a number of additional factors, including the following:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The willingness of the target patient population to use, and of physicians to prescribe, ARIKAYCE;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The efficacy and potential advantages of ARIKAYCE over alternative treatments;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The risk and safety profile of ARIKAYCE, including physician and patient concern regarding the boxed warning and other safety precautions resulting from its association with an increased risk of respiratory adverse reactions;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Relative convenience and ease of administration;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The ability of the patient to tolerate ARIKAYCE;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The pricing of ARIKAYCE;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The ability and willingness of the patient to pay out of pocket costs for ARIKAYCE, for example, co-payments;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sufficient third-party insurance coverage and reimbursement; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The strength of marketing and distribution support and timing of market introduction of competitive products and treatments; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Publicity concerning ARIKAYCE or any potential competitive products and treatments.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our efforts to educate physicians, patients, third-party payers and others in the health care community on the benefits of ARIKAYCE will require significant resources, which may be greater than those required to commercialize more established technologies and may never be successful.  </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We obtained regulatory approval of ARIKAYCE in the US through an accelerated approval process, and full approval will be contingent on successful completion of a confirmatory post-marketing study. Failure to obtain full approval or otherwise meet our post-marketing requirements and commitments would have a material adverse effect on our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The FDA approved ARIKAYCE under the LPAD and accelerated approval pathways, and full approval will be based on results from a post-approval confirmatory clinical trial. Accelerated approval allows drugs that (i) are being developed to treat a serious or life-threatening disease or condition and (ii) provide a meaningful therapeutic benefit over existing treatments to be approved substantially based on an intermediate endpoint or a surrogate endpoint that is reasonably likely to predict clinical benefit, rather than a clinical endpoint such as survival or irreversible morbidity. Accelerated approval of ARIKAYCE was supported by preliminary data from the Phase 3 CONVERT study, which evaluated the safety and efficacy of ARIKAYCE in adult patients with refractory MAC lung disease, using achievement of sputum culture conversion (defined as three consecutive negative monthly sputum cultures) by Month 6 as the primary endpoint. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The required confirmatory trial, which is currently under discussion with FDA, is proposed to be a randomized, double-blind, placebo-controlled clinical trial to assess and describe the clinical benefit of ARIKAYCE in patients with MAC lung disease. The trial will evaluate the effect of ARIKAYCE on a clinically meaningful endpoint, as compared to an appropriate control in the intended patient population of patients with MAC lung disease. Pursuant to the timetable agreed upon with the FDA, the study protocol is scheduled to be finalized in 2019, with trial results to be reported by 2024. There is little precedent for clinical development and regulatory expectations for agents to treat MAC lung disease. As a result, we may encounter challenges designing this trial, including developing and reaching agreement with FDA on the appropriate clinical endpoints. We may encounter substantial delays in enrolling and conducting the trial, and we may not be able to enroll and </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">28</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D0886DA1D655A85ACDCD91D659042CA"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">conduct the trial in a manner satisfactory to the FDA or within the time period required by the FDA. If the confirmatory trial is not successful, the FDA could, among other things, withdraw its approval of ARIKAYCE. Separate from the confirmatory trial, additional results from ongoing studies, including the CONVERT study and the 312 study, may not be consistent with the positive data generated from those trials to date, which may affect FDA&#8217;s benefit-risk analysis for the product. Additionally, ARIKAYCE is subject to post-marketing commitments consisting of implementation of a healthcare provider communication plan, conducting a drug utilization assessment, and conducting further studies to identify an optimal quality control in vitro drug release method. Failure to meet post-marketing commitments may raise additional regulatory challenges.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We remain subject to substantial, ongoing regulatory requirements in the US related to ARIKAYCE, and failure to comply with these requirements could lead to enforcement action or otherwise materially harm our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ARIKAYCE is subject to a variety of manufacturing, packaging, storage, labeling, advertising, promotion, and record-keeping requirements, including requirements to:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Conduct sales, marketing and promotion, scientific exchange, speaker programs, charitable donations and educational grant programs in compliance with federal and state laws; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Disclose clinical trial results on publicly available databases; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Monitor and report complaints, adverse events and instances of failure to meet product specifications; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Comply with current good manufacturing practices (cGMP) and certain quality systems requirements for device components. </span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Failure to comply with these ongoing regulatory obligations could have significant negative consequences, including:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Issuance of warning letters or untitled letters by FDA asserting that we are in violation of the law;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Imposition of injunctions or civil monetary penalties or pursuit by regulators of civil or criminal prosecutions and fines against us or our responsible officers;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Suspension or withdrawal of regulatory approval;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Suspension or termination of ongoing clinical trials or refusal by regulators to approve pending marketing applications or supplements to approved applications;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Seizure of products, required product recalls or refusal to allow us to enter into supply contracts, including government contracts, or to import or export products;&#160;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Suspension of, or imposition of restrictions on, our operations, including costly new manufacturing requirements with respect to ARIKAYCE; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Negative publicity, including communications issued by regulatory authorities, which could negatively impact the perception of us or ARIKAYCE by patients, physicians, third party payers or the health care community.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Any of these events could reduce market acceptance of ARIKAYCE, substantially reduce our revenue, increase the costs of operating our business, and cause us significant reputational damage.  If we ultimately receive approval for ARIKAYCE in other jurisdictions, we expect to be subject to similar ongoing regulatory oversight by the relevant foreign regulatory authorities.  </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are unable to obtain adequate reimbursement from government or third-party payers for ARIKAYCE or if we are unable to obtain acceptable prices for ARIKAYCE, our prospects for generating revenue and achieving profitability will be materially adversely affected.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our prospects for generating revenue and achieving profitability depend heavily upon the availability of adequate reimbursement for the use of ARIKAYCE from governmental and other third-party payers, both in the US and in other markets. We expect a substantial majority of ARIKAYCE revenue will come from Medicare reimbursement. Reimbursement by a third-party payer depends upon a number of factors, including the third-party payer&#8217;s determination that use of a product is:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A covered benefit under its health plan;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Safe, effective and medically necessary;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Appropriate for the specific patient;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost-effective; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Neither experimental nor investigational.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The addition of ARIKAYCE to the guidelines of the American Thoracic Society and Infection Diseases Society of America may also be a factor in this determination. Obtaining a determination of coverage and reimbursement for a product from each government or other third-party payer is a time-consuming and costly process that could require us to provide </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">29</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D0886DA1D655A85ACDCD91D659042CA"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">supporting scientific, clinical and cost-effectiveness data for the use of our products to each payer. We expect that, during the first six to twelve months that we commercialize ARIKAYCE, the payers will evaluate it for inclusion on formularies, during which time patients will need to rely primarily on the medical exception process to secure coverage. For sales after that time, we may not be able to provide data sufficient to gain a positive coverage and reimbursement determination or we might need to conduct post-marketing studies in order to demonstrate the cost-effectiveness of ARIKAYCE to such payers&#8217; satisfaction. Such studies might require us to commit a significant amount of management time and financial and other resources. Even when a payer determines that a product is eligible for reimbursement, the payer may impose coverage limitations that preclude payment for some uses that are approved by the FDA or non-US regulatory authorities. Subsequent approvals of competitive products could result in a detrimental change to the reimbursement of our products.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There is a significant focus in the US healthcare industry and elsewhere on drug prices and value, and public and private payers are taking increasingly aggressive steps to control their expenditures for pharmaceuticals by negotiating manufacturer discounts and placing restrictions on reimbursement, and patient access to, medications.  These pressures could negatively affect our business.  We expect changes in the Medicare program and state Medicaid programs, as well as managed care organizations and other third-party payers, to continue to put pressure on pharmaceutical product pricing. For instance, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) expanded Medicare outpatient prescription drug coverage for the elderly through Part D prescription drug plans sponsored by private entities and authorized such plans to use formularies where they can limit the number of drugs that will be covered in any therapeutic class. The plans generally negotiate significant price concessions as a condition of formulary placement. The MMA also introduced a new reimbursement methodology based on average sales prices for physician-administered drugs, which is generally believed to have resulted in lower Medicare reimbursement for physician-administered drugs. These cost reduction initiatives and other provisions of this legislation provide additional pressure to contain and reduce drug prices and could decrease the coverage and price that we receive for any approved products and could seriously harm our business. Although the MMA applies only to drug benefits for Medicare beneficiaries, private payers often follow Medicare coverage policy and payment limitations when setting their own reimbursement rates, and any reimbursement reduction resulting from the MMA may result in a similar reduction in payments from private payers. Additionally, the Patient Protection and Affordable Care Act (ACA) revised the definition of &#8220;average manufacturer price&#8221; for reporting purposes and increased the minimum percentage for Medicaid drug rebates to states, and has imposed a significant annual fee on companies that manufacture or import branded prescription drug products. We believe it is likely that the ACA, or any legislation enacted to amend or replace it, will continue the pressure on pharmaceutical pricing, especially under the Medicare program, and also may increase our regulatory burdens and operating costs. Such changes may have a significant impact on our ability to set a product price we believe is fair and may adversely affect our ability to generate revenue and achieve or maintain profitability. We expect further federal and state proposals and health care reforms to continue to be proposed by legislators and/or the US President, which could limit the prices that can be charged for the products we develop and may limit our commercial opportunity. In addition, in connection with various government programs, we are required to report certain pricing information to the government, and the failure to do so may subject us to penalties.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Moreover, in markets outside the US, including countries in the European Union (EU), Japan and Canada, pricing of pharmaceutical products is subject to governmental control. Evaluation criteria used by many EU government agencies for the purposes of pricing and reimbursement typically focus on a product&#8217;s degree of innovation and its ability to meet a clinical need unfulfilled by currently available therapies. The ACA created a similar entity, the Patient-Centered Outcomes Research Institute, designed to review the effectiveness of treatments and medications in federally-funded health care programs. An adverse result could lead to a treatment or product being removed from Medicare or Medicare coverage. The decisions of such governmental agencies could affect our ability to sell our products profitably.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have had discussions with third-party payers regarding our price for ARIKAYCE, but our pricing may meet resistance from them and the public generally. If we are unable to obtain adequate reimbursement of ARIKAYCE, the adoption of ARIKAYCE by physicians and patients may be limited. This, in turn, could affect our ability to successfully commercialize ARIKAYCE and adversely impact our business, financial condition, results of operations and prospects and the value of our common stock.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">ARIKAYCE could develop unexpected safety or efficacy concerns, which would likely have a material adverse effect on us.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ARIKAYCE was granted accelerated approval from the FDA based on Month 6 data from the CONVERT study.  In the US, ARIKAYCE will be used for longer periods of time by larger numbers of patients, and we and others (including regulatory agencies and private payers) will collect extensive information on the efficacy and safety of ARIKAYCE by monitoring its use in the marketplace. In addition, we will conduct a confirmatory trial to assess and describe the clinical benefit of ARIKAYCE in patients with MAC lung disease and may conduct additional trials in connection with lifecycle management programs for ARIKAYCE. New safety or efficacy data from both market surveillance and these clinical trials, which may not be consistent with existing safety and efficacy data from the CONVERT and 312 studies, may result in negative </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">30</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D0886DA1D655A85ACDCD91D659042CA"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">consequences including the following:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Modification to product labeling or promotional statements, such as additional boxed or other warnings or contraindications, or the issuance of additional &#8220;Dear Doctor Letters&#8221; or similar communications to healthcare professionals;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Required changes in the administration of ARIKAYCE;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Imposition of additional post-marketing surveillance, post-marketing clinical trial requirements, distribution restrictions or other risk management measures, such as a risk evaluation and mitigation strategy (REMS) or a REMS with elements to assure safe use (ETASU);</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Suspension or withdrawal of regulatory approval;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Suspension or termination of ongoing clinical trials or refusal by regulators to approve pending marketing applications or supplements to approved applications;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Suspension of, or imposition of restrictions on, our operations, including costly new manufacturing requirements with respect to ARIKAYCE; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Voluntary or mandatory product recalls or withdrawals from the market and costly product liability claims.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Any of these circumstances could reduce ARIKAYCE&#8217;s market acceptance and would be likely to materially adversely affect our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If estimates of the size of the potential markets for ARIKAYCE are overstated, our ability to earn revenue to support our business could be materially adversely affected.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have relied on currently available information from external sources, including market research funded by us and third parties, and internal analyses and calculations to estimate the potential market opportunities for MAC lung disease in 2018 in the US, where ARIKAYCE has obtained regulatory approval, as well as future jurisdiction in which we may seek approval, including the EU5 (comprised of France, Germany, Italy, Spain and the United Kingdom) and Japan. The externally sourced information used to develop these estimates has been obtained from sources we believe to be reliable, but we have not verified the data from such sources, and their accuracy and completeness cannot be assured. Similarly, our internal analyses and calculations are based upon management&#8217;s understanding and assessment of numerous inputs and market conditions, including, but not limited to, the projected increase in prevalence of MAC lung disease, Medicare patient population growth and ongoing population shifts to geographies with increased rates of MAC lung disease. These understandings and assessments necessarily require assumptions subject to significant judgment and may prove to be inaccurate. As a result, our estimates of the size of these potential markets for ARIKAYCE could prove to be overstated, perhaps materially. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, we are relying on third party data to identify the physicians who treat the majority of MAC lung disease patients in the US and to determine how to deploy our resources to market to those physicians; however, we may not be marketing to the appropriate physicians and may therefore be limiting our market opportunity. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may develop estimates with respect to market opportunities for product candidates in the future, and such estimates would be subject to similar risks. In addition, a potential market opportunity could be reduced if a regulator limits the proposed treatment population for one of our product candidates, similar to the limited population for which ARIKAYCE was approved.  In either circumstance, even if we obtain regulatory approval, we may be unable to commercialize the product on a scale sufficient to generate material revenue, which could have a material adverse effect on our business, financial condition, results of operations and prospects and the value of our common stock.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We currently are building our marketing and sales organization, and we have limited experience as a company in marketing drug products. If we are unable to successfully market and sell ARIKAYCE, our ability to generate revenue will be adversely affected.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In order to commercialize ARIKAYCE, we must develop marketing, market access, sales and distribution capabilities on our own or make arrangements with third parties for its marketing, sale and distribution. We have commenced commercialization of ARIKAYCE in the US, but we may not be successful in these efforts. The establishment and development of our own sales force is and will continue to be expensive and time-consuming. As a result, we may seek one or more partners to handle some or all of the sales and marketing of ARIKAYCE in certain markets outside the US following approval by the relevant regulatory authority in those markets. However, we may not be able to enter into arrangements with third parties to sell ARIKAYCE on favorable terms or at all. In the event that either our own marketing, market access, and sales force or third-party marketing, market access, and sales organizations are not effective, we would not be able to successfully commercialize ARIKAYCE, which would adversely affect our ability to generate revenue and materially harm us. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">31</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D0886DA1D655A85ACDCD91D659042CA"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">ARIKAYCE was approved for treatment in a limited population of patients with MAC lung disease, and additional clinical studies and regulatory applications will be required to expand its indication. We may not be successful in these trials or in obtaining such regulatory approval, which may materially adversely affect our prospects and the value of our common stock.  </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The FDA granted accelerated approval of ARIKAYCE for the treatment of MAC lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Our CONVERT study and 312 study have focused on this refractory population, and we do not anticipate obtaining an indication for a broader population of patients with MAC lung disease or any other illnesses or infections without additional clinical data. Additional clinical trials will require additional time and expense.  We expect to conduct our confirmatory clinical trial for full approval of ARIKAYCE in the broader population of patients with MAC lung disease, but this trial, along with any other clinical trials of ARIKAYCE may not be successful. Additional results from ongoing studies, including the CONVERT study and the 312 study, may not be consistent with the positive data generated from those trials to date, which may affect FDA&#8217;s benefit-risk analysis for the product. If we are unable to expand the indication for use of ARIKAYCE, our prospects and the value of our common stock may be materially adversely affected.  </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to the Development and Regulatory Approval of Our Product Candidates Generally</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Pharmaceutical research and development is very costly and highly uncertain, and we may not succeed in developing product candidates in the future.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product development in the pharmaceutical industry is an expensive, high-risk, lengthy, complicated, resource intensive process. In order to develop a product successfully, we must, among other things:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Identify potential product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Submit for and receive regulatory approval to perform clinical trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Design and conduct appropriate preclinical and clinical trials, including confirmatory clinical trials, according to good laboratory practices and good clinical practices and disease-specific expectations of the FDA and other regulatory bodies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Select and recruit clinical investigators and subjects for our clinical trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Obtain and correctly interpret data establishing adequate safety of our product candidates and demonstrating with statistical significance that our product candidates are effective for their proposed indications, as indicated by satisfaction of pre-established endpoints;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Submit for and receive regulatory approvals for marketing; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Manufacture the product candidates and device components according to cGMP and other applicable standards and regulations.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There is a high rate of failure inherent in this process, and potential products that appear promising at early stages of development may fail for a number of reasons. Importantly, positive results from preclinical studies of a product candidate may not be predictive of similar results in human clinical trials, and promising results from earlier clinical trials of a product candidate may not be replicated in later clinical trials. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late&#8209;stage clinical trials even after achieving positive results in earlier stages of development and have abandoned development efforts or sought partnerships in order to continue development. For example, the Month 6 data from the CONVERT study and interim durability data from the CONVERT study and interim efficacy data from the 312 study have thus far been positive. However, this data may not be predictive of the efficacy or safety results from the remainder of either the CONVERT study or the 312 study, or future trials related to ARIKAYCE.     </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, there are many other difficulties and uncertainties inherent in pharmaceutical research and development that could significantly delay or otherwise materially impair our ability to develop future product candidates, including the following:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Conditions imposed by regulators, ethics committees or institutional review boards for preclinical testing and clinical trials relating to the scope or design of our clinical trials, including selection of endpoints and number of required patients or clinical sites; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Challenges in designing our clinical trials to support potential claims of superiority over current standard of care or future competitive therapies; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restrictions placed upon, or other difficulties with respect to, clinical trials and clinical trial sites, including with respect to potential clinical holds or suspension or termination of clinical trials due to, among other things, potential safety or ethical concerns or noncompliance with regulatory requirements;  </span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">32</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D0886DA1D655A85ACDCD91D659042CA"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Delayed or reduced enrollment in clinical trials, or high discontinuation rates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Failure by third-party contractors, contract research organizations (CROs), clinical investigators, clinical laboratories, or suppliers to comply with regulatory requirements or meet their contractual obligations in a timely manner;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Greater than anticipated cost of our clinical trials; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Insufficient product supply or inadequate product quality.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Failure to successfully develop future product candidates for any of these reasons may materially adversely affect our business, financial condition, results of operations and prospects and the value of our common stock.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may not be able to obtain regulatory approvals for ARIKAYCE outside of the US or for our product candidates in the US, Europe, Japan or other markets. Any such failure to obtain regulatory approvals may materially adversely affect us.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are required to obtain various regulatory approvals prior to studying our products in humans and then again before we market and distribute our products, and the failure to obtain such approvals will prevent us from commercializing our products, which would materially adversely affect our business, financial condition, results of operations and prospects and the value of our common stock. While we have obtained accelerated approval for ARIKAYCE in the US, seeking approval for ARIKAYCE in other jurisdictions as well as approval for our product candidates in the US and foreign markets presents significant obstacles. Approval processes in the US, Europe and Japan require the submission of extensive preclinical and clinical data, manufacturing and quality information regarding the process and facility, scientific data characterizing our product and other supporting data in order to establish safety and effectiveness. These processes are complex, lengthy, expensive, resource intensive and uncertain. Regulators will also conduct a rigorous review of any trade name we intend to use for our products. Even after they approve a trade name, these regulators may request that we adopt an alternative name for the product if adverse event reports indicate a potential for confusion with other trade names and medication error. If we are required to adopt an alternative name, potential commercialization of ARIKAYCE or our product candidates could be delayed or interrupted. We have limited experience in submitting and pursuing applications necessary to obtain these regulatory approvals. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Data submitted to regulators are subject to varying interpretations that could delay, limit or prevent regulatory agency approval. Even if we believe our clinical trial results are promising, regulators may disagree with our interpretation of data, study design or execution and may refuse to accept our application for review or decline to grant approval. For example, in the fourth quarter of 2014, we filed a marketing authorization application (MAA) with the European Medicines Agency (EMA) for ARIKAYCE as a treatment for, among other things, MAC lung disease in adult patients. The filing was based in part on data from our phase 2 study in patients with MAC lung disease. We subsequently withdrew our MAA after the Committee for Medicinal Products for Human Use concluded that the data submitted did not provide enough evidence to support an approval. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, the grant of a designation by the FDA or approval by the FDA does not ensure a similar decision by the regulatory authorities of other countries, and a decision by one foreign regulatory authority does not ensure regulatory authorities in other foreign countries or the FDA will agree with the decision. For instance, although ARIKAYCE received orphan drug designation in the US, ARIKAYCE did not qualify for orphan drug designation in Japan due to the estimated number of NTM patients in Japan exceeding 50,000. Similarly, clinical studies conducted in one country may not be accepted by regulatory authorities in other countries. Approval procedures vary among countries and can involve additional product testing, including additional preclinical studies or clinical trials, and administrative review periods. The time required to obtain approval in these other territories might differ from that required to obtain FDA approval. We may never obtain approval for ARIKAYCE outside of the US or for our product candidates in the US or other jurisdictions, which would limit our market opportunities and materially adversely affect our business. Even if a product candidate is approved, regulators may limit the indications for which the product may be marketed, require extensive warnings on the product labeling or require expensive and time-consuming additional clinical trials or reporting as conditions of approval.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are currently assessing regulatory strategies which could expedite the development and regulatory review of INS1007 in the US and the EU, but we may be unsuccessful in pursuing such strategies. The FDA has denied our request for orphan drug designation for INS1007 in on-cystic fibrosis (non-CF) bronchiectasis. In addition, although we believe that INS1009 could be eligible for approval under Section 505(b)(2), and thus could rely at least in part on studies not conducted by or for us and for which we do not have a right of reference, we may not obtain approval from the FDA to use this pathway.  </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may also encounter delays or rejections based on changes in regulatory agency policies during the period in which we develop a product and the period required for review of any application for regulatory agency approval of a particular product. Resolving such delays could force us or third parties to incur significant costs, limit our allowed activities or the allowed activities of third parties, diminish any competitive advantages that we or our third parties may attain or adversely affect our ability to receive royalties, any of which could materially adversely affect our business, financial condition, results of </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">33</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D0886DA1D655A85ACDCD91D659042CA"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">operations and prospects and the value of our common stock.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">For ARIKAYCE to be commercialized in a given market, in addition to regulatory approvals required for ARIKAYCE, the Lamira Nebulizer System must satisfy certain regulatory requirements and its use as a delivery system for ARIKAYCE must be approved or cleared by regulators.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ARIKAYCE is administered using the Lamira Nebulizer System, and the Lamira Nebulizer System must receive regulatory approval or clearance on its own or in conjunction with ARIKAYCE as a combination product in order for us to develop and commercialize ARIKAYCE in a given market. The FDA granted accelerated approval of the Lamira Nebulizer System with ARIKAYCE as part of approval of the drug/device combination product, and the Lamira Nebulizer System is CE marked by PARI in the EU. However, outside the US and EU, the Lamira Nebulizer System is labeled as investigational for use in our clinical trials, including in Japan, Canada and Australia, and is not approved for commercial use in Japan, Canada or certain other markets in which we may seek to commercialize ARIKAYCE in the future.  </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we seek regulatory approval in markets in which the Lamira Nebulizer System is not approved and we and PARI are not successful in obtaining approval for the Lamira Nebulizer System, our ability to commercialize ARIKAYCE in those markets would be materially impaired.  In addition, failure to maintain regulatory approval or clearance of the Lamira Nebulizer System could result in increased development costs, withdrawal of regulatory approval, and delays in ARIKAYCE reaching the market. Failure to obtain or maintain regulatory approval or clearance of the Lamira Nebulizer System could result in potential loss of regulatory approval or otherwise materially harm our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have limited experience conducting and managing the preclinical development activities and clinical trials necessary to obtain regulatory approvals, and we may not succeed in doing so in the future.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ARIKAYCE is our first approved product candidate since our merger with Transave, and we have limited experience in conducting and managing the preclinical development activities and clinical trials necessary to obtain regulatory approvals, including approval by the FDA, EMA, Ministry of Health, Labour and Welfare (MHLW), and Pharmaceuticals and Medical Devices Agency (PMDA), which might prevent us from successfully designing, implementing, or completing the clinical trials required to support regulatory approval of our product candidates. The application processes for the FDA, MHLW, PMDA, EMA and other regulatory agencies are complex and difficult and vary by regulatory agency, and we might not be able to demonstrate that our product candidates meet the appropriate standards for regulatory approval or commercialize our product candidates in the US or elsewhere, or commercialize ARIKAYCE in jurisdictions outside of the US, or we might be significantly delayed in doing so. In such circumstances, our business, financial condition, results of operations and prospects and the value of our common stock may be materially adversely affected.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If our clinical studies do not produce positive results or our clinical trials are delayed, or if serious side effects are identified during drug development, we may experience delays, incur additional costs and ultimately be unable to commercialize our product candidates in the US, Europe, Japan or other markets.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Before obtaining regulatory approval for the sale of our product candidates, we must conduct, at our own expense, extensive preclinical tests to demonstrate the safety of our product candidates in animals, and clinical trials to demonstrate the safety and efficacy of our product candidates in humans. If we experience delays in our clinical trials or other testing or the results of these trials or tests are not positive or are only modestly positive, including with respect to safety, we may:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Experience increased product development costs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Be delayed in obtaining, or be unable to obtain, regulatory approval for one or more of our product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Obtain approval for indications or patient populations that are not as broad as intended or entirely different than those indications for which we sought approval or with labeling with boxed warnings or other warnings or contraindications;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Need to change the way the product is administered; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Be required to perform additional clinical trials to support approval or be subject to additional post-marketing testing requirements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Have regulatory authorities withdraw, or suspend, their approval of the product or impose risk mitigation strategies such as restrictions on distribution or other REMS;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Face a shortened patent protection period during which we may have the exclusive right to commercialize our products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Have competitors that are able to bring similar products to market before us;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Be sued for alleged injuries caused to patients using our products&#894; or</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Suffer reputational damage.</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">34</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D0886DA1D655A85ACDCD91D659042CA"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Such circumstances would impair our ability to commercialize our products and harm our business and results of operations.</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may not be able to enroll enough patients to complete our clinical trials or retain a sufficient number of patients in our clinical trials to generate the data necessary for regulatory approval of our product candidates.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The completion rate of our clinical trials is dependent on, among other factors, the patient enrollment rate. Patient enrollment is a function of many factors, including:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Investigator identification and recruitment;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Regulatory approvals to initiate study sites;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Patient population size;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The nature of the protocol to be used in the trial;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Patient proximity to clinical sites;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Eligibility criteria for the trial;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Patient willingness to participate in the trial;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discontinuation rates; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Competition from other companies&#8217; potential clinical trials for the same patient population.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Delays in patient enrollment for our clinical trials, including in the confirmatory clinical trial for ARIKAYCE and the WILLOW study, our global phase 2 study of INS1007 in non-CF bronchiectasis that currently is enrolling patients, like those we encountered in enrolling the CONVERT study, could increase costs and delay commercialization and sales, if any, of our products. Once enrolled, patients may elect to discontinue participation in a clinical trial at any time. If patients elect to discontinue participation in our clinical trials at a higher rate than expected, we may be unable to generate the data required by regulators for approval of our product candidates. </span></div><div style="line-height:174%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Our Reliance on Third Parties</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We rely on third parties including collaborators, CROs, clinical and analytical laboratories, contract manufacturing organizations (CMOs) and other providers for many services that are critical to our business. If we are unable to form and sustain these relationships, or if any third-party arrangements that we may enter into are unsuccessful, including due to non-compliance by such third parties with our agreements or applicable law, our ability to develop and commercialize our products may be materially adversely affected.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We currently rely, and expect to continue to rely, on third parties for significant research, analytical services, preclinical development, clinical development and manufacturing of our product candidates and commercial scale manufacturing of ARIKAYCE. For example, we do not own facilities for clinical-scale or commercial manufacturing of our product candidates, and we currently rely on Therapure Biopharma Inc. (Therapure) and Ajinimoto Althea,&#160;Inc. (Althea) to provide our clinical and commercial supply of ARIKAYCE. Additionally, almost all of our clinical trial work is done by CROs, such as SynteractHCR, Inc., our CRO for both the CONVERT and 312 studies, and clinical laboratories. Reliance on these third parties poses a number of risks, including the following:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The diversion of management time and cost of third-party advisers associated with the negotiation, documentation and implementation of agreements with third parties in the pharmaceutical industry;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The inability to control whether third parties devote sufficient resources to our programs or products, including with respect to meeting contractual deadlines;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The inability to control the regulatory and contractual compliance of third parties, including their quality systems, processes and procedures, systems utilized to collect and analyze data, and equipment used to test drug product and/or clinical supplies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The inability to establish and implement collaborations or other alternative arrangements on favorable terms;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Disputes with third parties, including CROs, leading to loss of intellectual property rights, delay or termination of research, development, or commercialization of product candidates or litigation or arbitration; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contracts with our collaborators fail to provide sufficient protection of our intellectual property; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Difficulty enforcing our contractual rights if one of these third parties fails to perform.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also rely on third parties to select and enter into agreements with clinical investigators to conduct clinical trials to support approval of our product candidates, and the failure of these third parties to appropriately carry out such evaluation and </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">35</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D0886DA1D655A85ACDCD91D659042CA"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">selection can adversely affect the quality of the data from these studies and, potentially, the approval of our products. In particular, as part of future drug approval submissions to the FDA, we must disclose certain financial interests of investigators who participated in any of the clinical studies being submitted in support of approval, or must certify to the absence of such financial interests. The FDA evaluates the information contained in such disclosures to determine whether disclosed interests may have an impact on the reliability of a study. If the FDA determines that financial interests of any clinical investigator raise serious questions of data integrity, the FDA can institute a data audit, request that we submit further data analyses, conduct additional independent studies to confirm the results of the questioned study, or refuse to use the data from the questioned study as a basis for approval. A finding by the FDA that a financial relationship of an investigator raises serious questions of data integrity could delay or otherwise adversely affect approval of our products.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">These risks could materially harm our business, financial condition, results of operations and prospects and the value of our common stock.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may not have, or may be unable to obtain, sufficient quantities of ARIKAYCE or our product candidates to meet our required supply for commercialization or clinical studies, which would materially harm our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We do not have any in-house manufacturing capability other than for small-scale pre-clinical development programs and depend completely on a small number of third-party manufacturers and suppliers for the manufacture of our product candidates on a clinical or commercial scale. For instance, we are and expect to remain dependent upon Therapure, Althea and eventually Patheon to supply ARIKAYCE both for our clinical trials and commercial sale. Althea currently manufactures ARIKAYCE at a relatively small scale. We also funded a manufacturing expansion at Therapure, which operates at a larger scale than Althea. ARIKAYCE currently has a limited shelf life, and we may not be able to maintain adequate quantities to meet future demand. As additional supporting data becomes available, we believe the current approved shelf life for product manufactured at our CMOs will increase. If we encounter delays or difficulties in the manufacturing process that disrupt our ability to supply our distributors with ARIKAYCE, we may experience a product stock-out, which would likely have a material adverse effect on our business and reputation. In addition, we have entered into certain agreements with Patheon related to increasing our long-term production capacity for ARIKAYCE commercial inventory, although Patheon&#8217;s supply obligations will commence only after certain technology transfer and construction services are completed. Any delay in the commencement of Patheon&#8217;s supply obligations, whether due to delays in technology transfer and construction or from adding Patheon to our New Drug Application (NDA) as a CMO, would increase the risks associated with either Therapure or Althea being unable to provide us with an adequate supply of ARIKAYCE. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are also dependent upon PARI being able to provide an adequate supply of nebulizers both for commercial sale of ARIKAYCE and any ongoing clinical trials, as PARI is the sole manufacturer of the Lamira Nebulizer System. We have no alternative supplier for the nebulizer, and because significant effort and time were expended in the optimization of the nebulizer for use with ARIKAYCE, we do not intend to seek an alternative or secondary supplier. In the event PARI cannot provide us with sufficient quantities of the nebulizer, replication of the optimized device by another party would likely require considerable time and additional regulatory approval. In the case of certain specified supply failures, we have the right under our commercialization agreement with PARI to make the nebulizer and have it made by certain third parties, but not those deemed under the commercialization agreement to compete with PARI.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We do not have long-term commercial agreements with all of our suppliers and if any of our suppliers are unable or unwilling to perform for any reason, we may not be able to locate suppliers or enter into favorable agreements with them. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">An inadequate supply of ARIKAYCE or the Lamira Nebulizer System could harm our commercial efforts or delay or impair clinical trials of ARIKAYCE or our product candidates and adversely affect our business, financial condition, results of operations and prospects and the value of our common stock. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The manufacturing facilities of our third-party manufacturers are subject to significant government regulations and approvals, which are often costly and could result in adverse consequences to our business if we and our manufacturing partners fail to comply with the regulations or maintain the approvals.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Manufacturers of ARIKAYCE and our product candidates are subject to cGMP and similar standards, and while we have policies and procedures in place to select manufacturers that adhere, and monitor their adherence to, such standards, they may nonetheless fail to do so. These manufacturers and their facilities will be subject to periodic review and inspections by the FDA and other regulatory authorities following regulatory approval of our products, as with ARIKAYCE. For instance, to monitor compliance with applicable regulations, the FDA routinely conducts inspections of facilities and may identify potential deficiencies. The FDA issues what are referred to as &#8220;FDA Form 483s&#8221; that set forth observations and concerns identified during its inspections. Failure to satisfactorily address the concerns or potential deficiencies identified in a Form 483 could </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">36</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D0886DA1D655A85ACDCD91D659042CA"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">result in the issuance of a warning letter, which is a notice of the issues that the FDA believes to be significant regulatory violations requiring prompt corrective actions. Failure to respond adequately to a warning letter, or to otherwise fail to comply with applicable regulatory requirements could result in enforcement, remedial and/or punitive actions by the FDA or other regulatory authorities.  </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If one of our manufacturers fails to maintain compliance with regulatory requirements or experiences supply problems, including in the scale-up of commercial production, the production of ARIKAYCE and our product candidates could be interrupted, resulting in delays, additional costs or restrictions on the marketing or sale of our products. An alternative manufacturer would need to be qualified, through regulatory filings, which could result in further delay. The regulatory authorities may also require additional testing if a new manufacturer is relied upon for commercial production.  In addition, with respect to our product candidates, our manufacturers and their facilities are subject to pre-approval cGMP inspection by the FDA and other regulatory authorities, and the findings of the cGMP inspection could result in a failure to obtain, or a delay in obtaining, regulatory approval for future product candidates.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to the Operation of our Business</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are dependent upon retaining and attracting key personnel, the loss of whose services could materially adversely affect our business, financial condition, results of operations and prospects and the value of our common stock.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We depend heavily on our management team and our principal clinical and commercial personnel, the loss of whose services might significantly delay or prevent the achievement of our research, development or commercialization objectives. Our success depends, in large part, on our ability to attract and retain qualified management, clinical and commercial personnel, and on our ability to develop and maintain important relationships with commercial partners, leading research institutions and key distributors. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Competition for skilled personnel in our industry and market is intense because of the numerous pharmaceutical and biotechnology companies that seek similar personnel. These companies may have greater financial and other resources, offer a greater opportunity for career advancement and have a longer history in the industry than we do. We also experience competition for the hiring of our clinical and commercial personnel from universities, research institutions, and other third parties. We cannot assure that we will attract and retain such persons or maintain such relationships. Our inability to retain and attract qualified employees would materially harm our business, financial condition, results of operations and prospects and the value of our common stock.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We expect to expand our development, regulatory and sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with our commercial launch of ARIKAYCE and international expansion, we expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of drug development, regulatory affairs, quality, commercial compliance, medical affairs, and sales and marketing. For example, we plan to hire additional personnel in connection with our commercial launch of ARIKAYCE and preparation for potential regulatory filings for ARIKAYCE in other markets. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to the limited experience of our management team in managing a company with this anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The physical expansion of our operations may lead to significant costs and may divert our management and business development resources. We may not be able to effectively manage the expansion of our operations, which could delay the execution of our business plans or disrupt our operations.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Any acquisitions we make, or collaborative relationships we enter into, may not be clinically or commercially successful, and may require financing or a significant amount of our available cash, which could adversely affect our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As part of our business strategy, we may effect acquisitions to obtain additional businesses, products, technologies, capabilities and personnel. Acquisitions involve a number of operational risks, including:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Failure to achieve expected synergies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Difficulty and expense of assimilating the operations, technology and personnel of any acquired business;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The inability to retain the management, key personnel and other employees of any acquired business;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The inability to maintain any acquired company&#8217;s relationship with key third parties, such as alliance partners;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exposure to legal claims for activities of any acquired business prior to acquisition;</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">37</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D0886DA1D655A85ACDCD91D659042CA"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diversion of our management&#8217;s attention from our core business; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Potential impairment of intangible assets, adversely affecting our reported results of operations and financial condition.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also may enter into collaborative relationships that would involve our collaborators conducting proprietary development programs. Disagreements with collaborators may develop over the rights to our intellectual property, and any conflict with our collaborators could limit our ability to obtain future collaboration agreements and negatively influence our relationship with existing collaborators. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we make one or more significant acquisitions or enter into a significant collaboration in which the consideration includes cash, we may be required to use a substantial portion of our available cash and/or need to raise additional capital, which could adversely affect our financial condition. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may be subject to product liability claims, and we have only limited product liability insurance.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The manufacture and sale of human therapeutic products involve an inherent risk of product liability claims, particularly as we now commercialize ARIKAYCE in the US. Regardless of merit or eventual outcome, liability claims may result in:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">decreased demand for ARIKAYCE and any other products that we may commercialize, and a corresponding loss of revenue&#894;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">substantial monetary awards to patients or trial participants;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">significant time and costs to defend the related litigation&#894;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">withdrawal or reduced enrollment of clinical trial participants; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">reputational harm and significant negative media attention.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We currently have only limited product liability insurance for our products. We do not know if we will be able to maintain existing, or obtain additional, product liability insurance on acceptable terms or with adequate coverage against potential liabilities. This type of insurance is expensive and may not be available on acceptable terms. If we are unable to obtain or maintain sufficient insurance coverage on reasonable terms or to otherwise protect against potential product liability claims, we may be unable to commercialize our products. A successful product liability claim brought against us in excess of our insurance coverage, if any, may require us to pay substantial amounts and may materially adversely affect our business, financial condition, results of operations and prospects and the value of our common stock.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our business and operations, including our drug development programs, could be materially disrupted in the event of system failures, security breaches, violations of data protection laws or data loss or damage by us or our CROs or other contractors or consultants.</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Despite the implementation of security measures, our internal computer systems and those of our CROs and other contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. If such an event were to occur and cause interruptions in our operations, it could have a material adverse effect on our business operations, including a material disruption of our drug development and commercialization programs. Unauthorized disclosure of sensitive or confidential patient or employee data, including personally identifiable information, whether through breach of computer systems, systems failure, employee negligence, fraud or misappropriation, or otherwise, or unauthorized access to or through our information systems and networks, whether by our employees or third parties, could result in negative publicity, legal liability and damage to our reputation. Unauthorized disclosure of personally identifiable information could also expose us to sanctions for violations of data privacy laws and regulations around the world. To the extent that any disruption or security breach resulted in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development of our product candidates could be delayed. For example, the loss of or damage to clinical trial data, such as from completed or ongoing clinical trials, for any of our product candidates could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. </span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Although we have general liability insurance coverage, including coverage for errors and omissions, our insurance may not cover all claims, continue to be available on reasonable terms or be sufficient in amount to cover one or more large claims; additionally, the insurer may disclaim coverage as to any claim. The successful assertion of one or more large claims against us that exceed or are not covered by our insurance coverage or changes in our insurance policies, including premium increases or the imposition of large deductible or co-insurance requirements, could have a material adverse effect on our business, financial condition, results of operations and prospects and the value of our common stock.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">38</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D0886DA1D655A85ACDCD91D659042CA"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have limited experience operating internationally, are subject to a number of risks associated with our international activities and operations and may not be successful in our efforts to expand internationally.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We currently have limited operations outside of the US. As of September 30, 2018, we had 27 employees located in Europe and 5 employees located in Japan, although we have clinical trial sites and suppliers located around the world. In order to meet our long-term goals, we expect to grow our international operations over the next several years, including in Europe and Japan, and continue to source material used in the manufacture of our product candidates from abroad. Consequently, we are and will continue to be subject to risks related to operating in foreign countries, including:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Limited experience with international regulatory requirements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">An inability to achieve optimal pricing and reimbursement for ARIKAYCE, if approved in another jurisdiction, or subsequent changes in reimbursement, pricing and other regulatory requirements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Any implementation of, or changes to, tariffs, trade barriers and other import-export regulations in the US or other countries in which we, or our third-party partners, operate;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unexpected adverse events related to ARIKAYCE or our product candidates occurring in foreign markets that we have not experienced in the US;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Economic and political conditions, including geopolitical events, such as war and terrorism, foreign currency fluctuations and inflation, which could result in reduced revenue, increased or unpredictable operating expenses and other obligations incident to doing business in, or with a company located in, another country;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Changes resulting from the UK's vote to exit the EU, including: (i) the uncertainty and instability in economic and market conditions; (ii) the uncertainty regarding the UK&#8217;s access to the EU Single Market and the impact on the wider trading, legal, regulatory and labor environments; and (iii) the uncertainty in the European regulatory framework, including the relocation of the EMA from the UK to the Netherlands, and the subsequent potential disruption and delay of EMA regulatory actions; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Compliance with foreign or US laws, rules and regulations, including data privacy requirements, labor relations laws, tax laws, anti-competition regulations, import, export and trade restrictions, anti-bribery/anti-corruption laws, regulations or rules, which could lead to actions by us or our licensees, distributors, manufacturers, other third parties who act on our behalf or with whom we do business in foreign countries or our employees who are working abroad that could subject us to investigation or prosecution under such foreign or US laws.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">These and other risks associated with our international operations may materially adversely affect our business, financial condition, results of operations and prospects and the value of our common stock.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We operate in a highly competitive and changing environment, and if we are unable to adapt to our environment, we may be unable to compete successfully.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Biotechnology and related pharmaceutical technology have undergone and are likely to continue to experience rapid and significant change. Our future success will depend in large part on our ability to maintain a competitive position with respect to these technologies and to obtain and maintain protection for our intellectual property. Compounds, products or processes that we develop may become obsolete before we recover any expenses incurred in connection with their development. We face substantial competition from pharmaceutical, biotechnology and other companies, universities and research institutions with respect to nontuberculous mycobacteria (NTM) lung disease, bronchiectasis, and pulmonary arterial hypertension (PAH). Relative to us, most of these entities have substantially greater capital resources, research and development staffs, facilities and experience in conducting clinical studies, obtaining regulatory approvals, and manufacturing and marketing pharmaceutical products. Many of our competitors may achieve product commercialization or obtain patent protection earlier than us. Furthermore, we believe that our competitors have used, and may continue to use, litigation to gain a competitive advantage. Our competitors may also use different technologies or approaches to develop products similar to ARIKAYCE and our product candidates.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We expect that competing successfully will depend, among other things, on the relative speed with which we can develop products, complete the clinical testing and regulatory approval processes and supply commercial quantities of the product to the market, as well as product efficacy, safety, reliability, availability, timing and scope of regulatory approval and price. We expect competition to increase as technological advances are made and commercial applications broaden. There are potential competitive products, both approved and in development, which include oral, systemic, or inhaled antibiotic products to treat chronic respiratory infections. For instance, certain entities have expressed interest in studying their products for NTM lung disease and are seeking to advance studies in NTM lung disease caused by mycobacterial species other than MAC; however, we are not aware of any entities currently conducting clinical trials for the treatment of refractory MAC lung disease or of any other approved inhaled therapies specifically indicated for NTM lung disease in North America, Japan or Europe. If any of our competitors develops a product that is more effective, safe, tolerable or, convenient or less expensive than </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">39</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D0886DA1D655A85ACDCD91D659042CA"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ARIKAYCE or our product candidates, it would likely materially adversely affect our ability to generate revenue. We also may face lower priced generic competitors if third-party payers encourage use of generic or lower-priced versions of our product or if competing products are imported into the US or other countries where we may sell ARIKAYCE.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, there are other amikacin products that have been approved by the FDA, MHLW and other regulatory agencies for use in other indications, and physicians may elect to prescribe those products rather than ARIKAYCE to treat the indications for which ARIKAYCE has received approval, which is commonly referred to as off-label use. Although regulations prohibit a drug company from promoting off-label use of its product, the FDA and other regulatory agencies do not regulate the practice of medicine and cannot direct physicians as to what product to prescribe to their patients. As a result, we would have limited ability to prevent any off-label use of a competitor&#8217;s product to treat diseases for which we have received FDA or other regulatory agency approval, even if this use violates our patents or any statutory exclusivities that FDA may grant for the use of amikacin to treat such diseases. If we are unable to compete successfully, it will materially adversely affect our business, financial condition, results of operations and prospects and the value of our common stock.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Our Intellectual Property</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are unable to protect our intellectual property rights adequately, the value of ARIKAYCE and our product candidates could be materially diminished.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain and involves complex legal, technical, scientific and factual questions, and our success depends in large part on our ability to protect our proprietary technology and to obtain and maintain patent protection for our products, prevent third parties from infringing our patents, both domestically and internationally. We have sought to protect our proprietary position by filing patent applications in the US and abroad related to our novel technologies and products that are important to our business. This process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Our existing patents and any future patents we obtain may not be sufficiently broad to prevent others from using our technologies or from developing competing products and technologies.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Even if our owned and licensed patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection or otherwise provide us with any competitive advantage. Any conclusions we may reach regarding non-infringement, inapplicability or invalidity of a third party&#8217;s intellectual property vis-&#224;-vis our proprietary rights, or those of a licensor, are based in significant part on a review of publicly available databases and other information. There may be information not available to us or otherwise not reviewed by us that could render these conclusions inaccurate. Our competitors may also be able to circumvent our owned or licensed patents by developing similar or alternative technologies or products in a non-infringing manner.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additionally, patents issued to us or our licensors may be challenged, narrowed, invalidated, held to be unenforceable or circumvented through litigation, which could limit our ability to stop competitors from marketing similar products or reduce the term of patent protection for amikacin liposome inhalation suspension or our product candidates. US patents and patent applications may also be subject to interference or derivation proceedings, and US patents may be subject to re-examination proceedings, reissue, post-grant review and/or </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">inter partes</span><span style="font-family:inherit;font-size:10pt;"> review in the US Patent and Trademark Office. Foreign patents may be subject to opposition or comparable proceedings in the corresponding foreign patent office, which could result in either loss of the patent or denial of the patent application or loss or reduction in the scope of one or more of the claims of the patent or patent application. See </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intellectual Property - ARIKAYCE Patents and Trade Secrets</span><span style="font-family:inherit;font-size:10pt;"> in Item 1 of Part I of our Annual Report on Form 10-K for the year ended December 31, 2017 (2017 Annual Report) for more information on our European patent that was previously opposed, the decision of which is now under appeal by Generics (UK) Ltd. Another of our European patents has been opposed by Generics (UK) Ltd. and was revoked in November 2017. We intend to appeal that decision, and the patent remains enforceable during the appeal. These European patents have statutory expiration dates in 2026 and 2023, respectively, not including additional term that might be added via a Supplementary Protection Certificate. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Changes in either patent laws or in interpretations of patent laws in the US and other countries may also diminish the value of our intellectual property or narrow the scope of our patent protection, including making it easier for competitors to challenge our patents. For example, the America Invents Act included a number of changes to established practices, including the transition to a first-inventor-to-file system and new procedures for challenging patents and implementation of different methods for invalidating patents.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are not able to adequately prevent disclosure of trade secrets and other proprietary information, the value of </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">40</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D0886DA1D655A85ACDCD91D659042CA"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">ARIKAYCE and our product candidates could be materially diminished.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We rely on trade secrets to protect our proprietary technologies, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. We rely in part on confidentiality agreements with our employees, consultants, advisors, collaborators, and other third parties and partners to protect our trade secrets and other proprietary information. These agreements may not effectively prevent disclosure of confidential information or may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, third parties may independently develop or discover our trade secrets and proprietary information. Regulators also may disclose information we consider to be proprietary to third parties under certain circumstances, including in response to third-party requests for such disclosure under the Freedom of Information Act or comparable laws. Additionally, the FDA, as part of its Transparency Initiative, continues to consider whether to make additional information publicly available on a routine basis, including information that we may consider to be trade secrets or other proprietary information, and it is not clear at the present time whether and how the FDA&#8217;s disclosure policies may change in the future.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may not be able to enforce our intellectual property rights throughout the world, which could harm our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The legal systems of some foreign countries, particularly developing countries, do not favor the enforcement of patents and other intellectual property protection, especially those relating to life sciences. Many companies have encountered significant problems in protecting and defending intellectual property rights in such foreign jurisdictions.  For example, certain foreign countries have compulsory licensing laws under which a patent owner may be required to grant licenses to third parties. In addition, many countries limit the enforceability of patents against third parties, including government agencies or government contractors. In these countries, patents may provide limited or no benefit. This legal environment could make it difficult for us to stop the infringement of our patents or in-licensed patents or the misappropriation of our other intellectual property rights. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, and our efforts to protect our intellectual property rights in such countries may be inadequate. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The drug research and development industry has a history of intellectual property litigation, and we could become involved in costly intellectual property disputes, which could delay or impair our product development efforts or prevent us from, or increase the cost of, commercializing ARIKAYCE or any other approved product candidate.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Third parties may claim that we have infringed upon or misappropriated their proprietary rights. Any existing third-party patents, or patents that may later issue to third parties, could negatively affect our commercialization of ARIKAYCE, INS1007, INS1009 or any other product candidate that receives regulatory approval. For instance, PAH is a competitive indication with established products, including other formulations of treprostinil. Our supply of the active pharmaceutical ingredient for INS1009 is dependent upon a single supplier. The supplier owns patents on its manufacturing process, and we have filed patent applications for INS1009; however, a competitor in the PAH indication may claim that we or our supplier have infringed upon or misappropriated its proprietary rights. Moreover, in the event that we pursue approval of INS1009, or any other product candidate, via the 505(b)(2) regulatory pathway, we will be required to file a certification against any unexpired patents listed in the Orange Book for the third-party drug we rely upon as part of our regulatory submission. This certification process may lead to litigation and could also delay launch of a product candidate, if approved by regulators.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the event of successful litigation or settlement of claims against us for infringement or misappropriation of a third party&#8217;s proprietary rights, as in 2007 with respect to IPLEX, we may be required to take actions including but not limited to the following:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Paying damages, including up to treble damages, royalties, and the other party&#8217;s attorneys&#8217; fees, which may be substantial;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Ceasing development, manufacture, marketing and sale of products or use of processes that infringe the proprietary rights of others;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expending significant resources to redesign our products or our processes so that they do not infringe the proprietary rights of others, which may not be possible, or may result in significant regulatory delays associated with conducting additional clinical trials or other steps to obtain regulatory approval; and/or</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquiring one or more licenses from third parties, which may not be available to us on acceptable terms or at all.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may also have to undertake costly litigation or engage in other proceedings, such as interference or </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">inter partes</span><span style="font-family:inherit;font-size:10pt;"> review, to enforce or defend the validity of any patents issued or licensed to us, to confirm the scope and validity of our or a licensor&#8217;s proprietary rights or to defend against allegations that we have infringed a third party&#8217;s intellectual property rights. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Any proceedings regarding our intellectual property rights are likely to be time consuming and may divert management </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">41</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D0886DA1D655A85ACDCD91D659042CA"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">attention from operation of our business, and could have a material adverse effect on our business, financial condition, results of operations and prospects and the value of our common stock.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Certain of our existing license agreements include, and our future license agreements also may include, restrictions on our ability to freely develop or commercialize the product candidates that are subject to those agreements. If we fail to comply with our obligations under these agreements, or if these license agreements are terminated for other reasons, we could lose license rights that are important to our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are a party to licensing agreements with PARI and AstraZeneca, which we view as material to our business. For additional information regarding the terms of these agreements, see </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Business - License and Other Agreements</span><span style="font-family:inherit;font-size:10pt;"> in Item 1 of Part I of our 2017 Annual Report. Under our license agreement with AstraZeneca, AstraZeneca retains a right of first negotiation pursuant to which it may exclusively negotiate with us before we can negotiate with a third party regarding any transaction to develop or commercialize INS1007, subject to certain exceptions. While this right of first negotiation is not triggered by a change of control, it may impede or delay our ability to consummate certain other transactions involving INS1007.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additionally, if we fail to comply with our obligations under the agreements with PARI and AstraZeneca, our counterparty may have the right to take action against us, up to and including termination of the relevant license. For instance, under our licensing agreement with PARI, with respect to NTM lung disease, CF and bronchiectasis, we have specific obligations to use commercially reasonable efforts to achieve certain developmental and regulatory milestones by set deadlines. Additionally, for NTM lung disease, we are obligated to use commercially reasonable efforts to achieve certain commercial milestones in Europe. The consequences of our failing to use commercially reasonable efforts to achieve certain commercial milestones are context-specific, but include ending PARI&#8217;s non-compete obligation, making the license non-exclusive and terminating the license, in each case with respect to the applicable indication. Similarly, under our license agreement with AstraZeneca, AstraZeneca may terminate our license to INS1007 if we fail to use commercially reasonable efforts to develop and commercialize a product based on INS1007, or we are subject to a bankruptcy or insolvency. Reduction or elimination of our licensed rights may result in our having to negotiate new or reinstated licenses with less favorable terms and may materially harm our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finally, if we do not proceed with the development of our ARIKAYCE program in the NTM lung disease or CF indications, certain of our contract counterparties may elect to proceed with the development of these indications.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Government Regulation </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Government health care reform could materially increase our costs, which could materially adversely affect our business, financial condition, results of operations and prospects and the value of our common stock.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our industry is highly regulated and changes in or revisions to laws and regulations that make gaining regulatory approval, reimbursement and pricing more difficult or subject to different criteria and standards may adversely impact our business, operations or financial results. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Administration and the majority party in both Houses of Congress have indicated their ongoing desire to repeal the ACA and, in December 2017, repealed the ACA's individual mandate, i.e., the penalty imposed on individuals who do not obtain health care coverage. It is unclear what the effect of this partial repeal will be and whether, when and how repeal of other sections of the law may be effectuated and what the effect on the healthcare sector will be. In addition, there is currently litigation challenging the constitutionality of the entire ACA.  It is unclear what the outcome of this litigation, and the effect of that outcome on the healthcare sector, will be.  The US President has indicated an interest in having the federal government negotiate drug prices with pharmaceutical manufacturers. Changes to the ACA, to the Medicare or Medicaid programs, or to the ability of the federal government to negotiate drug prices, or other federal legislation regarding healthcare access, financing or legislation in individual states, could affect our business, financial condition, results of operations and prospects and the value of our common stock. It remains unclear how any new legislation or regulation might affect the prices we may obtain for ARIKAYCE or any of our product candidates for which regulatory approval is obtained. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are found in violation of federal or state &#8220;fraud and abuse&#8221; laws, we may be required to pay a penalty or may be suspended from participation in federal or state health care programs, which may adversely affect our business, financial condition, results of operations and prospects and the value of our common stock.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the US, we are subject to various federal and state health care &#8220;fraud and abuse&#8221; laws, including anti&#8209;kickback laws, false claims laws and other laws intended to reduce fraud and abuse in federal and state health care programs. Although we seek to structure our business arrangements in compliance with all applicable requirements, these laws are broadly written, and </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">42</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D0886DA1D655A85ACDCD91D659042CA"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">it is often difficult to determine precisely how the law will be applied in specific circumstances. Accordingly, it is possible that our practices may be challenged under these laws. Violations of fraud and abuse laws may be punishable by criminal and/or civil sanctions, including fines or exclusion or suspension from federal and state health care programs such as Medicare and Medicaid and debarment from contracting with the US government, and our business, financial condition, results of operations and prospects and the value of our common stock may be adversely affected. Our reputation could also suffer. In addition, private individuals have the ability to bring actions on behalf of the government under the federal False Claims Act as well as under the false claims laws of several states.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the ACA, we are required to report information on payments or transfers of value to US physicians and teaching hospitals as well as investment interests held by physicians and their immediate family members, which is posted in searchable form on a public website. Failure to submit required information may result in civil monetary penalties. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Several states also impose other marketing restrictions or require pharmaceutical companies to make marketing or price disclosures to the state. In addition to the federal government, some states, as well as other countries, including France, require the disclosure of certain payments to health care professionals. Health record privacy laws may limit access to information identifying those individuals who may be prospective users. There are ambiguities as to what is required to comply with these state requirements, and we could be subject to penalties if a state determines that we have failed to comply with an applicable state law requirement. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are subject to anti-corruption laws and trade control laws, as well as other laws governing our operations. If we fail to comply with these laws, we could be subject to negative publicity, civil or criminal penalties, other remedial measures, and legal expenses, which could adversely affect our business, financial condition, results of operations and prospects and the value of our common stock.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our operations are subject to anti-corruption laws, including the US Foreign Corrupt Practices Act (FCPA), the UK Bribery Act and other anti-corruption laws that apply in countries where we do business. The FCPA, UK Bribery Act and these other laws generally prohibit us, our employees and our intermediaries from making prohibited payments to government officials or other persons to obtain or retain business or gain some other business advantage. The CONVERT study includes more than 125 sites in 18 countries, and we are conducting the 312 study and plan to conduct the WILLOW study, our global phase 2 study of INS1007 in non-CF bronchiectasis, at a broad range of trial sites around the world. Certain of these jurisdictions pose a risk of potential FCPA violations, and we have relationships with third parties whose actions could potentially subject us to liability under the FCPA or local anti-corruption laws. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are also subject to other laws and regulations governing our international operations, including regulations administered by the US Department of Commerce&#8217;s Bureau of Industry and Security, the US Department of Treasury&#8217;s Office of Foreign Assets Control, and various non-US government entities, including applicable export control regulations, economic sanctions on countries and persons, customs requirements, currency exchange regulations and transfer pricing regulations (collectively, Trade Control laws).</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may not be effective in ensuring our compliance with all applicable anti-corruption laws, including the FCPA or other legal requirements, including Trade Control laws. If we are not in compliance with the FCPA and other anti-corruption laws or Trade Control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our business, financial condition, results of operations and prospects and the value of our common stock. Likewise, even an investigation by US or foreign authorities of potential violations of the FCPA other anti-corruption laws or Trade Control laws could have an adverse impact on our reputation, business, financial condition, results of operations and prospects and the value of our common stock.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If another party obtains orphan drug exclusivity for a product that is essentially the same as a product we are developing for a particular indication, we may be precluded or delayed from commercializing the product in that indication.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the Orphan Drug Act, the FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition. The company that obtains the first regulatory approval from the FDA for a designated orphan drug for a rare disease generally receives marketing exclusivity for use of that drug for the designated condition for a period of seven years. Similar laws exist in the EU with a term of ten years. See </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Business - Government Regulation - Orphan Drugs</span><span style="font-family:inherit;font-size:10pt;"> in Item 1 of Part I of our 2017 Annual Report for additional information. If a competitor obtains approval of the same drug for the same indication or disease before us, and the FDA grants such orphan drug exclusivity, we would be prohibited from obtaining approval for our product for seven or more years, unless our product can be shown to be clinically superior. In addition, even if we obtain </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">43</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D0886DA1D655A85ACDCD91D659042CA"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">orphan exclusivity, the FDA may approve another product during our orphan exclusivity period for the same indication under certain circumstances.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our research, development and manufacturing activities used in the production of ARIKAYCE and our product candidates involve the use of hazardous materials, which could expose us to damages, fines, penalties and sanctions and materially adversely affect our results of operations and financial condition.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our research and development program and manufacturing activities for ARIKAYCE and our product candidates involve the controlled use of hazardous materials and chemicals. We generally contract with third parties for the disposal of these materials and wastes. Although we strive to comply with all pertinent regulations, the risk of environmental contamination, damage to facilities or injury to personnel from the accidental or improper use or control of these materials remains. In addition to any liability we could have for any misuse by us of hazardous materials and chemicals, we could also potentially be liable for activities of our CMOs or other third parties. Any such liability, or even allegations of such liability, could materially adversely affect our results of operations and financial condition. We also could incur significant costs as a result of civil or criminal fines and penalties.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, we may incur substantial costs to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Our Financial Condition and Need for Additional Capital</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have a history of operating losses, expect to incur operating losses for the foreseeable future and may never achieve or maintain profitability.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have incurred losses each previous year of our operation, except in 2009, when we sold our manufacturing facility and certain other assets to Merck, and we did not generate material revenue during the nine months ended September 30, 2018 or the years ended December 31, 2017, 2016 or 2015. As of September 30, 2018, our accumulated deficit was $1.2 billion. For the nine months ended September 30, 2018 and the years ended December 31, 2017 and 2016, our consolidated net loss was $232.7 million, $192.6 million and $176.3 million, respectively. Our ability to generate revenue will depend on the success of commercial sales of ARIKAYCE; however, we do not anticipate our revenue from the sale of ARIKAYCE will be sufficient for us to become profitable without reductions in our operating expenses. Despite our recent launch of ARIKAYCE in the US, we expect to continue to incur substantial operating expenses, and resulting operating losses, for the foreseeable future as we:</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup>&#160;</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">initiate or continue clinical studies of our product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">initiate a post-marketing clinical trial of ARIKAYCE, as required by the FDA&#894;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">seek to discover or in-license additional product candidates&#894;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">seek regulatory approvals for ARIKAYCE in foreign markets&#894; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">scale-up manufacturing capabilities for future ARIKAYCE production, including the build-out of production capacity at Patheon and process improvements in order to manufacture at a commercial scale&#894; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">enhance operational, compliance, financial, quality and information management systems and hire more personnel, including personnel to support our commercialization efforts and development of our product candidates.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis.   </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may need to raise additional funds to continue our operations, but we face uncertainties with respect to our ability to access capital.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our operations have consumed substantial amounts of cash since our inception. We expect to expend substantial financial resources to commercialize ARIKAYCE, including expenditures on product sales, marketing, manufacturing and distribution, fund the confirmatory post-marketing study and continue research and development of and, where applicable, seek regulatory approval for ARIKAYCE and our product candidates. We may need to raise additional capital to fund these activities, including due to changes in our product development plans or misjudgment of expected costs, to fund corporate development, to maintain our intellectual property portfolio or to resolve litigation. As of September 30, 2018, we had $567.6 million of cash and cash equivalents on hand. Our operating expenses, capital expenditures and long-term investments have been significantly higher in 2018 than in comparable periods of 2017, reflecting our investment in the build-out of our </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">44</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D0886DA1D655A85ACDCD91D659042CA"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">commercial organization to support global expansion activities for ARIKAYCE, including the launch of ARIKAYCE in the US in the fourth quarter of 2018, the build-up of third-party manufacturing capacity and manufacture of commercial inventory, which includes capital and long-term investments, and continued investment in research and development as well as general and administrative expenses. We do not know whether additional financing will be available when needed, or, if available, whether the terms will be favorable. If adequate funds are not available to us when needed, we may be forced to delay, restrict or eliminate all or a portion of our development programs or commercialization efforts.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have outstanding indebtedness in the form of convertible senior notes, and may incur additional indebtedness in the future, which could adversely affect our financial position, prevent us from implementing our strategy, and dilute the ownership interest of our existing shareholders.</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2018, we completed an underwritten public offering of 1.75% convertible senior notes due 2025 (the Convertible Notes). The Convertible Notes may be convertible into common stock at an initial conversion rate of 25.5384 shares of common stock per $1,000 principal amount of Convertible Notes. We sold $450.0 million aggregate principal amount of the Convertible Notes, including the exercise in full of the underwriters&#8217; option to purchase additional Convertible Notes, resulting in net proceeds of approximately $435.8 million. Holders of the Convertible Notes may convert their Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding October 15, 2024 only under certain circumstances. On or after October 15, 2024 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert their Convertible Notes at any time. Upon conversion of the Convertible Notes, we may deliver cash, shares of our common stock or a combination of cash and shares of our common stock, at our election. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The degree to which we are leveraged could have negative consequences, such as the following:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">we may be more vulnerable to economic downturns, less able to withstand competitive pressures, and less flexible in responding to changing economic conditions;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to obtain financing in the future may be limited;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">a substantial portion of our cash flows from operations in the future may be required for the payment of the principal amount of the Convertible Notes when they or any additional indebtedness become due&#894;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">we may elect to make cash payments upon conversion of the Convertible Notes, which would reduce our available cash.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our ability to pay principal or interest on or, if desired, to refinance our indebtedness, including the Convertible Notes, depends on our future performance, which is subject to economic, financial, competitive and other factors, some of which are beyond our control. Our business may not generate cash flow from operations in the future sufficient to satisfy any obligations under the Convertible Notes to make cash payments to noteholders or our obligations under any future indebtedness we may incur. If we are unable to generate such cash flow, we may be required to delay, restrict or eliminate all or a portion of our development programs or commercialization efforts or refinance or obtain additional equity capital on terms that may be onerous or highly dilutive. If we do not meet our debt obligations, it could materially adversely affect our results of operations, financial condition and the value of our common stock.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The conversion of some or all of the Convertible Notes will dilute the ownership interests of our existing shareholders to the extent we deliver shares upon their conversion. Any sales in the public market of the common stock issuable upon such conversion could adversely affect prevailing market prices of our common stock. In addition, the existence of the Convertible Notes may encourage short selling by market participants because the conversion of the Convertible Notes could be used to satisfy short positions, or anticipated conversion of the Convertible Notes into shares of our common stock could depress the price of our common stock. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The accounting method for the Convertible Notes may have an adverse effect on our reported financial results.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounting guidance requires that we separately account for the liability and equity components of the Convertible Notes because they may be settled entirely or partially in cash upon conversion in a manner that reflects our economic interest cost. As a result, the equity component of the Convertible Notes is required to be included in the additional paid-in capital section of shareholders&#8217; equity on our consolidated balance sheet, and the value of the equity component is treated as original issue discount for purposes of accounting for the debt component of the Convertible Notes. We may report greater net loss (or lower net income) in our financial results because this guidance requires interest to include both the current period&#8217;s amortization of the debt discount and the instrument&#8217;s coupon interest, which could adversely affect our reported or future financial results, the market price of our common stock and the trading price of the Convertible Notes.</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">45</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D0886DA1D655A85ACDCD91D659042CA"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Holders may convert their Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding October 15, 2024 only under certain circumstances. For example, holders may convert their Convertible Notes at their option during any quarter commencing after the quarter ending March 31, 2018 (and only during such quarter) if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding quarter is greater than or equal to 130% of the conversion price on each applicable trading day. If the Convertible Notes become convertible prior to October 15, 2024, we may be required to reclassify our Convertible Notes and the related debt issuance costs as current liabilities and certain portions of our equity outside of equity to mezzanine equity, which would have an adverse impact on our reported financial results for such quarter, and could have an adverse impact on the market price of our common stock and the trading price of the Convertible Notes.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Intangible assets comprised approximately 9% of our total assets as of September 30, 2018. A reduction in the value of our intangible assets could have a material adverse effect on our results of operations, financial condition and the value of our common stock.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of the merger with Transave in 2010, we recorded an intangible in-process research and development (IPRD) asset of $77.9 million and goodwill of $6.3 million on our balance sheet. As a result of the clinical hold on ARIKAYCE announced in late 2011, we recorded a charge of $26.0 million in the fourth quarter of 2011 that reduced the value of IPRD to $58.2 million and reduced goodwill to zero. In addition, in September 2018 we recorded an additional $1.7 million in intangible assets related to a milestone due to PARI as a result of FDA approval of ARIKAYCE. Future activities or events could result in additional write-downs of these intangible assets, which could materially adversely affect our results of operations, financial condition and the value of our common stock.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may be unable to use certain of our net operating losses and other tax assets.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have substantial tax loss carry forwards for US federal income tax and state income tax purposes, and beginning in 2015, we had tax loss carry forwards in Ireland as well. In general, our net operating losses and tax credits have been fully offset by a valuation allowance due to uncertainties surrounding our ability to realize these tax benefits. In particular, our ability to fully use certain US tax loss carry forwards and general business tax credit carry forwards recorded prior to December 2010 to offset future income or tax liability is limited under section 382 of the Internal Revenue Code of 1986, as amended (the Code). Changes in the ownership of our stock, including those resulting from the issuance of shares of our common stock offerings or upon exercise of outstanding options, may limit or eliminate our ability to use certain net operating losses and tax credit carry forwards in the future.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Ownership of Our Common Stock </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The market price of our stock has been and may continue to be highly volatile, which could lead to shareholder litigation against us.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our common stock is listed on the Nasdaq Global Select Market under the ticker symbol &#8220;INSM&#8221;. The market price of our stock has been and may continue to be highly volatile and could be subject to wide fluctuations in price in response to various factors, including those discussed herein, many of which are beyond our control. In addition, the stock market has from time to time experienced extreme price and volume fluctuations, which have particularly affected the market prices for emerging biotechnology and pharmaceutical companies like us, and which have often been unrelated to their operating performance. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Historically, when the market price of a stock has been volatile, shareholders are more likely to institute securities and derivative class action litigation against the issuer of such stock. We previously faced a shareholder suit following a decline in our stock price. If any of our shareholders bring a lawsuit against us in the future, it could have a material adverse effect on our business. We have insurance policies related to some of the risks associated with our business, including directors&#8217; and officers&#8217; liability insurance policies; however, our insurance coverage may not be sufficient and our insurance carriers may not cover all claims in a given litigation. If we are not successful in our defense of claims asserted in shareholder litigation, those claims are not covered by insurance or they exceed our insurance coverage, we may have to pay damage awards, indemnify our executive officers, directors and third parties from damage awards that may be entered against them and pay our and their costs and expenses incurred in defense of, or in any settlement of, such claims. In addition, such shareholder suits could divert the time and attention of management from our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Certain provisions of Virginia law, our articles of incorporation and amended and restated bylaws and arrangements between us and our employees could hamper a third party&#8217;s acquisition of, or discourage a third party from attempting to </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">46</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D0886DA1D655A85ACDCD91D659042CA"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">acquire control of us.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain provisions of Virginia law, our articles of incorporation and amended and restated bylaws and arrangements with our employees could hamper a third party&#8217;s acquisition of, or discourage a third party from attempting to acquire control of, us or limit the price that investors might be willing to pay for shares of our common stock. These provisions or arrangements include:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The ability to issue preferred stock with rights senior to those of our common stock without any further vote or action by the holders of our common stock. The issuance of preferred stock could decrease the amount of earnings and assets available for distribution to the holders of our common stock or could adversely affect the rights and powers, including voting rights, of the holders of our common stock. In certain circumstances, such issuance could have the effect of decreasing the market price of our common stock.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The existence of a staggered board of directors in which there are three classes of directors serving staggered three-year terms, thus expanding the time required to change the composition of a majority of directors.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The requirement that shareholders provide advance notice when nominating director candidates to serve on our Board of Directors.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The inability of shareholders to convene a shareholders&#8217; meeting without the chairman of the board, the president or a majority of the board of directors first calling the meeting.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The prohibition against entering into a business combination with the beneficial owner of 10% or more of our outstanding voting stock for a period of three years after the 10% or greater owner first reached that level of stock ownership, unless certain criteria are met.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to severance agreements with our officers and provisions in our incentive plans that permit acceleration of equity awards upon a change in control, a severance plan for eligible full-time employees that provides such employees with severance equal to six months of their then-current base salaries in connection with a termination of employment without cause upon, or within 18 months following, a change in control.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We previously had a shareholder rights plan, or &#8220;poison pill,&#8221; which expired in May 2011. Under Virginia law, our Board of Directors may implement a new shareholders&#8217; rights plan without shareholder approval. Our Board of Directors intends to regularly consider this matter, even in the absence of specific circumstances or takeover proposals, to facilitate its future ability to quickly and effectively protect shareholder value.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s44EC2A4B6C11540FBC65A797093F13FE"></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 2.</span><span style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There were no unregistered sales of the Company&#8217;s equity securities by the Company during the quarter ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">47</span></div></div><hr style="page-break-after:always"></hr><div><a id="s0145384789C05C12BD063B6EAE19DBC3"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D0886DA1D655A85ACDCD91D659042CA"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 6.</span><span style="font-family:inherit;font-size:3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBITS</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exhibit Index</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1104506/000114036113012797/ex3_1.htm"><span style="font-family:inherit;font-size:10pt;">3.1</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Articles of Incorporation of Insmed Incorporated, as amended through June&#160;14, 2012 (incorporated by reference from Exhibit&#160;3.1 to Insmed Incorporated&#8217;s Annual Report on Form&#160;10-K filed on March&#160;18, 2013) (File No. 000-30739).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465915056784/a15-12110_1ex3d1.htm"><span style="font-family:inherit;font-size:10pt;">3.2</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amended and Restated Bylaws of Insmed Incorporated (incorporated by reference from Exhibit&#160;3.1 to Insmed Incorporated&#8217;s Quarterly Report on Form&#160;10-Q filed on August&#160;6, 2015).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465918057228/a18-29057_1ex10d1.htm"><span style="font-family:inherit;font-size:10pt;">10.1</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lease Agreement, dated September 11, 2018, by and between Insmed Incorporated and Exeter 700 Route 202/206, LLC (incorporated by reference from Exhibit 10.1 to Insmed Incorporated&#8217;s Current Report on Form 8-K filed on September 17, 2018).</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="insm-20180930xex311.htm"><span style="font-family:inherit;font-size:10pt;">31.1</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certification of William H. Lewis, Chief Executive Officer of Insmed Incorporated, pursuant to Rules&#160;13a-14(a)&#160;and 15d-14(a)&#160;promulgated under the Securities Exchange Act of 1934, as adopted pursuant to Section&#160;302 of the Sarbanes Oxley Act of 2002.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="insm-20180930xex312.htm"><span style="font-family:inherit;font-size:10pt;">31.2</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certification of Paolo Tombesi, Chief Financial Officer (Principal Financial and Accounting Officer) of Insmed Incorporated, pursuant to Rules&#160;13a-14(a)&#160;and 15d-14(a)&#160;promulgated under the Securities Exchange Act of 1934, as adopted pursuant to Section&#160;302 of the Sarbanes Oxley Act of 2002.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="insm-20180930xex321.htm"><span style="font-family:inherit;font-size:10pt;">32.1</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certification of William H. Lewis, Chief Executive Officer of Insmed Incorporated, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes Oxley Act of 2002.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="insm-20180930xex322.htm"><span style="font-family:inherit;font-size:10pt;">32.2</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certification of Paolo Tombesi, Chief Financial Officer (Principal Financial and Accounting Officer) of Insmed Incorporated, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes Oxley Act of 2002.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following materials from Insmed Incorporated&#8217;s quarterly report on Form&#160;10-Q for the quarter ended September 30, 2018 formatted in XBRL (eXtensible Business Reporting Language): (i)&#160;Consolidated Balance Sheets as of September 30, 2018 and December&#160;31, 2017, (ii)&#160;Consolidated Statements of Comprehensive Loss for the three and nine months ended September 30, 2018 and 2017, (iii)&#160;Consolidated Statements of Cash Flows for the nine months ended September 30, 2018 and 2017, and (iv)&#160;Notes to the Unaudited Consolidated Financial Statements.</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">48</span></div></div><hr style="page-break-after:always"></hr><div><a id="sDCE75C8A9D1F502ABF2C5509E72C0443"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D0886DA1D655A85ACDCD91D659042CA"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURE</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:48%;"></td><td style="width:5%;"></td><td style="width:47%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">INSMED INCORPORATED</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Date: October 30, 2018</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">By</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/ Paolo Tombesi</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Paolo Tombesi</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Chief Financial Officer</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Principal Financial and Accounting Officer)</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">49</span></div></div>	</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>insm-20180930xex311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s008F626A7FFC5B4BAE9C8F92B62E7257"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT&#160;31.1</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Section&#160;302 Certification</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, William H. Lewis, Chief Executive Officer of Insmed Incorporated, certify that:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1)&#160;I have reviewed this Quarterly Report on Form&#160;10-Q of Insmed Incorporated;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2)&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3)&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4)&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;text-align:left;padding-left:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b)&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;text-align:left;padding-left:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(c)&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;text-align:left;padding-left:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d)&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5)&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;text-align:left;padding-left:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b)&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">Date:&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">October&#160;30, 2018</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:341px;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:341px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ William H. Lewis</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">William H. Lewis</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Executive Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>insm-20180930xex312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s9B5010200783547084E1C6FA12E1EAAF"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT&#160;31.2</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Section&#160;302 Certification</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I,&#160;Paolo Tombesi, Chief Financial Officer (Principal Financial and Accounting Officer) of Insmed Incorporated, certify that:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1)&#160;I have reviewed this Quarterly Report on Form&#160;10-Q of Insmed Incorporated;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2)&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3)&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4)&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;text-align:left;padding-left:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b)&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;text-align:left;padding-left:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(c)&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this&#160;report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;text-align:left;padding-left:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d)&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5)&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;text-align:left;padding-left:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b)&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">October&#160;30, 2018</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:341px;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:341px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Paolo Tombesi</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Paolo Tombesi</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Financial and Accounting Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>insm-20180930xex321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sAD16AC6263D85FB4A55720B9D8E399B1"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT&#160;32.1</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">18 U.S.C. SECTION&#160;1350,</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2003</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Solely for the purposes of complying with 18 U.S.C. &#167; 1350,&#160;I, William Lewis, Chief Executive Officer of Insmed Incorporated (the &#8220;Company&#8221;), hereby certify, based on my knowledge, that:</font></div><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:7pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">the Quarterly Report on Form&#160;10-Q of the Company for the quarter ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">&#160;(the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934, as amended; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:7pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:341px;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:341px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ William H. Lewis</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">William H. Lewis</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Executive Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">October&#160;30, 2018</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This certification accompanies the Quarterly Report on Form&#160;10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Insmed Incorporated under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form&#160;10-Q), irrespective of any general incorporation language contained in such filing.&#160; A signed original of this statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>insm-20180930xex322.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s9F9D14C369205566AD8D78DD01072324"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT&#160;32.2</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">18 U.S.C. SECTION&#160;1350,</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2003</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Solely for the purposes of complying with 18 U.S.C. &#167; 1350,&#160;I,&#160;Paolo Tombesi, Chief Financial Officer (Principal Financial and Accounting Officer) of Insmed Incorporated (the &#8220;Company&#8221;), hereby certify, based on my knowledge, that:</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:7pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">the Quarterly Report on Form&#160;10-Q of the Company for the quarter ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;(the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934, as amended; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:341px;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:341px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Paolo Tombesi</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Paolo Tombesi</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Financial and Accounting Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">October&#160;30, 2018</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This certification accompanies the Quarterly Report on Form&#160;10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Insmed Incorporated under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form&#160;10-Q), irrespective of any general incorporation language contained in such filing.&#160; A signed original of this statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>insm-20180930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.insmed.com/20180930" xmlns:insm="http://www.insmed.com/20180930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/us-gaap/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-roles-2017-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-types-2017-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2017-01-31" schemaLocation="http://xbrl.sec.gov/exch/2017/exch-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="insm-20180930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="insm-20180930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="insm-20180930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="insm-20180930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="AccruedExpenses" roleURI="http://www.insmed.com/role/AccruedExpenses">
        <link:definition>2104100 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesDetails" roleURI="http://www.insmed.com/role/AccruedExpensesDetails">
        <link:definition>2404402 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesTables" roleURI="http://www.insmed.com/role/AccruedExpensesTables">
        <link:definition>2304301 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingencies" roleURI="http://www.insmed.com/role/CommitmentsAndContingencies">
        <link:definition>2109100 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesMinimumRentalPaymentsDetails" roleURI="http://www.insmed.com/role/CommitmentsAndContingenciesMinimumRentalPaymentsDetails">
        <link:definition>2409403 - Disclosure - Commitments and Contingencies - Minimum Rental Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesNarrativeDetails" roleURI="http://www.insmed.com/role/CommitmentsAndContingenciesNarrativeDetails">
        <link:definition>2409402 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesTables" roleURI="http://www.insmed.com/role/CommitmentsAndContingenciesTables">
        <link:definition>2309301 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CompanyAndBasisOfPresentation" roleURI="http://www.insmed.com/role/CompanyAndBasisOfPresentation">
        <link:definition>2101100 - Disclosure - The Company and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CompanyAndBasisOfPresentationDetails" roleURI="http://www.insmed.com/role/CompanyAndBasisOfPresentationDetails">
        <link:definition>2401401 - Disclosure - The Company and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsUnaudited" roleURI="http://www.insmed.com/role/ConsolidatedBalanceSheetsUnaudited">
        <link:definition>1001000 - Statement - Consolidated Balance Sheets (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://www.insmed.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>1001501 - Statement - Consolidated Balance Sheets (unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>1003000 - Statement - Consolidated Statements of Cash Flows (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfCashFlowsUnauditedParenthetical" roleURI="http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnauditedParenthetical">
        <link:definition>1003001 - Statement - Consolidated Statements of Cash Flows (unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfComprehensiveLossUnaudited" roleURI="http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited">
        <link:definition>1002000 - Statement - Consolidated Statements of Comprehensive Loss (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.insmed.com/role/Debt">
        <link:definition>2105100 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtComponentsOfDebtDetails" roleURI="http://www.insmed.com/role/DebtComponentsOfDebtDetails">
        <link:definition>2405403 - Disclosure - Debt - Components of Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtFuturePrincipalRepaymentsOfDebtDetails" roleURI="http://www.insmed.com/role/DebtFuturePrincipalRepaymentsOfDebtDetails">
        <link:definition>2405404 - Disclosure - Debt - Future Principal Repayments of Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtInterestExpenseDetails" roleURI="http://www.insmed.com/role/DebtInterestExpenseDetails">
        <link:definition>2405405 - Disclosure - Debt - Interest Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNarrativeDetails" roleURI="http://www.insmed.com/role/DebtNarrativeDetails">
        <link:definition>2405402 - Disclosure - Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://www.insmed.com/role/DebtTables">
        <link:definition>2305301 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://www.insmed.com/role/DocumentAndEntityInformation">
        <link:definition>0001000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.insmed.com/role/IncomeTaxes">
        <link:definition>2108100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.insmed.com/role/IncomeTaxesDetails">
        <link:definition>2408401 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssets" roleURI="http://www.insmed.com/role/IntangibleAssets">
        <link:definition>2103100 - Disclosure - Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNarrativeDetails" roleURI="http://www.insmed.com/role/IntangibleAssetsNarrativeDetails">
        <link:definition>2403402 - Disclosure - Intangible Assets - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsScheduleOfIntangibleAssetsDetails" roleURI="http://www.insmed.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails">
        <link:definition>2403403 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsTables" roleURI="http://www.insmed.com/role/IntangibleAssetsTables">
        <link:definition>2303301 - Disclosure - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquity" roleURI="http://www.insmed.com/role/ShareholdersEquity">
        <link:definition>2106100 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityChangesInShareholdersEquityDetails" roleURI="http://www.insmed.com/role/ShareholdersEquityChangesInShareholdersEquityDetails">
        <link:definition>2406403 - Disclosure - Shareholders' Equity - Changes in Shareholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityNarrativeDetails" roleURI="http://www.insmed.com/role/ShareholdersEquityNarrativeDetails">
        <link:definition>2406402 - Disclosure - Shareholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityTables" roleURI="http://www.insmed.com/role/ShareholdersEquityTables">
        <link:definition>2306301 - Disclosure - Shareholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.insmed.com/role/StockBasedCompensation">
        <link:definition>2107100 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.insmed.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>2407402 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationRangeOfExercisePricesDetails" roleURI="http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails">
        <link:definition>2407404 - Disclosure - Stock-Based Compensation - Range of Exercise Prices (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails" roleURI="http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails">
        <link:definition>2407405 - Disclosure - Stock-Based Compensation - Restricted Stock and Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionsDetails" roleURI="http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails">
        <link:definition>2407403 - Disclosure - Stock-Based Compensation - Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.insmed.com/role/StockBasedCompensationTables">
        <link:definition>2307301 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPolicies" roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPolicies">
        <link:definition>2102100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesDetails" roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesDetails">
        <link:definition>2402406 - Disclosure - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails" roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails">
        <link:definition>2402404 - Disclosure - Summary of Significant Accounting Policies - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2402403 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails" roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails">
        <link:definition>2402405 - Disclosure - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesRecentlyAdoptedAccountingPronouncementsDetails" roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesRecentlyAdoptedAccountingPronouncementsDetails">
        <link:definition>2402407 - Disclosure - Summary of Significant Accounting Policies - Recently Adopted Accounting Pronouncements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>2302302 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="insm_AccruedClinicalTrialExpenses" name="AccruedClinicalTrialExpenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="insm_AccruedConstructionLiabilitiesCurrent" name="AccruedConstructionLiabilitiesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="insm_AccruedMilestonePaymentCurrent" name="AccruedMilestonePaymentCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="insm_AccruedTechnicalOperationExpenses" name="AccruedTechnicalOperationExpenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="insm_AdditionalLaboratorySpaceOperatingLeasesFutureMinimumPaymentsDue" name="AdditionalLaboratorySpaceOperatingLeasesFutureMinimumPaymentsDue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="insm_AmortizationOfBackendFee" name="AmortizationOfBackendFee" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities" name="AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="insm_BridgewaterNewJerseyFacilityMember" name="BridgewaterNewJerseyFacilityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_BridgewaterNewJerseyOfficeSpaceMember" name="BridgewaterNewJerseyOfficeSpaceMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption" name="CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="insm_DebtInstrumentConversionTermAxis" name="DebtInstrumentConversionTermAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_DebtInstrumentConversionTermDomain" name="DebtInstrumentConversionTermDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_DebtInstrumentConversionTermFourMember" name="DebtInstrumentConversionTermFourMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_DebtInstrumentConversionTermOneMember" name="DebtInstrumentConversionTermOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_DebtInstrumentConversionTermThreeMember" name="DebtInstrumentConversionTermThreeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_DebtInstrumentConversionTermTwoMember" name="DebtInstrumentConversionTermTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange" name="DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="insm_DebtInstrumentOptionToPurchaseAdditionalDebt" name="DebtInstrumentOptionToPurchaseAdditionalDebt" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" name="DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="insm_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_EmployeeAndDirectorsStockOptionsMember" name="EmployeeAndDirectorsStockOptionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_EmployeeStockPurchasePlan2018Member" name="EmployeeStockPurchasePlan2018Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="insm_FairValueLevel1Level2Level3TransfersAmount" name="FairValueLevel1Level2Level3TransfersAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities" name="IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="insm_LesseeOperatingLeaseNumberOfRenewals" name="LesseeOperatingLeaseNumberOfRenewals" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit" name="NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member" name="OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_Range10Member" name="Range10Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_Range1Member" name="Range1Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_Range2Member" name="Range2Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_Range3Member" name="Range3Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_Range4Member" name="Range4Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_Range5Member" name="Range5Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_Range6Member" name="Range6Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_Range7Member" name="Range7Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_Range8Member" name="Range8Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_Range9Member" name="Range9Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="insm_RepaymentsOfDebtFeesAndOutstandingInterest" name="RepaymentsOfDebtFeesAndOutstandingInterest" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_RestrictedStockAndRestrictedStockUnitsMember" name="RestrictedStockAndRestrictedStockUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_ScheduleofEarningsPerShareBasicandDilutedLineItems" name="ScheduleofEarningsPerShareBasicandDilutedLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_ScheduleofEarningsPerShareBasicandDilutedTable" name="ScheduleofEarningsPerShareBasicandDilutedTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_StockOptionsAndRestrictedStockUnitsMember" name="StockOptionsAndRestrictedStockUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="insm_WeightedAverageRemainingContractualLifeInYearsAbstract" name="WeightedAverageRemainingContractualLifeInYearsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>insm-20180930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.insmed.com/role/AccruedExpenses" xlink:href="insm-20180930.xsd#AccruedExpenses" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/AccruedExpensesDetails" xlink:href="insm-20180930.xsd#AccruedExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/AccruedExpensesTables" xlink:href="insm-20180930.xsd#AccruedExpensesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/CommitmentsAndContingencies" xlink:href="insm-20180930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/CommitmentsAndContingenciesMinimumRentalPaymentsDetails" xlink:href="insm-20180930.xsd#CommitmentsAndContingenciesMinimumRentalPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:href="insm-20180930.xsd#CommitmentsAndContingenciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/CommitmentsAndContingenciesTables" xlink:href="insm-20180930.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/CompanyAndBasisOfPresentation" xlink:href="insm-20180930.xsd#CompanyAndBasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/CompanyAndBasisOfPresentationDetails" xlink:href="insm-20180930.xsd#CompanyAndBasisOfPresentationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:href="insm-20180930.xsd#ConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="insm-20180930.xsd#ConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="insm-20180930.xsd#ConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnauditedParenthetical" xlink:href="insm-20180930.xsd#ConsolidatedStatementsOfCashFlowsUnauditedParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited" xlink:href="insm-20180930.xsd#ConsolidatedStatementsOfComprehensiveLossUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/Debt" xlink:href="insm-20180930.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/DebtComponentsOfDebtDetails" xlink:href="insm-20180930.xsd#DebtComponentsOfDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/DebtFuturePrincipalRepaymentsOfDebtDetails" xlink:href="insm-20180930.xsd#DebtFuturePrincipalRepaymentsOfDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/DebtInterestExpenseDetails" xlink:href="insm-20180930.xsd#DebtInterestExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/DebtNarrativeDetails" xlink:href="insm-20180930.xsd#DebtNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/DebtTables" xlink:href="insm-20180930.xsd#DebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/DocumentAndEntityInformation" xlink:href="insm-20180930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxes" xlink:href="insm-20180930.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxesDetails" xlink:href="insm-20180930.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/IntangibleAssets" xlink:href="insm-20180930.xsd#IntangibleAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/IntangibleAssetsNarrativeDetails" xlink:href="insm-20180930.xsd#IntangibleAssetsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails" xlink:href="insm-20180930.xsd#IntangibleAssetsScheduleOfIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/IntangibleAssetsTables" xlink:href="insm-20180930.xsd#IntangibleAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/ShareholdersEquity" xlink:href="insm-20180930.xsd#ShareholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/ShareholdersEquityChangesInShareholdersEquityDetails" xlink:href="insm-20180930.xsd#ShareholdersEquityChangesInShareholdersEquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/ShareholdersEquityNarrativeDetails" xlink:href="insm-20180930.xsd#ShareholdersEquityNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/ShareholdersEquityTables" xlink:href="insm-20180930.xsd#ShareholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensation" xlink:href="insm-20180930.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" xlink:href="insm-20180930.xsd#StockBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails" xlink:href="insm-20180930.xsd#StockBasedCompensationRangeOfExercisePricesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails" xlink:href="insm-20180930.xsd#StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails" xlink:href="insm-20180930.xsd#StockBasedCompensationStockOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensationTables" xlink:href="insm-20180930.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="insm-20180930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesDetails" xlink:href="insm-20180930.xsd#SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails" xlink:href="insm-20180930.xsd#SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:href="insm-20180930.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails" xlink:href="insm-20180930.xsd#SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="insm-20180930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesRecentlyAdoptedAccountingPronouncementsDetails" xlink:href="insm-20180930.xsd#SummaryOfSignificantAccountingPoliciesRecentlyAdoptedAccountingPronouncementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="insm-20180930.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/AccruedExpenses" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:type="locator" />
    <link:loc xlink:href="insm-20180930.xsd#insm_AccruedClinicalTrialExpenses" xlink:label="loc_insm_AccruedClinicalTrialExpenses_1382fe8e-8d11-3635-4b91-c90ad1b1c336" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:to="loc_insm_AccruedClinicalTrialExpenses_1382fe8e-8d11-3635-4b91-c90ad1b1c336" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_cf9ed09f-3dd1-4a4b-d3fc-3b0db18c1b40" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_cf9ed09f-3dd1-4a4b-d3fc-3b0db18c1b40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_98d31a39-575d-6ddd-42a2-18a0e94f1b32" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_98d31a39-575d-6ddd-42a2-18a0e94f1b32" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_AccruedTechnicalOperationExpenses" xlink:label="loc_insm_AccruedTechnicalOperationExpenses_46b5e3e6-838a-a37f-7cd9-c90ad1ac24ab" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:to="loc_insm_AccruedTechnicalOperationExpenses_46b5e3e6-838a-a37f-7cd9-c90ad1ac24ab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_f399ab19-6853-cf94-a0cf-c511e9e00641" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:to="loc_us-gaap_InterestPayableCurrent_f399ab19-6853-cf94-a0cf-c511e9e00641" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_AccruedConstructionLiabilitiesCurrent" xlink:label="loc_insm_AccruedConstructionLiabilitiesCurrent_BA462B01C136B7744C6794D466E60209" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:to="loc_insm_AccruedConstructionLiabilitiesCurrent_BA462B01C136B7744C6794D466E60209" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_00b000cf-7f1d-4891-7244-daf9f6335db0" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_00b000cf-7f1d-4891-7244-daf9f6335db0" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_AccruedMilestonePaymentCurrent" xlink:label="loc_insm_AccruedMilestonePaymentCurrent_156C67379A9BC5EDAC22AC5C552149C7" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:to="loc_insm_AccruedMilestonePaymentCurrent_156C67379A9BC5EDAC22AC5C552149C7" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.insmed.com/role/AccruedExpensesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/CommitmentsAndContingenciesMinimumRentalPaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_e7ae0c4b-54d0-1d15-1541-1fb5329d750c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_2a03e078-acdc-ce26-bc2c-c1c04ab9fd4f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_e7ae0c4b-54d0-1d15-1541-1fb5329d750c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_2a03e078-acdc-ce26-bc2c-c1c04ab9fd4f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_483c5d20-89a2-da39-b56f-2ea722d97042" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_e7ae0c4b-54d0-1d15-1541-1fb5329d750c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_483c5d20-89a2-da39-b56f-2ea722d97042" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_b5a3356e-f555-ddd5-297a-b04afe0bfd5c" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_e7ae0c4b-54d0-1d15-1541-1fb5329d750c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_b5a3356e-f555-ddd5-297a-b04afe0bfd5c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_6818de09-a032-5221-5ee6-896e1c2d0634" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_e7ae0c4b-54d0-1d15-1541-1fb5329d750c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_6818de09-a032-5221-5ee6-896e1c2d0634" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_56f89e4f-d247-3cf0-a749-00554ab475a6" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_e7ae0c4b-54d0-1d15-1541-1fb5329d750c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_56f89e4f-d247-3cf0-a749-00554ab475a6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_fb0efb32-4bb1-57d0-236e-d8af81dc125f" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_e7ae0c4b-54d0-1d15-1541-1fb5329d750c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_fb0efb32-4bb1-57d0-236e-d8af81dc125f" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.insmed.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/CompanyAndBasisOfPresentation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/CompanyAndBasisOfPresentationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:to="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_7a72b51a-735c-1ad4-bd3f-d9bcf2d6a26d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_AccountsPayableCurrent_7a72b51a-735c-1ad4-bd3f-d9bcf2d6a26d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_b4e6cca3-6c62-3e0a-6782-510b974f1199" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_b4e6cca3-6c62-3e0a-6782-510b974f1199" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_f234998c-5e05-09d0-d53e-5c44423c97c0" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_f234998c-5e05-09d0-d53e-5c44423c97c0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_822b66ff-44a1-e66b-5e0c-09356970a23d" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_822b66ff-44a1-e66b-5e0c-09356970a23d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:to="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_c3f7606a-e7e9-61d5-b60b-b4b059f68b26" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_CommonStockValue_c3f7606a-e7e9-61d5-b60b-b4b059f68b26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_2d1b9d27-8b19-82d9-2843-5b3d292b7fbb" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_AdditionalPaidInCapital_2d1b9d27-8b19-82d9-2843-5b3d292b7fbb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_065cb284-7fca-cc9b-5752-2feaf74d0011" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_065cb284-7fca-cc9b-5752-2feaf74d0011" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_04f0961a-a0bc-88cf-6658-3f950da4a458" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_04f0961a-a0bc-88cf-6658-3f950da4a458" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_07da1db4-2708-4446-4250-1fdd5956185e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_07da1db4-2708-4446-4250-1fdd5956185e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2294e6a2-7bab-43ed-d02c-bdf73b8fa561" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2294e6a2-7bab-43ed-d02c-bdf73b8fa561" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_49187b45-82fd-7060-b114-79ff249a4331" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_49187b45-82fd-7060-b114-79ff249a4331" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaap_OtherAssets_cb56b01f-b9c5-ca9e-8988-e23b27fc7a20" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_OtherAssets_cb56b01f-b9c5-ca9e-8988-e23b27fc7a20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.insmed.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_dd2e9db6-10f9-d78a-ba84-b18268245a83" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_dd2e9db6-10f9-d78a-ba84-b18268245a83" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_b4463f01-8926-c348-9c78-89e2ab0ed145" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_Depreciation_b4463f01-8926-c348-9c78-89e2ab0ed145" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_e3eecf87-b290-4567-8a59-5b0a8e27c85b" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_ShareBasedCompensation_e3eecf87-b290-4567-8a59-5b0a8e27c85b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_88999971-796e-a544-2b43-0669ab932f8e" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_88999971-796e-a544-2b43-0669ab932f8e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccretionExpense" xlink:label="loc_us-gaap_AccretionExpense_97b15c8a-d8d9-531b-f51b-82fe98727209" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_AccretionExpense_97b15c8a-d8d9-531b-f51b-82fe98727209" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c998cbd2-a633-c2ec-1932-e3bfedecbc9f" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c998cbd2-a633-c2ec-1932-e3bfedecbc9f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a8b6fe35-4809-bddf-7ef6-3144a6c89165" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a8b6fe35-4809-bddf-7ef6-3144a6c89165" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities" xlink:label="loc_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities_b5eda9bc-7930-4cc8-6fc9-c90ad1b2706a" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities_b5eda9bc-7930-4cc8-6fc9-c90ad1b2706a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_6998acca-43aa-59af-b14d-5e2253d7d1df" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_6998acca-43aa-59af-b14d-5e2253d7d1df" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_dd2e9db6-10f9-d78a-ba84-b18268245a83" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fee12b15-6b42-6245-2e2f-ff030b98332c" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fee12b15-6b42-6245-2e2f-ff030b98332c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_dd2e9db6-10f9-d78a-ba84-b18268245a83" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_d04df344-47da-0222-79d0-99b7d739fd60" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_d04df344-47da-0222-79d0-99b7d739fd60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_2afa112f-8746-a6f0-c674-adbee2f9fa7d" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_2afa112f-8746-a6f0-c674-adbee2f9fa7d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_6d9b7dce-39b9-34d3-9e48-3b74a3681093" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_RepaymentsOfDebt_6d9b7dce-39b9-34d3-9e48-3b74a3681093" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_2648fb49-ac2e-6969-ad2b-f3869ac97490" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_2648fb49-ac2e-6969-ad2b-f3869ac97490" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_f19a6911-0ca9-0f7f-0ae8-f18c6d766244" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_f19a6911-0ca9-0f7f-0ae8-f18c6d766244" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_dbbd5d91-eb58-fa81-2753-d9ddf4ada4c1" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_dbbd5d91-eb58-fa81-2753-d9ddf4ada4c1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_8629a772-7004-5d77-9980-0f501e29c5c8" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_dd2e9db6-10f9-d78a-ba84-b18268245a83" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_8629a772-7004-5d77-9980-0f501e29c5c8" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnauditedParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_499015ce-2160-aed2-85a3-080e8c4c6cdf" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_499015ce-2160-aed2-85a3-080e8c4c6cdf" xlink:to="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a53f52a4-7a54-3283-f734-95683c76ebff" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a53f52a4-7a54-3283-f734-95683c76ebff" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a53f52a4-7a54-3283-f734-95683c76ebff" xlink:to="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:to="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_25ae5ce2-b413-b975-9a84-c7503d2496cf" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_25ae5ce2-b413-b975-9a84-c7503d2496cf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_87411e46-c979-a1ff-e8b3-f4f75d86b855" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_87411e46-c979-a1ff-e8b3-f4f75d86b855" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_33f76b65-31cf-be04-0849-25af345446d5" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:to="loc_us-gaap_Revenues_33f76b65-31cf-be04-0849-25af345446d5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating_6d011e0e-8a4d-ead4-8ae2-208e1f9abb48" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a53f52a4-7a54-3283-f734-95683c76ebff" xlink:to="loc_us-gaap_InvestmentIncomeNonoperating_6d011e0e-8a4d-ead4-8ae2-208e1f9abb48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_7c9599ab-2a77-022c-c720-63fecff6a62c" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a53f52a4-7a54-3283-f734-95683c76ebff" xlink:to="loc_us-gaap_InterestExpense_7c9599ab-2a77-022c-c720-63fecff6a62c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_250c3b2f-7db5-7088-68cc-1dd831a2c2d7" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a53f52a4-7a54-3283-f734-95683c76ebff" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_250c3b2f-7db5-7088-68cc-1dd831a2c2d7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3db65903-3171-d63c-a688-532ba00b8108" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a53f52a4-7a54-3283-f734-95683c76ebff" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3db65903-3171-d63c-a688-532ba00b8108" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_4230dd8a-1a56-db80-c035-2fabf7b960fd" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_499015ce-2160-aed2-85a3-080e8c4c6cdf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_4230dd8a-1a56-db80-c035-2fabf7b960fd" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.insmed.com/role/Debt" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/DebtComponentsOfDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_6B1B60D9FC1E524681300C325A38D571" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SecuredDebt" xlink:label="loc_us-gaap_SecuredDebt_98E17DEABB17535CBEDAB242FC23EEF9" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_6B1B60D9FC1E524681300C325A38D571" xlink:to="loc_us-gaap_SecuredDebt_98E17DEABB17535CBEDAB242FC23EEF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_41583BD224F85E808C9C2EF1017E0F81" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_6B1B60D9FC1E524681300C325A38D571" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_41583BD224F85E808C9C2EF1017E0F81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_F2B678310FAC500688F51420D965F43C" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_6B1B60D9FC1E524681300C325A38D571" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_F2B678310FAC500688F51420D965F43C" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.insmed.com/role/DebtFuturePrincipalRepaymentsOfDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_3F33719B42F75E0C85DFB308A0F49304" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_6232D4B217E950C49DBEF48427351AF9" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_3F33719B42F75E0C85DFB308A0F49304" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_6232D4B217E950C49DBEF48427351AF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_93E936A533FE5D4EA4D3EC889F35CE85" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_3F33719B42F75E0C85DFB308A0F49304" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_93E936A533FE5D4EA4D3EC889F35CE85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_FE16640E277D5193AE1D6CD915AFF2F8" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_3F33719B42F75E0C85DFB308A0F49304" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_FE16640E277D5193AE1D6CD915AFF2F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_4D7D35BDA3EB5FCFBE859AFDBAB06F13" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_3F33719B42F75E0C85DFB308A0F49304" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_4D7D35BDA3EB5FCFBE859AFDBAB06F13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_55F211F9B0E457FFADF5C9E4E8B56F42" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_3F33719B42F75E0C85DFB308A0F49304" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_55F211F9B0E457FFADF5C9E4E8B56F42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_409E8583DEBD5EB989AF253F46B6EE2C" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_3F33719B42F75E0C85DFB308A0F49304" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_409E8583DEBD5EB989AF253F46B6EE2C" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.insmed.com/role/DebtInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_C4C49A1034DC54AE8DB50B2BFD87A88D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_5D3AAC2DE4985995A96F808B8EDFCA27" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpense_C4C49A1034DC54AE8DB50B2BFD87A88D" xlink:to="loc_us-gaap_InterestExpenseDebt_5D3AAC2DE4985995A96F808B8EDFCA27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_C76AA3FD26C05B78A9F6131575E16F5C" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpense_C4C49A1034DC54AE8DB50B2BFD87A88D" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_C76AA3FD26C05B78A9F6131575E16F5C" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_AmortizationOfBackendFee" xlink:label="loc_insm_AmortizationOfBackendFee_E4E961B3A021500991AC8964BE3A8363" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpense_C4C49A1034DC54AE8DB50B2BFD87A88D" xlink:to="loc_insm_AmortizationOfBackendFee_E4E961B3A021500991AC8964BE3A8363" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_374BA97E1AB05482914FB3FD28C36AD2" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpense_C4C49A1034DC54AE8DB50B2BFD87A88D" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_374BA97E1AB05482914FB3FD28C36AD2" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.insmed.com/role/DebtNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/DebtTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/IncomeTaxesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/IntangibleAssets" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/IntangibleAssetsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/IntangibleAssetsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/ShareholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/ShareholdersEquityChangesInShareholdersEquityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/ShareholdersEquityNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/ShareholdersEquityTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/StockBasedCompensationTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_223fd9c8-68e8-e433-7c40-f98b238e79de" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_86e61cf2-b7b2-e230-65f1-5a2b152f3a30" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_223fd9c8-68e8-e433-7c40-f98b238e79de" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_86e61cf2-b7b2-e230-65f1-5a2b152f3a30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_9f904e4b-2e06-aacf-a7ec-13e1e7c99c9e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_223fd9c8-68e8-e433-7c40-f98b238e79de" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_9f904e4b-2e06-aacf-a7ec-13e1e7c99c9e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_cee10fe8-a4bb-491c-22f6-69a723d6a718" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_223fd9c8-68e8-e433-7c40-f98b238e79de" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_cee10fe8-a4bb-491c-22f6-69a723d6a718" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesRecentlyAdoptedAccountingPronouncementsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>insm-20180930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.insmed.com/role/AccruedExpenses" xlink:href="insm-20180930.xsd#AccruedExpenses" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/AccruedExpensesDetails" xlink:href="insm-20180930.xsd#AccruedExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/AccruedExpensesTables" xlink:href="insm-20180930.xsd#AccruedExpensesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/CommitmentsAndContingencies" xlink:href="insm-20180930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/CommitmentsAndContingenciesMinimumRentalPaymentsDetails" xlink:href="insm-20180930.xsd#CommitmentsAndContingenciesMinimumRentalPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:href="insm-20180930.xsd#CommitmentsAndContingenciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/CommitmentsAndContingenciesTables" xlink:href="insm-20180930.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/CompanyAndBasisOfPresentation" xlink:href="insm-20180930.xsd#CompanyAndBasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/CompanyAndBasisOfPresentationDetails" xlink:href="insm-20180930.xsd#CompanyAndBasisOfPresentationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:href="insm-20180930.xsd#ConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="insm-20180930.xsd#ConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="insm-20180930.xsd#ConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnauditedParenthetical" xlink:href="insm-20180930.xsd#ConsolidatedStatementsOfCashFlowsUnauditedParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited" xlink:href="insm-20180930.xsd#ConsolidatedStatementsOfComprehensiveLossUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/Debt" xlink:href="insm-20180930.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/DebtComponentsOfDebtDetails" xlink:href="insm-20180930.xsd#DebtComponentsOfDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/DebtFuturePrincipalRepaymentsOfDebtDetails" xlink:href="insm-20180930.xsd#DebtFuturePrincipalRepaymentsOfDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/DebtInterestExpenseDetails" xlink:href="insm-20180930.xsd#DebtInterestExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/DebtNarrativeDetails" xlink:href="insm-20180930.xsd#DebtNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/DebtTables" xlink:href="insm-20180930.xsd#DebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/DocumentAndEntityInformation" xlink:href="insm-20180930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxes" xlink:href="insm-20180930.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxesDetails" xlink:href="insm-20180930.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/IntangibleAssets" xlink:href="insm-20180930.xsd#IntangibleAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/IntangibleAssetsNarrativeDetails" xlink:href="insm-20180930.xsd#IntangibleAssetsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails" xlink:href="insm-20180930.xsd#IntangibleAssetsScheduleOfIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/IntangibleAssetsTables" xlink:href="insm-20180930.xsd#IntangibleAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/ShareholdersEquity" xlink:href="insm-20180930.xsd#ShareholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/ShareholdersEquityChangesInShareholdersEquityDetails" xlink:href="insm-20180930.xsd#ShareholdersEquityChangesInShareholdersEquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/ShareholdersEquityNarrativeDetails" xlink:href="insm-20180930.xsd#ShareholdersEquityNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/ShareholdersEquityTables" xlink:href="insm-20180930.xsd#ShareholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensation" xlink:href="insm-20180930.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" xlink:href="insm-20180930.xsd#StockBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails" xlink:href="insm-20180930.xsd#StockBasedCompensationRangeOfExercisePricesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails" xlink:href="insm-20180930.xsd#StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails" xlink:href="insm-20180930.xsd#StockBasedCompensationStockOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensationTables" xlink:href="insm-20180930.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="insm-20180930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesDetails" xlink:href="insm-20180930.xsd#SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails" xlink:href="insm-20180930.xsd#SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:href="insm-20180930.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails" xlink:href="insm-20180930.xsd#SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="insm-20180930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesRecentlyAdoptedAccountingPronouncementsDetails" xlink:href="insm-20180930.xsd#SummaryOfSignificantAccountingPoliciesRecentlyAdoptedAccountingPronouncementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="insm-20180930.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/AccruedExpenses" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/AccruedExpensesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/AccruedExpensesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/CommitmentsAndContingenciesMinimumRentalPaymentsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_43B005EA778C5FE8863FAC58EA451D17" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_779F2EFF1DFA7F854243AC58EA4493B3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_43B005EA778C5FE8863FAC58EA451D17" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_779F2EFF1DFA7F854243AC58EA4493B3" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="loc_us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_98CC0CDDBAA13AA97847AC58EA446EB4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_779F2EFF1DFA7F854243AC58EA4493B3" xlink:to="loc_us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_98CC0CDDBAA13AA97847AC58EA446EB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="loc_us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_95AAEDA2D543B8214A2AAC58EA440B67_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_98CC0CDDBAA13AA97847AC58EA446EB4" xlink:to="loc_us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_95AAEDA2D543B8214A2AAC58EA440B67_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="loc_us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_95AAEDA2D543B8214A2AAC58EA440B67" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_98CC0CDDBAA13AA97847AC58EA446EB4" xlink:to="loc_us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_95AAEDA2D543B8214A2AAC58EA440B67" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_BridgewaterNewJerseyFacilityMember" xlink:label="loc_insm_BridgewaterNewJerseyFacilityMember_56E96F2AF56EC6CC6D99AC58EA45D772" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_95AAEDA2D543B8214A2AAC58EA440B67" xlink:to="loc_insm_BridgewaterNewJerseyFacilityMember_56E96F2AF56EC6CC6D99AC58EA45D772" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_BridgewaterNewJerseyOfficeSpaceMember" xlink:label="loc_insm_BridgewaterNewJerseyOfficeSpaceMember_3FD0C61F1B1A4C0CB1B1AC58EA45B0A8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_95AAEDA2D543B8214A2AAC58EA440B67" xlink:to="loc_insm_BridgewaterNewJerseyOfficeSpaceMember_3FD0C61F1B1A4C0CB1B1AC58EA45B0A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_24AF02F68AEACA6DC1CCAC58EA459161" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_43B005EA778C5FE8863FAC58EA451D17" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_24AF02F68AEACA6DC1CCAC58EA459161" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_AdditionalLaboratorySpaceOperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_insm_AdditionalLaboratorySpaceOperatingLeasesFutureMinimumPaymentsDue_7F0B07071F322C8BA06EAC58EA4640C2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_43B005EA778C5FE8863FAC58EA451D17" xlink:to="loc_insm_AdditionalLaboratorySpaceOperatingLeasesFutureMinimumPaymentsDue_7F0B07071F322C8BA06EAC58EA4640C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_D4FE0F52497C5FA1C114AC58EA46C15C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_43B005EA778C5FE8863FAC58EA451D17" xlink:to="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_D4FE0F52497C5FA1C114AC58EA46C15C" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_LesseeOperatingLeaseNumberOfRenewals" xlink:label="loc_insm_LesseeOperatingLeaseNumberOfRenewals_54BD7C4154E59CBB7205AC58EA46108B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_43B005EA778C5FE8863FAC58EA451D17" xlink:to="loc_insm_LesseeOperatingLeaseNumberOfRenewals_54BD7C4154E59CBB7205AC58EA46108B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_E45475F47DDAF8F2E4DBAC58EA461885" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_43B005EA778C5FE8863FAC58EA451D17" xlink:to="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_E45475F47DDAF8F2E4DBAC58EA461885" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_7CDE46DECE23B73A51D0AC58EA4659D6" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_43B005EA778C5FE8863FAC58EA451D17" xlink:to="loc_us-gaap_LeaseAndRentalExpense_7CDE46DECE23B73A51D0AC58EA4659D6" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.insmed.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/CompanyAndBasisOfPresentation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/CompanyAndBasisOfPresentationDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_93F0D8CC867E5552853FD29B032455A8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_E9E67DEC55695EDCB9C023BAC99FB42F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_93F0D8CC867E5552853FD29B032455A8" xlink:to="loc_us-gaap_StatementTable_E9E67DEC55695EDCB9C023BAC99FB42F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2DEBD773E5C35AD095EF9D13DA93F5E7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_E9E67DEC55695EDCB9C023BAC99FB42F" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2DEBD773E5C35AD095EF9D13DA93F5E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_FB02D59975BE1119AB95FF2F33580FC2_1227FFB3A4F65EC997EA7CB390A223FE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2DEBD773E5C35AD095EF9D13DA93F5E7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_FB02D59975BE1119AB95FF2F33580FC2_1227FFB3A4F65EC997EA7CB390A223FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_37F9F7ACED125DF095E27612E4F2A7AD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2DEBD773E5C35AD095EF9D13DA93F5E7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_37F9F7ACED125DF095E27612E4F2A7AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_91C10855EF4255E882DB5D5117B89185" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_37F9F7ACED125DF095E27612E4F2A7AD" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_91C10855EF4255E882DB5D5117B89185" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_8F14EE79483A5ACFB59D40A421D2F427" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_E9E67DEC55695EDCB9C023BAC99FB42F" xlink:to="loc_us-gaap_DebtInstrumentAxis_8F14EE79483A5ACFB59D40A421D2F427" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_14CB95F653D45D06A7C7FF2F335916AF_1227FFB3A4F65EC997EA7CB390A223FE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_8F14EE79483A5ACFB59D40A421D2F427" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_14CB95F653D45D06A7C7FF2F335916AF_1227FFB3A4F65EC997EA7CB390A223FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_A24B83DE3037523EB66A5DE7C6AA8F61" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_8F14EE79483A5ACFB59D40A421D2F427" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_A24B83DE3037523EB66A5DE7C6AA8F61" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member" xlink:label="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_2D680018F18056D080F17C607FC1A24D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A24B83DE3037523EB66A5DE7C6AA8F61" xlink:to="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_2D680018F18056D080F17C607FC1A24D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_A377B7A5ED8B5605AFCA7496E38C23CC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_93F0D8CC867E5552853FD29B032455A8" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_A377B7A5ED8B5605AFCA7496E38C23CC" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/Debt" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/DebtComponentsOfDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_F7AFE2FBF5D35C4D80778EF7C2761AF6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_0AD5FB52AEF35EC292AAE80DF3176EF9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F7AFE2FBF5D35C4D80778EF7C2761AF6" xlink:to="loc_us-gaap_DebtInstrumentTable_0AD5FB52AEF35EC292AAE80DF3176EF9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_FF6AB9E8AD6C52249F533A0873C12F37" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0AD5FB52AEF35EC292AAE80DF3176EF9" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_FF6AB9E8AD6C52249F533A0873C12F37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6787E0850AEC87D6D2394D12218682E5_644267BC62C7567B8405943251C5719A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_FF6AB9E8AD6C52249F533A0873C12F37" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6787E0850AEC87D6D2394D12218682E5_644267BC62C7567B8405943251C5719A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1B989057D2485A05A3C4715E8CDA57A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_FF6AB9E8AD6C52249F533A0873C12F37" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1B989057D2485A05A3C4715E8CDA57A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_9FAE1C638A905A6697E5212B9F08E083" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1B989057D2485A05A3C4715E8CDA57A2" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_9FAE1C638A905A6697E5212B9F08E083" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_B39294603CC35B1AAFFEF0D73D15638A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0AD5FB52AEF35EC292AAE80DF3176EF9" xlink:to="loc_us-gaap_DebtInstrumentAxis_B39294603CC35B1AAFFEF0D73D15638A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5C1CD94A27346845F0284D12218645D7_644267BC62C7567B8405943251C5719A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_B39294603CC35B1AAFFEF0D73D15638A" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5C1CD94A27346845F0284D12218645D7_644267BC62C7567B8405943251C5719A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0598885828F15183AAA9E145E0E1C090" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_B39294603CC35B1AAFFEF0D73D15638A" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0598885828F15183AAA9E145E0E1C090" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member" xlink:label="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_6D12B003B46756369AA937480AF9D119" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0598885828F15183AAA9E145E0E1C090" xlink:to="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_6D12B003B46756369AA937480AF9D119" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SecuredDebt" xlink:label="loc_us-gaap_SecuredDebt_B07D806391B1512493894BDB15B913CB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F7AFE2FBF5D35C4D80778EF7C2761AF6" xlink:to="loc_us-gaap_SecuredDebt_B07D806391B1512493894BDB15B913CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7B644D1E647D5EDC87B0F917E23CE586" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F7AFE2FBF5D35C4D80778EF7C2761AF6" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7B644D1E647D5EDC87B0F917E23CE586" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_1EC63E0E62675D70B52F9CE16A2D7489" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F7AFE2FBF5D35C4D80778EF7C2761AF6" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_1EC63E0E62675D70B52F9CE16A2D7489" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_E5CC7260B7C2506AABD0D7E1CA8F9DC2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F7AFE2FBF5D35C4D80778EF7C2761AF6" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_E5CC7260B7C2506AABD0D7E1CA8F9DC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_96018C0F0BF5550C905FDC794C56A9CB" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F7AFE2FBF5D35C4D80778EF7C2761AF6" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_96018C0F0BF5550C905FDC794C56A9CB" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.insmed.com/role/DebtFuturePrincipalRepaymentsOfDebtDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/DebtInterestExpenseDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_C41DC04876525570B647A0D76BF3F30B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_6ECBC424531357CB9B293B81C26EE7A5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C41DC04876525570B647A0D76BF3F30B" xlink:to="loc_us-gaap_DebtInstrumentTable_6ECBC424531357CB9B293B81C26EE7A5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_63D1000106A151958C1970F81DD7C44D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6ECBC424531357CB9B293B81C26EE7A5" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_63D1000106A151958C1970F81DD7C44D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4943F36FC29C4A5C5444F60EC15E5CE3_644267BC62C7567B8405943251C5719A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_63D1000106A151958C1970F81DD7C44D" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4943F36FC29C4A5C5444F60EC15E5CE3_644267BC62C7567B8405943251C5719A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_90196C73615552EFA39455EDF4504AA9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_63D1000106A151958C1970F81DD7C44D" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_90196C73615552EFA39455EDF4504AA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_2C7C3119544B5FA492530FC4C2CBB99D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_90196C73615552EFA39455EDF4504AA9" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_2C7C3119544B5FA492530FC4C2CBB99D" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_DebtInstrumentConversionTermAxis" xlink:label="loc_insm_DebtInstrumentConversionTermAxis_7201507BE3E450508BD3EDB11B1BB7DE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6ECBC424531357CB9B293B81C26EE7A5" xlink:to="loc_insm_DebtInstrumentConversionTermAxis_7201507BE3E450508BD3EDB11B1BB7DE" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_DebtInstrumentConversionTermDomain" xlink:label="loc_insm_DebtInstrumentConversionTermDomain_08E88FBE0B6C0CB39F26F60EC15F880B_644267BC62C7567B8405943251C5719A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_insm_DebtInstrumentConversionTermAxis_7201507BE3E450508BD3EDB11B1BB7DE" xlink:to="loc_insm_DebtInstrumentConversionTermDomain_08E88FBE0B6C0CB39F26F60EC15F880B_644267BC62C7567B8405943251C5719A" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_DebtInstrumentConversionTermDomain" xlink:label="loc_insm_DebtInstrumentConversionTermDomain_A7F89F6B1BB855EAAF6D4E7F9971CB22" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_insm_DebtInstrumentConversionTermAxis_7201507BE3E450508BD3EDB11B1BB7DE" xlink:to="loc_insm_DebtInstrumentConversionTermDomain_A7F89F6B1BB855EAAF6D4E7F9971CB22" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_DebtInstrumentConversionTermOneMember" xlink:label="loc_insm_DebtInstrumentConversionTermOneMember_0BAE622129815C4599199CBB6AD912BB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_DebtInstrumentConversionTermDomain_A7F89F6B1BB855EAAF6D4E7F9971CB22" xlink:to="loc_insm_DebtInstrumentConversionTermOneMember_0BAE622129815C4599199CBB6AD912BB" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_DebtInstrumentConversionTermTwoMember" xlink:label="loc_insm_DebtInstrumentConversionTermTwoMember_7CB12083991F564088F94E010BF66922" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_DebtInstrumentConversionTermDomain_A7F89F6B1BB855EAAF6D4E7F9971CB22" xlink:to="loc_insm_DebtInstrumentConversionTermTwoMember_7CB12083991F564088F94E010BF66922" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_DebtInstrumentConversionTermThreeMember" xlink:label="loc_insm_DebtInstrumentConversionTermThreeMember_0D4E82738BB9556FA199A1DB1733C30C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_DebtInstrumentConversionTermDomain_A7F89F6B1BB855EAAF6D4E7F9971CB22" xlink:to="loc_insm_DebtInstrumentConversionTermThreeMember_0D4E82738BB9556FA199A1DB1733C30C" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_DebtInstrumentConversionTermFourMember" xlink:label="loc_insm_DebtInstrumentConversionTermFourMember_146A4966BFDF55C68F963C90CF464FAD" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_DebtInstrumentConversionTermDomain_A7F89F6B1BB855EAAF6D4E7F9971CB22" xlink:to="loc_insm_DebtInstrumentConversionTermFourMember_146A4966BFDF55C68F963C90CF464FAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_C666C5455D3B5E4F886E4B8C38333FD1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6ECBC424531357CB9B293B81C26EE7A5" xlink:to="loc_us-gaap_DebtInstrumentAxis_C666C5455D3B5E4F886E4B8C38333FD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_430D3F7CBB8B0AB88404F60EC160A394_644267BC62C7567B8405943251C5719A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_C666C5455D3B5E4F886E4B8C38333FD1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_430D3F7CBB8B0AB88404F60EC160A394_644267BC62C7567B8405943251C5719A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_537E20702E0550E480FB79791868ED6F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_C666C5455D3B5E4F886E4B8C38333FD1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_537E20702E0550E480FB79791868ED6F" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member" xlink:label="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_2871A182E3BF5EA9BFFE45F6521B9CB0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_537E20702E0550E480FB79791868ED6F" xlink:to="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_2871A182E3BF5EA9BFFE45F6521B9CB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember_3A54F9D00D6F5A90B032D4579B17E226" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_537E20702E0550E480FB79791868ED6F" xlink:to="loc_us-gaap_LineOfCreditMember_3A54F9D00D6F5A90B032D4579B17E226" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_36F0407517635CE586BF4642DDFAC9B3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C41DC04876525570B647A0D76BF3F30B" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_36F0407517635CE586BF4642DDFAC9B3" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_DebtInstrumentOptionToPurchaseAdditionalDebt" xlink:label="loc_insm_DebtInstrumentOptionToPurchaseAdditionalDebt_545B50DB8BC85295B28569DE61F2E4C2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C41DC04876525570B647A0D76BF3F30B" xlink:to="loc_insm_DebtInstrumentOptionToPurchaseAdditionalDebt_545B50DB8BC85295B28569DE61F2E4C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_29E40E59124D5704B708D4807315D76B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C41DC04876525570B647A0D76BF3F30B" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_29E40E59124D5704B708D4807315D76B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_6EEAC89DC9AE55F08690F9C2FC4EFBAB" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C41DC04876525570B647A0D76BF3F30B" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_6EEAC89DC9AE55F08690F9C2FC4EFBAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_40BCAB7B7D5B55659779650BA2EF300D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C41DC04876525570B647A0D76BF3F30B" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_40BCAB7B7D5B55659779650BA2EF300D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_EDEE2C3924B856F3B327A8A2C4326A51" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C41DC04876525570B647A0D76BF3F30B" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_EDEE2C3924B856F3B327A8A2C4326A51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_2ECCCBFFC2755767BA3E155751DD5D24" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C41DC04876525570B647A0D76BF3F30B" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_2ECCCBFFC2755767BA3E155751DD5D24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_2BE5A4523A505966B4C83A14CF9CA517" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C41DC04876525570B647A0D76BF3F30B" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_2BE5A4523A505966B4C83A14CF9CA517" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_7AACF8FD89575370B69118217FC4BE7A" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C41DC04876525570B647A0D76BF3F30B" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_7AACF8FD89575370B69118217FC4BE7A" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange" xlink:label="loc_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange_1D5A1BD002345C81B766809A929C3451" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C41DC04876525570B647A0D76BF3F30B" xlink:to="loc_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange_1D5A1BD002345C81B766809A929C3451" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_42289268E47E5FECBC1B218B1E65C47C" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C41DC04876525570B647A0D76BF3F30B" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_42289268E47E5FECBC1B218B1E65C47C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_1863F5AB19315B7EB8B0D353A14D40E4" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C41DC04876525570B647A0D76BF3F30B" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_1863F5AB19315B7EB8B0D353A14D40E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_336460CCDA675AF7ADFDAB7A80FED141" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C41DC04876525570B647A0D76BF3F30B" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_336460CCDA675AF7ADFDAB7A80FED141" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_FF5C17462C8950BA920E56ECB4F31D92" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C41DC04876525570B647A0D76BF3F30B" xlink:to="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_FF5C17462C8950BA920E56ECB4F31D92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_86DE6ED42139533A89B431DC9FE02A69" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C41DC04876525570B647A0D76BF3F30B" xlink:to="loc_us-gaap_InterestExpense_86DE6ED42139533A89B431DC9FE02A69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_C9EBE0E4EA1A5082AA7D4B7861999D04" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C41DC04876525570B647A0D76BF3F30B" xlink:to="loc_us-gaap_RepaymentsOfDebt_C9EBE0E4EA1A5082AA7D4B7861999D04" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_RepaymentsOfDebtFeesAndOutstandingInterest" xlink:label="loc_insm_RepaymentsOfDebtFeesAndOutstandingInterest_FDA30A388417564D8312B02C4890409A" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C41DC04876525570B647A0D76BF3F30B" xlink:to="loc_insm_RepaymentsOfDebtFeesAndOutstandingInterest_FDA30A388417564D8312B02C4890409A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3E93E492F17E5176998CBBA8342254DB" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C41DC04876525570B647A0D76BF3F30B" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3E93E492F17E5176998CBBA8342254DB" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.insmed.com/role/DebtTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/IncomeTaxesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/IntangibleAssets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/IntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_DE6EC94AABB3F3EE3585AC52B2462C84" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_647248AF31F6DEEBFB3FAC52B2454D1D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_DE6EC94AABB3F3EE3585AC52B2462C84" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_647248AF31F6DEEBFB3FAC52B2454D1D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_024272AB2F79429520EDAC52B245803F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_647248AF31F6DEEBFB3FAC52B2454D1D" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_024272AB2F79429520EDAC52B245803F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_353913F729A81CEA226AAC52B2455162_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_024272AB2F79429520EDAC52B245803F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_353913F729A81CEA226AAC52B2455162_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_353913F729A81CEA226AAC52B2455162" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_024272AB2F79429520EDAC52B245803F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_353913F729A81CEA226AAC52B2455162" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_7AC77EBE9D6065868C0CAC52B24669AE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_353913F729A81CEA226AAC52B2455162" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_7AC77EBE9D6065868C0CAC52B24669AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1111BD7530FDD79FBA67AC52B246C331" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_DE6EC94AABB3F3EE3585AC52B2462C84" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1111BD7530FDD79FBA67AC52B246C331" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_AccruedMilestonePaymentCurrent" xlink:label="loc_insm_AccruedMilestonePaymentCurrent_D34C9B6F484149238950AC5CCF9B844B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_DE6EC94AABB3F3EE3585AC52B2462C84" xlink:to="loc_insm_AccruedMilestonePaymentCurrent_D34C9B6F484149238950AC5CCF9B844B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_47672B67B44376FF4DB2AC52B2470EAD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_DE6EC94AABB3F3EE3585AC52B2462C84" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_47672B67B44376FF4DB2AC52B2470EAD" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.insmed.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_26A7930BA6D7835D42C4AC3F2E334C02" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4D434AC826641A68234BAC3F2E325F95" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_26A7930BA6D7835D42C4AC3F2E334C02" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4D434AC826641A68234BAC3F2E325F95" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C04D24EBF34C58CBE72AAC3F2E327FBA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4D434AC826641A68234BAC3F2E325F95" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C04D24EBF34C58CBE72AAC3F2E327FBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B287AED4AB1BDEC06DA9AC3F2E32885A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C04D24EBF34C58CBE72AAC3F2E327FBA" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B287AED4AB1BDEC06DA9AC3F2E32885A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B287AED4AB1BDEC06DA9AC3F2E32885A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C04D24EBF34C58CBE72AAC3F2E327FBA" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B287AED4AB1BDEC06DA9AC3F2E32885A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_345755D287514E679F93AC3F2E33C7FB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B287AED4AB1BDEC06DA9AC3F2E32885A" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_345755D287514E679F93AC3F2E33C7FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_1A4719054CBB9E913DB7AC3F2E3392DA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B287AED4AB1BDEC06DA9AC3F2E32885A" xlink:to="loc_us-gaap_LicensingAgreementsMember_1A4719054CBB9E913DB7AC3F2E3392DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_D96E77306C3153DBED0EAC3F2E337923" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_26A7930BA6D7835D42C4AC3F2E334C02" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_D96E77306C3153DBED0EAC3F2E337923" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.insmed.com/role/IntangibleAssetsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/ShareholdersEquity" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/ShareholdersEquityChangesInShareholdersEquityDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/ShareholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_4DC440B4ACBE5479A36AAD513366124E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1406145270A4598C8D33ADF1664C9307" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_4DC440B4ACBE5479A36AAD513366124E" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1406145270A4598C8D33ADF1664C9307" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2E037A9E7C1950A6A2DC060D430C6993" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1406145270A4598C8D33ADF1664C9307" xlink:to="loc_us-gaap_DebtInstrumentAxis_2E037A9E7C1950A6A2DC060D430C6993" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_25A3310DAA7D61EB3A10F60EC1235942_644267BC62C7567B8405943251C5719A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2E037A9E7C1950A6A2DC060D430C6993" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_25A3310DAA7D61EB3A10F60EC1235942_644267BC62C7567B8405943251C5719A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0210A78EFDE3575788F3AFBE18344302" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2E037A9E7C1950A6A2DC060D430C6993" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0210A78EFDE3575788F3AFBE18344302" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member" xlink:label="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_111753AE5DEA5A9B8893072918232BDA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0210A78EFDE3575788F3AFBE18344302" xlink:to="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_111753AE5DEA5A9B8893072918232BDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_0A9C66524FA05BC2AE7C1633CC2DB61F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1406145270A4598C8D33ADF1664C9307" xlink:to="loc_us-gaap_AwardTypeAxis_0A9C66524FA05BC2AE7C1633CC2DB61F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B3E5D0A7FAB98F97BBFAF60EC1249F94_644267BC62C7567B8405943251C5719A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0A9C66524FA05BC2AE7C1633CC2DB61F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B3E5D0A7FAB98F97BBFAF60EC1249F94_644267BC62C7567B8405943251C5719A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CBAE01F62CDB5C05ADA69653E3609615" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0A9C66524FA05BC2AE7C1633CC2DB61F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CBAE01F62CDB5C05ADA69653E3609615" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_EmployeeAndDirectorsStockOptionsMember" xlink:label="loc_insm_EmployeeAndDirectorsStockOptionsMember_4C34ADA34A835D1E89FA071B50213548" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CBAE01F62CDB5C05ADA69653E3609615" xlink:to="loc_insm_EmployeeAndDirectorsStockOptionsMember_4C34ADA34A835D1E89FA071B50213548" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_A8C65DAD2A6D5B19806821F1617B2EB9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CBAE01F62CDB5C05ADA69653E3609615" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_A8C65DAD2A6D5B19806821F1617B2EB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5FE0535CEE415572BE81298F8FF3F518" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1406145270A4598C8D33ADF1664C9307" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5FE0535CEE415572BE81298F8FF3F518" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_83B1563F431B0FD58C3EF60EC125B7F6_644267BC62C7567B8405943251C5719A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5FE0535CEE415572BE81298F8FF3F518" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_83B1563F431B0FD58C3EF60EC125B7F6_644267BC62C7567B8405943251C5719A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5916417D6371526C8BBCAFA0251482C6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5FE0535CEE415572BE81298F8FF3F518" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5916417D6371526C8BBCAFA0251482C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_EDB9356F0B92572D9C15C7E213E03D8F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5916417D6371526C8BBCAFA0251482C6" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_EDB9356F0B92572D9C15C7E213E03D8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_DAB2CA2A8AA55D1687C2303C7A8D575D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4DC440B4ACBE5479A36AAD513366124E" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_DAB2CA2A8AA55D1687C2303C7A8D575D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5C10142B4840560A8E3D32D69C923EA3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4DC440B4ACBE5479A36AAD513366124E" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5C10142B4840560A8E3D32D69C923EA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_61C39E54AE645AC18342E3276E774CA1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4DC440B4ACBE5479A36AAD513366124E" xlink:to="loc_us-gaap_CommonStockSharesIssued_61C39E54AE645AC18342E3276E774CA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1E196B845F7D544F8233BEE80C7E3C4E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4DC440B4ACBE5479A36AAD513366124E" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1E196B845F7D544F8233BEE80C7E3C4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_A629A7F20DAE550F8917371CD430E27E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4DC440B4ACBE5479A36AAD513366124E" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_A629A7F20DAE550F8917371CD430E27E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2EFA641D84C75A268F8C0A5A2EE04BE7" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4DC440B4ACBE5479A36AAD513366124E" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2EFA641D84C75A268F8C0A5A2EE04BE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_B2FE23948C4F5CF492FF56B968397948" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4DC440B4ACBE5479A36AAD513366124E" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_B2FE23948C4F5CF492FF56B968397948" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_A50857335B405834836D145B96B9C8D2" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4DC440B4ACBE5479A36AAD513366124E" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_A50857335B405834836D145B96B9C8D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_D65B987E35F25567B00EDB4DC542F0BE" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4DC440B4ACBE5479A36AAD513366124E" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_D65B987E35F25567B00EDB4DC542F0BE" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption" xlink:label="loc_insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption_65225E076D045BACAB25A56D75CE4227" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4DC440B4ACBE5479A36AAD513366124E" xlink:to="loc_insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption_65225E076D045BACAB25A56D75CE4227" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_4D7E0165131554569E046388862D716A" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4DC440B4ACBE5479A36AAD513366124E" xlink:to="loc_us-gaap_SharePrice_4D7E0165131554569E046388862D716A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_43098723806C5D9BB9668F35CD8118B9" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4DC440B4ACBE5479A36AAD513366124E" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_43098723806C5D9BB9668F35CD8118B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9150930775C55061B5400D98295BD770" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4DC440B4ACBE5479A36AAD513366124E" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9150930775C55061B5400D98295BD770" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_B8E035705B585351816E0FB1CF1137B5" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4DC440B4ACBE5479A36AAD513366124E" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_B8E035705B585351816E0FB1CF1137B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_29A126212CC05CC0B7913FD4466F6393" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4DC440B4ACBE5479A36AAD513366124E" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_29A126212CC05CC0B7913FD4466F6393" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_F5F9E48F02BD52748E8F35B198D13617" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4DC440B4ACBE5479A36AAD513366124E" xlink:to="loc_us-gaap_PreferredStockSharesIssued_F5F9E48F02BD52748E8F35B198D13617" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_E15257B492815EFC85DC8CF250EB79BA" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4DC440B4ACBE5479A36AAD513366124E" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_E15257B492815EFC85DC8CF250EB79BA" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.insmed.com/role/ShareholdersEquityTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A4A0CB37DF50D90F267BC148098F67FE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_406C6AFA718704FFAFF9C148098C904C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A4A0CB37DF50D90F267BC148098F67FE" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_406C6AFA718704FFAFF9C148098C904C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_8E88FEE58A71C5A087A8C148098D8523" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_406C6AFA718704FFAFF9C148098C904C" xlink:to="loc_us-gaap_PlanNameAxis_8E88FEE58A71C5A087A8C148098D8523" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_666446A6C0C686BE6948C148098D8B1F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_8E88FEE58A71C5A087A8C148098D8523" xlink:to="loc_us-gaap_PlanNameDomain_666446A6C0C686BE6948C148098D8B1F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_666446A6C0C686BE6948C148098D8B1F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_8E88FEE58A71C5A087A8C148098D8523" xlink:to="loc_us-gaap_PlanNameDomain_666446A6C0C686BE6948C148098D8B1F" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_EmployeeStockPurchasePlan2018Member" xlink:label="loc_insm_EmployeeStockPurchasePlan2018Member_C2A76D89F13EA4CB1ACAC148098DF461" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_666446A6C0C686BE6948C148098D8B1F" xlink:to="loc_insm_EmployeeStockPurchasePlan2018Member_C2A76D89F13EA4CB1ACAC148098DF461" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_F889FFBB7B47F438EEAEC148098ED2AD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_406C6AFA718704FFAFF9C148098C904C" xlink:to="loc_us-gaap_AwardTypeAxis_F889FFBB7B47F438EEAEC148098ED2AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0C7E5D356AD2BFB860E0C148098EB962_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_F889FFBB7B47F438EEAEC148098ED2AD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0C7E5D356AD2BFB860E0C148098EB962_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0C7E5D356AD2BFB860E0C148098EB962" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_F889FFBB7B47F438EEAEC148098ED2AD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0C7E5D356AD2BFB860E0C148098EB962" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_1D17F4FFE9002B1CCA8BC148098F0122" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0C7E5D356AD2BFB860E0C148098EB962" xlink:to="loc_us-gaap_PerformanceSharesMember_1D17F4FFE9002B1CCA8BC148098F0122" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_456DFDF348508A72EE74C148098F0A05" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A4A0CB37DF50D90F267BC148098F67FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_456DFDF348508A72EE74C148098F0A05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0DF3E650E46F91FB0645C148099057A7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A4A0CB37DF50D90F267BC148098F67FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0DF3E650E46F91FB0645C148099057A7" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross" xlink:label="loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross_37CA1BE775FF8EF4EB1EC148099070B8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A4A0CB37DF50D90F267BC148098F67FE" xlink:to="loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross_37CA1BE775FF8EF4EB1EC148099070B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_44365255D9873063D8EAC14809901481" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A4A0CB37DF50D90F267BC148098F67FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_44365255D9873063D8EAC14809901481" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_B56F01959497ECB7AEECC1480990C527" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A4A0CB37DF50D90F267BC148098F67FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_B56F01959497ECB7AEECC1480990C527" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_8C21E40A6D807704E56AC1480990C05F" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A4A0CB37DF50D90F267BC148098F67FE" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_8C21E40A6D807704E56AC1480990C05F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_AC7F6A07F3E839928959C1480991417B" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A4A0CB37DF50D90F267BC148098F67FE" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_AC7F6A07F3E839928959C1480991417B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2E8FC7B2FE15A4E12333C14809911EAD" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A4A0CB37DF50D90F267BC148098F67FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2E8FC7B2FE15A4E12333C14809911EAD" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_B1CB273A774F540F88ACBECA4261B6FA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_ACC2E24D0412676BA649BECA425D3CE3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_B1CB273A774F540F88ACBECA4261B6FA" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_ACC2E24D0412676BA649BECA425D3CE3" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_762DCB913A7C350AAA5CBECA425EE9D8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_ACC2E24D0412676BA649BECA425D3CE3" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_762DCB913A7C350AAA5CBECA425EE9D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_250632757FC8172548C8BECA425E0F76_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_762DCB913A7C350AAA5CBECA425EE9D8" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_250632757FC8172548C8BECA425E0F76_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_250632757FC8172548C8BECA425E0F76" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_762DCB913A7C350AAA5CBECA425EE9D8" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_250632757FC8172548C8BECA425E0F76" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_Range1Member" xlink:label="loc_insm_Range1Member_7DCCA95ECF2DD4779C7CBECA425E24C2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_250632757FC8172548C8BECA425E0F76" xlink:to="loc_insm_Range1Member_7DCCA95ECF2DD4779C7CBECA425E24C2" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_Range2Member" xlink:label="loc_insm_Range2Member_D2818585F4758CC12782BECA425FE155" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_250632757FC8172548C8BECA425E0F76" xlink:to="loc_insm_Range2Member_D2818585F4758CC12782BECA425FE155" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_Range3Member" xlink:label="loc_insm_Range3Member_382E8EA41DA15E0DC520BECA425FD214" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_250632757FC8172548C8BECA425E0F76" xlink:to="loc_insm_Range3Member_382E8EA41DA15E0DC520BECA425FD214" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_Range4Member" xlink:label="loc_insm_Range4Member_A5D29416DB8B4E020553BECA425FA5BB" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_250632757FC8172548C8BECA425E0F76" xlink:to="loc_insm_Range4Member_A5D29416DB8B4E020553BECA425FA5BB" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_Range5Member" xlink:label="loc_insm_Range5Member_DFC0AD92F3105687D42BBECA425FB8C2" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_250632757FC8172548C8BECA425E0F76" xlink:to="loc_insm_Range5Member_DFC0AD92F3105687D42BBECA425FB8C2" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_Range6Member" xlink:label="loc_insm_Range6Member_DDE16ABF6557A3A9A24ABECA425FB0EE" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_250632757FC8172548C8BECA425E0F76" xlink:to="loc_insm_Range6Member_DDE16ABF6557A3A9A24ABECA425FB0EE" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_Range7Member" xlink:label="loc_insm_Range7Member_DD55379B0AED6765BD86BECA425FE2CF" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_250632757FC8172548C8BECA425E0F76" xlink:to="loc_insm_Range7Member_DD55379B0AED6765BD86BECA425FE2CF" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_Range8Member" xlink:label="loc_insm_Range8Member_BC2E8CCCC4CF296E7986BECA4260EC1F" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_250632757FC8172548C8BECA425E0F76" xlink:to="loc_insm_Range8Member_BC2E8CCCC4CF296E7986BECA4260EC1F" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_Range9Member" xlink:label="loc_insm_Range9Member_747E5AFE504CC200805EBECA42600AF2" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_250632757FC8172548C8BECA425E0F76" xlink:to="loc_insm_Range9Member_747E5AFE504CC200805EBECA42600AF2" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_Range10Member" xlink:label="loc_insm_Range10Member_8036ECD09DBD16A9DCA9BECA42604214" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_250632757FC8172548C8BECA425E0F76" xlink:to="loc_insm_Range10Member_8036ECD09DBD16A9DCA9BECA42604214" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_C500752134F13BB57704BECA42608315" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_ACC2E24D0412676BA649BECA425D3CE3" xlink:to="loc_us-gaap_AwardTypeAxis_C500752134F13BB57704BECA42608315" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_416BB31DFF130451E98EBECA4260BEA6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_C500752134F13BB57704BECA42608315" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_416BB31DFF130451E98EBECA4260BEA6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_416BB31DFF130451E98EBECA4260BEA6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_C500752134F13BB57704BECA42608315" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_416BB31DFF130451E98EBECA4260BEA6" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_EmployeeAndDirectorsStockOptionsMember" xlink:label="loc_insm_EmployeeAndDirectorsStockOptionsMember_5F54122BDF34B6C95DA2BECA42614520" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_416BB31DFF130451E98EBECA4260BEA6" xlink:to="loc_insm_EmployeeAndDirectorsStockOptionsMember_5F54122BDF34B6C95DA2BECA42614520" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_51D1C23EBC30332F6C1DBECA42629059" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_B1CB273A774F540F88ACBECA4261B6FA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_51D1C23EBC30332F6C1DBECA42629059" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_6B7F75E4F1DF7E500C0EBECA42622E27" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_B1CB273A774F540F88ACBECA4261B6FA" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_6B7F75E4F1DF7E500C0EBECA42622E27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_F25265C7E38B4F7553DABECA426233C3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_B1CB273A774F540F88ACBECA4261B6FA" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_F25265C7E38B4F7553DABECA426233C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_76F3CF54915C282F1509BECA426275BB" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_B1CB273A774F540F88ACBECA4261B6FA" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_76F3CF54915C282F1509BECA426275BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_F370AF5928D1E6E3705DBECA426352B6" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_B1CB273A774F540F88ACBECA4261B6FA" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_F370AF5928D1E6E3705DBECA426352B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_E95FC340454A64692967BECA42632D1B" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_B1CB273A774F540F88ACBECA4261B6FA" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_E95FC340454A64692967BECA42632D1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_7299DC2D19C683B2983BBECA426300BE" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_B1CB273A774F540F88ACBECA4261B6FA" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_7299DC2D19C683B2983BBECA426300BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_6A5BABD24C37E89A6AC2BECA42632E49" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_B1CB273A774F540F88ACBECA4261B6FA" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_6A5BABD24C37E89A6AC2BECA42632E49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_1CA43CE2089090A214A0BECA4263B304" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_B1CB273A774F540F88ACBECA4261B6FA" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_1CA43CE2089090A214A0BECA4263B304" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_B0783FEA62036C27F1DBBECA4263754A" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_B1CB273A774F540F88ACBECA4261B6FA" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_B0783FEA62036C27F1DBBECA4263754A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F624CCFEE12450E68B4AA8C3667972E5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C30B4165162A58878FD8FEC6693333AD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F624CCFEE12450E68B4AA8C3667972E5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C30B4165162A58878FD8FEC6693333AD" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_B5B0B51C39FE56CDB0E46F47B3BC736F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C30B4165162A58878FD8FEC6693333AD" xlink:to="loc_us-gaap_AwardTypeAxis_B5B0B51C39FE56CDB0E46F47B3BC736F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_985F0E533FCB25EF4E50F036DA418C63_644267BC62C7567B8405943251C5719A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_B5B0B51C39FE56CDB0E46F47B3BC736F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_985F0E533FCB25EF4E50F036DA418C63_644267BC62C7567B8405943251C5719A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_82D74F5849A058C18E8ECE8C7DFCF49A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_B5B0B51C39FE56CDB0E46F47B3BC736F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_82D74F5849A058C18E8ECE8C7DFCF49A" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_StockOptionsAndRestrictedStockUnitsMember" xlink:label="loc_insm_StockOptionsAndRestrictedStockUnitsMember_3E00AE39FBC25C1B93E05889F4B7741B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_82D74F5849A058C18E8ECE8C7DFCF49A" xlink:to="loc_insm_StockOptionsAndRestrictedStockUnitsMember_3E00AE39FBC25C1B93E05889F4B7741B" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_RestrictedStockAndRestrictedStockUnitsMember" xlink:label="loc_insm_RestrictedStockAndRestrictedStockUnitsMember_0BB42C7829B75BBE852E2987177CAFA6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_StockOptionsAndRestrictedStockUnitsMember_3E00AE39FBC25C1B93E05889F4B7741B" xlink:to="loc_insm_RestrictedStockAndRestrictedStockUnitsMember_0BB42C7829B75BBE852E2987177CAFA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_AC9E24A6B31753228E08213ADFEE0B0A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_StockOptionsAndRestrictedStockUnitsMember_3E00AE39FBC25C1B93E05889F4B7741B" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_AC9E24A6B31753228E08213ADFEE0B0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3CA2F91CC21C548DBCB046A4D429D6EA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C30B4165162A58878FD8FEC6693333AD" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3CA2F91CC21C548DBCB046A4D429D6EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_C8561A0BAA5457385B04F036DA4294E3_644267BC62C7567B8405943251C5719A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3CA2F91CC21C548DBCB046A4D429D6EA" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_C8561A0BAA5457385B04F036DA4294E3_644267BC62C7567B8405943251C5719A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0EC5BC8E893A5DCB9F8A9F5235A61B5B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3CA2F91CC21C548DBCB046A4D429D6EA" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0EC5BC8E893A5DCB9F8A9F5235A61B5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_FBEC69E38E5B5F4CBA089381C20D5609" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0EC5BC8E893A5DCB9F8A9F5235A61B5B" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_FBEC69E38E5B5F4CBA089381C20D5609" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3FAD068B36D050E9B66763CFBD26D308" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0EC5BC8E893A5DCB9F8A9F5235A61B5B" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3FAD068B36D050E9B66763CFBD26D308" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit" xlink:label="loc_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit_F6C06F28629F507EA1D41BCF063B0781" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F624CCFEE12450E68B4AA8C3667972E5" xlink:to="loc_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit_F6C06F28629F507EA1D41BCF063B0781" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_818A2860BCD65FF5AC97AB8C0DBC288B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F624CCFEE12450E68B4AA8C3667972E5" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_818A2860BCD65FF5AC97AB8C0DBC288B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_DC06FE7D9C0B5AA5B6140440C2F6CB34" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F624CCFEE12450E68B4AA8C3667972E5" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_DC06FE7D9C0B5AA5B6140440C2F6CB34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_28B5B7B882475F6FA026003484D863F1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F624CCFEE12450E68B4AA8C3667972E5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_28B5B7B882475F6FA026003484D863F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5925520DB8665856AA3B0CE2A2683FCA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_28B5B7B882475F6FA026003484D863F1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5925520DB8665856AA3B0CE2A2683FCA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_BEE32E957BE55575BA42C69F08253CD5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_28B5B7B882475F6FA026003484D863F1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_BEE32E957BE55575BA42C69F08253CD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1CF7B92C34C551328A58B3E8440A6335" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_28B5B7B882475F6FA026003484D863F1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1CF7B92C34C551328A58B3E8440A6335" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_304FFF5D515D599C9BA715D10F0694C7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_28B5B7B882475F6FA026003484D863F1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_304FFF5D515D599C9BA715D10F0694C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_B10BDCA2852E50C097E483064DFFC33A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F624CCFEE12450E68B4AA8C3667972E5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_B10BDCA2852E50C097E483064DFFC33A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_A3B1AC6F6E855E3A8FFB3BCC34F06960" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_B10BDCA2852E50C097E483064DFFC33A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_A3B1AC6F6E855E3A8FFB3BCC34F06960" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E5DC1AF19D3F5B8F9865C4FD0A7605CC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_B10BDCA2852E50C097E483064DFFC33A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E5DC1AF19D3F5B8F9865C4FD0A7605CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_B46C3D8931F254EE9380B12EBDBDF412" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_B10BDCA2852E50C097E483064DFFC33A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_B46C3D8931F254EE9380B12EBDBDF412" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_63155C3BDF795BBF939411DEBC92642D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_B10BDCA2852E50C097E483064DFFC33A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_63155C3BDF795BBF939411DEBC92642D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_EEC4C8462A7256788F1604A901592E09" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F624CCFEE12450E68B4AA8C3667972E5" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_EEC4C8462A7256788F1604A901592E09" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB0F46299742DED80F338222F33ACDF4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_A6EC8C5DDF917498A9BA8222F337B880" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB0F46299742DED80F338222F33ACDF4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_A6EC8C5DDF917498A9BA8222F337B880" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_197966ABA4750A79B78C8222F338D1E9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_A6EC8C5DDF917498A9BA8222F337B880" xlink:to="loc_us-gaap_AwardTypeAxis_197966ABA4750A79B78C8222F338D1E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F2CC1053865EB9458EFB8222F338FAC4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_197966ABA4750A79B78C8222F338D1E9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F2CC1053865EB9458EFB8222F338FAC4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F2CC1053865EB9458EFB8222F338FAC4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_197966ABA4750A79B78C8222F338D1E9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F2CC1053865EB9458EFB8222F338FAC4" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_EmployeeAndDirectorsStockOptionsMember" xlink:label="loc_insm_EmployeeAndDirectorsStockOptionsMember_C23267B11C6E025259648222F3388A77" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F2CC1053865EB9458EFB8222F338FAC4" xlink:to="loc_insm_EmployeeAndDirectorsStockOptionsMember_C23267B11C6E025259648222F3388A77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_A04D6D4C5EBEBCA8051F8222F3397061" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_A6EC8C5DDF917498A9BA8222F337B880" xlink:to="loc_us-gaap_RangeAxis_A04D6D4C5EBEBCA8051F8222F3397061" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_F86345798ACE00E670538222F339C99F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_A04D6D4C5EBEBCA8051F8222F3397061" xlink:to="loc_us-gaap_RangeMember_F86345798ACE00E670538222F339C99F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_F86345798ACE00E670538222F339C99F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_A04D6D4C5EBEBCA8051F8222F3397061" xlink:to="loc_us-gaap_RangeMember_F86345798ACE00E670538222F339C99F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_2E18F4FF0F32F9BB56608222F33A59B5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_F86345798ACE00E670538222F339C99F" xlink:to="loc_us-gaap_MinimumMember_2E18F4FF0F32F9BB56608222F33A59B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_1C8B6FE8C8185D75A52B8222F33A021A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_F86345798ACE00E670538222F339C99F" xlink:to="loc_us-gaap_MaximumMember_1C8B6FE8C8185D75A52B8222F33A021A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_D4A037638F3CB7B659F38222F33AAD40" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB0F46299742DED80F338222F33ACDF4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_D4A037638F3CB7B659F38222F33AAD40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7DAEB4B1BC5CCEBBEE848222F33BCCA6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_D4A037638F3CB7B659F38222F33AAD40" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7DAEB4B1BC5CCEBBEE848222F33BCCA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_F5E4EC916537ACA3683C8222F33BFF7E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_D4A037638F3CB7B659F38222F33AAD40" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_F5E4EC916537ACA3683C8222F33BFF7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5D93AD67AC7BFC642A178222F33CA202" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_D4A037638F3CB7B659F38222F33AAD40" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5D93AD67AC7BFC642A178222F33CA202" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_DFF898231B64AB7A4EEB8222F33CBE8B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_D4A037638F3CB7B659F38222F33AAD40" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_DFF898231B64AB7A4EEB8222F33CBE8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D9561799A248942C7B1A8222F33CDF0C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_D4A037638F3CB7B659F38222F33AAD40" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D9561799A248942C7B1A8222F33CDF0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65DA945BAA176A3A76458222F33C58F6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB0F46299742DED80F338222F33ACDF4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65DA945BAA176A3A76458222F33C58F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C2D4CAF34D40FC57FE3F8222F33C7041" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65DA945BAA176A3A76458222F33C58F6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C2D4CAF34D40FC57FE3F8222F33C7041" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8ACB6495A186525633D98222F33C76CE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65DA945BAA176A3A76458222F33C58F6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8ACB6495A186525633D98222F33C76CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_66905FB11112867C06A68222F33DD085" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65DA945BAA176A3A76458222F33C58F6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_66905FB11112867C06A68222F33DD085" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_E961EC3FF5B8FE6FDECC8222F33DA6D4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65DA945BAA176A3A76458222F33C58F6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_E961EC3FF5B8FE6FDECC8222F33DA6D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_F5D8B0D6427B24CCEBBA8222F33D3122" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB0F46299742DED80F338222F33ACDF4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_F5D8B0D6427B24CCEBBA8222F33D3122" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0910FB0B6F7A27C955328222F33EE641" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB0F46299742DED80F338222F33ACDF4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0910FB0B6F7A27C955328222F33EE641" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5B8E0C1E0B2581C3F5738222F33E730C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB0F46299742DED80F338222F33ACDF4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5B8E0C1E0B2581C3F5738222F33E730C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B30ECA97EA4E8E86C06E8222F33E3A7B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5B8E0C1E0B2581C3F5738222F33E730C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B30ECA97EA4E8E86C06E8222F33E3A7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_915F5EB0A785B395FDD98222F33EC2A4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5B8E0C1E0B2581C3F5738222F33E730C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_915F5EB0A785B395FDD98222F33EC2A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3931F74D384EEC967E398222F33FD06B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5B8E0C1E0B2581C3F5738222F33E730C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3931F74D384EEC967E398222F33FD06B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1D3D6DE2F739C2FF89B68222F33FFFB4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5B8E0C1E0B2581C3F5738222F33E730C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1D3D6DE2F739C2FF89B68222F33FFFB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_E1FC454BCA63304322528222F33FD71B" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB0F46299742DED80F338222F33ACDF4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_E1FC454BCA63304322528222F33FD71B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5E8EA90F76E2EDD8D5E18222F3403DFC" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB0F46299742DED80F338222F33ACDF4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5E8EA90F76E2EDD8D5E18222F3403DFC" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_WeightedAverageRemainingContractualLifeInYearsAbstract" xlink:label="loc_insm_WeightedAverageRemainingContractualLifeInYearsAbstract_BD8796E7D55F9E1EA2C28222F340D374" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB0F46299742DED80F338222F33ACDF4" xlink:to="loc_insm_WeightedAverageRemainingContractualLifeInYearsAbstract_BD8796E7D55F9E1EA2C28222F340D374" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6DF518EC2167D28F29558222F34022A7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_WeightedAverageRemainingContractualLifeInYearsAbstract_BD8796E7D55F9E1EA2C28222F340D374" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6DF518EC2167D28F29558222F34022A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_9F565E99DDA5AD23B9D28222F3407FD4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_WeightedAverageRemainingContractualLifeInYearsAbstract_BD8796E7D55F9E1EA2C28222F340D374" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_9F565E99DDA5AD23B9D28222F3407FD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_161E1B050B65DA6D41498222F341CAD7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_WeightedAverageRemainingContractualLifeInYearsAbstract_BD8796E7D55F9E1EA2C28222F340D374" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_161E1B050B65DA6D41498222F341CAD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1D5DF3859ED50034B9D58222F34133E1" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB0F46299742DED80F338222F33ACDF4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1D5DF3859ED50034B9D58222F34133E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6229591C2B615456F75E8222F341D582" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1D5DF3859ED50034B9D58222F34133E1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6229591C2B615456F75E8222F341D582" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2D77FD03299D81727C9F8222F3416FBE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1D5DF3859ED50034B9D58222F34133E1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2D77FD03299D81727C9F8222F3416FBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5DB94D7611B1A60564088222F34280C9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1D5DF3859ED50034B9D58222F34133E1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5DB94D7611B1A60564088222F34280C9" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.insmed.com/role/StockBasedCompensationTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_FAE51F87D0A65F16B209231F2994476F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_10B0BFFFFB0E5B14BA496847BCA3DEB5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_FAE51F87D0A65F16B209231F2994476F" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_10B0BFFFFB0E5B14BA496847BCA3DEB5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_E22AE92BC1025DDAA898BAA5D36C811B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_10B0BFFFFB0E5B14BA496847BCA3DEB5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_E22AE92BC1025DDAA898BAA5D36C811B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_36AF6D55C47056874A8CFDED37D18A4A_1227FFB3A4F65EC997EA7CB390A223FE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_E22AE92BC1025DDAA898BAA5D36C811B" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_36AF6D55C47056874A8CFDED37D18A4A_1227FFB3A4F65EC997EA7CB390A223FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C73551A0E57658F0A02395D8CEE69F4F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_E22AE92BC1025DDAA898BAA5D36C811B" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C73551A0E57658F0A02395D8CEE69F4F" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_EmployeeAndDirectorsStockOptionsMember" xlink:label="loc_insm_EmployeeAndDirectorsStockOptionsMember_A13F6A39E8555326892C6162854FC640" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C73551A0E57658F0A02395D8CEE69F4F" xlink:to="loc_insm_EmployeeAndDirectorsStockOptionsMember_A13F6A39E8555326892C6162854FC640" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_95C7FBD25C495C23B0D00024FDBF6EE6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C73551A0E57658F0A02395D8CEE69F4F" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_95C7FBD25C495C23B0D00024FDBF6EE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_E3DEDFC0293E57B58C1A7C6577614EEA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C73551A0E57658F0A02395D8CEE69F4F" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_E3DEDFC0293E57B58C1A7C6577614EEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C106037B2F3C5517AC68B522207350AA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_FAE51F87D0A65F16B209231F2994476F" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C106037B2F3C5517AC68B522207350AA" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsAssetsQuantitativeInformationLineItems" xlink:label="loc_us-gaap_FairValueInputsAssetsQuantitativeInformationLineItems_24C8093E6D0D5C8AB896F371B781FE65" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsAssetsQuantitativeInformationTable" xlink:label="loc_us-gaap_FairValueInputsAssetsQuantitativeInformationTable_7F0D9399712755BE865306DF08FA72FE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueInputsAssetsQuantitativeInformationLineItems_24C8093E6D0D5C8AB896F371B781FE65" xlink:to="loc_us-gaap_FairValueInputsAssetsQuantitativeInformationTable_7F0D9399712755BE865306DF08FA72FE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_11D8B2D5D5C553E4B4FF8461DF31DB24" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueInputsAssetsQuantitativeInformationTable_7F0D9399712755BE865306DF08FA72FE" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_11D8B2D5D5C553E4B4FF8461DF31DB24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_F61781B16DF20510E31AF60EC1CB643E_644267BC62C7567B8405943251C5719A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_11D8B2D5D5C553E4B4FF8461DF31DB24" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_F61781B16DF20510E31AF60EC1CB643E_644267BC62C7567B8405943251C5719A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_905BD46757D95D70995127A46D301723" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_11D8B2D5D5C553E4B4FF8461DF31DB24" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_905BD46757D95D70995127A46D301723" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_BE8CEC52ACA458EA8C5E4AFC0418102F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_905BD46757D95D70995127A46D301723" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_BE8CEC52ACA458EA8C5E4AFC0418102F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_F4FE0D2E81865581A65DD42B04184587" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueInputsAssetsQuantitativeInformationTable_7F0D9399712755BE865306DF08FA72FE" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_F4FE0D2E81865581A65DD42B04184587" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_65BA2015A614148C34E0F60EC1CC8A9F_644267BC62C7567B8405943251C5719A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_F4FE0D2E81865581A65DD42B04184587" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_65BA2015A614148C34E0F60EC1CC8A9F_644267BC62C7567B8405943251C5719A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_8DAE196EB90D5A0A8C66DA68D3E003E5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_F4FE0D2E81865581A65DD42B04184587" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_8DAE196EB90D5A0A8C66DA68D3E003E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_914E4FD920865BF18301F820F300F739" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_8DAE196EB90D5A0A8C66DA68D3E003E5" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_914E4FD920865BF18301F820F300F739" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_FCB4C7F841D25A589A8ED0F62803EC10" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_8DAE196EB90D5A0A8C66DA68D3E003E5" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_FCB4C7F841D25A589A8ED0F62803EC10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_A879D4D1138B5BE4891AB6EC7B0CBCBF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_8DAE196EB90D5A0A8C66DA68D3E003E5" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_A879D4D1138B5BE4891AB6EC7B0CBCBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_A9DD938327505B66B89A3320A26CBF9F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueInputsAssetsQuantitativeInformationTable_7F0D9399712755BE865306DF08FA72FE" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_A9DD938327505B66B89A3320A26CBF9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_60644C29D61A923F51ACF60EC1CD42F4_644267BC62C7567B8405943251C5719A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_A9DD938327505B66B89A3320A26CBF9F" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_60644C29D61A923F51ACF60EC1CD42F4_644267BC62C7567B8405943251C5719A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_A437932408EA5D6BB6BF33D0417087E6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_A9DD938327505B66B89A3320A26CBF9F" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_A437932408EA5D6BB6BF33D0417087E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_29028575CB1A5927BF6E79C31C88DA40" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_A437932408EA5D6BB6BF33D0417087E6" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_29028575CB1A5927BF6E79C31C88DA40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_AEF37D85237B5B54A0A98B225A28106D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_A437932408EA5D6BB6BF33D0417087E6" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_AEF37D85237B5B54A0A98B225A28106D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_F93A0517269A5860AABE97AC193B2F42" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueInputsAssetsQuantitativeInformationTable_7F0D9399712755BE865306DF08FA72FE" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_F93A0517269A5860AABE97AC193B2F42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9E0453A6691214E8313DF60EC1CE6EB3_644267BC62C7567B8405943251C5719A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_F93A0517269A5860AABE97AC193B2F42" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9E0453A6691214E8313DF60EC1CE6EB3_644267BC62C7567B8405943251C5719A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2333E1BE8DDD5D6CADA9BE22F741D699" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_F93A0517269A5860AABE97AC193B2F42" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2333E1BE8DDD5D6CADA9BE22F741D699" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_8509AD33421B5C7C88F7B672AA72AE0D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2333E1BE8DDD5D6CADA9BE22F741D699" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_8509AD33421B5C7C88F7B672AA72AE0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_13AA3AD0E21F5104A0453A9CAD136CF0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueInputsAssetsQuantitativeInformationLineItems_24C8093E6D0D5C8AB896F371B781FE65" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_13AA3AD0E21F5104A0453A9CAD136CF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_3C7F23080B2557DCBA626A3D639DEC0D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueInputsAssetsQuantitativeInformationLineItems_24C8093E6D0D5C8AB896F371B781FE65" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_3C7F23080B2557DCBA626A3D639DEC0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_D9FC9A95830253B2B2516EC338427AF2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueInputsAssetsQuantitativeInformationLineItems_24C8093E6D0D5C8AB896F371B781FE65" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_D9FC9A95830253B2B2516EC338427AF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_3A3B7AAF61A45907A07737C338FECBA5" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueInputsAssetsQuantitativeInformationLineItems_24C8093E6D0D5C8AB896F371B781FE65" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_3A3B7AAF61A45907A07737C338FECBA5" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsAssetsQuantitativeInformationLineItems" xlink:label="loc_us-gaap_FairValueInputsAssetsQuantitativeInformationLineItems_A1BC2E950478B8D06A1D8222F41261BC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsAssetsQuantitativeInformationTable" xlink:label="loc_us-gaap_FairValueInputsAssetsQuantitativeInformationTable_34FE08F48AE559665A668222F40F851D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueInputsAssetsQuantitativeInformationLineItems_A1BC2E950478B8D06A1D8222F41261BC" xlink:to="loc_us-gaap_FairValueInputsAssetsQuantitativeInformationTable_34FE08F48AE559665A668222F40F851D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_EDCFA29A021E266A59B48222F4107AED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueInputsAssetsQuantitativeInformationTable_34FE08F48AE559665A668222F40F851D" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_EDCFA29A021E266A59B48222F4107AED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_842834FFC680B582F8658222F410A64F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_EDCFA29A021E266A59B48222F4107AED" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_842834FFC680B582F8658222F410A64F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_842834FFC680B582F8658222F410A64F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_EDCFA29A021E266A59B48222F4107AED" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_842834FFC680B582F8658222F410A64F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_29E7DE7FAA6D1F37E1CB8222F4106163" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_842834FFC680B582F8658222F410A64F" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_29E7DE7FAA6D1F37E1CB8222F4106163" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3DBD5F76B6AE1DA790A48222F411375E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueInputsAssetsQuantitativeInformationTable_34FE08F48AE559665A668222F40F851D" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3DBD5F76B6AE1DA790A48222F411375E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_FFA4AC1C8D199685AC4C8222F41104F6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3DBD5F76B6AE1DA790A48222F411375E" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_FFA4AC1C8D199685AC4C8222F41104F6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_FFA4AC1C8D199685AC4C8222F41104F6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3DBD5F76B6AE1DA790A48222F411375E" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_FFA4AC1C8D199685AC4C8222F41104F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_E02464967E7180EA45D78222F41117FA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_FFA4AC1C8D199685AC4C8222F41104F6" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_E02464967E7180EA45D78222F41117FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1C0B793F308BBA7949CE8222F41261C1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueInputsAssetsQuantitativeInformationTable_34FE08F48AE559665A668222F40F851D" xlink:to="loc_us-gaap_DebtInstrumentAxis_1C0B793F308BBA7949CE8222F41261C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3F6F273C760D4438FB688222F41249D7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1C0B793F308BBA7949CE8222F41261C1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3F6F273C760D4438FB688222F41249D7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3F6F273C760D4438FB688222F41249D7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1C0B793F308BBA7949CE8222F41261C1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3F6F273C760D4438FB688222F41249D7" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member" xlink:label="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_D994B48EFCB065A295EE8222F4120447" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3F6F273C760D4438FB688222F41249D7" xlink:to="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_D994B48EFCB065A295EE8222F4120447" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0F1C09A9ED910FFAC2D48222F41304EF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueInputsAssetsQuantitativeInformationLineItems_A1BC2E950478B8D06A1D8222F41261BC" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0F1C09A9ED910FFAC2D48222F41304EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_76CFCAC21D2C043FE4BD8222F413A26F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueInputsAssetsQuantitativeInformationLineItems_A1BC2E950478B8D06A1D8222F41261BC" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_76CFCAC21D2C043FE4BD8222F413A26F" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_FairValueLevel1Level2Level3TransfersAmount" xlink:label="loc_insm_FairValueLevel1Level2Level3TransfersAmount_680FDE54B99905C1624F8222F41388FF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueInputsAssetsQuantitativeInformationLineItems_A1BC2E950478B8D06A1D8222F41261BC" xlink:to="loc_insm_FairValueLevel1Level2Level3TransfersAmount_680FDE54B99905C1624F8222F41388FF" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities" xlink:label="loc_insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities_38AE6E4B195F93730B068222F4147EB3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueInputsAssetsQuantitativeInformationLineItems_A1BC2E950478B8D06A1D8222F41261BC" xlink:to="loc_insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities_38AE6E4B195F93730B068222F4147EB3" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:href="insm-20180930.xsd#insm_ScheduleofEarningsPerShareBasicandDilutedLineItems" xlink:label="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_F87EF04B0501ABD010C0C1480A745092" xlink:type="locator" />
    <link:loc xlink:href="insm-20180930.xsd#insm_ScheduleofEarningsPerShareBasicandDilutedTable" xlink:label="loc_insm_ScheduleofEarningsPerShareBasicandDilutedTable_1075786D4D5C027C93BBC1480A72A8A1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_F87EF04B0501ABD010C0C1480A745092" xlink:to="loc_insm_ScheduleofEarningsPerShareBasicandDilutedTable_1075786D4D5C027C93BBC1480A72A8A1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_4A536C3BB21A1D5C59CAC1480A7397F7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedTable_1075786D4D5C027C93BBC1480A72A8A1" xlink:to="loc_us-gaap_AwardTypeAxis_4A536C3BB21A1D5C59CAC1480A7397F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D92C9F3F360F63E343BEC1480A731849_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_4A536C3BB21A1D5C59CAC1480A7397F7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D92C9F3F360F63E343BEC1480A731849_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D92C9F3F360F63E343BEC1480A731849" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_4A536C3BB21A1D5C59CAC1480A7397F7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D92C9F3F360F63E343BEC1480A731849" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0E189D36B1057F17CDE3C1480A73B042" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D92C9F3F360F63E343BEC1480A731849" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0E189D36B1057F17CDE3C1480A73B042" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_5CD981467B6AF82EC017C1480A74B5D4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D92C9F3F360F63E343BEC1480A731849" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_5CD981467B6AF82EC017C1480A74B5D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_8180943A4A490037F57EC1480A75FC45" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_F87EF04B0501ABD010C0C1480A745092" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_8180943A4A490037F57EC1480A75FC45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_69BCD4BA18E169E545C4C1480A75CAC3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_8180943A4A490037F57EC1480A75FC45" xlink:to="loc_us-gaap_NetIncomeLoss_69BCD4BA18E169E545C4C1480A75CAC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_9B6C5EA2998FE793DDB2C1480A751F97" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_F87EF04B0501ABD010C0C1480A745092" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_9B6C5EA2998FE793DDB2C1480A751F97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_AA921D2C402508D10ADFC1480A759D2D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_9B6C5EA2998FE793DDB2C1480A751F97" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_AA921D2C402508D10ADFC1480A759D2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_C2F7BE94A6198E6E6870C1480A760866" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_9B6C5EA2998FE793DDB2C1480A751F97" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_C2F7BE94A6198E6E6870C1480A760866" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_B6FA081A28848C0370A3C1480A76E354" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_C2F7BE94A6198E6E6870C1480A760866" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_B6FA081A28848C0370A3C1480A76E354" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_DC90EEFCCD60DDC1DDC6C1480A76D0F1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_C2F7BE94A6198E6E6870C1480A760866" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_DC90EEFCCD60DDC1DDC6C1480A76D0F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_F393AC1EA87F4287C072C1480A779938" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_9B6C5EA2998FE793DDB2C1480A751F97" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_F393AC1EA87F4287C072C1480A779938" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1ED81CD99D8EF3008AF1C1480A77E517" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_F87EF04B0501ABD010C0C1480A745092" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1ED81CD99D8EF3008AF1C1480A77E517" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_E617F269CBBC92D139E9C1480A77DFBE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1ED81CD99D8EF3008AF1C1480A77E517" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_E617F269CBBC92D139E9C1480A77DFBE" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesRecentlyAdoptedAccountingPronouncementsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>insm-20180930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_88AA23CEE3324C48336CAC52B232749D_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract_88AA23CEE3324C48336CAC52B232749D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_88AA23CEE3324C48336CAC52B232749D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_88AA23CEE3324C48336CAC52B232749D" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract_88AA23CEE3324C48336CAC52B232749D" xlink:type="arc" />
    <link:label id="lab_insm_AccruedClinicalTrialExpenses_6AEBE55357B800E5E98FAC52B23257D1_terseLabel_en-US" xlink:label="lab_insm_AccruedClinicalTrialExpenses_6AEBE55357B800E5E98FAC52B23257D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued clinical trial expenses</link:label>
    <link:label id="lab_insm_AccruedClinicalTrialExpenses_6AEBE55357B800E5E98FAC52B23257D1_label_en-US" xlink:label="lab_insm_AccruedClinicalTrialExpenses_6AEBE55357B800E5E98FAC52B23257D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Clinical Trial Expenses</link:label>
    <link:label id="lab_insm_AccruedClinicalTrialExpenses_6AEBE55357B800E5E98FAC52B23257D1_documentation_en-US" xlink:label="lab_insm_AccruedClinicalTrialExpenses_6AEBE55357B800E5E98FAC52B23257D1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical trial expenses.</link:label>
    <link:loc xlink:href="insm-20180930.xsd#insm_AccruedClinicalTrialExpenses" xlink:label="loc_insm_AccruedClinicalTrialExpenses_6AEBE55357B800E5E98FAC52B23257D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_AccruedClinicalTrialExpenses_6AEBE55357B800E5E98FAC52B23257D1" xlink:to="lab_insm_AccruedClinicalTrialExpenses_6AEBE55357B800E5E98FAC52B23257D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_83552C555106C719CFAEAC52B233E5FA_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_83552C555106C719CFAEAC52B233E5FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_83552C555106C719CFAEAC52B233E5FA_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_83552C555106C719CFAEAC52B233E5FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_83552C555106C719CFAEAC52B233E5FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_83552C555106C719CFAEAC52B233E5FA" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_83552C555106C719CFAEAC52B233E5FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_3B80844923CF7AC8A6EBAC52B233748F_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_3B80844923CF7AC8A6EBAC52B233748F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_3B80844923CF7AC8A6EBAC52B233748F_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_3B80844923CF7AC8A6EBAC52B233748F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_3B80844923CF7AC8A6EBAC52B233748F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent_3B80844923CF7AC8A6EBAC52B233748F" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent_3B80844923CF7AC8A6EBAC52B233748F" xlink:type="arc" />
    <link:label id="lab_insm_AccruedTechnicalOperationExpenses_3D1425D4C6543ECC6D4CAC52B2338164_terseLabel_en-US" xlink:label="lab_insm_AccruedTechnicalOperationExpenses_3D1425D4C6543ECC6D4CAC52B2338164" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued technical operation expenses</link:label>
    <link:label id="lab_insm_AccruedTechnicalOperationExpenses_3D1425D4C6543ECC6D4CAC52B2338164_label_en-US" xlink:label="lab_insm_AccruedTechnicalOperationExpenses_3D1425D4C6543ECC6D4CAC52B2338164" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Technical Operation Expenses</link:label>
    <link:label id="lab_insm_AccruedTechnicalOperationExpenses_3D1425D4C6543ECC6D4CAC52B2338164_documentation_en-US" xlink:label="lab_insm_AccruedTechnicalOperationExpenses_3D1425D4C6543ECC6D4CAC52B2338164" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for technical operation expenses.</link:label>
    <link:loc xlink:href="insm-20180930.xsd#insm_AccruedTechnicalOperationExpenses" xlink:label="loc_insm_AccruedTechnicalOperationExpenses_3D1425D4C6543ECC6D4CAC52B2338164" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_AccruedTechnicalOperationExpenses_3D1425D4C6543ECC6D4CAC52B2338164" xlink:to="lab_insm_AccruedTechnicalOperationExpenses_3D1425D4C6543ECC6D4CAC52B2338164" xlink:type="arc" />
    <link:label id="lab_insm_AccruedMilestonePaymentCurrent_5DBFE219F584D94D89EEAC5C71421100_terseLabel_en-US" xlink:label="lab_insm_AccruedMilestonePaymentCurrent_5DBFE219F584D94D89EEAC5C71421100" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued milestone payment</link:label>
    <link:label id="lab_insm_AccruedMilestonePaymentCurrent_5DBFE219F584D94D89EEAC5C71421100_label_en-US" xlink:label="lab_insm_AccruedMilestonePaymentCurrent_5DBFE219F584D94D89EEAC5C71421100" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Milestone Payment, Current</link:label>
    <link:label id="lab_insm_AccruedMilestonePaymentCurrent_5DBFE219F584D94D89EEAC5C71421100_documentation_en-US" xlink:label="lab_insm_AccruedMilestonePaymentCurrent_5DBFE219F584D94D89EEAC5C71421100" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Milestone Payment, Current</link:label>
    <link:loc xlink:href="insm-20180930.xsd#insm_AccruedMilestonePaymentCurrent" xlink:label="loc_insm_AccruedMilestonePaymentCurrent_5DBFE219F584D94D89EEAC5C71421100" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_AccruedMilestonePaymentCurrent_5DBFE219F584D94D89EEAC5C71421100" xlink:to="lab_insm_AccruedMilestonePaymentCurrent_5DBFE219F584D94D89EEAC5C71421100" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPayableCurrent_B1E5F25380192DEC4B76AC52B23375C7_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent_B1E5F25380192DEC4B76AC52B23375C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest payable</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_B1E5F25380192DEC4B76AC52B23375C7_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent_B1E5F25380192DEC4B76AC52B23375C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_B1E5F25380192DEC4B76AC52B23375C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent_B1E5F25380192DEC4B76AC52B23375C7" xlink:to="lab_us-gaap_InterestPayableCurrent_B1E5F25380192DEC4B76AC52B23375C7" xlink:type="arc" />
    <link:label id="lab_insm_AccruedConstructionLiabilitiesCurrent_F8011470B2BB3D4B73DAAC52B234D4BC_terseLabel_en-US" xlink:label="lab_insm_AccruedConstructionLiabilitiesCurrent_F8011470B2BB3D4B73DAAC52B234D4BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued construction costs</link:label>
    <link:label id="lab_insm_AccruedConstructionLiabilitiesCurrent_F8011470B2BB3D4B73DAAC52B234D4BC_label_en-US" xlink:label="lab_insm_AccruedConstructionLiabilitiesCurrent_F8011470B2BB3D4B73DAAC52B234D4BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Construction Liabilities, Current</link:label>
    <link:label id="lab_insm_AccruedConstructionLiabilitiesCurrent_F8011470B2BB3D4B73DAAC52B234D4BC_documentation_en-US" xlink:label="lab_insm_AccruedConstructionLiabilitiesCurrent_F8011470B2BB3D4B73DAAC52B234D4BC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Construction Liabilities, Current</link:label>
    <link:loc xlink:href="insm-20180930.xsd#insm_AccruedConstructionLiabilitiesCurrent" xlink:label="loc_insm_AccruedConstructionLiabilitiesCurrent_F8011470B2BB3D4B73DAAC52B234D4BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_AccruedConstructionLiabilitiesCurrent_F8011470B2BB3D4B73DAAC52B234D4BC" xlink:to="lab_insm_AccruedConstructionLiabilitiesCurrent_F8011470B2BB3D4B73DAAC52B234D4BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_0430F3E63AB52ED815A4AC52B2345470_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_0430F3E63AB52ED815A4AC52B2345470" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_0430F3E63AB52ED815A4AC52B2345470_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_0430F3E63AB52ED815A4AC52B2345470" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_0430F3E63AB52ED815A4AC52B2345470" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_0430F3E63AB52ED815A4AC52B2345470" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_0430F3E63AB52ED815A4AC52B2345470" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_8DB9DCD65315EA073215AC52B2348B65_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_8DB9DCD65315EA073215AC52B2348B65" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_8DB9DCD65315EA073215AC52B2348B65_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_8DB9DCD65315EA073215AC52B2348B65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8DB9DCD65315EA073215AC52B2348B65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8DB9DCD65315EA073215AC52B2348B65" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_8DB9DCD65315EA073215AC52B2348B65" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_979ABA71C94C63D3A8B6FF2DCE915735_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract_C4D0BF693DF3515999AB829CC9AF4801" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_C4D0BF693DF3515999AB829CC9AF4801" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_C4D0BF693DF3515999AB829CC9AF4801" xlink:to="lab_us-gaap_DebtDisclosureAbstract_C4D0BF693DF3515999AB829CC9AF4801" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_1EBDCE6B4128A8C655A9FF2DCE91642C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock_0B7C379D86C5557ABADA5B40F442660D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of Debt Balance</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_1EBDCE6B4128A8C655A9FF2DCE91642C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock_0B7C379D86C5557ABADA5B40F442660D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_0B7C379D86C5557ABADA5B40F442660D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock_0B7C379D86C5557ABADA5B40F442660D" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock_0B7C379D86C5557ABADA5B40F442660D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_480D2FC0E7671CC73B3CFF2DCE925E95_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_AD570A2DD14D5E0F9F4C6149A3EB9EDB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Future Principal Repayments of Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_480D2FC0E7671CC73B3CFF2DCE925E95_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_AD570A2DD14D5E0F9F4C6149A3EB9EDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_AD570A2DD14D5E0F9F4C6149A3EB9EDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_AD570A2DD14D5E0F9F4C6149A3EB9EDB" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_AD570A2DD14D5E0F9F4C6149A3EB9EDB" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_C72913D9F253201C899BFF2EE7910EDD_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_D4360B22292B5CE9963CD5CB494C2EA4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Interest Expense</link:label>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_C72913D9F253201C899BFF2EE7910EDD_label_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_D4360B22292B5CE9963CD5CB494C2EA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income and Interest Expense Disclosure [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_D4360B22292B5CE9963CD5CB494C2EA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_D4360B22292B5CE9963CD5CB494C2EA4" xlink:to="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_D4360B22292B5CE9963CD5CB494C2EA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_720459ECF0C19634352706F46BEF97A5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_B140BABC70475B1B93ABC4A1176F9331" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_720459ECF0C19634352706F46BEF97A5_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_B140BABC70475B1B93ABC4A1176F9331" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_B140BABC70475B1B93ABC4A1176F9331" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_B140BABC70475B1B93ABC4A1176F9331" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_B140BABC70475B1B93ABC4A1176F9331" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_340B35EC43A69EC5E541E766693ADC78_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0EC1E07B4249599EB59BE109735374A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0EC1E07B4249599EB59BE109735374A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0EC1E07B4249599EB59BE109735374A6" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0EC1E07B4249599EB59BE109735374A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_7003B89EC9300B42415EE766693A8F88_verboseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_35B2EE0FC6E457A3BE26E52E4CF04A3C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">The Company and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_7003B89EC9300B42415EE766693A8F88_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_35B2EE0FC6E457A3BE26E52E4CF04A3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_35B2EE0FC6E457A3BE26E52E4CF04A3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_35B2EE0FC6E457A3BE26E52E4CF04A3C" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_35B2EE0FC6E457A3BE26E52E4CF04A3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_41154CE2831B7035DAD7AC3F2E324E02_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_41154CE2831B7035DAD7AC3F2E324E02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_41154CE2831B7035DAD7AC3F2E324E02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_41154CE2831B7035DAD7AC3F2E324E02" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_41154CE2831B7035DAD7AC3F2E324E02" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4D434AC826641A68234BAC3F2E325F95_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4D434AC826641A68234BAC3F2E325F95" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4D434AC826641A68234BAC3F2E325F95_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4D434AC826641A68234BAC3F2E325F95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4D434AC826641A68234BAC3F2E325F95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4D434AC826641A68234BAC3F2E325F95" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4D434AC826641A68234BAC3F2E325F95" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C04D24EBF34C58CBE72AAC3F2E327FBA_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C04D24EBF34C58CBE72AAC3F2E327FBA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C04D24EBF34C58CBE72AAC3F2E327FBA_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C04D24EBF34C58CBE72AAC3F2E327FBA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C04D24EBF34C58CBE72AAC3F2E327FBA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C04D24EBF34C58CBE72AAC3F2E327FBA" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C04D24EBF34C58CBE72AAC3F2E327FBA" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B287AED4AB1BDEC06DA9AC3F2E32885A_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B287AED4AB1BDEC06DA9AC3F2E32885A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B287AED4AB1BDEC06DA9AC3F2E32885A_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B287AED4AB1BDEC06DA9AC3F2E32885A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B287AED4AB1BDEC06DA9AC3F2E32885A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B287AED4AB1BDEC06DA9AC3F2E32885A" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B287AED4AB1BDEC06DA9AC3F2E32885A" xlink:type="arc" />
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_345755D287514E679F93AC3F2E33C7FB_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember_345755D287514E679F93AC3F2E33C7FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired ARIKAYCE R&amp;D</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_345755D287514E679F93AC3F2E33C7FB_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember_345755D287514E679F93AC3F2E33C7FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_345755D287514E679F93AC3F2E33C7FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember_345755D287514E679F93AC3F2E33C7FB" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember_345755D287514E679F93AC3F2E33C7FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_LicensingAgreementsMember_1A4719054CBB9E913DB7AC3F2E3392DA_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember_1A4719054CBB9E913DB7AC3F2E3392DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PARI milestone upon FDA approval</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_1A4719054CBB9E913DB7AC3F2E3392DA_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember_1A4719054CBB9E913DB7AC3F2E3392DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_1A4719054CBB9E913DB7AC3F2E3392DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember_1A4719054CBB9E913DB7AC3F2E3392DA" xlink:to="lab_us-gaap_LicensingAgreementsMember_1A4719054CBB9E913DB7AC3F2E3392DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_26A7930BA6D7835D42C4AC3F2E334C02_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_26A7930BA6D7835D42C4AC3F2E334C02" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_26A7930BA6D7835D42C4AC3F2E334C02_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_26A7930BA6D7835D42C4AC3F2E334C02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_26A7930BA6D7835D42C4AC3F2E334C02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_26A7930BA6D7835D42C4AC3F2E334C02" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_26A7930BA6D7835D42C4AC3F2E334C02" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_D96E77306C3153DBED0EAC3F2E337923_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_D96E77306C3153DBED0EAC3F2E337923" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_D96E77306C3153DBED0EAC3F2E337923_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_D96E77306C3153DBED0EAC3F2E337923" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_D96E77306C3153DBED0EAC3F2E337923" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross_D96E77306C3153DBED0EAC3F2E337923" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross_D96E77306C3153DBED0EAC3F2E337923" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_3404DC8FBCD5C9B10BB5E7666965DC08_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_8C410D4DE22C58D1BC691240C94F9BB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8C410D4DE22C58D1BC691240C94F9BB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8C410D4DE22C58D1BC691240C94F9BB9" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_8C410D4DE22C58D1BC691240C94F9BB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_72BB5EE482EC21621E56E76669658431_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_E54119F767C151DDB9D4CE2B53EA42B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_72BB5EE482EC21621E56E76669658431_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_E54119F767C151DDB9D4CE2B53EA42B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_E54119F767C151DDB9D4CE2B53EA42B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_E54119F767C151DDB9D4CE2B53EA42B4" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_E54119F767C151DDB9D4CE2B53EA42B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_112C3D89C149D81BEC0AFDED37D1FFE9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_10B0BFFFFB0E5B14BA496847BCA3DEB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_112C3D89C149D81BEC0AFDED37D1FFE9_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_10B0BFFFFB0E5B14BA496847BCA3DEB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_10B0BFFFFB0E5B14BA496847BCA3DEB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_10B0BFFFFB0E5B14BA496847BCA3DEB5" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_10B0BFFFFB0E5B14BA496847BCA3DEB5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_B9FEC5B5741CACE8CBE9FDED37D1EE61_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_E22AE92BC1025DDAA898BAA5D36C811B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_B9FEC5B5741CACE8CBE9FDED37D1EE61_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_E22AE92BC1025DDAA898BAA5D36C811B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_E22AE92BC1025DDAA898BAA5D36C811B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_E22AE92BC1025DDAA898BAA5D36C811B" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_E22AE92BC1025DDAA898BAA5D36C811B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_36AF6D55C47056874A8CFDED37D18A4A_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_C73551A0E57658F0A02395D8CEE69F4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_36AF6D55C47056874A8CFDED37D18A4A_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_C73551A0E57658F0A02395D8CEE69F4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C73551A0E57658F0A02395D8CEE69F4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C73551A0E57658F0A02395D8CEE69F4F" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_C73551A0E57658F0A02395D8CEE69F4F" xlink:type="arc" />
    <link:label id="lab_insm_EmployeeAndDirectorsStockOptionsMember_16456DC6AEEB18FF8202FDED37D113D9_terseLabel_en-US" xlink:label="lab_insm_EmployeeAndDirectorsStockOptionsMember_A13F6A39E8555326892C6162854FC640" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options to purchase common stock</link:label>
    <link:label id="lab_insm_EmployeeAndDirectorsStockOptionsMember_16456DC6AEEB18FF8202FDED37D113D9_label_en-US" xlink:label="lab_insm_EmployeeAndDirectorsStockOptionsMember_A13F6A39E8555326892C6162854FC640" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee And Directors Stock Options [Member]</link:label>
    <link:label id="lab_insm_EmployeeAndDirectorsStockOptionsMember_16456DC6AEEB18FF8202FDED37D113D9_documentation_en-US" xlink:label="lab_insm_EmployeeAndDirectorsStockOptionsMember_A13F6A39E8555326892C6162854FC640" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">An arrangement whereby an employee or member of the Board of Directors is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement.</link:label>
    <link:loc xlink:href="insm-20180930.xsd#insm_EmployeeAndDirectorsStockOptionsMember" xlink:label="loc_insm_EmployeeAndDirectorsStockOptionsMember_A13F6A39E8555326892C6162854FC640" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_EmployeeAndDirectorsStockOptionsMember_A13F6A39E8555326892C6162854FC640" xlink:to="lab_insm_EmployeeAndDirectorsStockOptionsMember_A13F6A39E8555326892C6162854FC640" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_4ED3F551A2BA5AFDA976FDED37D1F3E8_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_95C7FBD25C495C23B0D00024FDBF6EE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unvested RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_4ED3F551A2BA5AFDA976FDED37D1F3E8_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_95C7FBD25C495C23B0D00024FDBF6EE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_95C7FBD25C495C23B0D00024FDBF6EE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_95C7FBD25C495C23B0D00024FDBF6EE6" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember_95C7FBD25C495C23B0D00024FDBF6EE6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_A09F2E2CC7DCB6418440FE2EDA8B8B4C_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember_E3DEDFC0293E57B58C1A7C6577614EEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible debt securities</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_A09F2E2CC7DCB6418440FE2EDA8B8B4C_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember_E3DEDFC0293E57B58C1A7C6577614EEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_E3DEDFC0293E57B58C1A7C6577614EEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember_E3DEDFC0293E57B58C1A7C6577614EEA" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember_E3DEDFC0293E57B58C1A7C6577614EEA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_FB8B63498D2F83969DD2FDED37D2F902_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_FAE51F87D0A65F16B209231F2994476F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Anti-dilutive securities excluded from computations of diluted weighted-average common shares outstanding</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_FB8B63498D2F83969DD2FDED37D2F902_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_FAE51F87D0A65F16B209231F2994476F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_FAE51F87D0A65F16B209231F2994476F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_FAE51F87D0A65F16B209231F2994476F" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_FAE51F87D0A65F16B209231F2994476F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7DA94CCAD92EAA609613FDED37D2EF53_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C106037B2F3C5517AC68B522207350AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potentially dilutive securities excluded from computations of diluted weighted-average shares outstanding</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7DA94CCAD92EAA609613FDED37D2EF53_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C106037B2F3C5517AC68B522207350AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C106037B2F3C5517AC68B522207350AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C106037B2F3C5517AC68B522207350AA" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C106037B2F3C5517AC68B522207350AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1CA875CD670F63A27862AC58EA3B46F0_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1CA875CD670F63A27862AC58EA3B46F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1CA875CD670F63A27862AC58EA3B46F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1CA875CD670F63A27862AC58EA3B46F0" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1CA875CD670F63A27862AC58EA3B46F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_779F2EFF1DFA7F854243AC58EA4493B3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_779F2EFF1DFA7F854243AC58EA4493B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_779F2EFF1DFA7F854243AC58EA4493B3_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_779F2EFF1DFA7F854243AC58EA4493B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_779F2EFF1DFA7F854243AC58EA4493B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_779F2EFF1DFA7F854243AC58EA4493B3" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_779F2EFF1DFA7F854243AC58EA4493B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_98CC0CDDBAA13AA97847AC58EA446EB4_terseLabel_en-US" xlink:label="lab_us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_98CC0CDDBAA13AA97847AC58EA446EB4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:label id="lab_us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_98CC0CDDBAA13AA97847AC58EA446EB4_label_en-US" xlink:label="lab_us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_98CC0CDDBAA13AA97847AC58EA446EB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="loc_us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_98CC0CDDBAA13AA97847AC58EA446EB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_98CC0CDDBAA13AA97847AC58EA446EB4" xlink:to="lab_us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_98CC0CDDBAA13AA97847AC58EA446EB4" xlink:type="arc" />
    <link:label id="lab_us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_95AAEDA2D543B8214A2AAC58EA440B67_terseLabel_en-US" xlink:label="lab_us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_95AAEDA2D543B8214A2AAC58EA440B67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:label id="lab_us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_95AAEDA2D543B8214A2AAC58EA440B67_label_en-US" xlink:label="lab_us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_95AAEDA2D543B8214A2AAC58EA440B67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="loc_us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_95AAEDA2D543B8214A2AAC58EA440B67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_95AAEDA2D543B8214A2AAC58EA440B67" xlink:to="lab_us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_95AAEDA2D543B8214A2AAC58EA440B67" xlink:type="arc" />
    <link:label id="lab_insm_BridgewaterNewJerseyFacilityMember_56E96F2AF56EC6CC6D99AC58EA45D772_terseLabel_en-US" xlink:label="lab_insm_BridgewaterNewJerseyFacilityMember_56E96F2AF56EC6CC6D99AC58EA45D772" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bridgewater, NJ facility</link:label>
    <link:label id="lab_insm_BridgewaterNewJerseyFacilityMember_56E96F2AF56EC6CC6D99AC58EA45D772_label_en-US" xlink:label="lab_insm_BridgewaterNewJerseyFacilityMember_56E96F2AF56EC6CC6D99AC58EA45D772" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bridgewater New Jersey Facility [Member]</link:label>
    <link:label id="lab_insm_BridgewaterNewJerseyFacilityMember_56E96F2AF56EC6CC6D99AC58EA45D772_documentation_en-US" xlink:label="lab_insm_BridgewaterNewJerseyFacilityMember_56E96F2AF56EC6CC6D99AC58EA45D772" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represent the Bridgewater location in New Jersey where the entity has leased office and laboratory space.</link:label>
    <link:loc xlink:href="insm-20180930.xsd#insm_BridgewaterNewJerseyFacilityMember" xlink:label="loc_insm_BridgewaterNewJerseyFacilityMember_56E96F2AF56EC6CC6D99AC58EA45D772" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_BridgewaterNewJerseyFacilityMember_56E96F2AF56EC6CC6D99AC58EA45D772" xlink:to="lab_insm_BridgewaterNewJerseyFacilityMember_56E96F2AF56EC6CC6D99AC58EA45D772" xlink:type="arc" />
    <link:label id="lab_insm_BridgewaterNewJerseyOfficeSpaceMember_3FD0C61F1B1A4C0CB1B1AC58EA45B0A8_terseLabel_en-US" xlink:label="lab_insm_BridgewaterNewJerseyOfficeSpaceMember_3FD0C61F1B1A4C0CB1B1AC58EA45B0A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bridgewater, NJ office space</link:label>
    <link:label id="lab_insm_BridgewaterNewJerseyOfficeSpaceMember_3FD0C61F1B1A4C0CB1B1AC58EA45B0A8_label_en-US" xlink:label="lab_insm_BridgewaterNewJerseyOfficeSpaceMember_3FD0C61F1B1A4C0CB1B1AC58EA45B0A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bridgewater, New Jersey Office Space [Member]</link:label>
    <link:label id="lab_insm_BridgewaterNewJerseyOfficeSpaceMember_3FD0C61F1B1A4C0CB1B1AC58EA45B0A8_documentation_en-US" xlink:label="lab_insm_BridgewaterNewJerseyOfficeSpaceMember_3FD0C61F1B1A4C0CB1B1AC58EA45B0A8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bridgewater, New Jersey Office Space [Member]</link:label>
    <link:loc xlink:href="insm-20180930.xsd#insm_BridgewaterNewJerseyOfficeSpaceMember" xlink:label="loc_insm_BridgewaterNewJerseyOfficeSpaceMember_3FD0C61F1B1A4C0CB1B1AC58EA45B0A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_BridgewaterNewJerseyOfficeSpaceMember_3FD0C61F1B1A4C0CB1B1AC58EA45B0A8" xlink:to="lab_insm_BridgewaterNewJerseyOfficeSpaceMember_3FD0C61F1B1A4C0CB1B1AC58EA45B0A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_43B005EA778C5FE8863FAC58EA451D17_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems_43B005EA778C5FE8863FAC58EA451D17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_43B005EA778C5FE8863FAC58EA451D17_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems_43B005EA778C5FE8863FAC58EA451D17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_43B005EA778C5FE8863FAC58EA451D17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_43B005EA778C5FE8863FAC58EA451D17" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems_43B005EA778C5FE8863FAC58EA451D17" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_24AF02F68AEACA6DC1CCAC58EA459161_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_24AF02F68AEACA6DC1CCAC58EA459161" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future minimum rental payments under lease</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_24AF02F68AEACA6DC1CCAC58EA459161_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_24AF02F68AEACA6DC1CCAC58EA459161" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_24AF02F68AEACA6DC1CCAC58EA459161" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_24AF02F68AEACA6DC1CCAC58EA459161" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_24AF02F68AEACA6DC1CCAC58EA459161" xlink:type="arc" />
    <link:label id="lab_insm_AdditionalLaboratorySpaceOperatingLeasesFutureMinimumPaymentsDue_7F0B07071F322C8BA06EAC58EA4640C2_terseLabel_en-US" xlink:label="lab_insm_AdditionalLaboratorySpaceOperatingLeasesFutureMinimumPaymentsDue_7F0B07071F322C8BA06EAC58EA4640C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future minimum rental payments for additional laboratory space</link:label>
    <link:label id="lab_insm_AdditionalLaboratorySpaceOperatingLeasesFutureMinimumPaymentsDue_7F0B07071F322C8BA06EAC58EA4640C2_label_en-US" xlink:label="lab_insm_AdditionalLaboratorySpaceOperatingLeasesFutureMinimumPaymentsDue_7F0B07071F322C8BA06EAC58EA4640C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Laboratory Space Operating Leases Future Minimum Payments Due</link:label>
    <link:label id="lab_insm_AdditionalLaboratorySpaceOperatingLeasesFutureMinimumPaymentsDue_7F0B07071F322C8BA06EAC58EA4640C2_documentation_en-US" xlink:label="lab_insm_AdditionalLaboratorySpaceOperatingLeasesFutureMinimumPaymentsDue_7F0B07071F322C8BA06EAC58EA4640C2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</link:label>
    <link:loc xlink:href="insm-20180930.xsd#insm_AdditionalLaboratorySpaceOperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_insm_AdditionalLaboratorySpaceOperatingLeasesFutureMinimumPaymentsDue_7F0B07071F322C8BA06EAC58EA4640C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_AdditionalLaboratorySpaceOperatingLeasesFutureMinimumPaymentsDue_7F0B07071F322C8BA06EAC58EA4640C2" xlink:to="lab_insm_AdditionalLaboratorySpaceOperatingLeasesFutureMinimumPaymentsDue_7F0B07071F322C8BA06EAC58EA4640C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_D4FE0F52497C5FA1C114AC58EA46C15C_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_D4FE0F52497C5FA1C114AC58EA46C15C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial lease term</link:label>
    <link:label id="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_D4FE0F52497C5FA1C114AC58EA46C15C_label_en-US" xlink:label="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_D4FE0F52497C5FA1C114AC58EA46C15C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_D4FE0F52497C5FA1C114AC58EA46C15C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_D4FE0F52497C5FA1C114AC58EA46C15C" xlink:to="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_D4FE0F52497C5FA1C114AC58EA46C15C" xlink:type="arc" />
    <link:label id="lab_insm_LesseeOperatingLeaseNumberOfRenewals_54BD7C4154E59CBB7205AC58EA46108B_terseLabel_en-US" xlink:label="lab_insm_LesseeOperatingLeaseNumberOfRenewals_54BD7C4154E59CBB7205AC58EA46108B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option to extend lease term</link:label>
    <link:label id="lab_insm_LesseeOperatingLeaseNumberOfRenewals_54BD7C4154E59CBB7205AC58EA46108B_label_en-US" xlink:label="lab_insm_LesseeOperatingLeaseNumberOfRenewals_54BD7C4154E59CBB7205AC58EA46108B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewals</link:label>
    <link:label id="lab_insm_LesseeOperatingLeaseNumberOfRenewals_54BD7C4154E59CBB7205AC58EA46108B_documentation_en-US" xlink:label="lab_insm_LesseeOperatingLeaseNumberOfRenewals_54BD7C4154E59CBB7205AC58EA46108B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewals</link:label>
    <link:loc xlink:href="insm-20180930.xsd#insm_LesseeOperatingLeaseNumberOfRenewals" xlink:label="loc_insm_LesseeOperatingLeaseNumberOfRenewals_54BD7C4154E59CBB7205AC58EA46108B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_LesseeOperatingLeaseNumberOfRenewals_54BD7C4154E59CBB7205AC58EA46108B" xlink:to="lab_insm_LesseeOperatingLeaseNumberOfRenewals_54BD7C4154E59CBB7205AC58EA46108B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_E45475F47DDAF8F2E4DBAC58EA461885_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_E45475F47DDAF8F2E4DBAC58EA461885" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period of lease extension</link:label>
    <link:label id="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_E45475F47DDAF8F2E4DBAC58EA461885_label_en-US" xlink:label="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_E45475F47DDAF8F2E4DBAC58EA461885" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_E45475F47DDAF8F2E4DBAC58EA461885" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_E45475F47DDAF8F2E4DBAC58EA461885" xlink:to="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_E45475F47DDAF8F2E4DBAC58EA461885" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_7CDE46DECE23B73A51D0AC58EA4659D6_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense_7CDE46DECE23B73A51D0AC58EA4659D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rent expense charged to operations</link:label>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_7CDE46DECE23B73A51D0AC58EA4659D6_label_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense_7CDE46DECE23B73A51D0AC58EA4659D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_7CDE46DECE23B73A51D0AC58EA4659D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense_7CDE46DECE23B73A51D0AC58EA4659D6" xlink:to="lab_us-gaap_LeaseAndRentalExpense_7CDE46DECE23B73A51D0AC58EA4659D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_4E212854D5AFA3337DA88222F41ECF4F_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_4E212854D5AFA3337DA88222F41ECF4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_4E212854D5AFA3337DA88222F41ECF4F_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_4E212854D5AFA3337DA88222F41ECF4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_4E212854D5AFA3337DA88222F41ECF4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_4E212854D5AFA3337DA88222F41ECF4F" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_4E212854D5AFA3337DA88222F41ECF4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_9E3962119AD463069F198222F41E4BF5_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_9E3962119AD463069F198222F41E4BF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_9E3962119AD463069F198222F41E4BF5_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_9E3962119AD463069F198222F41E4BF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_9E3962119AD463069F198222F41E4BF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_9E3962119AD463069F198222F41E4BF5" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_9E3962119AD463069F198222F41E4BF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_1D82AE8FD81643D0DE558231AA4C7781_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_1D82AE8FD81643D0DE558231AA4C7781" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_1D82AE8FD81643D0DE558231AA4C7781_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_1D82AE8FD81643D0DE558231AA4C7781" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_1D82AE8FD81643D0DE558231AA4C7781" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock_1D82AE8FD81643D0DE558231AA4C7781" xlink:to="lab_us-gaap_InventoryPolicyTextBlock_1D82AE8FD81643D0DE558231AA4C7781" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_E7857FEC7FC14B4BAE208222F41E0145_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_E7857FEC7FC14B4BAE208222F41E0145" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recently Adopted Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_E7857FEC7FC14B4BAE208222F41E0145_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_E7857FEC7FC14B4BAE208222F41E0145" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_E7857FEC7FC14B4BAE208222F41E0145" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_E7857FEC7FC14B4BAE208222F41E0145" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_E7857FEC7FC14B4BAE208222F41E0145" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_01D63A3E43EFE3AAFA54E76669445FB2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_2680579BEF3C571F8108C024B94E81C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_01D63A3E43EFE3AAFA54E76669445FB2_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_2680579BEF3C571F8108C024B94E81C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_2680579BEF3C571F8108C024B94E81C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_2680579BEF3C571F8108C024B94E81C4" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_2680579BEF3C571F8108C024B94E81C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_B4A57CBF13886D99184FFF2F33580386_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_B68286B4E5D557CA980E5C3CC001FADA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_B68286B4E5D557CA980E5C3CC001FADA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_B68286B4E5D557CA980E5C3CC001FADA" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_B68286B4E5D557CA980E5C3CC001FADA" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_FD5001667DFC09120951FF2F3358EB50_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_E9E67DEC55695EDCB9C023BAC99FB42F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_FD5001667DFC09120951FF2F3358EB50_label_en-US" xlink:label="lab_us-gaap_StatementTable_E9E67DEC55695EDCB9C023BAC99FB42F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_E9E67DEC55695EDCB9C023BAC99FB42F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_E9E67DEC55695EDCB9C023BAC99FB42F" xlink:to="lab_us-gaap_StatementTable_E9E67DEC55695EDCB9C023BAC99FB42F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_A2996B5DC5F81FE351C9FF2F3358B83C_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_2DEBD773E5C35AD095EF9D13DA93F5E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_A2996B5DC5F81FE351C9FF2F3358B83C_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_2DEBD773E5C35AD095EF9D13DA93F5E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2DEBD773E5C35AD095EF9D13DA93F5E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2DEBD773E5C35AD095EF9D13DA93F5E7" xlink:to="lab_us-gaap_LongtermDebtTypeAxis_2DEBD773E5C35AD095EF9D13DA93F5E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_FB02D59975BE1119AB95FF2F33580FC2_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_37F9F7ACED125DF095E27612E4F2A7AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_FB02D59975BE1119AB95FF2F33580FC2_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_37F9F7ACED125DF095E27612E4F2A7AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_37F9F7ACED125DF095E27612E4F2A7AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_37F9F7ACED125DF095E27612E4F2A7AD" xlink:to="lab_us-gaap_LongtermDebtTypeDomain_37F9F7ACED125DF095E27612E4F2A7AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_A18C72AB27156C03D0A6FF2F335907BF_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember_91C10855EF4255E882DB5D5117B89185" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_A18C72AB27156C03D0A6FF2F335907BF_label_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember_91C10855EF4255E882DB5D5117B89185" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Notes Payable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_91C10855EF4255E882DB5D5117B89185" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayableMember_91C10855EF4255E882DB5D5117B89185" xlink:to="lab_us-gaap_ConvertibleNotesPayableMember_91C10855EF4255E882DB5D5117B89185" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_D0E9BD90FE0586BF2250FF2F33594620_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_8F14EE79483A5ACFB59D40A421D2F427" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_D0E9BD90FE0586BF2250FF2F33594620_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_8F14EE79483A5ACFB59D40A421D2F427" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_8F14EE79483A5ACFB59D40A421D2F427" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_8F14EE79483A5ACFB59D40A421D2F427" xlink:to="lab_us-gaap_DebtInstrumentAxis_8F14EE79483A5ACFB59D40A421D2F427" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_14CB95F653D45D06A7C7FF2F335916AF_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_A24B83DE3037523EB66A5DE7C6AA8F61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_14CB95F653D45D06A7C7FF2F335916AF_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_A24B83DE3037523EB66A5DE7C6AA8F61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_A24B83DE3037523EB66A5DE7C6AA8F61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A24B83DE3037523EB66A5DE7C6AA8F61" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_A24B83DE3037523EB66A5DE7C6AA8F61" xlink:type="arc" />
    <link:label id="lab_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_D6D68AF5E63B03F5EE9AFF2F335A50BD_terseLabel_en-US" xlink:label="lab_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_2D680018F18056D080F17C607FC1A24D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1.75 convertible senior notes due 2025</link:label>
    <link:label id="lab_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_D6D68AF5E63B03F5EE9AFF2F335A50BD_label_en-US" xlink:label="lab_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_2D680018F18056D080F17C607FC1A24D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">One Point Seven Five Percent Convertible Senior Note Due 2025 [Member]</link:label>
    <link:label id="lab_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_D6D68AF5E63B03F5EE9AFF2F335A50BD_documentation_en-US" xlink:label="lab_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_2D680018F18056D080F17C607FC1A24D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">One Point Seven Five Percent Convertible Senior Note Due 2025 [Member]</link:label>
    <link:loc xlink:href="insm-20180930.xsd#insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member" xlink:label="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_2D680018F18056D080F17C607FC1A24D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_2D680018F18056D080F17C607FC1A24D" xlink:to="lab_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_2D680018F18056D080F17C607FC1A24D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_15E5B67C27AE007A8084FF2F335A138F_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_93F0D8CC867E5552853FD29B032455A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_15E5B67C27AE007A8084FF2F335A138F_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_93F0D8CC867E5552853FD29B032455A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_93F0D8CC867E5552853FD29B032455A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_93F0D8CC867E5552853FD29B032455A8" xlink:to="lab_us-gaap_StatementLineItems_93F0D8CC867E5552853FD29B032455A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_7A6A507696E0054E6988FF2F335A4B8C_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_A377B7A5ED8B5605AFCA7496E38C23CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_7A6A507696E0054E6988FF2F335A4B8C_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_A377B7A5ED8B5605AFCA7496E38C23CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_A377B7A5ED8B5605AFCA7496E38C23CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_A377B7A5ED8B5605AFCA7496E38C23CC" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_A377B7A5ED8B5605AFCA7496E38C23CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_77B5C02A5D3DC73348DF4D279B04899C_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0DBB66CC84B25EE098635DEA96EFF169" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0DBB66CC84B25EE098635DEA96EFF169" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0DBB66CC84B25EE098635DEA96EFF169" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0DBB66CC84B25EE098635DEA96EFF169" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1D1D05B8C5CB9A8A70484D279B0BBC94_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_319A8FDF62DE5302B25648A9AAE09CCA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Fair Value Assumptions for Stock Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1D1D05B8C5CB9A8A70484D279B0BBC94_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_319A8FDF62DE5302B25648A9AAE09CCA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_319A8FDF62DE5302B25648A9AAE09CCA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_319A8FDF62DE5302B25648A9AAE09CCA" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_319A8FDF62DE5302B25648A9AAE09CCA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7FF16401F849A4F777784D279B0BEBB1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_87EEFD1E85EA5783833EC94A7FEE00DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7FF16401F849A4F777784D279B0BEBB1_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_87EEFD1E85EA5783833EC94A7FEE00DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_87EEFD1E85EA5783833EC94A7FEE00DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_87EEFD1E85EA5783833EC94A7FEE00DF" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_87EEFD1E85EA5783833EC94A7FEE00DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_61112B754D8C00BCB3DB4D279B0B70E6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_9417B1CD14655562B9083742AF36C98C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Exercise Price and Number of Stock Options Exercisable</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_61112B754D8C00BCB3DB4D279B0B70E6_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_9417B1CD14655562B9083742AF36C98C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_9417B1CD14655562B9083742AF36C98C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_9417B1CD14655562B9083742AF36C98C" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_9417B1CD14655562B9083742AF36C98C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_F887A1402796401FEF4C4D279B0B55D0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_AD836FDBED465472B4E39F7F6138BAAA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of RSU Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_F887A1402796401FEF4C4D279B0B55D0_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_AD836FDBED465472B4E39F7F6138BAAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_AD836FDBED465472B4E39F7F6138BAAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_AD836FDBED465472B4E39F7F6138BAAA" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_AD836FDBED465472B4E39F7F6138BAAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_A070238BD6B09B0920FE4D279B0C4362_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_5BA2CEB3C80E5A3DA484A420DFDA4768" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Allocation of Employee Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_A070238BD6B09B0920FE4D279B0C4362_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_5BA2CEB3C80E5A3DA484A420DFDA4768" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_5BA2CEB3C80E5A3DA484A420DFDA4768" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_5BA2CEB3C80E5A3DA484A420DFDA4768" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_5BA2CEB3C80E5A3DA484A420DFDA4768" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_43595AA2F97DB5D979F4CE613B561999_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7D29007F60A35FDC91E9048E052BF8D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_43595AA2F97DB5D979F4CE613B561999_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7D29007F60A35FDC91E9048E052BF8D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7D29007F60A35FDC91E9048E052BF8D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7D29007F60A35FDC91E9048E052BF8D1" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7D29007F60A35FDC91E9048E052BF8D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_ECBBD7F5CC3FF64951E78222F35D6CFC_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_ECBBD7F5CC3FF64951E78222F35D6CFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_ECBBD7F5CC3FF64951E78222F35D6CFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_ECBBD7F5CC3FF64951E78222F35D6CFC" xlink:to="lab_us-gaap_EquityAbstract_ECBBD7F5CC3FF64951E78222F35D6CFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_653B8B8FF6040785F9918222F35D00A9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_653B8B8FF6040785F9918222F35D00A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_653B8B8FF6040785F9918222F35D00A9_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_653B8B8FF6040785F9918222F35D00A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_653B8B8FF6040785F9918222F35D00A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_653B8B8FF6040785F9918222F35D00A9" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_653B8B8FF6040785F9918222F35D00A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_45AFAAF568BFC92414788222F35E14CD_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_45AFAAF568BFC92414788222F35E14CD" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at December 31, 2017</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_45AFAAF568BFC92414788222F35E14CD_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_45AFAAF568BFC92414788222F35E14CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_45AFAAF568BFC92414788222F35E14CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_45AFAAF568BFC92414788222F35E14CD" xlink:to="lab_us-gaap_StockholdersEquity_45AFAAF568BFC92414788222F35E14CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_DDE602685B55017D91858222F35E955A_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_DDE602685B55017D91858222F35E955A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss for the period</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_DDE602685B55017D91858222F35E955A_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_DDE602685B55017D91858222F35E955A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_DDE602685B55017D91858222F35E955A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_DDE602685B55017D91858222F35E955A" xlink:to="lab_us-gaap_NetIncomeLoss_DDE602685B55017D91858222F35E955A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_F386A82CED53F2C100978222F35F8CF5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_F386A82CED53F2C100978222F35F8CF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_F386A82CED53F2C100978222F35F8CF5_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_F386A82CED53F2C100978222F35F8CF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_F386A82CED53F2C100978222F35F8CF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_F386A82CED53F2C100978222F35F8CF5" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_F386A82CED53F2C100978222F35F8CF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_E601CF9D94A11F0A95A18222F35F0939_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_E601CF9D94A11F0A95A18222F35F0939" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity component of Convertible Notes</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_E601CF9D94A11F0A95A18222F35F0939_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_E601CF9D94A11F0A95A18222F35F0939" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_E601CF9D94A11F0A95A18222F35F0939" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_E601CF9D94A11F0A95A18222F35F0939" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_E601CF9D94A11F0A95A18222F35F0939" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_C05E1C8B88132F802B208222F35F4EE8_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_C05E1C8B88132F802B208222F35F4EE8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_C05E1C8B88132F802B208222F35F4EE8_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_C05E1C8B88132F802B208222F35F4EE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_C05E1C8B88132F802B208222F35F4EE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_C05E1C8B88132F802B208222F35F4EE8" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_C05E1C8B88132F802B208222F35F4EE8" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_6D99F708433465FB10278222F35F2326_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_6D99F708433465FB10278222F35F2326" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in cumulative translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_6D99F708433465FB10278222F35F2326_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_6D99F708433465FB10278222F35F2326" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_6D99F708433465FB10278222F35F2326" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_6D99F708433465FB10278222F35F2326" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_6D99F708433465FB10278222F35F2326" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_A4BD3A3560843154C6638222F35F7C52_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_A4BD3A3560843154C6638222F35F7C52" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at September 30, 2018</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_A4BD3A3560843154C6638222F35F7C52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_A4BD3A3560843154C6638222F35F7C52" xlink:to="lab_us-gaap_StockholdersEquity_A4BD3A3560843154C6638222F35F7C52" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_23944BBB7A7628A7A6B7A868C999EC6D_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_2F9FFFE2BC555D8786A25034843A43E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2F9FFFE2BC555D8786A25034843A43E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2F9FFFE2BC555D8786A25034843A43E2" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_2F9FFFE2BC555D8786A25034843A43E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_AB7357DC33B6EE2FB4DAA868C99A5C74_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_2811FDFC42255D4A8D9B262C10E50B48" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_AB7357DC33B6EE2FB4DAA868C99A5C74_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_2811FDFC42255D4A8D9B262C10E50B48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2811FDFC42255D4A8D9B262C10E50B48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_2811FDFC42255D4A8D9B262C10E50B48" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_2811FDFC42255D4A8D9B262C10E50B48" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_7510225B147C13EF5243A868C99A8BFA_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_FF28F2E739D65A5C813CAC4D6D10601D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax benefit</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_7510225B147C13EF5243A868C99A8BFA_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_FF28F2E739D65A5C813CAC4D6D10601D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_FF28F2E739D65A5C813CAC4D6D10601D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_FF28F2E739D65A5C813CAC4D6D10601D" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_FF28F2E739D65A5C813CAC4D6D10601D" xlink:type="arc" />
    <link:label id="lab_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_97F4AFC1283A8FFCF866A868C99A7A36_terseLabel_en-US" xlink:label="lab_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_25179CEF8F2259DEAE5212779B5239F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisional deferred tax asset offset completely by valuation allowance</link:label>
    <link:label id="lab_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_97F4AFC1283A8FFCF866A868C99A7A36_label_en-US" xlink:label="lab_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_25179CEF8F2259DEAE5212779B5239F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets (Liabilities) Net before Valuation Allowances</link:label>
    <link:label id="lab_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_97F4AFC1283A8FFCF866A868C99A7A36_documentation_en-US" xlink:label="lab_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_25179CEF8F2259DEAE5212779B5239F4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards, net of deferred tax liability attributable to taxable temporary differences.</link:label>
    <link:loc xlink:href="insm-20180930.xsd#insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" xlink:label="loc_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_25179CEF8F2259DEAE5212779B5239F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_25179CEF8F2259DEAE5212779B5239F4" xlink:to="lab_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_25179CEF8F2259DEAE5212779B5239F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_9008118B74846AF35C68A868C99ABC14_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_918A5AD59B5B5F8DB280F5B1A8362659" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized income tax benefits, interest and penalties accrued</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_9008118B74846AF35C68A868C99ABC14_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_918A5AD59B5B5F8DB280F5B1A8362659" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_918A5AD59B5B5F8DB280F5B1A8362659" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_918A5AD59B5B5F8DB280F5B1A8362659" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_918A5AD59B5B5F8DB280F5B1A8362659" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_0A9F30EB569EDA8C29BFF60EC12265E1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_1406145270A4598C8D33ADF1664C9307" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_0A9F30EB569EDA8C29BFF60EC12265E1_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_1406145270A4598C8D33ADF1664C9307" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1406145270A4598C8D33ADF1664C9307" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1406145270A4598C8D33ADF1664C9307" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable_1406145270A4598C8D33ADF1664C9307" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_51E12CBD78EA71399E01F60EC12401F5_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_0A9C66524FA05BC2AE7C1633CC2DB61F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_51E12CBD78EA71399E01F60EC12401F5_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_0A9C66524FA05BC2AE7C1633CC2DB61F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_0A9C66524FA05BC2AE7C1633CC2DB61F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_0A9C66524FA05BC2AE7C1633CC2DB61F" xlink:to="lab_us-gaap_AwardTypeAxis_0A9C66524FA05BC2AE7C1633CC2DB61F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B3E5D0A7FAB98F97BBFAF60EC1249F94_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CBAE01F62CDB5C05ADA69653E3609615" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B3E5D0A7FAB98F97BBFAF60EC1249F94_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CBAE01F62CDB5C05ADA69653E3609615" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CBAE01F62CDB5C05ADA69653E3609615" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CBAE01F62CDB5C05ADA69653E3609615" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CBAE01F62CDB5C05ADA69653E3609615" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_6C7E56D2D5FB4E5F0790F60EC1254D4E_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember_EDB9356F0B92572D9C15C7E213E03D8F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Convertible debt securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_EDB9356F0B92572D9C15C7E213E03D8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayableMember_EDB9356F0B92572D9C15C7E213E03D8F" xlink:to="lab_us-gaap_ConvertibleNotesPayableMember_EDB9356F0B92572D9C15C7E213E03D8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockLineItems_115CE099F6B5B07F0610F60EC1262A4C_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_4DC440B4ACBE5479A36AAD513366124E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_115CE099F6B5B07F0610F60EC1262A4C_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_4DC440B4ACBE5479A36AAD513366124E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_4DC440B4ACBE5479A36AAD513366124E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems_4DC440B4ACBE5479A36AAD513366124E" xlink:to="lab_us-gaap_ClassOfStockLineItems_4DC440B4ACBE5479A36AAD513366124E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_D8AB3577D76B570607C5F60EC1261AB3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_DAB2CA2A8AA55D1687C2303C7A8D575D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, authorized shares (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_D8AB3577D76B570607C5F60EC1261AB3_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_DAB2CA2A8AA55D1687C2303C7A8D575D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_DAB2CA2A8AA55D1687C2303C7A8D575D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_DAB2CA2A8AA55D1687C2303C7A8D575D" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_DAB2CA2A8AA55D1687C2303C7A8D575D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_973FADD6E3DBC62C150CF60EC126B062_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_5C10142B4840560A8E3D32D69C923EA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_973FADD6E3DBC62C150CF60EC126B062_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_5C10142B4840560A8E3D32D69C923EA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5C10142B4840560A8E3D32D69C923EA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_5C10142B4840560A8E3D32D69C923EA3" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_5C10142B4840560A8E3D32D69C923EA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_7D780D9143936C29457FF60EC126B487_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_61C39E54AE645AC18342E3276E774CA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, issued shares (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_7D780D9143936C29457FF60EC126B487_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_61C39E54AE645AC18342E3276E774CA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_61C39E54AE645AC18342E3276E774CA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_61C39E54AE645AC18342E3276E774CA1" xlink:to="lab_us-gaap_CommonStockSharesIssued_61C39E54AE645AC18342E3276E774CA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_58117BA0338234506D3BF60EC1267BF3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_1E196B845F7D544F8233BEE80C7E3C4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, outstanding shares (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_58117BA0338234506D3BF60EC1267BF3_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_1E196B845F7D544F8233BEE80C7E3C4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1E196B845F7D544F8233BEE80C7E3C4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_1E196B845F7D544F8233BEE80C7E3C4E" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_1E196B845F7D544F8233BEE80C7E3C4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_5A078E25FABBB36517B2F60EC1272441_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_A629A7F20DAE550F8917371CD430E27E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock shares reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_5A078E25FABBB36517B2F60EC1272441_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_A629A7F20DAE550F8917371CD430E27E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_A629A7F20DAE550F8917371CD430E27E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_A629A7F20DAE550F8917371CD430E27E" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_A629A7F20DAE550F8917371CD430E27E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_9F5DF8275193BDDC2BBBF60EC127CC09_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_2EFA641D84C75A268F8C0A5A2EE04BE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_9F5DF8275193BDDC2BBBF60EC127CC09_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_2EFA641D84C75A268F8C0A5A2EE04BE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2EFA641D84C75A268F8C0A5A2EE04BE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_2EFA641D84C75A268F8C0A5A2EE04BE7" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_2EFA641D84C75A268F8C0A5A2EE04BE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_6A122945716EB06DB1CAF60EC127B019_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures_B2FE23948C4F5CF492FF56B968397948" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Notes ($450.0 face value)</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_6A122945716EB06DB1CAF60EC127B019_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures_B2FE23948C4F5CF492FF56B968397948" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_B2FE23948C4F5CF492FF56B968397948" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtFairValueDisclosures_B2FE23948C4F5CF492FF56B968397948" xlink:to="lab_us-gaap_ConvertibleDebtFairValueDisclosures_B2FE23948C4F5CF492FF56B968397948" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_1FA8237BADC8A0CDD5D0F60EC12763AE_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_A50857335B405834836D145B96B9C8D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity component of convertible debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_1FA8237BADC8A0CDD5D0F60EC12763AE_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_A50857335B405834836D145B96B9C8D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Carrying Amount of Equity Component</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_A50857335B405834836D145B96B9C8D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_A50857335B405834836D145B96B9C8D2" xlink:to="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_A50857335B405834836D145B96B9C8D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6F86083A3F415A653F14F60EC127F4DE_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_D65B987E35F25567B00EDB4DC542F0BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued under underwritten public offering (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6F86083A3F415A653F14F60EC127F4DE_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_D65B987E35F25567B00EDB4DC542F0BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_D65B987E35F25567B00EDB4DC542F0BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_D65B987E35F25567B00EDB4DC542F0BE" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_D65B987E35F25567B00EDB4DC542F0BE" xlink:type="arc" />
    <link:label id="lab_insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption_4D916DDC0E48BF33033CF60EC1283BD0_terseLabel_en-US" xlink:label="lab_insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption_65225E076D045BACAB25A56D75CE4227" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares exercised in full of over-allotment option by underwriter (in shares)</link:label>
    <link:label id="lab_insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption_4D916DDC0E48BF33033CF60EC1283BD0_label_en-US" xlink:label="lab_insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption_65225E076D045BACAB25A56D75CE4227" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Shares Exercise To Underwriters In Full Of Over Allotment Option</link:label>
    <link:label id="lab_insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption_4D916DDC0E48BF33033CF60EC1283BD0_documentation_en-US" xlink:label="lab_insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption_65225E076D045BACAB25A56D75CE4227" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock Shares Exercise To Underwriters In Full Of Over Allotment Option</link:label>
    <link:loc xlink:href="insm-20180930.xsd#insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption" xlink:label="loc_insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption_65225E076D045BACAB25A56D75CE4227" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption_65225E076D045BACAB25A56D75CE4227" xlink:to="lab_insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption_65225E076D045BACAB25A56D75CE4227" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharePrice_A83A0C8D0706431138A6F60EC1287E34_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice_4D7E0165131554569E046388862D716A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_A83A0C8D0706431138A6F60EC1287E34_label_en-US" xlink:label="lab_us-gaap_SharePrice_4D7E0165131554569E046388862D716A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_4D7E0165131554569E046388862D716A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice_4D7E0165131554569E046388862D716A" xlink:to="lab_us-gaap_SharePrice_4D7E0165131554569E046388862D716A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_8CAC4D48E59D5CE8F748F60EC128EFA2_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_43098723806C5D9BB9668F35CD8118B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underwriter's discount and offering expenses</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_8CAC4D48E59D5CE8F748F60EC128EFA2_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_43098723806C5D9BB9668F35CD8118B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_43098723806C5D9BB9668F35CD8118B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_43098723806C5D9BB9668F35CD8118B9" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_43098723806C5D9BB9668F35CD8118B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_F890895E68255502B560F60EC1288C91_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_9150930775C55061B5400D98295BD770" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from sale of shares</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_F890895E68255502B560F60EC1288C91_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_9150930775C55061B5400D98295BD770" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9150930775C55061B5400D98295BD770" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9150930775C55061B5400D98295BD770" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_9150930775C55061B5400D98295BD770" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_C7BD1CE87BF60C345133F60EC12814E5_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_B8E035705B585351816E0FB1CF1137B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_C7BD1CE87BF60C345133F60EC12814E5_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_B8E035705B585351816E0FB1CF1137B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_B8E035705B585351816E0FB1CF1137B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_B8E035705B585351816E0FB1CF1137B5" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_B8E035705B585351816E0FB1CF1137B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_CFF890B9FCC7F51223E2F60EC1282C91_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_29A126212CC05CC0B7913FD4466F6393" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_CFF890B9FCC7F51223E2F60EC1282C91_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_29A126212CC05CC0B7913FD4466F6393" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_29A126212CC05CC0B7913FD4466F6393" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_29A126212CC05CC0B7913FD4466F6393" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_29A126212CC05CC0B7913FD4466F6393" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_3B8ED66C303D189C45EEF60EC129809C_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_F5F9E48F02BD52748E8F35B198D13617" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_3B8ED66C303D189C45EEF60EC129809C_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_F5F9E48F02BD52748E8F35B198D13617" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_F5F9E48F02BD52748E8F35B198D13617" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_F5F9E48F02BD52748E8F35B198D13617" xlink:to="lab_us-gaap_PreferredStockSharesIssued_F5F9E48F02BD52748E8F35B198D13617" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_35C2C748B175FD515E63F60EC1296F36_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_E15257B492815EFC85DC8CF250EB79BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_35C2C748B175FD515E63F60EC1296F36_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_E15257B492815EFC85DC8CF250EB79BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_E15257B492815EFC85DC8CF250EB79BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_E15257B492815EFC85DC8CF250EB79BA" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_E15257B492815EFC85DC8CF250EB79BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_385F3CC2EC4BBDB5F207A147620E2123_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_385F3CC2EC4BBDB5F207A147620E2123" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_385F3CC2EC4BBDB5F207A147620E2123_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_385F3CC2EC4BBDB5F207A147620E2123" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_385F3CC2EC4BBDB5F207A147620E2123" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_385F3CC2EC4BBDB5F207A147620E2123" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_385F3CC2EC4BBDB5F207A147620E2123" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_06E8AAB86F53AA312B2FA147620E1141_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_06E8AAB86F53AA312B2FA147620E1141" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_06E8AAB86F53AA312B2FA147620E1141" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_06E8AAB86F53AA312B2FA147620E1141" xlink:to="lab_us-gaap_NetIncomeLoss_06E8AAB86F53AA312B2FA147620E1141" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_A6A70176C3C732FD779DECA89D7833C2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_9D7B2DDD31E05826B41270224221604D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Rental Payments Required Under Operating Leases</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_A6A70176C3C732FD779DECA89D7833C2_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_9D7B2DDD31E05826B41270224221604D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_9D7B2DDD31E05826B41270224221604D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_9D7B2DDD31E05826B41270224221604D" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_9D7B2DDD31E05826B41270224221604D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsAssetsQuantitativeInformationTable_34FE08F48AE559665A668222F40F851D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsAssetsQuantitativeInformationTable_34FE08F48AE559665A668222F40F851D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Inputs, Assets, Quantitative Information [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsAssetsQuantitativeInformationTable_34FE08F48AE559665A668222F40F851D_label_en-US" xlink:label="lab_us-gaap_FairValueInputsAssetsQuantitativeInformationTable_34FE08F48AE559665A668222F40F851D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Inputs, Assets, Quantitative Information [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsAssetsQuantitativeInformationTable" xlink:label="loc_us-gaap_FairValueInputsAssetsQuantitativeInformationTable_34FE08F48AE559665A668222F40F851D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsAssetsQuantitativeInformationTable_34FE08F48AE559665A668222F40F851D" xlink:to="lab_us-gaap_FairValueInputsAssetsQuantitativeInformationTable_34FE08F48AE559665A668222F40F851D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_EDCFA29A021E266A59B48222F4107AED_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis_EDCFA29A021E266A59B48222F4107AED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_EDCFA29A021E266A59B48222F4107AED_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis_EDCFA29A021E266A59B48222F4107AED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_EDCFA29A021E266A59B48222F4107AED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_EDCFA29A021E266A59B48222F4107AED" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis_EDCFA29A021E266A59B48222F4107AED" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_842834FFC680B582F8658222F410A64F_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_842834FFC680B582F8658222F410A64F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_842834FFC680B582F8658222F410A64F_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_842834FFC680B582F8658222F410A64F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_842834FFC680B582F8658222F410A64F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_842834FFC680B582F8658222F410A64F" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_842834FFC680B582F8658222F410A64F" xlink:type="arc" />
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_29E7DE7FAA6D1F37E1CB8222F4106163_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember_29E7DE7FAA6D1F37E1CB8222F4106163" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">US treasury bills</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_29E7DE7FAA6D1F37E1CB8222F4106163_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember_29E7DE7FAA6D1F37E1CB8222F4106163" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_29E7DE7FAA6D1F37E1CB8222F4106163" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember_29E7DE7FAA6D1F37E1CB8222F4106163" xlink:to="lab_us-gaap_USTreasurySecuritiesMember_29E7DE7FAA6D1F37E1CB8222F4106163" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsAssetsQuantitativeInformationLineItems_A1BC2E950478B8D06A1D8222F41261BC_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsAssetsQuantitativeInformationLineItems_A1BC2E950478B8D06A1D8222F41261BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Inputs, Assets, Quantitative Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsAssetsQuantitativeInformationLineItems_A1BC2E950478B8D06A1D8222F41261BC_label_en-US" xlink:label="lab_us-gaap_FairValueInputsAssetsQuantitativeInformationLineItems_A1BC2E950478B8D06A1D8222F41261BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Inputs, Assets, Quantitative Information [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsAssetsQuantitativeInformationLineItems" xlink:label="loc_us-gaap_FairValueInputsAssetsQuantitativeInformationLineItems_A1BC2E950478B8D06A1D8222F41261BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsAssetsQuantitativeInformationLineItems_A1BC2E950478B8D06A1D8222F41261BC" xlink:to="lab_us-gaap_FairValueInputsAssetsQuantitativeInformationLineItems_A1BC2E950478B8D06A1D8222F41261BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0F1C09A9ED910FFAC2D48222F41304EF_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0F1C09A9ED910FFAC2D48222F41304EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0F1C09A9ED910FFAC2D48222F41304EF_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0F1C09A9ED910FFAC2D48222F41304EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0F1C09A9ED910FFAC2D48222F41304EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0F1C09A9ED910FFAC2D48222F41304EF" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0F1C09A9ED910FFAC2D48222F41304EF" xlink:type="arc" />
    <link:label id="lab_insm_FairValueLevel1Level2Level3TransfersAmount_680FDE54B99905C1624F8222F41388FF_terseLabel_en-US" xlink:label="lab_insm_FairValueLevel1Level2Level3TransfersAmount_680FDE54B99905C1624F8222F41388FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value transfers in or out of Level 1, Level 2, or Level 3</link:label>
    <link:label id="lab_insm_FairValueLevel1Level2Level3TransfersAmount_680FDE54B99905C1624F8222F41388FF_label_en-US" xlink:label="lab_insm_FairValueLevel1Level2Level3TransfersAmount_680FDE54B99905C1624F8222F41388FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Level 1 Level 2 Level 3 Transfers Amount</link:label>
    <link:label id="lab_insm_FairValueLevel1Level2Level3TransfersAmount_680FDE54B99905C1624F8222F41388FF_documentation_en-US" xlink:label="lab_insm_FairValueLevel1Level2Level3TransfersAmount_680FDE54B99905C1624F8222F41388FF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of transfers measured on a recurring basis in or out of Level 1, Level 2, or Level 3.</link:label>
    <link:loc xlink:href="insm-20180930.xsd#insm_FairValueLevel1Level2Level3TransfersAmount" xlink:label="loc_insm_FairValueLevel1Level2Level3TransfersAmount_680FDE54B99905C1624F8222F41388FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_FairValueLevel1Level2Level3TransfersAmount_680FDE54B99905C1624F8222F41388FF" xlink:to="lab_insm_FairValueLevel1Level2Level3TransfersAmount_680FDE54B99905C1624F8222F41388FF" xlink:type="arc" />
    <link:label id="lab_insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities_38AE6E4B195F93730B068222F4147EB3_verboseLabel_en-US" xlink:label="lab_insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities_38AE6E4B195F93730B068222F4147EB3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Securities in an unrealized gain or loss position</link:label>
    <link:label id="lab_insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities_38AE6E4B195F93730B068222F4147EB3_label_en-US" xlink:label="lab_insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities_38AE6E4B195F93730B068222F4147EB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Gross Unrealized Gain (Loss), Number of Securities</link:label>
    <link:label id="lab_insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities_38AE6E4B195F93730B068222F4147EB3_documentation_en-US" xlink:label="lab_insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities_38AE6E4B195F93730B068222F4147EB3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Gross Unrealized Gain (Loss), Number of Securities</link:label>
    <link:loc xlink:href="insm-20180930.xsd#insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities" xlink:label="loc_insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities_38AE6E4B195F93730B068222F4147EB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities_38AE6E4B195F93730B068222F4147EB3" xlink:to="lab_insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities_38AE6E4B195F93730B068222F4147EB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_9B0B5D1E88D29E0DD994E766694984E9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_CFEEE6152BF250868E9C16A4F1F73FBA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_9B0B5D1E88D29E0DD994E766694984E9_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_CFEEE6152BF250868E9C16A4F1F73FBA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_CFEEE6152BF250868E9C16A4F1F73FBA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_CFEEE6152BF250868E9C16A4F1F73FBA" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_CFEEE6152BF250868E9C16A4F1F73FBA" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_949CBACCBA580471DDD6CE62E40A2BA4_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_BCDF3B85EB0A54B48C91B9A26ECEDAEF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_949CBACCBA580471DDD6CE62E40A2BA4_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_BCDF3B85EB0A54B48C91B9A26ECEDAEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_BCDF3B85EB0A54B48C91B9A26ECEDAEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_BCDF3B85EB0A54B48C91B9A26ECEDAEF" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_BCDF3B85EB0A54B48C91B9A26ECEDAEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_47672B67B44376FF4DB2AC52B2470EAD_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_47672B67B44376FF4DB2AC52B2470EAD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets estimated useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_47672B67B44376FF4DB2AC52B2470EAD_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_47672B67B44376FF4DB2AC52B2470EAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_47672B67B44376FF4DB2AC52B2470EAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_47672B67B44376FF4DB2AC52B2470EAD" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_47672B67B44376FF4DB2AC52B2470EAD" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_0AB70086FB19CE1B99974D172234E63F_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract_B9168D6ADCDF5BD98F8D0F844074E18B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year Ending December 31:</link:label>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_0AB70086FB19CE1B99974D172234E63F_label_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract_B9168D6ADCDF5BD98F8D0F844074E18B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_B9168D6ADCDF5BD98F8D0F844074E18B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_B9168D6ADCDF5BD98F8D0F844074E18B" xlink:to="lab_us-gaap_LongTermDebtByMaturityAbstract_B9168D6ADCDF5BD98F8D0F844074E18B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_84835DA29D1B45CE1BC54D0414A861C8_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_0776E46C04765AFBA3B2ECC2AD7CA044" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2018</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_84835DA29D1B45CE1BC54D0414A861C8_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_0776E46C04765AFBA3B2ECC2AD7CA044" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_0776E46C04765AFBA3B2ECC2AD7CA044" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_0776E46C04765AFBA3B2ECC2AD7CA044" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_0776E46C04765AFBA3B2ECC2AD7CA044" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_3DD115AC9BE07CB554E14D0414A802EA_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_CA695F1789BC524B83CCE767E838E737" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_3DD115AC9BE07CB554E14D0414A802EA_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_CA695F1789BC524B83CCE767E838E737" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_CA695F1789BC524B83CCE767E838E737" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_CA695F1789BC524B83CCE767E838E737" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_CA695F1789BC524B83CCE767E838E737" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_6254917B74E9EDD723454D0414A8D09B_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_33EBB790ADEB54198C91FADB8A84951B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_6254917B74E9EDD723454D0414A8D09B_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_33EBB790ADEB54198C91FADB8A84951B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_33EBB790ADEB54198C91FADB8A84951B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_33EBB790ADEB54198C91FADB8A84951B" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_33EBB790ADEB54198C91FADB8A84951B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_5E6E39A8887B18D9E2BB4D0414A8C311_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_B7A481199F985E74BB0E0786CE3F123B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_5E6E39A8887B18D9E2BB4D0414A8C311_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_B7A481199F985E74BB0E0786CE3F123B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_B7A481199F985E74BB0E0786CE3F123B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_B7A481199F985E74BB0E0786CE3F123B" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_B7A481199F985E74BB0E0786CE3F123B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_C82F81EA86CB8BC9B6CF4D0414A9C415_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_7FC3D71048F35FD8927C7AB28A17CE4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_C82F81EA86CB8BC9B6CF4D0414A9C415_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_7FC3D71048F35FD8927C7AB28A17CE4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_7FC3D71048F35FD8927C7AB28A17CE4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_7FC3D71048F35FD8927C7AB28A17CE4E" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_7FC3D71048F35FD8927C7AB28A17CE4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_27D9C1F741947A66671B4D0414A9DAC0_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_06FF70DD92C75834BF1212F0921E01EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023 and thereafter</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_27D9C1F741947A66671B4D0414A9DAC0_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_06FF70DD92C75834BF1212F0921E01EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal after Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_06FF70DD92C75834BF1212F0921E01EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_06FF70DD92C75834BF1212F0921E01EE" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_06FF70DD92C75834BF1212F0921E01EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_435288CC7DC956447E334D0414A96D9F_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_71417984935D5EDE8FDC7C67ED82BBDF" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_435288CC7DC956447E334D0414A96D9F_label_en-US" xlink:label="lab_us-gaap_LongTermDebt_71417984935D5EDE8FDC7C67ED82BBDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_71417984935D5EDE8FDC7C67ED82BBDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_71417984935D5EDE8FDC7C67ED82BBDF" xlink:to="lab_us-gaap_LongTermDebt_71417984935D5EDE8FDC7C67ED82BBDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_6EE839370798D28469FC8222DEF422E6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_6EE839370798D28469FC8222DEF422E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_6EE839370798D28469FC8222DEF422E6_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_6EE839370798D28469FC8222DEF422E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_6EE839370798D28469FC8222DEF422E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_6EE839370798D28469FC8222DEF422E6" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_6EE839370798D28469FC8222DEF422E6" xlink:type="arc" />
    <link:label id="lab_insm_DocumentAndEntityInformationAbstract_C80F0D6AC9834C377E4C821907676822_label_en-US" xlink:label="lab_insm_DocumentAndEntityInformationAbstract_C80F0D6AC9834C377E4C821907676822" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document and Entity Information</link:label>
    <link:label id="lab_insm_DocumentAndEntityInformationAbstract_C80F0D6AC9834C377E4C821907676822_documentation_en-US" xlink:label="lab_insm_DocumentAndEntityInformationAbstract_C80F0D6AC9834C377E4C821907676822" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="insm-20180930.xsd#insm_DocumentAndEntityInformationAbstract" xlink:label="loc_insm_DocumentAndEntityInformationAbstract_C80F0D6AC9834C377E4C821907676822" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_DocumentAndEntityInformationAbstract_C80F0D6AC9834C377E4C821907676822" xlink:to="lab_insm_DocumentAndEntityInformationAbstract_C80F0D6AC9834C377E4C821907676822" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_33F2C3E50C04F21870B78219076C453C_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_33F2C3E50C04F21870B78219076C453C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_33F2C3E50C04F21870B78219076C453C_label_en-US" xlink:label="lab_dei_EntityRegistrantName_33F2C3E50C04F21870B78219076C453C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_33F2C3E50C04F21870B78219076C453C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_33F2C3E50C04F21870B78219076C453C" xlink:to="lab_dei_EntityRegistrantName_33F2C3E50C04F21870B78219076C453C" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_4F1AF6612F76126DDA008219076DE176_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_4F1AF6612F76126DDA008219076DE176" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_4F1AF6612F76126DDA008219076DE176_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_4F1AF6612F76126DDA008219076DE176" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_4F1AF6612F76126DDA008219076DE176" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_4F1AF6612F76126DDA008219076DE176" xlink:to="lab_dei_EntityCentralIndexKey_4F1AF6612F76126DDA008219076DE176" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_722E54C7B03C6F4AC3828219076EB413_terseLabel_en-US" xlink:label="lab_dei_DocumentType_722E54C7B03C6F4AC3828219076EB413" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_722E54C7B03C6F4AC3828219076EB413_label_en-US" xlink:label="lab_dei_DocumentType_722E54C7B03C6F4AC3828219076EB413" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_722E54C7B03C6F4AC3828219076EB413" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_722E54C7B03C6F4AC3828219076EB413" xlink:to="lab_dei_DocumentType_722E54C7B03C6F4AC3828219076EB413" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_C309195298A4D7115DA88219076E0C18_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_C309195298A4D7115DA88219076E0C18" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_C309195298A4D7115DA88219076E0C18_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_C309195298A4D7115DA88219076E0C18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_C309195298A4D7115DA88219076E0C18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_C309195298A4D7115DA88219076E0C18" xlink:to="lab_dei_DocumentPeriodEndDate_C309195298A4D7115DA88219076E0C18" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_7967D5C0E4581475E8B98219076E45B0_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_7967D5C0E4581475E8B98219076E45B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_7967D5C0E4581475E8B98219076E45B0_label_en-US" xlink:label="lab_dei_AmendmentFlag_7967D5C0E4581475E8B98219076E45B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_7967D5C0E4581475E8B98219076E45B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_7967D5C0E4581475E8B98219076E45B0" xlink:to="lab_dei_AmendmentFlag_7967D5C0E4581475E8B98219076E45B0" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_D038E86451D4EC3C9D078219076E6087_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_D038E86451D4EC3C9D078219076E6087" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_D038E86451D4EC3C9D078219076E6087_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_D038E86451D4EC3C9D078219076E6087" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_D038E86451D4EC3C9D078219076E6087" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_D038E86451D4EC3C9D078219076E6087" xlink:to="lab_dei_CurrentFiscalYearEndDate_D038E86451D4EC3C9D078219076E6087" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_E6DC506555050F4B93AD8219076EF43D_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_E6DC506555050F4B93AD8219076EF43D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_E6DC506555050F4B93AD8219076EF43D_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_E6DC506555050F4B93AD8219076EF43D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_E6DC506555050F4B93AD8219076EF43D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_E6DC506555050F4B93AD8219076EF43D" xlink:to="lab_dei_EntityCurrentReportingStatus_E6DC506555050F4B93AD8219076EF43D" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_529EFC7FF5A0640136158219076F030F_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_529EFC7FF5A0640136158219076F030F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_529EFC7FF5A0640136158219076F030F_label_en-US" xlink:label="lab_dei_EntityFilerCategory_529EFC7FF5A0640136158219076F030F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_529EFC7FF5A0640136158219076F030F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_529EFC7FF5A0640136158219076F030F" xlink:to="lab_dei_EntityFilerCategory_529EFC7FF5A0640136158219076F030F" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_FFDF03F39A5046D330908219076FDB7C_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_FFDF03F39A5046D330908219076FDB7C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_FFDF03F39A5046D330908219076FDB7C_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_FFDF03F39A5046D330908219076FDB7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_FFDF03F39A5046D330908219076FDB7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_FFDF03F39A5046D330908219076FDB7C" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_FFDF03F39A5046D330908219076FDB7C" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_23364921CD15D198C9D58219076FDDC7_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_23364921CD15D198C9D58219076FDDC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_23364921CD15D198C9D58219076FDDC7_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_23364921CD15D198C9D58219076FDDC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_23364921CD15D198C9D58219076FDDC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_23364921CD15D198C9D58219076FDDC7" xlink:to="lab_dei_DocumentFiscalYearFocus_23364921CD15D198C9D58219076FDDC7" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_24FC0A07367AD7083E1C8219076FF4FD_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_24FC0A07367AD7083E1C8219076FF4FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_24FC0A07367AD7083E1C8219076FF4FD_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_24FC0A07367AD7083E1C8219076FF4FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_24FC0A07367AD7083E1C8219076FF4FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_24FC0A07367AD7083E1C8219076FF4FD" xlink:to="lab_dei_DocumentFiscalPeriodFocus_24FC0A07367AD7083E1C8219076FF4FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_A6EC8C5DDF917498A9BA8222F337B880_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_A6EC8C5DDF917498A9BA8222F337B880" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_A6EC8C5DDF917498A9BA8222F337B880_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_A6EC8C5DDF917498A9BA8222F337B880" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_A6EC8C5DDF917498A9BA8222F337B880" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_A6EC8C5DDF917498A9BA8222F337B880" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_A6EC8C5DDF917498A9BA8222F337B880" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeAxis_A04D6D4C5EBEBCA8051F8222F3397061_terseLabel_en-US" xlink:label="lab_us-gaap_RangeAxis_A04D6D4C5EBEBCA8051F8222F3397061" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_us-gaap_RangeAxis_A04D6D4C5EBEBCA8051F8222F3397061_label_en-US" xlink:label="lab_us-gaap_RangeAxis_A04D6D4C5EBEBCA8051F8222F3397061" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_A04D6D4C5EBEBCA8051F8222F3397061" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeAxis_A04D6D4C5EBEBCA8051F8222F3397061" xlink:to="lab_us-gaap_RangeAxis_A04D6D4C5EBEBCA8051F8222F3397061" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeMember_F86345798ACE00E670538222F339C99F_terseLabel_en-US" xlink:label="lab_us-gaap_RangeMember_F86345798ACE00E670538222F339C99F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_us-gaap_RangeMember_F86345798ACE00E670538222F339C99F_label_en-US" xlink:label="lab_us-gaap_RangeMember_F86345798ACE00E670538222F339C99F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_F86345798ACE00E670538222F339C99F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeMember_F86345798ACE00E670538222F339C99F" xlink:to="lab_us-gaap_RangeMember_F86345798ACE00E670538222F339C99F" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinimumMember_2E18F4FF0F32F9BB56608222F33A59B5_terseLabel_en-US" xlink:label="lab_us-gaap_MinimumMember_2E18F4FF0F32F9BB56608222F33A59B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_us-gaap_MinimumMember_2E18F4FF0F32F9BB56608222F33A59B5_label_en-US" xlink:label="lab_us-gaap_MinimumMember_2E18F4FF0F32F9BB56608222F33A59B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_2E18F4FF0F32F9BB56608222F33A59B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumMember_2E18F4FF0F32F9BB56608222F33A59B5" xlink:to="lab_us-gaap_MinimumMember_2E18F4FF0F32F9BB56608222F33A59B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_MaximumMember_1C8B6FE8C8185D75A52B8222F33A021A_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumMember_1C8B6FE8C8185D75A52B8222F33A021A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_us-gaap_MaximumMember_1C8B6FE8C8185D75A52B8222F33A021A_label_en-US" xlink:label="lab_us-gaap_MaximumMember_1C8B6FE8C8185D75A52B8222F33A021A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_1C8B6FE8C8185D75A52B8222F33A021A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumMember_1C8B6FE8C8185D75A52B8222F33A021A" xlink:to="lab_us-gaap_MaximumMember_1C8B6FE8C8185D75A52B8222F33A021A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB0F46299742DED80F338222F33ACDF4_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB0F46299742DED80F338222F33ACDF4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock Option disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB0F46299742DED80F338222F33ACDF4_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB0F46299742DED80F338222F33ACDF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB0F46299742DED80F338222F33ACDF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB0F46299742DED80F338222F33ACDF4" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB0F46299742DED80F338222F33ACDF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_D4A037638F3CB7B659F38222F33AAD40_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_D4A037638F3CB7B659F38222F33AAD40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value and assumptions used in determining fair value of stock options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_D4A037638F3CB7B659F38222F33AAD40_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_D4A037638F3CB7B659F38222F33AAD40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_D4A037638F3CB7B659F38222F33AAD40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_D4A037638F3CB7B659F38222F33AAD40" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_D4A037638F3CB7B659F38222F33AAD40" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7DAEB4B1BC5CCEBBEE848222F33BCCA6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7DAEB4B1BC5CCEBBEE848222F33BCCA6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7DAEB4B1BC5CCEBBEE848222F33BCCA6_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7DAEB4B1BC5CCEBBEE848222F33BCCA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7DAEB4B1BC5CCEBBEE848222F33BCCA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7DAEB4B1BC5CCEBBEE848222F33BCCA6" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7DAEB4B1BC5CCEBBEE848222F33BCCA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_F5E4EC916537ACA3683C8222F33BFF7E_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_F5E4EC916537ACA3683C8222F33BFF7E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_F5E4EC916537ACA3683C8222F33BFF7E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_F5E4EC916537ACA3683C8222F33BFF7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_F5E4EC916537ACA3683C8222F33BFF7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_F5E4EC916537ACA3683C8222F33BFF7E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_F5E4EC916537ACA3683C8222F33BFF7E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5D93AD67AC7BFC642A178222F33CA202_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5D93AD67AC7BFC642A178222F33CA202" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5D93AD67AC7BFC642A178222F33CA202_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5D93AD67AC7BFC642A178222F33CA202" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5D93AD67AC7BFC642A178222F33CA202" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5D93AD67AC7BFC642A178222F33CA202" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5D93AD67AC7BFC642A178222F33CA202" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_DFF898231B64AB7A4EEB8222F33CBE8B_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_DFF898231B64AB7A4EEB8222F33CBE8B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected option term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_DFF898231B64AB7A4EEB8222F33CBE8B_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_DFF898231B64AB7A4EEB8222F33CBE8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_DFF898231B64AB7A4EEB8222F33CBE8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_DFF898231B64AB7A4EEB8222F33CBE8B" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_DFF898231B64AB7A4EEB8222F33CBE8B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D9561799A248942C7B1A8222F33CDF0C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D9561799A248942C7B1A8222F33CDF0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average fair value of stock options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D9561799A248942C7B1A8222F33CDF0C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D9561799A248942C7B1A8222F33CDF0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D9561799A248942C7B1A8222F33CDF0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D9561799A248942C7B1A8222F33CDF0C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D9561799A248942C7B1A8222F33CDF0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65DA945BAA176A3A76458222F33C58F6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65DA945BAA176A3A76458222F33C58F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65DA945BAA176A3A76458222F33C58F6_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65DA945BAA176A3A76458222F33C58F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65DA945BAA176A3A76458222F33C58F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65DA945BAA176A3A76458222F33C58F6" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65DA945BAA176A3A76458222F33C58F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C2D4CAF34D40FC57FE3F8222F33C7041_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C2D4CAF34D40FC57FE3F8222F33C7041" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Options outstanding beginning of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C2D4CAF34D40FC57FE3F8222F33C7041_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C2D4CAF34D40FC57FE3F8222F33C7041" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C2D4CAF34D40FC57FE3F8222F33C7041" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C2D4CAF34D40FC57FE3F8222F33C7041" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C2D4CAF34D40FC57FE3F8222F33C7041" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8ACB6495A186525633D98222F33C76CE_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8ACB6495A186525633D98222F33C76CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8ACB6495A186525633D98222F33C76CE_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8ACB6495A186525633D98222F33C76CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8ACB6495A186525633D98222F33C76CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8ACB6495A186525633D98222F33C76CE" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8ACB6495A186525633D98222F33C76CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_66905FB11112867C06A68222F33DD085_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_66905FB11112867C06A68222F33DD085" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_66905FB11112867C06A68222F33DD085_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_66905FB11112867C06A68222F33DD085" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_66905FB11112867C06A68222F33DD085" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_66905FB11112867C06A68222F33DD085" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_66905FB11112867C06A68222F33DD085" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_E961EC3FF5B8FE6FDECC8222F33DA6D4_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_E961EC3FF5B8FE6FDECC8222F33DA6D4" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited or expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_E961EC3FF5B8FE6FDECC8222F33DA6D4_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_E961EC3FF5B8FE6FDECC8222F33DA6D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_E961EC3FF5B8FE6FDECC8222F33DA6D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_E961EC3FF5B8FE6FDECC8222F33DA6D4" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_E961EC3FF5B8FE6FDECC8222F33DA6D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_76A3761E8BE2C78CF4C48222F33D768D_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_76A3761E8BE2C78CF4C48222F33D768D" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Options outstanding end of the period (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_76A3761E8BE2C78CF4C48222F33D768D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_76A3761E8BE2C78CF4C48222F33D768D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_76A3761E8BE2C78CF4C48222F33D768D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_F5D8B0D6427B24CCEBBA8222F33D3122_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_F5D8B0D6427B24CCEBBA8222F33D3122" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_F5D8B0D6427B24CCEBBA8222F33D3122_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_F5D8B0D6427B24CCEBBA8222F33D3122" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_F5D8B0D6427B24CCEBBA8222F33D3122" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_F5D8B0D6427B24CCEBBA8222F33D3122" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_F5D8B0D6427B24CCEBBA8222F33D3122" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0910FB0B6F7A27C955328222F33EE641_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0910FB0B6F7A27C955328222F33EE641" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0910FB0B6F7A27C955328222F33EE641_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0910FB0B6F7A27C955328222F33EE641" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0910FB0B6F7A27C955328222F33EE641" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0910FB0B6F7A27C955328222F33EE641" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0910FB0B6F7A27C955328222F33EE641" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5B8E0C1E0B2581C3F5738222F33E730C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5B8E0C1E0B2581C3F5738222F33E730C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5B8E0C1E0B2581C3F5738222F33E730C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5B8E0C1E0B2581C3F5738222F33E730C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5B8E0C1E0B2581C3F5738222F33E730C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5B8E0C1E0B2581C3F5738222F33E730C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5B8E0C1E0B2581C3F5738222F33E730C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B30ECA97EA4E8E86C06E8222F33E3A7B_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B30ECA97EA4E8E86C06E8222F33E3A7B" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Options outstanding beginning of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B30ECA97EA4E8E86C06E8222F33E3A7B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B30ECA97EA4E8E86C06E8222F33E3A7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B30ECA97EA4E8E86C06E8222F33E3A7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B30ECA97EA4E8E86C06E8222F33E3A7B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B30ECA97EA4E8E86C06E8222F33E3A7B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_915F5EB0A785B395FDD98222F33EC2A4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_915F5EB0A785B395FDD98222F33EC2A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_915F5EB0A785B395FDD98222F33EC2A4_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_915F5EB0A785B395FDD98222F33EC2A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_915F5EB0A785B395FDD98222F33EC2A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_915F5EB0A785B395FDD98222F33EC2A4" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_915F5EB0A785B395FDD98222F33EC2A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3931F74D384EEC967E398222F33FD06B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3931F74D384EEC967E398222F33FD06B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3931F74D384EEC967E398222F33FD06B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3931F74D384EEC967E398222F33FD06B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3931F74D384EEC967E398222F33FD06B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3931F74D384EEC967E398222F33FD06B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3931F74D384EEC967E398222F33FD06B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1D3D6DE2F739C2FF89B68222F33FFFB4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1D3D6DE2F739C2FF89B68222F33FFFB4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited or expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1D3D6DE2F739C2FF89B68222F33FFFB4_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1D3D6DE2F739C2FF89B68222F33FFFB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1D3D6DE2F739C2FF89B68222F33FFFB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1D3D6DE2F739C2FF89B68222F33FFFB4" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1D3D6DE2F739C2FF89B68222F33FFFB4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_21A99D9CB5DFA06597198222F33F853C_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_21A99D9CB5DFA06597198222F33F853C" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Options outstanding end of the period (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_21A99D9CB5DFA06597198222F33F853C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_21A99D9CB5DFA06597198222F33F853C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_21A99D9CB5DFA06597198222F33F853C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_E1FC454BCA63304322528222F33FD71B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_E1FC454BCA63304322528222F33FD71B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_E1FC454BCA63304322528222F33FD71B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_E1FC454BCA63304322528222F33FD71B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_E1FC454BCA63304322528222F33FD71B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_E1FC454BCA63304322528222F33FD71B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_E1FC454BCA63304322528222F33FD71B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5E8EA90F76E2EDD8D5E18222F3403DFC_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5E8EA90F76E2EDD8D5E18222F3403DFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5E8EA90F76E2EDD8D5E18222F3403DFC_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5E8EA90F76E2EDD8D5E18222F3403DFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5E8EA90F76E2EDD8D5E18222F3403DFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5E8EA90F76E2EDD8D5E18222F3403DFC" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5E8EA90F76E2EDD8D5E18222F3403DFC" xlink:type="arc" />
    <link:label id="lab_insm_WeightedAverageRemainingContractualLifeInYearsAbstract_BD8796E7D55F9E1EA2C28222F340D374_terseLabel_en-US" xlink:label="lab_insm_WeightedAverageRemainingContractualLifeInYearsAbstract_BD8796E7D55F9E1EA2C28222F340D374" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Life in Years</link:label>
    <link:label id="lab_insm_WeightedAverageRemainingContractualLifeInYearsAbstract_BD8796E7D55F9E1EA2C28222F340D374_label_en-US" xlink:label="lab_insm_WeightedAverageRemainingContractualLifeInYearsAbstract_BD8796E7D55F9E1EA2C28222F340D374" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Life in Years [Abstract]</link:label>
    <link:label id="lab_insm_WeightedAverageRemainingContractualLifeInYearsAbstract_BD8796E7D55F9E1EA2C28222F340D374_documentation_en-US" xlink:label="lab_insm_WeightedAverageRemainingContractualLifeInYearsAbstract_BD8796E7D55F9E1EA2C28222F340D374" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="insm-20180930.xsd#insm_WeightedAverageRemainingContractualLifeInYearsAbstract" xlink:label="loc_insm_WeightedAverageRemainingContractualLifeInYearsAbstract_BD8796E7D55F9E1EA2C28222F340D374" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_WeightedAverageRemainingContractualLifeInYearsAbstract_BD8796E7D55F9E1EA2C28222F340D374" xlink:to="lab_insm_WeightedAverageRemainingContractualLifeInYearsAbstract_BD8796E7D55F9E1EA2C28222F340D374" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6DF518EC2167D28F29558222F34022A7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6DF518EC2167D28F29558222F34022A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6DF518EC2167D28F29558222F34022A7_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6DF518EC2167D28F29558222F34022A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6DF518EC2167D28F29558222F34022A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6DF518EC2167D28F29558222F34022A7" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6DF518EC2167D28F29558222F34022A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_9F565E99DDA5AD23B9D28222F3407FD4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_9F565E99DDA5AD23B9D28222F3407FD4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_9F565E99DDA5AD23B9D28222F3407FD4_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_9F565E99DDA5AD23B9D28222F3407FD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_9F565E99DDA5AD23B9D28222F3407FD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_9F565E99DDA5AD23B9D28222F3407FD4" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_9F565E99DDA5AD23B9D28222F3407FD4" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_161E1B050B65DA6D41498222F341CAD7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_161E1B050B65DA6D41498222F341CAD7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_161E1B050B65DA6D41498222F341CAD7_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_161E1B050B65DA6D41498222F341CAD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_161E1B050B65DA6D41498222F341CAD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_161E1B050B65DA6D41498222F341CAD7" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_161E1B050B65DA6D41498222F341CAD7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1D5DF3859ED50034B9D58222F34133E1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1D5DF3859ED50034B9D58222F34133E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1D5DF3859ED50034B9D58222F34133E1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1D5DF3859ED50034B9D58222F34133E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1D5DF3859ED50034B9D58222F34133E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1D5DF3859ED50034B9D58222F34133E1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1D5DF3859ED50034B9D58222F34133E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6229591C2B615456F75E8222F341D582_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6229591C2B615456F75E8222F341D582" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6229591C2B615456F75E8222F341D582_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6229591C2B615456F75E8222F341D582" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6229591C2B615456F75E8222F341D582" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6229591C2B615456F75E8222F341D582" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6229591C2B615456F75E8222F341D582" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2D77FD03299D81727C9F8222F3416FBE_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2D77FD03299D81727C9F8222F3416FBE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2D77FD03299D81727C9F8222F3416FBE_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2D77FD03299D81727C9F8222F3416FBE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2D77FD03299D81727C9F8222F3416FBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2D77FD03299D81727C9F8222F3416FBE" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2D77FD03299D81727C9F8222F3416FBE" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5DB94D7611B1A60564088222F34280C9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5DB94D7611B1A60564088222F34280C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5DB94D7611B1A60564088222F34280C9_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5DB94D7611B1A60564088222F34280C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5DB94D7611B1A60564088222F34280C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5DB94D7611B1A60564088222F34280C9" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5DB94D7611B1A60564088222F34280C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_B983CF81F1A198ACEF6E74E49A6CFB59_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_2D21B9F6B2D15519AB7045EB1CFA91D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_2D21B9F6B2D15519AB7045EB1CFA91D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2D21B9F6B2D15519AB7045EB1CFA91D3" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_2D21B9F6B2D15519AB7045EB1CFA91D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_A7055DAA1102627CCDC7A878968E5462_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_F68178F9A98550938AF8792A5F3CD21B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Carrying Value and Fair Value of Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_A7055DAA1102627CCDC7A878968E5462_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_F68178F9A98550938AF8792A5F3CD21B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_F68178F9A98550938AF8792A5F3CD21B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_F68178F9A98550938AF8792A5F3CD21B" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_F68178F9A98550938AF8792A5F3CD21B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_F8C98E93B22AF289A232A868CAF79DAE_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_A62E2DDF47E254F5BBFA6F4214A4E021" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of the Weighted Average Number of Shares Used to Compute Basic and Diluted Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_F8C98E93B22AF289A232A868CAF79DAE_label_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_A62E2DDF47E254F5BBFA6F4214A4E021" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Weighted Average Number of Shares [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_A62E2DDF47E254F5BBFA6F4214A4E021" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_A62E2DDF47E254F5BBFA6F4214A4E021" xlink:to="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_A62E2DDF47E254F5BBFA6F4214A4E021" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2C0FDEFCF09A5E423F72A868CAF7BACB_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0A2199098E2E567FAAE553CE9F62C96B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potentially Dilutive Securities Excluded from Computations of Diluted Weighted Average Common Shares Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2C0FDEFCF09A5E423F72A868CAF7BACB_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0A2199098E2E567FAAE553CE9F62C96B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0A2199098E2E567FAAE553CE9F62C96B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0A2199098E2E567FAAE553CE9F62C96B" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0A2199098E2E567FAAE553CE9F62C96B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_44ACF47100CE39736BACC147F2009EDC_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_44ACF47100CE39736BACC147F2009EDC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_44ACF47100CE39736BACC147F2009EDC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_44ACF47100CE39736BACC147F2009EDC" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_44ACF47100CE39736BACC147F2009EDC" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_F2A8E7DC18EC112A9B79C147F20490ED_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues_F2A8E7DC18EC112A9B79C147F20490ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_F2A8E7DC18EC112A9B79C147F20490ED_label_en-US" xlink:label="lab_us-gaap_Revenues_F2A8E7DC18EC112A9B79C147F20490ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_F2A8E7DC18EC112A9B79C147F20490ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_F2A8E7DC18EC112A9B79C147F20490ED" xlink:to="lab_us-gaap_Revenues_F2A8E7DC18EC112A9B79C147F20490ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_1F8B2079A262721866F7C147F207AE36_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_1F8B2079A262721866F7C147F207AE36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_1F8B2079A262721866F7C147F207AE36_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_1F8B2079A262721866F7C147F207AE36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_1F8B2079A262721866F7C147F207AE36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1F8B2079A262721866F7C147F207AE36" xlink:to="lab_us-gaap_OperatingExpensesAbstract_1F8B2079A262721866F7C147F207AE36" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_8BB799AE28BB9B57B93DC147F2077646_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_8BB799AE28BB9B57B93DC147F2077646" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_8BB799AE28BB9B57B93DC147F2077646_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_8BB799AE28BB9B57B93DC147F2077646" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8BB799AE28BB9B57B93DC147F2077646" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_8BB799AE28BB9B57B93DC147F2077646" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_8BB799AE28BB9B57B93DC147F2077646" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_B7B47E5E701ECA591909C147F208D97F_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_B7B47E5E701ECA591909C147F208D97F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_B7B47E5E701ECA591909C147F208D97F_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_B7B47E5E701ECA591909C147F208D97F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_B7B47E5E701ECA591909C147F208D97F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_B7B47E5E701ECA591909C147F208D97F" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_B7B47E5E701ECA591909C147F208D97F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_D71F118A627298F4FA51C147F208D3C5_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_D71F118A627298F4FA51C147F208D3C5" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_D71F118A627298F4FA51C147F208D3C5_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_D71F118A627298F4FA51C147F208D3C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_D71F118A627298F4FA51C147F208D3C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_D71F118A627298F4FA51C147F208D3C5" xlink:to="lab_us-gaap_OperatingExpenses_D71F118A627298F4FA51C147F208D3C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_CEAF304C0CC5484C2B79C147F20873BF_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_CEAF304C0CC5484C2B79C147F20873BF" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_CEAF304C0CC5484C2B79C147F20873BF_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_CEAF304C0CC5484C2B79C147F20873BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_CEAF304C0CC5484C2B79C147F20873BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_CEAF304C0CC5484C2B79C147F20873BF" xlink:to="lab_us-gaap_OperatingIncomeLoss_CEAF304C0CC5484C2B79C147F20873BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentIncomeNonoperating_603710D8ECEAF02D6297C147F208A03A_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNonoperating_603710D8ECEAF02D6297C147F208A03A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNonoperating_603710D8ECEAF02D6297C147F208A03A_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNonoperating_603710D8ECEAF02D6297C147F208A03A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Nonoperating</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating_603710D8ECEAF02D6297C147F208A03A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNonoperating_603710D8ECEAF02D6297C147F208A03A" xlink:to="lab_us-gaap_InvestmentIncomeNonoperating_603710D8ECEAF02D6297C147F208A03A" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_BA4B526DAEDB71A26F01C147F2082CA1_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_BA4B526DAEDB71A26F01C147F2082CA1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_BA4B526DAEDB71A26F01C147F2082CA1_label_en-US" xlink:label="lab_us-gaap_InterestExpense_BA4B526DAEDB71A26F01C147F2082CA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_BA4B526DAEDB71A26F01C147F2082CA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_BA4B526DAEDB71A26F01C147F2082CA1" xlink:to="lab_us-gaap_InterestExpense_BA4B526DAEDB71A26F01C147F2082CA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_5EDB4131EAC12859D4C0C147F2097265_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_5EDB4131EAC12859D4C0C147F2097265" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_5EDB4131EAC12859D4C0C147F2097265_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_5EDB4131EAC12859D4C0C147F2097265" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5EDB4131EAC12859D4C0C147F2097265" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5EDB4131EAC12859D4C0C147F2097265" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_5EDB4131EAC12859D4C0C147F2097265" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_5C537BD1729CA574D791C147F2094B04_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_5C537BD1729CA574D791C147F2094B04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_5C537BD1729CA574D791C147F2094B04_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_5C537BD1729CA574D791C147F2094B04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_5C537BD1729CA574D791C147F2094B04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_5C537BD1729CA574D791C147F2094B04" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_5C537BD1729CA574D791C147F2094B04" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_D8F7997B80447E5C73F7C147F2091774_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_D8F7997B80447E5C73F7C147F2091774" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_D8F7997B80447E5C73F7C147F2091774_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_D8F7997B80447E5C73F7C147F2091774" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_D8F7997B80447E5C73F7C147F2091774" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_D8F7997B80447E5C73F7C147F2091774" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_D8F7997B80447E5C73F7C147F2091774" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_50CDDB0CFCF3297F9830C147F209136F_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_50CDDB0CFCF3297F9830C147F209136F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_50CDDB0CFCF3297F9830C147F209136F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_50CDDB0CFCF3297F9830C147F209136F" xlink:to="lab_us-gaap_NetIncomeLoss_50CDDB0CFCF3297F9830C147F209136F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_16424836EE25455A65F4C147F2098B1A_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_16424836EE25455A65F4C147F2098B1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted net loss per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_16424836EE25455A65F4C147F2098B1A_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_16424836EE25455A65F4C147F2098B1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_16424836EE25455A65F4C147F2098B1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_16424836EE25455A65F4C147F2098B1A" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_16424836EE25455A65F4C147F2098B1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_4B26F76B31219A03F0A8C147F20AE77A_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_4B26F76B31219A03F0A8C147F20AE77A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average basic and diluted common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_4B26F76B31219A03F0A8C147F20AE77A_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_4B26F76B31219A03F0A8C147F20AE77A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_4B26F76B31219A03F0A8C147F20AE77A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_4B26F76B31219A03F0A8C147F20AE77A" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_4B26F76B31219A03F0A8C147F20AE77A" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_0D77E6A662CEACE376FDC147F20A37D7_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_0D77E6A662CEACE376FDC147F20A37D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0D77E6A662CEACE376FDC147F20A37D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_0D77E6A662CEACE376FDC147F20A37D7" xlink:to="lab_us-gaap_NetIncomeLoss_0D77E6A662CEACE376FDC147F20A37D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2544EA3537AE19F3BC3BC147F20A7885_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2544EA3537AE19F3BC3BC147F20A7885" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2544EA3537AE19F3BC3BC147F20A7885_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2544EA3537AE19F3BC3BC147F20A7885" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2544EA3537AE19F3BC3BC147F20A7885" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2544EA3537AE19F3BC3BC147F20A7885" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2544EA3537AE19F3BC3BC147F20A7885" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_F52C4BC293ED32A9A2DFC147F20ADB70_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_F52C4BC293ED32A9A2DFC147F20ADB70" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation gains</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_F52C4BC293ED32A9A2DFC147F20ADB70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_F52C4BC293ED32A9A2DFC147F20ADB70" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_F52C4BC293ED32A9A2DFC147F20ADB70" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_C17A7B2BA8AB1D3C9041C147F20A32E4_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_C17A7B2BA8AB1D3C9041C147F20A32E4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_C17A7B2BA8AB1D3C9041C147F20A32E4_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_C17A7B2BA8AB1D3C9041C147F20A32E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_C17A7B2BA8AB1D3C9041C147F20A32E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_C17A7B2BA8AB1D3C9041C147F20A32E4" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_C17A7B2BA8AB1D3C9041C147F20A32E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_33AB9B3A0A8118DEE8D0821BE5F83030_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_33AB9B3A0A8118DEE8D0821BE5F83030" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_33AB9B3A0A8118DEE8D0821BE5F83030_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_33AB9B3A0A8118DEE8D0821BE5F83030" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_33AB9B3A0A8118DEE8D0821BE5F83030" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_33AB9B3A0A8118DEE8D0821BE5F83030" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_33AB9B3A0A8118DEE8D0821BE5F83030" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1FF73BC9DB67452BAC6DE766691D90EE_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_F01BFA962A635CD4AC98B2D01CBBA243" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1FF73BC9DB67452BAC6DE766691D90EE_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_F01BFA962A635CD4AC98B2D01CBBA243" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_F01BFA962A635CD4AC98B2D01CBBA243" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_F01BFA962A635CD4AC98B2D01CBBA243" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_F01BFA962A635CD4AC98B2D01CBBA243" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_ACC2E24D0412676BA649BECA425D3CE3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_ACC2E24D0412676BA649BECA425D3CE3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_ACC2E24D0412676BA649BECA425D3CE3_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_ACC2E24D0412676BA649BECA425D3CE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_ACC2E24D0412676BA649BECA425D3CE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_ACC2E24D0412676BA649BECA425D3CE3" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_ACC2E24D0412676BA649BECA425D3CE3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_762DCB913A7C350AAA5CBECA425EE9D8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_762DCB913A7C350AAA5CBECA425EE9D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_762DCB913A7C350AAA5CBECA425EE9D8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_762DCB913A7C350AAA5CBECA425EE9D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_762DCB913A7C350AAA5CBECA425EE9D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_762DCB913A7C350AAA5CBECA425EE9D8" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_762DCB913A7C350AAA5CBECA425EE9D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_250632757FC8172548C8BECA425E0F76_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_250632757FC8172548C8BECA425E0F76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_250632757FC8172548C8BECA425E0F76_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_250632757FC8172548C8BECA425E0F76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_250632757FC8172548C8BECA425E0F76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_250632757FC8172548C8BECA425E0F76" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_250632757FC8172548C8BECA425E0F76" xlink:type="arc" />
    <link:label id="lab_insm_Range1Member_7DCCA95ECF2DD4779C7CBECA425E24C2_terseLabel_en-US" xlink:label="lab_insm_Range1Member_7DCCA95ECF2DD4779C7CBECA425E24C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$3.03 to $6.90</link:label>
    <link:label id="lab_insm_Range1Member_7DCCA95ECF2DD4779C7CBECA425E24C2_label_en-US" xlink:label="lab_insm_Range1Member_7DCCA95ECF2DD4779C7CBECA425E24C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range1 [Member]</link:label>
    <link:label id="lab_insm_Range1Member_7DCCA95ECF2DD4779C7CBECA425E24C2_documentation_en-US" xlink:label="lab_insm_Range1Member_7DCCA95ECF2DD4779C7CBECA425E24C2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Selected disclosure of Stock options outstanding and exercisable by share price exercise range.</link:label>
    <link:loc xlink:href="insm-20180930.xsd#insm_Range1Member" xlink:label="loc_insm_Range1Member_7DCCA95ECF2DD4779C7CBECA425E24C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_Range1Member_7DCCA95ECF2DD4779C7CBECA425E24C2" xlink:to="lab_insm_Range1Member_7DCCA95ECF2DD4779C7CBECA425E24C2" xlink:type="arc" />
    <link:label id="lab_insm_Range2Member_D2818585F4758CC12782BECA425FE155_terseLabel_en-US" xlink:label="lab_insm_Range2Member_D2818585F4758CC12782BECA425FE155" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$6.96 to $10.85</link:label>
    <link:label id="lab_insm_Range2Member_D2818585F4758CC12782BECA425FE155_label_en-US" xlink:label="lab_insm_Range2Member_D2818585F4758CC12782BECA425FE155" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range2 [Member]</link:label>
    <link:label id="lab_insm_Range2Member_D2818585F4758CC12782BECA425FE155_documentation_en-US" xlink:label="lab_insm_Range2Member_D2818585F4758CC12782BECA425FE155" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Selected disclosure of Stock options outstanding and exercisable by share price exercise range.</link:label>
    <link:loc xlink:href="insm-20180930.xsd#insm_Range2Member" xlink:label="loc_insm_Range2Member_D2818585F4758CC12782BECA425FE155" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_Range2Member_D2818585F4758CC12782BECA425FE155" xlink:to="lab_insm_Range2Member_D2818585F4758CC12782BECA425FE155" xlink:type="arc" />
    <link:label id="lab_insm_Range3Member_382E8EA41DA15E0DC520BECA425FD214_terseLabel_en-US" xlink:label="lab_insm_Range3Member_382E8EA41DA15E0DC520BECA425FD214" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$11.14 to $12.58</link:label>
    <link:label id="lab_insm_Range3Member_382E8EA41DA15E0DC520BECA425FD214_label_en-US" xlink:label="lab_insm_Range3Member_382E8EA41DA15E0DC520BECA425FD214" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range3 [Member]</link:label>
    <link:label id="lab_insm_Range3Member_382E8EA41DA15E0DC520BECA425FD214_documentation_en-US" xlink:label="lab_insm_Range3Member_382E8EA41DA15E0DC520BECA425FD214" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Selected disclosure of Stock options outstanding and exercisable by share price exercise range.</link:label>
    <link:loc xlink:href="insm-20180930.xsd#insm_Range3Member" xlink:label="loc_insm_Range3Member_382E8EA41DA15E0DC520BECA425FD214" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_Range3Member_382E8EA41DA15E0DC520BECA425FD214" xlink:to="lab_insm_Range3Member_382E8EA41DA15E0DC520BECA425FD214" xlink:type="arc" />
    <link:label id="lab_insm_Range4Member_A5D29416DB8B4E020553BECA425FA5BB_terseLabel_en-US" xlink:label="lab_insm_Range4Member_A5D29416DB8B4E020553BECA425FA5BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$12.66 to $13.67</link:label>
    <link:label id="lab_insm_Range4Member_A5D29416DB8B4E020553BECA425FA5BB_label_en-US" xlink:label="lab_insm_Range4Member_A5D29416DB8B4E020553BECA425FA5BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range4 [Member]</link:label>
    <link:label id="lab_insm_Range4Member_A5D29416DB8B4E020553BECA425FA5BB_documentation_en-US" xlink:label="lab_insm_Range4Member_A5D29416DB8B4E020553BECA425FA5BB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Selected disclosure of Stock options outstanding and exercisable by share price exercise range.</link:label>
    <link:loc xlink:href="insm-20180930.xsd#insm_Range4Member" xlink:label="loc_insm_Range4Member_A5D29416DB8B4E020553BECA425FA5BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_Range4Member_A5D29416DB8B4E020553BECA425FA5BB" xlink:to="lab_insm_Range4Member_A5D29416DB8B4E020553BECA425FA5BB" xlink:type="arc" />
    <link:label id="lab_insm_Range5Member_DFC0AD92F3105687D42BBECA425FB8C2_terseLabel_en-US" xlink:label="lab_insm_Range5Member_DFC0AD92F3105687D42BBECA425FB8C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$13.94 to $16.07</link:label>
    <link:label id="lab_insm_Range5Member_DFC0AD92F3105687D42BBECA425FB8C2_label_en-US" xlink:label="lab_insm_Range5Member_DFC0AD92F3105687D42BBECA425FB8C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range5 [Member]</link:label>
    <link:label id="lab_insm_Range5Member_DFC0AD92F3105687D42BBECA425FB8C2_documentation_en-US" xlink:label="lab_insm_Range5Member_DFC0AD92F3105687D42BBECA425FB8C2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Selected disclosure of Stock options outstanding and exercisable by share price exercise range.</link:label>
    <link:loc xlink:href="insm-20180930.xsd#insm_Range5Member" xlink:label="loc_insm_Range5Member_DFC0AD92F3105687D42BBECA425FB8C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_Range5Member_DFC0AD92F3105687D42BBECA425FB8C2" xlink:to="lab_insm_Range5Member_DFC0AD92F3105687D42BBECA425FB8C2" xlink:type="arc" />
    <link:label id="lab_insm_Range6Member_DDE16ABF6557A3A9A24ABECA425FB0EE_terseLabel_en-US" xlink:label="lab_insm_Range6Member_DDE16ABF6557A3A9A24ABECA425FB0EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$16.09 to $17.16</link:label>
    <link:label id="lab_insm_Range6Member_DDE16ABF6557A3A9A24ABECA425FB0EE_label_en-US" xlink:label="lab_insm_Range6Member_DDE16ABF6557A3A9A24ABECA425FB0EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range6 [Member]</link:label>
    <link:label id="lab_insm_Range6Member_DDE16ABF6557A3A9A24ABECA425FB0EE_documentation_en-US" xlink:label="lab_insm_Range6Member_DDE16ABF6557A3A9A24ABECA425FB0EE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Selected disclosure of Stock options outstanding and exercisable by share price exercise range.</link:label>
    <link:loc xlink:href="insm-20180930.xsd#insm_Range6Member" xlink:label="loc_insm_Range6Member_DDE16ABF6557A3A9A24ABECA425FB0EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_Range6Member_DDE16ABF6557A3A9A24ABECA425FB0EE" xlink:to="lab_insm_Range6Member_DDE16ABF6557A3A9A24ABECA425FB0EE" xlink:type="arc" />
    <link:label id="lab_insm_Range7Member_DD55379B0AED6765BD86BECA425FE2CF_terseLabel_en-US" xlink:label="lab_insm_Range7Member_DD55379B0AED6765BD86BECA425FE2CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$17.24 to $22.76</link:label>
    <link:label id="lab_insm_Range7Member_DD55379B0AED6765BD86BECA425FE2CF_label_en-US" xlink:label="lab_insm_Range7Member_DD55379B0AED6765BD86BECA425FE2CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range7 [Member]</link:label>
    <link:label id="lab_insm_Range7Member_DD55379B0AED6765BD86BECA425FE2CF_documentation_en-US" xlink:label="lab_insm_Range7Member_DD55379B0AED6765BD86BECA425FE2CF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Selected disclosure of Stock options outstanding and exercisable by share price exercise range.</link:label>
    <link:loc xlink:href="insm-20180930.xsd#insm_Range7Member" xlink:label="loc_insm_Range7Member_DD55379B0AED6765BD86BECA425FE2CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_Range7Member_DD55379B0AED6765BD86BECA425FE2CF" xlink:to="lab_insm_Range7Member_DD55379B0AED6765BD86BECA425FE2CF" xlink:type="arc" />
    <link:label id="lab_insm_Range8Member_BC2E8CCCC4CF296E7986BECA4260EC1F_terseLabel_en-US" xlink:label="lab_insm_Range8Member_BC2E8CCCC4CF296E7986BECA4260EC1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$22.84 to $30.46</link:label>
    <link:label id="lab_insm_Range8Member_BC2E8CCCC4CF296E7986BECA4260EC1F_label_en-US" xlink:label="lab_insm_Range8Member_BC2E8CCCC4CF296E7986BECA4260EC1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range8 [Member]</link:label>
    <link:label id="lab_insm_Range8Member_BC2E8CCCC4CF296E7986BECA4260EC1F_documentation_en-US" xlink:label="lab_insm_Range8Member_BC2E8CCCC4CF296E7986BECA4260EC1F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Selected disclosure of Stock options outstanding and exercisable by share price exercise range.</link:label>
    <link:loc xlink:href="insm-20180930.xsd#insm_Range8Member" xlink:label="loc_insm_Range8Member_BC2E8CCCC4CF296E7986BECA4260EC1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_Range8Member_BC2E8CCCC4CF296E7986BECA4260EC1F" xlink:to="lab_insm_Range8Member_BC2E8CCCC4CF296E7986BECA4260EC1F" xlink:type="arc" />
    <link:label id="lab_insm_Range9Member_747E5AFE504CC200805EBECA42600AF2_terseLabel_en-US" xlink:label="lab_insm_Range9Member_747E5AFE504CC200805EBECA42600AF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$30.86 to $31.78</link:label>
    <link:label id="lab_insm_Range9Member_747E5AFE504CC200805EBECA42600AF2_label_en-US" xlink:label="lab_insm_Range9Member_747E5AFE504CC200805EBECA42600AF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range9 [Member]</link:label>
    <link:label id="lab_insm_Range9Member_747E5AFE504CC200805EBECA42600AF2_documentation_en-US" xlink:label="lab_insm_Range9Member_747E5AFE504CC200805EBECA42600AF2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Selected disclosure of Stock options outstanding and exercisable by share price exercise range.</link:label>
    <link:loc xlink:href="insm-20180930.xsd#insm_Range9Member" xlink:label="loc_insm_Range9Member_747E5AFE504CC200805EBECA42600AF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_Range9Member_747E5AFE504CC200805EBECA42600AF2" xlink:to="lab_insm_Range9Member_747E5AFE504CC200805EBECA42600AF2" xlink:type="arc" />
    <link:label id="lab_insm_Range10Member_8036ECD09DBD16A9DCA9BECA42604214_terseLabel_en-US" xlink:label="lab_insm_Range10Member_8036ECD09DBD16A9DCA9BECA42604214" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$32.46 to $32.46</link:label>
    <link:label id="lab_insm_Range10Member_8036ECD09DBD16A9DCA9BECA42604214_label_en-US" xlink:label="lab_insm_Range10Member_8036ECD09DBD16A9DCA9BECA42604214" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range10 [Member]</link:label>
    <link:label id="lab_insm_Range10Member_8036ECD09DBD16A9DCA9BECA42604214_documentation_en-US" xlink:label="lab_insm_Range10Member_8036ECD09DBD16A9DCA9BECA42604214" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Selected disclosure of Stock options outstanding and exercisable by share price exercise range.</link:label>
    <link:loc xlink:href="insm-20180930.xsd#insm_Range10Member" xlink:label="loc_insm_Range10Member_8036ECD09DBD16A9DCA9BECA42604214" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_Range10Member_8036ECD09DBD16A9DCA9BECA42604214" xlink:to="lab_insm_Range10Member_8036ECD09DBD16A9DCA9BECA42604214" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_B1CB273A774F540F88ACBECA4261B6FA_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_B1CB273A774F540F88ACBECA4261B6FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_B1CB273A774F540F88ACBECA4261B6FA_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_B1CB273A774F540F88ACBECA4261B6FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_B1CB273A774F540F88ACBECA4261B6FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_B1CB273A774F540F88ACBECA4261B6FA" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_B1CB273A774F540F88ACBECA4261B6FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_51D1C23EBC30332F6C1DBECA42629059_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_51D1C23EBC30332F6C1DBECA42629059" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total intrinsic value of stock options exercised during the period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_51D1C23EBC30332F6C1DBECA42629059_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_51D1C23EBC30332F6C1DBECA42629059" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_51D1C23EBC30332F6C1DBECA42629059" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_51D1C23EBC30332F6C1DBECA42629059" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_51D1C23EBC30332F6C1DBECA42629059" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_6B7F75E4F1DF7E500C0EBECA42622E27_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_6B7F75E4F1DF7E500C0EBECA42622E27" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation expense related to unvested stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_6B7F75E4F1DF7E500C0EBECA42622E27_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_6B7F75E4F1DF7E500C0EBECA42622E27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_6B7F75E4F1DF7E500C0EBECA42622E27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_6B7F75E4F1DF7E500C0EBECA42622E27" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_6B7F75E4F1DF7E500C0EBECA42622E27" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_F25265C7E38B4F7553DABECA426233C3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_F25265C7E38B4F7553DABECA426233C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected weighted average period for recognized and unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_F25265C7E38B4F7553DABECA426233C3_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_F25265C7E38B4F7553DABECA426233C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_F25265C7E38B4F7553DABECA426233C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_F25265C7E38B4F7553DABECA426233C3" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_F25265C7E38B4F7553DABECA426233C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_76F3CF54915C282F1509BECA426275BB_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_76F3CF54915C282F1509BECA426275BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range of Exercise Prices lower range limit (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_76F3CF54915C282F1509BECA426275BB_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_76F3CF54915C282F1509BECA426275BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_76F3CF54915C282F1509BECA426275BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_76F3CF54915C282F1509BECA426275BB" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_76F3CF54915C282F1509BECA426275BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_F370AF5928D1E6E3705DBECA426352B6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_F370AF5928D1E6E3705DBECA426352B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range of Exercise Prices upper range limit (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_F370AF5928D1E6E3705DBECA426352B6_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_F370AF5928D1E6E3705DBECA426352B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_F370AF5928D1E6E3705DBECA426352B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_F370AF5928D1E6E3705DBECA426352B6" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_F370AF5928D1E6E3705DBECA426352B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_E95FC340454A64692967BECA42632D1B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_E95FC340454A64692967BECA42632D1B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Options Outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_E95FC340454A64692967BECA42632D1B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_E95FC340454A64692967BECA42632D1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_E95FC340454A64692967BECA42632D1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_E95FC340454A64692967BECA42632D1B" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_E95FC340454A64692967BECA42632D1B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_7299DC2D19C683B2983BBECA426300BE_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_7299DC2D19C683B2983BBECA426300BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_7299DC2D19C683B2983BBECA426300BE_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_7299DC2D19C683B2983BBECA426300BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_7299DC2D19C683B2983BBECA426300BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_7299DC2D19C683B2983BBECA426300BE" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_7299DC2D19C683B2983BBECA426300BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_6A5BABD24C37E89A6AC2BECA42632E49_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_6A5BABD24C37E89A6AC2BECA42632E49" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Options, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_6A5BABD24C37E89A6AC2BECA42632E49_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_6A5BABD24C37E89A6AC2BECA42632E49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_6A5BABD24C37E89A6AC2BECA42632E49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_6A5BABD24C37E89A6AC2BECA42632E49" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_6A5BABD24C37E89A6AC2BECA42632E49" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_1CA43CE2089090A214A0BECA4263B304_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_1CA43CE2089090A214A0BECA4263B304" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Options Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_1CA43CE2089090A214A0BECA4263B304_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_1CA43CE2089090A214A0BECA4263B304" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_1CA43CE2089090A214A0BECA4263B304" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_1CA43CE2089090A214A0BECA4263B304" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_1CA43CE2089090A214A0BECA4263B304" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_B0783FEA62036C27F1DBBECA4263754A_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_B0783FEA62036C27F1DBBECA4263754A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable Options, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_B0783FEA62036C27F1DBBECA4263754A_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_B0783FEA62036C27F1DBBECA4263754A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_B0783FEA62036C27F1DBBECA4263754A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_B0783FEA62036C27F1DBBECA4263754A" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_B0783FEA62036C27F1DBBECA4263754A" xlink:type="arc" />
    <link:label id="lab_insm_StockOptionsAndRestrictedStockUnitsMember_0B53FDB4C0669E1432D4F036DA410643_terseLabel_en-US" xlink:label="lab_insm_StockOptionsAndRestrictedStockUnitsMember_3E00AE39FBC25C1B93E05889F4B7741B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options and RSUs</link:label>
    <link:label id="lab_insm_StockOptionsAndRestrictedStockUnitsMember_0B53FDB4C0669E1432D4F036DA410643_label_en-US" xlink:label="lab_insm_StockOptionsAndRestrictedStockUnitsMember_3E00AE39FBC25C1B93E05889F4B7741B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Options And Restricted Stock Units [Member]</link:label>
    <link:label id="lab_insm_StockOptionsAndRestrictedStockUnitsMember_0B53FDB4C0669E1432D4F036DA410643_documentation_en-US" xlink:label="lab_insm_StockOptionsAndRestrictedStockUnitsMember_3E00AE39FBC25C1B93E05889F4B7741B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents contract that gives the holder the right, but not the obligation, either to purchase or to sell a certain number of shares of stock at a predetermined price for a specified period of time. It also includes stock units that an entity has not yet issued because the agreed-upon consideration, such as employee services, has not yet been received.</link:label>
    <link:loc xlink:href="insm-20180930.xsd#insm_StockOptionsAndRestrictedStockUnitsMember" xlink:label="loc_insm_StockOptionsAndRestrictedStockUnitsMember_3E00AE39FBC25C1B93E05889F4B7741B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_StockOptionsAndRestrictedStockUnitsMember_3E00AE39FBC25C1B93E05889F4B7741B" xlink:to="lab_insm_StockOptionsAndRestrictedStockUnitsMember_3E00AE39FBC25C1B93E05889F4B7741B" xlink:type="arc" />
    <link:label id="lab_insm_RestrictedStockAndRestrictedStockUnitsMember_39BDEE35339087F430C4F036DA4225F2_terseLabel_en-US" xlink:label="lab_insm_RestrictedStockAndRestrictedStockUnitsMember_0BB42C7829B75BBE852E2987177CAFA6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RS and RSUs</link:label>
    <link:label id="lab_insm_RestrictedStockAndRestrictedStockUnitsMember_39BDEE35339087F430C4F036DA4225F2_label_en-US" xlink:label="lab_insm_RestrictedStockAndRestrictedStockUnitsMember_0BB42C7829B75BBE852E2987177CAFA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock And Restricted Stock Units [Member]</link:label>
    <link:label id="lab_insm_RestrictedStockAndRestrictedStockUnitsMember_39BDEE35339087F430C4F036DA4225F2_documentation_en-US" xlink:label="lab_insm_RestrictedStockAndRestrictedStockUnitsMember_0BB42C7829B75BBE852E2987177CAFA6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares and stock units that an entity has not yet issued because the agreed-upon consideration, such as employee services, has not yet been received.</link:label>
    <link:loc xlink:href="insm-20180930.xsd#insm_RestrictedStockAndRestrictedStockUnitsMember" xlink:label="loc_insm_RestrictedStockAndRestrictedStockUnitsMember_0BB42C7829B75BBE852E2987177CAFA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_RestrictedStockAndRestrictedStockUnitsMember_0BB42C7829B75BBE852E2987177CAFA6" xlink:to="lab_insm_RestrictedStockAndRestrictedStockUnitsMember_0BB42C7829B75BBE852E2987177CAFA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_8545AE445C1D26462086F036DA426A1B_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_3CA2F91CC21C548DBCB046A4D429D6EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_8545AE445C1D26462086F036DA426A1B_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_3CA2F91CC21C548DBCB046A4D429D6EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3CA2F91CC21C548DBCB046A4D429D6EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3CA2F91CC21C548DBCB046A4D429D6EA" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_3CA2F91CC21C548DBCB046A4D429D6EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_C8561A0BAA5457385B04F036DA4294E3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_0EC5BC8E893A5DCB9F8A9F5235A61B5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_C8561A0BAA5457385B04F036DA4294E3_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_0EC5BC8E893A5DCB9F8A9F5235A61B5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0EC5BC8E893A5DCB9F8A9F5235A61B5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0EC5BC8E893A5DCB9F8A9F5235A61B5B" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_0EC5BC8E893A5DCB9F8A9F5235A61B5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_15FB530CC38A606BD76FF036DA436682_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_FBEC69E38E5B5F4CBA089381C20D5609" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_15FB530CC38A606BD76FF036DA436682_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_FBEC69E38E5B5F4CBA089381C20D5609" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_FBEC69E38E5B5F4CBA089381C20D5609" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_FBEC69E38E5B5F4CBA089381C20D5609" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_FBEC69E38E5B5F4CBA089381C20D5609" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_2B52614848A87EB69587F036DA451270_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_3FAD068B36D050E9B66763CFBD26D308" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_2B52614848A87EB69587F036DA451270_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_3FAD068B36D050E9B66763CFBD26D308" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3FAD068B36D050E9B66763CFBD26D308" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3FAD068B36D050E9B66763CFBD26D308" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember_3FAD068B36D050E9B66763CFBD26D308" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A233F6AC8C7C18CA347AF036DA457C12_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F624CCFEE12450E68B4AA8C3667972E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F624CCFEE12450E68B4AA8C3667972E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F624CCFEE12450E68B4AA8C3667972E5" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F624CCFEE12450E68B4AA8C3667972E5" xlink:type="arc" />
    <link:label id="lab_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit_386004D1A8881D094409F036DA454009_terseLabel_en-US" xlink:label="lab_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit_F6C06F28629F507EA1D41BCF063B0781" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of common shares each award holder is entitled to receive</link:label>
    <link:label id="lab_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit_386004D1A8881D094409F036DA454009_label_en-US" xlink:label="lab_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit_F6C06F28629F507EA1D41BCF063B0781" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Common Shares To Be Received In Lieu Of Per Restricted Stock And Restricted Stock Unit</link:label>
    <link:label id="lab_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit_386004D1A8881D094409F036DA454009_documentation_en-US" xlink:label="lab_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit_F6C06F28629F507EA1D41BCF063B0781" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares of common stock each restricted stock award entitles the holder to receive upon completion of a specific period of service or achievement of a specified milestone.</link:label>
    <link:loc xlink:href="insm-20180930.xsd#insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit" xlink:label="loc_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit_F6C06F28629F507EA1D41BCF063B0781" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit_F6C06F28629F507EA1D41BCF063B0781" xlink:to="lab_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit_F6C06F28629F507EA1D41BCF063B0781" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_B43678B6DE330295189FF037438234CA_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_818A2860BCD65FF5AC97AB8C0DBC288B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_B43678B6DE330295189FF037438234CA_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_818A2860BCD65FF5AC97AB8C0DBC288B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_818A2860BCD65FF5AC97AB8C0DBC288B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_818A2860BCD65FF5AC97AB8C0DBC288B" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_818A2860BCD65FF5AC97AB8C0DBC288B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_CE1D76D5BB703C193A1EF036DA4619B8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_28B5B7B882475F6FA026003484D863F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of RSUs</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_CE1D76D5BB703C193A1EF036DA4619B8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_28B5B7B882475F6FA026003484D863F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_28B5B7B882475F6FA026003484D863F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_28B5B7B882475F6FA026003484D863F1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_28B5B7B882475F6FA026003484D863F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_D8608D368CDD3145A8C2F036DA464CE3_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5925520DB8665856AA3B0CE2A2683FCA" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_D8608D368CDD3145A8C2F036DA464CE3_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5925520DB8665856AA3B0CE2A2683FCA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5925520DB8665856AA3B0CE2A2683FCA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5925520DB8665856AA3B0CE2A2683FCA" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5925520DB8665856AA3B0CE2A2683FCA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_C4FFEE9E573D5CB6EBC8F036DA46F07B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_BEE32E957BE55575BA42C69F08253CD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_C4FFEE9E573D5CB6EBC8F036DA46F07B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_BEE32E957BE55575BA42C69F08253CD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_BEE32E957BE55575BA42C69F08253CD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_BEE32E957BE55575BA42C69F08253CD5" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_BEE32E957BE55575BA42C69F08253CD5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_E4FD0356B21A002E70C9F036DA465050_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1CF7B92C34C551328A58B3E8440A6335" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Released (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_E4FD0356B21A002E70C9F036DA465050_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1CF7B92C34C551328A58B3E8440A6335" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1CF7B92C34C551328A58B3E8440A6335" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1CF7B92C34C551328A58B3E8440A6335" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1CF7B92C34C551328A58B3E8440A6335" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_E98B0A4A5C93D30EB530F036DA47D53B_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_304FFF5D515D599C9BA715D10F0694C7" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_E98B0A4A5C93D30EB530F036DA47D53B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_304FFF5D515D599C9BA715D10F0694C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_304FFF5D515D599C9BA715D10F0694C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_304FFF5D515D599C9BA715D10F0694C7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_304FFF5D515D599C9BA715D10F0694C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3F97C2616A7C96653CE6F036DA478D17_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_059ABCC935F2544CBD7BEF99C9280575" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_059ABCC935F2544CBD7BEF99C9280575" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_059ABCC935F2544CBD7BEF99C9280575" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_059ABCC935F2544CBD7BEF99C9280575" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7C60C183A757CB99FF08F036DA472783_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_B10BDCA2852E50C097E483064DFFC33A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Grant Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7C60C183A757CB99FF08F036DA472783_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_B10BDCA2852E50C097E483064DFFC33A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_B10BDCA2852E50C097E483064DFFC33A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_B10BDCA2852E50C097E483064DFFC33A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_B10BDCA2852E50C097E483064DFFC33A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_CBADF35E1FF64BB08B77F036DA470EA2_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_A3B1AC6F6E855E3A8FFB3BCC34F06960" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding Weighted Average Grant Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_CBADF35E1FF64BB08B77F036DA470EA2_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_A3B1AC6F6E855E3A8FFB3BCC34F06960" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_A3B1AC6F6E855E3A8FFB3BCC34F06960" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_A3B1AC6F6E855E3A8FFB3BCC34F06960" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_A3B1AC6F6E855E3A8FFB3BCC34F06960" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7018D5FEC212FB68721BF036DA489C29_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E5DC1AF19D3F5B8F9865C4FD0A7605CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7018D5FEC212FB68721BF036DA489C29_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E5DC1AF19D3F5B8F9865C4FD0A7605CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E5DC1AF19D3F5B8F9865C4FD0A7605CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E5DC1AF19D3F5B8F9865C4FD0A7605CC" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E5DC1AF19D3F5B8F9865C4FD0A7605CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_AFBD8C38F8F3F4062E68F036DA488B7C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_B46C3D8931F254EE9380B12EBDBDF412" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Released (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_AFBD8C38F8F3F4062E68F036DA488B7C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_B46C3D8931F254EE9380B12EBDBDF412" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_B46C3D8931F254EE9380B12EBDBDF412" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_B46C3D8931F254EE9380B12EBDBDF412" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_B46C3D8931F254EE9380B12EBDBDF412" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_DF58CD98A8D0906994A6F036DA488EC1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_63155C3BDF795BBF939411DEBC92642D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_DF58CD98A8D0906994A6F036DA488EC1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_63155C3BDF795BBF939411DEBC92642D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_63155C3BDF795BBF939411DEBC92642D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_63155C3BDF795BBF939411DEBC92642D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_63155C3BDF795BBF939411DEBC92642D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_BB239C6BB4262D9B89A4F036DA48E699_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_CF5EC623A2025D0FAFBFCC1F26A7989B" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding Weighted Average Grant Price (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_CF5EC623A2025D0FAFBFCC1F26A7989B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_CF5EC623A2025D0FAFBFCC1F26A7989B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_CF5EC623A2025D0FAFBFCC1F26A7989B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_4FF59F7596960A24C2DAF036DA4867A1_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_EEC4C8462A7256788F1604A901592E09" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allocated share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_4FF59F7596960A24C2DAF036DA4867A1_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_EEC4C8462A7256788F1604A901592E09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_EEC4C8462A7256788F1604A901592E09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_EEC4C8462A7256788F1604A901592E09" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_EEC4C8462A7256788F1604A901592E09" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpenseDebt_8F5F8D85B695C1A86F18A868CA4EC536_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt_622F1876C1FF5F9B84FEF2C191D575D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_8F5F8D85B695C1A86F18A868CA4EC536_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt_622F1876C1FF5F9B84FEF2C191D575D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_622F1876C1FF5F9B84FEF2C191D575D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt_622F1876C1FF5F9B84FEF2C191D575D8" xlink:to="lab_us-gaap_InterestExpenseDebt_622F1876C1FF5F9B84FEF2C191D575D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_81B0FE2482DD3E903A5CA868CA4EA93E_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts_7FD9B191CCBE57849B356A8DCBD78042" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_81B0FE2482DD3E903A5CA868CA4EA93E_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts_7FD9B191CCBE57849B356A8DCBD78042" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_7FD9B191CCBE57849B356A8DCBD78042" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts_7FD9B191CCBE57849B356A8DCBD78042" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts_7FD9B191CCBE57849B356A8DCBD78042" xlink:type="arc" />
    <link:label id="lab_insm_AmortizationOfBackendFee_1115B4BFCA459DE09AFCA868CA4E6654_terseLabel_en-US" xlink:label="lab_insm_AmortizationOfBackendFee_D571620410695010A84FE9EB77ECFEA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accretion of back-end fee on debt</link:label>
    <link:label id="lab_insm_AmortizationOfBackendFee_1115B4BFCA459DE09AFCA868CA4E6654_label_en-US" xlink:label="lab_insm_AmortizationOfBackendFee_D571620410695010A84FE9EB77ECFEA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization Of Backend Fee</link:label>
    <link:label id="lab_insm_AmortizationOfBackendFee_1115B4BFCA459DE09AFCA868CA4E6654_documentation_en-US" xlink:label="lab_insm_AmortizationOfBackendFee_D571620410695010A84FE9EB77ECFEA3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amortization Of Backend Fee</link:label>
    <link:loc xlink:href="insm-20180930.xsd#insm_AmortizationOfBackendFee" xlink:label="loc_insm_AmortizationOfBackendFee_D571620410695010A84FE9EB77ECFEA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_AmortizationOfBackendFee_D571620410695010A84FE9EB77ECFEA3" xlink:to="lab_insm_AmortizationOfBackendFee_D571620410695010A84FE9EB77ECFEA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_3ACD5A0069444FA3FD54A868CA4E7B50_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium_A601B816D609591BBE434F3D03B2BBEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accretion of debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_3ACD5A0069444FA3FD54A868CA4E7B50_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium_A601B816D609591BBE434F3D03B2BBEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_A601B816D609591BBE434F3D03B2BBEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium_A601B816D609591BBE434F3D03B2BBEC" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium_A601B816D609591BBE434F3D03B2BBEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_B61A4926565839BB9996A868CA4E1AEB_totalLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_E7626E51FD60577799B60A254B11EB8C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total interest expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_E7626E51FD60577799B60A254B11EB8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_E7626E51FD60577799B60A254B11EB8C" xlink:to="lab_us-gaap_InterestExpense_E7626E51FD60577799B60A254B11EB8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_774FE4C3C9BB63559ACB8222F472F8CA_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_774FE4C3C9BB63559ACB8222F472F8CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_774FE4C3C9BB63559ACB8222F472F8CA_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_774FE4C3C9BB63559ACB8222F472F8CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_774FE4C3C9BB63559ACB8222F472F8CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_774FE4C3C9BB63559ACB8222F472F8CA" xlink:to="lab_us-gaap_AssetsAbstract_774FE4C3C9BB63559ACB8222F472F8CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_0B9D9C157F2E17911A388222F4722769_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_0B9D9C157F2E17911A388222F4722769" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_0B9D9C157F2E17911A388222F4722769_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_0B9D9C157F2E17911A388222F4722769" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_0B9D9C157F2E17911A388222F4722769" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0B9D9C157F2E17911A388222F4722769" xlink:to="lab_us-gaap_AssetsCurrentAbstract_0B9D9C157F2E17911A388222F4722769" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_DC8A837085E46903F8D78222F47351CB_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_DC8A837085E46903F8D78222F47351CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_DC8A837085E46903F8D78222F47351CB_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_DC8A837085E46903F8D78222F47351CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_DC8A837085E46903F8D78222F47351CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_DC8A837085E46903F8D78222F47351CB" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_DC8A837085E46903F8D78222F47351CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_38AB23C456FF7B35E9E78222F4744E11_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_38AB23C456FF7B35E9E78222F4744E11" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_38AB23C456FF7B35E9E78222F4744E11_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_38AB23C456FF7B35E9E78222F4744E11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_38AB23C456FF7B35E9E78222F4744E11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_38AB23C456FF7B35E9E78222F4744E11" xlink:to="lab_us-gaap_AssetsCurrent_38AB23C456FF7B35E9E78222F4744E11" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_357A08C4692B8740BF5E8242BC68FD2B_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_357A08C4692B8740BF5E8242BC68FD2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_357A08C4692B8740BF5E8242BC68FD2B_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_357A08C4692B8740BF5E8242BC68FD2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_357A08C4692B8740BF5E8242BC68FD2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_357A08C4692B8740BF5E8242BC68FD2B" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_357A08C4692B8740BF5E8242BC68FD2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_C3DF206D128871A8C30B8222F4747B31_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_C3DF206D128871A8C30B8222F4747B31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed assets, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_C3DF206D128871A8C30B8222F4747B31_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_C3DF206D128871A8C30B8222F4747B31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_C3DF206D128871A8C30B8222F4747B31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_C3DF206D128871A8C30B8222F4747B31" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_C3DF206D128871A8C30B8222F4747B31" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssets_82143DBFF2BE8B516BB98222F4746A7F_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssets_82143DBFF2BE8B516BB98222F4746A7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssets_82143DBFF2BE8B516BB98222F4746A7F_label_en-US" xlink:label="lab_us-gaap_OtherAssets_82143DBFF2BE8B516BB98222F4746A7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaap_OtherAssets_82143DBFF2BE8B516BB98222F4746A7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssets_82143DBFF2BE8B516BB98222F4746A7F" xlink:to="lab_us-gaap_OtherAssets_82143DBFF2BE8B516BB98222F4746A7F" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_7361FA2012744FCC99568222F47537B9_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_7361FA2012744FCC99568222F47537B9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_7361FA2012744FCC99568222F47537B9_label_en-US" xlink:label="lab_us-gaap_Assets_7361FA2012744FCC99568222F47537B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_7361FA2012744FCC99568222F47537B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_7361FA2012744FCC99568222F47537B9" xlink:to="lab_us-gaap_Assets_7361FA2012744FCC99568222F47537B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_35B542B7C268337470678222F47506FA_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_35B542B7C268337470678222F47506FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_35B542B7C268337470678222F47506FA_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_35B542B7C268337470678222F47506FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_35B542B7C268337470678222F47506FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_35B542B7C268337470678222F47506FA" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_35B542B7C268337470678222F47506FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_A58382C7B70905FC07468222F4750A1A_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_A58382C7B70905FC07468222F4750A1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_A58382C7B70905FC07468222F4750A1A_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_A58382C7B70905FC07468222F4750A1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_A58382C7B70905FC07468222F4750A1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_A58382C7B70905FC07468222F4750A1A" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_A58382C7B70905FC07468222F4750A1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_58496A0BC2F0AA5E48468222F475225C_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_58496A0BC2F0AA5E48468222F475225C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_58496A0BC2F0AA5E48468222F475225C_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_58496A0BC2F0AA5E48468222F475225C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_58496A0BC2F0AA5E48468222F475225C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_58496A0BC2F0AA5E48468222F475225C" xlink:to="lab_us-gaap_AccountsPayableCurrent_58496A0BC2F0AA5E48468222F475225C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_2D3A122DA0CB83038C458222F4769504_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_2D3A122DA0CB83038C458222F4769504" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_2D3A122DA0CB83038C458222F4769504" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2D3A122DA0CB83038C458222F4769504" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_2D3A122DA0CB83038C458222F4769504" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_EDA224AD31ABDDD761C38222F47620C6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_EDA224AD31ABDDD761C38222F47620C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_EDA224AD31ABDDD761C38222F47620C6_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_EDA224AD31ABDDD761C38222F47620C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_EDA224AD31ABDDD761C38222F47620C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_EDA224AD31ABDDD761C38222F47620C6" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_EDA224AD31ABDDD761C38222F47620C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_1505C868CADCD0BE02FC8222F476C1E2_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_1505C868CADCD0BE02FC8222F476C1E2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_1505C868CADCD0BE02FC8222F476C1E2_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_1505C868CADCD0BE02FC8222F476C1E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_1505C868CADCD0BE02FC8222F476C1E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_1505C868CADCD0BE02FC8222F476C1E2" xlink:to="lab_us-gaap_LiabilitiesCurrent_1505C868CADCD0BE02FC8222F476C1E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_72FEC3030312F3EF95748222F4762F0D_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_72FEC3030312F3EF95748222F4762F0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_72FEC3030312F3EF95748222F4762F0D_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_72FEC3030312F3EF95748222F4762F0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_72FEC3030312F3EF95748222F4762F0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_72FEC3030312F3EF95748222F4762F0D" xlink:to="lab_us-gaap_LongTermDebtNoncurrent_72FEC3030312F3EF95748222F4762F0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_E012004AAD722FF616348222F4778BB3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_E012004AAD722FF616348222F4778BB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_E012004AAD722FF616348222F4778BB3_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_E012004AAD722FF616348222F4778BB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_E012004AAD722FF616348222F4778BB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_E012004AAD722FF616348222F4778BB3" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_E012004AAD722FF616348222F4778BB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_12AC7C0DB6F1F97841ED8222F47705F1_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_12AC7C0DB6F1F97841ED8222F47705F1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_12AC7C0DB6F1F97841ED8222F47705F1_label_en-US" xlink:label="lab_us-gaap_Liabilities_12AC7C0DB6F1F97841ED8222F47705F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_12AC7C0DB6F1F97841ED8222F47705F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_12AC7C0DB6F1F97841ED8222F47705F1" xlink:to="lab_us-gaap_Liabilities_12AC7C0DB6F1F97841ED8222F47705F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_EA9C21FC2CDCEF53B81D8222F477279F_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_EA9C21FC2CDCEF53B81D8222F477279F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shareholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_EA9C21FC2CDCEF53B81D8222F477279F_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_EA9C21FC2CDCEF53B81D8222F477279F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_EA9C21FC2CDCEF53B81D8222F477279F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_EA9C21FC2CDCEF53B81D8222F477279F" xlink:to="lab_us-gaap_StockholdersEquityAbstract_EA9C21FC2CDCEF53B81D8222F477279F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_27B541E48837619581B28222F477DC4B_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_27B541E48837619581B28222F477DC4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.01 par value; 500,000,000 authorized shares, 77,085,715 and 76,610,508 issued and outstanding shares at September 30, 2018 and December 31, 2017, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_27B541E48837619581B28222F477DC4B_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_27B541E48837619581B28222F477DC4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_27B541E48837619581B28222F477DC4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_27B541E48837619581B28222F477DC4B" xlink:to="lab_us-gaap_CommonStockValue_27B541E48837619581B28222F477DC4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_61B9B0A72D8E5652DECD8222F47802ED_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_61B9B0A72D8E5652DECD8222F47802ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_61B9B0A72D8E5652DECD8222F47802ED_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_61B9B0A72D8E5652DECD8222F47802ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_61B9B0A72D8E5652DECD8222F47802ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_61B9B0A72D8E5652DECD8222F47802ED" xlink:to="lab_us-gaap_AdditionalPaidInCapital_61B9B0A72D8E5652DECD8222F47802ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_E7D8EF09925B88B48EBF8222F4787590_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_E7D8EF09925B88B48EBF8222F4787590" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_E7D8EF09925B88B48EBF8222F4787590_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_E7D8EF09925B88B48EBF8222F4787590" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_E7D8EF09925B88B48EBF8222F4787590" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_E7D8EF09925B88B48EBF8222F4787590" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_E7D8EF09925B88B48EBF8222F4787590" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0B5B1C53C7278A08D9638222F478635A_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0B5B1C53C7278A08D9638222F478635A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0B5B1C53C7278A08D9638222F478635A_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0B5B1C53C7278A08D9638222F478635A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0B5B1C53C7278A08D9638222F478635A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0B5B1C53C7278A08D9638222F478635A" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0B5B1C53C7278A08D9638222F478635A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_09BB709C9D5294CED3B28222F479E889_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_09BB709C9D5294CED3B28222F479E889" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_09BB709C9D5294CED3B28222F479E889" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_09BB709C9D5294CED3B28222F479E889" xlink:to="lab_us-gaap_StockholdersEquity_09BB709C9D5294CED3B28222F479E889" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_744D3F0D509E2D65948C8222F479A996_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_744D3F0D509E2D65948C8222F479A996" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_744D3F0D509E2D65948C8222F479A996_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_744D3F0D509E2D65948C8222F479A996" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_744D3F0D509E2D65948C8222F479A996" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_744D3F0D509E2D65948C8222F479A996" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_744D3F0D509E2D65948C8222F479A996" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_7FCD15F9DBA608E3BE5CA89C9D4B5D2C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_E3E527F29A375F0A894FA8764B954399" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Changes in Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_7FCD15F9DBA608E3BE5CA89C9D4B5D2C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_E3E527F29A375F0A894FA8764B954399" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stockholders Equity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_E3E527F29A375F0A894FA8764B954399" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_E3E527F29A375F0A894FA8764B954399" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_E3E527F29A375F0A894FA8764B954399" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_6CEE38D9BCD923D8D60AF60EC1CB310E_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_11D8B2D5D5C553E4B4FF8461DF31DB24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_6CEE38D9BCD923D8D60AF60EC1CB310E_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_11D8B2D5D5C553E4B4FF8461DF31DB24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_11D8B2D5D5C553E4B4FF8461DF31DB24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_11D8B2D5D5C553E4B4FF8461DF31DB24" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis_11D8B2D5D5C553E4B4FF8461DF31DB24" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_F61781B16DF20510E31AF60EC1CB643E_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_905BD46757D95D70995127A46D301723" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_F61781B16DF20510E31AF60EC1CB643E_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_905BD46757D95D70995127A46D301723" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_905BD46757D95D70995127A46D301723" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_905BD46757D95D70995127A46D301723" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain_905BD46757D95D70995127A46D301723" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_1A97499FA78B4A8D7914F60EC1CB683D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_BE8CEC52ACA458EA8C5E4AFC0418102F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_1A97499FA78B4A8D7914F60EC1CB683D_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_BE8CEC52ACA458EA8C5E4AFC0418102F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_BE8CEC52ACA458EA8C5E4AFC0418102F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_BE8CEC52ACA458EA8C5E4AFC0418102F" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_BE8CEC52ACA458EA8C5E4AFC0418102F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_BBCF88076854C0B4C10AF60EC1CC42CB_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis_F4FE0D2E81865581A65DD42B04184587" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_BBCF88076854C0B4C10AF60EC1CC42CB_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis_F4FE0D2E81865581A65DD42B04184587" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_F4FE0D2E81865581A65DD42B04184587" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_F4FE0D2E81865581A65DD42B04184587" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis_F4FE0D2E81865581A65DD42B04184587" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_5586C652424656992769F60EC1CC46D4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain_8DAE196EB90D5A0A8C66DA68D3E003E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_5586C652424656992769F60EC1CC46D4_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain_8DAE196EB90D5A0A8C66DA68D3E003E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_8DAE196EB90D5A0A8C66DA68D3E003E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_8DAE196EB90D5A0A8C66DA68D3E003E5" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain_8DAE196EB90D5A0A8C66DA68D3E003E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_65BA2015A614148C34E0F60EC1CC8A9F_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_914E4FD920865BF18301F820F300F739" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_65BA2015A614148C34E0F60EC1CC8A9F_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_914E4FD920865BF18301F820F300F739" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_914E4FD920865BF18301F820F300F739" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_914E4FD920865BF18301F820F300F739" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_914E4FD920865BF18301F820F300F739" xlink:type="arc" />
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_6972D21B9F3EF7D2F8ABF60EC1CC487D_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_FCB4C7F841D25A589A8ED0F62803EC10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying Value</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_6972D21B9F3EF7D2F8ABF60EC1CC487D_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_FCB4C7F841D25A589A8ED0F62803EC10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_FCB4C7F841D25A589A8ED0F62803EC10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_FCB4C7F841D25A589A8ED0F62803EC10" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_FCB4C7F841D25A589A8ED0F62803EC10" xlink:type="arc" />
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_3E4D48FF62EFD3F353B4F60EC1CD1FA2_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_A879D4D1138B5BE4891AB6EC7B0CBCBF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_3E4D48FF62EFD3F353B4F60EC1CD1FA2_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_A879D4D1138B5BE4891AB6EC7B0CBCBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_A879D4D1138B5BE4891AB6EC7B0CBCBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_A879D4D1138B5BE4891AB6EC7B0CBCBF" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_A879D4D1138B5BE4891AB6EC7B0CBCBF" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_EBA98027C442542C8B13F60EC1CDEE2E_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_A9DD938327505B66B89A3320A26CBF9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_EBA98027C442542C8B13F60EC1CDEE2E_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_A9DD938327505B66B89A3320A26CBF9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_A9DD938327505B66B89A3320A26CBF9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_A9DD938327505B66B89A3320A26CBF9F" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_A9DD938327505B66B89A3320A26CBF9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_60644C29D61A923F51ACF60EC1CD42F4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_A437932408EA5D6BB6BF33D0417087E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_60644C29D61A923F51ACF60EC1CD42F4_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_A437932408EA5D6BB6BF33D0417087E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_A437932408EA5D6BB6BF33D0417087E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_A437932408EA5D6BB6BF33D0417087E6" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_A437932408EA5D6BB6BF33D0417087E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_D051EB6C892D0C332146F60EC1CD622E_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_29028575CB1A5927BF6E79C31C88DA40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_D051EB6C892D0C332146F60EC1CD622E_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_29028575CB1A5927BF6E79C31C88DA40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_29028575CB1A5927BF6E79C31C88DA40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_29028575CB1A5927BF6E79C31C88DA40" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_29028575CB1A5927BF6E79C31C88DA40" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_CCB845857D7B8BC733D3F60EC1CEB0DF_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_AEF37D85237B5B54A0A98B225A28106D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_CCB845857D7B8BC733D3F60EC1CEB0DF_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_AEF37D85237B5B54A0A98B225A28106D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_AEF37D85237B5B54A0A98B225A28106D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_AEF37D85237B5B54A0A98B225A28106D" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_AEF37D85237B5B54A0A98B225A28106D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_319E9A95592C516B9D6AF60EC1CF653E_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_D9FC9A95830253B2B2516EC338427AF2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Face amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_D9FC9A95830253B2B2516EC338427AF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_D9FC9A95830253B2B2516EC338427AF2" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_D9FC9A95830253B2B2516EC338427AF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_5A70354E7CF90D298272F60EC1D03E61_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount_3A3B7AAF61A45907A07737C338FECBA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unamortized portion of debt discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_5A70354E7CF90D298272F60EC1D03E61_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount_3A3B7AAF61A45907A07737C338FECBA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_3A3B7AAF61A45907A07737C338FECBA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount_3A3B7AAF61A45907A07737C338FECBA5" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount_3A3B7AAF61A45907A07737C338FECBA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_22B28EF0782AC5CD8EE36FD829A517EB_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_22B28EF0782AC5CD8EE36FD829A517EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_22B28EF0782AC5CD8EE36FD829A517EB_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_22B28EF0782AC5CD8EE36FD829A517EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_22B28EF0782AC5CD8EE36FD829A517EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_22B28EF0782AC5CD8EE36FD829A517EB" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_22B28EF0782AC5CD8EE36FD829A517EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2505C4591FC3C3B3B69E6FD829A6816B_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2505C4591FC3C3B3B69E6FD829A6816B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2505C4591FC3C3B3B69E6FD829A6816B_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2505C4591FC3C3B3B69E6FD829A6816B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2505C4591FC3C3B3B69E6FD829A6816B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2505C4591FC3C3B3B69E6FD829A6816B" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2505C4591FC3C3B3B69E6FD829A6816B" xlink:type="arc" />
    <link:label id="lab_us-gaap_Depreciation_0711B03F9FAEA7EE1B436FD829A6DC32_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation_0711B03F9FAEA7EE1B436FD829A6DC32" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_0711B03F9FAEA7EE1B436FD829A6DC32_label_en-US" xlink:label="lab_us-gaap_Depreciation_0711B03F9FAEA7EE1B436FD829A6DC32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_0711B03F9FAEA7EE1B436FD829A6DC32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_0711B03F9FAEA7EE1B436FD829A6DC32" xlink:to="lab_us-gaap_Depreciation_0711B03F9FAEA7EE1B436FD829A6DC32" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_8A3A05B65E618F0ACDD96FD829A7A514_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_8A3A05B65E618F0ACDD96FD829A7A514" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_8A3A05B65E618F0ACDD96FD829A7A514_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_8A3A05B65E618F0ACDD96FD829A7A514" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_8A3A05B65E618F0ACDD96FD829A7A514" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_8A3A05B65E618F0ACDD96FD829A7A514" xlink:to="lab_us-gaap_ShareBasedCompensation_8A3A05B65E618F0ACDD96FD829A7A514" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccretionExpense_682F0185520C1E5D95D06FD829A72D15_terseLabel_en-US" xlink:label="lab_us-gaap_AccretionExpense_682F0185520C1E5D95D06FD829A72D15" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accretion of back-end fee on debt</link:label>
    <link:label id="lab_us-gaap_AccretionExpense_682F0185520C1E5D95D06FD829A72D15_label_en-US" xlink:label="lab_us-gaap_AccretionExpense_682F0185520C1E5D95D06FD829A72D15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accretion Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccretionExpense" xlink:label="loc_us-gaap_AccretionExpense_682F0185520C1E5D95D06FD829A72D15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionExpense_682F0185520C1E5D95D06FD829A72D15" xlink:to="lab_us-gaap_AccretionExpense_682F0185520C1E5D95D06FD829A72D15" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_F0DEB99BCD6FAB62EB536FD829A800C8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_F0DEB99BCD6FAB62EB536FD829A800C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_F0DEB99BCD6FAB62EB536FD829A800C8_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_F0DEB99BCD6FAB62EB536FD829A800C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_F0DEB99BCD6FAB62EB536FD829A800C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_F0DEB99BCD6FAB62EB536FD829A800C8" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_F0DEB99BCD6FAB62EB536FD829A800C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_65365F68595EB727229D6FD829A892BB_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_65365F68595EB727229D6FD829A892BB" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_65365F68595EB727229D6FD829A892BB_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_65365F68595EB727229D6FD829A892BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_65365F68595EB727229D6FD829A892BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_65365F68595EB727229D6FD829A892BB" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_65365F68595EB727229D6FD829A892BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_48C915A1C8777D5A6A506FD829A9C1DD_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_48C915A1C8777D5A6A506FD829A9C1DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_48C915A1C8777D5A6A506FD829A9C1DD_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_48C915A1C8777D5A6A506FD829A9C1DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_48C915A1C8777D5A6A506FD829A9C1DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_48C915A1C8777D5A6A506FD829A9C1DD" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_48C915A1C8777D5A6A506FD829A9C1DD" xlink:type="arc" />
    <link:label id="lab_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities_904290ED9640021EB8906FD829A90869_terseLabel_en-US" xlink:label="lab_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities_904290ED9640021EB8906FD829A90869" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities_904290ED9640021EB8906FD829A90869_label_en-US" xlink:label="lab_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities_904290ED9640021EB8906FD829A90869" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Current Liabilities</link:label>
    <link:label id="lab_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities_904290ED9640021EB8906FD829A90869_documentation_en-US" xlink:label="lab_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities_904290ED9640021EB8906FD829A90869" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The increase (decrease) during the reporting period in the sum of accrued expenses and Other Current Liabilities.</link:label>
    <link:loc xlink:href="insm-20180930.xsd#insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities" xlink:label="loc_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities_904290ED9640021EB8906FD829A90869" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities_904290ED9640021EB8906FD829A90869" xlink:to="lab_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities_904290ED9640021EB8906FD829A90869" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_644350EFC6EDCA433DD06FD829A9F60F_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_644350EFC6EDCA433DD06FD829A9F60F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_644350EFC6EDCA433DD06FD829A9F60F_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_644350EFC6EDCA433DD06FD829A9F60F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_644350EFC6EDCA433DD06FD829A9F60F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_644350EFC6EDCA433DD06FD829A9F60F" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_644350EFC6EDCA433DD06FD829A9F60F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_289A895691C02FAB2B076FD829A9E6F2_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_289A895691C02FAB2B076FD829A9E6F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_289A895691C02FAB2B076FD829A9E6F2_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_289A895691C02FAB2B076FD829A9E6F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_289A895691C02FAB2B076FD829A9E6F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_289A895691C02FAB2B076FD829A9E6F2" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_289A895691C02FAB2B076FD829A9E6F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_F080A3AC17EB9BB9621C6FD829AAE036_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_F080A3AC17EB9BB9621C6FD829AAE036" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of fixed assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_F080A3AC17EB9BB9621C6FD829AAE036_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_F080A3AC17EB9BB9621C6FD829AAE036" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_F080A3AC17EB9BB9621C6FD829AAE036" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_F080A3AC17EB9BB9621C6FD829AAE036" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_F080A3AC17EB9BB9621C6FD829AAE036" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_54E239159FB7C989493D6FD829AA3D01_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_54E239159FB7C989493D6FD829AA3D01" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_54E239159FB7C989493D6FD829AA3D01_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_54E239159FB7C989493D6FD829AA3D01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_54E239159FB7C989493D6FD829AA3D01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_54E239159FB7C989493D6FD829AA3D01" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_54E239159FB7C989493D6FD829AA3D01" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5267A1CD5BFD697B24706FD829AA6FEC_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5267A1CD5BFD697B24706FD829AA6FEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5267A1CD5BFD697B24706FD829AA6FEC_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5267A1CD5BFD697B24706FD829AA6FEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5267A1CD5BFD697B24706FD829AA6FEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5267A1CD5BFD697B24706FD829AA6FEC" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5267A1CD5BFD697B24706FD829AA6FEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_18A9E5E0DEEC16A552626FD829AB1E17_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_18A9E5E0DEEC16A552626FD829AB1E17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_18A9E5E0DEEC16A552626FD829AB1E17_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_18A9E5E0DEEC16A552626FD829AB1E17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_18A9E5E0DEEC16A552626FD829AB1E17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_18A9E5E0DEEC16A552626FD829AB1E17" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_18A9E5E0DEEC16A552626FD829AB1E17" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_E98A8645E363125A18C66FD829AB7783_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_E98A8645E363125A18C66FD829AB7783" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_E98A8645E363125A18C66FD829AB7783_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_E98A8645E363125A18C66FD829AB7783" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment for Debt Extinguishment or Debt Prepayment Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_E98A8645E363125A18C66FD829AB7783" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_E98A8645E363125A18C66FD829AB7783" xlink:to="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_E98A8645E363125A18C66FD829AB7783" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfDebt_1948A3801C48042CC5286FD829AB00BC_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt_1948A3801C48042CC5286FD829AB00BC" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_1948A3801C48042CC5286FD829AB00BC_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt_1948A3801C48042CC5286FD829AB00BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_1948A3801C48042CC5286FD829AB00BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt_1948A3801C48042CC5286FD829AB00BC" xlink:to="lab_us-gaap_RepaymentsOfDebt_1948A3801C48042CC5286FD829AB00BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_F4CD84B113BEC0DF12C06FD829ACD1B4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt_F4CD84B113BEC0DF12C06FD829ACD1B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of 1.75% convertible senior notes due 2025</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_F4CD84B113BEC0DF12C06FD829ACD1B4_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt_F4CD84B113BEC0DF12C06FD829ACD1B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_F4CD84B113BEC0DF12C06FD829ACD1B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt_F4CD84B113BEC0DF12C06FD829ACD1B4" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt_F4CD84B113BEC0DF12C06FD829ACD1B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_BD05EAE6D242CE74C78B6FD829AC6AC7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts_BD05EAE6D242CE74C78B6FD829AC6AC7" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_BD05EAE6D242CE74C78B6FD829AC6AC7_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts_BD05EAE6D242CE74C78B6FD829AC6AC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_BD05EAE6D242CE74C78B6FD829AC6AC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts_BD05EAE6D242CE74C78B6FD829AC6AC7" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts_BD05EAE6D242CE74C78B6FD829AC6AC7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_109A3BB3BC10C97B872C6FD829AC0EC3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_109A3BB3BC10C97B872C6FD829AC0EC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_109A3BB3BC10C97B872C6FD829AC0EC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_109A3BB3BC10C97B872C6FD829AC0EC3" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_109A3BB3BC10C97B872C6FD829AC0EC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_DACC9424CBF17CF3E69E6FD829AC3433_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_DACC9424CBF17CF3E69E6FD829AC3433" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_DACC9424CBF17CF3E69E6FD829AC3433_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_DACC9424CBF17CF3E69E6FD829AC3433" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_DACC9424CBF17CF3E69E6FD829AC3433" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_DACC9424CBF17CF3E69E6FD829AC3433" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_DACC9424CBF17CF3E69E6FD829AC3433" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_244EDFDAE0411809B2346FD829ADD6B2_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_244EDFDAE0411809B2346FD829ADD6B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rates on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_244EDFDAE0411809B2346FD829ADD6B2_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_244EDFDAE0411809B2346FD829ADD6B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_244EDFDAE0411809B2346FD829ADD6B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_244EDFDAE0411809B2346FD829ADD6B2" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_244EDFDAE0411809B2346FD829ADD6B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_CB1686398F8D0068A57E6FD829AD527E_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_CB1686398F8D0068A57E6FD829AD527E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_CB1686398F8D0068A57E6FD829AD527E_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_CB1686398F8D0068A57E6FD829AD527E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_CB1686398F8D0068A57E6FD829AD527E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_CB1686398F8D0068A57E6FD829AD527E" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_CB1686398F8D0068A57E6FD829AD527E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_F107EF065C2B8A9E0E636FD829AD2360_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_F107EF065C2B8A9E0E636FD829AD2360" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_F107EF065C2B8A9E0E636FD829AD2360" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_F107EF065C2B8A9E0E636FD829AD2360" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_F107EF065C2B8A9E0E636FD829AD2360" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_076FA04B8BB7CA87C0316FD829AD271B_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_076FA04B8BB7CA87C0316FD829AD271B" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_076FA04B8BB7CA87C0316FD829AD271B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_076FA04B8BB7CA87C0316FD829AD271B" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_076FA04B8BB7CA87C0316FD829AD271B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_45763AD2FBC41E2BBE2B6FD829AE61AA_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_45763AD2FBC41E2BBE2B6FD829AE61AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosures of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_45763AD2FBC41E2BBE2B6FD829AE61AA_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_45763AD2FBC41E2BBE2B6FD829AE61AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_45763AD2FBC41E2BBE2B6FD829AE61AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_45763AD2FBC41E2BBE2B6FD829AE61AA" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_45763AD2FBC41E2BBE2B6FD829AE61AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPaidNet_5B3912469E56CB310A7D6FD829AEDF17_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet_5B3912469E56CB310A7D6FD829AEDF17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_5B3912469E56CB310A7D6FD829AEDF17_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet_5B3912469E56CB310A7D6FD829AEDF17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_5B3912469E56CB310A7D6FD829AEDF17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet_5B3912469E56CB310A7D6FD829AEDF17" xlink:to="lab_us-gaap_InterestPaidNet_5B3912469E56CB310A7D6FD829AEDF17" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_33893344E72A56DC8B746FD829AF8FC0_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_33893344E72A56DC8B746FD829AF8FC0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_33893344E72A56DC8B746FD829AF8FC0_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_33893344E72A56DC8B746FD829AF8FC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_33893344E72A56DC8B746FD829AF8FC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet_33893344E72A56DC8B746FD829AF8FC0" xlink:to="lab_us-gaap_IncomeTaxesPaidNet_33893344E72A56DC8B746FD829AF8FC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_FAF95AEDFF262A58338DF60EC15D5D89_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_6ECBC424531357CB9B293B81C26EE7A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_FAF95AEDFF262A58338DF60EC15D5D89_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_6ECBC424531357CB9B293B81C26EE7A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_6ECBC424531357CB9B293B81C26EE7A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_6ECBC424531357CB9B293B81C26EE7A5" xlink:to="lab_us-gaap_DebtInstrumentTable_6ECBC424531357CB9B293B81C26EE7A5" xlink:type="arc" />
    <link:label id="lab_insm_DebtInstrumentConversionTermAxis_4961A933660AAD4DFB18F60EC15EEC7C_terseLabel_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermAxis_7201507BE3E450508BD3EDB11B1BB7DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument Conversion Term [Axis]</link:label>
    <link:label id="lab_insm_DebtInstrumentConversionTermAxis_4961A933660AAD4DFB18F60EC15EEC7C_label_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermAxis_7201507BE3E450508BD3EDB11B1BB7DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Conversion Term [Axis]</link:label>
    <link:label id="lab_insm_DebtInstrumentConversionTermAxis_4961A933660AAD4DFB18F60EC15EEC7C_documentation_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermAxis_7201507BE3E450508BD3EDB11B1BB7DE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument Conversion Term [Axis]</link:label>
    <link:loc xlink:href="insm-20180930.xsd#insm_DebtInstrumentConversionTermAxis" xlink:label="loc_insm_DebtInstrumentConversionTermAxis_7201507BE3E450508BD3EDB11B1BB7DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_DebtInstrumentConversionTermAxis_7201507BE3E450508BD3EDB11B1BB7DE" xlink:to="lab_insm_DebtInstrumentConversionTermAxis_7201507BE3E450508BD3EDB11B1BB7DE" xlink:type="arc" />
    <link:label id="lab_insm_DebtInstrumentConversionTermDomain_08E88FBE0B6C0CB39F26F60EC15F880B_terseLabel_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermDomain_A7F89F6B1BB855EAAF6D4E7F9971CB22" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument Conversion Term [Domain]</link:label>
    <link:label id="lab_insm_DebtInstrumentConversionTermDomain_08E88FBE0B6C0CB39F26F60EC15F880B_label_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermDomain_A7F89F6B1BB855EAAF6D4E7F9971CB22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Conversion Term [Domain]</link:label>
    <link:label id="lab_insm_DebtInstrumentConversionTermDomain_08E88FBE0B6C0CB39F26F60EC15F880B_documentation_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermDomain_A7F89F6B1BB855EAAF6D4E7F9971CB22" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Debt Instrument Conversion Term [Axis]</link:label>
    <link:loc xlink:href="insm-20180930.xsd#insm_DebtInstrumentConversionTermDomain" xlink:label="loc_insm_DebtInstrumentConversionTermDomain_A7F89F6B1BB855EAAF6D4E7F9971CB22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_DebtInstrumentConversionTermDomain_A7F89F6B1BB855EAAF6D4E7F9971CB22" xlink:to="lab_insm_DebtInstrumentConversionTermDomain_A7F89F6B1BB855EAAF6D4E7F9971CB22" xlink:type="arc" />
    <link:label id="lab_insm_DebtInstrumentConversionTermOneMember_71B4F069D98913EF05C0F60EC15F8A4F_terseLabel_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermOneMember_0BAE622129815C4599199CBB6AD912BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion Term (i)</link:label>
    <link:label id="lab_insm_DebtInstrumentConversionTermOneMember_71B4F069D98913EF05C0F60EC15F8A4F_label_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermOneMember_0BAE622129815C4599199CBB6AD912BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Conversion Term One [Member]</link:label>
    <link:label id="lab_insm_DebtInstrumentConversionTermOneMember_71B4F069D98913EF05C0F60EC15F8A4F_documentation_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermOneMember_0BAE622129815C4599199CBB6AD912BB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Conversion Term One [Member]</link:label>
    <link:loc xlink:href="insm-20180930.xsd#insm_DebtInstrumentConversionTermOneMember" xlink:label="loc_insm_DebtInstrumentConversionTermOneMember_0BAE622129815C4599199CBB6AD912BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_DebtInstrumentConversionTermOneMember_0BAE622129815C4599199CBB6AD912BB" xlink:to="lab_insm_DebtInstrumentConversionTermOneMember_0BAE622129815C4599199CBB6AD912BB" xlink:type="arc" />
    <link:label id="lab_insm_DebtInstrumentConversionTermTwoMember_81F0A50158A5AD8724B3F60EC15F3F29_terseLabel_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermTwoMember_7CB12083991F564088F94E010BF66922" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion Term (ii)</link:label>
    <link:label id="lab_insm_DebtInstrumentConversionTermTwoMember_81F0A50158A5AD8724B3F60EC15F3F29_label_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermTwoMember_7CB12083991F564088F94E010BF66922" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Conversion Term Two [Member]</link:label>
    <link:label id="lab_insm_DebtInstrumentConversionTermTwoMember_81F0A50158A5AD8724B3F60EC15F3F29_documentation_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermTwoMember_7CB12083991F564088F94E010BF66922" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Conversion Term Two [Member]</link:label>
    <link:loc xlink:href="insm-20180930.xsd#insm_DebtInstrumentConversionTermTwoMember" xlink:label="loc_insm_DebtInstrumentConversionTermTwoMember_7CB12083991F564088F94E010BF66922" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_DebtInstrumentConversionTermTwoMember_7CB12083991F564088F94E010BF66922" xlink:to="lab_insm_DebtInstrumentConversionTermTwoMember_7CB12083991F564088F94E010BF66922" xlink:type="arc" />
    <link:label id="lab_insm_DebtInstrumentConversionTermThreeMember_5FB84451BB4B8191394BF60EC15F8BF5_terseLabel_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermThreeMember_0D4E82738BB9556FA199A1DB1733C30C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion Term (iii)</link:label>
    <link:label id="lab_insm_DebtInstrumentConversionTermThreeMember_5FB84451BB4B8191394BF60EC15F8BF5_label_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermThreeMember_0D4E82738BB9556FA199A1DB1733C30C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Conversion Term Three [Member]</link:label>
    <link:label id="lab_insm_DebtInstrumentConversionTermThreeMember_5FB84451BB4B8191394BF60EC15F8BF5_documentation_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermThreeMember_0D4E82738BB9556FA199A1DB1733C30C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Conversion Term Three [Member]</link:label>
    <link:loc xlink:href="insm-20180930.xsd#insm_DebtInstrumentConversionTermThreeMember" xlink:label="loc_insm_DebtInstrumentConversionTermThreeMember_0D4E82738BB9556FA199A1DB1733C30C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_DebtInstrumentConversionTermThreeMember_0D4E82738BB9556FA199A1DB1733C30C" xlink:to="lab_insm_DebtInstrumentConversionTermThreeMember_0D4E82738BB9556FA199A1DB1733C30C" xlink:type="arc" />
    <link:label id="lab_insm_DebtInstrumentConversionTermFourMember_2301147F9731BBEBEA97F60EC160945A_terseLabel_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermFourMember_146A4966BFDF55C68F963C90CF464FAD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion Term (iv)</link:label>
    <link:label id="lab_insm_DebtInstrumentConversionTermFourMember_2301147F9731BBEBEA97F60EC160945A_label_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermFourMember_146A4966BFDF55C68F963C90CF464FAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Conversion Term Four [Member]</link:label>
    <link:label id="lab_insm_DebtInstrumentConversionTermFourMember_2301147F9731BBEBEA97F60EC160945A_documentation_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermFourMember_146A4966BFDF55C68F963C90CF464FAD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Conversion Term Four [Member]</link:label>
    <link:loc xlink:href="insm-20180930.xsd#insm_DebtInstrumentConversionTermFourMember" xlink:label="loc_insm_DebtInstrumentConversionTermFourMember_146A4966BFDF55C68F963C90CF464FAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_DebtInstrumentConversionTermFourMember_146A4966BFDF55C68F963C90CF464FAD" xlink:to="lab_insm_DebtInstrumentConversionTermFourMember_146A4966BFDF55C68F963C90CF464FAD" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditMember_9B8BD2CC4523BC153FEFF60EC1619AF4_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember_3A54F9D00D6F5A90B032D4579B17E226" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">A&amp;R Loan Agreement with Hercules</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_9B8BD2CC4523BC153FEFF60EC1619AF4_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember_3A54F9D00D6F5A90B032D4579B17E226" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember_3A54F9D00D6F5A90B032D4579B17E226" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember_3A54F9D00D6F5A90B032D4579B17E226" xlink:to="lab_us-gaap_LineOfCreditMember_3A54F9D00D6F5A90B032D4579B17E226" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_68548C4525C51CA86E4EF60EC1614C53_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_C41DC04876525570B647A0D76BF3F30B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_68548C4525C51CA86E4EF60EC1614C53_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_C41DC04876525570B647A0D76BF3F30B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_C41DC04876525570B647A0D76BF3F30B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C41DC04876525570B647A0D76BF3F30B" xlink:to="lab_us-gaap_DebtInstrumentLineItems_C41DC04876525570B647A0D76BF3F30B" xlink:type="arc" />
    <link:label id="lab_insm_DebtInstrumentOptionToPurchaseAdditionalDebt_83F4C57BF381763E56C2F60EC16297CB_terseLabel_en-US" xlink:label="lab_insm_DebtInstrumentOptionToPurchaseAdditionalDebt_545B50DB8BC85295B28569DE61F2E4C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option to purchase additional debt</link:label>
    <link:label id="lab_insm_DebtInstrumentOptionToPurchaseAdditionalDebt_83F4C57BF381763E56C2F60EC16297CB_label_en-US" xlink:label="lab_insm_DebtInstrumentOptionToPurchaseAdditionalDebt_545B50DB8BC85295B28569DE61F2E4C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Option To Purchase Additional Debt</link:label>
    <link:label id="lab_insm_DebtInstrumentOptionToPurchaseAdditionalDebt_83F4C57BF381763E56C2F60EC16297CB_documentation_en-US" xlink:label="lab_insm_DebtInstrumentOptionToPurchaseAdditionalDebt_545B50DB8BC85295B28569DE61F2E4C2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Option To Purchase Additional Debt</link:label>
    <link:loc xlink:href="insm-20180930.xsd#insm_DebtInstrumentOptionToPurchaseAdditionalDebt" xlink:label="loc_insm_DebtInstrumentOptionToPurchaseAdditionalDebt_545B50DB8BC85295B28569DE61F2E4C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_DebtInstrumentOptionToPurchaseAdditionalDebt_545B50DB8BC85295B28569DE61F2E4C2" xlink:to="lab_insm_DebtInstrumentOptionToPurchaseAdditionalDebt_545B50DB8BC85295B28569DE61F2E4C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_824A19D3702A4DC5BF7CF60EC162DDB0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet_29E40E59124D5704B708D4807315D76B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underwriting discounts and commissions and other offering expenses</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_824A19D3702A4DC5BF7CF60EC162DDB0_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet_29E40E59124D5704B708D4807315D76B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_29E40E59124D5704B708D4807315D76B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet_29E40E59124D5704B708D4807315D76B" xlink:to="lab_us-gaap_DeferredFinanceCostsNet_29E40E59124D5704B708D4807315D76B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_19DB86E613259D3DD9CAF60EC163B1A3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt_6EEAC89DC9AE55F08690F9C2FC4EFBAB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_19DB86E613259D3DD9CAF60EC163B1A3_label_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt_6EEAC89DC9AE55F08690F9C2FC4EFBAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_6EEAC89DC9AE55F08690F9C2FC4EFBAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt_6EEAC89DC9AE55F08690F9C2FC4EFBAB" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt_6EEAC89DC9AE55F08690F9C2FC4EFBAB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_D7B479B413B28A25AE29F60EC1639353_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_40BCAB7B7D5B55659779650BA2EF300D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial conversion rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_D7B479B413B28A25AE29F60EC1639353_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_40BCAB7B7D5B55659779650BA2EF300D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_40BCAB7B7D5B55659779650BA2EF300D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_40BCAB7B7D5B55659779650BA2EF300D" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_40BCAB7B7D5B55659779650BA2EF300D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_FB542CA89EEE70902A80F60EC164FC2B_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_EDEE2C3924B856F3B327A8A2C4326A51" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial conversion price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_FB542CA89EEE70902A80F60EC164FC2B_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_EDEE2C3924B856F3B327A8A2C4326A51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_EDEE2C3924B856F3B327A8A2C4326A51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_EDEE2C3924B856F3B327A8A2C4326A51" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_EDEE2C3924B856F3B327A8A2C4326A51" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_2306C8BC1B426C86488CF60EC16454CB_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_2ECCCBFFC2755767BA3E155751DD5D24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_2306C8BC1B426C86488CF60EC16454CB_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_2ECCCBFFC2755767BA3E155751DD5D24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_2ECCCBFFC2755767BA3E155751DD5D24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_2ECCCBFFC2755767BA3E155751DD5D24" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_2ECCCBFFC2755767BA3E155751DD5D24" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_C22FA8E07AAA3454DE00F60EC1658A1F_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_2BE5A4523A505966B4C83A14CF9CA517" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold consecutive trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_C22FA8E07AAA3454DE00F60EC1658A1F_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_2BE5A4523A505966B4C83A14CF9CA517" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_2BE5A4523A505966B4C83A14CF9CA517" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_2BE5A4523A505966B4C83A14CF9CA517" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_2BE5A4523A505966B4C83A14CF9CA517" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_4E0F74B4FD2BEB27FE71F60EC165568D_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_7AACF8FD89575370B69118217FC4BE7A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold percent of stock price trigger</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_4E0F74B4FD2BEB27FE71F60EC165568D_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_7AACF8FD89575370B69118217FC4BE7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_7AACF8FD89575370B69118217FC4BE7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_7AACF8FD89575370B69118217FC4BE7A" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_7AACF8FD89575370B69118217FC4BE7A" xlink:type="arc" />
    <link:label id="lab_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange_EE585390A5B3CACD7BC0F60EC165F0EB_terseLabel_en-US" xlink:label="lab_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange_1D5A1BD002345C81B766809A929C3451" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold trading days following fundamental change</link:label>
    <link:label id="lab_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange_EE585390A5B3CACD7BC0F60EC165F0EB_label_en-US" xlink:label="lab_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange_1D5A1BD002345C81B766809A929C3451" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Trading Days Prior To Effective Data Of Fundamental Change</link:label>
    <link:label id="lab_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange_EE585390A5B3CACD7BC0F60EC165F0EB_documentation_en-US" xlink:label="lab_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange_1D5A1BD002345C81B766809A929C3451" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Trading Days Prior To Effective Data Of Fundamental Change</link:label>
    <link:loc xlink:href="insm-20180930.xsd#insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange" xlink:label="loc_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange_1D5A1BD002345C81B766809A929C3451" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange_1D5A1BD002345C81B766809A929C3451" xlink:to="lab_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange_1D5A1BD002345C81B766809A929C3451" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_19F3CDD26413E36FDFC1F60EC16520AA_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_1863F5AB19315B7EB8B0D353A14D40E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_19F3CDD26413E36FDFC1F60EC16520AA_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_1863F5AB19315B7EB8B0D353A14D40E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_1863F5AB19315B7EB8B0D353A14D40E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_1863F5AB19315B7EB8B0D353A14D40E4" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_1863F5AB19315B7EB8B0D353A14D40E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_6C8F37C9AF5A5FB374A3F60EC16683F4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_FF5C17462C8950BA920E56ECB4F31D92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining discount amortization period</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_6C8F37C9AF5A5FB374A3F60EC16683F4_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_FF5C17462C8950BA920E56ECB4F31D92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Remaining Discount Amortization Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_FF5C17462C8950BA920E56ECB4F31D92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_FF5C17462C8950BA920E56ECB4F31D92" xlink:to="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_FF5C17462C8950BA920E56ECB4F31D92" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_3BC2921975C5F7E8135BF60EC166F0A9_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_86DE6ED42139533A89B431DC9FE02A69" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_86DE6ED42139533A89B431DC9FE02A69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_86DE6ED42139533A89B431DC9FE02A69" xlink:to="lab_us-gaap_InterestExpense_86DE6ED42139533A89B431DC9FE02A69" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfDebt_362491E692C6C79D0F31F60EC166D256_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt_C9EBE0E4EA1A5082AA7D4B7861999D04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayment of debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_C9EBE0E4EA1A5082AA7D4B7861999D04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt_C9EBE0E4EA1A5082AA7D4B7861999D04" xlink:to="lab_us-gaap_RepaymentsOfDebt_C9EBE0E4EA1A5082AA7D4B7861999D04" xlink:type="arc" />
    <link:label id="lab_insm_RepaymentsOfDebtFeesAndOutstandingInterest_81BD6F0F0A5FF242ED86F60EC1677E76_terseLabel_en-US" xlink:label="lab_insm_RepaymentsOfDebtFeesAndOutstandingInterest_FDA30A388417564D8312B02C4890409A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayment of debt, back end fees, outstanding interest, and prepayment penalty fees</link:label>
    <link:label id="lab_insm_RepaymentsOfDebtFeesAndOutstandingInterest_81BD6F0F0A5FF242ED86F60EC1677E76_label_en-US" xlink:label="lab_insm_RepaymentsOfDebtFeesAndOutstandingInterest_FDA30A388417564D8312B02C4890409A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments Of Debt, Fees And Outstanding Interest</link:label>
    <link:label id="lab_insm_RepaymentsOfDebtFeesAndOutstandingInterest_81BD6F0F0A5FF242ED86F60EC1677E76_documentation_en-US" xlink:label="lab_insm_RepaymentsOfDebtFeesAndOutstandingInterest_FDA30A388417564D8312B02C4890409A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Repayments Of Debt, Fees And Outstanding Interest</link:label>
    <link:loc xlink:href="insm-20180930.xsd#insm_RepaymentsOfDebtFeesAndOutstandingInterest" xlink:label="loc_insm_RepaymentsOfDebtFeesAndOutstandingInterest_FDA30A388417564D8312B02C4890409A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_RepaymentsOfDebtFeesAndOutstandingInterest_FDA30A388417564D8312B02C4890409A" xlink:to="lab_insm_RepaymentsOfDebtFeesAndOutstandingInterest_FDA30A388417564D8312B02C4890409A" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_5568E529BC7607FDC596F60EC16762B8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_3E93E492F17E5176998CBBA8342254DB" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3E93E492F17E5176998CBBA8342254DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3E93E492F17E5176998CBBA8342254DB" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_3E93E492F17E5176998CBBA8342254DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameAxis_8E88FEE58A71C5A087A8C148098D8523_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis_8E88FEE58A71C5A087A8C148098D8523" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_8E88FEE58A71C5A087A8C148098D8523_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis_8E88FEE58A71C5A087A8C148098D8523" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_8E88FEE58A71C5A087A8C148098D8523" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_8E88FEE58A71C5A087A8C148098D8523" xlink:to="lab_us-gaap_PlanNameAxis_8E88FEE58A71C5A087A8C148098D8523" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameDomain_666446A6C0C686BE6948C148098D8B1F_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain_666446A6C0C686BE6948C148098D8B1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_666446A6C0C686BE6948C148098D8B1F_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain_666446A6C0C686BE6948C148098D8B1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_666446A6C0C686BE6948C148098D8B1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_666446A6C0C686BE6948C148098D8B1F" xlink:to="lab_us-gaap_PlanNameDomain_666446A6C0C686BE6948C148098D8B1F" xlink:type="arc" />
    <link:label id="lab_insm_EmployeeStockPurchasePlan2018Member_C2A76D89F13EA4CB1ACAC148098DF461_terseLabel_en-US" xlink:label="lab_insm_EmployeeStockPurchasePlan2018Member_C2A76D89F13EA4CB1ACAC148098DF461" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2018 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_insm_EmployeeStockPurchasePlan2018Member_C2A76D89F13EA4CB1ACAC148098DF461_label_en-US" xlink:label="lab_insm_EmployeeStockPurchasePlan2018Member_C2A76D89F13EA4CB1ACAC148098DF461" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan 2018 [Member]</link:label>
    <link:label id="lab_insm_EmployeeStockPurchasePlan2018Member_C2A76D89F13EA4CB1ACAC148098DF461_documentation_en-US" xlink:label="lab_insm_EmployeeStockPurchasePlan2018Member_C2A76D89F13EA4CB1ACAC148098DF461" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan 2018 [Member]</link:label>
    <link:loc xlink:href="insm-20180930.xsd#insm_EmployeeStockPurchasePlan2018Member" xlink:label="loc_insm_EmployeeStockPurchasePlan2018Member_C2A76D89F13EA4CB1ACAC148098DF461" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_EmployeeStockPurchasePlan2018Member_C2A76D89F13EA4CB1ACAC148098DF461" xlink:to="lab_insm_EmployeeStockPurchasePlan2018Member_C2A76D89F13EA4CB1ACAC148098DF461" xlink:type="arc" />
    <link:label id="lab_us-gaap_PerformanceSharesMember_1D17F4FFE9002B1CCA8BC148098F0122_verboseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_1D17F4FFE9002B1CCA8BC148098F0122" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Performance options</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_1D17F4FFE9002B1CCA8BC148098F0122_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_1D17F4FFE9002B1CCA8BC148098F0122" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_1D17F4FFE9002B1CCA8BC148098F0122" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember_1D17F4FFE9002B1CCA8BC148098F0122" xlink:to="lab_us-gaap_PerformanceSharesMember_1D17F4FFE9002B1CCA8BC148098F0122" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_456DFDF348508A72EE74C148098F0A05_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_456DFDF348508A72EE74C148098F0A05" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares of common stock, maximum authorized for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_456DFDF348508A72EE74C148098F0A05_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_456DFDF348508A72EE74C148098F0A05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_456DFDF348508A72EE74C148098F0A05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_456DFDF348508A72EE74C148098F0A05" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_456DFDF348508A72EE74C148098F0A05" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0DF3E650E46F91FB0645C148099057A7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0DF3E650E46F91FB0645C148099057A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0DF3E650E46F91FB0645C148099057A7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0DF3E650E46F91FB0645C148099057A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0DF3E650E46F91FB0645C148099057A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0DF3E650E46F91FB0645C148099057A7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0DF3E650E46F91FB0645C148099057A7" xlink:type="arc" />
    <link:label id="lab_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross_37CA1BE775FF8EF4EB1EC148099070B8_terseLabel_en-US" xlink:label="lab_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross_37CA1BE775FF8EF4EB1EC148099070B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inducement stock options granted to new employees (in shares)</link:label>
    <link:label id="lab_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross_37CA1BE775FF8EF4EB1EC148099070B8_label_en-US" xlink:label="lab_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross_37CA1BE775FF8EF4EB1EC148099070B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Inducement Options Grants In Period Gross</link:label>
    <link:label id="lab_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross_37CA1BE775FF8EF4EB1EC148099070B8_documentation_en-US" xlink:label="lab_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross_37CA1BE775FF8EF4EB1EC148099070B8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gross number of inducement share options (or share units) granted during the period.</link:label>
    <link:loc xlink:href="insm-20180930.xsd#insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross" xlink:label="loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross_37CA1BE775FF8EF4EB1EC148099070B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross_37CA1BE775FF8EF4EB1EC148099070B8" xlink:to="lab_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross_37CA1BE775FF8EF4EB1EC148099070B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_44365255D9873063D8EAC14809901481_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_44365255D9873063D8EAC14809901481" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of additional shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_44365255D9873063D8EAC14809901481_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_44365255D9873063D8EAC14809901481" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_44365255D9873063D8EAC14809901481" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_44365255D9873063D8EAC14809901481" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_44365255D9873063D8EAC14809901481" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_B56F01959497ECB7AEECC1480990C527_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_B56F01959497ECB7AEECC1480990C527" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of outstanding shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_B56F01959497ECB7AEECC1480990C527_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_B56F01959497ECB7AEECC1480990C527" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_B56F01959497ECB7AEECC1480990C527" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_B56F01959497ECB7AEECC1480990C527" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_B56F01959497ECB7AEECC1480990C527" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_8C21E40A6D807704E56AC1480990C05F_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_8C21E40A6D807704E56AC1480990C05F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Value of options vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_8C21E40A6D807704E56AC1480990C05F_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_8C21E40A6D807704E56AC1480990C05F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_8C21E40A6D807704E56AC1480990C05F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_8C21E40A6D807704E56AC1480990C05F" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_8C21E40A6D807704E56AC1480990C05F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_AC7F6A07F3E839928959C1480991417B_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_AC7F6A07F3E839928959C1480991417B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options vested (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_AC7F6A07F3E839928959C1480991417B_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_AC7F6A07F3E839928959C1480991417B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_AC7F6A07F3E839928959C1480991417B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_AC7F6A07F3E839928959C1480991417B" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_AC7F6A07F3E839928959C1480991417B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2E8FC7B2FE15A4E12333C14809911EAD_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2E8FC7B2FE15A4E12333C14809911EAD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2E8FC7B2FE15A4E12333C14809911EAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2E8FC7B2FE15A4E12333C14809911EAD" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2E8FC7B2FE15A4E12333C14809911EAD" xlink:type="arc" />
    <link:label id="lab_us-gaap_SecuredDebt_CD39AD3FD8A6CE3F998B4D125C50424D_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebt_B07D806391B1512493894BDB15B913CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1.75% convertible senior notes due 2025</link:label>
    <link:label id="lab_us-gaap_SecuredDebt_CD39AD3FD8A6CE3F998B4D125C50424D_label_en-US" xlink:label="lab_us-gaap_SecuredDebt_B07D806391B1512493894BDB15B913CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SecuredDebt" xlink:label="loc_us-gaap_SecuredDebt_B07D806391B1512493894BDB15B913CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebt_B07D806391B1512493894BDB15B913CB" xlink:to="lab_us-gaap_SecuredDebt_B07D806391B1512493894BDB15B913CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_D04033874941F88848B34D125C698D05_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet_1EC63E0E62675D70B52F9CE16A2D7489" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Debt issuance costs, unamortized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_1EC63E0E62675D70B52F9CE16A2D7489" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet_1EC63E0E62675D70B52F9CE16A2D7489" xlink:to="lab_us-gaap_DeferredFinanceCostsNet_1EC63E0E62675D70B52F9CE16A2D7489" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_80F420204ADCA13B5C284D125C6ED709_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount_E5CC7260B7C2506AABD0D7E1CA8F9DC2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Discount on debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_E5CC7260B7C2506AABD0D7E1CA8F9DC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount_E5CC7260B7C2506AABD0D7E1CA8F9DC2" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount_E5CC7260B7C2506AABD0D7E1CA8F9DC2" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_F6E76B60A1A4C8E344824D125C79BA37_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_96018C0F0BF5550C905FDC794C56A9CB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Long-term debt, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_96018C0F0BF5550C905FDC794C56A9CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_96018C0F0BF5550C905FDC794C56A9CB" xlink:to="lab_us-gaap_LongTermDebtNoncurrent_96018C0F0BF5550C905FDC794C56A9CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_86D7198DE967F3B109B58222F2E6ABDF_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_86D7198DE967F3B109B58222F2E6ABDF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future minimum rental payments under operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_86D7198DE967F3B109B58222F2E6ABDF_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_86D7198DE967F3B109B58222F2E6ABDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_86D7198DE967F3B109B58222F2E6ABDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_86D7198DE967F3B109B58222F2E6ABDF" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_86D7198DE967F3B109B58222F2E6ABDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_211192FF1C014C99D1A98222F2E60798_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_211192FF1C014C99D1A98222F2E60798" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2018 (remaining)</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_211192FF1C014C99D1A98222F2E60798_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_211192FF1C014C99D1A98222F2E60798" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Remainder of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_211192FF1C014C99D1A98222F2E60798" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_211192FF1C014C99D1A98222F2E60798" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_211192FF1C014C99D1A98222F2E60798" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_5CABF39467EA4A88727F8222F2E6BB3A_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_5CABF39467EA4A88727F8222F2E6BB3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_5CABF39467EA4A88727F8222F2E6BB3A_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_5CABF39467EA4A88727F8222F2E6BB3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_5CABF39467EA4A88727F8222F2E6BB3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_5CABF39467EA4A88727F8222F2E6BB3A" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_5CABF39467EA4A88727F8222F2E6BB3A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_AA26531B81CC63FF94E18222F2E6D7BC_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_AA26531B81CC63FF94E18222F2E6D7BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_AA26531B81CC63FF94E18222F2E6D7BC_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_AA26531B81CC63FF94E18222F2E6D7BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_AA26531B81CC63FF94E18222F2E6D7BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_AA26531B81CC63FF94E18222F2E6D7BC" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_AA26531B81CC63FF94E18222F2E6D7BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_5CFB8D50B0C5E14040458222F2E8D405_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_5CFB8D50B0C5E14040458222F2E8D405" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_5CFB8D50B0C5E14040458222F2E8D405_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_5CFB8D50B0C5E14040458222F2E8D405" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_5CFB8D50B0C5E14040458222F2E8D405" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_5CFB8D50B0C5E14040458222F2E8D405" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_5CFB8D50B0C5E14040458222F2E8D405" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_79CDE8E1AB8579E15D6B8222F2E85FDE_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_79CDE8E1AB8579E15D6B8222F2E85FDE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_79CDE8E1AB8579E15D6B8222F2E85FDE_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_79CDE8E1AB8579E15D6B8222F2E85FDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_79CDE8E1AB8579E15D6B8222F2E85FDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_79CDE8E1AB8579E15D6B8222F2E85FDE" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_79CDE8E1AB8579E15D6B8222F2E85FDE" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_35E6AEC5526966FE04E58222F2E8E286_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_35E6AEC5526966FE04E58222F2E8E286" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023 and thereafter</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_35E6AEC5526966FE04E58222F2E8E286_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_35E6AEC5526966FE04E58222F2E8E286" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_35E6AEC5526966FE04E58222F2E8E286" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_35E6AEC5526966FE04E58222F2E8E286" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_35E6AEC5526966FE04E58222F2E8E286" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_FDFF820639BEBD6762F48222F2E9C98C_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_FDFF820639BEBD6762F48222F2E9C98C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_FDFF820639BEBD6762F48222F2E9C98C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_FDFF820639BEBD6762F48222F2E9C98C" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_FDFF820639BEBD6762F48222F2E9C98C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_3C9D8C2CD7818C759D7506F42D68E883_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_6E917DAA116551F8975241FF21D065E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_3C9D8C2CD7818C759D7506F42D68E883_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_6E917DAA116551F8975241FF21D065E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_6E917DAA116551F8975241FF21D065E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_6E917DAA116551F8975241FF21D065E4" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_6E917DAA116551F8975241FF21D065E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_71AD8F4C89F0E36715D53B7F7F3E0C62_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_71AD8F4C89F0E36715D53B7F7F3E0C62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_71AD8F4C89F0E36715D53B7F7F3E0C62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_71AD8F4C89F0E36715D53B7F7F3E0C62" xlink:to="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_71AD8F4C89F0E36715D53B7F7F3E0C62" xlink:type="arc" />
    <link:label id="lab_insm_ScheduleofEarningsPerShareBasicandDilutedTable_1075786D4D5C027C93BBC1480A72A8A1_terseLabel_en-US" xlink:label="lab_insm_ScheduleofEarningsPerShareBasicandDilutedTable_1075786D4D5C027C93BBC1480A72A8A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table]</link:label>
    <link:label id="lab_insm_ScheduleofEarningsPerShareBasicandDilutedTable_1075786D4D5C027C93BBC1480A72A8A1_label_en-US" xlink:label="lab_insm_ScheduleofEarningsPerShareBasicandDilutedTable_1075786D4D5C027C93BBC1480A72A8A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table]</link:label>
    <link:label id="lab_insm_ScheduleofEarningsPerShareBasicandDilutedTable_1075786D4D5C027C93BBC1480A72A8A1_documentation_en-US" xlink:label="lab_insm_ScheduleofEarningsPerShareBasicandDilutedTable_1075786D4D5C027C93BBC1480A72A8A1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table]</link:label>
    <link:loc xlink:href="insm-20180930.xsd#insm_ScheduleofEarningsPerShareBasicandDilutedTable" xlink:label="loc_insm_ScheduleofEarningsPerShareBasicandDilutedTable_1075786D4D5C027C93BBC1480A72A8A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedTable_1075786D4D5C027C93BBC1480A72A8A1" xlink:to="lab_insm_ScheduleofEarningsPerShareBasicandDilutedTable_1075786D4D5C027C93BBC1480A72A8A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_0E189D36B1057F17CDE3C1480A73B042_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_0E189D36B1057F17CDE3C1480A73B042" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_0E189D36B1057F17CDE3C1480A73B042_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_0E189D36B1057F17CDE3C1480A73B042" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0E189D36B1057F17CDE3C1480A73B042" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_0E189D36B1057F17CDE3C1480A73B042" xlink:to="lab_us-gaap_EmployeeStockOptionMember_0E189D36B1057F17CDE3C1480A73B042" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_5CD981467B6AF82EC017C1480A74B5D4_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_5CD981467B6AF82EC017C1480A74B5D4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">RSUs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_5CD981467B6AF82EC017C1480A74B5D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_5CD981467B6AF82EC017C1480A74B5D4" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember_5CD981467B6AF82EC017C1480A74B5D4" xlink:type="arc" />
    <link:label id="lab_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_F87EF04B0501ABD010C0C1480A745092_terseLabel_en-US" xlink:label="lab_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_F87EF04B0501ABD010C0C1480A745092" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Line Items]</link:label>
    <link:label id="lab_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_F87EF04B0501ABD010C0C1480A745092_label_en-US" xlink:label="lab_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_F87EF04B0501ABD010C0C1480A745092" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Line Items]</link:label>
    <link:label id="lab_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_F87EF04B0501ABD010C0C1480A745092_documentation_en-US" xlink:label="lab_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_F87EF04B0501ABD010C0C1480A745092" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Line Items] for Schedule of Earnings Per Share, Basic and Diluted [Table]</link:label>
    <link:loc xlink:href="insm-20180930.xsd#insm_ScheduleofEarningsPerShareBasicandDilutedLineItems" xlink:label="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_F87EF04B0501ABD010C0C1480A745092" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_F87EF04B0501ABD010C0C1480A745092" xlink:to="lab_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_F87EF04B0501ABD010C0C1480A745092" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_8180943A4A490037F57EC1480A75FC45_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_8180943A4A490037F57EC1480A75FC45" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_8180943A4A490037F57EC1480A75FC45_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_8180943A4A490037F57EC1480A75FC45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_8180943A4A490037F57EC1480A75FC45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_8180943A4A490037F57EC1480A75FC45" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_8180943A4A490037F57EC1480A75FC45" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_9B6C5EA2998FE793DDB2C1480A751F97_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_9B6C5EA2998FE793DDB2C1480A751F97" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_9B6C5EA2998FE793DDB2C1480A751F97_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_9B6C5EA2998FE793DDB2C1480A751F97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_9B6C5EA2998FE793DDB2C1480A751F97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_9B6C5EA2998FE793DDB2C1480A751F97" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_9B6C5EA2998FE793DDB2C1480A751F97" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_AA921D2C402508D10ADFC1480A759D2D_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_AA921D2C402508D10ADFC1480A759D2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average common shares used in calculation of basic net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_AA921D2C402508D10ADFC1480A759D2D_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_AA921D2C402508D10ADFC1480A759D2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_AA921D2C402508D10ADFC1480A759D2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_AA921D2C402508D10ADFC1480A759D2D" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_AA921D2C402508D10ADFC1480A759D2D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_C2F7BE94A6198E6E6870C1480A760866_terseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract_C2F7BE94A6198E6E6870C1480A760866" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_C2F7BE94A6198E6E6870C1480A760866_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract_C2F7BE94A6198E6E6870C1480A760866" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_C2F7BE94A6198E6E6870C1480A760866" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_C2F7BE94A6198E6E6870C1480A760866" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract_C2F7BE94A6198E6E6870C1480A760866" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_B6FA081A28848C0370A3C1480A76E354_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_B6FA081A28848C0370A3C1480A76E354" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dilutive securities, share-based payment (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_B6FA081A28848C0370A3C1480A76E354_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_B6FA081A28848C0370A3C1480A76E354" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_B6FA081A28848C0370A3C1480A76E354" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_B6FA081A28848C0370A3C1480A76E354" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_B6FA081A28848C0370A3C1480A76E354" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_DC90EEFCCD60DDC1DDC6C1480A76D0F1_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_DC90EEFCCD60DDC1DDC6C1480A76D0F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dilutive securities, convertible debt (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_DC90EEFCCD60DDC1DDC6C1480A76D0F1_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_DC90EEFCCD60DDC1DDC6C1480A76D0F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_DC90EEFCCD60DDC1DDC6C1480A76D0F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_DC90EEFCCD60DDC1DDC6C1480A76D0F1" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_DC90EEFCCD60DDC1DDC6C1480A76D0F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_F393AC1EA87F4287C072C1480A779938_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_F393AC1EA87F4287C072C1480A779938" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Weighted average common shares outstanding used in calculation of diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_F393AC1EA87F4287C072C1480A779938_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_F393AC1EA87F4287C072C1480A779938" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_F393AC1EA87F4287C072C1480A779938" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_F393AC1EA87F4287C072C1480A779938" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_F393AC1EA87F4287C072C1480A779938" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1ED81CD99D8EF3008AF1C1480A77E517_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1ED81CD99D8EF3008AF1C1480A77E517" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1ED81CD99D8EF3008AF1C1480A77E517_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1ED81CD99D8EF3008AF1C1480A77E517" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1ED81CD99D8EF3008AF1C1480A77E517" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1ED81CD99D8EF3008AF1C1480A77E517" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1ED81CD99D8EF3008AF1C1480A77E517" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_E617F269CBBC92D139E9C1480A77DFBE_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_E617F269CBBC92D139E9C1480A77DFBE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_E617F269CBBC92D139E9C1480A77DFBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_E617F269CBBC92D139E9C1480A77DFBE" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_E617F269CBBC92D139E9C1480A77DFBE" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>insm-20180930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.insmed.com/role/AccruedExpenses" xlink:href="insm-20180930.xsd#AccruedExpenses" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/AccruedExpensesDetails" xlink:href="insm-20180930.xsd#AccruedExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/AccruedExpensesTables" xlink:href="insm-20180930.xsd#AccruedExpensesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/CommitmentsAndContingencies" xlink:href="insm-20180930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/CommitmentsAndContingenciesMinimumRentalPaymentsDetails" xlink:href="insm-20180930.xsd#CommitmentsAndContingenciesMinimumRentalPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:href="insm-20180930.xsd#CommitmentsAndContingenciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/CommitmentsAndContingenciesTables" xlink:href="insm-20180930.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/CompanyAndBasisOfPresentation" xlink:href="insm-20180930.xsd#CompanyAndBasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/CompanyAndBasisOfPresentationDetails" xlink:href="insm-20180930.xsd#CompanyAndBasisOfPresentationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:href="insm-20180930.xsd#ConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="insm-20180930.xsd#ConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="insm-20180930.xsd#ConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnauditedParenthetical" xlink:href="insm-20180930.xsd#ConsolidatedStatementsOfCashFlowsUnauditedParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited" xlink:href="insm-20180930.xsd#ConsolidatedStatementsOfComprehensiveLossUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/Debt" xlink:href="insm-20180930.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/DebtComponentsOfDebtDetails" xlink:href="insm-20180930.xsd#DebtComponentsOfDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/DebtFuturePrincipalRepaymentsOfDebtDetails" xlink:href="insm-20180930.xsd#DebtFuturePrincipalRepaymentsOfDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/DebtInterestExpenseDetails" xlink:href="insm-20180930.xsd#DebtInterestExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/DebtNarrativeDetails" xlink:href="insm-20180930.xsd#DebtNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/DebtTables" xlink:href="insm-20180930.xsd#DebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/DocumentAndEntityInformation" xlink:href="insm-20180930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxes" xlink:href="insm-20180930.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxesDetails" xlink:href="insm-20180930.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/IntangibleAssets" xlink:href="insm-20180930.xsd#IntangibleAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/IntangibleAssetsNarrativeDetails" xlink:href="insm-20180930.xsd#IntangibleAssetsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails" xlink:href="insm-20180930.xsd#IntangibleAssetsScheduleOfIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/IntangibleAssetsTables" xlink:href="insm-20180930.xsd#IntangibleAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/ShareholdersEquity" xlink:href="insm-20180930.xsd#ShareholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/ShareholdersEquityChangesInShareholdersEquityDetails" xlink:href="insm-20180930.xsd#ShareholdersEquityChangesInShareholdersEquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/ShareholdersEquityNarrativeDetails" xlink:href="insm-20180930.xsd#ShareholdersEquityNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/ShareholdersEquityTables" xlink:href="insm-20180930.xsd#ShareholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensation" xlink:href="insm-20180930.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" xlink:href="insm-20180930.xsd#StockBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails" xlink:href="insm-20180930.xsd#StockBasedCompensationRangeOfExercisePricesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails" xlink:href="insm-20180930.xsd#StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails" xlink:href="insm-20180930.xsd#StockBasedCompensationStockOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensationTables" xlink:href="insm-20180930.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="insm-20180930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesDetails" xlink:href="insm-20180930.xsd#SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails" xlink:href="insm-20180930.xsd#SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:href="insm-20180930.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails" xlink:href="insm-20180930.xsd#SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="insm-20180930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesRecentlyAdoptedAccountingPronouncementsDetails" xlink:href="insm-20180930.xsd#SummaryOfSignificantAccountingPoliciesRecentlyAdoptedAccountingPronouncementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="insm-20180930.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.insmed.com/role/AccruedExpenses" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_38892222733E520EAB96390F204A5592" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_AB74A6BE2D4754DB9B57F481C62EA93E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_38892222733E520EAB96390F204A5592" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_AB74A6BE2D4754DB9B57F481C62EA93E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_88AA23CEE3324C48336CAC52B232749D" xlink:type="locator" />
    <link:loc xlink:href="insm-20180930.xsd#insm_AccruedClinicalTrialExpenses" xlink:label="loc_insm_AccruedClinicalTrialExpenses_6AEBE55357B800E5E98FAC52B23257D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_88AA23CEE3324C48336CAC52B232749D" xlink:to="loc_insm_AccruedClinicalTrialExpenses_6AEBE55357B800E5E98FAC52B23257D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_83552C555106C719CFAEAC52B233E5FA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_88AA23CEE3324C48336CAC52B232749D" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_83552C555106C719CFAEAC52B233E5FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_3B80844923CF7AC8A6EBAC52B233748F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_88AA23CEE3324C48336CAC52B232749D" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_3B80844923CF7AC8A6EBAC52B233748F" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_AccruedTechnicalOperationExpenses" xlink:label="loc_insm_AccruedTechnicalOperationExpenses_3D1425D4C6543ECC6D4CAC52B2338164" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_88AA23CEE3324C48336CAC52B232749D" xlink:to="loc_insm_AccruedTechnicalOperationExpenses_3D1425D4C6543ECC6D4CAC52B2338164" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_AccruedMilestonePaymentCurrent" xlink:label="loc_insm_AccruedMilestonePaymentCurrent_5DBFE219F584D94D89EEAC5C71421100" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_88AA23CEE3324C48336CAC52B232749D" xlink:to="loc_insm_AccruedMilestonePaymentCurrent_5DBFE219F584D94D89EEAC5C71421100" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_B1E5F25380192DEC4B76AC52B23375C7" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_88AA23CEE3324C48336CAC52B232749D" xlink:to="loc_us-gaap_InterestPayableCurrent_B1E5F25380192DEC4B76AC52B23375C7" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_AccruedConstructionLiabilitiesCurrent" xlink:label="loc_insm_AccruedConstructionLiabilitiesCurrent_F8011470B2BB3D4B73DAAC52B234D4BC" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_88AA23CEE3324C48336CAC52B232749D" xlink:to="loc_insm_AccruedConstructionLiabilitiesCurrent_F8011470B2BB3D4B73DAAC52B234D4BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_0430F3E63AB52ED815A4AC52B2345470" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_88AA23CEE3324C48336CAC52B232749D" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_0430F3E63AB52ED815A4AC52B2345470" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8DB9DCD65315EA073215AC52B2348B65" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_88AA23CEE3324C48336CAC52B232749D" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_8DB9DCD65315EA073215AC52B2348B65" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/AccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_54284E08C4395FCC8D62BDB4E5CDBD68" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_8381461FF35F544699CF5750BD342E33" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_54284E08C4395FCC8D62BDB4E5CDBD68" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_8381461FF35F544699CF5750BD342E33" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/CommitmentsAndContingencies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_C1C1956D26C45A02B015B1BF8D3441B4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_F01BFA962A635CD4AC98B2D01CBBA243" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_C1C1956D26C45A02B015B1BF8D3441B4" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_F01BFA962A635CD4AC98B2D01CBBA243" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/CommitmentsAndContingenciesMinimumRentalPaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5C8E53E7B5C6F1FC91048222F2E668E3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_86D7198DE967F3B109B58222F2E6ABDF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5C8E53E7B5C6F1FC91048222F2E668E3" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_86D7198DE967F3B109B58222F2E6ABDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_211192FF1C014C99D1A98222F2E60798" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_86D7198DE967F3B109B58222F2E6ABDF" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_211192FF1C014C99D1A98222F2E60798" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_5CABF39467EA4A88727F8222F2E6BB3A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_86D7198DE967F3B109B58222F2E6ABDF" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_5CABF39467EA4A88727F8222F2E6BB3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_AA26531B81CC63FF94E18222F2E6D7BC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_86D7198DE967F3B109B58222F2E6ABDF" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_AA26531B81CC63FF94E18222F2E6D7BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_5CFB8D50B0C5E14040458222F2E8D405" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_86D7198DE967F3B109B58222F2E6ABDF" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_5CFB8D50B0C5E14040458222F2E8D405" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_79CDE8E1AB8579E15D6B8222F2E85FDE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_86D7198DE967F3B109B58222F2E6ABDF" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_79CDE8E1AB8579E15D6B8222F2E85FDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_35E6AEC5526966FE04E58222F2E8E286" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_86D7198DE967F3B109B58222F2E6ABDF" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_35E6AEC5526966FE04E58222F2E8E286" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_FDFF820639BEBD6762F48222F2E9C98C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_86D7198DE967F3B109B58222F2E6ABDF" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_FDFF820639BEBD6762F48222F2E9C98C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1CA875CD670F63A27862AC58EA3B46F0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_779F2EFF1DFA7F854243AC58EA4493B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1CA875CD670F63A27862AC58EA3B46F0" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_779F2EFF1DFA7F854243AC58EA4493B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="loc_us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_98CC0CDDBAA13AA97847AC58EA446EB4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_779F2EFF1DFA7F854243AC58EA4493B3" xlink:to="loc_us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_98CC0CDDBAA13AA97847AC58EA446EB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="loc_us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_95AAEDA2D543B8214A2AAC58EA440B67" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_98CC0CDDBAA13AA97847AC58EA446EB4" xlink:to="loc_us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_95AAEDA2D543B8214A2AAC58EA440B67" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_BridgewaterNewJerseyFacilityMember" xlink:label="loc_insm_BridgewaterNewJerseyFacilityMember_56E96F2AF56EC6CC6D99AC58EA45D772" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_95AAEDA2D543B8214A2AAC58EA440B67" xlink:to="loc_insm_BridgewaterNewJerseyFacilityMember_56E96F2AF56EC6CC6D99AC58EA45D772" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_BridgewaterNewJerseyOfficeSpaceMember" xlink:label="loc_insm_BridgewaterNewJerseyOfficeSpaceMember_3FD0C61F1B1A4C0CB1B1AC58EA45B0A8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_95AAEDA2D543B8214A2AAC58EA440B67" xlink:to="loc_insm_BridgewaterNewJerseyOfficeSpaceMember_3FD0C61F1B1A4C0CB1B1AC58EA45B0A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_43B005EA778C5FE8863FAC58EA451D17" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_779F2EFF1DFA7F854243AC58EA4493B3" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_43B005EA778C5FE8863FAC58EA451D17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_24AF02F68AEACA6DC1CCAC58EA459161" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_43B005EA778C5FE8863FAC58EA451D17" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_24AF02F68AEACA6DC1CCAC58EA459161" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_AdditionalLaboratorySpaceOperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_insm_AdditionalLaboratorySpaceOperatingLeasesFutureMinimumPaymentsDue_7F0B07071F322C8BA06EAC58EA4640C2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_43B005EA778C5FE8863FAC58EA451D17" xlink:to="loc_insm_AdditionalLaboratorySpaceOperatingLeasesFutureMinimumPaymentsDue_7F0B07071F322C8BA06EAC58EA4640C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_D4FE0F52497C5FA1C114AC58EA46C15C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_43B005EA778C5FE8863FAC58EA451D17" xlink:to="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_D4FE0F52497C5FA1C114AC58EA46C15C" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_LesseeOperatingLeaseNumberOfRenewals" xlink:label="loc_insm_LesseeOperatingLeaseNumberOfRenewals_54BD7C4154E59CBB7205AC58EA46108B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_43B005EA778C5FE8863FAC58EA451D17" xlink:to="loc_insm_LesseeOperatingLeaseNumberOfRenewals_54BD7C4154E59CBB7205AC58EA46108B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_E45475F47DDAF8F2E4DBAC58EA461885" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_43B005EA778C5FE8863FAC58EA451D17" xlink:to="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_E45475F47DDAF8F2E4DBAC58EA461885" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_7CDE46DECE23B73A51D0AC58EA4659D6" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_43B005EA778C5FE8863FAC58EA451D17" xlink:to="loc_us-gaap_LeaseAndRentalExpense_7CDE46DECE23B73A51D0AC58EA4659D6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/CommitmentsAndContingenciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_963FC2B23DC95A26A1277A21761DD9C6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_9D7B2DDD31E05826B41270224221604D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_963FC2B23DC95A26A1277A21761DD9C6" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_9D7B2DDD31E05826B41270224221604D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/CompanyAndBasisOfPresentation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0EC1E07B4249599EB59BE109735374A6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_35B2EE0FC6E457A3BE26E52E4CF04A3C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0EC1E07B4249599EB59BE109735374A6" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_35B2EE0FC6E457A3BE26E52E4CF04A3C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/CompanyAndBasisOfPresentationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5A0EAC0FC0FBB8494973A147620DFC93" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_385F3CC2EC4BBDB5F207A147620E2123" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5A0EAC0FC0FBB8494973A147620DFC93" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_385F3CC2EC4BBDB5F207A147620E2123" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_06E8AAB86F53AA312B2FA147620E1141" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5A0EAC0FC0FBB8494973A147620DFC93" xlink:to="loc_us-gaap_NetIncomeLoss_06E8AAB86F53AA312B2FA147620E1141" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_3AB4D00FAE86AFE454E28222F4720325" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_774FE4C3C9BB63559ACB8222F472F8CA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3AB4D00FAE86AFE454E28222F4720325" xlink:to="loc_us-gaap_AssetsAbstract_774FE4C3C9BB63559ACB8222F472F8CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_0B9D9C157F2E17911A388222F4722769" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_774FE4C3C9BB63559ACB8222F472F8CA" xlink:to="loc_us-gaap_AssetsCurrentAbstract_0B9D9C157F2E17911A388222F4722769" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4A6879B58B6DC3AD49F18222F473121E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0B9D9C157F2E17911A388222F4722769" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4A6879B58B6DC3AD49F18222F473121E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_DC8A837085E46903F8D78222F47351CB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0B9D9C157F2E17911A388222F4722769" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_DC8A837085E46903F8D78222F47351CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_38AB23C456FF7B35E9E78222F4744E11" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0B9D9C157F2E17911A388222F4722769" xlink:to="loc_us-gaap_AssetsCurrent_38AB23C456FF7B35E9E78222F4744E11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_357A08C4692B8740BF5E8242BC68FD2B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_774FE4C3C9BB63559ACB8222F472F8CA" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_357A08C4692B8740BF5E8242BC68FD2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_C3DF206D128871A8C30B8222F4747B31" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_774FE4C3C9BB63559ACB8222F472F8CA" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_C3DF206D128871A8C30B8222F4747B31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaap_OtherAssets_82143DBFF2BE8B516BB98222F4746A7F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_774FE4C3C9BB63559ACB8222F472F8CA" xlink:to="loc_us-gaap_OtherAssets_82143DBFF2BE8B516BB98222F4746A7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_7361FA2012744FCC99568222F47537B9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_774FE4C3C9BB63559ACB8222F472F8CA" xlink:to="loc_us-gaap_Assets_7361FA2012744FCC99568222F47537B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_35B542B7C268337470678222F47506FA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3AB4D00FAE86AFE454E28222F4720325" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_35B542B7C268337470678222F47506FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_A58382C7B70905FC07468222F4750A1A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_35B542B7C268337470678222F47506FA" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_A58382C7B70905FC07468222F4750A1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_58496A0BC2F0AA5E48468222F475225C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_A58382C7B70905FC07468222F4750A1A" xlink:to="loc_us-gaap_AccountsPayableCurrent_58496A0BC2F0AA5E48468222F475225C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_2D3A122DA0CB83038C458222F4769504" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_A58382C7B70905FC07468222F4750A1A" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_2D3A122DA0CB83038C458222F4769504" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_EDA224AD31ABDDD761C38222F47620C6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_A58382C7B70905FC07468222F4750A1A" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_EDA224AD31ABDDD761C38222F47620C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_1505C868CADCD0BE02FC8222F476C1E2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_A58382C7B70905FC07468222F4750A1A" xlink:to="loc_us-gaap_LiabilitiesCurrent_1505C868CADCD0BE02FC8222F476C1E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_72FEC3030312F3EF95748222F4762F0D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_35B542B7C268337470678222F47506FA" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_72FEC3030312F3EF95748222F4762F0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_E012004AAD722FF616348222F4778BB3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_35B542B7C268337470678222F47506FA" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_E012004AAD722FF616348222F4778BB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_12AC7C0DB6F1F97841ED8222F47705F1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_35B542B7C268337470678222F47506FA" xlink:to="loc_us-gaap_Liabilities_12AC7C0DB6F1F97841ED8222F47705F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_EA9C21FC2CDCEF53B81D8222F477279F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_35B542B7C268337470678222F47506FA" xlink:to="loc_us-gaap_StockholdersEquityAbstract_EA9C21FC2CDCEF53B81D8222F477279F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_27B541E48837619581B28222F477DC4B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_EA9C21FC2CDCEF53B81D8222F477279F" xlink:to="loc_us-gaap_CommonStockValue_27B541E48837619581B28222F477DC4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_61B9B0A72D8E5652DECD8222F47802ED" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_EA9C21FC2CDCEF53B81D8222F477279F" xlink:to="loc_us-gaap_AdditionalPaidInCapital_61B9B0A72D8E5652DECD8222F47802ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_E7D8EF09925B88B48EBF8222F4787590" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_EA9C21FC2CDCEF53B81D8222F477279F" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_E7D8EF09925B88B48EBF8222F4787590" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0B5B1C53C7278A08D9638222F478635A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_EA9C21FC2CDCEF53B81D8222F477279F" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0B5B1C53C7278A08D9638222F478635A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_09BB709C9D5294CED3B28222F479E889" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_EA9C21FC2CDCEF53B81D8222F477279F" xlink:to="loc_us-gaap_StockholdersEquity_09BB709C9D5294CED3B28222F479E889" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_744D3F0D509E2D65948C8222F479A996" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_35B542B7C268337470678222F47506FA" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_744D3F0D509E2D65948C8222F479A996" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_2D21B9F6B2D15519AB7045EB1CFA91D3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1402EE7B33365182B88F18A46CB142E5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2D21B9F6B2D15519AB7045EB1CFA91D3" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1402EE7B33365182B88F18A46CB142E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_010C564A0564577FA8421DB7E0FFF000" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2D21B9F6B2D15519AB7045EB1CFA91D3" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_010C564A0564577FA8421DB7E0FFF000" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_1C8226C35C6B5E96930C0A59650B8248" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2D21B9F6B2D15519AB7045EB1CFA91D3" xlink:to="loc_us-gaap_CommonStockSharesIssued_1C8226C35C6B5E96930C0A59650B8248" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8DFFF526D8AF55118E6DBEFD31EBC3DC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2D21B9F6B2D15519AB7045EB1CFA91D3" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8DFFF526D8AF55118E6DBEFD31EBC3DC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_6408FE65C4AC6B1597C06FD829A488E6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_22B28EF0782AC5CD8EE36FD829A517EB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6408FE65C4AC6B1597C06FD829A488E6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_22B28EF0782AC5CD8EE36FD829A517EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_41FECEBD4CD32D71265A6FD829A5ED64" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_22B28EF0782AC5CD8EE36FD829A517EB" xlink:to="loc_us-gaap_NetIncomeLoss_41FECEBD4CD32D71265A6FD829A5ED64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2505C4591FC3C3B3B69E6FD829A6816B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_22B28EF0782AC5CD8EE36FD829A517EB" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2505C4591FC3C3B3B69E6FD829A6816B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_0711B03F9FAEA7EE1B436FD829A6DC32" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2505C4591FC3C3B3B69E6FD829A6816B" xlink:to="loc_us-gaap_Depreciation_0711B03F9FAEA7EE1B436FD829A6DC32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_8A3A05B65E618F0ACDD96FD829A7A514" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2505C4591FC3C3B3B69E6FD829A6816B" xlink:to="loc_us-gaap_ShareBasedCompensation_8A3A05B65E618F0ACDD96FD829A7A514" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_D3DCEC9FF10591D2BB2A6FD829A7A5A5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2505C4591FC3C3B3B69E6FD829A6816B" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_D3DCEC9FF10591D2BB2A6FD829A7A5A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_609F565BF20B4FEE613C6FD829A71C5A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2505C4591FC3C3B3B69E6FD829A6816B" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_609F565BF20B4FEE613C6FD829A71C5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccretionExpense" xlink:label="loc_us-gaap_AccretionExpense_682F0185520C1E5D95D06FD829A72D15" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2505C4591FC3C3B3B69E6FD829A6816B" xlink:to="loc_us-gaap_AccretionExpense_682F0185520C1E5D95D06FD829A72D15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_F0DEB99BCD6FAB62EB536FD829A800C8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2505C4591FC3C3B3B69E6FD829A6816B" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_F0DEB99BCD6FAB62EB536FD829A800C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_65365F68595EB727229D6FD829A892BB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_F0DEB99BCD6FAB62EB536FD829A800C8" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_65365F68595EB727229D6FD829A892BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_48C915A1C8777D5A6A506FD829A9C1DD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_F0DEB99BCD6FAB62EB536FD829A800C8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_48C915A1C8777D5A6A506FD829A9C1DD" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities" xlink:label="loc_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities_904290ED9640021EB8906FD829A90869" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_F0DEB99BCD6FAB62EB536FD829A800C8" xlink:to="loc_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities_904290ED9640021EB8906FD829A90869" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_644350EFC6EDCA433DD06FD829A9F60F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_22B28EF0782AC5CD8EE36FD829A517EB" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_644350EFC6EDCA433DD06FD829A9F60F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_289A895691C02FAB2B076FD829A9E6F2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6408FE65C4AC6B1597C06FD829A488E6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_289A895691C02FAB2B076FD829A9E6F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_F080A3AC17EB9BB9621C6FD829AAE036" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_289A895691C02FAB2B076FD829A9E6F2" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_F080A3AC17EB9BB9621C6FD829AAE036" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_54E239159FB7C989493D6FD829AA3D01" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_289A895691C02FAB2B076FD829A9E6F2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_54E239159FB7C989493D6FD829AA3D01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5267A1CD5BFD697B24706FD829AA6FEC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6408FE65C4AC6B1597C06FD829A488E6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5267A1CD5BFD697B24706FD829AA6FEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_18A9E5E0DEEC16A552626FD829AB1E17" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5267A1CD5BFD697B24706FD829AA6FEC" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_18A9E5E0DEEC16A552626FD829AB1E17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_E98A8645E363125A18C66FD829AB7783" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5267A1CD5BFD697B24706FD829AA6FEC" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_E98A8645E363125A18C66FD829AB7783" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_1948A3801C48042CC5286FD829AB00BC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5267A1CD5BFD697B24706FD829AA6FEC" xlink:to="loc_us-gaap_RepaymentsOfDebt_1948A3801C48042CC5286FD829AB00BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_F4CD84B113BEC0DF12C06FD829ACD1B4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5267A1CD5BFD697B24706FD829AA6FEC" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_F4CD84B113BEC0DF12C06FD829ACD1B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_BD05EAE6D242CE74C78B6FD829AC6AC7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5267A1CD5BFD697B24706FD829AA6FEC" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_BD05EAE6D242CE74C78B6FD829AC6AC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_109A3BB3BC10C97B872C6FD829AC0EC3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5267A1CD5BFD697B24706FD829AA6FEC" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_109A3BB3BC10C97B872C6FD829AC0EC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_DACC9424CBF17CF3E69E6FD829AC3433" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5267A1CD5BFD697B24706FD829AA6FEC" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_DACC9424CBF17CF3E69E6FD829AC3433" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_244EDFDAE0411809B2346FD829ADD6B2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6408FE65C4AC6B1597C06FD829A488E6" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_244EDFDAE0411809B2346FD829ADD6B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_CB1686398F8D0068A57E6FD829AD527E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6408FE65C4AC6B1597C06FD829A488E6" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_CB1686398F8D0068A57E6FD829AD527E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_F107EF065C2B8A9E0E636FD829AD2360" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6408FE65C4AC6B1597C06FD829A488E6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_F107EF065C2B8A9E0E636FD829AD2360" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_076FA04B8BB7CA87C0316FD829AD271B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6408FE65C4AC6B1597C06FD829A488E6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_076FA04B8BB7CA87C0316FD829AD271B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_45763AD2FBC41E2BBE2B6FD829AE61AA" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6408FE65C4AC6B1597C06FD829A488E6" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_45763AD2FBC41E2BBE2B6FD829AE61AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_5B3912469E56CB310A7D6FD829AEDF17" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_45763AD2FBC41E2BBE2B6FD829AE61AA" xlink:to="loc_us-gaap_InterestPaidNet_5B3912469E56CB310A7D6FD829AEDF17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_33893344E72A56DC8B746FD829AF8FC0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_45763AD2FBC41E2BBE2B6FD829AE61AA" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_33893344E72A56DC8B746FD829AF8FC0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_B68286B4E5D557CA980E5C3CC001FADA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_E9E67DEC55695EDCB9C023BAC99FB42F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_B68286B4E5D557CA980E5C3CC001FADA" xlink:to="loc_us-gaap_StatementTable_E9E67DEC55695EDCB9C023BAC99FB42F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2DEBD773E5C35AD095EF9D13DA93F5E7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_E9E67DEC55695EDCB9C023BAC99FB42F" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2DEBD773E5C35AD095EF9D13DA93F5E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_37F9F7ACED125DF095E27612E4F2A7AD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2DEBD773E5C35AD095EF9D13DA93F5E7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_37F9F7ACED125DF095E27612E4F2A7AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_91C10855EF4255E882DB5D5117B89185" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_37F9F7ACED125DF095E27612E4F2A7AD" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_91C10855EF4255E882DB5D5117B89185" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_8F14EE79483A5ACFB59D40A421D2F427" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_E9E67DEC55695EDCB9C023BAC99FB42F" xlink:to="loc_us-gaap_DebtInstrumentAxis_8F14EE79483A5ACFB59D40A421D2F427" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_A24B83DE3037523EB66A5DE7C6AA8F61" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_8F14EE79483A5ACFB59D40A421D2F427" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_A24B83DE3037523EB66A5DE7C6AA8F61" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member" xlink:label="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_2D680018F18056D080F17C607FC1A24D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A24B83DE3037523EB66A5DE7C6AA8F61" xlink:to="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_2D680018F18056D080F17C607FC1A24D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_93F0D8CC867E5552853FD29B032455A8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_E9E67DEC55695EDCB9C023BAC99FB42F" xlink:to="loc_us-gaap_StatementLineItems_93F0D8CC867E5552853FD29B032455A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_A377B7A5ED8B5605AFCA7496E38C23CC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_93F0D8CC867E5552853FD29B032455A8" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_A377B7A5ED8B5605AFCA7496E38C23CC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_44ACF47100CE39736BACC147F2009EDC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_F2A8E7DC18EC112A9B79C147F20490ED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_44ACF47100CE39736BACC147F2009EDC" xlink:to="loc_us-gaap_Revenues_F2A8E7DC18EC112A9B79C147F20490ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_1F8B2079A262721866F7C147F207AE36" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_44ACF47100CE39736BACC147F2009EDC" xlink:to="loc_us-gaap_OperatingExpensesAbstract_1F8B2079A262721866F7C147F207AE36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8BB799AE28BB9B57B93DC147F2077646" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1F8B2079A262721866F7C147F207AE36" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8BB799AE28BB9B57B93DC147F2077646" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_B7B47E5E701ECA591909C147F208D97F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1F8B2079A262721866F7C147F207AE36" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_B7B47E5E701ECA591909C147F208D97F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_D71F118A627298F4FA51C147F208D3C5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1F8B2079A262721866F7C147F207AE36" xlink:to="loc_us-gaap_OperatingExpenses_D71F118A627298F4FA51C147F208D3C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_CEAF304C0CC5484C2B79C147F20873BF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_44ACF47100CE39736BACC147F2009EDC" xlink:to="loc_us-gaap_OperatingIncomeLoss_CEAF304C0CC5484C2B79C147F20873BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating_603710D8ECEAF02D6297C147F208A03A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_44ACF47100CE39736BACC147F2009EDC" xlink:to="loc_us-gaap_InvestmentIncomeNonoperating_603710D8ECEAF02D6297C147F208A03A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_BA4B526DAEDB71A26F01C147F2082CA1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_44ACF47100CE39736BACC147F2009EDC" xlink:to="loc_us-gaap_InterestExpense_BA4B526DAEDB71A26F01C147F2082CA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5EDB4131EAC12859D4C0C147F2097265" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_44ACF47100CE39736BACC147F2009EDC" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5EDB4131EAC12859D4C0C147F2097265" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_5C537BD1729CA574D791C147F2094B04" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_44ACF47100CE39736BACC147F2009EDC" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_5C537BD1729CA574D791C147F2094B04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_D8F7997B80447E5C73F7C147F2091774" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_44ACF47100CE39736BACC147F2009EDC" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_D8F7997B80447E5C73F7C147F2091774" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_81B0A7036A9BB7D6143BC147F209BAE6" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_44ACF47100CE39736BACC147F2009EDC" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_81B0A7036A9BB7D6143BC147F209BAE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_50CDDB0CFCF3297F9830C147F209136F" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_44ACF47100CE39736BACC147F2009EDC" xlink:to="loc_us-gaap_NetIncomeLoss_50CDDB0CFCF3297F9830C147F209136F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_16424836EE25455A65F4C147F2098B1A" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_44ACF47100CE39736BACC147F2009EDC" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_16424836EE25455A65F4C147F2098B1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_4B26F76B31219A03F0A8C147F20AE77A" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_44ACF47100CE39736BACC147F2009EDC" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_4B26F76B31219A03F0A8C147F20AE77A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0D77E6A662CEACE376FDC147F20A37D7" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_44ACF47100CE39736BACC147F2009EDC" xlink:to="loc_us-gaap_NetIncomeLoss_0D77E6A662CEACE376FDC147F20A37D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2544EA3537AE19F3BC3BC147F20A7885" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_44ACF47100CE39736BACC147F2009EDC" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2544EA3537AE19F3BC3BC147F20A7885" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_F52C4BC293ED32A9A2DFC147F20ADB70" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2544EA3537AE19F3BC3BC147F20A7885" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_F52C4BC293ED32A9A2DFC147F20ADB70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_C17A7B2BA8AB1D3C9041C147F20A32E4" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_44ACF47100CE39736BACC147F2009EDC" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_C17A7B2BA8AB1D3C9041C147F20A32E4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/Debt" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_26061BAE7959534D8A3A4964308F4A10" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_2680579BEF3C571F8108C024B94E81C4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_26061BAE7959534D8A3A4964308F4A10" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_2680579BEF3C571F8108C024B94E81C4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/DebtComponentsOfDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_EAE800329E865BFEBF9D4ED53E0DD1EB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_0AD5FB52AEF35EC292AAE80DF3176EF9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_EAE800329E865BFEBF9D4ED53E0DD1EB" xlink:to="loc_us-gaap_DebtInstrumentTable_0AD5FB52AEF35EC292AAE80DF3176EF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_FF6AB9E8AD6C52249F533A0873C12F37" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0AD5FB52AEF35EC292AAE80DF3176EF9" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_FF6AB9E8AD6C52249F533A0873C12F37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1B989057D2485A05A3C4715E8CDA57A2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_FF6AB9E8AD6C52249F533A0873C12F37" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1B989057D2485A05A3C4715E8CDA57A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_9FAE1C638A905A6697E5212B9F08E083" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1B989057D2485A05A3C4715E8CDA57A2" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_9FAE1C638A905A6697E5212B9F08E083" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_B39294603CC35B1AAFFEF0D73D15638A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0AD5FB52AEF35EC292AAE80DF3176EF9" xlink:to="loc_us-gaap_DebtInstrumentAxis_B39294603CC35B1AAFFEF0D73D15638A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0598885828F15183AAA9E145E0E1C090" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_B39294603CC35B1AAFFEF0D73D15638A" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0598885828F15183AAA9E145E0E1C090" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member" xlink:label="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_6D12B003B46756369AA937480AF9D119" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0598885828F15183AAA9E145E0E1C090" xlink:to="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_6D12B003B46756369AA937480AF9D119" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_F7AFE2FBF5D35C4D80778EF7C2761AF6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0AD5FB52AEF35EC292AAE80DF3176EF9" xlink:to="loc_us-gaap_DebtInstrumentLineItems_F7AFE2FBF5D35C4D80778EF7C2761AF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SecuredDebt" xlink:label="loc_us-gaap_SecuredDebt_F04999354CDC56358C768B8F415999C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F7AFE2FBF5D35C4D80778EF7C2761AF6" xlink:to="loc_us-gaap_SecuredDebt_F04999354CDC56358C768B8F415999C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1DB5AD7BE3155A56977CB50F157932F2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F7AFE2FBF5D35C4D80778EF7C2761AF6" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1DB5AD7BE3155A56977CB50F157932F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_22A1F07F9C3153D39BE2688FF49920FE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F7AFE2FBF5D35C4D80778EF7C2761AF6" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_22A1F07F9C3153D39BE2688FF49920FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_008BA52216D759F1A8D14544E0AD3187" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F7AFE2FBF5D35C4D80778EF7C2761AF6" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_008BA52216D759F1A8D14544E0AD3187" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_E464BBDC0BA1541BB1AF0035DF531FA9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F7AFE2FBF5D35C4D80778EF7C2761AF6" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_E464BBDC0BA1541BB1AF0035DF531FA9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/DebtFuturePrincipalRepaymentsOfDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_E00909F677AF537399C564BC865528E2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_B9168D6ADCDF5BD98F8D0F844074E18B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_E00909F677AF537399C564BC865528E2" xlink:to="loc_us-gaap_LongTermDebtByMaturityAbstract_B9168D6ADCDF5BD98F8D0F844074E18B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_0776E46C04765AFBA3B2ECC2AD7CA044" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_B9168D6ADCDF5BD98F8D0F844074E18B" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_0776E46C04765AFBA3B2ECC2AD7CA044" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_CA695F1789BC524B83CCE767E838E737" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_B9168D6ADCDF5BD98F8D0F844074E18B" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_CA695F1789BC524B83CCE767E838E737" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_33EBB790ADEB54198C91FADB8A84951B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_B9168D6ADCDF5BD98F8D0F844074E18B" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_33EBB790ADEB54198C91FADB8A84951B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_B7A481199F985E74BB0E0786CE3F123B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_B9168D6ADCDF5BD98F8D0F844074E18B" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_B7A481199F985E74BB0E0786CE3F123B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_7FC3D71048F35FD8927C7AB28A17CE4E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_B9168D6ADCDF5BD98F8D0F844074E18B" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_7FC3D71048F35FD8927C7AB28A17CE4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_06FF70DD92C75834BF1212F0921E01EE" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_B9168D6ADCDF5BD98F8D0F844074E18B" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_06FF70DD92C75834BF1212F0921E01EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_71417984935D5EDE8FDC7C67ED82BBDF" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_B9168D6ADCDF5BD98F8D0F844074E18B" xlink:to="loc_us-gaap_LongTermDebt_71417984935D5EDE8FDC7C67ED82BBDF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/DebtInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_CF986D7E7B0B5BEEB6183E3E4B6BF67F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_622F1876C1FF5F9B84FEF2C191D575D8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_CF986D7E7B0B5BEEB6183E3E4B6BF67F" xlink:to="loc_us-gaap_InterestExpenseDebt_622F1876C1FF5F9B84FEF2C191D575D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_7FD9B191CCBE57849B356A8DCBD78042" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_CF986D7E7B0B5BEEB6183E3E4B6BF67F" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_7FD9B191CCBE57849B356A8DCBD78042" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_AmortizationOfBackendFee" xlink:label="loc_insm_AmortizationOfBackendFee_D571620410695010A84FE9EB77ECFEA3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_CF986D7E7B0B5BEEB6183E3E4B6BF67F" xlink:to="loc_insm_AmortizationOfBackendFee_D571620410695010A84FE9EB77ECFEA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_A601B816D609591BBE434F3D03B2BBEC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_CF986D7E7B0B5BEEB6183E3E4B6BF67F" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_A601B816D609591BBE434F3D03B2BBEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_E7626E51FD60577799B60A254B11EB8C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_CF986D7E7B0B5BEEB6183E3E4B6BF67F" xlink:to="loc_us-gaap_InterestExpense_E7626E51FD60577799B60A254B11EB8C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_3FC92BC3CB4E57EA9AF1148FA5B9F04A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_6ECBC424531357CB9B293B81C26EE7A5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3FC92BC3CB4E57EA9AF1148FA5B9F04A" xlink:to="loc_us-gaap_DebtInstrumentTable_6ECBC424531357CB9B293B81C26EE7A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_63D1000106A151958C1970F81DD7C44D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6ECBC424531357CB9B293B81C26EE7A5" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_63D1000106A151958C1970F81DD7C44D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_90196C73615552EFA39455EDF4504AA9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_63D1000106A151958C1970F81DD7C44D" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_90196C73615552EFA39455EDF4504AA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_2C7C3119544B5FA492530FC4C2CBB99D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_90196C73615552EFA39455EDF4504AA9" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_2C7C3119544B5FA492530FC4C2CBB99D" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_DebtInstrumentConversionTermAxis" xlink:label="loc_insm_DebtInstrumentConversionTermAxis_7201507BE3E450508BD3EDB11B1BB7DE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6ECBC424531357CB9B293B81C26EE7A5" xlink:to="loc_insm_DebtInstrumentConversionTermAxis_7201507BE3E450508BD3EDB11B1BB7DE" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_DebtInstrumentConversionTermDomain" xlink:label="loc_insm_DebtInstrumentConversionTermDomain_A7F89F6B1BB855EAAF6D4E7F9971CB22" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_DebtInstrumentConversionTermAxis_7201507BE3E450508BD3EDB11B1BB7DE" xlink:to="loc_insm_DebtInstrumentConversionTermDomain_A7F89F6B1BB855EAAF6D4E7F9971CB22" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_DebtInstrumentConversionTermOneMember" xlink:label="loc_insm_DebtInstrumentConversionTermOneMember_0BAE622129815C4599199CBB6AD912BB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_DebtInstrumentConversionTermDomain_A7F89F6B1BB855EAAF6D4E7F9971CB22" xlink:to="loc_insm_DebtInstrumentConversionTermOneMember_0BAE622129815C4599199CBB6AD912BB" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_DebtInstrumentConversionTermTwoMember" xlink:label="loc_insm_DebtInstrumentConversionTermTwoMember_7CB12083991F564088F94E010BF66922" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_DebtInstrumentConversionTermDomain_A7F89F6B1BB855EAAF6D4E7F9971CB22" xlink:to="loc_insm_DebtInstrumentConversionTermTwoMember_7CB12083991F564088F94E010BF66922" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_DebtInstrumentConversionTermThreeMember" xlink:label="loc_insm_DebtInstrumentConversionTermThreeMember_0D4E82738BB9556FA199A1DB1733C30C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_DebtInstrumentConversionTermDomain_A7F89F6B1BB855EAAF6D4E7F9971CB22" xlink:to="loc_insm_DebtInstrumentConversionTermThreeMember_0D4E82738BB9556FA199A1DB1733C30C" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_DebtInstrumentConversionTermFourMember" xlink:label="loc_insm_DebtInstrumentConversionTermFourMember_146A4966BFDF55C68F963C90CF464FAD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_DebtInstrumentConversionTermDomain_A7F89F6B1BB855EAAF6D4E7F9971CB22" xlink:to="loc_insm_DebtInstrumentConversionTermFourMember_146A4966BFDF55C68F963C90CF464FAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_C666C5455D3B5E4F886E4B8C38333FD1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6ECBC424531357CB9B293B81C26EE7A5" xlink:to="loc_us-gaap_DebtInstrumentAxis_C666C5455D3B5E4F886E4B8C38333FD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_537E20702E0550E480FB79791868ED6F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_C666C5455D3B5E4F886E4B8C38333FD1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_537E20702E0550E480FB79791868ED6F" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member" xlink:label="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_2871A182E3BF5EA9BFFE45F6521B9CB0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_537E20702E0550E480FB79791868ED6F" xlink:to="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_2871A182E3BF5EA9BFFE45F6521B9CB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember_3A54F9D00D6F5A90B032D4579B17E226" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_537E20702E0550E480FB79791868ED6F" xlink:to="loc_us-gaap_LineOfCreditMember_3A54F9D00D6F5A90B032D4579B17E226" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_C41DC04876525570B647A0D76BF3F30B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6ECBC424531357CB9B293B81C26EE7A5" xlink:to="loc_us-gaap_DebtInstrumentLineItems_C41DC04876525570B647A0D76BF3F30B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_36F0407517635CE586BF4642DDFAC9B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C41DC04876525570B647A0D76BF3F30B" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_36F0407517635CE586BF4642DDFAC9B3" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_DebtInstrumentOptionToPurchaseAdditionalDebt" xlink:label="loc_insm_DebtInstrumentOptionToPurchaseAdditionalDebt_545B50DB8BC85295B28569DE61F2E4C2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C41DC04876525570B647A0D76BF3F30B" xlink:to="loc_insm_DebtInstrumentOptionToPurchaseAdditionalDebt_545B50DB8BC85295B28569DE61F2E4C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_29E40E59124D5704B708D4807315D76B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C41DC04876525570B647A0D76BF3F30B" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_29E40E59124D5704B708D4807315D76B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_6EEAC89DC9AE55F08690F9C2FC4EFBAB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C41DC04876525570B647A0D76BF3F30B" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_6EEAC89DC9AE55F08690F9C2FC4EFBAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_40BCAB7B7D5B55659779650BA2EF300D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C41DC04876525570B647A0D76BF3F30B" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_40BCAB7B7D5B55659779650BA2EF300D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_EDEE2C3924B856F3B327A8A2C4326A51" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C41DC04876525570B647A0D76BF3F30B" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_EDEE2C3924B856F3B327A8A2C4326A51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_2ECCCBFFC2755767BA3E155751DD5D24" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C41DC04876525570B647A0D76BF3F30B" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_2ECCCBFFC2755767BA3E155751DD5D24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_2BE5A4523A505966B4C83A14CF9CA517" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C41DC04876525570B647A0D76BF3F30B" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_2BE5A4523A505966B4C83A14CF9CA517" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_7AACF8FD89575370B69118217FC4BE7A" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C41DC04876525570B647A0D76BF3F30B" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_7AACF8FD89575370B69118217FC4BE7A" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange" xlink:label="loc_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange_1D5A1BD002345C81B766809A929C3451" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C41DC04876525570B647A0D76BF3F30B" xlink:to="loc_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange_1D5A1BD002345C81B766809A929C3451" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_42289268E47E5FECBC1B218B1E65C47C" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C41DC04876525570B647A0D76BF3F30B" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_42289268E47E5FECBC1B218B1E65C47C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_1863F5AB19315B7EB8B0D353A14D40E4" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C41DC04876525570B647A0D76BF3F30B" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_1863F5AB19315B7EB8B0D353A14D40E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_336460CCDA675AF7ADFDAB7A80FED141" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C41DC04876525570B647A0D76BF3F30B" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_336460CCDA675AF7ADFDAB7A80FED141" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_FF5C17462C8950BA920E56ECB4F31D92" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C41DC04876525570B647A0D76BF3F30B" xlink:to="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_FF5C17462C8950BA920E56ECB4F31D92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_86DE6ED42139533A89B431DC9FE02A69" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C41DC04876525570B647A0D76BF3F30B" xlink:to="loc_us-gaap_InterestExpense_86DE6ED42139533A89B431DC9FE02A69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_C9EBE0E4EA1A5082AA7D4B7861999D04" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C41DC04876525570B647A0D76BF3F30B" xlink:to="loc_us-gaap_RepaymentsOfDebt_C9EBE0E4EA1A5082AA7D4B7861999D04" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_RepaymentsOfDebtFeesAndOutstandingInterest" xlink:label="loc_insm_RepaymentsOfDebtFeesAndOutstandingInterest_FDA30A388417564D8312B02C4890409A" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C41DC04876525570B647A0D76BF3F30B" xlink:to="loc_insm_RepaymentsOfDebtFeesAndOutstandingInterest_FDA30A388417564D8312B02C4890409A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3E93E492F17E5176998CBBA8342254DB" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_C41DC04876525570B647A0D76BF3F30B" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3E93E492F17E5176998CBBA8342254DB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_C4D0BF693DF3515999AB829CC9AF4801" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_0B7C379D86C5557ABADA5B40F442660D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_C4D0BF693DF3515999AB829CC9AF4801" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_0B7C379D86C5557ABADA5B40F442660D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_AD570A2DD14D5E0F9F4C6149A3EB9EDB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_C4D0BF693DF3515999AB829CC9AF4801" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_AD570A2DD14D5E0F9F4C6149A3EB9EDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_D4360B22292B5CE9963CD5CB494C2EA4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_C4D0BF693DF3515999AB829CC9AF4801" xlink:to="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_D4360B22292B5CE9963CD5CB494C2EA4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:href="insm-20180930.xsd#insm_DocumentAndEntityInformationAbstract" xlink:label="loc_insm_DocumentAndEntityInformationAbstract_C80F0D6AC9834C377E4C821907676822" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_33F2C3E50C04F21870B78219076C453C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_DocumentAndEntityInformationAbstract_C80F0D6AC9834C377E4C821907676822" xlink:to="loc_dei_EntityRegistrantName_33F2C3E50C04F21870B78219076C453C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_4F1AF6612F76126DDA008219076DE176" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_DocumentAndEntityInformationAbstract_C80F0D6AC9834C377E4C821907676822" xlink:to="loc_dei_EntityCentralIndexKey_4F1AF6612F76126DDA008219076DE176" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_722E54C7B03C6F4AC3828219076EB413" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_DocumentAndEntityInformationAbstract_C80F0D6AC9834C377E4C821907676822" xlink:to="loc_dei_DocumentType_722E54C7B03C6F4AC3828219076EB413" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_C309195298A4D7115DA88219076E0C18" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_DocumentAndEntityInformationAbstract_C80F0D6AC9834C377E4C821907676822" xlink:to="loc_dei_DocumentPeriodEndDate_C309195298A4D7115DA88219076E0C18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_7967D5C0E4581475E8B98219076E45B0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_DocumentAndEntityInformationAbstract_C80F0D6AC9834C377E4C821907676822" xlink:to="loc_dei_AmendmentFlag_7967D5C0E4581475E8B98219076E45B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_D038E86451D4EC3C9D078219076E6087" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_DocumentAndEntityInformationAbstract_C80F0D6AC9834C377E4C821907676822" xlink:to="loc_dei_CurrentFiscalYearEndDate_D038E86451D4EC3C9D078219076E6087" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_E6DC506555050F4B93AD8219076EF43D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_DocumentAndEntityInformationAbstract_C80F0D6AC9834C377E4C821907676822" xlink:to="loc_dei_EntityCurrentReportingStatus_E6DC506555050F4B93AD8219076EF43D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_529EFC7FF5A0640136158219076F030F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_DocumentAndEntityInformationAbstract_C80F0D6AC9834C377E4C821907676822" xlink:to="loc_dei_EntityFilerCategory_529EFC7FF5A0640136158219076F030F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_FFDF03F39A5046D330908219076FDB7C" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_DocumentAndEntityInformationAbstract_C80F0D6AC9834C377E4C821907676822" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_FFDF03F39A5046D330908219076FDB7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_23364921CD15D198C9D58219076FDDC7" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_DocumentAndEntityInformationAbstract_C80F0D6AC9834C377E4C821907676822" xlink:to="loc_dei_DocumentFiscalYearFocus_23364921CD15D198C9D58219076FDDC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_24FC0A07367AD7083E1C8219076FF4FD" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_DocumentAndEntityInformationAbstract_C80F0D6AC9834C377E4C821907676822" xlink:to="loc_dei_DocumentFiscalPeriodFocus_24FC0A07367AD7083E1C8219076FF4FD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_5ED5DAF93B6A51C4902EFB22D72B5C5C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_CFEEE6152BF250868E9C16A4F1F73FBA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5ED5DAF93B6A51C4902EFB22D72B5C5C" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_CFEEE6152BF250868E9C16A4F1F73FBA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2F9FFFE2BC555D8786A25034843A43E2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2811FDFC42255D4A8D9B262C10E50B48" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2F9FFFE2BC555D8786A25034843A43E2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2811FDFC42255D4A8D9B262C10E50B48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_FF28F2E739D65A5C813CAC4D6D10601D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2F9FFFE2BC555D8786A25034843A43E2" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_FF28F2E739D65A5C813CAC4D6D10601D" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" xlink:label="loc_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_25179CEF8F2259DEAE5212779B5239F4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2F9FFFE2BC555D8786A25034843A43E2" xlink:to="loc_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_25179CEF8F2259DEAE5212779B5239F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_918A5AD59B5B5F8DB280F5B1A8362659" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2F9FFFE2BC555D8786A25034843A43E2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_918A5AD59B5B5F8DB280F5B1A8362659" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/IntangibleAssets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8D294BFB3D5B663A6194821BE5F850BF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_33AB9B3A0A8118DEE8D0821BE5F83030" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8D294BFB3D5B663A6194821BE5F850BF" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_33AB9B3A0A8118DEE8D0821BE5F83030" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/IntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7EF481B1B6F01FBAC95DAC52B244A9A0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_647248AF31F6DEEBFB3FAC52B2454D1D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7EF481B1B6F01FBAC95DAC52B244A9A0" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_647248AF31F6DEEBFB3FAC52B2454D1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_024272AB2F79429520EDAC52B245803F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_647248AF31F6DEEBFB3FAC52B2454D1D" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_024272AB2F79429520EDAC52B245803F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_353913F729A81CEA226AAC52B2455162" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_024272AB2F79429520EDAC52B245803F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_353913F729A81CEA226AAC52B2455162" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_7AC77EBE9D6065868C0CAC52B24669AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_353913F729A81CEA226AAC52B2455162" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_7AC77EBE9D6065868C0CAC52B24669AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_DE6EC94AABB3F3EE3585AC52B2462C84" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_647248AF31F6DEEBFB3FAC52B2454D1D" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_DE6EC94AABB3F3EE3585AC52B2462C84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1111BD7530FDD79FBA67AC52B246C331" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_DE6EC94AABB3F3EE3585AC52B2462C84" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1111BD7530FDD79FBA67AC52B246C331" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_AccruedMilestonePaymentCurrent" xlink:label="loc_insm_AccruedMilestonePaymentCurrent_D34C9B6F484149238950AC5CCF9B844B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_DE6EC94AABB3F3EE3585AC52B2462C84" xlink:to="loc_insm_AccruedMilestonePaymentCurrent_D34C9B6F484149238950AC5CCF9B844B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_47672B67B44376FF4DB2AC52B2470EAD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_DE6EC94AABB3F3EE3585AC52B2462C84" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_47672B67B44376FF4DB2AC52B2470EAD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_41154CE2831B7035DAD7AC3F2E324E02" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4D434AC826641A68234BAC3F2E325F95" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_41154CE2831B7035DAD7AC3F2E324E02" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4D434AC826641A68234BAC3F2E325F95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C04D24EBF34C58CBE72AAC3F2E327FBA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4D434AC826641A68234BAC3F2E325F95" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C04D24EBF34C58CBE72AAC3F2E327FBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B287AED4AB1BDEC06DA9AC3F2E32885A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C04D24EBF34C58CBE72AAC3F2E327FBA" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B287AED4AB1BDEC06DA9AC3F2E32885A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_345755D287514E679F93AC3F2E33C7FB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B287AED4AB1BDEC06DA9AC3F2E32885A" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_345755D287514E679F93AC3F2E33C7FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_1A4719054CBB9E913DB7AC3F2E3392DA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B287AED4AB1BDEC06DA9AC3F2E32885A" xlink:to="loc_us-gaap_LicensingAgreementsMember_1A4719054CBB9E913DB7AC3F2E3392DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_26A7930BA6D7835D42C4AC3F2E334C02" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4D434AC826641A68234BAC3F2E325F95" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_26A7930BA6D7835D42C4AC3F2E334C02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_D96E77306C3153DBED0EAC3F2E337923" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_26A7930BA6D7835D42C4AC3F2E334C02" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_D96E77306C3153DBED0EAC3F2E337923" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/IntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_C2E1B7B8FE52ADDFD8368222DED35F54" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_6EE839370798D28469FC8222DEF422E6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_C2E1B7B8FE52ADDFD8368222DED35F54" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_6EE839370798D28469FC8222DEF422E6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/ShareholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_2B0B6186A5E557A3AD189E95C9D41226" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_842F77DD112E5444B7CB2295EA500442" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2B0B6186A5E557A3AD189E95C9D41226" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_842F77DD112E5444B7CB2295EA500442" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/ShareholdersEquityChangesInShareholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_ECBBD7F5CC3FF64951E78222F35D6CFC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_653B8B8FF6040785F9918222F35D00A9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ECBBD7F5CC3FF64951E78222F35D6CFC" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_653B8B8FF6040785F9918222F35D00A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_45AFAAF568BFC92414788222F35E14CD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_653B8B8FF6040785F9918222F35D00A9" xlink:to="loc_us-gaap_StockholdersEquity_45AFAAF568BFC92414788222F35E14CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_DDE602685B55017D91858222F35E955A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_653B8B8FF6040785F9918222F35D00A9" xlink:to="loc_us-gaap_NetIncomeLoss_DDE602685B55017D91858222F35E955A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_F386A82CED53F2C100978222F35F8CF5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_653B8B8FF6040785F9918222F35D00A9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_F386A82CED53F2C100978222F35F8CF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_E601CF9D94A11F0A95A18222F35F0939" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_653B8B8FF6040785F9918222F35D00A9" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_E601CF9D94A11F0A95A18222F35F0939" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_C05E1C8B88132F802B208222F35F4EE8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_653B8B8FF6040785F9918222F35D00A9" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_C05E1C8B88132F802B208222F35F4EE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_6D99F708433465FB10278222F35F2326" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_653B8B8FF6040785F9918222F35D00A9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_6D99F708433465FB10278222F35F2326" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_A4BD3A3560843154C6638222F35F7C52" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_653B8B8FF6040785F9918222F35D00A9" xlink:to="loc_us-gaap_StockholdersEquity_A4BD3A3560843154C6638222F35F7C52" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/ShareholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_5D58479515A45826A12ECE224AA38EF9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1406145270A4598C8D33ADF1664C9307" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5D58479515A45826A12ECE224AA38EF9" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1406145270A4598C8D33ADF1664C9307" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2E037A9E7C1950A6A2DC060D430C6993" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1406145270A4598C8D33ADF1664C9307" xlink:to="loc_us-gaap_DebtInstrumentAxis_2E037A9E7C1950A6A2DC060D430C6993" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0210A78EFDE3575788F3AFBE18344302" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2E037A9E7C1950A6A2DC060D430C6993" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0210A78EFDE3575788F3AFBE18344302" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member" xlink:label="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_111753AE5DEA5A9B8893072918232BDA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0210A78EFDE3575788F3AFBE18344302" xlink:to="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_111753AE5DEA5A9B8893072918232BDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_0A9C66524FA05BC2AE7C1633CC2DB61F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1406145270A4598C8D33ADF1664C9307" xlink:to="loc_us-gaap_AwardTypeAxis_0A9C66524FA05BC2AE7C1633CC2DB61F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CBAE01F62CDB5C05ADA69653E3609615" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0A9C66524FA05BC2AE7C1633CC2DB61F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CBAE01F62CDB5C05ADA69653E3609615" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_EmployeeAndDirectorsStockOptionsMember" xlink:label="loc_insm_EmployeeAndDirectorsStockOptionsMember_4C34ADA34A835D1E89FA071B50213548" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CBAE01F62CDB5C05ADA69653E3609615" xlink:to="loc_insm_EmployeeAndDirectorsStockOptionsMember_4C34ADA34A835D1E89FA071B50213548" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_A8C65DAD2A6D5B19806821F1617B2EB9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CBAE01F62CDB5C05ADA69653E3609615" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_A8C65DAD2A6D5B19806821F1617B2EB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5FE0535CEE415572BE81298F8FF3F518" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1406145270A4598C8D33ADF1664C9307" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5FE0535CEE415572BE81298F8FF3F518" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5916417D6371526C8BBCAFA0251482C6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5FE0535CEE415572BE81298F8FF3F518" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5916417D6371526C8BBCAFA0251482C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_EDB9356F0B92572D9C15C7E213E03D8F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5916417D6371526C8BBCAFA0251482C6" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_EDB9356F0B92572D9C15C7E213E03D8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_4DC440B4ACBE5479A36AAD513366124E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1406145270A4598C8D33ADF1664C9307" xlink:to="loc_us-gaap_ClassOfStockLineItems_4DC440B4ACBE5479A36AAD513366124E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_DAB2CA2A8AA55D1687C2303C7A8D575D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4DC440B4ACBE5479A36AAD513366124E" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_DAB2CA2A8AA55D1687C2303C7A8D575D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5C10142B4840560A8E3D32D69C923EA3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4DC440B4ACBE5479A36AAD513366124E" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5C10142B4840560A8E3D32D69C923EA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_61C39E54AE645AC18342E3276E774CA1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4DC440B4ACBE5479A36AAD513366124E" xlink:to="loc_us-gaap_CommonStockSharesIssued_61C39E54AE645AC18342E3276E774CA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1E196B845F7D544F8233BEE80C7E3C4E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4DC440B4ACBE5479A36AAD513366124E" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1E196B845F7D544F8233BEE80C7E3C4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_A629A7F20DAE550F8917371CD430E27E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4DC440B4ACBE5479A36AAD513366124E" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_A629A7F20DAE550F8917371CD430E27E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2EFA641D84C75A268F8C0A5A2EE04BE7" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4DC440B4ACBE5479A36AAD513366124E" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2EFA641D84C75A268F8C0A5A2EE04BE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_B2FE23948C4F5CF492FF56B968397948" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4DC440B4ACBE5479A36AAD513366124E" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_B2FE23948C4F5CF492FF56B968397948" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_A50857335B405834836D145B96B9C8D2" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4DC440B4ACBE5479A36AAD513366124E" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_A50857335B405834836D145B96B9C8D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_D65B987E35F25567B00EDB4DC542F0BE" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4DC440B4ACBE5479A36AAD513366124E" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_D65B987E35F25567B00EDB4DC542F0BE" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption" xlink:label="loc_insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption_65225E076D045BACAB25A56D75CE4227" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4DC440B4ACBE5479A36AAD513366124E" xlink:to="loc_insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption_65225E076D045BACAB25A56D75CE4227" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_4D7E0165131554569E046388862D716A" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4DC440B4ACBE5479A36AAD513366124E" xlink:to="loc_us-gaap_SharePrice_4D7E0165131554569E046388862D716A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_43098723806C5D9BB9668F35CD8118B9" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4DC440B4ACBE5479A36AAD513366124E" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_43098723806C5D9BB9668F35CD8118B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9150930775C55061B5400D98295BD770" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4DC440B4ACBE5479A36AAD513366124E" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9150930775C55061B5400D98295BD770" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_B8E035705B585351816E0FB1CF1137B5" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4DC440B4ACBE5479A36AAD513366124E" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_B8E035705B585351816E0FB1CF1137B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_29A126212CC05CC0B7913FD4466F6393" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4DC440B4ACBE5479A36AAD513366124E" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_29A126212CC05CC0B7913FD4466F6393" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_F5F9E48F02BD52748E8F35B198D13617" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4DC440B4ACBE5479A36AAD513366124E" xlink:to="loc_us-gaap_PreferredStockSharesIssued_F5F9E48F02BD52748E8F35B198D13617" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_E15257B492815EFC85DC8CF250EB79BA" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4DC440B4ACBE5479A36AAD513366124E" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_E15257B492815EFC85DC8CF250EB79BA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/ShareholdersEquityTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_48A8FD6E537B54EC95516CBE982771E2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_E3E527F29A375F0A894FA8764B954399" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_48A8FD6E537B54EC95516CBE982771E2" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_E3E527F29A375F0A894FA8764B954399" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3E2014F9BDC05DDB9499C748D4688EDC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_06E570FE834759F3A9F6A4BB1EB9233A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3E2014F9BDC05DDB9499C748D4688EDC" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_06E570FE834759F3A9F6A4BB1EB9233A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_28ED880003813B6F7F01C148098CAFE1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_406C6AFA718704FFAFF9C148098C904C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_28ED880003813B6F7F01C148098CAFE1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_406C6AFA718704FFAFF9C148098C904C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_8E88FEE58A71C5A087A8C148098D8523" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_406C6AFA718704FFAFF9C148098C904C" xlink:to="loc_us-gaap_PlanNameAxis_8E88FEE58A71C5A087A8C148098D8523" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_666446A6C0C686BE6948C148098D8B1F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_8E88FEE58A71C5A087A8C148098D8523" xlink:to="loc_us-gaap_PlanNameDomain_666446A6C0C686BE6948C148098D8B1F" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_EmployeeStockPurchasePlan2018Member" xlink:label="loc_insm_EmployeeStockPurchasePlan2018Member_C2A76D89F13EA4CB1ACAC148098DF461" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_666446A6C0C686BE6948C148098D8B1F" xlink:to="loc_insm_EmployeeStockPurchasePlan2018Member_C2A76D89F13EA4CB1ACAC148098DF461" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_F889FFBB7B47F438EEAEC148098ED2AD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_406C6AFA718704FFAFF9C148098C904C" xlink:to="loc_us-gaap_AwardTypeAxis_F889FFBB7B47F438EEAEC148098ED2AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0C7E5D356AD2BFB860E0C148098EB962" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_F889FFBB7B47F438EEAEC148098ED2AD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0C7E5D356AD2BFB860E0C148098EB962" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_1D17F4FFE9002B1CCA8BC148098F0122" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0C7E5D356AD2BFB860E0C148098EB962" xlink:to="loc_us-gaap_PerformanceSharesMember_1D17F4FFE9002B1CCA8BC148098F0122" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A4A0CB37DF50D90F267BC148098F67FE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_406C6AFA718704FFAFF9C148098C904C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A4A0CB37DF50D90F267BC148098F67FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_456DFDF348508A72EE74C148098F0A05" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A4A0CB37DF50D90F267BC148098F67FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_456DFDF348508A72EE74C148098F0A05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0DF3E650E46F91FB0645C148099057A7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A4A0CB37DF50D90F267BC148098F67FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0DF3E650E46F91FB0645C148099057A7" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross" xlink:label="loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross_37CA1BE775FF8EF4EB1EC148099070B8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A4A0CB37DF50D90F267BC148098F67FE" xlink:to="loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross_37CA1BE775FF8EF4EB1EC148099070B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_44365255D9873063D8EAC14809901481" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A4A0CB37DF50D90F267BC148098F67FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_44365255D9873063D8EAC14809901481" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_B56F01959497ECB7AEECC1480990C527" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A4A0CB37DF50D90F267BC148098F67FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_B56F01959497ECB7AEECC1480990C527" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_8C21E40A6D807704E56AC1480990C05F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A4A0CB37DF50D90F267BC148098F67FE" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_8C21E40A6D807704E56AC1480990C05F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_AC7F6A07F3E839928959C1480991417B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A4A0CB37DF50D90F267BC148098F67FE" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_AC7F6A07F3E839928959C1480991417B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2E8FC7B2FE15A4E12333C14809911EAD" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A4A0CB37DF50D90F267BC148098F67FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2E8FC7B2FE15A4E12333C14809911EAD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3C72DC7CA77D6BCD02CBBECA425DC050" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_ACC2E24D0412676BA649BECA425D3CE3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3C72DC7CA77D6BCD02CBBECA425DC050" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_ACC2E24D0412676BA649BECA425D3CE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_762DCB913A7C350AAA5CBECA425EE9D8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_ACC2E24D0412676BA649BECA425D3CE3" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_762DCB913A7C350AAA5CBECA425EE9D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_250632757FC8172548C8BECA425E0F76" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_762DCB913A7C350AAA5CBECA425EE9D8" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_250632757FC8172548C8BECA425E0F76" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_Range1Member" xlink:label="loc_insm_Range1Member_7DCCA95ECF2DD4779C7CBECA425E24C2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_250632757FC8172548C8BECA425E0F76" xlink:to="loc_insm_Range1Member_7DCCA95ECF2DD4779C7CBECA425E24C2" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_Range2Member" xlink:label="loc_insm_Range2Member_D2818585F4758CC12782BECA425FE155" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_250632757FC8172548C8BECA425E0F76" xlink:to="loc_insm_Range2Member_D2818585F4758CC12782BECA425FE155" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_Range3Member" xlink:label="loc_insm_Range3Member_382E8EA41DA15E0DC520BECA425FD214" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_250632757FC8172548C8BECA425E0F76" xlink:to="loc_insm_Range3Member_382E8EA41DA15E0DC520BECA425FD214" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_Range4Member" xlink:label="loc_insm_Range4Member_A5D29416DB8B4E020553BECA425FA5BB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_250632757FC8172548C8BECA425E0F76" xlink:to="loc_insm_Range4Member_A5D29416DB8B4E020553BECA425FA5BB" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_Range5Member" xlink:label="loc_insm_Range5Member_DFC0AD92F3105687D42BBECA425FB8C2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_250632757FC8172548C8BECA425E0F76" xlink:to="loc_insm_Range5Member_DFC0AD92F3105687D42BBECA425FB8C2" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_Range6Member" xlink:label="loc_insm_Range6Member_DDE16ABF6557A3A9A24ABECA425FB0EE" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_250632757FC8172548C8BECA425E0F76" xlink:to="loc_insm_Range6Member_DDE16ABF6557A3A9A24ABECA425FB0EE" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_Range7Member" xlink:label="loc_insm_Range7Member_DD55379B0AED6765BD86BECA425FE2CF" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_250632757FC8172548C8BECA425E0F76" xlink:to="loc_insm_Range7Member_DD55379B0AED6765BD86BECA425FE2CF" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_Range8Member" xlink:label="loc_insm_Range8Member_BC2E8CCCC4CF296E7986BECA4260EC1F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_250632757FC8172548C8BECA425E0F76" xlink:to="loc_insm_Range8Member_BC2E8CCCC4CF296E7986BECA4260EC1F" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_Range9Member" xlink:label="loc_insm_Range9Member_747E5AFE504CC200805EBECA42600AF2" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_250632757FC8172548C8BECA425E0F76" xlink:to="loc_insm_Range9Member_747E5AFE504CC200805EBECA42600AF2" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_Range10Member" xlink:label="loc_insm_Range10Member_8036ECD09DBD16A9DCA9BECA42604214" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_250632757FC8172548C8BECA425E0F76" xlink:to="loc_insm_Range10Member_8036ECD09DBD16A9DCA9BECA42604214" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_C500752134F13BB57704BECA42608315" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_ACC2E24D0412676BA649BECA425D3CE3" xlink:to="loc_us-gaap_AwardTypeAxis_C500752134F13BB57704BECA42608315" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_416BB31DFF130451E98EBECA4260BEA6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_C500752134F13BB57704BECA42608315" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_416BB31DFF130451E98EBECA4260BEA6" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_EmployeeAndDirectorsStockOptionsMember" xlink:label="loc_insm_EmployeeAndDirectorsStockOptionsMember_5F54122BDF34B6C95DA2BECA42614520" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_416BB31DFF130451E98EBECA4260BEA6" xlink:to="loc_insm_EmployeeAndDirectorsStockOptionsMember_5F54122BDF34B6C95DA2BECA42614520" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_B1CB273A774F540F88ACBECA4261B6FA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_ACC2E24D0412676BA649BECA425D3CE3" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_B1CB273A774F540F88ACBECA4261B6FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_51D1C23EBC30332F6C1DBECA42629059" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_B1CB273A774F540F88ACBECA4261B6FA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_51D1C23EBC30332F6C1DBECA42629059" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_6B7F75E4F1DF7E500C0EBECA42622E27" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_B1CB273A774F540F88ACBECA4261B6FA" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_6B7F75E4F1DF7E500C0EBECA42622E27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_F25265C7E38B4F7553DABECA426233C3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_B1CB273A774F540F88ACBECA4261B6FA" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_F25265C7E38B4F7553DABECA426233C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_76F3CF54915C282F1509BECA426275BB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_B1CB273A774F540F88ACBECA4261B6FA" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_76F3CF54915C282F1509BECA426275BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_F370AF5928D1E6E3705DBECA426352B6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_B1CB273A774F540F88ACBECA4261B6FA" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_F370AF5928D1E6E3705DBECA426352B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_E95FC340454A64692967BECA42632D1B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_B1CB273A774F540F88ACBECA4261B6FA" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_E95FC340454A64692967BECA42632D1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_7299DC2D19C683B2983BBECA426300BE" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_B1CB273A774F540F88ACBECA4261B6FA" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_7299DC2D19C683B2983BBECA426300BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_6A5BABD24C37E89A6AC2BECA42632E49" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_B1CB273A774F540F88ACBECA4261B6FA" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_6A5BABD24C37E89A6AC2BECA42632E49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_1CA43CE2089090A214A0BECA4263B304" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_B1CB273A774F540F88ACBECA4261B6FA" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_1CA43CE2089090A214A0BECA4263B304" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_B0783FEA62036C27F1DBBECA4263754A" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_B1CB273A774F540F88ACBECA4261B6FA" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_B0783FEA62036C27F1DBBECA4263754A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_BF9545FB98B45625A4E4A0CCD9CF9AD7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C30B4165162A58878FD8FEC6693333AD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_BF9545FB98B45625A4E4A0CCD9CF9AD7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C30B4165162A58878FD8FEC6693333AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_B5B0B51C39FE56CDB0E46F47B3BC736F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C30B4165162A58878FD8FEC6693333AD" xlink:to="loc_us-gaap_AwardTypeAxis_B5B0B51C39FE56CDB0E46F47B3BC736F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_82D74F5849A058C18E8ECE8C7DFCF49A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_B5B0B51C39FE56CDB0E46F47B3BC736F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_82D74F5849A058C18E8ECE8C7DFCF49A" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_StockOptionsAndRestrictedStockUnitsMember" xlink:label="loc_insm_StockOptionsAndRestrictedStockUnitsMember_3E00AE39FBC25C1B93E05889F4B7741B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_82D74F5849A058C18E8ECE8C7DFCF49A" xlink:to="loc_insm_StockOptionsAndRestrictedStockUnitsMember_3E00AE39FBC25C1B93E05889F4B7741B" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_RestrictedStockAndRestrictedStockUnitsMember" xlink:label="loc_insm_RestrictedStockAndRestrictedStockUnitsMember_0BB42C7829B75BBE852E2987177CAFA6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_StockOptionsAndRestrictedStockUnitsMember_3E00AE39FBC25C1B93E05889F4B7741B" xlink:to="loc_insm_RestrictedStockAndRestrictedStockUnitsMember_0BB42C7829B75BBE852E2987177CAFA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_AC9E24A6B31753228E08213ADFEE0B0A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_StockOptionsAndRestrictedStockUnitsMember_3E00AE39FBC25C1B93E05889F4B7741B" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_AC9E24A6B31753228E08213ADFEE0B0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3CA2F91CC21C548DBCB046A4D429D6EA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C30B4165162A58878FD8FEC6693333AD" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3CA2F91CC21C548DBCB046A4D429D6EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0EC5BC8E893A5DCB9F8A9F5235A61B5B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3CA2F91CC21C548DBCB046A4D429D6EA" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0EC5BC8E893A5DCB9F8A9F5235A61B5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_FBEC69E38E5B5F4CBA089381C20D5609" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0EC5BC8E893A5DCB9F8A9F5235A61B5B" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_FBEC69E38E5B5F4CBA089381C20D5609" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3FAD068B36D050E9B66763CFBD26D308" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0EC5BC8E893A5DCB9F8A9F5235A61B5B" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3FAD068B36D050E9B66763CFBD26D308" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F624CCFEE12450E68B4AA8C3667972E5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C30B4165162A58878FD8FEC6693333AD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F624CCFEE12450E68B4AA8C3667972E5" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit" xlink:label="loc_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit_F6C06F28629F507EA1D41BCF063B0781" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F624CCFEE12450E68B4AA8C3667972E5" xlink:to="loc_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit_F6C06F28629F507EA1D41BCF063B0781" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_818A2860BCD65FF5AC97AB8C0DBC288B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F624CCFEE12450E68B4AA8C3667972E5" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_818A2860BCD65FF5AC97AB8C0DBC288B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_DC06FE7D9C0B5AA5B6140440C2F6CB34" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F624CCFEE12450E68B4AA8C3667972E5" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_DC06FE7D9C0B5AA5B6140440C2F6CB34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_28B5B7B882475F6FA026003484D863F1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F624CCFEE12450E68B4AA8C3667972E5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_28B5B7B882475F6FA026003484D863F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5925520DB8665856AA3B0CE2A2683FCA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_28B5B7B882475F6FA026003484D863F1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5925520DB8665856AA3B0CE2A2683FCA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_BEE32E957BE55575BA42C69F08253CD5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_28B5B7B882475F6FA026003484D863F1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_BEE32E957BE55575BA42C69F08253CD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1CF7B92C34C551328A58B3E8440A6335" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_28B5B7B882475F6FA026003484D863F1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1CF7B92C34C551328A58B3E8440A6335" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_304FFF5D515D599C9BA715D10F0694C7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_28B5B7B882475F6FA026003484D863F1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_304FFF5D515D599C9BA715D10F0694C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_059ABCC935F2544CBD7BEF99C9280575" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_28B5B7B882475F6FA026003484D863F1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_059ABCC935F2544CBD7BEF99C9280575" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_B10BDCA2852E50C097E483064DFFC33A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F624CCFEE12450E68B4AA8C3667972E5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_B10BDCA2852E50C097E483064DFFC33A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_A3B1AC6F6E855E3A8FFB3BCC34F06960" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_B10BDCA2852E50C097E483064DFFC33A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_A3B1AC6F6E855E3A8FFB3BCC34F06960" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E5DC1AF19D3F5B8F9865C4FD0A7605CC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_B10BDCA2852E50C097E483064DFFC33A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E5DC1AF19D3F5B8F9865C4FD0A7605CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_B46C3D8931F254EE9380B12EBDBDF412" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_B10BDCA2852E50C097E483064DFFC33A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_B46C3D8931F254EE9380B12EBDBDF412" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_63155C3BDF795BBF939411DEBC92642D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_B10BDCA2852E50C097E483064DFFC33A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_63155C3BDF795BBF939411DEBC92642D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_CF5EC623A2025D0FAFBFCC1F26A7989B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_B10BDCA2852E50C097E483064DFFC33A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_CF5EC623A2025D0FAFBFCC1F26A7989B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_EEC4C8462A7256788F1604A901592E09" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F624CCFEE12450E68B4AA8C3667972E5" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_EEC4C8462A7256788F1604A901592E09" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2B392210FB691395ED7E8222F3377929" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_A6EC8C5DDF917498A9BA8222F337B880" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2B392210FB691395ED7E8222F3377929" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_A6EC8C5DDF917498A9BA8222F337B880" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_197966ABA4750A79B78C8222F338D1E9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_A6EC8C5DDF917498A9BA8222F337B880" xlink:to="loc_us-gaap_AwardTypeAxis_197966ABA4750A79B78C8222F338D1E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F2CC1053865EB9458EFB8222F338FAC4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_197966ABA4750A79B78C8222F338D1E9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F2CC1053865EB9458EFB8222F338FAC4" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_EmployeeAndDirectorsStockOptionsMember" xlink:label="loc_insm_EmployeeAndDirectorsStockOptionsMember_C23267B11C6E025259648222F3388A77" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F2CC1053865EB9458EFB8222F338FAC4" xlink:to="loc_insm_EmployeeAndDirectorsStockOptionsMember_C23267B11C6E025259648222F3388A77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_A04D6D4C5EBEBCA8051F8222F3397061" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_A6EC8C5DDF917498A9BA8222F337B880" xlink:to="loc_us-gaap_RangeAxis_A04D6D4C5EBEBCA8051F8222F3397061" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_F86345798ACE00E670538222F339C99F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_A04D6D4C5EBEBCA8051F8222F3397061" xlink:to="loc_us-gaap_RangeMember_F86345798ACE00E670538222F339C99F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_2E18F4FF0F32F9BB56608222F33A59B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_F86345798ACE00E670538222F339C99F" xlink:to="loc_us-gaap_MinimumMember_2E18F4FF0F32F9BB56608222F33A59B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_1C8B6FE8C8185D75A52B8222F33A021A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_F86345798ACE00E670538222F339C99F" xlink:to="loc_us-gaap_MaximumMember_1C8B6FE8C8185D75A52B8222F33A021A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB0F46299742DED80F338222F33ACDF4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_A6EC8C5DDF917498A9BA8222F337B880" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB0F46299742DED80F338222F33ACDF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_D4A037638F3CB7B659F38222F33AAD40" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB0F46299742DED80F338222F33ACDF4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_D4A037638F3CB7B659F38222F33AAD40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7DAEB4B1BC5CCEBBEE848222F33BCCA6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_D4A037638F3CB7B659F38222F33AAD40" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7DAEB4B1BC5CCEBBEE848222F33BCCA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_F5E4EC916537ACA3683C8222F33BFF7E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_D4A037638F3CB7B659F38222F33AAD40" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_F5E4EC916537ACA3683C8222F33BFF7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5D93AD67AC7BFC642A178222F33CA202" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_D4A037638F3CB7B659F38222F33AAD40" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5D93AD67AC7BFC642A178222F33CA202" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_DFF898231B64AB7A4EEB8222F33CBE8B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_D4A037638F3CB7B659F38222F33AAD40" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_DFF898231B64AB7A4EEB8222F33CBE8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D9561799A248942C7B1A8222F33CDF0C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_D4A037638F3CB7B659F38222F33AAD40" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D9561799A248942C7B1A8222F33CDF0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65DA945BAA176A3A76458222F33C58F6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB0F46299742DED80F338222F33ACDF4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65DA945BAA176A3A76458222F33C58F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C2D4CAF34D40FC57FE3F8222F33C7041" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65DA945BAA176A3A76458222F33C58F6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C2D4CAF34D40FC57FE3F8222F33C7041" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8ACB6495A186525633D98222F33C76CE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65DA945BAA176A3A76458222F33C58F6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8ACB6495A186525633D98222F33C76CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_66905FB11112867C06A68222F33DD085" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65DA945BAA176A3A76458222F33C58F6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_66905FB11112867C06A68222F33DD085" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_E961EC3FF5B8FE6FDECC8222F33DA6D4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65DA945BAA176A3A76458222F33C58F6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_E961EC3FF5B8FE6FDECC8222F33DA6D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_76A3761E8BE2C78CF4C48222F33D768D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65DA945BAA176A3A76458222F33C58F6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_76A3761E8BE2C78CF4C48222F33D768D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_F5D8B0D6427B24CCEBBA8222F33D3122" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB0F46299742DED80F338222F33ACDF4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_F5D8B0D6427B24CCEBBA8222F33D3122" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0910FB0B6F7A27C955328222F33EE641" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB0F46299742DED80F338222F33ACDF4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0910FB0B6F7A27C955328222F33EE641" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5B8E0C1E0B2581C3F5738222F33E730C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB0F46299742DED80F338222F33ACDF4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5B8E0C1E0B2581C3F5738222F33E730C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B30ECA97EA4E8E86C06E8222F33E3A7B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5B8E0C1E0B2581C3F5738222F33E730C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B30ECA97EA4E8E86C06E8222F33E3A7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_915F5EB0A785B395FDD98222F33EC2A4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5B8E0C1E0B2581C3F5738222F33E730C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_915F5EB0A785B395FDD98222F33EC2A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3931F74D384EEC967E398222F33FD06B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5B8E0C1E0B2581C3F5738222F33E730C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3931F74D384EEC967E398222F33FD06B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1D3D6DE2F739C2FF89B68222F33FFFB4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5B8E0C1E0B2581C3F5738222F33E730C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1D3D6DE2F739C2FF89B68222F33FFFB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_21A99D9CB5DFA06597198222F33F853C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5B8E0C1E0B2581C3F5738222F33E730C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_21A99D9CB5DFA06597198222F33F853C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_E1FC454BCA63304322528222F33FD71B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB0F46299742DED80F338222F33ACDF4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_E1FC454BCA63304322528222F33FD71B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5E8EA90F76E2EDD8D5E18222F3403DFC" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB0F46299742DED80F338222F33ACDF4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5E8EA90F76E2EDD8D5E18222F3403DFC" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_WeightedAverageRemainingContractualLifeInYearsAbstract" xlink:label="loc_insm_WeightedAverageRemainingContractualLifeInYearsAbstract_BD8796E7D55F9E1EA2C28222F340D374" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB0F46299742DED80F338222F33ACDF4" xlink:to="loc_insm_WeightedAverageRemainingContractualLifeInYearsAbstract_BD8796E7D55F9E1EA2C28222F340D374" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6DF518EC2167D28F29558222F34022A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_WeightedAverageRemainingContractualLifeInYearsAbstract_BD8796E7D55F9E1EA2C28222F340D374" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6DF518EC2167D28F29558222F34022A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_9F565E99DDA5AD23B9D28222F3407FD4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_WeightedAverageRemainingContractualLifeInYearsAbstract_BD8796E7D55F9E1EA2C28222F340D374" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_9F565E99DDA5AD23B9D28222F3407FD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_161E1B050B65DA6D41498222F341CAD7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_WeightedAverageRemainingContractualLifeInYearsAbstract_BD8796E7D55F9E1EA2C28222F340D374" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_161E1B050B65DA6D41498222F341CAD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1D5DF3859ED50034B9D58222F34133E1" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB0F46299742DED80F338222F33ACDF4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1D5DF3859ED50034B9D58222F34133E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6229591C2B615456F75E8222F341D582" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1D5DF3859ED50034B9D58222F34133E1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6229591C2B615456F75E8222F341D582" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2D77FD03299D81727C9F8222F3416FBE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1D5DF3859ED50034B9D58222F34133E1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2D77FD03299D81727C9F8222F3416FBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5DB94D7611B1A60564088222F34280C9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1D5DF3859ED50034B9D58222F34133E1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5DB94D7611B1A60564088222F34280C9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0DBB66CC84B25EE098635DEA96EFF169" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_FDE1C0C81C3658F68A50A4FCA536B411" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0DBB66CC84B25EE098635DEA96EFF169" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_FDE1C0C81C3658F68A50A4FCA536B411" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_34CB2A85DBEA51ED98EE4CF837A18750" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0DBB66CC84B25EE098635DEA96EFF169" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_34CB2A85DBEA51ED98EE4CF837A18750" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_CA2776325D0C5D05B3C91284E20118AA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0DBB66CC84B25EE098635DEA96EFF169" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_CA2776325D0C5D05B3C91284E20118AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_1403FCA9857655F18231DD44439E3DFC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0DBB66CC84B25EE098635DEA96EFF169" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_1403FCA9857655F18231DD44439E3DFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_237E355142895D02937B9AE7931CC25A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0DBB66CC84B25EE098635DEA96EFF169" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_237E355142895D02937B9AE7931CC25A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8C410D4DE22C58D1BC691240C94F9BB9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_E54119F767C151DDB9D4CE2B53EA42B4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8C410D4DE22C58D1BC691240C94F9BB9" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_E54119F767C151DDB9D4CE2B53EA42B4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_760FFF0EF4835AFCA362908100BC6BB5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_10B0BFFFFB0E5B14BA496847BCA3DEB5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_760FFF0EF4835AFCA362908100BC6BB5" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_10B0BFFFFB0E5B14BA496847BCA3DEB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_E22AE92BC1025DDAA898BAA5D36C811B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_10B0BFFFFB0E5B14BA496847BCA3DEB5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_E22AE92BC1025DDAA898BAA5D36C811B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C73551A0E57658F0A02395D8CEE69F4F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_E22AE92BC1025DDAA898BAA5D36C811B" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C73551A0E57658F0A02395D8CEE69F4F" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_EmployeeAndDirectorsStockOptionsMember" xlink:label="loc_insm_EmployeeAndDirectorsStockOptionsMember_A13F6A39E8555326892C6162854FC640" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C73551A0E57658F0A02395D8CEE69F4F" xlink:to="loc_insm_EmployeeAndDirectorsStockOptionsMember_A13F6A39E8555326892C6162854FC640" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_95C7FBD25C495C23B0D00024FDBF6EE6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C73551A0E57658F0A02395D8CEE69F4F" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_95C7FBD25C495C23B0D00024FDBF6EE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_E3DEDFC0293E57B58C1A7C6577614EEA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C73551A0E57658F0A02395D8CEE69F4F" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_E3DEDFC0293E57B58C1A7C6577614EEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_FAE51F87D0A65F16B209231F2994476F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_10B0BFFFFB0E5B14BA496847BCA3DEB5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_FAE51F87D0A65F16B209231F2994476F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C106037B2F3C5517AC68B522207350AA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_FAE51F87D0A65F16B209231F2994476F" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C106037B2F3C5517AC68B522207350AA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8C41B60A4E0D50CBBE81841A0D12083B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsAssetsQuantitativeInformationTable" xlink:label="loc_us-gaap_FairValueInputsAssetsQuantitativeInformationTable_7F0D9399712755BE865306DF08FA72FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8C41B60A4E0D50CBBE81841A0D12083B" xlink:to="loc_us-gaap_FairValueInputsAssetsQuantitativeInformationTable_7F0D9399712755BE865306DF08FA72FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_11D8B2D5D5C553E4B4FF8461DF31DB24" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInputsAssetsQuantitativeInformationTable_7F0D9399712755BE865306DF08FA72FE" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_11D8B2D5D5C553E4B4FF8461DF31DB24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_905BD46757D95D70995127A46D301723" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_11D8B2D5D5C553E4B4FF8461DF31DB24" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_905BD46757D95D70995127A46D301723" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_BE8CEC52ACA458EA8C5E4AFC0418102F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_905BD46757D95D70995127A46D301723" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_BE8CEC52ACA458EA8C5E4AFC0418102F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_F4FE0D2E81865581A65DD42B04184587" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInputsAssetsQuantitativeInformationTable_7F0D9399712755BE865306DF08FA72FE" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_F4FE0D2E81865581A65DD42B04184587" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_8DAE196EB90D5A0A8C66DA68D3E003E5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_F4FE0D2E81865581A65DD42B04184587" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_8DAE196EB90D5A0A8C66DA68D3E003E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_914E4FD920865BF18301F820F300F739" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_8DAE196EB90D5A0A8C66DA68D3E003E5" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_914E4FD920865BF18301F820F300F739" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_FCB4C7F841D25A589A8ED0F62803EC10" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_8DAE196EB90D5A0A8C66DA68D3E003E5" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_FCB4C7F841D25A589A8ED0F62803EC10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_A879D4D1138B5BE4891AB6EC7B0CBCBF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_8DAE196EB90D5A0A8C66DA68D3E003E5" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_A879D4D1138B5BE4891AB6EC7B0CBCBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_A9DD938327505B66B89A3320A26CBF9F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInputsAssetsQuantitativeInformationTable_7F0D9399712755BE865306DF08FA72FE" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_A9DD938327505B66B89A3320A26CBF9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_A437932408EA5D6BB6BF33D0417087E6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_A9DD938327505B66B89A3320A26CBF9F" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_A437932408EA5D6BB6BF33D0417087E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_29028575CB1A5927BF6E79C31C88DA40" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_A437932408EA5D6BB6BF33D0417087E6" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_29028575CB1A5927BF6E79C31C88DA40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_AEF37D85237B5B54A0A98B225A28106D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_A437932408EA5D6BB6BF33D0417087E6" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_AEF37D85237B5B54A0A98B225A28106D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_F93A0517269A5860AABE97AC193B2F42" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInputsAssetsQuantitativeInformationTable_7F0D9399712755BE865306DF08FA72FE" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_F93A0517269A5860AABE97AC193B2F42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2333E1BE8DDD5D6CADA9BE22F741D699" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_F93A0517269A5860AABE97AC193B2F42" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2333E1BE8DDD5D6CADA9BE22F741D699" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_8509AD33421B5C7C88F7B672AA72AE0D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2333E1BE8DDD5D6CADA9BE22F741D699" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_8509AD33421B5C7C88F7B672AA72AE0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsAssetsQuantitativeInformationLineItems" xlink:label="loc_us-gaap_FairValueInputsAssetsQuantitativeInformationLineItems_24C8093E6D0D5C8AB896F371B781FE65" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInputsAssetsQuantitativeInformationTable_7F0D9399712755BE865306DF08FA72FE" xlink:to="loc_us-gaap_FairValueInputsAssetsQuantitativeInformationLineItems_24C8093E6D0D5C8AB896F371B781FE65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_13AA3AD0E21F5104A0453A9CAD136CF0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInputsAssetsQuantitativeInformationLineItems_24C8093E6D0D5C8AB896F371B781FE65" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_13AA3AD0E21F5104A0453A9CAD136CF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_3C7F23080B2557DCBA626A3D639DEC0D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInputsAssetsQuantitativeInformationLineItems_24C8093E6D0D5C8AB896F371B781FE65" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_3C7F23080B2557DCBA626A3D639DEC0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_D9FC9A95830253B2B2516EC338427AF2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInputsAssetsQuantitativeInformationLineItems_24C8093E6D0D5C8AB896F371B781FE65" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_D9FC9A95830253B2B2516EC338427AF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_3A3B7AAF61A45907A07737C338FECBA5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInputsAssetsQuantitativeInformationLineItems_24C8093E6D0D5C8AB896F371B781FE65" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_3A3B7AAF61A45907A07737C338FECBA5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_FCE219E52DDA5FC70F588222F40F2897" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsAssetsQuantitativeInformationTable" xlink:label="loc_us-gaap_FairValueInputsAssetsQuantitativeInformationTable_34FE08F48AE559665A668222F40F851D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_FCE219E52DDA5FC70F588222F40F2897" xlink:to="loc_us-gaap_FairValueInputsAssetsQuantitativeInformationTable_34FE08F48AE559665A668222F40F851D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_EDCFA29A021E266A59B48222F4107AED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInputsAssetsQuantitativeInformationTable_34FE08F48AE559665A668222F40F851D" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_EDCFA29A021E266A59B48222F4107AED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_842834FFC680B582F8658222F410A64F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_EDCFA29A021E266A59B48222F4107AED" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_842834FFC680B582F8658222F410A64F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_29E7DE7FAA6D1F37E1CB8222F4106163" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_842834FFC680B582F8658222F410A64F" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_29E7DE7FAA6D1F37E1CB8222F4106163" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3DBD5F76B6AE1DA790A48222F411375E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInputsAssetsQuantitativeInformationTable_34FE08F48AE559665A668222F40F851D" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3DBD5F76B6AE1DA790A48222F411375E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_FFA4AC1C8D199685AC4C8222F41104F6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3DBD5F76B6AE1DA790A48222F411375E" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_FFA4AC1C8D199685AC4C8222F41104F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_E02464967E7180EA45D78222F41117FA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_FFA4AC1C8D199685AC4C8222F41104F6" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_E02464967E7180EA45D78222F41117FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1C0B793F308BBA7949CE8222F41261C1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInputsAssetsQuantitativeInformationTable_34FE08F48AE559665A668222F40F851D" xlink:to="loc_us-gaap_DebtInstrumentAxis_1C0B793F308BBA7949CE8222F41261C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3F6F273C760D4438FB688222F41249D7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1C0B793F308BBA7949CE8222F41261C1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3F6F273C760D4438FB688222F41249D7" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member" xlink:label="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_D994B48EFCB065A295EE8222F4120447" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3F6F273C760D4438FB688222F41249D7" xlink:to="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_D994B48EFCB065A295EE8222F4120447" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsAssetsQuantitativeInformationLineItems" xlink:label="loc_us-gaap_FairValueInputsAssetsQuantitativeInformationLineItems_A1BC2E950478B8D06A1D8222F41261BC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInputsAssetsQuantitativeInformationTable_34FE08F48AE559665A668222F40F851D" xlink:to="loc_us-gaap_FairValueInputsAssetsQuantitativeInformationLineItems_A1BC2E950478B8D06A1D8222F41261BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0F1C09A9ED910FFAC2D48222F41304EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInputsAssetsQuantitativeInformationLineItems_A1BC2E950478B8D06A1D8222F41261BC" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0F1C09A9ED910FFAC2D48222F41304EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_76CFCAC21D2C043FE4BD8222F413A26F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInputsAssetsQuantitativeInformationLineItems_A1BC2E950478B8D06A1D8222F41261BC" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_76CFCAC21D2C043FE4BD8222F413A26F" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_FairValueLevel1Level2Level3TransfersAmount" xlink:label="loc_insm_FairValueLevel1Level2Level3TransfersAmount_680FDE54B99905C1624F8222F41388FF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInputsAssetsQuantitativeInformationLineItems_A1BC2E950478B8D06A1D8222F41261BC" xlink:to="loc_insm_FairValueLevel1Level2Level3TransfersAmount_680FDE54B99905C1624F8222F41388FF" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities" xlink:label="loc_insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities_38AE6E4B195F93730B068222F4147EB3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInputsAssetsQuantitativeInformationLineItems_A1BC2E950478B8D06A1D8222F41261BC" xlink:to="loc_insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities_38AE6E4B195F93730B068222F4147EB3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3B60319E2CCDA379F20BC1480A722847" xlink:type="locator" />
    <link:loc xlink:href="insm-20180930.xsd#insm_ScheduleofEarningsPerShareBasicandDilutedTable" xlink:label="loc_insm_ScheduleofEarningsPerShareBasicandDilutedTable_1075786D4D5C027C93BBC1480A72A8A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3B60319E2CCDA379F20BC1480A722847" xlink:to="loc_insm_ScheduleofEarningsPerShareBasicandDilutedTable_1075786D4D5C027C93BBC1480A72A8A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_4A536C3BB21A1D5C59CAC1480A7397F7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedTable_1075786D4D5C027C93BBC1480A72A8A1" xlink:to="loc_us-gaap_AwardTypeAxis_4A536C3BB21A1D5C59CAC1480A7397F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D92C9F3F360F63E343BEC1480A731849" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4A536C3BB21A1D5C59CAC1480A7397F7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D92C9F3F360F63E343BEC1480A731849" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0E189D36B1057F17CDE3C1480A73B042" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D92C9F3F360F63E343BEC1480A731849" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0E189D36B1057F17CDE3C1480A73B042" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_5CD981467B6AF82EC017C1480A74B5D4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D92C9F3F360F63E343BEC1480A731849" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_5CD981467B6AF82EC017C1480A74B5D4" xlink:type="arc" />
    <link:loc xlink:href="insm-20180930.xsd#insm_ScheduleofEarningsPerShareBasicandDilutedLineItems" xlink:label="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_F87EF04B0501ABD010C0C1480A745092" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedTable_1075786D4D5C027C93BBC1480A72A8A1" xlink:to="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_F87EF04B0501ABD010C0C1480A745092" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_8180943A4A490037F57EC1480A75FC45" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_F87EF04B0501ABD010C0C1480A745092" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_8180943A4A490037F57EC1480A75FC45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_69BCD4BA18E169E545C4C1480A75CAC3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_8180943A4A490037F57EC1480A75FC45" xlink:to="loc_us-gaap_NetIncomeLoss_69BCD4BA18E169E545C4C1480A75CAC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_9B6C5EA2998FE793DDB2C1480A751F97" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_F87EF04B0501ABD010C0C1480A745092" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_9B6C5EA2998FE793DDB2C1480A751F97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_AA921D2C402508D10ADFC1480A759D2D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_9B6C5EA2998FE793DDB2C1480A751F97" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_AA921D2C402508D10ADFC1480A759D2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_C2F7BE94A6198E6E6870C1480A760866" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_9B6C5EA2998FE793DDB2C1480A751F97" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_C2F7BE94A6198E6E6870C1480A760866" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_B6FA081A28848C0370A3C1480A76E354" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_C2F7BE94A6198E6E6870C1480A760866" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_B6FA081A28848C0370A3C1480A76E354" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_DC90EEFCCD60DDC1DDC6C1480A76D0F1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_C2F7BE94A6198E6E6870C1480A760866" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_DC90EEFCCD60DDC1DDC6C1480A76D0F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_F393AC1EA87F4287C072C1480A779938" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_9B6C5EA2998FE793DDB2C1480A751F97" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_F393AC1EA87F4287C072C1480A779938" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1ED81CD99D8EF3008AF1C1480A77E517" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_F87EF04B0501ABD010C0C1480A745092" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1ED81CD99D8EF3008AF1C1480A77E517" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_E617F269CBBC92D139E9C1480A77DFBE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1ED81CD99D8EF3008AF1C1480A77E517" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_E617F269CBBC92D139E9C1480A77DFBE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_174C4100EB7D90B3891B8222F41DD51F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_4E212854D5AFA3337DA88222F41ECF4F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_174C4100EB7D90B3891B8222F41DD51F" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_4E212854D5AFA3337DA88222F41ECF4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_9E3962119AD463069F198222F41E4BF5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_174C4100EB7D90B3891B8222F41DD51F" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_9E3962119AD463069F198222F41E4BF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_1D82AE8FD81643D0DE558231AA4C7781" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_174C4100EB7D90B3891B8222F41DD51F" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_1D82AE8FD81643D0DE558231AA4C7781" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_E7857FEC7FC14B4BAE208222F41E0145" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_174C4100EB7D90B3891B8222F41DD51F" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_E7857FEC7FC14B4BAE208222F41E0145" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesRecentlyAdoptedAccountingPronouncementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_19FD58B7E669209139613B6BAFCCAAEF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_FBA1A6A4FD31B60C298C3B6BAFCEDD0F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_19FD58B7E669209139613B6BAFCCAAEF" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_FBA1A6A4FD31B60C298C3B6BAFCEDD0F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_36E0318726E85D79926DBBCB5154382A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_F68178F9A98550938AF8792A5F3CD21B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_36E0318726E85D79926DBBCB5154382A" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_F68178F9A98550938AF8792A5F3CD21B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_A62E2DDF47E254F5BBFA6F4214A4E021" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_36E0318726E85D79926DBBCB5154382A" xlink:to="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_A62E2DDF47E254F5BBFA6F4214A4E021" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0A2199098E2E567FAAE553CE9F62C96B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_36E0318726E85D79926DBBCB5154382A" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0A2199098E2E567FAAE553CE9F62C96B" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>insm-20180930x10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31"
  xmlns:insm="http://www.insmed.com/20180930"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="insm-20180930.xsd" xlink:type="simple"/>
    <context id="FD2018Q3YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FI2018Q3_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FI2018Q3_us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_insm_BridgewaterNewJerseyOfficeSpaceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">insm:BridgewaterNewJerseyOfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="FI2018Q3_us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_insm_BridgewaterNewJerseyFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">insm:BridgewaterNewJerseyFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="D2018Q3Sept2018_us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_insm_BridgewaterNewJerseyOfficeSpaceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">insm:BridgewaterNewJerseyOfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="FI2018Q3_us-gaap_CashAndCashEquivalentsAxis_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="FI2018Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="FD2018Q1YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="I2018Q4Oct26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <instant>2018-10-26</instant>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_insm_EmployeeAndDirectorsStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_insm_EmployeeAndDirectorsStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FI2018Q3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="FI2018Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="I2018Q3Sept28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <instant>2018-09-28</instant>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="I2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-31</instant>
        </period>
    </context>
    <context id="D2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_DebtInstrumentConversionTermOneMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:DebtInstrumentConversionTermOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_DebtInstrumentConversionTermFourMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:DebtInstrumentConversionTermFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_DebtInstrumentConversionTermTwoMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:DebtInstrumentConversionTermTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="D2018Q1Feb2018_us-gaap_DebtInstrumentAxis_us-gaap_LineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-01</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="D2018Q1Feb28-Feb28_us-gaap_DebtInstrumentAxis_us-gaap_LineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-28</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="D2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_DebtInstrumentConversionTermThreeMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:DebtInstrumentConversionTermThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="FI2018Q3_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="D2017Q3Sept17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <startDate>2017-07-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="FI2018Q3_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range5Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range6Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range6Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range6Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range6Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range7Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range7Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range5Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range7Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range7Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range9Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range9Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range10Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range10Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range10Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range10Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range8Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range8Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FI2016Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range9Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range9Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range8Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">insm:Range8Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="D2018Q2May15_us-gaap_PlanNameAxis_insm_EmployeeStockPurchasePlan2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">insm:EmployeeStockPurchasePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-15</startDate>
            <endDate>2018-05-15</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="I2018Q2May15_us-gaap_PlanNameAxis_insm_EmployeeStockPurchasePlan2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">insm:EmployeeStockPurchasePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-15</instant>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="I2017Q2May18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <instant>2017-05-18</instant>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FI2017Q3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <instant>2017-09-30</instant>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="FI2018Q3_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_AwardTypeAxis_insm_RestrictedStockAndRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:RestrictedStockAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="FD2017Q3QTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="FD2017Q3YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="security">
        <measure>insm:security</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="day">
        <measure>insm:day</measure>
    </unit>
    <unit id="renewal">
        <measure>insm:renewal</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="FD2018Q3YTD"
      id="Fact-543F3E0B5837592781A8F14A08E21347-wk-Fact-543F3E0B5837592781A8F14A08E21347">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="FD2018Q3YTD"
      id="Fact-CC10964958695483A39C99C87BD983DA-wk-Fact-CC10964958695483A39C99C87BD983DA">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus
      contextRef="FD2018Q3YTD"
      id="Fact-A18F8FD64E0D5BDCA7D710A93D51B3E4-wk-Fact-A18F8FD64E0D5BDCA7D710A93D51B3E4">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus
      contextRef="FD2018Q3YTD"
      id="Fact-A1C899A3F7D659D8A08DE3ABB9F1FD83-wk-Fact-A1C899A3F7D659D8A08DE3ABB9F1FD83">2018</dei:DocumentFiscalYearFocus>
    <dei:DocumentPeriodEndDate
      contextRef="FD2018Q3YTD"
      id="Fact-3A5ED426961258329C99D45289710BB5-wk-Fact-3A5ED426961258329C99D45289710BB5">2018-09-30</dei:DocumentPeriodEndDate>
    <dei:EntityCentralIndexKey
      contextRef="FD2018Q3YTD"
      id="Fact-17C53AFAA4B15BB4A330C0DB7036C011-wk-Fact-17C53AFAA4B15BB4A330C0DB7036C011">0001104506</dei:EntityCentralIndexKey>
    <dei:EntityCurrentReportingStatus
      contextRef="FD2018Q3YTD"
      id="Fact-DE29AFFA4E9C5EAE8024595FF092CACA-wk-Fact-DE29AFFA4E9C5EAE8024595FF092CACA">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityFilerCategory
      contextRef="FD2018Q3YTD"
      id="Fact-8CCD433BE5F25D4E9F942B77F63466DE-wk-Fact-8CCD433BE5F25D4E9F942B77F63466DE">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityRegistrantName
      contextRef="FD2018Q3YTD"
      id="Fact-CF2A5C6B5669B06A89E3821902D2019B-wk-Fact-CF2A5C6B5669B06A89E3821902D2019B">INSMED INC</dei:EntityRegistrantName>
    <insm:AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities
      contextRef="FI2017Q4"
      decimals="INF"
      id="Fact-11A40782930A582E92AACCD41378BB31-wk-Fact-11A40782930A582E92AACCD41378BB31"
      unitRef="security">0</insm:AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities>
    <insm:FairValueLevel1Level2Level3TransfersAmount
      contextRef="FD2017Q3YTD"
      decimals="INF"
      id="Fact-F14C860551DA53BB856ACC0B53020162-wk-Fact-F14C860551DA53BB856ACC0B53020162"
      unitRef="usd">0</insm:FairValueLevel1Level2Level3TransfersAmount>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2017Q4"
      decimals="INF"
      id="Fact-2CD2012CF84559E88D2932DA0F65CDA4-wk-Fact-2CD2012CF84559E88D2932DA0F65CDA4"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="FI2017Q4"
      decimals="INF"
      id="Fact-CAE4BEFC077056BCBFE65619D04273F0-wk-Fact-CAE4BEFC077056BCBFE65619D04273F0"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2017Q4"
      decimals="INF"
      id="Fact-1C675F1059225E248F007A9591DCCA7E-wk-Fact-1C675F1059225E248F007A9591DCCA7E"
      unitRef="shares">76610508</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2017Q4"
      decimals="INF"
      id="Fact-D5D07AA52D5550259B028B5D1A0C1C29-wk-Fact-D5D07AA52D5550259B028B5D1A0C1C29"
      unitRef="shares">76610508</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2018Q3"
      decimals="INF"
      id="Fact-374CE66BBB7953838E975C2421E20727-wk-Fact-374CE66BBB7953838E975C2421E20727"
      unitRef="shares">77085715</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="D2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member"
      decimals="7"
      id="Fact-BA08EA6723775C3EA27D3C7D4F8A0ADA-wk-Fact-BA08EA6723775C3EA27D3C7D4F8A0ADA"
      unitRef="number">0.0255384</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="FI2018Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember"
      decimals="INF"
      id="Fact-89107A10925F5D6096107CCFBC490452-wk-Fact-89107A10925F5D6096107CCFBC490452"
      unitRef="usd">450000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="Fact-C8567F8D1E3C9530211B824AD8DD1FFC-wk-Fact-C8567F8D1E3C9530211B824AD8DD1FFC"
      unitRef="usd">58200000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:LesseeLeasingArrangementsOperatingLeasesRenewalTerm
      contextRef="D2018Q3Sept2018_us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_insm_BridgewaterNewJerseyOfficeSpaceMember"
      id="Fact-C41D4D0D9308FFC84366835924AFACEE-wk-Fact-C41D4D0D9308FFC84366835924AFACEE">P5Y</us-gaap:LesseeLeasingArrangementsOperatingLeasesRenewalTerm>
    <us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract
      contextRef="D2018Q3Sept2018_us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_insm_BridgewaterNewJerseyOfficeSpaceMember"
      id="Fact-7001F6E2EE3786E9A5C4A14C770B7518-wk-Fact-7001F6E2EE3786E9A5C4A14C770B7518">P130M</us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="FI2018Q3"
      decimals="INF"
      id="Fact-4CD592D6B98D590491D358AD48B35942-wk-Fact-4CD592D6B98D590491D358AD48B35942"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="FD2017Q3QTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember_us-gaap_RangeAxis_us-gaap_MaximumMember"
      decimals="2"
      id="Fact-D12148CC3AB66FCB81723BB4F8F55EB6-wk-Fact-D12148CC3AB66FCB81723BB4F8F55EB6"
      unitRef="number">0.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="FD2017Q3QTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember_us-gaap_RangeAxis_us-gaap_MinimumMember"
      decimals="2"
      id="Fact-927A05914930E246271C3BB5075D187C-wk-Fact-927A05914930E246271C3BB5075D187C"
      unitRef="number">0.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember_us-gaap_RangeAxis_us-gaap_MaximumMember"
      decimals="2"
      id="Fact-C3C4E8934DEA57CC85898ADD083E6171-wk-Fact-C3C4E8934DEA57CC85898ADD083E6171"
      unitRef="number">0.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember_us-gaap_RangeAxis_us-gaap_MinimumMember"
      decimals="2"
      id="Fact-73F6C01DE9935E6FA5B60FF997845FF9-wk-Fact-73F6C01DE9935E6FA5B60FF997845FF9"
      unitRef="number">0.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember_us-gaap_RangeAxis_us-gaap_MaximumMember"
      decimals="2"
      id="Fact-4FDC96981958593DA3F1F474AF4C57EC-wk-Fact-4FDC96981958593DA3F1F474AF4C57EC"
      unitRef="number">0.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember_us-gaap_RangeAxis_us-gaap_MinimumMember"
      decimals="2"
      id="Fact-C21756C45D635F84B1CCF0FA4183D792-wk-Fact-C21756C45D635F84B1CCF0FA4183D792"
      unitRef="number">0.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember_us-gaap_RangeAxis_us-gaap_MaximumMember"
      decimals="2"
      id="Fact-C34223AFCCB95389B52F2D705A4E4D76-wk-Fact-C34223AFCCB95389B52F2D705A4E4D76"
      unitRef="number">0.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember_us-gaap_RangeAxis_us-gaap_MinimumMember"
      decimals="2"
      id="Fact-20D6D76E96A1580BA310C99B5D37A764-wk-Fact-20D6D76E96A1580BA310C99B5D37A764"
      unitRef="number">0.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="FD2017Q3QTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember_us-gaap_RangeAxis_us-gaap_MaximumMember"
      decimals="4"
      id="Fact-7063A5EEE56C54F49B9C01086E85DE69-wk-Fact-7063A5EEE56C54F49B9C01086E85DE69"
      unitRef="number">0.0193</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="FD2017Q3QTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember_us-gaap_RangeAxis_us-gaap_MinimumMember"
      decimals="4"
      id="Fact-0EB21FF5544E5A8AAE10005F91E25388-wk-Fact-0EB21FF5544E5A8AAE10005F91E25388"
      unitRef="number">0.0173</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember_us-gaap_RangeAxis_us-gaap_MaximumMember"
      decimals="4"
      id="Fact-980E832750B65DA8A010F9A72B74F27D-wk-Fact-980E832750B65DA8A010F9A72B74F27D"
      unitRef="number">0.0199</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember_us-gaap_RangeAxis_us-gaap_MinimumMember"
      decimals="4"
      id="Fact-5834BA2E4C5E5C559FF6BC637F8C0346-wk-Fact-5834BA2E4C5E5C559FF6BC637F8C0346"
      unitRef="number">0.0173</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember_us-gaap_RangeAxis_us-gaap_MaximumMember"
      decimals="4"
      id="Fact-B12F50C6DB2F5C46AB0F9FA0461FB669-wk-Fact-B12F50C6DB2F5C46AB0F9FA0461FB669"
      unitRef="number">0.0287</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember_us-gaap_RangeAxis_us-gaap_MinimumMember"
      decimals="4"
      id="Fact-0C97547B79615897800A62828116E661-wk-Fact-0C97547B79615897800A62828116E661"
      unitRef="number">0.0275</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember_us-gaap_RangeAxis_us-gaap_MaximumMember"
      decimals="4"
      id="Fact-F743CC836A1756199B244396AC526299-wk-Fact-F743CC836A1756199B244396AC526299"
      unitRef="number">0.0287</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember_us-gaap_RangeAxis_us-gaap_MinimumMember"
      decimals="4"
      id="Fact-BE5608E429985D96B5D4F9BC1ED78E1D-wk-Fact-BE5608E429985D96B5D4F9BC1ED78E1D"
      unitRef="number">0.0225</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="FI2017Q4"
      decimals="INF"
      id="Fact-A280AAFE9638552388A749DD3402F950-wk-Fact-A280AAFE9638552388A749DD3402F950"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <dei:DocumentType
      contextRef="FD2018Q3YTD"
      id="d37580207e332-wk-Fact-F4B36C32C5D0E4BCB96B3BBF183AAA89">10-Q</dei:DocumentType>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="I2018Q4Oct26"
      decimals="INF"
      id="d37580207e625-wk-Fact-C49EE1B59FEC5B03BF8BE8B903C25788"
      unitRef="shares">77090229</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2018Q3"
      decimals="-3"
      id="d37583484e548-wk-Fact-1BE6FE185E03589087FAB308105B46AE"
      unitRef="usd">567574000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2017Q4"
      decimals="-3"
      id="d37583484e567-wk-Fact-7D13774CB56B50F691CFDF9E0DC702CA"
      unitRef="usd">381165000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="FI2018Q3"
      decimals="-3"
      id="d37583484e582-wk-Fact-D47441EDA0585ADE97F115D0940BC64D"
      unitRef="usd">9921000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="FI2017Q4"
      decimals="-3"
      id="d37583484e601-wk-Fact-EF54DAF161805C2AA6FD9ED09E742FCE"
      unitRef="usd">8279000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2018Q3"
      decimals="-3"
      id="d37583484e621-wk-Fact-C25B303449F755A49D250CC3C6741DE4"
      unitRef="usd">577495000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2017Q4"
      decimals="-3"
      id="d37583484e640-wk-Fact-BCE7AD2ECB7054B696F5FE2DCA5BBF1A"
      unitRef="usd">389444000</us-gaap:AssetsCurrent>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2018Q3"
      decimals="-3"
      id="d37583484e701-wk-Fact-4F558109777F5EF1B435D05517A69E5D"
      unitRef="usd">59941000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2017Q4"
      decimals="-3"
      id="d37583484e720-wk-Fact-228FB3CE6C5A54FEB27E748DEE513810"
      unitRef="usd">58200000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2018Q3"
      decimals="-3"
      id="d37583484e740-wk-Fact-DC88FE0A5313545BB8465E20A121D7FB"
      unitRef="usd">19526000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2017Q4"
      decimals="-3"
      id="d37583484e759-wk-Fact-156D85310A4B52B1A8E6337BE4AF64C3"
      unitRef="usd">12432000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssets
      contextRef="FI2018Q3"
      decimals="-3"
      id="d37583484e780-wk-Fact-E59EDB06600C53A8A153DF114AAD5B22"
      unitRef="usd">4551000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="FI2017Q4"
      decimals="-3"
      id="d37583484e799-wk-Fact-5D9AE20127855D33B0CC637FB85439B5"
      unitRef="usd">1971000</us-gaap:OtherAssets>
    <us-gaap:Assets
      contextRef="FI2018Q3"
      decimals="-3"
      id="d37583484e824-wk-Fact-F81963E8F7C950C69217B1B80C545E54"
      unitRef="usd">661513000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="FI2017Q4"
      decimals="-3"
      id="d37583484e843-wk-Fact-24873CE6AEAB52C58826775DE5AA8DBA"
      unitRef="usd">462047000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="FI2018Q3"
      decimals="-3"
      id="d37583484e982-wk-Fact-BA82280C790853F88E587CC1BEEB2CCE"
      unitRef="usd">16579000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="FI2017Q4"
      decimals="-3"
      id="d37583484e1001-wk-Fact-966E10614E66513B962D2D82804C4E4F"
      unitRef="usd">14671000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="FI2018Q3"
      decimals="-3"
      id="d37583484e1016-wk-Fact-E7A53E4292C3507FAAB562842E428728"
      unitRef="usd">40368000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="FI2017Q4"
      decimals="-3"
      id="d37583484e1035-wk-Fact-1C594FB75856593F8B96A3EA9DEA6C7E"
      unitRef="usd">29339000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="FI2018Q3"
      decimals="-3"
      id="d37583484e1055-wk-Fact-7C0A9C8F75FD55B69CBFC0C58C872963"
      unitRef="usd">472000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="FI2017Q4"
      decimals="-3"
      id="d37583484e1074-wk-Fact-78326A3073545EE6B19D1D245B98D7F3"
      unitRef="usd">646000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2018Q3"
      decimals="-3"
      id="d37583484e1094-wk-Fact-41616F63FF475BB08916FA9BCD82ED7C"
      unitRef="usd">57419000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2017Q4"
      decimals="-3"
      id="d37583484e1113-wk-Fact-1580018AC4AF5E28978B3A5E59DF9D61"
      unitRef="usd">44656000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="FI2018Q3"
      decimals="-3"
      id="d37583484e1174-wk-Fact-04AAF8399F7F50089D01A23C0F563455"
      unitRef="usd">311861000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="FI2017Q4"
      decimals="-3"
      id="d37583484e1193-wk-Fact-9577E81E82835150BD2F46CA10306CF9"
      unitRef="usd">55567000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2018Q3"
      decimals="-3"
      id="d37583484e1214-wk-Fact-D81997447C3C5A77AC609DCC733E7525"
      unitRef="usd">826000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2017Q4"
      decimals="-3"
      id="d37583484e1233-wk-Fact-99865EE4A16956BBB42442A6B5582E15"
      unitRef="usd">765000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="FI2018Q3"
      decimals="-3"
      id="d37583484e1253-wk-Fact-5E51F8D8956E589AA9D8A85C310318A9"
      unitRef="usd">370106000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="FI2017Q4"
      decimals="-3"
      id="d37583484e1272-wk-Fact-C6C9340214765FFC8EF695D7AC4AE2BD"
      unitRef="usd">100988000</us-gaap:Liabilities>
    <us-gaap:CommonStockValue
      contextRef="FI2018Q3"
      decimals="-3"
      id="d37583484e1372-wk-Fact-484D376419005F36A7CEF2173700892F"
      unitRef="usd">771000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="FI2017Q4"
      decimals="-3"
      id="d37583484e1391-wk-Fact-61D3CD136480528EB2DF81797EF839DE"
      unitRef="usd">766000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="FI2018Q3"
      decimals="-3"
      id="d37583484e1411-wk-Fact-45658F35E7ED501187EA19BAC08B5996"
      unitRef="usd">1481205000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="FI2017Q4"
      decimals="-3"
      id="d37583484e1430-wk-Fact-C0E9D6D306695EAB8C9DF8E07E9B8A85"
      unitRef="usd">1318181000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2018Q3"
      decimals="-3"
      id="d37583484e1450-wk-Fact-CCD314E789965563ADE88BF94D40AD89"
      unitRef="usd">-1190589000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2017Q4"
      decimals="-3"
      id="d37583484e1470-wk-Fact-6561564BB8325502904169C95BF65F8E"
      unitRef="usd">-957885000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q3"
      decimals="-3"
      id="d37583484e1491-wk-Fact-69E699855907599A9338BBF5A72A4CA8"
      unitRef="usd">20000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2017Q4"
      decimals="-3"
      id="d37583484e1510-wk-Fact-56CA53231A8F59FA9C8DCD0D0DED5678"
      unitRef="usd">-3000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q3"
      decimals="-3"
      id="d37583484e1531-wk-Fact-ACB053F2369A5B66BE981E31DC8D38E2"
      unitRef="usd">291407000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q4"
      decimals="-3"
      id="d37583484e1550-wk-Fact-5115DD7C33225595A9655F911DF6011A"
      unitRef="usd">361059000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2018Q3"
      decimals="-3"
      id="d37583484e1575-wk-Fact-4AFEC3B136AA509BA110354EDDD0EE33"
      unitRef="usd">661513000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2017Q4"
      decimals="-3"
      id="d37583484e1594-wk-Fact-D810C1897EBA5AD1B381F61680DD0492"
      unitRef="usd">462047000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d37585990e598-wk-Fact-B064ED96C98058ADB3E4E526BBB142F6"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q3QTD"
      decimals="-3"
      id="d37585990e617-wk-Fact-B5463B46287F503EA7212507B016D886"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d37585990e636-wk-Fact-4A241F7DC38C57A5B1315FBEEAB0A867"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2017Q3YTD"
      decimals="-3"
      id="d37585990e656-wk-Fact-38C0125A41FB5826A7A165748ACE9DAB"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d37585990e831-wk-Fact-CEF7523E10E755FA98744C92480FFF83"
      unitRef="usd">39538000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2017Q3QTD"
      decimals="-3"
      id="d37585990e850-wk-Fact-D877494A358A595B95F1EA041193CFEE"
      unitRef="usd">26675000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d37585990e869-wk-Fact-22DF3451332B59D5949236B046D8431E"
      unitRef="usd">105358000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2017Q3YTD"
      decimals="-3"
      id="d37585990e889-wk-Fact-325322EADD9F5EC2B0777B4B99483E0A"
      unitRef="usd">75800000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d37585990e909-wk-Fact-E6365763DCC055A5AAD948C79CAC1579"
      unitRef="usd">44445000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="FD2017Q3QTD"
      decimals="-3"
      id="d37585990e928-wk-Fact-B481D2585D75561EB430E823359932ED"
      unitRef="usd">17408000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d37585990e947-wk-Fact-1A44B26777715D349880DBD55C3E78A7"
      unitRef="usd">114258000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="FD2017Q3YTD"
      decimals="-3"
      id="d37585990e967-wk-Fact-A6F76D9758D15055B225021A84055620"
      unitRef="usd">47767000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d37585990e987-wk-Fact-31150344694E5A879C9AD0A0738C20AE"
      unitRef="usd">83983000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="FD2017Q3QTD"
      decimals="-3"
      id="d37585990e1006-wk-Fact-0B466BDE4F1B59AE89F50C1964C4C424"
      unitRef="usd">44083000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d37585990e1025-wk-Fact-23E0C78CE32B521B814627BA22DD3EE6"
      unitRef="usd">219616000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="FD2017Q3YTD"
      decimals="-3"
      id="d37585990e1045-wk-Fact-3CC32A48A0CD5B319D68CEF6035B1650"
      unitRef="usd">123567000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d37585990e1147-wk-Fact-6AE039E33D9C5CDEAE1012967F96DFBD"
      unitRef="usd">-83983000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2017Q3QTD"
      decimals="-3"
      id="d37585990e1167-wk-Fact-40677A16031B540E973B20BBF5C9DE82"
      unitRef="usd">-44083000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d37585990e1187-wk-Fact-0DB77577FC045D58A94069007BC33552"
      unitRef="usd">-219616000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2017Q3YTD"
      decimals="-3"
      id="d37585990e1208-wk-Fact-8E43775313085116A5CA0A7EEFE9CEBF"
      unitRef="usd">-123567000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d37585990e1312-wk-Fact-F76E8021626558E88A3085C079EB3E80"
      unitRef="usd">2741000</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="FD2017Q3QTD"
      decimals="-3"
      id="d37585990e1331-wk-Fact-B0578478606E59C6B48D35C4676179F5"
      unitRef="usd">326000</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d37585990e1350-wk-Fact-5F89EE90EA5456EAB6F8B5C5CA302BD8"
      unitRef="usd">7510000</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="FD2017Q3YTD"
      decimals="-3"
      id="d37585990e1370-wk-Fact-6EB92D84DD4A54DB83D8E2833231A3FD"
      unitRef="usd">649000</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InterestExpense
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d37585990e1390-wk-Fact-5298773546E956B2A476B4D00B0CC953"
      unitRef="usd">6675000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2017Q3QTD"
      decimals="-3"
      id="d37585990e1410-wk-Fact-46AD3F5FEC25521788BB47B9D992E8D5"
      unitRef="usd">1496000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d37585990e1430-wk-Fact-0261293D4CE557119BC44A95C1CB75EE"
      unitRef="usd">18805000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2017Q3YTD"
      decimals="-3"
      id="d37585990e1451-wk-Fact-1E85C2C8082B598EB0AA11002F15739B"
      unitRef="usd">4459000</us-gaap:InterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d37585990e1472-wk-Fact-EAB8C2DD87AF53349CE1BB115E64CFC6"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="FD2017Q3QTD"
      decimals="-3"
      id="d37585990e1491-wk-Fact-78EDC684840D5BCEA35159C6FEF06B8C"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d37585990e1510-wk-Fact-796B77D246935C489EF999DC75EF64A2"
      unitRef="usd">-2209000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="FD2017Q3YTD"
      decimals="-3"
      id="d37585990e1531-wk-Fact-A0E4D1FE0A705237AF09DD43A976115F"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d37585990e1551-wk-Fact-B43EE1099717593BB7B456D1D863E4ED"
      unitRef="usd">220000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2017Q3QTD"
      decimals="-3"
      id="d37585990e1570-wk-Fact-8B3723818D2252BA9443479D1C2F4A30"
      unitRef="usd">101000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d37585990e1589-wk-Fact-667E1B0D901654C39AF62E0D6074DB77"
      unitRef="usd">550000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2017Q3YTD"
      decimals="-3"
      id="d37585990e1609-wk-Fact-284A37198851572EA1C9050AEA57AFDA"
      unitRef="usd">206000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d37585990e1629-wk-Fact-27E44007A5375504ADEE6AF20ABF6227"
      unitRef="usd">-87697000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2017Q3QTD"
      decimals="-3"
      id="d37585990e1649-wk-Fact-C81801AAE97D58C396E2A7B78B5EF32A"
      unitRef="usd">-45152000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d37585990e1669-wk-Fact-4A79887409225F2BA0603FD9145B50A8"
      unitRef="usd">-232570000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2017Q3YTD"
      decimals="-3"
      id="d37585990e1690-wk-Fact-8E6ADF844FD257E89EE14B6395F3CB32"
      unitRef="usd">-127171000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d37585990e1793-wk-Fact-69971A3E7D3F57BAAF3705F5AD80D4F4"
      unitRef="usd">46000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2017Q3QTD"
      decimals="-3"
      id="d37585990e1812-wk-Fact-35D2D40AA43F5C9D9B5934F32E20F1BA"
      unitRef="usd">27000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d37585990e1831-wk-Fact-C45D6E334FD15D42A9DA0E8FAE4EA341"
      unitRef="usd">134000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2017Q3YTD"
      decimals="-3"
      id="d37585990e1851-wk-Fact-1FD78E5302455C94BB9DC295F0C61BE6"
      unitRef="usd">94000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d37585990e1958-wk-Fact-140F3BA91E2256A5BF9E0BE306FB0BF7"
      unitRef="usd">-87743000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2017Q3QTD"
      decimals="-3"
      id="d37585990e1978-wk-Fact-943BC7301A8358DDB78350FA470D31A1"
      unitRef="usd">-45179000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d37585990e1998-wk-Fact-B45A0729B05C59668CED7875FF86978E"
      unitRef="usd">-232704000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2017Q3YTD"
      decimals="-3"
      id="d37585990e2019-wk-Fact-E7598833183958F9826A9C7E045F8A51"
      unitRef="usd">-127265000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2018Q3QTD"
      decimals="2"
      id="d37585990e2123-wk-Fact-9B35FCB3B7EB583994D0E1C89E3CB22A"
      unitRef="usdPerShare">-1.14</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2017Q3QTD"
      decimals="2"
      id="d37585990e2143-wk-Fact-9951475A6A9F50B7B0578A1952AF668A"
      unitRef="usdPerShare">-0.69</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2018Q3YTD"
      decimals="2"
      id="d37585990e2163-wk-Fact-6C2CDE809B045C2FA0991187295B38A6"
      unitRef="usdPerShare">-3.03</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2017Q3YTD"
      decimals="2"
      id="d37585990e2184-wk-Fact-07424B054FE3587D9AE84C3BB0C6517A"
      unitRef="usdPerShare">-2.01</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d37585990e2282-wk-Fact-2E4D3BAA30465324A79605758B5C141E"
      unitRef="shares">77066000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2017Q3QTD"
      decimals="-3"
      id="d37585990e2301-wk-Fact-EC588876091D5D438C89DFAEAC2F2059"
      unitRef="shares">65312000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d37585990e2320-wk-Fact-173C030FB9C754C0A58729C30EB60806"
      unitRef="shares">76819000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="FD2017Q3YTD"
      decimals="-3"
      id="d37585990e2340-wk-Fact-461B720DDB4B5D3384EEF5D36885D351"
      unitRef="shares">63199000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d37585990e2447-wk-Fact-140F3BA91E2256A5BF9E0BE306FB0BF7"
      unitRef="usd">-87743000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2017Q3QTD"
      decimals="-3"
      id="d37585990e2467-wk-Fact-943BC7301A8358DDB78350FA470D31A1"
      unitRef="usd">-45179000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d37585990e2487-wk-Fact-B45A0729B05C59668CED7875FF86978E"
      unitRef="usd">-232704000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2017Q3YTD"
      decimals="-3"
      id="d37585990e2508-wk-Fact-E7598833183958F9826A9C7E045F8A51"
      unitRef="usd">-127265000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d37585990e2602-wk-Fact-7828C1CEF9975AB38D6278420B92CEF9"
      unitRef="usd">2000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="FD2017Q3QTD"
      decimals="-3"
      id="d37585990e2621-wk-Fact-94F335F6955557C0B0720F6F0E0E7909"
      unitRef="usd">76000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d37585990e2640-wk-Fact-39AC78B296FA55BA8F3AB1B66723D287"
      unitRef="usd">23000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="FD2017Q3YTD"
      decimals="-3"
      id="d37585990e2660-wk-Fact-04A2F27FFC0A5DAEBFD11DDE6BE34845"
      unitRef="usd">99000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d37585990e2685-wk-Fact-F317265E3B6755FBBB8BC2470F1CCE9E"
      unitRef="usd">-87741000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2017Q3QTD"
      decimals="-3"
      id="d37585990e2705-wk-Fact-0EBB8D7ABC9B50DBBDEA6F6945F9F1EE"
      unitRef="usd">-45103000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d37585990e2725-wk-Fact-8B7F65D180075E55952DD3AAE4B311B0"
      unitRef="usd">-232681000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2017Q3YTD"
      decimals="-3"
      id="d37585990e2746-wk-Fact-08B649D205FB559BA2FC47D553EC8BC5"
      unitRef="usd">-127166000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d37585999e464-wk-Fact-B45A0729B05C59668CED7875FF86978E"
      unitRef="usd">-232704000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2017Q3YTD"
      decimals="-3"
      id="d37585999e484-wk-Fact-E7598833183958F9826A9C7E045F8A51"
      unitRef="usd">-127265000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d37585999e539-wk-Fact-821EA4960E3B59DE80B070E6D3EDC4DA"
      unitRef="usd">2652000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="FD2017Q3YTD"
      decimals="-3"
      id="d37585999e558-wk-Fact-68AD4DFD2A5E54E88E0FAE6998D7D857"
      unitRef="usd">2168000</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d37585999e578-wk-Fact-42DEFC89C84C5EA9BB4530260E2E97D1"
      unitRef="usd">20205000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2017Q3YTD"
      decimals="-3"
      id="d37585999e597-wk-Fact-2194940E11ED5CD1A3AC537A9BB4FDF5"
      unitRef="usd">13332000</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d37585999e617-wk-Fact-2DCBC22CAE23561D8C8137E0A74483C2"
      unitRef="usd">1000000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="FD2017Q3YTD"
      decimals="-3"
      id="d37585999e636-wk-Fact-5288C234F50F548E9EB138AA0CE2764E"
      unitRef="usd">91000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d37585999e656-wk-Fact-9F140DB9CAD55F8A82F57323DE07C7D4"
      unitRef="usd">11541000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="FD2017Q3YTD"
      decimals="-3"
      id="d37585999e675-wk-Fact-E7408D702B955003AD3C8811576D0C16"
      unitRef="usd">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AccretionExpense
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d37585999e695-wk-Fact-FFA531B819255E8DBE34E9085DB5F0F4"
      unitRef="usd">50000</us-gaap:AccretionExpense>
    <us-gaap:AccretionExpense
      contextRef="FD2017Q3YTD"
      decimals="-3"
      id="d37585999e714-wk-Fact-0B815E0BF6A3502EB1CCF4823C6F02AA"
      unitRef="usd">506000</us-gaap:AccretionExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d37585999e774-wk-Fact-FFD637D42AA85FE1B9A9D287D1FDAF28"
      unitRef="usd">4315000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="FD2017Q3YTD"
      decimals="-3"
      id="d37585999e794-wk-Fact-262892DB6746582692B79919FE229CEF"
      unitRef="usd">1052000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d37585999e815-wk-Fact-2F18932E9E6B54D4A4BE63FA708C8AB2"
      unitRef="usd">2536000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="FD2017Q3YTD"
      decimals="-3"
      id="d37585999e834-wk-Fact-F94F34F8B19D558687869483F8E5D6EF"
      unitRef="usd">-921000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <insm:IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d37585999e855-wk-Fact-9567954D18F45B6A9CB178B3D041DD25"
      unitRef="usd">10596000</insm:IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities>
    <insm:IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities
      contextRef="FD2017Q3YTD"
      decimals="-3"
      id="d37585999e874-wk-Fact-F6073B5D5BDF520B8F901C3AB8F9106B"
      unitRef="usd">1745000</insm:IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d37585999e894-wk-Fact-2B0AC5D865105ABA82CF4C22998ABF04"
      unitRef="usd">-188439000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2017Q3YTD"
      decimals="-3"
      id="d37585999e914-wk-Fact-71F9B8FABD1F54C18B8CC23D297B4F35"
      unitRef="usd">-111396000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d37585999e974-wk-Fact-8A348B5E40AB5DF48936C7DA066F301A"
      unitRef="usd">10063000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2017Q3YTD"
      decimals="-3"
      id="d37585999e994-wk-Fact-B2EE5197455152A99A69B9CD0C9DB840"
      unitRef="usd">1301000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d37585999e1015-wk-Fact-D274D600333253D89630796D38990604"
      unitRef="usd">-10063000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2017Q3YTD"
      decimals="-3"
      id="d37585999e1035-wk-Fact-9498FB4146825B3FA2B2D0D7D4BAA244"
      unitRef="usd">-1301000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d37585999e1095-wk-Fact-CDA468C1448459BFAE8B0DBA1BBA12B9"
      unitRef="usd">6390000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="FD2017Q3YTD"
      decimals="-3"
      id="d37585999e1114-wk-Fact-593FA62967C858529615D6B0A6ED8E62"
      unitRef="usd">2953000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d37585999e1134-wk-Fact-FBB052B514595206B29873038BF50CCB"
      unitRef="usd">2209000</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="FD2017Q3YTD"
      decimals="-3"
      id="d37585999e1154-wk-Fact-3BAA2EF98BF55EACB6A05DCD12E9474F"
      unitRef="usd">0</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:RepaymentsOfDebt
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d37585999e1174-wk-Fact-18D9125B85745404916A2107ED70E6F3"
      unitRef="usd">55000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="FD2017Q3YTD"
      decimals="-3"
      id="d37585999e1194-wk-Fact-15AFF01F57D65BB1BF05A81A603DB0C7"
      unitRef="usd">0</us-gaap:RepaymentsOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d37585999e1215-wk-Fact-96F71BE14A4C5E7CA12B89D9803E76FC"
      unitRef="usd">450000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="FD2017Q3YTD"
      decimals="-3"
      id="d37585999e1234-wk-Fact-3F1EBFF13FF05728BA62207CA682556A"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d37585999e1254-wk-Fact-65B6033193DA5876A2261D420C74BE1C"
      unitRef="usd">14235000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="FD2017Q3YTD"
      decimals="-3"
      id="d37585999e1274-wk-Fact-ACD08068D5A550D2A48F6ADCEAA4FF79"
      unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d37585999e1294-wk-Fact-604A61E13AC859908E6585A41F505718"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="FD2017Q3YTD"
      decimals="-3"
      id="d37585999e1313-wk-Fact-8B64CB7C78275771B9423691F7B6958B"
      unitRef="usd">377703000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d37585999e1333-wk-Fact-AA53131971885D349FCCD5A2E4AFE614"
      unitRef="usd">384946000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2017Q3YTD"
      decimals="-3"
      id="d37585999e1352-wk-Fact-2209022AB29E5628ADF80B00AE16A896"
      unitRef="usd">380656000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d37585999e1372-wk-Fact-474DE0A8777B52F38BC2A99912FE40FF"
      unitRef="usd">-35000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="FD2017Q3YTD"
      decimals="-3"
      id="d37585999e1392-wk-Fact-D4542103BF6157BCBE22F138C5324C18"
      unitRef="usd">128000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d37585999e1412-wk-Fact-66F2C24A57E159E6B61E347B889AE7E3"
      unitRef="usd">186409000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="FD2017Q3YTD"
      decimals="-3"
      id="d37585999e1431-wk-Fact-3B38744A1C535769BA42BA7AC1AD9D81"
      unitRef="usd">268087000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2017Q4"
      decimals="-3"
      id="d37585999e1451-wk-Fact-7D13774CB56B50F691CFDF9E0DC702CA"
      unitRef="usd">381165000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2016Q4"
      decimals="-3"
      id="d37585999e1470-wk-Fact-E238271D7691568095B282B08F275FAD"
      unitRef="usd">162591000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2018Q3"
      decimals="-3"
      id="d37585999e1495-wk-Fact-1BE6FE185E03589087FAB308105B46AE"
      unitRef="usd">567574000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2017Q3"
      decimals="-3"
      id="d37585999e1514-wk-Fact-DE71C8EC598D50E1B813FC06C1BAD600"
      unitRef="usd">430678000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:InterestPaidNet
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d37585999e1614-wk-Fact-C590F6852E8B5E71886E699DF042397F"
      unitRef="usd">4975000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="FD2017Q3YTD"
      decimals="-3"
      id="d37585999e1633-wk-Fact-216AD199E9655B5D985797FB54052D70"
      unitRef="usd">3876000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d37585999e1654-wk-Fact-D5AC3E36B91C5482A405C7A6C88524DC"
      unitRef="usd">127000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="FD2017Q3YTD"
      decimals="-3"
      id="d37585999e1673-wk-Fact-C8A1FA92B8DA5B5B852F740DB37E66C6"
      unitRef="usd">62000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="FD2018Q3YTD"
      id="TextSelection-034D62C3CE8957B1B7BF0DD4EE4000D7-0-wk-Fact-24D1DF213843532F98897F2D1FAB6A60">&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;The Company and Basis of Presentation&lt;/span&gt;&lt;div style="line-height:120%;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), received accelerated approval in the United States (US) on September 28, 2018 for the treatment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Mycobacterium avium&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. The Company's clinical-stage pipeline includes INS1007 and INS1009. INS1007 is a novel oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1) with therapeutic potential in non-cystic fibrosis (non-CF) bronchiectasis and other inflammatory diseases. INS1009 is an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension (PAH).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company was incorporated in the Commonwealth of Virginia on November&#160;29, 1999 and its principal executive offices are in Bridgewater, New Jersey. The Company has legal entities in the US,&#160;Ireland, Germany, France, the United Kingdom (UK), the Netherlands, and Japan. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The accompanying unaudited interim consolidated financial statements have been prepared pursuant to the rules&#160;and regulations for reporting on Form&#160;10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the US for complete consolidated financial statements are not included herein. The unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company&#x2019;s Annual Report on Form&#160;10-K for the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. The unaudited interim consolidated financial information presented herein reflects all normal adjustments that are, in the opinion of management, necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company had &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$567.6 million&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in cash and cash equivalents as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and reported a net loss of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$232.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. Historically, the Company has funded its operations through public offerings of equity securities and debt financings. To date, the Company has not generated material revenue from ARIKAYCE. The Company commenced commercial shipments in October 2018. The Company expects to continue to incur operating losses while funding commercial launch efforts for ARIKAYCE, research and development (R&amp;amp;D) activities, regulatory submissions outside the US, and general and administrative expenses. The Company expects its future cash requirements to be substantial, and the Company may need to raise additional capital to fund operations, including the commercialization of ARIKAYCE and additional clinical trials related to ARIKAYCE, to develop INS1007 and INS1009 and to develop, acquire, in-license or co-promote other products that address orphan or rare diseases.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;The source, timing and availability of any future financing or other transaction will depend principally upon continued progress in the Company&#x2019;s commercial, regulatory and development activities. Any equity or debt financing will also be contingent upon equity and debt market conditions and interest rates at the time. If the Company is unable to obtain sufficient additional funds when required, the Company may be forced to delay, restrict or eliminate all or a portion of its development programs or commercialization efforts.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d37586247e361-wk-Fact-F0A239BFB7D05E44887AEC2D14180C00"
      unitRef="usd">-232700000</us-gaap:NetIncomeLoss>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="FD2018Q3YTD"
      id="TextSelection-4F1E881A2A775975BD5D364C77D2E618-0-wk-Fact-E0862973C8525EAE8717DA115CF7CC67">&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;The following are the required interim disclosure updates to the Company's significant accounting policies described in Note 2 of the notes to the consolidated financial statements in the Company&#x2019;s Annual Report on Form&#160;10-K for the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;December&#160;31, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; - The Company categorizes its financial assets and liabilities measured and reported at fair value in the financial statements on a recurring basis based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs used to determine the fair value of financial assets and liabilities, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Level 1 &#x2014; Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Level 2 &#x2014; Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the assets or liability through correlation with market data at the measurement date and for the duration of the instrument&#x2019;s anticipated life.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Level 3 &#x2014; Inputs reflect management&#x2019;s best estimate of what market participants would use in pricing the asset or liability at the measurement date.&#160;Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Each major category of financial assets and liabilities measured at fair value on a recurring basis is categorized based upon the lowest level of significant input to the valuations. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Financial instruments in Level 1 generally include US treasuries and mutual funds listed in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company&#x2019;s only financial assets and liabilities which were measured at fair value as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; were Level 1 assets comprised of cash and cash equivalents of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$567.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$381.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively. The estimated fair value of the liability component of the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.75%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; convertible senior notes due 2025 (the Convertible Notes) (categorized as a Level 2 liability for fair value measurement purposes) was determined using current market factors and the ability of the Company to obtain debt on comparable terms to the Convertible Notes. The following table shows certain assets and liabilities and their carrying values and fair values:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:83.0078125%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:55%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:19%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:3%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:19%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of September 30, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Carrying Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;567.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;567.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Convertible Notes ($450.0 face value)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;311.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;381.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;* The carrying value of the Convertible Notes excludes &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$129.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; of the unamortized portion of the debt discount.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company&#x2019;s cash and cash equivalents permit daily redemption and the fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions. Cash equivalents consist of liquid investments with an original maturity of three months or less from the date of purchase. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company's cash and cash equivalents balance included US treasury bills of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$399.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter. There were &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; transfers in or out of Level 1, Level 2 or Level 3 during the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company held &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; securities that were in an unrealized gain or loss position. The Company reviews the status of each security quarterly to determine whether an other-than-temporary impairment has occurred. In making its determination, the Company considers a number of factors, including: (1) the significance of the decline; (2)&#160;whether the securities were rated below investment grade; (3)&#160;how long the securities have been in an unrealized loss position; and (4) the Company&#x2019;s ability and intent to retain the investment for a sufficient period of time for it to recover.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Net Loss Per Share&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; - Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period.&#160;Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares and other dilutive securities outstanding during the period. Potentially dilutive securities from stock options, restricted stock units (RSUs) and convertible debt securities would be anti-dilutive as the Company incurred a net loss. Potentially dilutive common shares resulting from the assumed exercise of outstanding stock options and from the assumed conversion of the Convertible Notes are determined based on the treasury stock method.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table sets forth the reconciliation of the weighted average number of common shares used to compute basic and diluted net loss per share for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in&#160;thousands,&#160;except&#160;per&#160;share&#160;amounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Numerator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(87,743&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(45,179&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(232,704&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(127,265&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Denominator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted average common shares used in calculation of basic net loss per share:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;77,066&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;65,312&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;76,819&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;63,199&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Common stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&lt;/span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;RSUs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&lt;/span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Convertible debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted average common shares outstanding used&#160;in calculation of diluted net loss per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;77,066&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;65,312&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;76,819&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;63,199&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net loss per share:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1.14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.69&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3.03&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2.01&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following potentially dilutive securities have been excluded from the computations of diluted weighted average common shares outstanding as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as their effect would have been anti-dilutive (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.4140625%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:69%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,608&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,601&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Unvested RSUs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;245&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;47&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Convertible debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,492&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Inventory - &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Inventory is stated at the lower of cost and net realizable value with cost determined on a standard costing method. The Company began capitalizing inventory costs subsequent to US Food and Drug Administration (FDA) approval of ARIKAYCE on September 28, 2018, when it was determined that the inventory had a probable future economic benefit. Inventory will be sold beginning in the fourth quarter of 2018 based on first-in, first out basis. Manufacturing variances, such as material usage variance and yield variance, will be capitalized in inventory until the respective units are sold at which point the variances will be released in cost of goods sold. The Company will periodically review inventory for expiry and obsolescence and write down accordingly.  The Company performs quality control procedures throughout the manufacturing processes of ARIKAYCE; however, certain batches or units of ARIKAYCE may not meet quality specifications and result in a charge to cost of goods sold.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Prior to FDA approval of ARIKAYCE, the Company expensed all inventory related costs in the period incurred; therefore, inventory is not included in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; consolidated balance sheet. Inventory used for clinical development purposes is expensed to research and development (R&amp;amp;D) expense when consumed.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; - In August 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standard Update (ASU) 2016-15, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which addressed eight specific cash flow issues with the objective of reducing the existing diversity in practice. Among the updates, the standard requires debt extinguishment costs to be classified as cash outflows for financing activities. This standard update is effective as of the first quarter of 2018. As a result of the adoption of the standard, in the first quarter of 2018, the Company reported a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; loss on extinguishment of debt in the financing activities section of its consolidated statement of cash flows. The Company had no material debt extinguishment costs prior to the first quarter of 2018. The impact of adopting this standard was not material to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;New Accounting Pronouncements (Not Yet Adopted)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;In February 2016, the FASB issued ASU 2016-2, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in order to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous generally accepted accounting principles. ASU 2016-2 requires a lessee to recognize a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term on the balance sheet. ASU 2016-2 is effective for fiscal years beginning after December&#160;15, 2018 (including interim periods within those periods) and early adoption is permitted. In August 2018, the FASB issued ASU 2018-11, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Targeted Improvements to ASC 842&lt;/span&gt;, which provides a new transition option in which an entity initially applies ASU 2016-2 at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company will use the new transition option and is also utilizing the package of practical expedients that allows it to not reassess: (1) whether any expired or existing contracts are or contain leases, (2) lease classification for any expired or existing leases, and (3) initial direct costs for any expired or existing leases. The Company additionally expects to use the practical expedient that allows it to treat the lease and non-lease components of its leases as a single component. The Company has identified approximately ten leasing arrangements and is currently assessing the financial impact on the consolidated balance sheet. The Company expects to adopt ASU 2016-2 in the first quarter of 2019 and is in the process of evaluating the impact of adoption on its consolidated financial statements.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="FD2018Q3YTD"
      id="TextSelection-5A4CAE62761D50CC9C8586B7AC0E38C0-0-wk-Fact-E597CC14C2BB58C08DE14D2E9C5CB8CC">Fair Value Measurements&lt;span style="font-family:inherit;font-size:10pt;"&gt; - The Company categorizes its financial assets and liabilities measured and reported at fair value in the financial statements on a recurring basis based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs used to determine the fair value of financial assets and liabilities, are as follows:&lt;/span&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Level 1 &#x2014; Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Level 2 &#x2014; Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the assets or liability through correlation with market data at the measurement date and for the duration of the instrument&#x2019;s anticipated life.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Level 3 &#x2014; Inputs reflect management&#x2019;s best estimate of what market participants would use in pricing the asset or liability at the measurement date.&#160;Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Each major category of financial assets and liabilities measured at fair value on a recurring basis is categorized based upon the lowest level of significant input to the valuations. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Financial instruments in Level 1 generally include US treasuries and mutual funds listed in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company&#x2019;s only financial assets and liabilities which were measured at fair value as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; were Level 1 assets comprised of cash and cash equivalents of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$567.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$381.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively. The estimated fair value of the liability component of the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.75%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; convertible senior notes due 2025 (the Convertible Notes) (categorized as a Level 2 liability for fair value measurement purposes) was determined using current market factors and the ability of the Company to obtain debt on comparable terms to the Convertible Notes. The following table shows certain assets and liabilities and their carrying values and fair values:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:83.0078125%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:55%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:19%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:3%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:19%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of September 30, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Carrying Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;567.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;567.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Convertible Notes ($450.0 face value)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;311.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;381.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;* The carrying value of the Convertible Notes excludes &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$129.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt; of the unamortized portion of the debt discount.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company&#x2019;s cash and cash equivalents permit daily redemption and the fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions. Cash equivalents consist of liquid investments with an original maturity of three months or less from the date of purchase. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company's cash and cash equivalents balance included US treasury bills of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$399.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter. There were &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; transfers in or out of Level 1, Level 2 or Level 3 during the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company held &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt; securities that were in an unrealized gain or loss position. The Company reviews the status of each security quarterly to determine whether an other-than-temporary impairment has occurred. In making its determination, the Company considers a number of factors, including: (1) the significance of the decline; (2)&#160;whether the securities were rated below investment grade; (3)&#160;how long the securities have been in an unrealized loss position; and (4) the Company&#x2019;s ability and intent to retain the investment for a sufficient period of time for it to recover.</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q3"
      decimals="-5"
      id="d37589112e388-wk-Fact-262A8C3075AB59F6A9434AEB56E78F03"
      unitRef="usd">567600000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2017Q4"
      decimals="-5"
      id="d37589112e392-wk-Fact-4BEC86EEFC125BCD97660C358B830578"
      unitRef="usd">381200000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2018Q3_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember"
      decimals="INF"
      id="d37589112e396-wk-Fact-755C13FF89B15B2CB9781EF2E9B053C7"
      unitRef="number">0.0175</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="FD2018Q3YTD"
      id="TextSelection-BF9D7701CC7A5E3EB7504546ED8F5DB8-0-wk-Fact-565738CC69E65C35A9CB7FFF9DAF0976">The following table shows certain assets and liabilities and their carrying values and fair values:&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:83.0078125%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:55%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:19%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:3%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:19%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of September 30, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Carrying Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;567.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;567.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Convertible Notes ($450.0 face value)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;311.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;381.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#160;* The carrying value of the Convertible Notes excludes &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;span&gt;$129.4 million&lt;/span&gt;&lt;/span&gt; of the unamortized portion of the debt discount.</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d37589112e595-wk-Fact-970EEA3A52C751799958B6AFC30E2A59"
      unitRef="usd">567600000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d37589112e614-wk-Fact-78C20C0BC2F35EF4BA46C572F3653EE6"
      unitRef="usd">567600000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d37589112e675-wk-Fact-F0C0A9216C1A5F87A2F0C1C891430137"
      unitRef="usd">311900000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-5"
      id="d37589112e694-wk-Fact-FA39F73B0BF056E2A4157CE28EC82553"
      unitRef="usd">381600000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="FI2018Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember"
      decimals="-5"
      id="d37589112e705-wk-Fact-4998B9312C95515C9EA11C5B4F3DBFB2"
      unitRef="usd">129400000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q3_us-gaap_CashAndCashEquivalentsAxis_us-gaap_USTreasurySecuritiesMember"
      decimals="-5"
      id="d37589112e719-wk-Fact-508D6DEF54345B8CA9F4292E5B48ECF6"
      unitRef="usd">399800000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <insm:FairValueLevel1Level2Level3TransfersAmount
      contextRef="FD2018Q3YTD"
      decimals="INF"
      id="d37589112e730-wk-Fact-35CC56CB07455FF089D209A8A6DACB69"
      unitRef="usd">0</insm:FairValueLevel1Level2Level3TransfersAmount>
    <insm:AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities
      contextRef="FI2018Q3"
      decimals="INF"
      id="d37589112e759-wk-Fact-BC704597F57451B886DA07B6F9F379C2"
      unitRef="security">0</insm:AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="FD2018Q3YTD"
      id="TextSelection-73F518D94512557FA5054386AED0870A-0-wk-Fact-B4E22C47503E559982F2F3C982E8FF89">Net Loss Per Share&lt;span style="font-family:inherit;font-size:10pt;"&gt; - Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period.&#160;Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares and other dilutive securities outstanding during the period. Potentially dilutive securities from stock options, restricted stock units (RSUs) and convertible debt securities would be anti-dilutive as the Company incurred a net loss. Potentially dilutive common shares resulting from the assumed exercise of outstanding stock options and from the assumed conversion of the Convertible Notes are determined based on the treasury stock method.&lt;/span&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table sets forth the reconciliation of the weighted average number of common shares used to compute basic and diluted net loss per share for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in&#160;thousands,&#160;except&#160;per&#160;share&#160;amounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Numerator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(87,743&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(45,179&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(232,704&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(127,265&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Denominator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted average common shares used in calculation of basic net loss per share:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;77,066&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;65,312&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;76,819&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;63,199&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Common stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&lt;/span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;RSUs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&lt;/span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Convertible debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted average common shares outstanding used&#160;in calculation of diluted net loss per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;77,066&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;65,312&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;76,819&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;63,199&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net loss per share:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1.14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.69&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3.03&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2.01&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following potentially dilutive securities have been excluded from the computations of diluted weighted average common shares outstanding as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as their effect would have been anti-dilutive (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.4140625%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:69%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,608&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,601&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Unvested RSUs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;245&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;47&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Convertible debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,492&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock
      contextRef="FD2018Q3YTD"
      id="TextSelection-1FEF68C38DC75760A6899529939F8605-0-wk-Fact-85A75E625E0A556C9B7D4D018EAA786C">The following table sets forth the reconciliation of the weighted average number of common shares used to compute basic and diluted net loss per share for the &lt;span style="font-family:inherit;font-size:10pt;"&gt;three and nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in&#160;thousands,&#160;except&#160;per&#160;share&#160;amounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Numerator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(87,743&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(45,179&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(232,704&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(127,265&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Denominator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted average common shares used in calculation of basic net loss per share:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;77,066&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;65,312&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;76,819&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;63,199&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Common stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&lt;/span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;RSUs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&lt;/span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Convertible debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted average common shares outstanding used&#160;in calculation of diluted net loss per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;77,066&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;65,312&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;76,819&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;63,199&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net loss per share:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1.14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.69&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3.03&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2.01&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d37589112e1157-wk-Fact-140F3BA91E2256A5BF9E0BE306FB0BF7"
      unitRef="usd">-87743000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2017Q3QTD"
      decimals="-3"
      id="d37589112e1177-wk-Fact-943BC7301A8358DDB78350FA470D31A1"
      unitRef="usd">-45179000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d37589112e1197-wk-Fact-B45A0729B05C59668CED7875FF86978E"
      unitRef="usd">-232704000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2017Q3YTD"
      decimals="-3"
      id="d37589112e1218-wk-Fact-E7598833183958F9826A9C7E045F8A51"
      unitRef="usd">-127265000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d37589112e1312-wk-Fact-4EC56997C8285C5383565676429B7A91"
      unitRef="shares">77066000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2017Q3QTD"
      decimals="-3"
      id="d37589112e1331-wk-Fact-03944E6867D6537B9F235AEF82777579"
      unitRef="shares">65312000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d37589112e1350-wk-Fact-FE4F8D92CAC2575AA3BFFB67AE510E53"
      unitRef="shares">76819000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2017Q3YTD"
      decimals="-3"
      id="d37589112e1370-wk-Fact-28532D3BB595506AA35E9B66A7C81C4E"
      unitRef="shares">63199000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="-3"
      id="d37589112e1468-wk-Fact-1467CE3DC3DD5424A5AAC80CC92C4757"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2017Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="-3"
      id="d37589112e1487-wk-Fact-22BAAB400BEA502C90A72E9677A17720"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="-3"
      id="d37589112e1506-wk-Fact-DED0A91F646B54308A5BC3B1D7BA401B"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="d37589112e1526-wk-Fact-260212FAA27C59DEB974FE0D02CCA3A7"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="d37589112e1545-wk-Fact-3EC30ED4368E5D1BB016279689B5A139"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2017Q3QTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="d37589112e1564-wk-Fact-BE7AFFD406DF5980967FB912E04B368C"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="d37589112e1583-wk-Fact-83FDBA66F3685798BDC0D1F8E9C4957F"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      id="d37589112e1603-wk-Fact-F598E555C7805778BAF7B83ED44D6FF0"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d37589112e1622-wk-Fact-6E1A8A195F425F3190A6036A681A8F03"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="FD2017Q3QTD"
      decimals="-3"
      id="d37589112e1641-wk-Fact-E982E47291085B59B56D42427ADC43C3"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d37589112e1660-wk-Fact-4E49C286A8D254E09921353B0734B4E3"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="FD2017Q3YTD"
      decimals="-3"
      id="d37589112e1680-wk-Fact-32CB443CF5745EC9A9108699711D70E8"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d37589112e1701-wk-Fact-ED081918EC395B68A8E74B9F49849B81"
      unitRef="shares">77066000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2017Q3QTD"
      decimals="-3"
      id="d37589112e1720-wk-Fact-D9D3BF1000E3566FAB3956FD24834197"
      unitRef="shares">65312000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d37589112e1739-wk-Fact-230B7F6508B651079FFFDECCECED7982"
      unitRef="shares">76819000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2017Q3YTD"
      decimals="-3"
      id="d37589112e1759-wk-Fact-3A1288C5C261588E9669FA4F1468373E"
      unitRef="shares">63199000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2018Q3QTD"
      decimals="2"
      id="d37589112e1862-wk-Fact-9B35FCB3B7EB583994D0E1C89E3CB22A"
      unitRef="usdPerShare">-1.14</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2017Q3QTD"
      decimals="2"
      id="d37589112e1882-wk-Fact-9951475A6A9F50B7B0578A1952AF668A"
      unitRef="usdPerShare">-0.69</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2018Q3YTD"
      decimals="2"
      id="d37589112e1902-wk-Fact-6C2CDE809B045C2FA0991187295B38A6"
      unitRef="usdPerShare">-3.03</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2017Q3YTD"
      decimals="2"
      id="d37589112e1923-wk-Fact-07424B054FE3587D9AE84C3BB0C6517A"
      unitRef="usdPerShare">-2.01</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="FD2018Q3YTD"
      id="TextSelection-66BE67F067115AB391655C180079E493-0-wk-Fact-FFF82E2B3BD55D80B8261A37015F111F">The following potentially dilutive securities have been excluded from the computations of diluted weighted average common shares outstanding as of &lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as their effect would have been anti-dilutive (in thousands):&lt;/span&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.4140625%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:69%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,608&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,601&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Unvested RSUs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;245&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;47&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Convertible debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,492&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2018Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_insm_EmployeeAndDirectorsStockOptionsMember"
      decimals="-3"
      id="d37589112e2036-wk-Fact-DDE26BFF50665DC5B4E367A0C281D047"
      unitRef="shares">9608000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2017Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_insm_EmployeeAndDirectorsStockOptionsMember"
      decimals="-3"
      id="d37589112e2050-wk-Fact-7A4CDD4A23DC5110947F5C310265AC6E"
      unitRef="shares">8601000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2018Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="d37589112e2065-wk-Fact-9950304EFEE150CC9A074A1535EFBB93"
      unitRef="shares">245000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2017Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="d37589112e2079-wk-Fact-07F53D264BF65A209CB3E4B8B0912E31"
      unitRef="shares">47000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2018Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember"
      decimals="-3"
      id="d37589112e2094-wk-Fact-9DE2C8E047DD5987B08ECCC0C034A32D"
      unitRef="shares">11492000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2017Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember"
      decimals="-3"
      id="d37589112e2108-wk-Fact-7669FAB07F8C533992ED1490FEFB356B"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="FD2018Q3YTD"
      id="TextSelection-EF5482DFE4FF844A11788231595E4A37-0-wk-Fact-3398BE7FE1A97174CA778231AA7DB4C2">Inventory - &lt;span style="font-family:inherit;font-size:10pt;"&gt;Inventory is stated at the lower of cost and net realizable value with cost determined on a standard costing method. The Company began capitalizing inventory costs subsequent to US Food and Drug Administration (FDA) approval of ARIKAYCE on September 28, 2018, when it was determined that the inventory had a probable future economic benefit. Inventory will be sold beginning in the fourth quarter of 2018 based on first-in, first out basis. Manufacturing variances, such as material usage variance and yield variance, will be capitalized in inventory until the respective units are sold at which point the variances will be released in cost of goods sold. The Company will periodically review inventory for expiry and obsolescence and write down accordingly.  The Company performs quality control procedures throughout the manufacturing processes of ARIKAYCE; however, certain batches or units of ARIKAYCE may not meet quality specifications and result in a charge to cost of goods sold.&lt;/span&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Prior to FDA approval of ARIKAYCE, the Company expensed all inventory related costs in the period incurred; therefore, inventory is not included in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt; consolidated balance sheet. Inventory used for clinical development purposes is expensed to research and development (R&amp;amp;D) expense when consumed.</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="FD2018Q3YTD"
      id="TextSelection-54729AE8417850398774DC3093645532-0-wk-Fact-85E9015FE8D85175A711DD937AC708BE">Recently Adopted Accounting Pronouncements&lt;span style="font-family:inherit;font-size:10pt;"&gt; - In August 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standard Update (ASU) 2016-15, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which addressed eight specific cash flow issues with the objective of reducing the existing diversity in practice. Among the updates, the standard requires debt extinguishment costs to be classified as cash outflows for financing activities. This standard update is effective as of the first quarter of 2018. As a result of the adoption of the standard, in the first quarter of 2018, the Company reported a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; loss on extinguishment of debt in the financing activities section of its consolidated statement of cash flows. The Company had no material debt extinguishment costs prior to the first quarter of 2018. The impact of adopting this standard was not material to the Company.&lt;/span&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:56px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;New Accounting Pronouncements (Not Yet Adopted)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;In February 2016, the FASB issued ASU 2016-2, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in order to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous generally accepted accounting principles. ASU 2016-2 requires a lessee to recognize a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term on the balance sheet. ASU 2016-2 is effective for fiscal years beginning after December&#160;15, 2018 (including interim periods within those periods) and early adoption is permitted. In August 2018, the FASB issued ASU 2018-11, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Targeted Improvements to ASC 842&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which provides a new transition option in which an entity initially applies ASU 2016-2 at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company will use the new transition option and is also utilizing the package of practical expedients that allows it to not reassess: (1) whether any expired or existing contracts are or contain leases, (2) lease classification for any expired or existing leases, and (3) initial direct costs for any expired or existing leases. The Company additionally expects to use the practical expedient that allows it to treat the lease and non-lease components of its leases as a single component. The Company has identified approximately ten leasing arrangements and is currently assessing the financial impact on the consolidated balance sheet. The Company expects to adopt ASU 2016-2 in the first quarter of 2019 and is in the process of evaluating the impact of adoption on its consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&#160;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="FD2018Q1YTD"
      decimals="-5"
      id="d37589112e2149-wk-Fact-294C9818237154148BE8AA50B2B54BD3"
      unitRef="usd">2200000</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="FD2018Q3YTD"
      id="TextSelection-07483B66448E5C1EAAF5467A69B18EBB-0-wk-Fact-588B7305E6EE5C46AE232851B257F7F5">&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Intangible Assets&lt;/span&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of September 30, 2018, the Company's identifiable intangible assets consisted of acquired ARIKAYCE R&amp;amp;D, formerly referred to as in-process research and development, and a milestone payable to PARI Pharma GmbH (PARI) for the license to use PARI's Lamira&#x2122; Nebulizer System for the delivery of ARIKAYCE to patients. The total carrying value of the acquired ARIKAYCE R&amp;amp;D was&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$58.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;as of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, resulting from the initial amount recorded at the time of the Company's merger with Transave, Inc. (Transave) in 2010 and subsequent adjustments. On September 28, 2018, as a result of the FDA approval for ARIKAYCE, the Company recorded a milestone payment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; due to PARI. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Intangible assets consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:72.4609375%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:20%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of September 30, &lt;br/&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of December 31, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Acquired ARIKAYCE R&amp;amp;D&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;58,200&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;58,200&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;PARI milestone upon FDA approval&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,741&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;&#160;&#160;Intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;59,941&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;58,200&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Intangible assets are measured at their respective fair values on the date they were recorded and, with respect to the Acquired ARIKAYCE milestone, at the date of subsequent adjustments of fair value. Intangible assets will be amortized beginning October 1, 2018 over the initial regulatory exclusivity period for ARIKAYCE (&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12 years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;). As of&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;, the Company performed a qualitative assessment on the assets. This assessment did not identify any indicators of impairment of the intangible assets and indicated that the implied value of the assets was more than&#160;100%&#160;greater than the book value as of that date.</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2018Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-5"
      id="d37586553e324-wk-Fact-AD20B71B1B6826A1C1538248F08C6A5D"
      unitRef="usd">58200000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <insm:AccruedMilestonePaymentCurrent
      contextRef="I2018Q3Sept28"
      decimals="-5"
      id="d37586553e336-wk-Fact-FD81903B8A3D9AD08B2682699717D45B"
      unitRef="usd">1700000</insm:AccruedMilestonePaymentCurrent>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="FD2018Q3YTD"
      id="TextSelection-0E037DA458F05449D593821FDC8841EA-0-wk-Fact-C752B2F0E5813C997F1882218D914ED2">Intangible assets consist of the following:&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:72.4609375%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:20%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of September 30, &lt;br/&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of December 31, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Acquired ARIKAYCE R&amp;amp;D&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;58,200&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;58,200&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;PARI milestone upon FDA approval&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,741&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;&#160;&#160;Intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;59,941&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;58,200&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2018Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-3"
      id="d37586553e457-wk-Fact-1C61BDCDA05AF27723578243D86410B4"
      unitRef="usd">58200000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-3"
      id="d37586553e476-wk-Fact-E550D66824F4A7ADCA5D8243D857646F"
      unitRef="usd">58200000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2018Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember"
      decimals="-3"
      id="d37586553e491-wk-Fact-5FD26FBADD337F16781C8243D8819991"
      unitRef="usd">1741000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember"
      decimals="-3"
      id="d37586553e510-wk-Fact-177C426B32364CBC24CA8243D86FA182"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2018Q3"
      decimals="-3"
      id="d37586553e535-wk-Fact-BCE69FE0C62A914B7A8A8243D869478E"
      unitRef="usd">59941000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2017Q4"
      decimals="-3"
      id="d37586553e554-wk-Fact-DCB56C97A1E2B61CB9F78243D876B48C"
      unitRef="usd">58200000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2018Q3YTD"
      id="d37586553e569-wk-Fact-552349AA3A0164E5C222824793D1CBDC">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="FD2018Q3YTD"
      id="TextSelection-F665474877C956D09544A8AC6C140D60-0-wk-Fact-F2D87B8B788B5307B137BB35ED79E931">&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Accrued Expenses&lt;/span&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued expenses consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.96875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of September&#160;30, &lt;br/&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of December&#160;31, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in&#160;thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued clinical trial expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,576&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,837&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,387&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,197&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued professional fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,746&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,500&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued technical operation expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,137&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,182&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued milestone payment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,741&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued interest payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,663&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;423&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued construction costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,069&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,719&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other accrued expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,049&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;481&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;40,368&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;29,339&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="FD2018Q3YTD"
      id="TextSelection-1F5074DD33C85E9F8A5757AF4942A3DD-0-wk-Fact-B2C2EA35F5AF5065B93B778633239490">Accrued expenses consist of the following:&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.96875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of September&#160;30, &lt;br/&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of December&#160;31, &lt;br/&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in&#160;thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued clinical trial expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,576&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,837&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,387&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,197&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued professional fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,746&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,500&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued technical operation expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,137&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,182&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued milestone payment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,741&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued interest payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,663&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;423&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accrued construction costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,069&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,719&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other accrued expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,049&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;481&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;40,368&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;29,339&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <insm:AccruedClinicalTrialExpenses
      contextRef="FI2018Q3"
      decimals="-3"
      id="d37588595e438-wk-Fact-66886C3E48C952D680072FCBC36B0AA9"
      unitRef="usd">6576000</insm:AccruedClinicalTrialExpenses>
    <insm:AccruedClinicalTrialExpenses
      contextRef="FI2017Q4"
      decimals="-3"
      id="d37588595e457-wk-Fact-C5AE24FBAE1B5FF494CDC10E4A27E6A2"
      unitRef="usd">7837000</insm:AccruedClinicalTrialExpenses>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="FI2018Q3"
      decimals="-3"
      id="d37588595e472-wk-Fact-81680FA69D6F5319848DB75AC5FB1755"
      unitRef="usd">11387000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="FI2017Q4"
      decimals="-3"
      id="d37588595e491-wk-Fact-F105BE16978F5B888879EBC86DC5E548"
      unitRef="usd">12197000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="FI2018Q3"
      decimals="-3"
      id="d37588595e511-wk-Fact-28CF2535C82F5F168C38480FFF3A835B"
      unitRef="usd">10746000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="FI2017Q4"
      decimals="-3"
      id="d37588595e530-wk-Fact-FD091747DC7153ADB6BA9002399E767E"
      unitRef="usd">4500000</us-gaap:AccruedProfessionalFeesCurrent>
    <insm:AccruedTechnicalOperationExpenses
      contextRef="FI2018Q3"
      decimals="-3"
      id="d37588595e550-wk-Fact-8CE50102244D593B81657187DE73ED2D"
      unitRef="usd">5137000</insm:AccruedTechnicalOperationExpenses>
    <insm:AccruedTechnicalOperationExpenses
      contextRef="FI2017Q4"
      decimals="-3"
      id="d37588595e569-wk-Fact-1A28B7C9EAF853E7A5A4EAF449514C11"
      unitRef="usd">2182000</insm:AccruedTechnicalOperationExpenses>
    <insm:AccruedMilestonePaymentCurrent
      contextRef="FI2018Q3"
      decimals="-3"
      id="d37588595e589-wk-Fact-30DBF05FAB924AADE6C5826D0799865F"
      unitRef="usd">1741000</insm:AccruedMilestonePaymentCurrent>
    <insm:AccruedMilestonePaymentCurrent
      contextRef="FI2017Q4"
      decimals="-3"
      id="d37588595e608-wk-Fact-58881E4BFC557B8AF6BB826D07AABA4F"
      unitRef="usd">0</insm:AccruedMilestonePaymentCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="FI2018Q3"
      decimals="-3"
      id="d37588595e628-wk-Fact-E7EDBAA1A19254E48F527962CA404603"
      unitRef="usd">1663000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="FI2017Q4"
      decimals="-3"
      id="d37588595e647-wk-Fact-DF59140E6DB158208117DAF6EDFBD1A0"
      unitRef="usd">423000</us-gaap:InterestPayableCurrent>
    <insm:AccruedConstructionLiabilitiesCurrent
      contextRef="FI2018Q3"
      decimals="-3"
      id="d37588595e667-wk-Fact-8D2CE62F710256C4867627D2673FA135"
      unitRef="usd">2069000</insm:AccruedConstructionLiabilitiesCurrent>
    <insm:AccruedConstructionLiabilitiesCurrent
      contextRef="FI2017Q4"
      decimals="-3"
      id="d37588595e686-wk-Fact-3AB1CABE9DEA50A48D81863FBCDE743E"
      unitRef="usd">1719000</insm:AccruedConstructionLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="FI2018Q3"
      decimals="-3"
      id="d37588595e706-wk-Fact-556B917E54F45BB0BC136644B1CC1AF2"
      unitRef="usd">1049000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="FI2017Q4"
      decimals="-3"
      id="d37588595e725-wk-Fact-93C99C26AB0059D2A3AEC6BD8093C56C"
      unitRef="usd">481000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="FI2018Q3"
      decimals="-3"
      id="d37588595e750-wk-Fact-E7A53E4292C3507FAAB562842E428728"
      unitRef="usd">40368000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="FI2017Q4"
      decimals="-3"
      id="d37588595e769-wk-Fact-1C594FB75856593F8B96A3EA9DEA6C7E"
      unitRef="usd">29339000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="FD2018Q3YTD"
      id="TextSelection-92EFBAF97FE3567C966C9F3BCEEBD55C-0-wk-Fact-EE00012398585A3791EAE44FEE5F315E">&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Debt&lt;/span&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In January 2018, the Company completed an underwritten public offering of the Convertible Notes, in which the Company sold &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$450.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; aggregate principal amount of Convertible Notes, including the exercise in full of the underwriters' option to purchase additional Convertible Notes of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$50.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The Company's net proceeds from the offering, after deducting underwriting discounts and commissions and other offering expenses of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$14.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, were approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$435.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The Convertible Notes bear interest payable semiannually in arrears on January 15 and July 15 of each year, beginning on July 15, 2018. The Convertible Notes mature on January 15, 2025, unless earlier converted, redeemed, or repurchased. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On or after October&#160;15, 2024, until the close of business on the second scheduled trading day immediately preceding January 15, 2025, holders may convert their Convertible Notes at any time. Upon conversion, holders may receive cash, shares of the Company's common stock or a combination of cash and shares of the Company's common stock, at the Company's option. The initial conversion rate is &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;25.5384&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of common stock per $1,000 principal amount of Convertible Notes (equivalent to an initial conversion price of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$39.16&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share of common stock). The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Holders may convert their Convertible Notes prior to October 15, 2024, only under the following circumstances, subject to the conditions set forth in an indenture, dated as of January 26, 2018, between the Company and Wells Fargo Bank, National Association (Wells Fargo), as trustee, as supplemented by the first supplemental indenture, dated January 26, 2018, between the Company and Wells Fargo (as supplemented, the Indenture): (i) during the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;five&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; business day period immediately after any &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;five&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; consecutive trading day period (the measurement period) in which the trading price per $1,000 principal amount of convertible notes, as determined following a request by a holder of the convertible notes, for each trading day of the measurement period was less than &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;98%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the product of the last reported sale price of the common stock and the conversion rate on such trading day, (ii) the Company elects to distribute to all or substantially all holders of the common stock (a) any rights, options or warrants (other than in connection with a stockholder rights plan for so long as the rights issued under such plan have not detached from the associated shares of common stock) entitling them, for a period of not more than &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;45&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; days from the declaration date for such distribution, to subscribe for or purchase shares of common stock at a price per share that is less than the average of the last reported sale prices of the common stock for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; consecutive trading day period ending on, and including, the trading day immediately preceding the declaration date for such distribution, or (b) the Company&#x2019;s assets, debt securities or rights to purchase securities of the Company, which distribution has a per share value, as reasonably determined by the board of directors, exceeding &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the last reported sale price of the common stock on the trading day immediately preceding the declaration date for such distribution, (iii) if a transaction or event that constitutes a fundamental change or a make-whole fundamental change occurs, or if the Company is a party to (a) a consolidation, merger, combination, statutory or binding share exchange or similar transaction, pursuant to which the common stock would be converted into, or exchanged for, cash, securities or other property or assets, or (b) any sale, conveyance, lease or other transfer or similar transaction in one transaction or a series of transactions of all or substantially all of the consolidated assets of the Company and its subsidiaries, taken as a whole, all or any portion of the Convertible Notes may be surrendered by a holder for conversion at any time from or after the date that is &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; scheduled trading days prior to the anticipated effective date of the transaction, (iv) if during any calendar quarter commencing after the calendar quarter ending on March&#160;31, 2018 (and only during such calendar quarter), the last reported sale price of the common stock for at least &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; trading days (whether or not consecutive) during the period of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;130%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the conversion price on each applicable trading day, or, (v) if the Company sends a notice of redemption, a holder may &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;surrender all or any portion of its Convertible Notes, to which the notice of redemption relates, for conversion at any time on or after the date the applicable notice of redemption was sent until the close of business on (a)&#160;the second business day immediately preceding the related redemption date or (b)&#160;if the Company fails to pay the redemption price on the redemption date as specified in such notice of redemption, such later date on which the redemption price is paid.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Convertible Notes can be settled in cash, common stock, or a combination of cash and common stock at the Company's option, and thus, the Company determined the embedded conversion options in the convertible notes are not required to be separately accounted for as a derivative. However, since the Convertible Notes are within the scope of the accounting guidance for cash convertible instruments, the Company is required to separate the Convertible Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the fair value of a similar liability that does not have an associated equity component. The fair value was based on data from readily available pricing sources which utilize market observable inputs and other characteristics for similar types of instruments. The carrying amount of the equity component representing the embedded conversion option was determined by deducting the fair value of the liability component from the gross proceeds of the Convertible Notes. The excess of the principal amount of the liability component over its carrying amount is amortized to interest expense over the expected life of a similar liability that does not have an associated equity component using the effective interest method. The equity component is not remeasured as long as it continues to meet the conditions for equity classification in the accounting guidance for contracts in an entity&#x2019;s own equity.  The fair value of the liability component of the Convertible Notes on the date of issuance was estimated at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$309.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; using an effective interest rate of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.6%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, and accordingly, the residual equity component on the date of issuance was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$140.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The discount is being amortized to interest expense over the term of the Convertible Notes and has a remaining period of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.28 years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, total interest expense related to the Convertible Notes was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$6.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$17.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, which includes the contractual interest coupon payable semi-annually in cash, the amortization of the issuance costs, and accretion of debt discount, as described in the table below. The following table presents the carrying value of the Company&#x2019;s debt balance as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.96875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:84%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;1.75% convertible senior notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;450,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;Debt issuance costs, unamortized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(8,789&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;Discount on debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(129,350&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Long-term debt, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;311,861&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, future principal repayments of the debt for each of the fiscal years through maturity were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.96875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:84%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Year Ending December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2023 and thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;450,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;450,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In February 2018, the Company used part of the net proceeds from the issuance of the Convertible Notes to pay off its outstanding debt to Hercules Capital (Hercules). The payments to Hercules consisted of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$55.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the principal amount and an additional &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in back-end fees, outstanding interest, and prepayment penalty fees, which resulted in a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; loss on extinguishment of debt in the quarter ended March 31, 2018.&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Interest Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table sets forth the total interest expense recognized in the periods presented (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:82.421875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:37%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Contractual interest expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,971&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,302&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,214&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,862&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;415&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;91&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accretion of back-end fee on debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;164&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;50&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;506&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accretion of debt discount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,289&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,541&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total interest expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,675&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,496&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18,805&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,459&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="I2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember"
      decimals="INF"
      id="d37590224e324-wk-Fact-7E4A9357C5E15E559A53F43438548641"
      unitRef="usd">450000000.0</us-gaap:DebtInstrumentFaceAmount>
    <insm:DebtInstrumentOptionToPurchaseAdditionalDebt
      contextRef="I2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember"
      decimals="INF"
      id="d37590224e328-wk-Fact-345AD2CA179752AA825673E8760EC16E"
      unitRef="usd">50000000.0</insm:DebtInstrumentOptionToPurchaseAdditionalDebt>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="I2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember"
      decimals="-5"
      id="d37590224e332-wk-Fact-8DC678152A7652C482C25373DA3D75DB"
      unitRef="usd">14200000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="D2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member"
      decimals="-5"
      id="d37590224e336-wk-Fact-C7C8C725F0B3500198F89DE37AA0C1B2"
      unitRef="usd">435800000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="I2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember"
      decimals="2"
      id="d37590224e351-wk-Fact-4D041FB2AF7D5A91A88CDEF5C0721A55"
      unitRef="usdPerShare">39.16</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_DebtInstrumentConversionTermOneMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember"
      decimals="INF"
      id="d37590224e361-wk-Fact-1860C51771A85B85994795C837B0C6BE"
      unitRef="day">5</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_DebtInstrumentConversionTermOneMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember"
      decimals="INF"
      id="d37590224e365-wk-Fact-3053D2613E905CA5BA1DA5E51C484BFD"
      unitRef="day">5</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_DebtInstrumentConversionTermOneMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember"
      decimals="INF"
      id="d37590224e369-wk-Fact-9D0E49F95C015086AAE78CF35B2CBBFA"
      unitRef="number">0.98</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_DebtInstrumentConversionTermTwoMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember"
      decimals="INF"
      id="d37590224e373-wk-Fact-0C2F3580B9B45F7A809BB4BF53118911"
      unitRef="day">45</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_DebtInstrumentConversionTermTwoMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember"
      decimals="INF"
      id="d37590224e377-wk-Fact-7A3190B8AE84538CB44026DF751D68B6"
      unitRef="day">10</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_DebtInstrumentConversionTermTwoMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember"
      decimals="INF"
      id="d37590224e382-wk-Fact-482FCC034EB85DDB8BE94373AE6BA8A4"
      unitRef="number">0.10</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <insm:DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange
      contextRef="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_DebtInstrumentConversionTermThreeMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember"
      decimals="INF"
      id="d37590224e386-wk-Fact-C3022FBDC3E25803BCA97471C7C5A997"
      unitRef="day">30</insm:DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_DebtInstrumentConversionTermFourMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember"
      decimals="INF"
      id="d37590224e390-wk-Fact-64DD445CD13653DD9E213D225A4F235C"
      unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_DebtInstrumentConversionTermFourMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember"
      decimals="INF"
      id="d37590224e394-wk-Fact-BD23F4F6AC7B5B4AAD209DBA42344B8D"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="D2018Q1Jan31_insm_DebtInstrumentConversionTermAxis_insm_DebtInstrumentConversionTermFourMember_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember"
      decimals="INF"
      id="d37590224e398-wk-Fact-251126F334385D76BBAA260CC4412FEE"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="I2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember"
      decimals="-5"
      id="d37590224e412-wk-Fact-6213C958474757D787B50EA834F44A2C"
      unitRef="usd">309100000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="I2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember"
      decimals="3"
      id="d37590224e416-wk-Fact-1E1F39EA84AD5BD989A27A3E4DC62E95"
      unitRef="number">0.076</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="I2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember"
      decimals="-5"
      id="d37590224e420-wk-Fact-FBD59C907D965D3ABD0967FEF6CA4C54"
      unitRef="usd">140900000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="D2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember"
      id="d37590224e424-wk-Fact-ACFE8AE29C0E580F8D1D767FDAE7A575">P6Y3M10D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:InterestExpense
      contextRef="FD2018Q3QTD_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember"
      decimals="-5"
      id="d37590224e442-wk-Fact-8600FFB679DD5930AF42ADF360AE9B7A"
      unitRef="usd">6700000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2018Q3YTD_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember"
      decimals="-5"
      id="d37590224e446-wk-Fact-5FD0C162FF595C3CA1A93EF2E89E12B4"
      unitRef="usd">17900000</us-gaap:InterestExpense>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="FD2018Q3YTD"
      id="TextSelection-C90F1D5E53BF59F3A5DED3E32085B0C6-0-wk-Fact-278627BB7121577FB530886AD706AF39">The following table presents the carrying value of the Company&#x2019;s debt balance as of &lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (in thousands):&lt;/span&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.96875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:84%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;1.75% convertible senior notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;450,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;Debt issuance costs, unamortized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(8,789&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;Discount on debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(129,350&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Long-term debt, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;311,861&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:SecuredDebt
      contextRef="FI2018Q3"
      decimals="-3"
      id="d37590224e485-wk-Fact-63BCB9E07D84541D968DBD78CEF77F5B"
      unitRef="usd">450000000</us-gaap:SecuredDebt>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="FI2018Q3"
      decimals="-3"
      id="d37590224e500-wk-Fact-81BBE5D4E1F652CB8E694D57C3503390"
      unitRef="usd">8789000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="FI2018Q3"
      decimals="-3"
      id="d37590224e521-wk-Fact-7C40E6C310BB53459A386372C4754FAE"
      unitRef="usd">129350000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="FI2018Q3"
      decimals="-3"
      id="d37590224e547-wk-Fact-04AAF8399F7F50089D01A23C0F563455"
      unitRef="usd">311861000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="FD2018Q3YTD"
      id="TextSelection-EBF9AF87D8EB585587C302CA9743DE00-0-wk-Fact-6D28D41BFA5B55CBA9C9DB97215C7F56">As of &lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, future principal repayments of the debt for each of the fiscal years through maturity were as follows (in thousands):&lt;/span&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.96875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:84%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Year Ending December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2023 and thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;450,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;450,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="FI2018Q3"
      decimals="-3"
      id="d37590224e616-wk-Fact-956C3D4C46755B40A79756A9A9AD817C"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="FI2018Q3"
      decimals="-3"
      id="d37590224e631-wk-Fact-3FFEB2388F5257258A561EB5777F3AFA"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="FI2018Q3"
      decimals="-3"
      id="d37590224e651-wk-Fact-7B64441B7EF45330BD8A465EB8F1B93E"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="FI2018Q3"
      decimals="-3"
      id="d37590224e671-wk-Fact-A7F148E8E77E5A9AADD5EA1E2BE05E9B"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="FI2018Q3"
      decimals="-3"
      id="d37590224e691-wk-Fact-17E81A5D169E592489166C86109A6A3F"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="FI2018Q3"
      decimals="-3"
      id="d37590224e711-wk-Fact-D8A23D53CDD8581D9AD83F0A8958B54E"
      unitRef="usd">450000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:LongTermDebt
      contextRef="FI2018Q3"
      decimals="-3"
      id="d37590224e736-wk-Fact-F50B2E0DDBDD5041B2E899A6DDAB035D"
      unitRef="usd">450000000</us-gaap:LongTermDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="D2018Q1Feb28-Feb28_us-gaap_DebtInstrumentAxis_us-gaap_LineOfCreditMember"
      decimals="-5"
      id="d37590224e754-wk-Fact-D1BA5C40A59F5505BEC996903C978815"
      unitRef="usd">55000000.0</us-gaap:RepaymentsOfDebt>
    <insm:RepaymentsOfDebtFeesAndOutstandingInterest
      contextRef="D2018Q1Feb2018_us-gaap_DebtInstrumentAxis_us-gaap_LineOfCreditMember"
      decimals="-5"
      id="d37590224e758-wk-Fact-8B2C149F4D175609AD186D639666A554"
      unitRef="usd">3200000</insm:RepaymentsOfDebtFeesAndOutstandingInterest>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="FD2018Q1YTD"
      decimals="-5"
      id="d37590224e762-wk-Fact-8F99C5D4DAAE5FD89F9B3F727258D6C7"
      unitRef="usd">-2200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock
      contextRef="FD2018Q3YTD"
      id="TextSelection-0BFEBE0667735D93A7DAEBA55CE0435E-0-wk-Fact-A7FE7B2B6EF45DE38AE7BB2E927227E6">The following table sets forth the total interest expense recognized in the periods presented (in thousands):&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:82.421875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:37%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Contractual interest expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,971&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,302&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,214&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,862&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;415&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;91&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accretion of back-end fee on debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;164&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;50&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;506&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accretion of debt discount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,289&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,541&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total interest expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,675&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,496&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18,805&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,459&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:InterestExpenseDebt
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d37590224e979-wk-Fact-4378B2392B7E55ECA171B5B6F61C04EF"
      unitRef="usd">1971000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="FD2017Q3QTD"
      decimals="-3"
      id="d37590224e998-wk-Fact-25EF54A1EE30544291CD49D1A93A8D95"
      unitRef="usd">1302000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d37590224e1017-wk-Fact-818EE6EB8884530F995A75A2E2B80D3C"
      unitRef="usd">6214000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="FD2017Q3YTD"
      decimals="-3"
      id="d37590224e1037-wk-Fact-A9E2E23A780C5F2892A216F76C9B178F"
      unitRef="usd">3862000</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d37590224e1052-wk-Fact-8775519611E355C5B1CC57ED3A8C0096"
      unitRef="usd">415000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="FD2017Q3QTD"
      decimals="-3"
      id="d37590224e1071-wk-Fact-2960E48E1CAB55CCB362A519DB56F8DC"
      unitRef="usd">30000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d37590224e1090-wk-Fact-2DCBC22CAE23561D8C8137E0A74483C2"
      unitRef="usd">1000000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="FD2017Q3YTD"
      decimals="-3"
      id="d37590224e1110-wk-Fact-5288C234F50F548E9EB138AA0CE2764E"
      unitRef="usd">91000</us-gaap:AmortizationOfFinancingCosts>
    <insm:AmortizationOfBackendFee
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d37590224e1130-wk-Fact-80B09A4F20715E50B54ECCDCBA869DE7"
      unitRef="usd">0</insm:AmortizationOfBackendFee>
    <insm:AmortizationOfBackendFee
      contextRef="FD2017Q3QTD"
      decimals="-3"
      id="d37590224e1149-wk-Fact-FCB72504E51459D39150C190C88ABD21"
      unitRef="usd">164000</insm:AmortizationOfBackendFee>
    <insm:AmortizationOfBackendFee
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d37590224e1168-wk-Fact-BF43524D7117515D8A4E3DD3B8BEF22D"
      unitRef="usd">50000</insm:AmortizationOfBackendFee>
    <insm:AmortizationOfBackendFee
      contextRef="FD2017Q3YTD"
      decimals="-3"
      id="d37590224e1188-wk-Fact-C489ECA8A49C566F92A47918C38B28BD"
      unitRef="usd">506000</insm:AmortizationOfBackendFee>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d37590224e1208-wk-Fact-1D33054849665ACA859C363371960D43"
      unitRef="usd">4289000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="FD2017Q3QTD"
      decimals="-3"
      id="d37590224e1227-wk-Fact-64BB61762B345F9391ED6DD0A704BB0D"
      unitRef="usd">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d37590224e1246-wk-Fact-9F140DB9CAD55F8A82F57323DE07C7D4"
      unitRef="usd">11541000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="FD2017Q3YTD"
      decimals="-3"
      id="d37590224e1266-wk-Fact-E7408D702B955003AD3C8811576D0C16"
      unitRef="usd">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:InterestExpense
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d37590224e1291-wk-Fact-5298773546E956B2A476B4D00B0CC953"
      unitRef="usd">6675000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2017Q3QTD"
      decimals="-3"
      id="d37590224e1310-wk-Fact-46AD3F5FEC25521788BB47B9D992E8D5"
      unitRef="usd">1496000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d37590224e1329-wk-Fact-0261293D4CE557119BC44A95C1CB75EE"
      unitRef="usd">18805000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2017Q3YTD"
      decimals="-3"
      id="d37590224e1349-wk-Fact-1E85C2C8082B598EB0AA11002F15739B"
      unitRef="usd">4459000</us-gaap:InterestExpense>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="FD2018Q3YTD"
      id="TextSelection-D5D1788D83865FFEA73440DC4DBDBC06-0-wk-Fact-2FF54B0995B354309640F4D6CE4E14BD">&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Shareholders&#x2019; Equity&lt;/span&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Common Stock&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &#x2014; As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company had &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;500,000,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of common stock authorized with a par value of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.01&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;77,085,715&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of common stock issued and outstanding. In addition, as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company had reserved &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,608,344&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of common stock for issuance upon the exercise of outstanding stock options and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;244,801&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of common stock for issuance upon the vesting of RSUs. The Company has also reserved &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"&gt;&lt;span&gt;11,492,280&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;shares of common stock for issuance upon conversion of the Convertible Notes, subject to adjustment in accordance with the Indenture.&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In January 2018, the Company completed an underwritten public offering of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$450.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; aggregate principal amount of Convertible Notes, including the exercise in full of the underwriter's option to purchase additional Convertible Notes. The fair value of the liability component of the Convertible Notes on the date of issuance was estimated at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$309.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, and accordingly, the equity component (included in additional paid-in capital) on the date of issuance was calculated as &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$140.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; using the residual method, as further described in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Note 5 Debt&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In September 2017, the Company completed an underwritten public offering of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14,123,150&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of the Company&#x2019;s common stock, which included the underwriter&#x2019;s exercise in full of its over-allotment option of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,842,150&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares, at a price to the public of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$28.50&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share.&#160; The Company&#x2019;s net proceeds from the sale of the shares, after deducting the underwriter&#x2019;s discount and offering expenses of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$24.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, were $&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;377.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Preferred Stock&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &#x2014; As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company had &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;200,000,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of preferred stock authorized with a par value of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.01&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of preferred stock were issued and outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes the changes in total shareholders' equity for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:61.328125%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:82%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance at December 31, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;361,059&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net loss for the period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(232,704&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Proceeds from exercise of stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,390&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Equity component of Convertible Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;136,434&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20,205&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Change in cumulative translation adjustment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance at September 30, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;291,407&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="FI2018Q3"
      decimals="INF"
      id="d37590573e331-wk-Fact-AC16D73A88E954E697D03E834320F06E"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2018Q3"
      decimals="INF"
      id="d37590573e335-wk-Fact-66DD83FC3C975DDDB45E789302396230"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2018Q3"
      decimals="INF"
      id="d37590573e339-wk-Fact-EB0E193E026659B496BD06BED17E8E20"
      unitRef="shares">77085715</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="FI2018Q3_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember"
      decimals="INF"
      id="d37590573e348-wk-Fact-A4F9AD54A21E5BC8965C6E02853578EF"
      unitRef="shares">9608344</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="FI2018Q3_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d37590573e352-wk-Fact-0C531E1106865DACA89C577A153349C5"
      unitRef="shares">244801</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="FI2018Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember"
      decimals="INF"
      id="d37590573e356-wk-Fact-53C2B3EAA9425F78AF9AD48149337C83"
      unitRef="shares">11492280</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="I2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember"
      decimals="INF"
      id="d37590573e368-wk-Fact-7E4A9357C5E15E559A53F43438548641"
      unitRef="usd">450000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="I2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember"
      decimals="-5"
      id="d37590573e372-wk-Fact-6213C958474757D787B50EA834F44A2C"
      unitRef="usd">309100000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="I2018Q1Jan31_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember"
      decimals="-5"
      id="d37590573e376-wk-Fact-FBD59C907D965D3ABD0967FEF6CA4C54"
      unitRef="usd">140900000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="D2017Q3Sept17"
      decimals="INF"
      id="d37590573e390-wk-Fact-B9E42C065B8F54C6AB1BB60742CBF249"
      unitRef="shares">14123150</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <insm:CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption
      contextRef="FI2017Q3"
      decimals="INF"
      id="d37590573e394-wk-Fact-AC6C0C409AF95A3B943ECCE99614530B"
      unitRef="shares">1842150</insm:CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption>
    <us-gaap:SharePrice
      contextRef="FI2017Q3"
      decimals="INF"
      id="d37590573e398-wk-Fact-9CE2A821B041564D8BBCF422983331E7"
      unitRef="usdPerShare">28.50</us-gaap:SharePrice>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="D2017Q3Sept17"
      decimals="-5"
      id="d37590573e402-wk-Fact-C5588C77CB9B5FBFB416A1ABEBB5FBA6"
      unitRef="usd">24800000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="D2017Q3Sept17"
      decimals="-5"
      id="d37590573e406-wk-Fact-0C136B6B2B075856A9D312C7F4FF21C2"
      unitRef="usd">377700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="FI2018Q3"
      decimals="INF"
      id="d37590573e422-wk-Fact-8F74BBD921865D81A803DF38E48CC344"
      unitRef="shares">200000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="FI2018Q3"
      decimals="INF"
      id="d37590573e426-wk-Fact-493EE2C5118650E882E50A82BEE0095E"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="FI2018Q3"
      decimals="INF"
      id="d37590573e430-wk-Fact-9EBC6D072F1C5ED684726953D3AFF37A"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:ScheduleOfStockholdersEquityTableTextBlock
      contextRef="FD2018Q3YTD"
      id="TextSelection-E1F8F3D2AFE456F3931488F0917D9F1C-0-wk-Fact-04F546C013DF51B48D39C5155AB7FE46">The following table summarizes the changes in total shareholders' equity for the &lt;span style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (in thousands):&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:61.328125%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:82%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance at December 31, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;361,059&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net loss for the period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(232,704&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Proceeds from exercise of stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,390&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Equity component of Convertible Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;136,434&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20,205&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Change in cumulative translation adjustment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance at September 30, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;291,407&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityTableTextBlock>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q4"
      decimals="-3"
      id="d37590573e475-wk-Fact-5115DD7C33225595A9655F911DF6011A"
      unitRef="usd">361059000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d37590573e490-wk-Fact-B45A0729B05C59668CED7875FF86978E"
      unitRef="usd">-232704000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d37590573e511-wk-Fact-30EE0C7EC8FDE992CC143B984DFC694C"
      unitRef="usd">6390000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d37590573e531-wk-Fact-4A3FA2F0B53F8EA9B5BC3B984DF2CCC8"
      unitRef="usd">136434000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d37590573e551-wk-Fact-257ED560AA631EB44D413B984DFF813C"
      unitRef="usd">20205000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d37590573e571-wk-Fact-39AC78B296FA55BA8F3AB1B66723D287"
      unitRef="usd">23000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q3"
      decimals="-3"
      id="d37590573e596-wk-Fact-ACB053F2369A5B66BE981E31DC8D38E2"
      unitRef="usd">291407000</us-gaap:StockholdersEquity>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="FD2018Q3YTD"
      id="TextSelection-2EF1C0DFA0D65408A6BD3E9996D416DD-0-wk-Fact-3AA6C8A8F72654B3B6D369B9A002E0DB">&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company&#x2019;s current equity compensation plan, the 2017 Incentive Plan, was approved by shareholders at the Company&#x2019;s Annual Meeting of Shareholders on May&#160;18, 2017.&#160;The 2017 Incentive Plan is administered by the Compensation Committee and the Board of Directors of the Company.&#160;Under the terms of the 2017 Incentive Plan, the Company is authorized to grant a variety of incentive awards based on its common stock, including stock options (both incentive stock options and non-qualified stock options), RSUs, performance options/shares and other stock awards, as well as pay incentive bonuses to eligible employees and non-employee directors.&#160;On May&#160;18, 2017, upon the approval of the 2017 Incentive Plan by shareholders, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,000,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares were authorized for issuance thereunder, plus any shares subject to then-outstanding awards under the 2015 Incentive Plan and the 2013 Incentive Plan that subsequently were canceled, terminated unearned, expired, were forfeited, lapsed for any reason or were settled in cash without the delivery of shares. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,408,995&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares remained for future issuance under the 2017 Incentive Plan. The 2017 Incentive Plan will terminate on April&#160;3, 2027 unless it is extended or terminated earlier pursuant to its terms. In addition, from time to time, the Company makes inducement grants of stock options to new hires, which awards are made pursuant to the NASDAQ inducement grant exception. During the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company granted inducement stock options covering &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;236,730&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of the Company's common stock to new employees.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On May 15, 2018, the 2018 Employee Stock Purchase Plan (2018 ESPP) was approved by shareholders at the Company&#x2019;s Annual Meeting of Shareholders. The Company has reserved the following for issuance under the 2018 ESPP: (i)&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,000,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of common stock,&#160;plus&#160;(ii)&#160;commencing on January&#160;1, 2019 and ending on December&#160;31, 2023, an additional number of shares to be added on the first day of each calendar year equal to the lesser of (A)&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,200,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of common stock, (B)&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the number of outstanding shares of common stock on such date and (C)&#160;an amount determined by the administrator.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Stock Options&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; - The Company calculates the fair value of stock options granted using the Black-Scholes valuation model. The following table summarizes the Company&#x2019;s grant date fair value and assumptions used in determining the fair value of all stock options granted during the periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.484375%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;66%-67%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;72%-73%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;66%-68%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;72%-74%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2.75%-2.87%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;1.73%-1.93%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2.25%-2.87%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;1.73%-1.99%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.0%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.0%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.0%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.0%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected option term (in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.09&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted average fair value of stock options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$13.62&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$9.59&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$16.56&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$10.18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For each period presented, the volatility factor was based on the Company&#x2019;s historical volatility during the expected option term.&#160;Estimated forfeitures are based on the actual percentage of option forfeitures since the closing of the Company&#x2019;s merger with Transave in December&#160;2010. The expected option term for these grants was determined using the Company&#x2019;s historical exercise behavior of grantees. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;From time to time, the Company has granted performance-condition options to certain of its employees. Vesting of these options was subject to the Company achieving certain performance criteria established at the date of grant and the grantees fulfilling a service condition (continued employment). During the quarter ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, performance-condition options totaling &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, or &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;133,334&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares, met their recognition criteria as a result of the FDA approval of ARIKAYCE and vested in full. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, there were &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; performance-condition options outstanding. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes the Company&#x2019;s aggregate stock option activity for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Number&#160;of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Life&#160;in&#160;Years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Value&#160;(in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Options outstanding at December&#160;31, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,608,921&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14.08&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,610,010&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;28.57&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(427,729&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14.94&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Forfeited or expired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(182,858&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;19.15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Options outstanding at September&#160;30, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,608,344&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16.37&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.08&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;52,765&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Vested and expected to vest at September&#160;30, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,760,828&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15.90&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.92&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;50,354&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Exercisable at September&#160;30, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,317,732&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13.23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.96&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;38,723&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The total intrinsic value of stock options exercised during the three months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, and during the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$5.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, there was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$34.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted average period of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.5 years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The following table summarizes the range of exercise prices and the number of stock options outstanding and exercisable as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.1328125%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="23"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="16" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Outstanding as of September&#160;30, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Exercisable as of September&#160;30, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Range of Exercise Prices&#160;($)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Number of Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted Average Remaining Contractual Term (in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted Average Exercise&#160;Price&#160;($)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Number of Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted Average Exercise&#160;Price&#160;($)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.03&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.90&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,087,941&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.94&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.99&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,087,941&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.99&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.96&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10.85&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;997,221&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.53&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10.77&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;481,574&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10.68&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11.14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12.58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;984,936&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.49&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12.17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;893,989&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12.20&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12.66&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13.67&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;984,161&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.97&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13.60&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;428,577&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13.56&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13.94&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16.07&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,139,533&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.80&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15.26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;765,384&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15.17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16.09&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17.16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,438,502&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.95&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16.69&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;602,949&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16.48&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17.24&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22.76&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,366,680&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.56&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;21.20&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,017,263&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;21.26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22.84&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30.46&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,439,910&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9.21&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;28.61&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;40,055&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;24.26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30.86&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;31.78&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;155,960&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9.25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;31.10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;32.46&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;32.46&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13,500&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9.26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;32.46&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Restricted Stock and Restricted Stock Units&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &#x2014; Under the 2017 Incentive Plan, the Company may grant restricted stock (RS) and RSUs to eligible participants, including its executives, non-employee directors, and other service providers. Each share of RS vests, and each RSU represents a right to receive &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; share of the Company&#x2019;s common stock, upon the completion of a specific period of continued service or achievement of a certain milestone. RS and RSU awards are valued at the market price of the Company&#x2019;s common stock on the date of grant. The Company recognizes noncash compensation expense for the fair values of these RS and RSU awards on a straight-line basis over the requisite service period of these awards. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, there was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of unrecognized compensation expense related to unvested RSU awards which is expected to be recognized over a weighted average period of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.8 years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The following table summarizes the Company&#x2019;s RSU award activity during the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.96875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Number&#160;of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;RSUs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Grant&#160;Price&#160;($)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Outstanding at December&#160;31, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;46,914&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17.16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;248,468&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;29.41&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Released&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(47,478&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17.32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3,103&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30.46&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Outstanding at September&#160;30, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;244,801&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;29.40&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes the aggregate stock-based compensation expense recorded in the consolidated statements of comprehensive loss related to stock options and RSUs during the three and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in&#160;millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;General and administrative expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="I2017Q2May18"
      decimals="INF"
      id="d37594213e323-wk-Fact-7ECC6221F1F2532AA9421C0BF38526A4"
      unitRef="shares">5000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="FI2018Q3"
      decimals="INF"
      id="d37594213e332-wk-Fact-43F67A890AB556A081B4D336712D33D9"
      unitRef="shares">3408995</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <insm:ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross
      contextRef="FD2018Q3YTD"
      decimals="INF"
      id="d37594213e344-wk-Fact-0AA6EE81DFB7511E88A8220D1FDC68A2"
      unitRef="shares">236730</insm:ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="I2018Q2May15_us-gaap_PlanNameAxis_insm_EmployeeStockPurchasePlan2018Member"
      decimals="INF"
      id="d37594213e354-wk-Fact-C652ECC9EE0F331174069DE5B3C7AEF9"
      unitRef="shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="D2018Q2May15_us-gaap_PlanNameAxis_insm_EmployeeStockPurchasePlan2018Member"
      decimals="INF"
      id="d37594213e358-wk-Fact-DA79DFBA19DA36691F4F9DE96F1B5CCC"
      unitRef="shares">1200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="D2018Q2May15_us-gaap_PlanNameAxis_insm_EmployeeStockPurchasePlan2018Member"
      decimals="INF"
      id="d37594213e362-wk-Fact-11FFF0C8601F2C8795AE9DEAF9DD1E07"
      unitRef="number">0.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="FD2018Q3YTD"
      id="TextSelection-82E23812858D573291FC4C45C019730C-0-wk-Fact-F43EB96BBBD25807848FD3680051A8A5">The following table summarizes the Company&#x2019;s grant date fair value and assumptions used in determining the fair value of all stock options granted during the periods presented:&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.484375%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;66%-67%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;72%-73%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;66%-68%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;72%-74%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2.75%-2.87%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;1.73%-1.93%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2.25%-2.87%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;1.73%-1.99%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.0%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.0%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.0%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.0%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected option term (in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.09&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted average fair value of stock options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$13.62&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$9.59&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$16.56&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$10.18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember"
      decimals="INF"
      id="d37594213e566-wk-Fact-A51681E09A37514DB5F3143E09054C59"
      unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="FD2017Q3QTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember"
      decimals="INF"
      id="d37594213e576-wk-Fact-A978281FB63F5536B5FB2B17A0798BA2"
      unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember"
      decimals="INF"
      id="d37594213e586-wk-Fact-4952654B434D5B49AE49D24DED8A0467"
      unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember"
      decimals="INF"
      id="d37594213e596-wk-Fact-BE7E067587525369B6F8A78876494803"
      unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember"
      id="d37594213e607-wk-Fact-894BC61A91315A358714DBBCF282A05D">P5Y1M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2017Q3QTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember"
      id="d37594213e617-wk-Fact-0CD3EDB8D1AE5F37A22E3162D002DF2E">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember"
      id="d37594213e627-wk-Fact-68AC34C6106650A3B114F5808E96BC3C">P5Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember"
      id="d37594213e637-wk-Fact-F13232A56BEC51BEB2F170F9F6C48500">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember"
      decimals="2"
      id="d37594213e648-wk-Fact-46153BC343CB50EE9DB33F8057CCB15B"
      unitRef="usdPerShare">13.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2017Q3QTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember"
      decimals="2"
      id="d37594213e658-wk-Fact-3FDE8523F97E5614A70FCC3C1EFC9172"
      unitRef="usdPerShare">9.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember"
      decimals="2"
      id="d37594213e668-wk-Fact-63F150AC5B5A5BA98787BFA14F2AC304"
      unitRef="usdPerShare">16.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember"
      decimals="2"
      id="d37594213e678-wk-Fact-9B6B3ACA56645783AA53CD95D7118F41"
      unitRef="usdPerShare">10.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="-5"
      id="d37594213e700-wk-Fact-A7FEB966C382A7D381FE9DE1D6B19337"
      unitRef="usd">1100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="d37594213e704-wk-Fact-6A5AE218B37A5FDB8495617480F9751F"
      unitRef="shares">133334</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="FI2018Q3_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="d37594213e712-wk-Fact-E514305F6B4EF9D907DB827940438FBA"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="FD2018Q3YTD"
      id="TextSelection-4DD890629F1B5F9CBB54C688183D3964-0-wk-Fact-6AAFA28D2C795AAD803ADAD1B815D724">The following table summarizes the Company&#x2019;s aggregate stock option activity for the &lt;span style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&#160;&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Number&#160;of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Life&#160;in&#160;Years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Value&#160;(in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Options outstanding at December&#160;31, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,608,921&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14.08&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,610,010&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;28.57&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(427,729&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14.94&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Forfeited or expired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(182,858&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;19.15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Options outstanding at September&#160;30, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,608,344&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16.37&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.08&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;52,765&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Vested and expected to vest at September&#160;30, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,760,828&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15.90&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.92&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;50,354&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Exercisable at September&#160;30, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,317,732&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13.23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.96&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;38,723&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="FI2017Q4"
      decimals="INF"
      id="d37594213e862-wk-Fact-D8E859F3971E543397E456351E5C50AE"
      unitRef="shares">8608921</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="FI2017Q4"
      decimals="2"
      id="d37594213e881-wk-Fact-8F6D99238C1B50BB89E86204002ABAB4"
      unitRef="usdPerShare">14.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="FD2018Q3YTD"
      decimals="INF"
      id="d37594213e926-wk-Fact-A129EC8410355CF69573B15DB4E1A87E"
      unitRef="shares">1610010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="FD2018Q3YTD"
      decimals="2"
      id="d37594213e945-wk-Fact-441D5DA3C6CE5901B9522915B3470157"
      unitRef="usdPerShare">28.57</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2018Q3YTD"
      decimals="INF"
      id="d37594213e990-wk-Fact-96B457DEF18D52288580888A0FBBD3E7"
      unitRef="shares">427729</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="FD2018Q3YTD"
      decimals="2"
      id="d37594213e1010-wk-Fact-6F3A927911305166A10B5B827EE63C72"
      unitRef="usdPerShare">14.94</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="FD2018Q3YTD"
      decimals="INF"
      id="d37594213e1055-wk-Fact-61E6E5A89E67573C9422C86891D3EB25"
      unitRef="shares">182858</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="FD2018Q3YTD"
      decimals="2"
      id="d37594213e1075-wk-Fact-E258850E24725DE39658D49473C86B33"
      unitRef="usdPerShare">19.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="FI2018Q3"
      decimals="INF"
      id="d37594213e1120-wk-Fact-88B35D2EB9B9581FA0289B7336391AE9"
      unitRef="shares">9608344</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="FI2018Q3"
      decimals="2"
      id="d37594213e1139-wk-Fact-3D55AF88E4D75F1380B89C916E2D86B6"
      unitRef="usdPerShare">16.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="FD2018Q3YTD"
      id="d37594213e1153-wk-Fact-9F8F9253042D5F279A47F2D018553342">P7Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="FI2018Q3"
      decimals="-3"
      id="d37594213e1169-wk-Fact-09606A8F8F7159B380FA395AD0CAF075"
      unitRef="usd">52765000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="FI2018Q3"
      decimals="INF"
      id="d37594213e1184-wk-Fact-79D57883AFFE53618D061D01BC4268B1"
      unitRef="shares">8760828</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="FI2018Q3"
      decimals="2"
      id="d37594213e1203-wk-Fact-C439DBE219F9518AB9122B8522525BB1"
      unitRef="usdPerShare">15.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="FD2018Q3YTD"
      id="d37594213e1217-wk-Fact-C951238361FC5F47B3611DCEC5BD8A2D">P6Y11M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="FI2018Q3"
      decimals="-3"
      id="d37594213e1233-wk-Fact-30F593F6E5815034ABE7966464349666"
      unitRef="usd">50354000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="FI2018Q3"
      decimals="INF"
      id="d37594213e1248-wk-Fact-6C0DDD925E03599D83BB6DD6724B4400"
      unitRef="shares">5317732</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="FI2018Q3"
      decimals="2"
      id="d37594213e1267-wk-Fact-55C2C1C8DB795647908936C5F9A70699"
      unitRef="usdPerShare">13.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="FD2018Q3YTD"
      id="d37594213e1281-wk-Fact-38BB648AFF3956A7A5DF0ED6C7BF05BE">P5Y11M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="FI2018Q3"
      decimals="-3"
      id="d37594213e1297-wk-Fact-7F7F08004F6B518293B44139791CB772"
      unitRef="usd">38723000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember"
      decimals="-5"
      id="d37594213e1320-wk-Fact-29D8296083F95575BC7D174DF7FD070D"
      unitRef="usd">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="FD2017Q3QTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember"
      decimals="-5"
      id="d37594213e1324-wk-Fact-9D47B37AF72C577093D242920E6ECA43"
      unitRef="usd">1400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember"
      decimals="-5"
      id="d37594213e1341-wk-Fact-49B9117B8BE251C7B68428C64ABC080F"
      unitRef="usd">5500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember"
      decimals="-5"
      id="d37594213e1345-wk-Fact-506544425EC05DB9BFD9A25845721727"
      unitRef="usd">3500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="FI2018Q3_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember"
      decimals="-5"
      id="d37594213e1359-wk-Fact-3FAE02F463F7514380A21436E302BDC8"
      unitRef="usd">34700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember"
      id="d37594213e1363-wk-Fact-586730FA0C585667A1E3B42CCBC7DCA3">P2Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock
      contextRef="FD2018Q3YTD"
      id="TextSelection-2926B02ECA945782B45A2187E6AB5160-0-wk-Fact-0020DD4F0D6E55CDBBCD0CBBAF477555">The following table summarizes the range of exercise prices and the number of stock options outstanding and exercisable as of &lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.1328125%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="23"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="16" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Outstanding as of September&#160;30, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Exercisable as of September&#160;30, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Range of Exercise Prices&#160;($)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Number of Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted Average Remaining Contractual Term (in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted Average Exercise&#160;Price&#160;($)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Number of Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted Average Exercise&#160;Price&#160;($)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.03&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.90&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,087,941&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.94&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.99&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,087,941&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.99&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.96&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10.85&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;997,221&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.53&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10.77&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;481,574&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10.68&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11.14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12.58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;984,936&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.49&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12.17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;893,989&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12.20&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12.66&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13.67&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;984,161&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.97&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13.60&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;428,577&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13.56&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13.94&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16.07&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,139,533&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.80&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15.26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;765,384&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15.17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16.09&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17.16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,438,502&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.95&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16.69&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;602,949&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16.48&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17.24&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22.76&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,366,680&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.56&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;21.20&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,017,263&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;21.26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22.84&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30.46&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,439,910&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9.21&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;28.61&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;40,055&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;24.26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30.86&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;31.78&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;155,960&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9.25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;31.10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;32.46&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;32.46&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13,500&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9.26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;32.46&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range1Member"
      decimals="INF"
      id="d37594213e1652-wk-Fact-42F0833A9C135AFF9CE114E286F09D57"
      unitRef="usdPerShare">3.03</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range1Member"
      decimals="INF"
      id="d37594213e1671-wk-Fact-2F85D5919B7350EDA088FDD5795BED51"
      unitRef="usdPerShare">6.90</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range1Member"
      decimals="INF"
      id="d37594213e1685-wk-Fact-0D3232FE979A52D2B917D6A3F6F06DA4"
      unitRef="shares">1087941</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range1Member"
      id="d37594213e1700-wk-Fact-4514043CCB4553F0A0F68E44844ABF30">P3Y11M8D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range1Member"
      decimals="2"
      id="d37594213e1715-wk-Fact-0BD9EFF14F555BB787FA1A1E2BBFE6B9"
      unitRef="usdPerShare">3.99</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range1Member"
      decimals="INF"
      id="d37594213e1729-wk-Fact-2358F84249AA57FCB336DE23F60D65F4"
      unitRef="shares">1087941</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range1Member"
      decimals="2"
      id="d37594213e1748-wk-Fact-D5219E28BA8B54229604E884DC3B42D9"
      unitRef="usdPerShare">3.99</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range2Member"
      decimals="INF"
      id="d37594213e1764-wk-Fact-BFA67709AB6B5F7B8AA0DF97F7D73E93"
      unitRef="usdPerShare">6.96</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range2Member"
      decimals="INF"
      id="d37594213e1783-wk-Fact-4723C2395CF9519BA3B77381989B27BF"
      unitRef="usdPerShare">10.85</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range2Member"
      decimals="INF"
      id="d37594213e1797-wk-Fact-87024A29AFFB5A3D992552E54FD5540F"
      unitRef="shares">997221</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range2Member"
      id="d37594213e1812-wk-Fact-86920ED302FE5006919C0E38ACD79B1F">P7Y6M10D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range2Member"
      decimals="2"
      id="d37594213e1827-wk-Fact-927C79A20C4E5966BC3A17D3C983EBB4"
      unitRef="usdPerShare">10.77</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range2Member"
      decimals="INF"
      id="d37594213e1841-wk-Fact-FF1C466DED965DA9A0994FA1DF724E50"
      unitRef="shares">481574</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range2Member"
      decimals="2"
      id="d37594213e1860-wk-Fact-91F3D9B3E488597F9273360395EDC246"
      unitRef="usdPerShare">10.68</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range3Member"
      decimals="INF"
      id="d37594213e1876-wk-Fact-3832DE4DE23A55A88F2C9E9BD375ADC9"
      unitRef="usdPerShare">11.14</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range3Member"
      decimals="INF"
      id="d37594213e1895-wk-Fact-3C0225188E495D3A97C517E87961B2A1"
      unitRef="usdPerShare">12.58</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range3Member"
      decimals="INF"
      id="d37594213e1909-wk-Fact-60825299B9A55E1A80A8A76D2CA86201"
      unitRef="shares">984936</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range3Member"
      id="d37594213e1924-wk-Fact-8FCFE7374A0E546A9CD6AAF8ACDF1EA9">P5Y5M26D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range3Member"
      decimals="2"
      id="d37594213e1939-wk-Fact-42960A9B1355533F98D1638C6577F1F8"
      unitRef="usdPerShare">12.17</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range3Member"
      decimals="INF"
      id="d37594213e1953-wk-Fact-792BDAC79E3E5A2CBFDDA74822726253"
      unitRef="shares">893989</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range3Member"
      decimals="2"
      id="d37594213e1972-wk-Fact-C8CAE378BE70566881CDB4830EDBDFD0"
      unitRef="usdPerShare">12.20</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range4Member"
      decimals="INF"
      id="d37594213e1988-wk-Fact-FCB756A455D757B0B4B497087B2584AD"
      unitRef="usdPerShare">12.66</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range4Member"
      decimals="INF"
      id="d37594213e2007-wk-Fact-77952169A65E580AB56430F59BCF8912"
      unitRef="usdPerShare">13.67</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range4Member"
      decimals="INF"
      id="d37594213e2021-wk-Fact-3F6279C6D13451948DB9C314600001BD"
      unitRef="shares">984161</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range4Member"
      id="d37594213e2036-wk-Fact-A287DA45C39D5A1396EADC4DE3A959F6">P7Y11M19D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range4Member"
      decimals="2"
      id="d37594213e2051-wk-Fact-25D051DFDED6527BB08AAC7F666F0358"
      unitRef="usdPerShare">13.60</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range4Member"
      decimals="INF"
      id="d37594213e2065-wk-Fact-5770A88F8D8A5CB7B3865EC5F662B787"
      unitRef="shares">428577</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range4Member"
      decimals="2"
      id="d37594213e2084-wk-Fact-9EA65CC85F905BBFA85AF5B9FE98A965"
      unitRef="usdPerShare">13.56</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range5Member"
      decimals="INF"
      id="d37594213e2100-wk-Fact-CEE2760183C15C93825CFBCF130B8707"
      unitRef="usdPerShare">13.94</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range5Member"
      decimals="INF"
      id="d37594213e2119-wk-Fact-705519525ACD531F912AB893CEF6C9C2"
      unitRef="usdPerShare">16.07</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range5Member"
      decimals="INF"
      id="d37594213e2133-wk-Fact-DCF33F34A963589A8DD047BD9785E165"
      unitRef="shares">1139533</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range5Member"
      id="d37594213e2148-wk-Fact-02420044A741557EB61883EAEDAE9333">P6Y9M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range5Member"
      decimals="2"
      id="d37594213e2163-wk-Fact-43DA51A416E452DFBAF219FFCCB99FB0"
      unitRef="usdPerShare">15.26</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range5Member"
      decimals="INF"
      id="d37594213e2177-wk-Fact-1FEEA0935B5B579CBBC52B8E17B799B7"
      unitRef="shares">765384</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range5Member"
      decimals="2"
      id="d37594213e2196-wk-Fact-A77BA5E57F6D583D95769E6A0A604059"
      unitRef="usdPerShare">15.17</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range6Member"
      decimals="INF"
      id="d37594213e2212-wk-Fact-D7F0D2BA6B19522EA8EEE81C27E8B91F"
      unitRef="usdPerShare">16.09</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range6Member"
      decimals="INF"
      id="d37594213e2231-wk-Fact-59F0CAA976BA505DB52756FF57D78275"
      unitRef="usdPerShare">17.16</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range6Member"
      decimals="INF"
      id="d37594213e2245-wk-Fact-31FCD1AE49975DFCBB85EE599E2614F0"
      unitRef="shares">1438502</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range6Member"
      id="d37594213e2260-wk-Fact-C177B417566A5BB68A391827BB893CB4">P7Y11M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range6Member"
      decimals="2"
      id="d37594213e2275-wk-Fact-925669E147B658799229DE9855ABEA1C"
      unitRef="usdPerShare">16.69</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range6Member"
      decimals="INF"
      id="d37594213e2289-wk-Fact-E9C5A168271553B1819040AAC91C935A"
      unitRef="shares">602949</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range6Member"
      decimals="2"
      id="d37594213e2308-wk-Fact-17B081C609B450EDB3E56D17C4DCACA6"
      unitRef="usdPerShare">16.48</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range7Member"
      decimals="INF"
      id="d37594213e2324-wk-Fact-794CBC6A90CA5AC68DAB47FC46C61E1B"
      unitRef="usdPerShare">17.24</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range7Member"
      decimals="INF"
      id="d37594213e2343-wk-Fact-38F3841EFD0D5E2A86B4FD8B8D5A8E77"
      unitRef="usdPerShare">22.76</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range7Member"
      decimals="INF"
      id="d37594213e2357-wk-Fact-FAFBD7B15896546F974481ABF750FCF0"
      unitRef="shares">1366680</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range7Member"
      id="d37594213e2372-wk-Fact-37AAA64834995FF697D2FFAEB21FBF56">P6Y6M21D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range7Member"
      decimals="2"
      id="d37594213e2387-wk-Fact-B7F591D387295CF881CFE2B3D2E2606C"
      unitRef="usdPerShare">21.20</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range7Member"
      decimals="INF"
      id="d37594213e2401-wk-Fact-82EEF6FE87965A0EA64EC43CAC56AF81"
      unitRef="shares">1017263</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range7Member"
      decimals="2"
      id="d37594213e2420-wk-Fact-8BCD7C8FD178522F825FAB14925452D8"
      unitRef="usdPerShare">21.26</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range8Member"
      decimals="INF"
      id="d37594213e2436-wk-Fact-7F6E966710975039ACEF9EC9D90D56F7"
      unitRef="usdPerShare">22.84</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range8Member"
      decimals="INF"
      id="d37594213e2455-wk-Fact-44745C6633AE5AF7AEE9DD7A4363757D"
      unitRef="usdPerShare">30.46</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range8Member"
      decimals="INF"
      id="d37594213e2469-wk-Fact-388D9F32407558C6B28F707C7BACA536"
      unitRef="shares">1439910</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range8Member"
      id="d37594213e2484-wk-Fact-BC7F45FB56B8521FA4658F30232D37A5">P9Y2M15D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range8Member"
      decimals="2"
      id="d37594213e2499-wk-Fact-C57844E9F03A5C0F91352AB308A01199"
      unitRef="usdPerShare">28.61</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range8Member"
      decimals="INF"
      id="d37594213e2513-wk-Fact-CC36D05104F954D9A9C86D941860F0A8"
      unitRef="shares">40055</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range8Member"
      decimals="2"
      id="d37594213e2532-wk-Fact-BC9DEDACEA2F577BB06F9D0174DB06CF"
      unitRef="usdPerShare">24.26</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range9Member"
      decimals="INF"
      id="d37594213e2548-wk-Fact-3F03C016F96255E5AF14D83D2072A2CC"
      unitRef="usdPerShare">30.86</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range9Member"
      decimals="INF"
      id="d37594213e2567-wk-Fact-91D5DDC70794516F970800CB3776A50B"
      unitRef="usdPerShare">31.78</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range9Member"
      decimals="INF"
      id="d37594213e2581-wk-Fact-D041F8F63205579BBC5F459D0F7F7EA0"
      unitRef="shares">155960</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range9Member"
      id="d37594213e2596-wk-Fact-6B70E334A75F57D889717D232BB2FCFE">P9Y3M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range9Member"
      decimals="2"
      id="d37594213e2611-wk-Fact-2CB1EC1CB60959B0A54829501506F1BD"
      unitRef="usdPerShare">31.10</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range9Member"
      decimals="INF"
      id="d37594213e2625-wk-Fact-6A68AA239916587BAE69181D272404A4"
      unitRef="shares">0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range9Member"
      decimals="2"
      id="d37594213e2644-wk-Fact-7F7EF982A42F5DCA8C2F660E9C827BD0"
      unitRef="usdPerShare">0</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range10Member"
      decimals="INF"
      id="d37594213e2661-wk-Fact-23BA4CACD2B7525EA61CC3834C985D03"
      unitRef="usdPerShare">32.46</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range10Member"
      decimals="INF"
      id="d37594213e2680-wk-Fact-22532F065516570285097C8E8853E960"
      unitRef="usdPerShare">32.46</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range10Member"
      decimals="INF"
      id="d37594213e2694-wk-Fact-5A93E822189C548EA1B78320F86A646F"
      unitRef="shares">13500</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="FD2018Q3YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range10Member"
      id="d37594213e2709-wk-Fact-13BFDF3B61955C7CBB326ECE53779A00">P9Y3M3D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range10Member"
      decimals="2"
      id="d37594213e2724-wk-Fact-43259AD1C5255AEA8DC4FCFFBCEB7221"
      unitRef="usdPerShare">32.46</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range10Member"
      decimals="INF"
      id="d37594213e2738-wk-Fact-61EFFACCB01951348D46752E28C2FCE2"
      unitRef="shares">0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="FI2018Q3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_insm_Range10Member"
      decimals="2"
      id="d37594213e2757-wk-Fact-8C8C6B7F10C25B00B9D0AA6FA2948794"
      unitRef="usdPerShare">0</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <insm:NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit
      contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_insm_RestrictedStockAndRestrictedStockUnitsMember"
      decimals="INF"
      id="d37594213e2774-wk-Fact-1715F306546C5CB08627E11D83122A50"
      unitRef="shares">1</insm:NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="FI2018Q3_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-5"
      id="d37594213e2782-wk-Fact-67751CBFB6035D91B46F8ABEA0BA0066"
      unitRef="usd">4200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      id="d37594213e2786-wk-Fact-183CDC7022B45960B929D68177A36A42">P2Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="FD2018Q3YTD"
      id="TextSelection-54CAD63D01C251BE870E2341B6E8859B-0-wk-Fact-5C463E62A40951A58A64A179E7928773">The following table summarizes the Company&#x2019;s RSU award activity during the &lt;span style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.96875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Number&#160;of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;RSUs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Grant&#160;Price&#160;($)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Outstanding at December&#160;31, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;46,914&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17.16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;248,468&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;29.41&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Released&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(47,478&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17.32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3,103&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30.46&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Outstanding at September&#160;30, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;244,801&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;29.40&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d37594213e2873-wk-Fact-157E1A5783C15A05A3E1C33AF8946F14"
      unitRef="shares">46914</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d37594213e2892-wk-Fact-7BDBE861F98B5FE1975A6B381588EF8E"
      unitRef="usdPerShare">17.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d37594213e2907-wk-Fact-E47C68E50C705699950452445FB00E94"
      unitRef="shares">248468</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d37594213e2926-wk-Fact-40FF1FDCD63956F99537A1FE49A0C85C"
      unitRef="usdPerShare">29.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d37594213e2941-wk-Fact-01CB6EFAC9BD55DF98C822C1D6DFFF02"
      unitRef="shares">47478</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d37594213e2961-wk-Fact-E12EAB76A83B5712BA586877F0736CA1"
      unitRef="usdPerShare">17.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d37594213e2976-wk-Fact-B6B378A04B105962B219E298CA8A8E69"
      unitRef="shares">3103</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d37594213e2996-wk-Fact-02222A22BEFA5EBA964F0993F4BA8D17"
      unitRef="usdPerShare">30.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2018Q3_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d37594213e3011-wk-Fact-013DAB26E52050D4851CBD309A10786B"
      unitRef="shares">244801</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="FI2018Q3_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d37594213e3030-wk-Fact-A65C71FB9C5D59CD967D216E99BEAB63"
      unitRef="usdPerShare">29.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="FD2018Q3YTD"
      id="TextSelection-94E34DAAC8A25936A53343267BC252B2-0-wk-Fact-0EBDA34B2CCA554E8CC9B05187720583">The following table summarizes the aggregate stock-based compensation expense recorded in the consolidated statements of comprehensive loss related to stock options and RSUs during the three and &lt;span style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively:&lt;/span&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in&#160;millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;General and administrative expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="d37594213e3343-wk-Fact-EE4A3076DD1658B3A107CEE4ECE6E777"
      unitRef="usd">2800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2017Q3QTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="d37594213e3362-wk-Fact-D3D216BE593C57BAAC3F074105E07550"
      unitRef="usd">1800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="d37594213e3381-wk-Fact-E9BDE0B5AD37547790E5745C4615F946"
      unitRef="usd">7400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="d37594213e3401-wk-Fact-E275ED6C602C5AF5BC351BDDD678BC02"
      unitRef="usd">4800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-5"
      id="d37594213e3416-wk-Fact-A676DCC6D466585DB18F2870A73D44F5"
      unitRef="usd">5100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2017Q3QTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-5"
      id="d37594213e3435-wk-Fact-3344763DAE7D5AD1A62D50AB11882519"
      unitRef="usd">2900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-5"
      id="d37594213e3454-wk-Fact-70033FE6959A5A039AB17C9A6EA1461A"
      unitRef="usd">12800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-5"
      id="d37594213e3474-wk-Fact-FC3E12C8099553BB8B4EAF22982F77F0"
      unitRef="usd">8500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember"
      decimals="-5"
      id="d37594213e3499-wk-Fact-0EE854EF16B559C9860D082C60393614"
      unitRef="usd">7900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2017Q3QTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember"
      decimals="-5"
      id="d37594213e3518-wk-Fact-FE61A3350D3752FEAE4F69B0F37DA6D3"
      unitRef="usd">4700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember"
      decimals="-5"
      id="d37594213e3537-wk-Fact-53BD971A06C55BF6934E3B46D290C361"
      unitRef="usd">20200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember"
      decimals="-5"
      id="d37594213e3557-wk-Fact-5C0FC6E616FD570FAF4A461BA561F613"
      unitRef="usd">13300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="FD2018Q3YTD"
      id="TextSelection-2EC5356E60FB571088C30BCF246BE7CD-0-wk-Fact-CEFE1E6685D45CD79BEC0773F9272749">&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/span&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company&#x2019;s provision for income taxes was $&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;46,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and $&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;134,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, and $&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;27,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and $&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;94,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively. The provision for income taxes in all periods was a result of certain of the Company&#x2019;s subsidiaries in Europe, which had taxable income during the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. In jurisdictions where the Company has net losses, there was a full valuation allowance recorded against the Company&#x2019;s deferred tax assets and therefore &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; tax benefit was recorded. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Following adoption of the Tax Cuts and Jobs Act during the fourth quarter of 2017, the Company remeasured certain deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future, which is generally 21%. The Company recorded a provisional amount of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$94.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as of December 31, 2017 related to the re-measurement of certain deferred tax balances, which was completely offset by a full valuation allowance. Upon further analyses, the Company determined in the second quarter of 2018 that the provisional amount would not need to be adjusted.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In addition to local taxes in foreign jurisdictions, the Company is subject to US federal, US state, and US tax on foreign earnings.&#160;In regard to the US tax on foreign earnings, the Company was subject to a one-time transition tax based on its total earnings and profits, which were generally deferred from US income taxes under previous US law.&#160;Due to the aggregate loss position of the Company's foreign subsidiaries, the Company did not record any provisional amount for the one-time transition tax liability at December 31, 2017.&#160;Additionally, the global intangible low-taxed income tax and base erosion provisions in the Tax Cuts and Jobs Act are effective for taxable years beginning after December 31, 2017. The Company does not currently expect these provisions to have a material impact (i) due to the aggregate loss position of its foreign subsidiaries and (ii) because the Company currently expects to be below the gross receipts threshold for purposes of the base erosion provisions. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company is subject to US federal and state income taxes and the statute of limitations for tax audit is open for the Company's federal tax returns for the years ended 2014 and later, and is generally open for certain states for the years 2013 and later. The Company has incurred net operating losses since inception, except for the year ended December&#160;31, 2009. Such loss carryforwards would be subject to audit in any tax year in which those losses are utilized, notwithstanding the year of origin. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company had recorded &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt; reserves for unrecognized income tax benefits, nor had it recorded any accrued interest or penalties related to uncertain tax positions. The Company does not anticipate any material changes in the amount of unrecognized tax positions over the next 12 months.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d37594215e323-wk-Fact-69971A3E7D3F57BAAF3705F5AD80D4F4"
      unitRef="usd">46000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d37594215e327-wk-Fact-C45D6E334FD15D42A9DA0E8FAE4EA341"
      unitRef="usd">134000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2017Q3QTD"
      decimals="-3"
      id="d37594215e339-wk-Fact-35D2D40AA43F5C9D9B5934F32E20F1BA"
      unitRef="usd">27000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2017Q3YTD"
      decimals="-3"
      id="d37594215e344-wk-Fact-1FD78E5302455C94BB9DC295F0C61BE6"
      unitRef="usd">94000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="FD2018Q3YTD"
      decimals="INF"
      id="d37594215e369-wk-Fact-0FA583432F045200A5AC06F484429E63"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <insm:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances
      contextRef="FI2017Q4"
      decimals="-5"
      id="d37594215e378-wk-Fact-E918824083575108A1A82ED71883C41D"
      unitRef="usd">94000000.0</insm:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="FI2018Q3"
      decimals="INF"
      id="d37594215e400-wk-Fact-9265F0928DA955D8907D6E0B3C8A7CA7"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="FD2018Q3YTD"
      id="TextSelection-66D61AD7349A586D81984FB8AF590692-0-wk-Fact-B61D104013855BF4A3AC0DF4EFD433F2">&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Commitments and Contingencies&lt;/span&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company has an operating lease for office and laboratory space located in Bridgewater, NJ, its corporate headquarters, for which the initial lease term expires in November&#160;2019. Future minimum rental payments under this lease are &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. In July&#160;2016, the Company signed an operating lease for laboratory space located in Bridgewater, NJ for which the initial lease term expires in December&#160;2021. Future minimum rental payments under this lease are &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In September 2018, the Company entered into a lease agreement for office space in Bridgewater, NJ for its future corporate headquarters. The lease provides for a commencement date of the earlier of (1)&#160;September&#160;1, 2019, subject to completion of certain improvements by specified dates, and (2)&#160;the date on which the Company takes possession of the premises to commence its business operations therein (the Commencement Date).&#160;The initial lease term runs &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;130 months&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; from the Commencement Date (plus any partial month from the Commencement Date until the first day of the next full calendar month during the term), and the Company has the option to extend that term for up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; additional &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;five&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-year periods. Future minimum rental payments under this lease are &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$32.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Rent expense charged to operations was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the three months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively. Future minimum rental payments required under the Company&#x2019;s leases for the period from October 1, 2018 to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and for each of the five years thereafter are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.96875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:84%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Year Ending December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018 (remaining)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;490&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,863&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,185&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,958&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,281&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2023 and thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;23,261&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;37,038&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;From time to time, the Company is a party to various lawsuits, claims and other legal proceedings that arise in the ordinary course of business. While the outcomes of these matters are uncertain, management does not expect that the ultimate costs to resolve these matters will have a material adverse effect on the Company&#x2019;s consolidated financial position, results of operations or cash flows.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue
      contextRef="FI2018Q3_us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_insm_BridgewaterNewJerseyFacilityMember"
      decimals="-5"
      id="d37594520e323-wk-Fact-7B1C43E099F250F596559BDF454E71BF"
      unitRef="usd">1200000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <insm:AdditionalLaboratorySpaceOperatingLeasesFutureMinimumPaymentsDue
      contextRef="FI2018Q3_us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_insm_BridgewaterNewJerseyFacilityMember"
      decimals="-5"
      id="d37594520e327-wk-Fact-96E3BFADE2695C879F843B21D61CE3FF"
      unitRef="usd">1500000</insm:AdditionalLaboratorySpaceOperatingLeasesFutureMinimumPaymentsDue>
    <insm:LesseeOperatingLeaseNumberOfRenewals
      contextRef="D2018Q3Sept2018_us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_insm_BridgewaterNewJerseyOfficeSpaceMember"
      decimals="INF"
      id="d37594520e341-wk-Fact-7CB87852A83D8157DEB1834EFBEEAC1D"
      unitRef="renewal">3</insm:LesseeOperatingLeaseNumberOfRenewals>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue
      contextRef="FI2018Q3_us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_insm_BridgewaterNewJerseyOfficeSpaceMember"
      decimals="-5"
      id="d37594520e349-wk-Fact-594B02D028E7E162C7B19DF1B02DA817"
      unitRef="usd">32300000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:LeaseAndRentalExpense
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d37594520e359-wk-Fact-538AC9A04BD65180816DE21476FFB01D"
      unitRef="usd">400000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="FD2017Q3QTD"
      decimals="-5"
      id="d37594520e363-wk-Fact-DCBDD01FF9515C578561B47F5B8E5CB4"
      unitRef="usd">400000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d37594520e375-wk-Fact-A800BBBCE61E52CA8D88A0E0028DF35D"
      unitRef="usd">1200000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="FD2017Q3YTD"
      decimals="-5"
      id="d37594520e380-wk-Fact-A90FB18502E1505988609E848F60280F"
      unitRef="usd">1100000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock
      contextRef="FD2018Q3YTD"
      id="TextSelection-7BC686E6921E5CBC96A734742B382900-0-wk-Fact-15B5A4EE0B0E5DF8ABEF402832AA41EA">Future minimum rental payments required under the Company&#x2019;s leases for the period from October 1, 2018 to &lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and for each of the five years thereafter are as follows (in thousands):&lt;/span&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.96875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:84%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Year Ending December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018 (remaining)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;490&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,863&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,185&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,958&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,281&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2023 and thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;23,261&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:1pt;"&gt;&lt;span style="font-family:inherit;font-size:1pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;37,038&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
      contextRef="FI2018Q3"
      decimals="-3"
      id="d37594520e450-wk-Fact-B370F1D8989556EE88501F6713A77F21"
      unitRef="usd">490000</us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears
      contextRef="FI2018Q3"
      decimals="-3"
      id="d37594520e465-wk-Fact-A347ECA5EA0D5AC4BAEEB8F9D2A05D05"
      unitRef="usd">3863000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears
      contextRef="FI2018Q3"
      decimals="-3"
      id="d37594520e485-wk-Fact-6780772832E85EB187A96CBB4987BDC0"
      unitRef="usd">4185000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears
      contextRef="FI2018Q3"
      decimals="-3"
      id="d37594520e505-wk-Fact-49D60C0EB18C5FF9B1B35C59F0913678"
      unitRef="usd">3958000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears
      contextRef="FI2018Q3"
      decimals="-3"
      id="d37594520e525-wk-Fact-A0D28E1B01BD5BB7824152F7C4816377"
      unitRef="usd">1281000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter
      contextRef="FI2018Q3"
      decimals="-3"
      id="d37594520e545-wk-Fact-A643D0D35E1250EDA5ECB3856A61D83C"
      unitRef="usd">23261000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue
      contextRef="FI2018Q3"
      decimals="-3"
      id="d37594520e570-wk-Fact-719C3F077501527EBC95E4493774863F"
      unitRef="usd">37038000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6863350832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Oct. 26, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INSMED INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001104506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,090,229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6863666080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 567,574<span></span>
</td>
<td class="nump">$ 381,165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">9,921<span></span>
</td>
<td class="nump">8,279<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">577,495<span></span>
</td>
<td class="nump">389,444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets</a></td>
<td class="nump">59,941<span></span>
</td>
<td class="nump">58,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">19,526<span></span>
</td>
<td class="nump">12,432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
<td class="nump">4,551<span></span>
</td>
<td class="nump">1,971<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">661,513<span></span>
</td>
<td class="nump">462,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">16,579<span></span>
</td>
<td class="nump">14,671<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">40,368<span></span>
</td>
<td class="nump">29,339<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">472<span></span>
</td>
<td class="nump">646<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">57,419<span></span>
</td>
<td class="nump">44,656<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net</a></td>
<td class="nump">311,861<span></span>
</td>
<td class="nump">55,567<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">826<span></span>
</td>
<td class="nump">765<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">370,106<span></span>
</td>
<td class="nump">100,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value; 500,000,000 authorized shares, 77,085,715 and 76,610,508 issued and outstanding shares at September 30, 2018 and December 31, 2017, respectively</a></td>
<td class="nump">771<span></span>
</td>
<td class="nump">766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,481,205<span></span>
</td>
<td class="nump">1,318,181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,190,589)<span></span>
</td>
<td class="num">(957,885)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="nump">20<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">291,407<span></span>
</td>
<td class="nump">361,059<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#8217; equity</a></td>
<td class="nump">$ 661,513<span></span>
</td>
<td class="nump">$ 462,047<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6904-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6860864800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares (in shares)</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued shares (in shares)</a></td>
<td class="nump">77,085,715<span></span>
</td>
<td class="nump">76,610,508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding shares (in shares)</a></td>
<td class="nump">77,085,715<span></span>
</td>
<td class="nump">76,610,508<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6863545792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss (unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">39,538<span></span>
</td>
<td class="nump">26,675<span></span>
</td>
<td class="nump">105,358<span></span>
</td>
<td class="nump">75,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">44,445<span></span>
</td>
<td class="nump">17,408<span></span>
</td>
<td class="nump">114,258<span></span>
</td>
<td class="nump">47,767<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">83,983<span></span>
</td>
<td class="nump">44,083<span></span>
</td>
<td class="nump">219,616<span></span>
</td>
<td class="nump">123,567<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(83,983)<span></span>
</td>
<td class="num">(44,083)<span></span>
</td>
<td class="num">(219,616)<span></span>
</td>
<td class="num">(123,567)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNonoperating', window );">Investment income</a></td>
<td class="nump">2,741<span></span>
</td>
<td class="nump">326<span></span>
</td>
<td class="nump">7,510<span></span>
</td>
<td class="nump">649<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(6,675)<span></span>
</td>
<td class="num">(1,496)<span></span>
</td>
<td class="num">(18,805)<span></span>
</td>
<td class="num">(4,459)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,209)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">220<span></span>
</td>
<td class="nump">101<span></span>
</td>
<td class="nump">550<span></span>
</td>
<td class="nump">206<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(87,697)<span></span>
</td>
<td class="num">(45,152)<span></span>
</td>
<td class="num">(232,570)<span></span>
</td>
<td class="num">(127,171)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="nump">134<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (87,743)<span></span>
</td>
<td class="num">$ (45,179)<span></span>
</td>
<td class="num">$ (232,704)<span></span>
</td>
<td class="num">$ (127,265)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share (in dollars per share)</a></td>
<td class="num">$ (1.14)<span></span>
</td>
<td class="num">$ (0.69)<span></span>
</td>
<td class="num">$ (3.03)<span></span>
</td>
<td class="num">$ (2.01)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average basic and diluted common shares outstanding (in shares)</a></td>
<td class="nump">77,066<span></span>
</td>
<td class="nump">65,312<span></span>
</td>
<td class="nump">76,819<span></span>
</td>
<td class="nump">63,199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (87,743)<span></span>
</td>
<td class="num">$ (45,179)<span></span>
</td>
<td class="num">$ (232,704)<span></span>
</td>
<td class="num">$ (127,265)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">76<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (87,741)<span></span>
</td>
<td class="num">$ (45,103)<span></span>
</td>
<td class="num">$ (232,681)<span></span>
</td>
<td class="num">$ (127,166)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e557-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569643-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6863355248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (232,704)<span></span>
</td>
<td class="num">$ (127,265)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">2,652<span></span>
</td>
<td class="nump">2,168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">20,205<span></span>
</td>
<td class="nump">13,332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Accretion of debt discount</a></td>
<td class="nump">11,541<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionExpense', window );">Accretion of back-end fee on debt</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(4,315)<span></span>
</td>
<td class="num">(1,052)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">2,536<span></span>
</td>
<td class="num">(921)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities', window );">Accrued expenses and other</a></td>
<td class="nump">10,596<span></span>
</td>
<td class="nump">1,745<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(188,439)<span></span>
</td>
<td class="num">(111,396)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of fixed assets</a></td>
<td class="num">(10,063)<span></span>
</td>
<td class="num">(1,301)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(10,063)<span></span>
</td>
<td class="num">(1,301)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">6,390<span></span>
</td>
<td class="nump">2,953<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Loss on extinguishment of debt</a></td>
<td class="num">(2,209)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Payment of debt</a></td>
<td class="num">(55,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of 1.75% convertible senior notes due 2025</a></td>
<td class="nump">450,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of debt issuance costs</a></td>
<td class="num">(14,235)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">377,703<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">384,946<span></span>
</td>
<td class="nump">380,656<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rates on cash and cash equivalents</a></td>
<td class="num">(35)<span></span>
</td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">186,409<span></span>
</td>
<td class="nump">268,087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">381,165<span></span>
</td>
<td class="nump">162,591<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">567,574<span></span>
</td>
<td class="nump">430,678<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">4,975<span></span>
</td>
<td class="nump">3,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">$ 127<span></span>
</td>
<td class="nump">$ 62<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the sum of accrued expenses and Other Current Liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6392676&amp;loc=d3e7480-110848<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6394232&amp;loc=d3e17558-110866<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid, after deduction of cash paid for capitalized interest, for interest. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtExtinguishmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtExtinguishmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6778270928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (unaudited) (Parenthetical)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes | 1.75 convertible senior notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="nump">1.75%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6772686368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">The Company and Basis of Presentation</a></td>
<td class="text"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The Company and Basis of Presentation</span><div style="line-height:120%;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), received accelerated approval in the United States (US) on September 28, 2018 for the treatment of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Mycobacterium avium</span><span style="font-family:inherit;font-size:10pt;"> complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. The Company's clinical-stage pipeline includes INS1007 and INS1009. INS1007 is a novel oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1) with therapeutic potential in non-cystic fibrosis (non-CF) bronchiectasis and other inflammatory diseases. INS1009 is an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension (PAH).</span></div><div style="line-height:120%;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company was incorporated in the Commonwealth of Virginia on November&#160;29, 1999 and its principal executive offices are in Bridgewater, New Jersey. The Company has legal entities in the US,&#160;Ireland, Germany, France, the United Kingdom (UK), the Netherlands, and Japan. All intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying unaudited interim consolidated financial statements have been prepared pursuant to the rules&#160;and regulations for reporting on Form&#160;10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the US for complete consolidated financial statements are not included herein. The unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company&#8217;s Annual Report on Form&#160;10-K for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. The unaudited interim consolidated financial information presented herein reflects all normal adjustments that are, in the opinion of management, necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company had </span><span style="font-family:inherit;font-size:10pt;">$567.6 million</span><span style="font-family:inherit;font-size:10pt;"> in cash and cash equivalents as of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and reported a net loss of </span><span style="font-family:inherit;font-size:10pt;"><span>$232.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">. Historically, the Company has funded its operations through public offerings of equity securities and debt financings. To date, the Company has not generated material revenue from ARIKAYCE. The Company commenced commercial shipments in October 2018. The Company expects to continue to incur operating losses while funding commercial launch efforts for ARIKAYCE, research and development (R&amp;D) activities, regulatory submissions outside the US, and general and administrative expenses. The Company expects its future cash requirements to be substantial, and the Company may need to raise additional capital to fund operations, including the commercialization of ARIKAYCE and additional clinical trials related to ARIKAYCE, to develop INS1007 and INS1009 and to develop, acquire, in-license or co-promote other products that address orphan or rare diseases.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>The source, timing and availability of any future financing or other transaction will depend principally upon continued progress in the Company&#8217;s commercial, regulatory and development activities. Any equity or debt financing will also be contingent upon equity and debt market conditions and interest rates at the time. If the Company is unable to obtain sufficient additional funds when required, the Company may be forced to delay, restrict or eliminate all or a portion of its development programs or commercialization efforts.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6857351024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Summary of Significant Accounting Policies</span><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The following are the required interim disclosure updates to the Company's significant accounting policies described in Note 2 of the notes to the consolidated financial statements in the Company&#8217;s Annual Report on Form&#160;10-K for the year ended </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">December&#160;31, 2017</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value Measurements</span><span style="font-family:inherit;font-size:10pt;"> - The Company categorizes its financial assets and liabilities measured and reported at fair value in the financial statements on a recurring basis based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs used to determine the fair value of financial assets and liabilities, are as follows:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 1 &#8212; Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 2 &#8212; Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the assets or liability through correlation with market data at the measurement date and for the duration of the instrument&#8217;s anticipated life.</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 3 &#8212; Inputs reflect management&#8217;s best estimate of what market participants would use in pricing the asset or liability at the measurement date.&#160;Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Each major category of financial assets and liabilities measured at fair value on a recurring basis is categorized based upon the lowest level of significant input to the valuations. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Financial instruments in Level 1 generally include US treasuries and mutual funds listed in active markets.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s only financial assets and liabilities which were measured at fair value as of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</span><span style="font-family:inherit;font-size:10pt;"> were Level 1 assets comprised of cash and cash equivalents of </span><span style="font-family:inherit;font-size:10pt;"><span>$567.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$381.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. The estimated fair value of the liability component of the </span><span style="font-family:inherit;font-size:10pt;"><span>1.75%</span></span><span style="font-family:inherit;font-size:10pt;"> convertible senior notes due 2025 (the Convertible Notes) (categorized as a Level 2 liability for fair value measurement purposes) was determined using current market factors and the ability of the Company to obtain debt on comparable terms to the Convertible Notes. The following table shows certain assets and liabilities and their carrying values and fair values:</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:83.0078125%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:55%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of September 30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Level 1</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>567.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>567.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Level 2</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Convertible Notes ($450.0 face value)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>311.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>381.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;* The carrying value of the Convertible Notes excludes </span><span style="font-family:inherit;font-size:9pt;"><span>$129.4 million</span></span><span style="font-family:inherit;font-size:9pt;"> of the unamortized portion of the debt discount.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s cash and cash equivalents permit daily redemption and the fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions. Cash equivalents consist of liquid investments with an original maturity of three months or less from the date of purchase. As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company's cash and cash equivalents balance included US treasury bills of </span><span style="font-family:inherit;font-size:10pt;"><span>$399.8 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter. There were </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> transfers in or out of Level 1, Level 2 or Level 3 during the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</span><span style="font-family:inherit;font-size:10pt;">, the Company held </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> securities that were in an unrealized gain or loss position. The Company reviews the status of each security quarterly to determine whether an other-than-temporary impairment has occurred. In making its determination, the Company considers a number of factors, including: (1) the significance of the decline; (2)&#160;whether the securities were rated below investment grade; (3)&#160;how long the securities have been in an unrealized loss position; and (4) the Company&#8217;s ability and intent to retain the investment for a sufficient period of time for it to recover.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Loss Per Share</span><span style="font-family:inherit;font-size:10pt;"> - Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period.&#160;Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares and other dilutive securities outstanding during the period. Potentially dilutive securities from stock options, restricted stock units (RSUs) and convertible debt securities would be anti-dilutive as the Company incurred a net loss. Potentially dilutive common shares resulting from the assumed exercise of outstanding stock options and from the assumed conversion of the Convertible Notes are determined based on the treasury stock method.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table sets forth the reconciliation of the weighted average number of common shares used to compute basic and diluted net loss per share for the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in&#160;thousands,&#160;except&#160;per&#160;share&#160;amounts)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Numerator:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(87,743</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(45,179</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(232,704</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(127,265</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Denominator:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average common shares used in calculation of basic net loss per share:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,066</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65,312</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>76,819</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>63,199</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of dilutive securities:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock options</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span></span><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">RSUs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span></span><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Convertible debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average common shares outstanding used&#160;in calculation of diluted net loss per share</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,066</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65,312</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>76,819</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>63,199</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss per share:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.14</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.69</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3.03</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.01</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following potentially dilutive securities have been excluded from the computations of diluted weighted average common shares outstanding as of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> as their effect would have been anti-dilutive (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.4140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:69%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock options to purchase common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,608</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,601</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unvested RSUs</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>245</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Convertible debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,492</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Inventory - </span><span style="font-family:inherit;font-size:10pt;">Inventory is stated at the lower of cost and net realizable value with cost determined on a standard costing method. The Company began capitalizing inventory costs subsequent to US Food and Drug Administration (FDA) approval of ARIKAYCE on September 28, 2018, when it was determined that the inventory had a probable future economic benefit. Inventory will be sold beginning in the fourth quarter of 2018 based on first-in, first out basis. Manufacturing variances, such as material usage variance and yield variance, will be capitalized in inventory until the respective units are sold at which point the variances will be released in cost of goods sold. The Company will periodically review inventory for expiry and obsolescence and write down accordingly.  The Company performs quality control procedures throughout the manufacturing processes of ARIKAYCE; however, certain batches or units of ARIKAYCE may not meet quality specifications and result in a charge to cost of goods sold.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior to FDA approval of ARIKAYCE, the Company expensed all inventory related costs in the period incurred; therefore, inventory is not included in the </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> consolidated balance sheet. Inventory used for clinical development purposes is expensed to research and development (R&amp;D) expense when consumed.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Adopted Accounting Pronouncements</span><span style="font-family:inherit;font-size:10pt;"> - In August 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standard Update (ASU) 2016-15, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments</span><span style="font-family:inherit;font-size:10pt;">, which addressed eight specific cash flow issues with the objective of reducing the existing diversity in practice. Among the updates, the standard requires debt extinguishment costs to be classified as cash outflows for financing activities. This standard update is effective as of the first quarter of 2018. As a result of the adoption of the standard, in the first quarter of 2018, the Company reported a </span><span style="font-family:inherit;font-size:10pt;"><span>$2.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> loss on extinguishment of debt in the financing activities section of its consolidated statement of cash flows. The Company had no material debt extinguishment costs prior to the first quarter of 2018. The impact of adopting this standard was not material to the Company.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">New Accounting Pronouncements (Not Yet Adopted)</span><span style="font-family:inherit;font-size:10pt;">&#8212;In February 2016, the FASB issued ASU 2016-2, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</span><span style="font-family:inherit;font-size:10pt;"> in order to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous generally accepted accounting principles. ASU 2016-2 requires a lessee to recognize a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term on the balance sheet. ASU 2016-2 is effective for fiscal years beginning after December&#160;15, 2018 (including interim periods within those periods) and early adoption is permitted. In August 2018, the FASB issued ASU 2018-11, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Targeted Improvements to ASC 842</span>, which provides a new transition option in which an entity initially applies ASU 2016-2 at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company will use the new transition option and is also utilizing the package of practical expedients that allows it to not reassess: (1) whether any expired or existing contracts are or contain leases, (2) lease classification for any expired or existing leases, and (3) initial direct costs for any expired or existing leases. The Company additionally expects to use the practical expedient that allows it to treat the lease and non-lease components of its leases as a single component. The Company has identified approximately ten leasing arrangements and is currently assessing the financial impact on the consolidated balance sheet. The Company expects to adopt ASU 2016-2 in the first quarter of 2019 and is in the process of evaluating the impact of adoption on its consolidated financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6857290208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
<td class="text"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Intangible Assets</span><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of September 30, 2018, the Company's identifiable intangible assets consisted of acquired ARIKAYCE R&amp;D, formerly referred to as in-process research and development, and a milestone payable to PARI Pharma GmbH (PARI) for the license to use PARI's Lamira&#8482; Nebulizer System for the delivery of ARIKAYCE to patients. The total carrying value of the acquired ARIKAYCE R&amp;D was&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$58.2 million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;as of&#160;</span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</span><span style="font-family:inherit;font-size:10pt;">, resulting from the initial amount recorded at the time of the Company's merger with Transave, Inc. (Transave) in 2010 and subsequent adjustments. On September 28, 2018, as a result of the FDA approval for ARIKAYCE, the Company recorded a milestone payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> due to PARI. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets consist of the following:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:72.4609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of September 30, <br/>2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of December 31, <br/>2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquired ARIKAYCE R&amp;D</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,200</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,200</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PARI milestone upon FDA approval</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,741</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Intangible assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59,941</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,200</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</span></div><span style="font-family:inherit;font-size:10pt;">Intangible assets are measured at their respective fair values on the date they were recorded and, with respect to the Acquired ARIKAYCE milestone, at the date of subsequent adjustments of fair value. Intangible assets will be amortized beginning October 1, 2018 over the initial regulatory exclusivity period for ARIKAYCE (</span><span style="font-family:inherit;font-size:10pt;"><span>12 years</span></span><span style="font-family:inherit;font-size:10pt;">). As of&#160;</span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span>, the Company performed a qualitative assessment on the assets. This assessment did not identify any indicators of impairment of the intangible assets and indicated that the implied value of the assets was more than&#160;100%&#160;greater than the book value as of that date.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6772768160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accrued Expenses</span><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses consist of the following:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.96875%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of September&#160;30, <br/>2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of December&#160;31, <br/>2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in&#160;thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued clinical trial expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,576</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,837</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued compensation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,387</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,197</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued professional fees</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,746</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,500</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued technical operation expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,137</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,182</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued milestone payment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,741</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued interest payable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,663</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>423</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued construction costs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,069</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,719</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other accrued expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,049</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>481</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,368</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29,339</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6772751104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Debt</span><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2018, the Company completed an underwritten public offering of the Convertible Notes, in which the Company sold </span><span style="font-family:inherit;font-size:10pt;"><span>$450.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> aggregate principal amount of Convertible Notes, including the exercise in full of the underwriters' option to purchase additional Convertible Notes of </span><span style="font-family:inherit;font-size:10pt;"><span>$50.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. The Company's net proceeds from the offering, after deducting underwriting discounts and commissions and other offering expenses of </span><span style="font-family:inherit;font-size:10pt;"><span>$14.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, were approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$435.8 million</span></span><span style="font-family:inherit;font-size:10pt;">. The Convertible Notes bear interest payable semiannually in arrears on January 15 and July 15 of each year, beginning on July 15, 2018. The Convertible Notes mature on January 15, 2025, unless earlier converted, redeemed, or repurchased. </span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On or after October&#160;15, 2024, until the close of business on the second scheduled trading day immediately preceding January 15, 2025, holders may convert their Convertible Notes at any time. Upon conversion, holders may receive cash, shares of the Company's common stock or a combination of cash and shares of the Company's common stock, at the Company's option. The initial conversion rate is </span><span style="font-family:inherit;font-size:10pt;">25.5384</span><span style="font-family:inherit;font-size:10pt;"> shares of common stock per $1,000 principal amount of Convertible Notes (equivalent to an initial conversion price of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$39.16</span></span><span style="font-family:inherit;font-size:10pt;"> per share of common stock). The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Holders may convert their Convertible Notes prior to October 15, 2024, only under the following circumstances, subject to the conditions set forth in an indenture, dated as of January 26, 2018, between the Company and Wells Fargo Bank, National Association (Wells Fargo), as trustee, as supplemented by the first supplemental indenture, dated January 26, 2018, between the Company and Wells Fargo (as supplemented, the Indenture): (i) during the </span><span style="font-family:inherit;font-size:10pt;"><span>five</span></span><span style="font-family:inherit;font-size:10pt;"> business day period immediately after any </span><span style="font-family:inherit;font-size:10pt;"><span>five</span></span><span style="font-family:inherit;font-size:10pt;"> consecutive trading day period (the measurement period) in which the trading price per $1,000 principal amount of convertible notes, as determined following a request by a holder of the convertible notes, for each trading day of the measurement period was less than </span><span style="font-family:inherit;font-size:10pt;"><span>98%</span></span><span style="font-family:inherit;font-size:10pt;"> of the product of the last reported sale price of the common stock and the conversion rate on such trading day, (ii) the Company elects to distribute to all or substantially all holders of the common stock (a) any rights, options or warrants (other than in connection with a stockholder rights plan for so long as the rights issued under such plan have not detached from the associated shares of common stock) entitling them, for a period of not more than </span><span style="font-family:inherit;font-size:10pt;"><span>45</span></span><span style="font-family:inherit;font-size:10pt;"> days from the declaration date for such distribution, to subscribe for or purchase shares of common stock at a price per share that is less than the average of the last reported sale prices of the common stock for the </span><span style="font-family:inherit;font-size:10pt;"><span>10</span></span><span style="font-family:inherit;font-size:10pt;"> consecutive trading day period ending on, and including, the trading day immediately preceding the declaration date for such distribution, or (b) the Company&#8217;s assets, debt securities or rights to purchase securities of the Company, which distribution has a per share value, as reasonably determined by the board of directors, exceeding </span><span style="font-family:inherit;font-size:10pt;"><span>10%</span></span><span style="font-family:inherit;font-size:10pt;"> of the last reported sale price of the common stock on the trading day immediately preceding the declaration date for such distribution, (iii) if a transaction or event that constitutes a fundamental change or a make-whole fundamental change occurs, or if the Company is a party to (a) a consolidation, merger, combination, statutory or binding share exchange or similar transaction, pursuant to which the common stock would be converted into, or exchanged for, cash, securities or other property or assets, or (b) any sale, conveyance, lease or other transfer or similar transaction in one transaction or a series of transactions of all or substantially all of the consolidated assets of the Company and its subsidiaries, taken as a whole, all or any portion of the Convertible Notes may be surrendered by a holder for conversion at any time from or after the date that is </span><span style="font-family:inherit;font-size:10pt;"><span>30</span></span><span style="font-family:inherit;font-size:10pt;"> scheduled trading days prior to the anticipated effective date of the transaction, (iv) if during any calendar quarter commencing after the calendar quarter ending on March&#160;31, 2018 (and only during such calendar quarter), the last reported sale price of the common stock for at least </span><span style="font-family:inherit;font-size:10pt;"><span>20</span></span><span style="font-family:inherit;font-size:10pt;"> trading days (whether or not consecutive) during the period of </span><span style="font-family:inherit;font-size:10pt;"><span>30</span></span><span style="font-family:inherit;font-size:10pt;"> consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to </span><span style="font-family:inherit;font-size:10pt;"><span>130%</span></span><span style="font-family:inherit;font-size:10pt;"> of the conversion price on each applicable trading day, or, (v) if the Company sends a notice of redemption, a holder may </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">surrender all or any portion of its Convertible Notes, to which the notice of redemption relates, for conversion at any time on or after the date the applicable notice of redemption was sent until the close of business on (a)&#160;the second business day immediately preceding the related redemption date or (b)&#160;if the Company fails to pay the redemption price on the redemption date as specified in such notice of redemption, such later date on which the redemption price is paid.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Convertible Notes can be settled in cash, common stock, or a combination of cash and common stock at the Company's option, and thus, the Company determined the embedded conversion options in the convertible notes are not required to be separately accounted for as a derivative. However, since the Convertible Notes are within the scope of the accounting guidance for cash convertible instruments, the Company is required to separate the Convertible Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the fair value of a similar liability that does not have an associated equity component. The fair value was based on data from readily available pricing sources which utilize market observable inputs and other characteristics for similar types of instruments. The carrying amount of the equity component representing the embedded conversion option was determined by deducting the fair value of the liability component from the gross proceeds of the Convertible Notes. The excess of the principal amount of the liability component over its carrying amount is amortized to interest expense over the expected life of a similar liability that does not have an associated equity component using the effective interest method. The equity component is not remeasured as long as it continues to meet the conditions for equity classification in the accounting guidance for contracts in an entity&#8217;s own equity.  The fair value of the liability component of the Convertible Notes on the date of issuance was estimated at </span><span style="font-family:inherit;font-size:10pt;"><span>$309.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> using an effective interest rate of </span><span style="font-family:inherit;font-size:10pt;"><span>7.6%</span></span><span style="font-family:inherit;font-size:10pt;">, and accordingly, the residual equity component on the date of issuance was </span><span style="font-family:inherit;font-size:10pt;"><span>$140.9 million</span></span><span style="font-family:inherit;font-size:10pt;">. The discount is being amortized to interest expense over the term of the Convertible Notes and has a remaining period of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>6.28 years</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, total interest expense related to the Convertible Notes was </span><span style="font-family:inherit;font-size:10pt;"><span>$6.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$17.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, which includes the contractual interest coupon payable semi-annually in cash, the amortization of the issuance costs, and accretion of debt discount, as described in the table below. The following table presents the carrying value of the Company&#8217;s debt balance as of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.96875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:84%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;1.75% convertible senior notes due 2025</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>450,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;Debt issuance costs, unamortized</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8,789</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;Discount on debt</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(129,350</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term debt, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>311,861</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, future principal repayments of the debt for each of the fiscal years through maturity were as follows (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.96875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:84%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ending December&#160;31:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>450,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>450,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2018, the Company used part of the net proceeds from the issuance of the Convertible Notes to pay off its outstanding debt to Hercules Capital (Hercules). The payments to Hercules consisted of </span><span style="font-family:inherit;font-size:10pt;"><span>$55.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the principal amount and an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$3.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> in back-end fees, outstanding interest, and prepayment penalty fees, which resulted in a </span><span style="font-family:inherit;font-size:10pt;"><span>$2.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> loss on extinguishment of debt in the quarter ended March 31, 2018.&#160;&#160;&#160;&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Interest Expense</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table sets forth the total interest expense recognized in the periods presented (in thousands):</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:82.421875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:37%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contractual interest expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,971</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,302</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,214</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,862</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of debt issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>415</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>91</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accretion of back-end fee on debt</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>164</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>506</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accretion of debt discount</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,289</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,541</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total interest expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,675</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,496</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,805</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,459</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6772768160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders' Equity</a></td>
<td class="text"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Shareholders&#8217; Equity</span><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock</span><span style="font-family:inherit;font-size:10pt;"> &#8212; As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span>500,000,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock authorized with a par value of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.01</span></span><span style="font-family:inherit;font-size:10pt;"> per share and </span><span style="font-family:inherit;font-size:10pt;"><span>77,085,715</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock issued and outstanding. In addition, as of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company had reserved </span><span style="font-family:inherit;font-size:10pt;"><span>9,608,344</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock for issuance upon the exercise of outstanding stock options and </span><span style="font-family:inherit;font-size:10pt;"><span>244,801</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock for issuance upon the vesting of RSUs. The Company has also reserved </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"><span>11,492,280</span></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">shares of common stock for issuance upon conversion of the Convertible Notes, subject to adjustment in accordance with the Indenture.&#160;&#160;&#160;&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2018, the Company completed an underwritten public offering of </span><span style="font-family:inherit;font-size:10pt;"><span>$450.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> aggregate principal amount of Convertible Notes, including the exercise in full of the underwriter's option to purchase additional Convertible Notes. The fair value of the liability component of the Convertible Notes on the date of issuance was estimated at </span><span style="font-family:inherit;font-size:10pt;"><span>$309.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, and accordingly, the equity component (included in additional paid-in capital) on the date of issuance was calculated as </span><span style="font-family:inherit;font-size:10pt;"><span>$140.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> using the residual method, as further described in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note 5 Debt</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In September 2017, the Company completed an underwritten public offering of </span><span style="font-family:inherit;font-size:10pt;"><span>14,123,150</span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s common stock, which included the underwriter&#8217;s exercise in full of its over-allotment option of </span><span style="font-family:inherit;font-size:10pt;"><span>1,842,150</span></span><span style="font-family:inherit;font-size:10pt;"> shares, at a price to the public of </span><span style="font-family:inherit;font-size:10pt;"><span>$28.50</span></span><span style="font-family:inherit;font-size:10pt;"> per share.&#160; The Company&#8217;s net proceeds from the sale of the shares, after deducting the underwriter&#8217;s discount and offering expenses of </span><span style="font-family:inherit;font-size:10pt;"><span>$24.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, were $</span><span style="font-family:inherit;font-size:10pt;"><span>377.7 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Preferred Stock</span><span style="font-family:inherit;font-size:10pt;"> &#8212; As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span>200,000,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of preferred stock authorized with a par value of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.01</span></span><span style="font-family:inherit;font-size:10pt;"> per share and </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> shares of preferred stock were issued and outstanding.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the changes in total shareholders' equity for the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:61.328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:82%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>361,059</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss for the period</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(232,704</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Proceeds from exercise of stock options</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,390</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity component of Convertible Notes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>136,434</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,205</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change in cumulative translation adjustment</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at September 30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>291,407</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6858016656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-Based Compensation</span><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s current equity compensation plan, the 2017 Incentive Plan, was approved by shareholders at the Company&#8217;s Annual Meeting of Shareholders on May&#160;18, 2017.&#160;The 2017 Incentive Plan is administered by the Compensation Committee and the Board of Directors of the Company.&#160;Under the terms of the 2017 Incentive Plan, the Company is authorized to grant a variety of incentive awards based on its common stock, including stock options (both incentive stock options and non-qualified stock options), RSUs, performance options/shares and other stock awards, as well as pay incentive bonuses to eligible employees and non-employee directors.&#160;On May&#160;18, 2017, upon the approval of the 2017 Incentive Plan by shareholders, </span><span style="font-family:inherit;font-size:10pt;"><span>5,000,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares were authorized for issuance thereunder, plus any shares subject to then-outstanding awards under the 2015 Incentive Plan and the 2013 Incentive Plan that subsequently were canceled, terminated unearned, expired, were forfeited, lapsed for any reason or were settled in cash without the delivery of shares. As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,408,995</span></span><span style="font-family:inherit;font-size:10pt;"> shares remained for future issuance under the 2017 Incentive Plan. The 2017 Incentive Plan will terminate on April&#160;3, 2027 unless it is extended or terminated earlier pursuant to its terms. In addition, from time to time, the Company makes inducement grants of stock options to new hires, which awards are made pursuant to the NASDAQ inducement grant exception. During the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company granted inducement stock options covering </span><span style="font-family:inherit;font-size:10pt;"><span>236,730</span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock to new employees.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On May 15, 2018, the 2018 Employee Stock Purchase Plan (2018 ESPP) was approved by shareholders at the Company&#8217;s Annual Meeting of Shareholders. The Company has reserved the following for issuance under the 2018 ESPP: (i)&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>1,000,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock,&#160;plus&#160;(ii)&#160;commencing on January&#160;1, 2019 and ending on December&#160;31, 2023, an additional number of shares to be added on the first day of each calendar year equal to the lesser of (A)&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>1,200,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock, (B)&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>2%</span></span><span style="font-family:inherit;font-size:10pt;"> of the number of outstanding shares of common stock on such date and (C)&#160;an amount determined by the administrator.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock Options</span><span style="font-family:inherit;font-size:10pt;"> - The Company calculates the fair value of stock options granted using the Black-Scholes valuation model. The following table summarizes the Company&#8217;s grant date fair value and assumptions used in determining the fair value of all stock options granted during the periods presented:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.484375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:45%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:13%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Volatility</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">66%-67%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">72%-73%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">66%-68%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">72%-74%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.75%-2.87%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.73%-1.93%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.25%-2.87%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.73%-1.99%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Dividend yield</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.0%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.0%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.0%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.0%</span></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected option term (in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.14</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.25</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.09</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.25</span></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average fair value of stock options granted</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$13.62</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$9.59</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$16.56</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$10.18</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For each period presented, the volatility factor was based on the Company&#8217;s historical volatility during the expected option term.&#160;Estimated forfeitures are based on the actual percentage of option forfeitures since the closing of the Company&#8217;s merger with Transave in December&#160;2010. The expected option term for these grants was determined using the Company&#8217;s historical exercise behavior of grantees. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From time to time, the Company has granted performance-condition options to certain of its employees. Vesting of these options was subject to the Company achieving certain performance criteria established at the date of grant and the grantees fulfilling a service condition (continued employment). During the quarter ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, performance-condition options totaling </span><span style="font-family:inherit;font-size:10pt;"><span>$1.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;"><span>133,334</span></span><span style="font-family:inherit;font-size:10pt;"> shares, met their recognition criteria as a result of the FDA approval of ARIKAYCE and vested in full. As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, there were </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> performance-condition options outstanding. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the Company&#8217;s aggregate stock option activity for the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">:&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:45%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Number&#160;of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Life&#160;in&#160;Years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Intrinsic</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value&#160;(in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options outstanding at December&#160;31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,608,921</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14.08</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,610,010</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28.57</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(427,729</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14.94</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited or expired</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(182,858</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19.15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options outstanding at September&#160;30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,608,344</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.37</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.08</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,765</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested and expected to vest at September&#160;30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,760,828</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.90</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.92</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50,354</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercisable at September&#160;30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,317,732</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.23</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.96</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,723</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The total intrinsic value of stock options exercised during the three months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$0.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.4 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, and during the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$5.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$3.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, there was </span><span style="font-family:inherit;font-size:10pt;"><span>$34.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> of unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted average period of </span><span style="font-family:inherit;font-size:10pt;"><span>2.5 years</span></span><span style="font-family:inherit;font-size:10pt;">. The following table summarizes the range of exercise prices and the number of stock options outstanding and exercisable as of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.1328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"/></tr><tr><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td colspan="16" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Outstanding as of September&#160;30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercisable as of September&#160;30, 2018</span></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Range of Exercise Prices&#160;($)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of Options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average Remaining Contractual Term (in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average Exercise&#160;Price&#160;($)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of Options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average Exercise&#160;Price&#160;($)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.03</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,087,941</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.94</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.99</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,087,941</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.99</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.96</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.85</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>997,221</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.53</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.77</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>481,574</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.68</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.58</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>984,936</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.49</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.17</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>893,989</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.20</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.66</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.67</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>984,161</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.97</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.60</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>428,577</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.56</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.94</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.07</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,139,533</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.80</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.26</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>765,384</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.17</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.09</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17.16</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,438,502</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.95</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.69</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>602,949</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.48</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17.24</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22.76</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,366,680</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.56</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.20</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,017,263</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.26</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22.84</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30.46</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,439,910</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.21</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28.61</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,055</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24.26</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30.86</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31.78</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>155,960</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.25</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31.10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32.46</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32.46</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,500</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.26</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32.46</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Stock and Restricted Stock Units</span><span style="font-family:inherit;font-size:10pt;"> &#8212; Under the 2017 Incentive Plan, the Company may grant restricted stock (RS) and RSUs to eligible participants, including its executives, non-employee directors, and other service providers. Each share of RS vests, and each RSU represents a right to receive </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> share of the Company&#8217;s common stock, upon the completion of a specific period of continued service or achievement of a certain milestone. RS and RSU awards are valued at the market price of the Company&#8217;s common stock on the date of grant. The Company recognizes noncash compensation expense for the fair values of these RS and RSU awards on a straight-line basis over the requisite service period of these awards. As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, there was </span><span style="font-family:inherit;font-size:10pt;"><span>$4.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> of unrecognized compensation expense related to unvested RSU awards which is expected to be recognized over a weighted average period of </span><span style="font-family:inherit;font-size:10pt;"><span>2.8 years</span></span><span style="font-family:inherit;font-size:10pt;">. The following table summarizes the Company&#8217;s RSU award activity during the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.96875%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:67%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Number&#160;of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">RSUs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Grant&#160;Price&#160;($)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at December&#160;31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46,914</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17.16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>248,468</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29.41</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Released</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(47,478</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17.32</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,103</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30.46</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at September&#160;30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>244,801</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29.40</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the aggregate stock-based compensation expense recorded in the consolidated statements of comprehensive loss related to stock options and RSUs during the three and </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in&#160;millions)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6860862048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</span><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s provision for income taxes was $</span><span style="font-family:inherit;font-size:10pt;"><span>46,000</span></span><span style="font-family:inherit;font-size:10pt;"> and $</span><span style="font-family:inherit;font-size:10pt;"><span>134,000</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, respectively, and $</span><span style="font-family:inherit;font-size:10pt;"><span>27,000</span></span><span style="font-family:inherit;font-size:10pt;"> and $</span><span style="font-family:inherit;font-size:10pt;"><span>94,000</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;">, respectively. The provision for income taxes in all periods was a result of certain of the Company&#8217;s subsidiaries in Europe, which had taxable income during the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">. In jurisdictions where the Company has net losses, there was a full valuation allowance recorded against the Company&#8217;s deferred tax assets and therefore </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> tax benefit was recorded. </span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Following adoption of the Tax Cuts and Jobs Act during the fourth quarter of 2017, the Company remeasured certain deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future, which is generally 21%. The Company recorded a provisional amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$94.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of December 31, 2017 related to the re-measurement of certain deferred tax balances, which was completely offset by a full valuation allowance. Upon further analyses, the Company determined in the second quarter of 2018 that the provisional amount would not need to be adjusted.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to local taxes in foreign jurisdictions, the Company is subject to US federal, US state, and US tax on foreign earnings.&#160;In regard to the US tax on foreign earnings, the Company was subject to a one-time transition tax based on its total earnings and profits, which were generally deferred from US income taxes under previous US law.&#160;Due to the aggregate loss position of the Company's foreign subsidiaries, the Company did not record any provisional amount for the one-time transition tax liability at December 31, 2017.&#160;Additionally, the global intangible low-taxed income tax and base erosion provisions in the Tax Cuts and Jobs Act are effective for taxable years beginning after December 31, 2017. The Company does not currently expect these provisions to have a material impact (i) due to the aggregate loss position of its foreign subsidiaries and (ii) because the Company currently expects to be below the gross receipts threshold for purposes of the base erosion provisions. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">The Company is subject to US federal and state income taxes and the statute of limitations for tax audit is open for the Company's federal tax returns for the years ended 2014 and later, and is generally open for certain states for the years 2013 and later. The Company has incurred net operating losses since inception, except for the year ended December&#160;31, 2009. Such loss carryforwards would be subject to audit in any tax year in which those losses are utilized, notwithstanding the year of origin. As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</span><span style="font-family:inherit;font-size:10pt;">, the Company had recorded </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span> reserves for unrecognized income tax benefits, nor had it recorded any accrued interest or penalties related to uncertain tax positions. The Company does not anticipate any material changes in the amount of unrecognized tax positions over the next 12 months.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6857436080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Commitments and Contingencies</span><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has an operating lease for office and laboratory space located in Bridgewater, NJ, its corporate headquarters, for which the initial lease term expires in November&#160;2019. Future minimum rental payments under this lease are </span><span style="font-family:inherit;font-size:10pt;"><span>$1.2 million</span></span><span style="font-family:inherit;font-size:10pt;">. In July&#160;2016, the Company signed an operating lease for laboratory space located in Bridgewater, NJ for which the initial lease term expires in December&#160;2021. Future minimum rental payments under this lease are </span><span style="font-family:inherit;font-size:10pt;"><span>$1.5 million</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In September 2018, the Company entered into a lease agreement for office space in Bridgewater, NJ for its future corporate headquarters. The lease provides for a commencement date of the earlier of (1)&#160;September&#160;1, 2019, subject to completion of certain improvements by specified dates, and (2)&#160;the date on which the Company takes possession of the premises to commence its business operations therein (the Commencement Date).&#160;The initial lease term runs </span><span style="font-family:inherit;font-size:10pt;">130 months</span><span style="font-family:inherit;font-size:10pt;"> from the Commencement Date (plus any partial month from the Commencement Date until the first day of the next full calendar month during the term), and the Company has the option to extend that term for up to </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> additional </span><span style="font-family:inherit;font-size:10pt;">five</span><span style="font-family:inherit;font-size:10pt;">-year periods. Future minimum rental payments under this lease are </span><span style="font-family:inherit;font-size:10pt;"><span>$32.3 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Rent expense charged to operations was </span><span style="font-family:inherit;font-size:10pt;"><span>$0.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the three months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively, and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively. Future minimum rental payments required under the Company&#8217;s leases for the period from October 1, 2018 to </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and for each of the five years thereafter are as follows (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.96875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:84%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ending December&#160;31:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018 (remaining)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>490</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,863</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,185</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,958</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,281</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,261</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,038</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Legal Proceedings</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div>From time to time, the Company is a party to various lawsuits, claims and other legal proceedings that arise in the ordinary course of business. While the outcomes of these matters are uncertain, management does not expect that the ultimate costs to resolve these matters will have a material adverse effect on the Company&#8217;s consolidated financial position, results of operations or cash flows.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6855354256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<span style="font-family:inherit;font-size:10pt;"> - The Company categorizes its financial assets and liabilities measured and reported at fair value in the financial statements on a recurring basis based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs used to determine the fair value of financial assets and liabilities, are as follows:</span><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 1 &#8212; Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 2 &#8212; Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the assets or liability through correlation with market data at the measurement date and for the duration of the instrument&#8217;s anticipated life.</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 3 &#8212; Inputs reflect management&#8217;s best estimate of what market participants would use in pricing the asset or liability at the measurement date.&#160;Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Each major category of financial assets and liabilities measured at fair value on a recurring basis is categorized based upon the lowest level of significant input to the valuations. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Financial instruments in Level 1 generally include US treasuries and mutual funds listed in active markets.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s only financial assets and liabilities which were measured at fair value as of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</span><span style="font-family:inherit;font-size:10pt;"> were Level 1 assets comprised of cash and cash equivalents of </span><span style="font-family:inherit;font-size:10pt;"><span>$567.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$381.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. The estimated fair value of the liability component of the </span><span style="font-family:inherit;font-size:10pt;"><span>1.75%</span></span><span style="font-family:inherit;font-size:10pt;"> convertible senior notes due 2025 (the Convertible Notes) (categorized as a Level 2 liability for fair value measurement purposes) was determined using current market factors and the ability of the Company to obtain debt on comparable terms to the Convertible Notes. The following table shows certain assets and liabilities and their carrying values and fair values:</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:83.0078125%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:55%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of September 30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Level 1</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>567.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>567.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Level 2</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Convertible Notes ($450.0 face value)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>311.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>381.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;* The carrying value of the Convertible Notes excludes </span><span style="font-family:inherit;font-size:9pt;"><span>$129.4 million</span></span><span style="font-family:inherit;font-size:9pt;"> of the unamortized portion of the debt discount.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s cash and cash equivalents permit daily redemption and the fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions. Cash equivalents consist of liquid investments with an original maturity of three months or less from the date of purchase. As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company's cash and cash equivalents balance included US treasury bills of </span><span style="font-family:inherit;font-size:10pt;"><span>$399.8 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter. There were </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> transfers in or out of Level 1, Level 2 or Level 3 during the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</span><span style="font-family:inherit;font-size:10pt;">, the Company held </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span> securities that were in an unrealized gain or loss position. The Company reviews the status of each security quarterly to determine whether an other-than-temporary impairment has occurred. In making its determination, the Company considers a number of factors, including: (1) the significance of the decline; (2)&#160;whether the securities were rated below investment grade; (3)&#160;how long the securities have been in an unrealized loss position; and (4) the Company&#8217;s ability and intent to retain the investment for a sufficient period of time for it to recover.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per Share<span style="font-family:inherit;font-size:10pt;"> - Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period.&#160;Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares and other dilutive securities outstanding during the period. Potentially dilutive securities from stock options, restricted stock units (RSUs) and convertible debt securities would be anti-dilutive as the Company incurred a net loss. Potentially dilutive common shares resulting from the assumed exercise of outstanding stock options and from the assumed conversion of the Convertible Notes are determined based on the treasury stock method.</span><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table sets forth the reconciliation of the weighted average number of common shares used to compute basic and diluted net loss per share for the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in&#160;thousands,&#160;except&#160;per&#160;share&#160;amounts)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Numerator:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(87,743</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(45,179</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(232,704</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(127,265</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Denominator:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average common shares used in calculation of basic net loss per share:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,066</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65,312</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>76,819</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>63,199</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of dilutive securities:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock options</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span></span><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">RSUs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span></span><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Convertible debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average common shares outstanding used&#160;in calculation of diluted net loss per share</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,066</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65,312</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>76,819</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>63,199</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss per share:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.14</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.69</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3.03</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.01</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following potentially dilutive securities have been excluded from the computations of diluted weighted average common shares outstanding as of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> as their effect would have been anti-dilutive (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.4140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:69%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock options to purchase common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,608</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,601</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unvested RSUs</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>245</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Convertible debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,492</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text">Inventory - <span style="font-family:inherit;font-size:10pt;">Inventory is stated at the lower of cost and net realizable value with cost determined on a standard costing method. The Company began capitalizing inventory costs subsequent to US Food and Drug Administration (FDA) approval of ARIKAYCE on September 28, 2018, when it was determined that the inventory had a probable future economic benefit. Inventory will be sold beginning in the fourth quarter of 2018 based on first-in, first out basis. Manufacturing variances, such as material usage variance and yield variance, will be capitalized in inventory until the respective units are sold at which point the variances will be released in cost of goods sold. The Company will periodically review inventory for expiry and obsolescence and write down accordingly.  The Company performs quality control procedures throughout the manufacturing processes of ARIKAYCE; however, certain batches or units of ARIKAYCE may not meet quality specifications and result in a charge to cost of goods sold.</span><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">Prior to FDA approval of ARIKAYCE, the Company expensed all inventory related costs in the period incurred; therefore, inventory is not included in the </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span> consolidated balance sheet. Inventory used for clinical development purposes is expensed to research and development (R&amp;D) expense when consumed.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text">Recently Adopted Accounting Pronouncements<span style="font-family:inherit;font-size:10pt;"> - In August 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standard Update (ASU) 2016-15, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments</span><span style="font-family:inherit;font-size:10pt;">, which addressed eight specific cash flow issues with the objective of reducing the existing diversity in practice. Among the updates, the standard requires debt extinguishment costs to be classified as cash outflows for financing activities. This standard update is effective as of the first quarter of 2018. As a result of the adoption of the standard, in the first quarter of 2018, the Company reported a </span><span style="font-family:inherit;font-size:10pt;"><span>$2.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> loss on extinguishment of debt in the financing activities section of its consolidated statement of cash flows. The Company had no material debt extinguishment costs prior to the first quarter of 2018. The impact of adopting this standard was not material to the Company.</span><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:56px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">New Accounting Pronouncements (Not Yet Adopted)</span><span style="font-family:inherit;font-size:10pt;">&#8212;In February 2016, the FASB issued ASU 2016-2, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</span><span style="font-family:inherit;font-size:10pt;"> in order to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous generally accepted accounting principles. ASU 2016-2 requires a lessee to recognize a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term on the balance sheet. ASU 2016-2 is effective for fiscal years beginning after December&#160;15, 2018 (including interim periods within those periods) and early adoption is permitted. In August 2018, the FASB issued ASU 2018-11, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Targeted Improvements to ASC 842</span><span style="font-family:inherit;font-size:10pt;">, which provides a new transition option in which an entity initially applies ASU 2016-2 at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company will use the new transition option and is also utilizing the package of practical expedients that allows it to not reassess: (1) whether any expired or existing contracts are or contain leases, (2) lease classification for any expired or existing leases, and (3) initial direct costs for any expired or existing leases. The Company additionally expects to use the practical expedient that allows it to treat the lease and non-lease components of its leases as a single component. The Company has identified approximately ten leasing arrangements and is currently assessing the financial impact on the consolidated balance sheet. The Company expects to adopt ASU 2016-2 in the first quarter of 2019 and is in the process of evaluating the impact of adoption on its consolidated financial statements. </span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13279-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4492-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4556-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6661397920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Carrying Value and Fair Value of Assets and Liabilities</a></td>
<td class="text">The following table shows certain assets and liabilities and their carrying values and fair values:<div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;text-indent:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:83.0078125%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:55%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of September 30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Level 1</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>567.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>567.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Level 2</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Convertible Notes ($450.0 face value)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>311.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>381.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:9pt;">&#160;* The carrying value of the Convertible Notes excludes </span><span style="font-family:inherit;font-size:9pt;"><span>$129.4 million</span></span> of the unamortized portion of the debt discount.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Reconciliation of the Weighted Average Number of Shares Used to Compute Basic and Diluted Net Loss per Share</a></td>
<td class="text">The following table sets forth the reconciliation of the weighted average number of common shares used to compute basic and diluted net loss per share for the <span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">:</span><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in&#160;thousands,&#160;except&#160;per&#160;share&#160;amounts)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Numerator:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(87,743</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(45,179</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(232,704</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(127,265</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Denominator:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average common shares used in calculation of basic net loss per share:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,066</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65,312</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>76,819</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>63,199</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of dilutive securities:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock options</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span></span><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">RSUs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span></span><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Convertible debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average common shares outstanding used&#160;in calculation of diluted net loss per share</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,066</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65,312</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>76,819</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>63,199</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss per share:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.14</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.69</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3.03</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.01</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Potentially Dilutive Securities Excluded from Computations of Diluted Weighted Average Common Shares Outstanding</a></td>
<td class="text">The following potentially dilutive securities have been excluded from the computations of diluted weighted average common shares outstanding as of <span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> as their effect would have been anti-dilutive (in thousands):</span><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.4140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:69%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock options to purchase common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,608</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,601</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unvested RSUs</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>245</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Convertible debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,492</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6860862048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets</a></td>
<td class="text">Intangible assets consist of the following:<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:72.4609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of September 30, <br/>2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of December 31, <br/>2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquired ARIKAYCE R&amp;D</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,200</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,200</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PARI milestone upon FDA approval</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,741</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Intangible assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59,941</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,200</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6857320784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text">Accrued expenses consist of the following:<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.96875%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of September&#160;30, <br/>2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of December&#160;31, <br/>2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in&#160;thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued clinical trial expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,576</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,837</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued compensation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,387</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,197</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued professional fees</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,746</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,500</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued technical operation expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,137</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,182</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued milestone payment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,741</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued interest payable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,663</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>423</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued construction costs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,069</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,719</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other accrued expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,049</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>481</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,368</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29,339</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6855048320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Components of Debt Balance</a></td>
<td class="text">The following table presents the carrying value of the Company&#8217;s debt balance as of <span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.96875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:84%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;1.75% convertible senior notes due 2025</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>450,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;Debt issuance costs, unamortized</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8,789</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;Discount on debt</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(129,350</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term debt, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>311,861</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Future Principal Repayments of Debt</a></td>
<td class="text">As of <span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, future principal repayments of the debt for each of the fiscal years through maturity were as follows (in thousands):</span><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.96875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:84%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ending December&#160;31:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>450,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>450,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Summary of Interest Expense</a></td>
<td class="text">The following table sets forth the total interest expense recognized in the periods presented (in thousands):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:82.421875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:37%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contractual interest expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,971</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,302</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,214</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,862</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of debt issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>415</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>91</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accretion of back-end fee on debt</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>164</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>506</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accretion of debt discount</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,289</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,541</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total interest expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,675</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,496</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,805</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,459</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6857374480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock', window );">Schedule of Changes in Shareholders' Equity</a></td>
<td class="text">The following table summarizes the changes in total shareholders' equity for the <span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:61.328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:82%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>361,059</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss for the period</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(232,704</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Proceeds from exercise of stock options</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,390</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity component of Convertible Notes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>136,434</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,205</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change in cumulative translation adjustment</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at September 30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>291,407</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6608278112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Fair Value Assumptions for Stock Options</a></td>
<td class="text">The following table summarizes the Company&#8217;s grant date fair value and assumptions used in determining the fair value of all stock options granted during the periods presented:<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.484375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:45%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:13%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Volatility</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">66%-67%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">72%-73%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">66%-68%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">72%-74%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.75%-2.87%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.73%-1.93%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.25%-2.87%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.73%-1.99%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Dividend yield</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.0%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.0%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.0%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.0%</span></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected option term (in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.14</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.25</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.09</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.25</span></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average fair value of stock options granted</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$13.62</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$9.59</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$16.56</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$10.18</span></span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text">The following table summarizes the Company&#8217;s aggregate stock option activity for the <span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">:&#160;</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:45%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Number&#160;of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Life&#160;in&#160;Years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Intrinsic</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value&#160;(in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options outstanding at December&#160;31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,608,921</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14.08</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,610,010</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28.57</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(427,729</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14.94</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited or expired</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(182,858</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19.15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options outstanding at September&#160;30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,608,344</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.37</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.08</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,765</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested and expected to vest at September&#160;30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,760,828</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.90</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.92</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50,354</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercisable at September&#160;30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,317,732</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.23</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.96</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,723</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Summary of Exercise Price and Number of Stock Options Exercisable</a></td>
<td class="text">The following table summarizes the range of exercise prices and the number of stock options outstanding and exercisable as of <span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">:</span><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.1328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"/></tr><tr><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td colspan="16" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Outstanding as of September&#160;30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercisable as of September&#160;30, 2018</span></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Range of Exercise Prices&#160;($)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of Options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average Remaining Contractual Term (in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average Exercise&#160;Price&#160;($)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of Options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average Exercise&#160;Price&#160;($)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.03</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,087,941</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.94</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.99</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,087,941</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.99</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.96</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.85</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>997,221</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.53</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.77</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>481,574</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.68</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.58</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>984,936</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.49</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.17</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>893,989</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.20</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.66</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.67</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>984,161</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.97</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.60</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>428,577</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.56</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.94</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.07</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,139,533</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.80</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.26</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>765,384</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.17</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.09</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17.16</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,438,502</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.95</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.69</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>602,949</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.48</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17.24</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22.76</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,366,680</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.56</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.20</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,017,263</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.26</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22.84</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30.46</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,439,910</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.21</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28.61</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,055</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24.26</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30.86</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31.78</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>155,960</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.25</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31.10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32.46</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32.46</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,500</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.26</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32.46</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Summary of RSU Activity</a></td>
<td class="text">The following table summarizes the Company&#8217;s RSU award activity during the <span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">:</span><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.96875%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:67%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Number&#160;of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">RSUs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Grant&#160;Price&#160;($)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at December&#160;31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46,914</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17.16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>248,468</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29.41</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Released</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(47,478</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17.32</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,103</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30.46</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding at September&#160;30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>244,801</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29.40</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Allocation of Employee Stock-Based Compensation</a></td>
<td class="text">The following table summarizes the aggregate stock-based compensation expense recorded in the consolidated statements of comprehensive loss related to stock options and RSUs during the three and <span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively:</span><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in&#160;millions)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6772783408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of Future Minimum Rental Payments Required Under Operating Leases</a></td>
<td class="text">Future minimum rental payments required under the Company&#8217;s leases for the period from October 1, 2018 to <span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and for each of the five years thereafter are as follows (in thousands):</span><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.96875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:84%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year Ending December&#160;31:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018 (remaining)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>490</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,863</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,185</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,958</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,281</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,261</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><span style="font-family:inherit;font-size:1pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,038</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6864040256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company and Basis of Presentation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 567,574<span></span>
</td>
<td class="nump">$ 430,678<span></span>
</td>
<td class="nump">$ 567,574<span></span>
</td>
<td class="nump">$ 430,678<span></span>
</td>
<td class="nump">$ 381,165<span></span>
</td>
<td class="nump">$ 162,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 87,743<span></span>
</td>
<td class="nump">$ 45,179<span></span>
</td>
<td class="nump">$ 232,704<span></span>
</td>
<td class="nump">$ 127,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6855125040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($) </div>
<div>security</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>security</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsAssetsQuantitativeInformationLineItems', window );"><strong>Fair Value Inputs, Assets, Quantitative Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 567,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 381,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_FairValueLevel1Level2Level3TransfersAmount', window );">Fair value transfers in or out of Level 1, Level 2, or Level 3</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities', window );">Securities in an unrealized gain or loss position | security</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes | 1.75 convertible senior notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsAssetsQuantitativeInformationLineItems', window );"><strong>Fair Value Inputs, Assets, Quantitative Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember', window );">US treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsAssetsQuantitativeInformationLineItems', window );"><strong>Fair Value Inputs, Assets, Quantitative Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 399,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available-for-sale Securities, Gross Unrealized Gain (Loss), Number of Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_FairValueLevel1Level2Level3TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers measured on a recurring basis in or out of Level 1, Level 2, or Level 3.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_FairValueLevel1Level2Level3TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInputsAssetsQuantitativeInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInputsAssetsQuantitativeInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6862807264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Fair Value Measurements (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsAssetsQuantitativeInformationLineItems', window );"><strong>Fair Value Inputs, Assets, Quantitative Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 567,600,000<span></span>
</td>
<td class="nump">$ 381,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized portion of debt discount</a></td>
<td class="nump">129,350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsAssetsQuantitativeInformationLineItems', window );"><strong>Fair Value Inputs, Assets, Quantitative Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">450,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized portion of debt discount</a></td>
<td class="nump">129,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Carrying Value | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsAssetsQuantitativeInformationLineItems', window );"><strong>Fair Value Inputs, Assets, Quantitative Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">567,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Carrying Value | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsAssetsQuantitativeInformationLineItems', window );"><strong>Fair Value Inputs, Assets, Quantitative Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible Notes ($450.0 face value)</a></td>
<td class="nump">311,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Fair Value | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsAssetsQuantitativeInformationLineItems', window );"><strong>Fair Value Inputs, Assets, Quantitative Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">567,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Fair Value | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsAssetsQuantitativeInformationLineItems', window );"><strong>Fair Value Inputs, Assets, Quantitative Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible Notes ($450.0 face value)</a></td>
<td class="nump">$ 381,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInputsAssetsQuantitativeInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInputsAssetsQuantitativeInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6863801040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Net Loss Per Common Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (87,743)<span></span>
</td>
<td class="num">$ (45,179)<span></span>
</td>
<td class="num">$ (232,704)<span></span>
</td>
<td class="num">$ (127,265)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares used in calculation of basic net loss per share (in shares)</a></td>
<td class="nump">77,066<span></span>
</td>
<td class="nump">65,312<span></span>
</td>
<td class="nump">76,819<span></span>
</td>
<td class="nump">63,199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities', window );">Dilutive securities, convertible debt (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding used in calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">77,066<span></span>
</td>
<td class="nump">65,312<span></span>
</td>
<td class="nump">76,819<span></span>
</td>
<td class="nump">63,199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted (in dollars per share)</a></td>
<td class="num">$ (1.14)<span></span>
</td>
<td class="num">$ (0.69)<span></span>
</td>
<td class="num">$ (3.03)<span></span>
</td>
<td class="num">$ (2.01)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive securities, share-based payment (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive securities, share-based payment (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1500-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6863823600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=insm_EmployeeAndDirectorsStockOptionsMember', window );">Stock options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive securities excluded from computations of diluted weighted-average common shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from computations of diluted weighted-average shares outstanding</a></td>
<td class="nump">9,608<span></span>
</td>
<td class="nump">8,601<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive securities excluded from computations of diluted weighted-average common shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from computations of diluted weighted-average shares outstanding</a></td>
<td class="nump">245<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive securities excluded from computations of diluted weighted-average common shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from computations of diluted weighted-average shares outstanding</a></td>
<td class="nump">11,492<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=insm_EmployeeAndDirectorsStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=insm_EmployeeAndDirectorsStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6863696240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Recently Adopted Accounting Pronouncements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Loss on extinguishment of debt</a></td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="nump">$ 2,209<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtExtinguishmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtExtinguishmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6863335680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible Assets</a></td>
<td class="nump">$ 59,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_AccruedMilestonePaymentCurrent', window );">Accrued milestone payment</a></td>
<td class="nump">$ 1,741<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets estimated useful life</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">Acquired ARIKAYCE R&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible Assets</a></td>
<td class="nump">$ 58,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_AccruedMilestonePaymentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Milestone Payment, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_AccruedMilestonePaymentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6864433744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible Assets</a></td>
<td class="nump">$ 59,941<span></span>
</td>
<td class="nump">$ 58,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">Acquired ARIKAYCE R&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible Assets</a></td>
<td class="nump">58,200<span></span>
</td>
<td class="nump">58,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">PARI milestone upon FDA approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible Assets</a></td>
<td class="nump">$ 1,741<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6855123168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_AccruedClinicalTrialExpenses', window );">Accrued clinical trial expenses</a></td>
<td class="nump">$ 6,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,837<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">11,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">10,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_AccruedTechnicalOperationExpenses', window );">Accrued technical operation expenses</a></td>
<td class="nump">5,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,182<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_AccruedMilestonePaymentCurrent', window );">Accrued milestone payment</a></td>
<td class="nump">1,741<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest payable</a></td>
<td class="nump">1,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">423<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_AccruedConstructionLiabilitiesCurrent', window );">Accrued construction costs</a></td>
<td class="nump">2,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">1,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">481<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 40,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,339<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_AccruedClinicalTrialExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical trial expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_AccruedClinicalTrialExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_AccruedConstructionLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Construction Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_AccruedConstructionLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_AccruedMilestonePaymentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Milestone Payment, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_AccruedMilestonePaymentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_AccruedTechnicalOperationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for technical operation expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_AccruedTechnicalOperationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e7018-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e7018-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6866349536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 28, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2018 </div>
<div>USD ($) </div>
<div>day </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Underwriting discounts and commissions and other offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,789,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,789,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,675,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,496,000<span></span>
</td>
<td class="nump">18,805,000<span></span>
</td>
<td class="nump">$ 4,459,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,209,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member', window );">1.75 convertible senior notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 435,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Initial conversion rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0255384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_LineOfCreditMember', window );">A&amp;R Loan Agreement with Hercules</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment of debt</a></td>
<td class="nump">$ 55,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_RepaymentsOfDebtFeesAndOutstandingInterest', window );">Repayment of debt, back end fees, outstanding interest, and prepayment penalty fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes | 1.75 convertible senior notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_DebtInstrumentOptionToPurchaseAdditionalDebt', window );">Option to purchase additional debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Underwriting discounts and commissions and other offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Initial conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible Notes ($450.0 face value)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 309,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Equity component of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1', window );">Remaining discount amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 3 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes | Conversion Term (i) | 1.75 convertible senior notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold consecutive trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Threshold percent of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes | Conversion Term (ii) | 1.75 convertible senior notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold consecutive trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Threshold percent of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes | Conversion Term (iii) | 1.75 convertible senior notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange', window );">Threshold trading days following fundamental change | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes | Conversion Term (iv) | 1.75 convertible senior notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold consecutive trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Threshold percent of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Trading Days Prior To Effective Data Of Fundamental Change</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_DebtInstrumentOptionToPurchaseAdditionalDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Option To Purchase Additional Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_DebtInstrumentOptionToPurchaseAdditionalDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_RepaymentsOfDebtFeesAndOutstandingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayments Of Debt, Fees And Outstanding Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_RepaymentsOfDebtFeesAndOutstandingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031897-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21506-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21521-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_DebtInstrumentConversionTermAxis=insm_DebtInstrumentConversionTermOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_DebtInstrumentConversionTermAxis=insm_DebtInstrumentConversionTermOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_DebtInstrumentConversionTermAxis=insm_DebtInstrumentConversionTermTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_DebtInstrumentConversionTermAxis=insm_DebtInstrumentConversionTermTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_DebtInstrumentConversionTermAxis=insm_DebtInstrumentConversionTermThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_DebtInstrumentConversionTermAxis=insm_DebtInstrumentConversionTermThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_DebtInstrumentConversionTermAxis=insm_DebtInstrumentConversionTermFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_DebtInstrumentConversionTermAxis=insm_DebtInstrumentConversionTermFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6855126336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Components of Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jan. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuredDebt', window );">1.75% convertible senior notes due 2025</a></td>
<td class="nump">$ 450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs, unamortized</a></td>
<td class="num">(8,789)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Discount on debt</a></td>
<td class="num">(129,350)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net</a></td>
<td class="nump">311,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,567<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Discount on debt</a></td>
<td class="num">$ (129,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes | 1.75 convertible senior notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs, unamortized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (14,200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6772894800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Future Principal Repayments of Debt (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Year Ending December 31:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2018</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2019</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2020</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2021</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2022</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">2023 and thereafter</a></td>
<td class="nump">450,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 450,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6864281888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Interest Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Contractual interest expense</a></td>
<td class="nump">$ 1,971<span></span>
</td>
<td class="nump">$ 1,302<span></span>
</td>
<td class="nump">$ 6,214<span></span>
</td>
<td class="nump">$ 3,862<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">415<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_AmortizationOfBackendFee', window );">Accretion of back-end fee on debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">164<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Accretion of debt discount</a></td>
<td class="nump">4,289<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,541<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Total interest expense</a></td>
<td class="nump">$ 6,675<span></span>
</td>
<td class="nump">$ 1,496<span></span>
</td>
<td class="nump">$ 18,805<span></span>
</td>
<td class="nump">$ 4,459<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_AmortizationOfBackendFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization Of Backend Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_AmortizationOfBackendFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6865805088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jan. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,085,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,610,508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,085,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,610,508<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued under underwritten public offering (in shares)</a></td>
<td class="nump">14,123,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption', window );">Shares exercised in full of over-allotment option by underwriter (in shares)</a></td>
<td class="nump">1,842,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,842,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="nump">$ 28.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Underwriter's discount and offering expenses</a></td>
<td class="nump">$ 24,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from sale of shares</a></td>
<td class="nump">$ 377,700,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 377,703,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,492,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=insm_EmployeeAndDirectorsStockOptionsMember', window );">Stock options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,608,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">244,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member', window );">1.75 convertible senior notes due 2025 | Convertible debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible Notes ($450.0 face value)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Equity component of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Shares Exercise To Underwriters In Full Of Over Allotment Option</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031897-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=insm_EmployeeAndDirectorsStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=insm_EmployeeAndDirectorsStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6866484000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity - Changes in Shareholders' Equity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at December 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 361,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="num">$ (87,743)<span></span>
</td>
<td class="num">$ (45,179)<span></span>
</td>
<td class="num">(232,704)<span></span>
</td>
<td class="num">$ (127,265)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Equity component of Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Change in cumulative translation adjustment</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">$ 76<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">$ 99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at September 30, 2018</a></td>
<td class="nump">$ 291,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 291,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=51819886&amp;loc=SL6014347-161799<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507207&amp;loc=d3e4534-113899<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=96864182&amp;loc=d3e11149-113907<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=96864182&amp;loc=d3e11178-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569643-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6863843632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 15, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>May 18, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares of common stock, maximum authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,408,995<span></span>
</td>
<td class="nump">3,408,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross', window );">Inducement stock options granted to new employees (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">236,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,608,344<span></span>
</td>
<td class="nump">9,608,344<span></span>
</td>
<td class="nump">8,608,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Value of options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Options vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=insm_EmployeeStockPurchasePlan2018Member', window );">2018 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares of common stock, maximum authorized for issuance (in shares)</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized (in shares)</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of outstanding shares</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of inducement share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under an established share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=insm_EmployeeStockPurchasePlan2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=insm_EmployeeStockPurchasePlan2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6866211408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Options (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding beginning of the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,608,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,610,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(427,729)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited or expired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(182,858)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding end of the period (in shares)</a></td>
<td class="nump">9,608,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,608,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">8,760,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,760,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">5,317,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,317,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding beginning of the period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited or expired (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding end of the period (in dollars per share)</a></td>
<td class="nump">$ 16.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest (in dollars per share)</a></td>
<td class="nump">15.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share)</a></td>
<td class="nump">$ 13.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_WeightedAverageRemainingContractualLifeInYearsAbstract', window );"><strong>Weighted Average Remaining Contractual Life in Years</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 11 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 11 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding</a></td>
<td class="nump">$ 52,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest</a></td>
<td class="nump">50,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable</a></td>
<td class="nump">$ 38,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=insm_EmployeeAndDirectorsStockOptionsMember', window );">Stock options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair value and assumptions used in determining fair value of stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option term (in years)</a></td>
<td class="text">5 years 1 month 20 days<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">5 years 1 month 2 days<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of stock options granted (in dollars per share)</a></td>
<td class="nump">$ 13.62<span></span>
</td>
<td class="nump">$ 9.59<span></span>
</td>
<td class="nump">$ 16.56<span></span>
</td>
<td class="nump">$ 10.18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=insm_EmployeeAndDirectorsStockOptionsMember', window );">Stock options to purchase common stock | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair value and assumptions used in determining fair value of stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">66.00%<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
<td class="nump">66.00%<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.75%<span></span>
</td>
<td class="nump">1.73%<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="nump">1.73%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=insm_EmployeeAndDirectorsStockOptionsMember', window );">Stock options to purchase common stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair value and assumptions used in determining fair value of stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">67.00%<span></span>
</td>
<td class="nump">73.00%<span></span>
</td>
<td class="nump">68.00%<span></span>
</td>
<td class="nump">74.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.87%<span></span>
</td>
<td class="nump">1.93%<span></span>
</td>
<td class="nump">2.87%<span></span>
</td>
<td class="nump">1.99%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_WeightedAverageRemainingContractualLifeInYearsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_WeightedAverageRemainingContractualLifeInYearsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=insm_EmployeeAndDirectorsStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=insm_EmployeeAndDirectorsStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6865584512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Range of Exercise Prices (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=insm_EmployeeAndDirectorsStockOptionsMember', window );">Stock options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of stock options exercised during the period</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="nump">$ 5.5<span></span>
</td>
<td class="nump">$ 3.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense related to unvested stock options</a></td>
<td class="nump">$ 34.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected weighted average period for recognized and unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range1Member', window );">$3.03 to $6.90</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices lower range limit (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices upper range limit (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options Outstanding (in shares)</a></td>
<td class="nump">1,087,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,087,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 11 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Options, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 3.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of Options Exercisable (in shares)</a></td>
<td class="nump">1,087,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,087,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable Options, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 3.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range2Member', window );">$6.96 to $10.85</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices lower range limit (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices upper range limit (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options Outstanding (in shares)</a></td>
<td class="nump">997,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">997,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 6 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Options, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 10.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of Options Exercisable (in shares)</a></td>
<td class="nump">481,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">481,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable Options, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 10.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range3Member', window );">$11.14 to $12.58</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices lower range limit (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices upper range limit (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options Outstanding (in shares)</a></td>
<td class="nump">984,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">984,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 5 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Options, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 12.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of Options Exercisable (in shares)</a></td>
<td class="nump">893,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">893,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable Options, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 12.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range4Member', window );">$12.66 to $13.67</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices lower range limit (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices upper range limit (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options Outstanding (in shares)</a></td>
<td class="nump">984,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">984,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 11 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Options, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 13.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of Options Exercisable (in shares)</a></td>
<td class="nump">428,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">428,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable Options, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 13.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range5Member', window );">$13.94 to $16.07</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices lower range limit (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices upper range limit (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options Outstanding (in shares)</a></td>
<td class="nump">1,139,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,139,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Options, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 15.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of Options Exercisable (in shares)</a></td>
<td class="nump">765,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">765,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable Options, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 15.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range6Member', window );">$16.09 to $17.16</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices lower range limit (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices upper range limit (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options Outstanding (in shares)</a></td>
<td class="nump">1,438,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,438,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 11 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Options, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 16.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of Options Exercisable (in shares)</a></td>
<td class="nump">602,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">602,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable Options, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 16.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range7Member', window );">$17.24 to $22.76</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices lower range limit (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices upper range limit (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options Outstanding (in shares)</a></td>
<td class="nump">1,366,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,366,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 6 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Options, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 21.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of Options Exercisable (in shares)</a></td>
<td class="nump">1,017,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,017,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable Options, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 21.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range8Member', window );">$22.84 to $30.46</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices lower range limit (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices upper range limit (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options Outstanding (in shares)</a></td>
<td class="nump">1,439,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,439,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 2 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Options, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 28.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of Options Exercisable (in shares)</a></td>
<td class="nump">40,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable Options, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 24.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range9Member', window );">$30.86 to $31.78</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices lower range limit (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices upper range limit (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options Outstanding (in shares)</a></td>
<td class="nump">155,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Options, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 31.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of Options Exercisable (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable Options, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range10Member', window );">$32.46 to $32.46</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices lower range limit (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices upper range limit (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options Outstanding (in shares)</a></td>
<td class="nump">13,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 3 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Options, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 32.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of Options Exercisable (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable Options, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested options awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=insm_EmployeeAndDirectorsStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=insm_EmployeeAndDirectorsStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range5Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range5Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range6Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range6Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range7Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range7Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range8Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range8Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range9Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range9Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range10Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=insm_Range10Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6865732496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Restricted Stock and Restricted Stock Units (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=insm_StockOptionsAndRestrictedStockUnitsMember', window );">Stock options and RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="nump">$ 7.9<span></span>
</td>
<td class="nump">$ 4.7<span></span>
</td>
<td class="nump">$ 20.2<span></span>
</td>
<td class="nump">$ 13.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=insm_StockOptionsAndRestrictedStockUnitsMember', window );">Stock options and RSUs | Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="nump">2.8<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">7.4<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=insm_StockOptionsAndRestrictedStockUnitsMember', window );">Stock options and RSUs | General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="nump">5.1<span></span>
</td>
<td class="nump">$ 2.9<span></span>
</td>
<td class="nump">$ 12.8<span></span>
</td>
<td class="nump">$ 8.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=insm_RestrictedStockAndRestrictedStockUnitsMember', window );">RS and RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit', window );">Number of common shares each award holder is entitled to receive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense</a></td>
<td class="nump">$ 4.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected weighted average period for recognized and unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">248,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Released (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47,478)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,103)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="nump">244,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">244,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding Weighted Average Grant Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Released (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding Weighted Average Grant Price (in dollars per share)</a></td>
<td class="nump">$ 29.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock each restricted stock award entitles the holder to receive upon completion of a specific period of service or achievement of a specified milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based awards, other than options, awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=insm_StockOptionsAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=insm_StockOptionsAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=insm_RestrictedStockAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=insm_RestrictedStockAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6772893584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 46,000<span></span>
</td>
<td class="nump">$ 27,000<span></span>
</td>
<td class="nump">$ 134,000<span></span>
</td>
<td class="nump">$ 94,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances', window );">Provisional deferred tax asset offset completely by valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized income tax benefits, interest and penalties accrued</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards, net of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6866484288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($) </div>
<div>renewal</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Future minimum rental payments under lease</a></td>
<td class="nump">$ 37,038<span></span>
</td>
<td class="nump">$ 37,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expense charged to operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=insm_BridgewaterNewJerseyFacilityMember', window );">Bridgewater, NJ facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Future minimum rental payments under lease</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_AdditionalLaboratorySpaceOperatingLeasesFutureMinimumPaymentsDue', window );">Future minimum rental payments for additional laboratory space</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=insm_BridgewaterNewJerseyOfficeSpaceMember', window );">Bridgewater, NJ office space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Future minimum rental payments under lease</a></td>
<td class="nump">$ 32,300<span></span>
</td>
<td class="nump">$ 32,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract', window );">Initial lease term</a></td>
<td class="text">130 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_LesseeOperatingLeaseNumberOfRenewals', window );">Option to extend lease term | renewal</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm', window );">Period of lease extension</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_AdditionalLaboratorySpaceOperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_AdditionalLaboratorySpaceOperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_LesseeOperatingLeaseNumberOfRenewals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Renewals</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_LesseeOperatingLeaseNumberOfRenewals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=insm_BridgewaterNewJerseyFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=insm_BridgewaterNewJerseyFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=insm_BridgewaterNewJerseyOfficeSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=insm_BridgewaterNewJerseyOfficeSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6659835424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Minimum Rental Payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Future minimum rental payments under operating leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear', window );">2018 (remaining)</a></td>
<td class="nump">$ 490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2019</a></td>
<td class="nump">3,863<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2020</a></td>
<td class="nump">4,185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2021</a></td>
<td class="nump">3,958<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2022</a></td>
<td class="nump">1,281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">2023 and thereafter</a></td>
<td class="nump">23,261<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
<td class="nump">$ 37,038<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>57
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M\+L(NV#LSOYCX[-@W\&ON^B_ %!+ P04    " #J.UY-F5R<(Q &  "<)P
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MQ!F'JC"D%$I#(AS3$ZKHBLYQ2=>PI _,>/\P.C90&,&%BBL!M1&<D$(9I(\
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M[[UMIC6;'(?]_(+8\HR+7U!+ P04    " #J.UY-\9?F!;0!  #2 P  &
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MP)=-_6^L#8!2=C<X0AU^L,50T(1XO,>SF\9L,H+MYQ_$EF]<_@)02P,$%
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M^U\C.O!2DAL_0JW_8(NAH';A>.O/9AJSR7#8SS^(+=^X^ -02P,$%     @
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M!9U_V=C_&M&!3R6Y\2/4^@^V& IJ%X[W_FRF,9L,A_W\@]CRC8L_4$L#!!0
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M*A^.MWBVXYB-AC?=](/8_(WS?U!+ P04    " #J.UY-@/G/5>L!  !F!0
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M7^ &TL-#)CY&A=+&E52#=:AF%9^*XJ_3+G3<Q^GFXV&F;1.RF9 MA&.,PZ9
M,?-'[GB9&QR)F7K?\_#$Z2GSO:F",[8BWOGDK??>RO28Y.P6A&;,><)D:\R"
M8%Y]"9%MA3AG_]&S;?IN,\-=I._6T7>';8']IL ^"NS_*3%]5^(6YGV6;-53
M!::-TV1)A8..D[SR+@-[G\4W^0N?IOTK-ZW0EES1^9>-_6\0'?A4DCL_0IW_
M8(LAH7'AZ >"F&G,)L-A/_\@MGSC\@]02P,$%     @ ZCM>3?NBT+5= @
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ME=" R7N,.\6,""#5QQ2N*47NWM+C<)YB:\)$<\S.A(G-1CQCK9X6\&8"B5G
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M<WN;V(%DPW11HOFV+OX!4$L#!!0    ( .H[7DV:>IV\E@(  -$(   9
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M>I#OC>*_DBNI)5QE(F.4M.;ZURLO7-!F9)&I-/AM>%:M?O;#&Y2/;FX'.#K
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M12K3V:02)Z?J%M ^;=8IO0_5\UTU@^WC;.^I!U"KT>,,8C;QCDTBC7GL,##
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M9J;PJ1- D.V]!SL.!X[CT\4)09:AY]AO.'AUL>U"'/L(1SY"37\ A?=>SL.
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M-V_-NI</3OHV[MOU?OPYNW_==^TFUM);V2R_'7ZOMN/O]UC_]V*X@(P%Y+%
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M@PH?N'S-Q#OM6K5NP$FKV]"@[X57_P%02P,$%     @ ZCM>33>M!F(  @
MQ 4  !D   !X;"]W;W)K<VAE971S+W-H965T-#4N>&UL=93;CILP$(9?!?$
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MAX.Y;/5D,!0"&&/J3+]Q O='F*$5D_\D2J)F%7S"3+!4C:1U5+L7ZJ M3D>
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MLD'P(DFIK_^,H1@XX19[I4QVJ_3]X8&^ P:@JL[[7J<#UX!GMZ"2?/]\#Q%
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MIV& ?Y)>#8C7#CRD ^>4@#SEA5SV72?=4\1:JCNC\#&) >EC7=L> U(">49
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MQ,V1=:_U!:;]:;Y8.1PYQC)V9[D?_@902P,$%     @ ZCM>36=M&I;  0
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M<',O87!P+GAM;%!+ 0(4 Q0    ( .H[7DVG*MRP[@   "L"   1
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M965T,BYX;6Q02P$"% ,4    " #J.UY-P3KN2/<!  "'!0  &
M    @ %&#P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @
MZCM>34[:V28^!   RQ,  !@              ( !<Q$  'AL+W=O<FMS:&5E
M=',O<VAE970T+GAM;%!+ 0(4 Q0    ( .H[7DUHE=>J)@0   43   8
M          "  ><5  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M    " #J.UY-]SYP\)4!  !8 P  &               @ %#&@  >&PO=V]R
M:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ ZCM>338S9,:N 0  T@,
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M:&5E=#$Q+GAM;%!+ 0(4 Q0    ( .H[7DU]?%:GM $  -(#   9
M      "  9LE  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%
M  @ ZCM>3:K3L$*U 0  T@,  !D              ( !AB<  'AL+W=O<FMS
M:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " #J.UY-GI:<L+,!  #2 P
M&0              @ %R*0  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+
M 0(4 Q0    ( .H[7DW=2%A0M $  -(#   9              "  5PK  !X
M;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ ZCM>314Y5]'@
M 0   04  !D              ( !1RT  'AL+W=O<FMS:&5E=',O<VAE970Q
M-BYX;6Q02P$"% ,4    " #J.UY-UH2H9<X!  "<!   &0
M@ %>+P  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( .H[
M7DUW,/YGM@$  -(#   9              "  6,Q  !X;"]W;W)K<VAE971S
M+W-H965T,3@N>&UL4$L! A0#%     @ ZCM>31NM3?*V 0  T@,  !D
M         ( !4#,  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4
M    " #J.UY-0\\.7M,!  "<!   &0              @ $]-0  >&PO=V]R
M:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( .H[7DU>LS 5M@$  -(#
M   9              "  4<W  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL
M4$L! A0#%     @ ZCM>38#YSU7K 0  9@4  !D              ( !-#D
M 'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " #J.UY-8OT.
M:+8!  #2 P  &0              @ %6.P  >&PO=V]R:W-H965T<R]S:&5E
M=#(S+GAM;%!+ 0(4 Q0    ( .H[7DW[HM"U70(  &@'   9
M  "  4,]  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @
MZCM>391[!Y=8 @  J@<  !D              ( !US\  'AL+W=O<FMS:&5E
M=',O<VAE970R-2YX;6Q02P$"% ,4    " #J.UY-)W"\GG0"  !K"0  &0
M            @ %F0@  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4
M Q0    ( .H[7DU^G5"-#0,  '4,   9              "  1%%  !X;"]W
M;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ ZCM>33!E DPP @
MP08  !D              ( !54@  'AL+W=O<FMS:&5E=',O<VAE970R."YX
M;6Q02P$"% ,4    " #J.UY-T]<-TO,!  #]!   &0              @ &\
M2@  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( .H[7DU?
M-,[[, (  ,0&   9              "  >9,  !X;"]W;W)K<VAE971S+W-H
M965T,S N>&UL4$L! A0#%     @ ZCM>35<>T8CY 0  [04  !D
M     ( !34\  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .H[7DV:>IV\E@(  -$(   9              "
M 69=  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ ZCM>
M3=K?R7BQ P  IQ   !D              ( !,V   'AL+W=O<FMS:&5E=',O
M<VAE970S-RYX;6Q02P$"% ,4    " #J.UY-D-;48Y@"  "5"   &0
M        @ $;9   >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0
M   ( .H[7DT<E59*H0(   (*   9              "  >IF  !X;"]W;W)K
M<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ ZCM>3=C[*#UW!   I!8
M !D              ( !PFD  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q0
M2P$"% ,4    " #J.UY-RJ5V<H<'   #+P  &0              @ %P;@
M>&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( .H[7DUU>-RL
MH0,  /$/   9              "  2YV  !X;"]W;W)K<VAE971S+W-H965T
M-#(N>&UL4$L! A0#%     @ ZCM>362YE[-- @  7 <  !D
M ( !!GH  'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " #J
M.UY-DDTYXL<"   7"P  &0              @ &*?   >&PO=V]R:W-H965T
M<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( .H[7DTWK09B  (  ,0%   9
M          "  8A_  !X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#
M%     @ ZCM>39*,A<"L2   J"H! !0              ( !OX$  'AL+W-H
M87)E9%-T<FEN9W,N>&UL4$L! A0#%     @ ZCM>378!2V%@ @  YPP   T
M             ( !G<H  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #J.UY-
MP[P0@O #  !/'@  #P              @ $HS0  >&PO=V]R:V)O;VLN>&UL
M4$L! A0#%     @ ZCM>36=M&I;  0  O!L  !H              ( !1=$
M 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ ZCM>33<9
M?<BX 0  VQL  !,              ( !/=,  %M#;VYT96YT7U1Y<&5S72YX
8;6Q02P4&     #8 -@"L#@  )M4

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.10.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>104</ContextCount>
  <ElementCount>224</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>41</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="insm-20180930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="insm-20180930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Consolidated Balance Sheets (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/ConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Consolidated Balance Sheets (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="insm-20180930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001501 - Statement - Consolidated Balance Sheets (unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="insm-20180930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - Consolidated Statements of Comprehensive Loss (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="insm-20180930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - Consolidated Statements of Cash Flows (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Consolidated Statements of Cash Flows (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="insm-20180930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1003001 - Statement - Consolidated Statements of Cash Flows (unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnauditedParenthetical</Role>
      <ShortName>Consolidated Statements of Cash Flows (unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="insm-20180930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - The Company and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/CompanyAndBasisOfPresentation</Role>
      <ShortName>The Company and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="insm-20180930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="insm-20180930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103100 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/IntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="insm-20180930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="insm-20180930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2105100 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="insm-20180930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="insm-20180930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="insm-20180930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="insm-20180930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="insm-20180930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.insmed.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="insm-20180930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2302302 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.insmed.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="insm-20180930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/IntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.insmed.com/role/IntangibleAssets</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="insm-20180930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.insmed.com/role/AccruedExpenses</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="insm-20180930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.insmed.com/role/Debt</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="insm-20180930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Shareholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/ShareholdersEquityTables</Role>
      <ShortName>Shareholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.insmed.com/role/ShareholdersEquity</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="insm-20180930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.insmed.com/role/StockBasedCompensation</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="insm-20180930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2309301 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.insmed.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="insm-20180930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2401401 - Disclosure - The Company and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/CompanyAndBasisOfPresentationDetails</Role>
      <ShortName>The Company and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.insmed.com/role/CompanyAndBasisOfPresentation</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="insm-20180930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2402403 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="insm-20180930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2402404 - Disclosure - Summary of Significant Accounting Policies - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="insm-20180930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2402405 - Disclosure - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Net Loss Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="insm-20180930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2402406 - Disclosure - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Anti-dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="insm-20180930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2402407 - Disclosure - Summary of Significant Accounting Policies - Recently Adopted Accounting Pronouncements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesRecentlyAdoptedAccountingPronouncementsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Recently Adopted Accounting Pronouncements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="insm-20180930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2403402 - Disclosure - Intangible Assets - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/IntangibleAssetsNarrativeDetails</Role>
      <ShortName>Intangible Assets - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="insm-20180930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2403403 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets - Schedule of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="insm-20180930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2404402 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/AccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.insmed.com/role/AccruedExpensesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="insm-20180930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DebtNarrativeDetails</Role>
      <ShortName>Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="insm-20180930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2405403 - Disclosure - Debt - Components of Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DebtComponentsOfDebtDetails</Role>
      <ShortName>Debt - Components of Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="insm-20180930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2405404 - Disclosure - Debt - Future Principal Repayments of Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DebtFuturePrincipalRepaymentsOfDebtDetails</Role>
      <ShortName>Debt - Future Principal Repayments of Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="insm-20180930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2405405 - Disclosure - Debt - Interest Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DebtInterestExpenseDetails</Role>
      <ShortName>Debt - Interest Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="insm-20180930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Shareholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/ShareholdersEquityNarrativeDetails</Role>
      <ShortName>Shareholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="insm-20180930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Shareholders' Equity - Changes in Shareholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/ShareholdersEquityChangesInShareholdersEquityDetails</Role>
      <ShortName>Shareholders' Equity - Changes in Shareholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="insm-20180930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="insm-20180930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Stock-Based Compensation - Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="insm-20180930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2407404 - Disclosure - Stock-Based Compensation - Range of Exercise Prices (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails</Role>
      <ShortName>Stock-Based Compensation - Range of Exercise Prices (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="insm-20180930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2407405 - Disclosure - Stock-Based Compensation - Restricted Stock and Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails</Role>
      <ShortName>Stock-Based Compensation - Restricted Stock and Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="insm-20180930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2408401 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.insmed.com/role/IncomeTaxes</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="insm-20180930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/CommitmentsAndContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="insm-20180930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Commitments and Contingencies - Minimum Rental Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/CommitmentsAndContingenciesMinimumRentalPaymentsDetails</Role>
      <ShortName>Commitments and Contingencies - Minimum Rental Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="insm-20180930x10q.htm">insm-20180930x10q.htm</File>
    <File>insm-20180930.xsd</File>
    <File>insm-20180930_cal.xml</File>
    <File>insm-20180930_def.xml</File>
    <File>insm-20180930_lab.xml</File>
    <File>insm-20180930_pre.xml</File>
    <File>insm-20180930xex311.htm</File>
    <File>insm-20180930xex312.htm</File>
    <File>insm-20180930xex321.htm</File>
    <File>insm-20180930xex322.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2014-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2017-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>63
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "insm-20180930x10q.htm": {
   "axisCustom": 1,
   "axisStandard": 14,
   "contextCount": 104,
   "dts": {
    "calculationLink": {
     "local": [
      "insm-20180930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "insm-20180930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "insm-20180930x10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "insm-20180930_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-doc-2017-01-31.xml",
      "http://xbrl.sec.gov/dei/2014/dei-doc-2014-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "insm-20180930_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-ref-2017-01-31.xml",
      "http://xbrl.sec.gov/dei/2014/dei-ref-2014-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "insm-20180930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2017/elts/us-parts-codification-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2017/elts/us-roles-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2017/elts/us-types-2017-01-31.xsd",
      "http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd",
      "http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd",
      "http://xbrl.sec.gov/exch/2017/exch-2017-01-31.xsd",
      "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd",
      "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"
     ]
    }
   },
   "elementCount": 354,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2017-01-31": 28,
    "http://www.insmed.com/20180930": 2,
    "http://xbrl.sec.gov/dei/2014-01-31": 9,
    "total": 39
   },
   "keyCustom": 17,
   "keyStandard": 207,
   "memberCustom": 21,
   "memberStandard": 18,
   "nsprefix": "insm",
   "nsuri": "http://www.insmed.com/20180930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001000 - Document - Document and Entity Information",
     "role": "http://www.insmed.com/role/DocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104100 - Disclosure - Accrued Expenses",
     "role": "http://www.insmed.com/role/AccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105100 - Disclosure - Debt",
     "role": "http://www.insmed.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106100 - Disclosure - Shareholders' Equity",
     "role": "http://www.insmed.com/role/ShareholdersEquity",
     "shortName": "Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107100 - Disclosure - Stock-Based Compensation",
     "role": "http://www.insmed.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108100 - Disclosure - Income Taxes",
     "role": "http://www.insmed.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109100 - Disclosure - Commitments and Contingencies",
     "role": "http://www.insmed.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueOfFinancialInstrumentsPolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueOfFinancialInstrumentsPolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2302302 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2303301 - Disclosure - Intangible Assets (Tables)",
     "role": "http://www.insmed.com/role/IntangibleAssetsTables",
     "shortName": "Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2304301 - Disclosure - Accrued Expenses (Tables)",
     "role": "http://www.insmed.com/role/AccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FI2018Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001000 - Statement - Consolidated Balance Sheets (unaudited)",
     "role": "http://www.insmed.com/role/ConsolidatedBalanceSheetsUnaudited",
     "shortName": "Consolidated Balance Sheets (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FI2018Q3",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Debt (Tables)",
     "role": "http://www.insmed.com/role/DebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2306301 - Disclosure - Shareholders' Equity (Tables)",
     "role": "http://www.insmed.com/role/ShareholdersEquityTables",
     "shortName": "Shareholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.insmed.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309301 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.insmed.com/role/CommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FI2018Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401401 - Disclosure - The Company and Basis of Presentation (Details)",
     "role": "http://www.insmed.com/role/CompanyAndBasisOfPresentationDetails",
     "shortName": "The Company and Basis of Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2018Q3",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402403 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "role": "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3YTD",
      "decimals": "INF",
      "lang": null,
      "name": "insm:FairValueLevel1Level2Level3TransfersAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2018Q3",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402404 - Disclosure - Summary of Significant Accounting Policies - Fair Value Measurements (Details)",
     "role": "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails",
     "shortName": "Summary of Significant Accounting Policies - Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2018Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402405 - Disclosure - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details)",
     "role": "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails",
     "shortName": "Summary of Significant Accounting Policies - Net Loss Per Common Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3QTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_insm_EmployeeAndDirectorsStockOptionsMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402406 - Disclosure - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details)",
     "role": "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesDetails",
     "shortName": "Summary of Significant Accounting Policies - Anti-dilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_insm_EmployeeAndDirectorsStockOptionsMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q1YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsOfDebtExtinguishmentCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402407 - Disclosure - Summary of Significant Accounting Policies - Recently Adopted Accounting Pronouncements (Details)",
     "role": "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesRecentlyAdoptedAccountingPronouncementsDetails",
     "shortName": "Summary of Significant Accounting Policies - Recently Adopted Accounting Pronouncements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q1YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsOfDebtExtinguishmentCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2018Q3",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001501 - Statement - Consolidated Balance Sheets (unaudited) (Parenthetical)",
     "role": "http://www.insmed.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical",
     "shortName": "Consolidated Balance Sheets (unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2018Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403402 - Disclosure - Intangible Assets - Narrative (Details)",
     "role": "http://www.insmed.com/role/IntangibleAssetsNarrativeDetails",
     "shortName": "Intangible Assets - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3YTD",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2018Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403403 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details)",
     "role": "http://www.insmed.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails",
     "shortName": "Intangible Assets - Schedule of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2018Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FI2018Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "insm:AccruedClinicalTrialExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404402 - Disclosure - Accrued Expenses (Details)",
     "role": "http://www.insmed.com/role/AccruedExpensesDetails",
     "shortName": "Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FI2018Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "insm:AccruedClinicalTrialExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2018Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredFinanceCostsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Debt - Narrative (Details)",
     "role": "http://www.insmed.com/role/DebtNarrativeDetails",
     "shortName": "Debt - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q1YTD",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2018Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SecuredDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405403 - Disclosure - Debt - Components of Debt (Details)",
     "role": "http://www.insmed.com/role/DebtComponentsOfDebtDetails",
     "shortName": "Debt - Components of Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2018Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SecuredDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2018Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405404 - Disclosure - Debt - Future Principal Repayments of Debt (Details)",
     "role": "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsOfDebtDetails",
     "shortName": "Debt - Future Principal Repayments of Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2018Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestExpenseDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405405 - Disclosure - Debt - Interest Expense (Details)",
     "role": "http://www.insmed.com/role/DebtInterestExpenseDetails",
     "shortName": "Debt - Interest Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestExpenseDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2018Q3",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Shareholders' Equity - Narrative (Details)",
     "role": "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails",
     "shortName": "Shareholders' Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "D2017Q3Sept17",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FI2017Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406403 - Disclosure - Shareholders' Equity - Changes in Shareholders' Equity (Details)",
     "role": "http://www.insmed.com/role/ShareholdersEquityChangesInShareholdersEquityDetails",
     "shortName": "Shareholders' Equity - Changes in Shareholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3YTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "I2017Q2May18",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407402 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "role": "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "I2017Q2May18",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002000 - Statement - Consolidated Statements of Comprehensive Loss (unaudited)",
     "role": "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited",
     "shortName": "Consolidated Statements of Comprehensive Loss (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2017Q4",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Stock-Based Compensation - Stock Options (Details)",
     "role": "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails",
     "shortName": "Stock-Based Compensation - Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3YTD",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3QTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407404 - Disclosure - Stock-Based Compensation - Range of Exercise Prices (Details)",
     "role": "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails",
     "shortName": "Stock-Based Compensation - Range of Exercise Prices (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3QTD_us-gaap_AwardTypeAxis_insm_EmployeeAndDirectorsStockOptionsMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3QTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407405 - Disclosure - Stock-Based Compensation - Restricted Stock and Restricted Stock Units (Details)",
     "role": "http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails",
     "shortName": "Stock-Based Compensation - Restricted Stock and Restricted Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3QTD_us-gaap_AwardTypeAxis_insm_StockOptionsAndRestrictedStockUnitsMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408401 - Disclosure - Income Taxes (Details)",
     "role": "http://www.insmed.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3YTD",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:DeferredIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2018Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409402 - Disclosure - Commitments and Contingencies - Narrative (Details)",
     "role": "http://www.insmed.com/role/CommitmentsAndContingenciesNarrativeDetails",
     "shortName": "Commitments and Contingencies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3QTD",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:LeaseAndRentalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2018Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409403 - Disclosure - Commitments and Contingencies - Minimum Rental Payments (Details)",
     "role": "http://www.insmed.com/role/CommitmentsAndContingenciesMinimumRentalPaymentsDetails",
     "shortName": "Commitments and Contingencies - Minimum Rental Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2018Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003000 - Statement - Consolidated Statements of Cash Flows (unaudited)",
     "role": "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited",
     "shortName": "Consolidated Statements of Cash Flows (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3YTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2018Q3_us-gaap_DebtInstrumentAxis_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003001 - Statement - Consolidated Statements of Cash Flows (unaudited) (Parenthetical)",
     "role": "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnauditedParenthetical",
     "shortName": "Consolidated Statements of Cash Flows (unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101100 - Disclosure - The Company and Basis of Presentation",
     "role": "http://www.insmed.com/role/CompanyAndBasisOfPresentation",
     "shortName": "The Company and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102100 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.insmed.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103100 - Disclosure - Intangible Assets",
     "role": "http://www.insmed.com/role/IntangibleAssets",
     "shortName": "Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2018Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 41,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "If the value is true, then the document is an amendment to previously-filed/accepted document.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2014-01-31",
     "presentation": [
      "http://www.insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2014-01-31",
     "presentation": [
      "http://www.insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2014-01-31",
     "presentation": [
      "http://www.insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2014-01-31",
     "presentation": [
      "http://www.insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2014-01-31",
     "presentation": [
      "http://www.insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word \"Other\".",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2014-01-31",
     "presentation": [
      "http://www.insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2014-01-31",
     "presentation": [
      "http://www.insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2014-01-31",
     "presentation": [
      "http://www.insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate \"Yes\" or \"No\" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2014-01-31",
     "presentation": [
      "http://www.insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2014-01-31",
     "presentation": [
      "http://www.insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2014-01-31",
     "presentation": [
      "http://www.insmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "insm_AccruedClinicalTrialExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.insmed.com/role/AccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical trial expenses.",
        "label": "Accrued Clinical Trial Expenses",
        "terseLabel": "Accrued clinical trial expenses"
       }
      }
     },
     "localname": "AccruedClinicalTrialExpenses",
     "nsuri": "http://www.insmed.com/20180930",
     "presentation": [
      "http://www.insmed.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_AccruedConstructionLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.insmed.com/role/AccruedExpensesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Construction Liabilities, Current",
        "label": "Accrued Construction Liabilities, Current",
        "terseLabel": "Accrued construction costs"
       }
      }
     },
     "localname": "AccruedConstructionLiabilitiesCurrent",
     "nsuri": "http://www.insmed.com/20180930",
     "presentation": [
      "http://www.insmed.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_AccruedMilestonePaymentCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.insmed.com/role/AccruedExpensesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Milestone Payment, Current",
        "label": "Accrued Milestone Payment, Current",
        "terseLabel": "Accrued milestone payment"
       }
      }
     },
     "localname": "AccruedMilestonePaymentCurrent",
     "nsuri": "http://www.insmed.com/20180930",
     "presentation": [
      "http://www.insmed.com/role/AccruedExpensesDetails",
      "http://www.insmed.com/role/IntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_AccruedTechnicalOperationExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.insmed.com/role/AccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for technical operation expenses.",
        "label": "Accrued Technical Operation Expenses",
        "terseLabel": "Accrued technical operation expenses"
       }
      }
     },
     "localname": "AccruedTechnicalOperationExpenses",
     "nsuri": "http://www.insmed.com/20180930",
     "presentation": [
      "http://www.insmed.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_AdditionalLaboratorySpaceOperatingLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.",
        "label": "Additional Laboratory Space Operating Leases Future Minimum Payments Due",
        "terseLabel": "Future minimum rental payments for additional laboratory space"
       }
      }
     },
     "localname": "AdditionalLaboratorySpaceOperatingLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://www.insmed.com/20180930",
     "presentation": [
      "http://www.insmed.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_AmortizationOfBackendFee": {
     "auth_ref": [],
     "calculation": {
      "http://www.insmed.com/role/DebtInterestExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InterestExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortization Of Backend Fee",
        "label": "Amortization Of Backend Fee",
        "terseLabel": "Accretion of back-end fee on debt"
       }
      }
     },
     "localname": "AmortizationOfBackendFee",
     "nsuri": "http://www.insmed.com/20180930",
     "presentation": [
      "http://www.insmed.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Available-for-sale Securities, Gross Unrealized Gain (Loss), Number of Securities",
        "label": "Available-for-sale Securities, Gross Unrealized Gain (Loss), Number of Securities",
        "verboseLabel": "Securities in an unrealized gain or loss position"
       }
      }
     },
     "localname": "AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities",
     "nsuri": "http://www.insmed.com/20180930",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "insm_BridgewaterNewJerseyFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represent the Bridgewater location in New Jersey where the entity has leased office and laboratory space.",
        "label": "Bridgewater New Jersey Facility [Member]",
        "terseLabel": "Bridgewater, NJ facility"
       }
      }
     },
     "localname": "BridgewaterNewJerseyFacilityMember",
     "nsuri": "http://www.insmed.com/20180930",
     "presentation": [
      "http://www.insmed.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_BridgewaterNewJerseyOfficeSpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bridgewater, New Jersey Office Space [Member]",
        "label": "Bridgewater, New Jersey Office Space [Member]",
        "terseLabel": "Bridgewater, NJ office space"
       }
      }
     },
     "localname": "BridgewaterNewJerseyOfficeSpaceMember",
     "nsuri": "http://www.insmed.com/20180930",
     "presentation": [
      "http://www.insmed.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common Stock Shares Exercise To Underwriters In Full Of Over Allotment Option",
        "label": "Common Stock Shares Exercise To Underwriters In Full Of Over Allotment Option",
        "terseLabel": "Shares exercised in full of over-allotment option by underwriter (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption",
     "nsuri": "http://www.insmed.com/20180930",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "insm_DebtInstrumentConversionTermAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument Conversion Term [Axis]",
        "label": "Debt Instrument Conversion Term [Axis]",
        "terseLabel": "Debt Instrument Conversion Term [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentConversionTermAxis",
     "nsuri": "http://www.insmed.com/20180930",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "insm_DebtInstrumentConversionTermDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Debt Instrument Conversion Term [Axis]",
        "label": "Debt Instrument Conversion Term [Domain]",
        "terseLabel": "Debt Instrument Conversion Term [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentConversionTermDomain",
     "nsuri": "http://www.insmed.com/20180930",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_DebtInstrumentConversionTermFourMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Conversion Term Four [Member]",
        "label": "Debt Instrument, Conversion Term Four [Member]",
        "terseLabel": "Conversion Term (iv)"
       }
      }
     },
     "localname": "DebtInstrumentConversionTermFourMember",
     "nsuri": "http://www.insmed.com/20180930",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_DebtInstrumentConversionTermOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Conversion Term One [Member]",
        "label": "Debt Instrument, Conversion Term One [Member]",
        "terseLabel": "Conversion Term (i)"
       }
      }
     },
     "localname": "DebtInstrumentConversionTermOneMember",
     "nsuri": "http://www.insmed.com/20180930",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_DebtInstrumentConversionTermThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Conversion Term Three [Member]",
        "label": "Debt Instrument, Conversion Term Three [Member]",
        "terseLabel": "Conversion Term (iii)"
       }
      }
     },
     "localname": "DebtInstrumentConversionTermThreeMember",
     "nsuri": "http://www.insmed.com/20180930",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_DebtInstrumentConversionTermTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Conversion Term Two [Member]",
        "label": "Debt Instrument, Conversion Term Two [Member]",
        "terseLabel": "Conversion Term (ii)"
       }
      }
     },
     "localname": "DebtInstrumentConversionTermTwoMember",
     "nsuri": "http://www.insmed.com/20180930",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Convertible, Trading Days Prior To Effective Data Of Fundamental Change",
        "label": "Debt Instrument, Convertible, Trading Days Prior To Effective Data Of Fundamental Change",
        "terseLabel": "Threshold trading days following fundamental change"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange",
     "nsuri": "http://www.insmed.com/20180930",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "insm_DebtInstrumentOptionToPurchaseAdditionalDebt": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Option To Purchase Additional Debt",
        "label": "Debt Instrument, Option To Purchase Additional Debt",
        "terseLabel": "Option to purchase additional debt"
       }
      }
     },
     "localname": "DebtInstrumentOptionToPurchaseAdditionalDebt",
     "nsuri": "http://www.insmed.com/20180930",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards, net of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Assets (Liabilities) Net before Valuation Allowances",
        "terseLabel": "Provisional deferred tax asset offset completely by valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances",
     "nsuri": "http://www.insmed.com/20180930",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Document and Entity Information"
       }
      }
     },
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://www.insmed.com/20180930",
     "xbrltype": "stringItemType"
    },
    "insm_EmployeeAndDirectorsStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An arrangement whereby an employee or member of the Board of Directors is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement.",
        "label": "Employee And Directors Stock Options [Member]",
        "terseLabel": "Stock options to purchase common stock"
       }
      }
     },
     "localname": "EmployeeAndDirectorsStockOptionsMember",
     "nsuri": "http://www.insmed.com/20180930",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails",
      "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails",
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_EmployeeStockPurchasePlan2018Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Employee Stock Purchase Plan 2018 [Member]",
        "label": "Employee Stock Purchase Plan 2018 [Member]",
        "terseLabel": "2018 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlan2018Member",
     "nsuri": "http://www.insmed.com/20180930",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_FairValueLevel1Level2Level3TransfersAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of transfers measured on a recurring basis in or out of Level 1, Level 2, or Level 3.",
        "label": "Fair Value Level 1 Level 2 Level 3 Transfers Amount",
        "terseLabel": "Fair value transfers in or out of Level 1, Level 2, or Level 3"
       }
      }
     },
     "localname": "FairValueLevel1Level2Level3TransfersAmount",
     "nsuri": "http://www.insmed.com/20180930",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the sum of accrued expenses and Other Current Liabilities.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Current Liabilities",
        "terseLabel": "Accrued expenses and other"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities",
     "nsuri": "http://www.insmed.com/20180930",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_LesseeOperatingLeaseNumberOfRenewals": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Number Of Renewals",
        "label": "Lessee, Operating Lease, Number Of Renewals",
        "terseLabel": "Option to extend lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfRenewals",
     "nsuri": "http://www.insmed.com/20180930",
     "presentation": [
      "http://www.insmed.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock each restricted stock award entitles the holder to receive upon completion of a specific period of service or achievement of a specified milestone.",
        "label": "Number Of Common Shares To Be Received In Lieu Of Per Restricted Stock And Restricted Stock Unit",
        "terseLabel": "Number of common shares each award holder is entitled to receive"
       }
      }
     },
     "localname": "NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit",
     "nsuri": "http://www.insmed.com/20180930",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "One Point Seven Five Percent Convertible Senior Note Due 2025 [Member]",
        "label": "One Point Seven Five Percent Convertible Senior Note Due 2025 [Member]",
        "terseLabel": "1.75 convertible senior notes due 2025"
       }
      }
     },
     "localname": "OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member",
     "nsuri": "http://www.insmed.com/20180930",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnauditedParenthetical",
      "http://www.insmed.com/role/DebtComponentsOfDebtDetails",
      "http://www.insmed.com/role/DebtNarrativeDetails",
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_Range10Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Selected disclosure of Stock options outstanding and exercisable by share price exercise range.",
        "label": "Range10 [Member]",
        "terseLabel": "$32.46 to $32.46"
       }
      }
     },
     "localname": "Range10Member",
     "nsuri": "http://www.insmed.com/20180930",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_Range1Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Selected disclosure of Stock options outstanding and exercisable by share price exercise range.",
        "label": "Range1 [Member]",
        "terseLabel": "$3.03 to $6.90"
       }
      }
     },
     "localname": "Range1Member",
     "nsuri": "http://www.insmed.com/20180930",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_Range2Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Selected disclosure of Stock options outstanding and exercisable by share price exercise range.",
        "label": "Range2 [Member]",
        "terseLabel": "$6.96 to $10.85"
       }
      }
     },
     "localname": "Range2Member",
     "nsuri": "http://www.insmed.com/20180930",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_Range3Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Selected disclosure of Stock options outstanding and exercisable by share price exercise range.",
        "label": "Range3 [Member]",
        "terseLabel": "$11.14 to $12.58"
       }
      }
     },
     "localname": "Range3Member",
     "nsuri": "http://www.insmed.com/20180930",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_Range4Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Selected disclosure of Stock options outstanding and exercisable by share price exercise range.",
        "label": "Range4 [Member]",
        "terseLabel": "$12.66 to $13.67"
       }
      }
     },
     "localname": "Range4Member",
     "nsuri": "http://www.insmed.com/20180930",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_Range5Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Selected disclosure of Stock options outstanding and exercisable by share price exercise range.",
        "label": "Range5 [Member]",
        "terseLabel": "$13.94 to $16.07"
       }
      }
     },
     "localname": "Range5Member",
     "nsuri": "http://www.insmed.com/20180930",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_Range6Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Selected disclosure of Stock options outstanding and exercisable by share price exercise range.",
        "label": "Range6 [Member]",
        "terseLabel": "$16.09 to $17.16"
       }
      }
     },
     "localname": "Range6Member",
     "nsuri": "http://www.insmed.com/20180930",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_Range7Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Selected disclosure of Stock options outstanding and exercisable by share price exercise range.",
        "label": "Range7 [Member]",
        "terseLabel": "$17.24 to $22.76"
       }
      }
     },
     "localname": "Range7Member",
     "nsuri": "http://www.insmed.com/20180930",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_Range8Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Selected disclosure of Stock options outstanding and exercisable by share price exercise range.",
        "label": "Range8 [Member]",
        "terseLabel": "$22.84 to $30.46"
       }
      }
     },
     "localname": "Range8Member",
     "nsuri": "http://www.insmed.com/20180930",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_Range9Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Selected disclosure of Stock options outstanding and exercisable by share price exercise range.",
        "label": "Range9 [Member]",
        "terseLabel": "$30.86 to $31.78"
       }
      }
     },
     "localname": "Range9Member",
     "nsuri": "http://www.insmed.com/20180930",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_RepaymentsOfDebtFeesAndOutstandingInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Repayments Of Debt, Fees And Outstanding Interest",
        "label": "Repayments Of Debt, Fees And Outstanding Interest",
        "terseLabel": "Repayment of debt, back end fees, outstanding interest, and prepayment penalty fees"
       }
      }
     },
     "localname": "RepaymentsOfDebtFeesAndOutstandingInterest",
     "nsuri": "http://www.insmed.com/20180930",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_RestrictedStockAndRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares and stock units that an entity has not yet issued because the agreed-upon consideration, such as employee services, has not yet been received.",
        "label": "Restricted Stock And Restricted Stock Units [Member]",
        "terseLabel": "RS and RSUs"
       }
      }
     },
     "localname": "RestrictedStockAndRestrictedStockUnitsMember",
     "nsuri": "http://www.insmed.com/20180930",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_ScheduleofEarningsPerShareBasicandDilutedLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Line Items] for Schedule of Earnings Per Share, Basic and Diluted [Table]",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Line Items]",
        "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted [Line Items]"
       }
      }
     },
     "localname": "ScheduleofEarningsPerShareBasicandDilutedLineItems",
     "nsuri": "http://www.insmed.com/20180930",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "insm_ScheduleofEarningsPerShareBasicandDilutedTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of Earnings Per Share, Basic and Diluted [Table]",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table]",
        "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted [Table]"
       }
      }
     },
     "localname": "ScheduleofEarningsPerShareBasicandDilutedTable",
     "nsuri": "http://www.insmed.com/20180930",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of inducement share options (or share units) granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Inducement Options Grants In Period Gross",
        "terseLabel": "Inducement stock options granted to new employees (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross",
     "nsuri": "http://www.insmed.com/20180930",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "insm_StockOptionsAndRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents contract that gives the holder the right, but not the obligation, either to purchase or to sell a certain number of shares of stock at a predetermined price for a specified period of time. It also includes stock units that an entity has not yet issued because the agreed-upon consideration, such as employee services, has not yet been received.",
        "label": "Stock Options And Restricted Stock Units [Member]",
        "terseLabel": "Stock options and RSUs"
       }
      }
     },
     "localname": "StockOptionsAndRestrictedStockUnitsMember",
     "nsuri": "http://www.insmed.com/20180930",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_WeightedAverageRemainingContractualLifeInYearsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Weighted Average Remaining Contractual Life in Years [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Life in Years"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualLifeInYearsAbstract",
     "nsuri": "http://www.insmed.com/20180930",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/AccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionExpense": {
     "auth_ref": [
      "r92",
      "r93"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.",
        "label": "Accretion Expense",
        "terseLabel": "Accretion of back-end fee on debt"
       }
      }
     },
     "localname": "AccretionExpense",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.insmed.com/role/AccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/AccruedExpensesDetails",
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r30"
     ],
     "calculation": {
      "http://www.insmed.com/role/AccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r41",
      "r42",
      "r43"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt": {
     "auth_ref": [
      "r99"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.",
        "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt",
        "terseLabel": "Equity component of Convertible Notes"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityChangesInShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r120",
      "r122",
      "r158",
      "r159"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityChangesInShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r122",
      "r152",
      "r157"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.",
        "label": "Allocated Share-based Compensation Expense",
        "terseLabel": "Allocated share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r52",
      "r64",
      "r189"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.insmed.com/role/DebtInterestExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_InterestExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Accretion of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.insmed.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r48",
      "r65",
      "r191",
      "r206"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.insmed.com/role/DebtInterestExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InterestExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.insmed.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potentially dilutive securities excluded from computations of diluted weighted-average shares outstanding"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Anti-dilutive securities excluded from computations of diluted weighted-average common shares outstanding"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r199",
      "r211"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r40"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r123",
      "r154"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by award type pertaining to equity-based compensation.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails",
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails",
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails",
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r184",
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Carrying Value"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r25",
      "r66"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/CompanyAndBasisOfPresentationDetails",
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": {
     "auth_ref": [
      "r60",
      "r187"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.",
        "label": "Cash and Cash Equivalents, Period Increase (Decrease)",
        "totalLabel": "Net increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r94",
      "r95"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock shares reserved for issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, authorized shares (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued shares (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r17",
      "r109"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, outstanding shares (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.01 par value; 500,000,000 authorized shares, 77,085,715 and 76,610,508 issued and outstanding shares at September 30, 2018 and December 31, 2017, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt, Fair Value Disclosures",
        "terseLabel": "Convertible Notes ($450.0 face value)"
       }
      }
     },
     "localname": "ConvertibleDebtFairValueDisclosures",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails",
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.",
        "label": "Convertible Debt Securities [Member]",
        "terseLabel": "Convertible debt securities"
       }
      }
     },
     "localname": "ConvertibleDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleNotesPayableMember": {
     "auth_ref": [
      "r13",
      "r200",
      "r209",
      "r218"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Notes Payable [Member]",
        "terseLabel": "Convertible Notes",
        "verboseLabel": "Convertible debt securities"
       }
      }
     },
     "localname": "ConvertibleNotesPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnauditedParenthetical",
      "http://www.insmed.com/role/DebtComponentsOfDebtDetails",
      "http://www.insmed.com/role/DebtNarrativeDetails",
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r200",
      "r201",
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnauditedParenthetical",
      "http://www.insmed.com/role/DebtComponentsOfDebtDetails",
      "http://www.insmed.com/role/DebtNarrativeDetails",
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": {
     "auth_ref": [
      "r100"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.",
        "label": "Debt Instrument, Convertible, Carrying Amount of Equity Component",
        "terseLabel": "Equity component of convertible debt"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails",
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Initial conversion price (in dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r33",
      "r110",
      "r113",
      "r115"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Initial conversion rate"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Convertible, Remaining Discount Amortization Period",
        "terseLabel": "Remaining discount amortization period"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "terseLabel": "Threshold consecutive trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "terseLabel": "Threshold percent of stock price trigger"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "terseLabel": "Threshold trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r190",
      "r192"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Aggregate principal amount",
        "verboseLabel": "Face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails",
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r32",
      "r190"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnauditedParenthetical",
      "http://www.insmed.com/role/DebtComponentsOfDebtDetails",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtComponentsOfDebtDetails",
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnauditedParenthetical",
      "http://www.insmed.com/role/DebtComponentsOfDebtDetails",
      "http://www.insmed.com/role/DebtNarrativeDetails",
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r34",
      "r71",
      "r110",
      "r114",
      "r115",
      "r116",
      "r189",
      "r190",
      "r192",
      "r208"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtComponentsOfDebtDetails",
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r189",
      "r192"
     ],
     "calculation": {
      "http://www.insmed.com/role/DebtComponentsOfDebtDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedTerseLabel": "Discount on debt",
        "terseLabel": "Unamortized portion of debt discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtComponentsOfDebtDetails",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r26",
      "r191"
     ],
     "calculation": {
      "http://www.insmed.com/role/DebtComponentsOfDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "negatedLabel": "Debt issuance costs, unamortized",
        "terseLabel": "Underwriting discounts and commissions and other offering expenses"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtComponentsOfDebtDetails",
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r64",
      "r69",
      "r164",
      "r165"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred tax benefit"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r64",
      "r90"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DilutiveSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]",
        "terseLabel": "Effect of dilutive securities:"
       }
      }
     },
     "localname": "DilutiveSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r118",
      "r160"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.",
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Basic and diluted net loss per share (in dollars per share)",
        "verboseLabel": "Basic and diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "terseLabel": "Net loss per share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r68",
      "r80",
      "r81",
      "r82"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": {
     "auth_ref": [
      "r187"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.",
        "label": "Effect of Exchange Rate on Cash and Cash Equivalents",
        "terseLabel": "Effect of exchange rates on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.insmed.com/role/AccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Expected weighted average period for recognized and unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails",
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r153"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unrecognized cost of unvested share-based awards, other than options, awarded to employees as compensation.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r153"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unrecognized cost of unvested options awarded to employees as compensation.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options",
        "terseLabel": "Unrecognized compensation expense related to unvested stock options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Common stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r174",
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within the fair value hierarchy.",
        "label": "Fair Value, Hierarchy [Axis]",
        "terseLabel": "Fair Value, Hierarchy [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r174",
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r174",
      "r181",
      "r183",
      "r184",
      "r185",
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsAssetsQuantitativeInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Inputs, Assets, Quantitative Information [Line Items]",
        "terseLabel": "Fair Value Inputs, Assets, Quantitative Information [Line Items]"
       }
      }
     },
     "localname": "FairValueInputsAssetsQuantitativeInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsAssetsQuantitativeInformationTable": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of the inputs used in the fair value measurement of assets. This disclosure may include, but is not limited to, the fair value of the asset, valuation technique used to measure fair value, the inputs used to measure fair value, the ranges of the inputs, and the weighted averages of the inputs.",
        "label": "Fair Value Inputs, Assets, Quantitative Information [Table]",
        "terseLabel": "Fair Value Inputs, Assets, Quantitative Information [Table]"
       }
      }
     },
     "localname": "FairValueInputsAssetsQuantitativeInformationTable",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r172",
      "r175"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [
      "r173",
      "r177"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Provides the general categories used to describe the frequency with which financial assets and liabilities (as defined) are measured at fair value (on a recurring or nonrecurring basis).",
        "label": "Fair Value, Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r173",
      "r177"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents a description of the frequency with which certain items are measured at fair value. Items measured at fair value on a recurring basis generally include those items for which measurement inputs are readily available and which are measured at fair value at successive reporting periods.",
        "label": "Fair Value, Measurements, Recurring [Member]",
        "terseLabel": "Recurring basis"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r68",
      "r179",
      "r182"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Intangible assets estimated useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/IntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r86",
      "r87"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.insmed.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r88"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.insmed.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.insmed.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r86",
      "r87"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.insmed.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r64",
      "r103",
      "r104"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Loss on extinguishment of debt",
        "terseLabel": "Loss on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited",
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "Acquired ARIKAYCE R&amp;D"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.insmed.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r45",
      "r197",
      "r204",
      "r217"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r72",
      "r163"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited",
      "http://www.insmed.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r67"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "verboseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityChangesInShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": {
     "auth_ref": [
      "r78",
      "r81"
     ],
     "calculation": {
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities",
        "terseLabel": "Dilutive securities, convertible debt (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r77",
      "r81"
     ],
     "calculation": {
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Dilutive securities, share-based payment (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/IntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r188",
      "r191",
      "r207"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      },
      "http://www.insmed.com/role/DebtInterestExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "totalLabel": "Total interest expense",
        "verboseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited",
      "http://www.insmed.com/role/DebtInterestExpenseDetails",
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.insmed.com/role/DebtInterestExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InterestExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Contractual interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.",
        "label": "Interest Income and Interest Expense Disclosure [Table Text Block]",
        "terseLabel": "Summary of Interest Expense"
       }
      }
     },
     "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r67"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid, after deduction of cash paid for capitalized interest, for interest. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Net",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r30"
     ],
     "calculation": {
      "http://www.insmed.com/role/AccruedExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Accrued interest payable"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r9",
      "r39",
      "r68",
      "r84",
      "r85"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentIncomeNonoperating": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.",
        "label": "Investment Income, Nonoperating",
        "terseLabel": "Investment income"
       }
      }
     },
     "localname": "InvestmentIncomeNonoperating",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Operating Leases, Rent Expense",
        "terseLabel": "Rent expense charged to operations"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Period of lease extension"
       }
      }
     },
     "localname": "LesseeLeasingArrangementsOperatingLeasesRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Initial lease term"
       }
      }
     },
     "localname": "LesseeLeasingArrangementsOperatingLeasesTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r22",
      "r202",
      "r214"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and shareholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "PARI milestone upon FDA approval"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "A&amp;R Loan Agreement with Hercules"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r15",
      "r201",
      "r212"
     ],
     "calculation": {
      "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsOfDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtByMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Long-term Debt, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Year Ending December 31:"
       }
      }
     },
     "localname": "LongTermDebtByMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsOfDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "auth_ref": [
      "r73",
      "r96"
     ],
     "calculation": {
      "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsOfDebtDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal after Year Five",
        "terseLabel": "2023 and thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r73",
      "r96"
     ],
     "calculation": {
      "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsOfDebtDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Five",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r73",
      "r96"
     ],
     "calculation": {
      "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsOfDebtDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Four",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r73",
      "r96"
     ],
     "calculation": {
      "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsOfDebtDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Three",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r73",
      "r96"
     ],
     "calculation": {
      "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsOfDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Two",
        "terseLabel": "2019"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsOfDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year",
        "terseLabel": "2018"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.insmed.com/role/DebtComponentsOfDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt, net",
        "totalLabel": "Long-term debt, net"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.insmed.com/role/DebtComponentsOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnauditedParenthetical",
      "http://www.insmed.com/role/DebtComponentsOfDebtDetails",
      "http://www.insmed.com/role/DebtNarrativeDetails",
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r34",
      "r97"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnauditedParenthetical",
      "http://www.insmed.com/role/DebtComponentsOfDebtDetails",
      "http://www.insmed.com/role/DebtNarrativeDetails",
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r60",
      "r62"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r60",
      "r62"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r60",
      "r61",
      "r65"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r46",
      "r65",
      "r81",
      "r205",
      "r216"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "negatedLabel": "Net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss for the period"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/CompanyAndBasisOfPresentationDetails",
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited",
      "http://www.insmed.com/role/ShareholdersEquityChangesInShareholdersEquityDetails",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Leased Assets [Line Items]",
        "terseLabel": "Commitments"
       }
      }
     },
     "localname": "OperatingLeasedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [
      "r193",
      "r194"
     ],
     "calculation": {
      "http://www.insmed.com/role/CommitmentsAndContingenciesMinimumRentalPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.",
        "label": "Operating Leases, Future Minimum Payments Due",
        "terseLabel": "Future minimum rental payments under lease",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/CommitmentsAndContingenciesMinimumRentalPaymentsDetails",
      "http://www.insmed.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Future minimum rental payments under operating leases"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/CommitmentsAndContingenciesMinimumRentalPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": {
     "auth_ref": [
      "r193",
      "r194"
     ],
     "calculation": {
      "http://www.insmed.com/role/CommitmentsAndContingenciesMinimumRentalPaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Five Years",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/CommitmentsAndContingenciesMinimumRentalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": {
     "auth_ref": [
      "r193",
      "r194"
     ],
     "calculation": {
      "http://www.insmed.com/role/CommitmentsAndContingenciesMinimumRentalPaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Four Years",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/CommitmentsAndContingenciesMinimumRentalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": {
     "auth_ref": [
      "r193",
      "r194"
     ],
     "calculation": {
      "http://www.insmed.com/role/CommitmentsAndContingenciesMinimumRentalPaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Three Years",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/CommitmentsAndContingenciesMinimumRentalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": {
     "auth_ref": [
      "r193",
      "r194"
     ],
     "calculation": {
      "http://www.insmed.com/role/CommitmentsAndContingenciesMinimumRentalPaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Two Years",
        "terseLabel": "2019"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/CommitmentsAndContingenciesMinimumRentalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": {
     "auth_ref": [
      "r193",
      "r194"
     ],
     "calculation": {
      "http://www.insmed.com/role/CommitmentsAndContingenciesMinimumRentalPaymentsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due Thereafter",
        "terseLabel": "2023 and thereafter"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/CommitmentsAndContingenciesMinimumRentalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.insmed.com/role/CommitmentsAndContingenciesMinimumRentalPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Remainder of Fiscal Year",
        "terseLabel": "2018 (remaining)"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/CommitmentsAndContingenciesMinimumRentalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r1",
      "r171"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "verboseLabel": "The Company and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/CompanyAndBasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r30"
     ],
     "calculation": {
      "http://www.insmed.com/role/AccruedExpensesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssets": {
     "auth_ref": [
      "r12",
      "r198",
      "r210"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets classified as other.",
        "label": "Other Assets",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r168",
      "r169",
      "r170"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Change in cumulative translation adjustment",
        "verboseLabel": "Foreign currency translation gains"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited",
      "http://www.insmed.com/role/ShareholdersEquityChangesInShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "verboseLabel": "Other comprehensive income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r30"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfDebtExtinguishmentCosts": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.",
        "label": "Payment for Debt Extinguishment or Debt Prepayment Cost",
        "negatedLabel": "Loss on extinguishment of debt",
        "terseLabel": "Loss on extinguishment of debt"
       }
      }
     },
     "localname": "PaymentsOfDebtExtinguishmentCosts",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesRecentlyAdoptedAccountingPronouncementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedTerseLabel": "Payment of debt issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r59"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Underwriter's discount and offering expenses"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of fixed assets"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares or units awarded to employees for meeting certain performance targets.",
        "label": "Performance Shares [Member]",
        "verboseLabel": "Performance options"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r123",
      "r154"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name pertaining to equity-based compensation arrangements.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the equity-based compensation arrangement plan.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r180",
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r3",
      "r23",
      "r24"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r56"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Net proceeds"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock, net",
        "verboseLabel": "Net proceeds from sale of shares"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from issuance of 1.75% convertible senior notes due 2025"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r55",
      "r155"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r10",
      "r11",
      "r91",
      "r215"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Fixed assets, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by range, including, but not limited to, upper and lower bounds.",
        "label": "Range [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Extent of variation, for example, but not limited to, upper and lower bounds.",
        "label": "Range [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": {
     "auth_ref": [
      "r0",
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by name of property.",
        "label": "Name of Property [Axis]",
        "terseLabel": "Name of Property [Axis]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
     "auth_ref": [
      "r0",
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the property, for example, but not limited to, ABC Shopping Center.",
        "label": "Name of Property [Domain]",
        "terseLabel": "Name of Property [Domain]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "negatedTerseLabel": "Payment of debt",
        "terseLabel": "Repayment of debt"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r161",
      "r220"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Unvested RSUs",
        "verboseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails",
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesDetails",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r19",
      "r117",
      "r213"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/AccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Potentially Dilutive Securities Excluded from Computations of Diluted Weighted Average Common Shares Outstanding"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Components of Debt Balance"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r122",
      "r151",
      "r157"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.",
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]",
        "terseLabel": "Summary of Allocation of Employee Stock-Based Compensation"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Carrying Value and Fair Value of Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r86",
      "r87"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/IntangibleAssetsNarrativeDetails",
      "http://www.insmed.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r86",
      "r87"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Rental Payments Required Under Operating Leases"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Future Principal Repayments of Debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Schedule of Operating Leased Assets [Table]",
        "terseLabel": "Schedule of Operating Leased Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r123",
      "r154"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of an equity-based arrangement under which compensation is awarded to employees, typically comprised of compensation expense; changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan; and cash flow effects resulting from the equity-based payment arrangement. Component disclosures are by type of award and plan name.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails",
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]",
        "terseLabel": "Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.",
        "label": "Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]",
        "terseLabel": "Summary of Exercise Price and Number of Stock Options Exercisable"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r127",
      "r139",
      "r142"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Compensation, Stock Options, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of Fair Value Assumptions for Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Summary of RSU Activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r36",
      "r70",
      "r106",
      "r107",
      "r108",
      "r110",
      "r111",
      "r112",
      "r114",
      "r115",
      "r116",
      "r117"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.",
        "label": "Schedule of Stockholders Equity [Table Text Block]",
        "terseLabel": "Schedule of Changes in Shareholders' Equity"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).",
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "terseLabel": "Reconciliation of the Weighted Average Number of Shares Used to Compute Basic and Diluted Net Loss per Share"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebt": {
     "auth_ref": [
      "r15",
      "r201",
      "r212"
     ],
     "calculation": {
      "http://www.insmed.com/role/DebtComponentsOfDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.",
        "label": "Secured Debt",
        "terseLabel": "1.75% convertible senior notes due 2025"
       }
      }
     },
     "localname": "SecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtComponentsOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.",
        "label": "Share-based Compensation",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "periodStartLabel": "Outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of RSUs"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding Weighted Average Grant Price (in dollars per share)",
        "periodStartLabel": "Outstanding Weighted Average Grant Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Released (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Released (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Fair value and assumptions used in determining fair value of stock options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Stock-Based Compensation",
        "verboseLabel": "Stock Option disclosures"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails",
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under an established share-based compensation plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Shares of common stock, maximum authorized for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r141"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Total intrinsic value of stock options exercised during the period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Forfeited or expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited or expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average fair value of stock options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r154"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r129",
      "r154"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options outstanding end of the period (in shares)",
        "periodStartLabel": "Options outstanding beginning of the period (in shares)",
        "terseLabel": "Options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options outstanding end of the period (in dollars per share)",
        "periodStartLabel": "Options outstanding beginning of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r142"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Percentage of outstanding shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r121",
      "r125"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity-based compensation award.",
        "label": "Equity Award [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails",
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails",
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsDetails",
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails",
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]",
        "terseLabel": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]",
        "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]",
        "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit",
        "terseLabel": "Range of Exercise Prices lower range limit (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options",
        "terseLabel": "Number of Options Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options",
        "terseLabel": "Number of Options Outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit",
        "terseLabel": "Range of Exercise Prices upper range limit (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share price (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r146",
      "r156"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected option term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r154"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r126"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Value of options vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares",
        "terseLabel": "Options vested (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price",
        "terseLabel": "Exercisable Options, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price",
        "terseLabel": "Outstanding Options, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRangeOfExercisePricesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnauditedParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnauditedParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r16",
      "r17",
      "r109",
      "r117"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Shares issued under underwritten public offering (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r16",
      "r17",
      "r109",
      "r117",
      "r131"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r38",
      "r109",
      "r117"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityChangesInShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r17",
      "r20",
      "r21",
      "r83"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance at September 30, 2018",
        "periodStartLabel": "Balance at December 31, 2017",
        "totalLabel": "Total shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.insmed.com/role/ShareholdersEquityChangesInShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Shareholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "US treasury bills"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r162"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Unrecognized income tax benefits, interest and penalties accrued"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r76",
      "r79"
     ],
     "calculation": {
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Weighted average common shares outstanding used in calculation of diluted net loss per share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted average basic and diluted common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsOfComprehensiveLossUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r75",
      "r79"
     ],
     "calculation": {
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average common shares used in calculation of basic net loss per share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2017-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryOfSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-04.(c) Schedule III)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=27047687&loc=d3e5864-122674"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6928298&loc=SL6031897-161870"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6928298&loc=SL6031898-161870"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6928298&loc=SL6031898-161870"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=49170532&loc=d3e12317-112629"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=49170532&loc=d3e12355-112629"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=84159872&loc=d3e21553-112644"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=84159872&loc=d3e21475-112644"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=84159872&loc=d3e21484-112644"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=84159872&loc=d3e21488-112644"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=84159872&loc=d3e21506-112644"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=84159872&loc=d3e21506-112644"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=84159872&loc=d3e21521-112644"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=84159872&loc=d3e21538-112644"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/subtopic&trid=2208855"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=79507207&loc=d3e4534-113899"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5047-113901"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5047-113901"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5047-113901"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=96867065&loc=SL79508275-113901"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=96864182&loc=d3e11149-113907"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=96864182&loc=d3e11178-113907"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5419-128473"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=96868048&loc=SL4569616-111683"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=96868048&loc=SL4569643-111683"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=84161450&loc=SL4573702-111684"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "48",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=65894324&loc=d3e18349-110257"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19190-110258"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=SL6742756-110258"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75026489&loc=d3e13217-108610"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75026489&loc=d3e13220-108610"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=77997519&loc=d3e13279-108611"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=77997519&loc=d3e13433-108611"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=77997519&loc=d3e13467-108611"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=77997519&loc=d3e13476-108611"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14172-108612"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=64930785&loc=d3e28541-108399"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=64930785&loc=d3e28555-108399"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.6(a)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "225",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "225",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "225",
   "Subparagraph": "(SX 210.9-04(8))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "225",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "225",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "225",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=6488278&loc=d3e603758-122996"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28)",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r221": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12b",
   "Subsection": "1"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=84228862&loc=d3e637-108580"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=84228862&loc=d3e681-108580"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=84228862&loc=SL7669686-108580"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=84228862&loc=d3e557-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "225",
   "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "225",
   "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "225",
   "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "225",
   "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "225",
   "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6904-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "225",
   "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "225",
   "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "225",
   "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "225",
   "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3213-108585"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3255-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3255-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3291-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3291-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3291-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6911-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3521-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3536-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3574-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98514028&loc=d3e3044-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(d),(e))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04.(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=96947427&loc=d3e1448-109256"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=96947427&loc=d3e1505-109256"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=96947427&loc=d3e1500-109256"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=96947427&loc=d3e1930-109256"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e7018-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=66092785&loc=d3e4492-108314"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=66092785&loc=d3e4556-108314"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "410",
   "URI": "http://asc.fasb.org/extlink&oid=6392676&loc=d3e7480-110848"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394232&loc=d3e17558-110866"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=79512289&loc=d3e4875-112606"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=51819886&loc=SL6014347-161799"
  }
 },
 "version": "2.0"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>64
<FILENAME>0001104506-18-000011-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104506-18-000011-xbrl.zip
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M:OE' 3ZY.*YD(&MPK'<2LNKI,K/46FKS/'62,4]ECZ$:3E6"63\OL:16>R)
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M,0>E6M\#(&QB7' NP\_3[QU9C!;@Y)M)U>%(M=*ZGT;.IK,'%#9.A5[/5LB
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MU%OG8_=]6O]PP)F__NG_ %!+ P04    " #J.UY-!_6%8GP\   *!@, %0
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M>*=2TPQH#IU^%(![;?[N"7N;[@;!I36"(W5D#%EGK+32PUS(!==2:L&1-20
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MA@I%]QX[&Z.L?K_N\&)FQS9*&I#7*,?(?G;PLZ^SRWQQV<=:<O_=&?>:&B\
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MB15I^OC_)P@ZO<P?,O[T]T/;4/3WHEC]N=YLJO4*-_K6+N\6^WU^"N(8#A$
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M:RY=)HFWU]?+W?>R[M)=%:83N.43(J5-26U4X QR9$^VG'W.UXF!,]?:$._
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MXY?\P=,H"V"%FV=3*;1B(E5:8]V<?Z(D$Z9[)A:&0^"489IE6*(4LPRQC&B
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M9P1N6.;G(7,#V_3P9F$$QMI*WF_YH7I7\4VQWR]28I@0DA&+,R$R "6T31L
M(+#8EA4/5NW$+>RS6XTU7HVU4QA!FYP;AV3<X72/A#/#IAM9\Q@>';$70W27
MK@]Y5@52?EUOU]>WU^_]\=Y-<Q;!%KNW-_EN>7!C[TV^W.?5RWT?\V\'N?'[
M=X((ZKQ-5*9H!JVFE&NC!..:LBQ30<>:AD'D6I90:YT!DV+FJU@"2%,($82
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MKK(&5)Q@K)QCY1!W4WK$/CT^@7,<J;/GXR=/QM#)V)ED#W6DCAS+?0XPE'Y
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M#.NR.FF_^[#\OOQT4S;[8%00R130!GF@%'5$W#>&$$UZX+UC$YD%J$%5?#W
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M)9T6=+RTEC,DDS-8Q!G4G$VF$9<8*9;;Z\WV-KZ]^%M\.6;7U%:QD'OBO9,
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MGU^L_-_!#KH-%.T$:@MBZ0^T3VJ.[(7/)V,+)JW"H+&50@@'FFNH%A5EL1M
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M=KFBX.QVN5B.IG$!OZJ/OL->6# 3]_>"&XH)5AK1@+3<<$=[(;) .<![I:Y
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M!2$:!R2"LI% ZJ@RGG I0XA:1E#(Z9]W:!?X9S$&_'APU023^[%9?TY'-RE
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MND3-\7E 6'L_'Y^7F5A;OZ/PSGMBJ4HU>8 ':B@16FIB&25<0\XQ]0#3U7O
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M<)N@">-).;<1R%>S^?:-RJ,GB[A"^F!%"* 19PBGHNH;"@*B**>VV8#R:[J
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MU93_G(Z7BP\?_]R9C[=U7*&EY:F\ -'<@<%*(BX)CNL/%H9XDW-).L1,J2%
ML0W!=)80.IM>13'=)!>YA@OXTN,%!(^ @O6>80!!C)>8*!ED"#3 TR[MQQY9
MTH;SUP!;^P+,3B_NY0$%*,P9%HY3@8%P*XVQ.IIE IA)8D\LER9/P#O0<A!'
MN\++@UUQV@\OH@U.JK)SE=LZKO#.* H\(*-(Y)Q3%H,5/B[G'E$G.RV$W448
M9:[(9^TQMS,@)3.[,;IO:^25O_A\P9QE#!FFK?' A-*4:^T 4\HY)BRG;/
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M_/DIR9ME])_E8EE>5,OH7;$8O$M76OAD(2W!GB'-G41"(.:!WUDDBR#G8GN
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M9#L8/V1'-'-%\5WJ\:?9<C1Y,UW.HU49GZ\285J,@Z_S^0*PPY90;RQ%E)+
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M'.#X?Z6L,EK$/V(4$%?,YA0RK;_5>ZR'GWXNAT/'P?'KXQ"WA@B4-M8J"H$
M8]:XZ)^$) PB4?12,G1Q[TIRZZVAG_Y<%0<,@1-2PR<9V"M_W<75((S&\U6Y
M\\$<E.XST\)@9)S5)(79 [)("<\D19RY$"RE.:<]#342[KCQVJD<J[:(@A])
MJP>NRH6F!FO+ _<2P%,M0TB9AW';DOPBWFECIA,ZK6U'>P9H!?8$T/&K_N.#
MMF'J_YYS+#PXBW7 RM$ 1@8E.5@6'-*"([#VYUGQCZ7^[>+G^&W XZ.^8=J
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M-[2D/G2GUKB]>PQLK6*['_<'LS\[@BJV@41W%P&5'+Q1#*0/IN)LT#8G=7.
MN#X055U4L=U/$ ?7RZ@R2%,EI/&\/(_27#QTX;;7$JTWNK"$$BX,QI;[N*\B
MH#BK:)%:Y(2O-E2_JK]C^5:Q,6M;5IW56$OLVK% WSU3:,0<=\Q&[GACM42
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MJ,X%\5:4S;S[#'@<XW^E/:?2!%F4Z-':I)7V5.+V[&P0/C(G>03!:AU.'6"
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M\F6<#AGII/$4M%=2:T5%C"/+XK4&JF;9_$J<E;?[(Q[M>28/C\@21$F3T8&
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M<T\RJ6#A[?ZC_/%ELLS_^8__ U!+ P04    " #J.UY-"WGOCYS. 0"IH1(
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ML7&+Z0^ZHZ*PPO5N>:>F=Y>,I#L8Y</BL=^-;R[YV3.XZSYG53)GN%0@T;%
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M1S>]P7#2]. SYQT@00>Y+.+[8YSMYGTMY8)QOZ:@*Q971[O5R.U#[= [P;^
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MYM-52-GKSB]\JGCI4S];Y\M:%?I9<Q"D5F?V77W<!5DD7CI8L5P250=7M#0
MY.=V/7/K ;SR>(;%LQ.VE0EF!126EW+WD-\K;IB6!@P6J@*V1#PTO.E^"0GV
M6B4LVS'O)4 ;9GCM[-W*0AJ->=2J+!?\_(4Y7T<N^?.7I5XSP6]8HEWS'"R-
MK^^=%/$<M0F.>I[HNDBZ?UP5@U'><T&<0?'I3]UNFEY>;H=,._@<C8K":H4@
MJ439IS=R7J/4:"U+/CK*UDJ_C7)I6\6B9\XV"])[DP!;+#!=,4FW5-)U'])_
MC+)O2?_>DO!ZC9*U#_!?WC"01@#S:OX;=_NQLX,Q$22E1,S.#H:A8;&K;FD
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MPR;U'&]TH\36%6[:9\_5@_@I$/-YKB47&%D%"[C;?V@,"Z'44"-"0RDTC]\
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M]/#/M!CTDO+: 5<@B'[9ZR3/?4[4]K)ISV43@WPNFRAA."0,"7<0'3:*6]E
M 0\!9%J(E\@F[F63ETU>-GG9]";9A%DM+QT1&',=81%1KF@(,:1Q:(P*@1*,
MO\QN^KN735XV>=GD9=/K91.=RR8KDH UE)054"$5B"FN(*.<"!49J57X,KO)
MRZ8&9)-?$-JC(*.?X[T8]SZ-U<_Q[H]U+^=X/Q:$3F[3(AG:EP;IC]LT+]/R
MK2<PO5,AC-<DL:[C$#;OY+YGMIEG3L^<GCD]<WKF],RY&\RY6Z603],R38KN
M=57/J9=^2_N#6[>E>A_/!:FBLZ)6)C$R,:<(&P@,IS164G!"(HF( '$<BX6*
M1E-BJKRGYZ0T8SN^T32<AP779(?B)H_J;JWHWR<)O\4@JM4IU()S(HG"5"@J
M:2AI#(T"!$*)H]@L.0/@92!Z?;[(P\JCK,.X/Z'*@Z@M(&)R!B*$=(P)A1BC
MD$I-)9$(LQ 0I@7!\,T@>GUBP\/C< #M6*1[%'D4M01%8HXBC"A&R"BM94Q-
MA$+ .0])*"41V("%DKFO4$7-H(C3C@!-GDS1<F]IZP][^VN:IT72K[RHI'>3
MY5DY=&'\;ZFO<OU2Q$HP1ZQAF%'.L(XB0*FB2FF+U8C+2$60\H43X2;S8 &K
M[LW"!GPP0CJ$-'ILU-:ESOBXG4?T4D2CVBXF(J!&]H;FE#)H0H*!$0ACVQ(C
MH]^.Z,8<0L@[!#1IRGI$>T3O"*+)?.\/5(2$B%E3FD.J,9%" !UJ2B-LN% +
M^?6OTM$->:>0=%"CWJF'M(?TCD":S2&M6,R9EO:6AM0:WB%"%""H!+%?& *-
M*.EF($UXA[/]/BYJ%X^:&2RDP>WQL8\K@"OFP,70XA43PB0Q5 GK)TNE@0(<
MBP@!M1 GGF4;3I#:;+& !U 5N"/%)D]U;*V.]:IT%X ' 9COY (A82S4AL0P
MI%(9(6,*(B@9B>S_$'D-\AKS9 GI (\\C[S=01Z:GSN&L $1%Y%Q:Z,(A@(2
MAGBH$-(:&[-0>^*9.J\9\Q1!V6&0>>AYZ.T*],@<>CB*,%)$*!!I&F(H-;,X
MC!G -(2,+OB)SU1Z#05[$.[0C;J&+?8 VQ#<F1Y8(UJT06Y?".*)X+G"<X7G
M"L\5GBO6MO=Z'2->ZQ;K_J!\:URYS9;\3RM,>5A;Q67* "P-QEI&--)&&0@@
MDHS'DNDX7,C+F!'Q*.\.;E)WWN*;8\>EI8&]MMD@\B(#OF4&F^+1G[V#O;NP
MJZVT$L"XJ_D%, PI 49R'"(0AC&-I#9BX7CKY\'N98'CY\"N\0BRAYV'W89A
M5ULG!3KDG'(>1X!03862%H@2 !Y&&%/Z2MB]+&K\'-@U'S[VN/.XVRSN$)AG
M_PI#L 4>AA@(:A6AHI$"BAL3&QF9,'ZUNFL8=\W'CK<'=SZ8[$,!/D#DN<)S
MA><*SQ6>*WPP^:E1'N7?TG+H]H4'666C[K"EO\+0QQ#-#/V8,R, @@PQ2H41
M0CF+/P)<FA#;.P\-_3D9QY;^\2"?I8"O,R<9=3B!N[#1WGO+NX&A6OFQ$% N
M"!<,,$-EQ$(B-*8189Q!+F/Z1@PUEEV,49,!*H\@CZ W(:A6>XS&0AHC@5&4
M4&94R&(1THA&5ANA4(NW:Z&&ZKUT*-R)<B\>0[N!(3['$#.A1%H0K8E%D0X%
MUL(@@3'"4.%X(3'@Y5JH&0PQ(G<!0?MQRL&1Y8+"LLET=^=VUD)>[[H)EC5%
MAJ3@'%/"C*0L1(IP:PYJ $(019(N5**=TG<#=8^:KIJY<B[;OX+2ZK!76]3C
M3F*6P#EF"5,:QS0V$:(402Y$&!(>2BTE,D(O<=]68;:YRD8=(AO=D^8QZS&[
MM9C%<\P"Q""26)/(4,HAE&%$B)(T@E'(Z6*QZF?IV8:VLXF. %[1>M!ZT#K0
MTGF<%!I!(Q0)(%QQ;&%"H!2$ * 84H[EPB&ZSU*T#54GZA#:I%NZ YC=J=4_
MEY 66.ZT3[9O'F7E=;42.+BTS'*QOX>H0,+G2X%&A2)"6@NN8HHQD9&!80@A
M-8Q$<;10G^&O29:7CK!I>9*;>X0]N=26K(UZL^L\_-J'85N@_K8917*NY+@P
M.F*"" (T#2.C,(5N43 V,6 68$V@Z/7^I4>11U%K;45:"\IPR4+.-2),NJ5T
M(4TLI=21=>YB1M3"QH]7*J.FMX%T$&C2C-P>:]%C<#LPN J"M;06!0S1,#9
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MAF9AB_N+%%\SX)-[@3T?:_:1 A\_\ESAN<)SA><*SQ4^UOS4*(_3X1-'H+_
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M:3ZTSNC)Y7GRX^N@J&X,AT5V,1HF%_WT?/ UL8]9Z\GSZTM5;]$9H'L0H/*
MMH!&L+:<%&-,8R:I_8]'( 0<@9C%P ##)6@=H!L[SIZO;X.81[1'](8174MK
MQU)%7(1(LEA1&BH18Q7"D#&.L$9B(7ODO1']LC6F)Y>6/*(]HG<%T6R.:$ 4
MBA&/8[>/3"L3QAI"K0T+#2:"T+8A^F7K0D\@>HT;6UJ$Z$87?D1K7?#SP3#I
M/UCY:=,1NN\7@EE+/;R5_-("&;AJ\9H).A.",88<,6IPR#BE<1B&(HP0X2"&
M463D0FK+$ODWE6:;2Y'=:'V\E3/>_C7P?8Z(>XGG)1[B8"[Q@+$R3G,51C*D
M0(>A-HK%3!(:RQB:-TJ\]>3];K90L9=X7N)YB;?E$@_-)9X(><RHA@( 3@VE
MDB*ML5*&A!C"$+S9QEM#,C,3WLCS(L^+/"_RGB_R")L;>2)D1%KQ9%U:*_!"
MA>*(<$TI-I%U<!=B>R\V\M:0H0TW6UQQ!T1>%>+[6,5-9]>KO[6N]+,\/9QN
M=4?@S^L214^]LD:.;FIYJ7A[)\9?7?-/V= ^NFN?<9:F0=)UH< DO[/S$^2#
M85H&PX'CX"HJF[B*KI=9GN3=+.G;U]D++B!=/G\LZXG85G_&EQ_V8)%X!VOO
M(7G ;-7?ZV+ZC-OD*CV\*-+DC\/DTO;H4]+_GMR5]DT?KXO)8))*/)6Q.TY0
M1QP;*"@QD9(Q$ IHBK7A,>3N-\D]*KQL:,E+QA5<%TY:_:D$&@C!M(*:4:H$
M59&.M'3?)" H4J\*1#L8!H/+('+BLLY3R0(X'YOKC2'G^_@=%X-^SS[BZ/CL
MB]'!T7%T<OKUY%2=&_W^X+[?Q:B.X+,9;BMZ)^5U$%MCJPQ^&N7)J)?9-C^W
M;0 _97DPO!Z,RB3OE2_HW6)?:JWO66ZN.GB]2K;[7G]<[M1O_YXR@V"LNBH5
M$G33?G]RMSJMQ7VWW>Q.OR\9_WEV8R7L<?H].!W<) MV[O>L-[RV'^TX)OK8
MJMI^<ENFGZ8??GFH*P]FJU:S!5MQ\/B:UO@5G/[YEX,%RV#R^B=N@=?];)TO
M>W8]N@UOS7I-ZO(2'#QKA9ZW:85^02B(EY)"+"?%L05G\,5>ORX#8S%K!5MZ
M:P7;15H$&'3>4JMPAWEC94VI-?#&"TBS-FYQH:8]3]S9XZGG>[JU=PDU3F[3
M(ADZ_\X%";YEPRQ]\S8+OQNHE5F'NQRS]<S9<N;T=1M]?95WB>7+E##BBR]M
M10A^#\QO+QQ:)AQJYSS[VDMMX;G]K;TTW]=1K;45J>6J;M9/@WQB<[BK[G/7
M!>I'9=H+LCP8+/'B?*VF[;24O1OGF;.US+E;%4=T>FL%;%9MJ'LC0ZZ7[]:W
MC5&F%,MY<B>"1A')@,$AE=H(5VL &*:QT1'1ZJ$%5"?@6K<-=QAMLKI':X7[
M/LGP+88,G1=L94)IHBV[*VHH,4(8$"O#I!2::T$7MO*O@$QC^W)1!S*Q"Y!I
MTNYOL2XZ&PZZ?QQ>).7XF/3;-"_'E:_2'^YSNIT&TUI1R.<H)$B;.!(R$B2B
M1LDP)!0#9!49,I+K!=>].A R=,2.:K1>JPH#'02:]-S;9QQZSV5/@2CGIQL@
M*(DDP$!H-(TT5%A%%/,*D;&.%W+EGPW$QA0CQ!V,&RT5USH@[I:7IFY<99-_
MCK7AX-+.^<4PR,IRE.3=U#)*^3#C?(\L409KT--1&"$4*8,P95"+2$#,#5"<
M$($C]!!Z=;J>7,;C1/[\*G($7:<FA!T P"Y8IMZ9VPD(X?E.+XJ$B! F,04Q
M)<)($T(LE *109R1A>7A%T*HN:)+3>YG;;F:VGK/3G6[17I/>?6RLFL'-/2F
MY (8Z1R,,H8$Z%!&2E.W "M03#E&6!O (Z[)TV#4EM!Z0N>O17J3C6[6JM1@
MAS9;2JAU5J5W[_84DYS64B0($)H#%$I* <!*XT@(""EG&D20-8')UVO)?Z;%
MH)>4UVXN!8+HEYW&XXYY>74MZ8A]F.:]X#)- WO):<W]-5!EK<)>K"B&H8 2
M46J$=M5%C02"ZI#&(%[4B5.JFG$4>9TJD'JG;L>4V?9BAL-Y6A^P<*$&A#%3
MF )D7;HHBHE .&(Q0&IA4?L9F&G,D:.@R3(=+5=%6^_)1==)?I66#S+NRC(=
MED%BM54_2RZROL^^VV*CRCLYGCE;RYROV435WF+CU@.\3;+>-,%A+$('U=FS
M8YFZP];+BET)G).:R:\9YII82T70V,!0*NG."-$PUBI&XJ'Y<I1;\R4I4YV.
M_SW*)X36Z65:%&EO8M:HO%<=0J J6J_3,2 =#/=SSX)W)G8#CG(.1\20D$B'
MC!-&!6(2A5Q**&.#D(Q,O#8X-I< T0&-)M-N#QSWY!0/Z\"Z"&L9W"9WKA;5
M=EI[ZPP/"#@/J:$8"HF1D8:%E&BB2&@8CA4'(A(J7$B;6 3TE-Y?Q^1>;R(\
MQ8T6]FR=C>L=L%V%Y HE*W#-YG5'7I)8A%!J2@437#!)!(Z%H9H]1\FNQF3S
MNW,EVL@"\*[IVRU2J\4H7>:O^B/R'L,TG>M921F75L%"$1,:NIWU(>0BQ!H0
MJ#6:909G>7FS'-".^K_-0ZQ3BWE\5MZP=F>MB1Z@0Z4_EW;/G-<=AF@]U,0
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MH1<$(*^X,HH) X*D0AX&,@P?)6D;YUEA ;@EQ^S)^1OH;O.RB6)>ILDMZ]Q
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MP!(:!4G@/1Z2_CO\B$4@_Y6-$.E1^-E L@X2+KXKLA-/7;!M,Q)6@?;)EW$
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ME&0JD-O6<8GL!:WD\+ZT2BZ[P\/)\ONSQ?O-XKG7B0B1BFB0$-AJ3+GO)SH
M?/<!(9FDC*B5\+7]\?RD"\N<\?R,YZ\'SZGJPE2I&XC$YZX,?$Y<H9(DB>(P
MC+$#@9+>4?CYZ=:Y.>/Y&<]?#Y[S#L^I)IZ4(0\]GW I8^7[*M$LP<Q,*NBV
M17>>QL]/M^S."\3S5U5C]=<75B?UF9/S3Y:9O"6><8:H,T2=(>H,46>(>NT0
M]39\*Z8^I@/R>N,>.95.;S].UCY*"[B-<'("FN.FWG#2[T(D54!Y$@8T$''
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M,M0*[V&<S^X-%I;%&"]ZF(WF&.$[NP'%^/H&+P W=KMP^N:YJLJJ/K3][-P
M @%?'3A#8*XI;/@RG0UO\*FR/KL^<-ZF]\ZDF &2 )8U*\&SSJ]@]]9ACEN"
MU<S',SR_U!F"G !W"UBQYBSW#U7=@N3L1;$VA:H>)<)^C<3QI$#5)3&;M-&<
M/<EHBX4?X/3I?J?/=CF^+X"-)0(<4-FU1'9@\*-!+<#-;(+H#NC;0UN@ H;3
M6/I>$T.+Z? )Q.(R&_V,7Y898"80J+S/IA!+X"D;NE^_O',X^(;(]D/(F >X
M:K@KO&OC$#0G=YF.#36O;H!<]!D.5O4W9'$(D(MD$UC:]VQ<3+']!(;;3 LD
M5'",[=W ;0)1R=(2&0=6M^F]\.ZW_YW>3G^.WC>/6VZ):P$!"(G,*G5YE9+L
MK]F=!@Z"C'!R_:4$CC^'\S>]**ULNX6$R[$!%^;"P?5R%V18(5@44E=1GW%.
MO9Z$*WFL,%LFEI'D1'"-K44B184.A0NR[Z.HOW&>%0GWMPS#VH##ZE$Q1?CJ
M]NHL;G9W^7>;5>VSJ9WD7Y#H/TT</;^> _^$R_<M_4KR": 72D^]@_A:R[.5
M$Q0HUKY+]-?@/:!2-5\\L>9!Y_<I8JOS3G_]_;T9_0/A@UUIU2IP8SP=C&\0
M%4APF%8W3@)B>^6\^U9, ;8]ZK[_Z(3CM*I:*<(\60LDY@V\^WPZL]*%^:;N
MMUKM3%0'M20(K+)$P6CD& QLQ1D0-&$:M*S9TZNL%H$G7US^O18O89W !N:8
MU6!^R?[(K1H!- 7[Y(!X!%N8&BO',+MP]&U1/SDWQU[9JVRUD!)TB!QE.6-\
M!]B"L>9Y=6..SW(BH(0H!=?GA6RKLDL%N>_*'"Q2UBL+')CKA2LU)AR47*T&
M92>S2S!DUF09X89L9IB1^XTTOR3VPP[@#AKYKGXR'=E@R>9S,\&@52'6#;7(
MA,ML6I1&L=N=35H[WY\V&?I8KS"Z8J&2!-B8()P1!D1+:LW=P LX"Z*5>($&
MZ&SSHWCA>D*\G;56>[*2!KQ@->.MU<S?D/:[:B-WX$3&\,>2^>SI),;4Z2TF
MRR"'Z84(B>U%KD(5NHB:VT=]84$$J/JXWR)4M:A#H<8Z*3IE\&'8GS:2W2,
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M$C*0_O$Z)*_KZO=#P7:OSG[']L.^DE#T?4WZ?\-."J9ZQ.>K/CYL-O/'0:(
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MD$&<>%ZT!RL\C&CZ/&TBSTAX1L)G1D+9(6'(I(I##;BG0N[[B?(T$XK(D,K
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M%O X+T96E?LUNS,_+7&T.FP##X>(0RE?;$ \.B";B^SLH[?W[J]VX%4+>M7
MN;O)AS=.RS^6Q*;VI74B5CZ#.8!H?4C'X\)J5K6,=7P 8#U'C!^Z(7,5Z.]<
MTT Q&H=AK)1/L/%+L%#!9<6\'-?[^E;\WNVZ^C1)8(^?KS[#[G2S.6O/6Z/4
MBX-9HLE ,N^8,#% 63-%*1N8/DC">-TM]AZ;Y_?ZAZDP]C2 5N RPGT6R2 (
M$^9Y2E)*25<&LL5:7/T77/7&\]_;_^+)BV-<0.N J:T+??M8BV:3; :74PRS
M; 1<LRQNS0U5L.H&F]M[O)H9ACJ:#V<-ZUV'N$WU&>MK:"ATG4&XGX-AJUMG
M;J=ZA)Q+&0H1!BK@29 $C/B:Z" .\*->2:$%&0@1K_I\U5)ME%;7U.1]B$+O
M*BUY[$(>4:J_R\K,^=-1221S_9YIG% _\ ,O< 67W-<JHL0+1<*2Q".K]<2_
MU!"8   VA_[YJD<[CWOX5(@+<;33?X*<]W:B1+Z4&5"&$@2 <Z#((9#/Z_63
M200+@DAY!/U2DFCITBBA,F8R#"E;46_;JWC^6!'O>6)%IBVPG4"X"/,Z.LD4
MC6,OY 2ORHVE]&+N@I@2Q+'K*KX2T[-X5>>(D=WQI5<A7,5!Z$>N\!(2\CCR
M)1.>KSB-J$X2*O0V^'*$H)$/53;$<[\KRE&537[ZZZ1X3APQ$L,#42-OWG"Q
M8R3P\ :DYW%62Y<+,<'?T/;V:"AP3!*9T,C32<RXGU!%"9,R<141D0+0[84"
MNRSA#)14 G2?DX#)B"H@,ISK0,#;_J.AKAOG60D%-FZ+ K36.Z,7X$Z<:GY[
MFR*)K0PC'-ZDDVOX.T=W")86J7J1OG]I[,OH<\6G5Z-\6Y3>$.:[S>+WV;NW
M"[1, "1W1U$0@6<WE9--1OO$/1U:OD$/ -Q5,:^ )E3O/_;CLY<27AY(A-F(
MLS9I!TW>6;D-%A\@"-S;:IBMH*2WO87T/A?6WM\,?N[O?X(<8+R0V49<F]YH
M,6N8C<?UKX9EX&<X^V'S><TM?LMO ?=^S>Z<WXK;="49$A#U.I_8Y8%H5#1?
MV-Q*\\U=/IK=?/3)!?4D\?B?FPRL(:!].JVRC\T?_:LS^58_M063VOI>[*>'
MRRG9B:3WYY^;AY9_(X_\Y&_UVFNK !RD8^-32V=.E VM-9T2@^#BF4K)G61>
MZ8LH^V:D4=%%D(,NP*-(A)1Z'N>*:^5SGBA"HL1W"5F11E=%B;4&2W:(]H4^
M&;@'S0 ]%W([]@'\FLV<<5%5K6PU-=ZG?2LPOL0B_>\V(&'?Q\>X!H50!2X/
MN?)]&<88MP(R@_25D"MZ.9SRI\FPN,U^@:/>NPA%!9N'[QZWG%!O(-QG:5JS
M"K6GP!#>[X/5+P1YORPX9OHA\ MA[WLB\RGC[.,H"[RR15GJQK$;BCB4210K
MY84A8310DD5)Z"NV$F7V@%O>&-+ZV12-OW;9N'/0VC+^@*I7T=?TS?#5>#DB
M;EW8Z%ODLALPMI?0RC1-M)>X :>)C+4*>!#6& O8&\J5^L9M/'WUK=!MS.&7
M-!]]FM0)$DOA=^A#7 @F/6J!*.H/&'W=?>1>&X<UE/[#90KTW>!R-JFLU>?1
MBL=O@;7R#E$]+N*(^Z[6/B5QP%C$2(VHB21TA;5N@ZC&;6+./>P=^V]H"*[R
M6?8U*[_GP\SRY-^R87$],:,8]GQ,)/;<@7?0*F^GCZHOG16'QK> KH7A_!;C
MR?/OF3,KTTDUMKC<)6+MRY WU*5_C0Q;]$1LI4,A T_YB>8\T#*A&/SJ^\*C
MD2=78N@^8P@VHG>9W0"&P[58)3DIR@PV$L[+,IL,[[_A5=G)]63TK;NXCHZ
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M]ZOY 6JJD^DTGP#<S?G=0HX=*+OK:O/4> REL[^F:86ET\;@A/+M7Y,[NU:
MO@'O+<N)?JP?AI/I=PVOLW%6 #"U&4CUXGHB4-D!E9PVTQ=^]B=)#N5"3@UI
MM51-6+[5%,V9[Z&PN;YH[7JT,_!A5$W6]VSB7&H[$RK3;I(\2_5"0WEA?7\"
MT$J%8_V"P &SY2K&!@]B$8'JO5:/KEI/6L6GTOQV]A^]YME%5B?;EK]_Z!DD
MHQX$Z8UJ!U9*^=N?RU1=DXMK:IO+7'8S5%/T?)N.1O#O-+EKC>!\,IY#X96>
M<ZH5+A.=2$L(L69$U3?.L%K_<L&_K*& 7@/"9.DM&3VP$<NDV-M;:K=+,$TI
MH2TDEB#@A. 8QX118I"7M.3Q8RH8X6JE%*(Y3=KDJO(</$QPNOAW*P>.@>'2
M$E0;D5\N'JZ>L*DX1*\G%KM"V]Q[_81)!&_QS@(P$A!B:JH -=&.YD!/=]6-
M+2@D?=GXK W;5C+8O.9FO3)LF6XJV:!_H\N_S:ZT0--O*+2<U-^/[NPX!S"J
M43KL&?&0C0VXQ'R<)OD8ODS_F&KR'I;U<'HF%VDV@[]-[J*=&\P@3Y,"JHIS
M>V&1SF8CBR$P2(HK4S2B9V.1+313:7O)"! [\?[AU2(MF47K<G$K57[Y(%Q-
MQ=W_V8S)TH#-?Z_R)J'V,CT[UYOT^YFI2OTY&=TF=P58$U=Y.9NG#3%YROB<
MJQS8]K\*%"(A>*BP5F.8$DP%81!*^$LBEP3J63J!2?*UT>09Z+/U4B2+R[&\
M9SO0VLAV6AO=/V5L= #0IA;.I3'WE- 6J,\85TA@WPTIY1XF^I]P%:QA1P?
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MMW?H60( ^])^>I]51 &7I>.!(<$:*;9T5AB&D,:*3*W5J2^I"J3*@\E<1"C
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MD0<\%_>VP/-:Q6[;-X(\67;H3NRW<&+SYL1&DB.NA&9J#S/IZQ,[5E0R%:)
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M.0"E:F5:AW2Q_ZUE@=MJ%!Z@, PE81&B3,I04-_G8<@]XOJNB]"N94%K)U_
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M+"]FHQC):H3DT^0VS>VG[#J;/1Z0VG&$I@EKF3_QNF#JNDJ]S6N.:1^]2"W
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MCT'W#"&DA[V04.+[) [BJ L[/RQR'@H[[Q!3^V09LC-MWH""PG&CH)# QU&
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MP8=KR9M&Q(>"37>@/2:>Y>3<&J3F;?=VH:Z4K1KK2# WBC'W&9.!%!R%2)"
M:U6*\M6.6(?@!=E)#&>7!LWS*>HP.[1T$:!.M':B]3FBE6'1J*V1MC\I90C"
M[22.5.3&7/HHIEZH>+@"A7,(WJ>=1(N\3K1VHK43K9UHW:UHI4W3,4;]4'I8
M(1XPYFNI2MV(^BX/B42!5EL/T>NW"S<\ZN\47[Z3K9UL[61K)ULI8RW9&J X
MX%IWY7'(/!2KV%4NQ[YB',<<[U1M/2#9BFG_10'[#Y1]MD)I/";<QK_\/XGA
MDD($)$2N"G" !<-4J4@2XE'L,1>[V/?T._^<O,A8[9]P^<_93&_[8%U9J^@_
M'1^.MA;B6/_[?,"^%HCBT[$U;?CG1_)'F!6#T:28Y^F#\)@D"AAE6ORB&'HS
M(2$"BOP@)B[W(R\(6_"8011'..)<L-!E0>A)/PJ0Y]%8$H]XKGP0>^_1]ZS
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M59H,2]>7/O_@N;535]^MSQ9]'-EW@M\,K,@LMR?39WWB- J:9E&M"\?&S>L
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M'TH__(_U4C*?ZR<\FRTP1:7]N44B%H1$U@[=>3\=S0L;G=";#R,W+WOH%FU
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M"<'_/3, :S$ %2J0"KE^R!D62&"NU7OL>CR.?817?%Z&[DVU-?#Q8X!N.R!
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M%T?JP?#/H^]9B9 ]8MCDZ7_F&;B>*@MGM2;$&#Q-1I$UF:P;X<M@-@&/EG4
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M2^"N<%DK\9!Z*,:AD$(RQJ-("(9PS#U,E>?%9 6/9Y,0R3=##D.(\L49^"1
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M/N<B&93 1M5D$F=LBIGA4?=.YI]0$>R4Y?(%X#GJ";R[3N[T5-Z!6(=_BRL
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M S,_G ]FZU9FP;W0D=P)D=RBR"IUKV$*V$L@B:^3_/=T!MBVZ=2<[/!E162
M8#2]NBNT[ 1]1AOR^B%&,YA=95I<6L-^FMP9H[J2AO5;KM)D-+LZ&R0&K^GZ
M&OR!=QUU=M394"<(L6Q<=8H !(YS(_8,$E,M^-HD6:L%6C+&D\G0T%V8SR\=
M-80BT&)F'2/.^SA4'WKED5Q!.,$Y;@V'V]3Z:L!X6);%IN&,N5YKP!<9^*<!
M=G Z*69GEF&LDC ?WC4%IB"=%X;=47I'Z0VE-U0.$-Y:A'[5).U\O4HT=3E_
MO3[_;^<]?/,!3G_@"B-A2]>IWM YJ)A:=<B+&GSNSH%F -#;!F"+@$!+6JPJ
MGVM \IIYRA+G3WKT>:*IY7P."D?N?+\KM+[;$6Q'L(^+YF2HJ0P<-WF:79^#
M ]YB.()<O@0 ^K'M\96O4Q+:*BQ<4NH=0%;3/!NDBU=T!-D19$.00VWNCR;3
MJH/<?%RW&BR2BQ0$:PX1%CWR 9SBH/>.UXK!CJPZLEHXF >#>9X,2OL(Y%[M
MFZT@+ ICEY?XJY4CMC2>.IG5$=?&A^@@3VVGEU87NJ'6V0;:"DE&I5.QL3&R
M\46>:)-F;I0_<ZA.C%(X!G<^J'^-G@CT:TR;B7&EVA#&>/D10*M#L)*R\WF%
M7MS1;D>[#SHK2]6O96K4MKF!.YX"U5945"<TE&[V$A0Y<<[S26*:65HWDA:D
M4WB<_KTCO([P-O&2C\&_74/ Z]&9@.\,(D9+MH7Q1L[SRB?N#*!E7HG!WKB$
MRJZ;<*'I<JCU1% J\\QBJH^K5\*U@ E<O;&MBD)2XDU6!X261S5.80*0UP#C
M6\=!U5 7SHETG$]&(\?<8OL>SD&UM7Q3NF%;,/366U6^4M]D&RC.#+Q\\O@8
M.O[K^*_A/YLB854)B#-7% T.3R!SXS<]ARC"2%OU0VOJZXN+U*;W%=FPRG5K
M+B[3!4PK! NI/P2G;8N3.B+LB/")VL>R0VD^,[17A@? (5]Z4U>/@2I(]=OW
MGA/- =B]Y_PM@7'#+2:J7YIWC]+E\,#P]GB'M_=DO+U.MIR@;#$.G;;Y7/?A
MN;4=,(;I-#4IG""&6E&8MC;VGSED%]G;+Q:<V_<('M/-ND[X,)EUU0D[3M,A
M1-<GM:Z[< !;_:Y7N@':02"3DU7U4S(:(.38&]6R%)ME-R!(\;1=Y^&6*FV^
M.WH[]GC :97,9E![59*3.8Q_3^\@'Z^8C,?IJ"3(VJ,UNBMK*@R17>:3V]G5
M+TY'8QV-/4!CPV0ZJXSQ*SV:,A4C!=EZ8[-*34ML,!W2\4V63\:=U="1U:-D
M9:/5FIKT43Q+RX,/\NI'4.<VM]5FIJV38PISS>DYS4UJLDDGM@VD3=45Y&7D
M^I':U!WDZ:R= @P/R3,M'+5YDHUM42MX/@W=FIJQI"@FT%5*6\#FS!XUU0ZU
MR=$N?&M%+HTOORPQZPB^(_B6KR:%4,[ JG=:LYN4!0)STWZRKD#4%YM>5XV.
MV':#6O_G\A662DV:DG'O0V;=_Y>.TT'B*-]YW_J[;(K8,MF7==/)^:BD]:K7
MG U/U2_KJ+JCZH:J;>IE837.)MZ>I].Y+70!'WQR#1JFK0XQQ4N0@=02JIH,
M%XPYDU9_YYRG4!5<E26WV:"RU499=8#8\N2.-CO:;&AS3:"H:5<.>D4^+DET
MU"6[=Y33HAQCOEC/\UKO3#*=Z@L-191V4-W1^8'CU1RDZY[W"WS1$6!'@&MR
MT U^Q13:7T.VVQ]944JO87JN95M-<HO%0V6Z>3$M6Z ;IV/+U#*A^CHZGTSA
MO?T-@B</+\J+ %*\Z!#^":MCDZ_R%#)B+.0(9':-D@% DT!>@C;_,EN096M4
M#9_?7ZA:U>GJW4E^+PL#Z_1%TV1>?[@SBM"U?F??40_5O4*]?EULW#9GJZ+C
MI6=;3_K]4 2.02$PE>HPOF+M &OONYGJPEC*(5M[O:P:-JD,%A$%]+J-*HA-
M7;XYI<=U7?M2_713*6PCA$7Z$&A" @ W]ODPE\1@W*2VRJ.NH+Z&_=-?V-F9
M0N[T;E*F?4 I?SX9]9U?)WFZL-;Z_ZK"8N.X-Y #91'V8@'V@Q74$[B\/:VZ
M3KGL<M>&[ZDR8'.S?9J;LU'EKX"5;($UP&9&?]@S#;!LKC,#*."\_QX%[;JK
MGC[%9H; *\UI-NF5PQJ:[MKG#2A$D9:F["R;P8N-L$6_?(.RK=BNA?D*F\.M
M^OG7&L"GSCT+;1UXY8%16AV[*S)#;W$-K1-4^ ;FFF\-O,Z7&EZG>EN]8F:@
M&U$Z+*,:CV&;[L'E^#]UT\$+TW[#-,G;MBGFVHY^SV],V7?^F5HWF#:%C"!J
M;/F>YAVHWP N@%,A@^1[H+RZ*.[\#E237@T!D,]':6%'5G*^IA83\)K.]6,'
M^M[YU H#H,&;S-#NW9)$*/&7+L"!9WXNJ;#*WFXSM"GWWP31HA$_ZUYH+4<K
M$WMUQ@M\FUA0)YC+*/M="^TKJ$JTX"2+3&I284HV;?%FD<Z #C2'E4RP$T"-
M'9Q3KP]Y P W+>B$"MT!.-8BL<">P!E:YNK]6RLLAI]KQ],]H%IM"6ZT9NMJ
MU5(J+9M4:@JK>3X=%>DM?/D0]]O56L+=J>A^NV$\290<H@PY!+*M,<=\);$K
M$0D]&3,_#&04A;[O1E'@*X20_^XOKX@Y]N4?T;=_?(S^^73D'$#)V1'3/0QW
M\T_K3DN<R]'D7%/D>3:9FC+603HW5H\Q3\U),084O%(O  4CU^J7P76RTO+&
MYDS4^:S6GBVS" U#F"0,?0@ _&C?^:+9X"++BUD[?Z+TVO6:U(OW>GJ_@_&J
M7S&=%!.CU5PEUBS6DKV UMWZXP> U!ND&6!G@/$R,BFSPR8SMTH1&QNUQ0"/
M%<[[W[Y_@)G5S:<=(LKVP!4+SJ#(HZI3VR$ZT*]W [WB U#PYOHLOM'_?7ZG
M7ILY_(?S_E<5?'!&<RM>8:7A. ?GJ%5H]77GV;@*9LVR<@#@@84$SCR]U&KC
MV,P]&8(:O+B=E=*G?QYK&W%4^L=N%E9I:HYDK0*K8'$D!C_24('1J"ZTWJX/
M^WPRS@:@*EMML=2.]0)8W3C+(7J7%QFX-NSCK*_8Q.+T9?K0N$C .#445:77
MZ-6&BZ;9- 4FJ\1_X7S\_!TCY)G;[6?9K[\T(QQ/;DP61#("DJK?K1<_.\]F
M$P,\-M3/U?,<WFF2-1]@?MAY'W[]BC_4&G:>3 T7M;S>F@K'D_'9X*Z [R^R
M\WP"FNQ[^#*(/T!9Q1C D+3* ]\W(4F]0*/DN@0O:+BHG((9^=ARAH4ON"X]
M1W;?]?9H-@#'0&:9#':[UGILC5%2JC-FI+,&@@;^!<O!YIO#]DWGHVL+[Z<'
M8E!X%R)0S<_F7(5I7]U!4-9R*M3&__>'9\")54)Q7ZJ)=9^=IUH_T8)%KW6N
M+RCLD5]:RG#&E^*L;87I9Z?%;#).-RY<6$N'AXGN>4#)L-Z2 ZI+AGT\&?9I
M$VY=O>!A/<#FRV5[8H2V:ZK,WMWOI+:O@)5ZM^(6?K2I,I5;W_:XWWS#%@Q[
M;F6P@B4KGLKA8KT&_377QXH6L@;P&T3HG\M_K?8:5/+TA3K@;K,DS^KOL&9)
M=M3PX7AHY+LYDSL*.%T*^*S?81<E*E%$[%^_UFK9LWK 7&?#X2@]E'[V\JF+
M96]HL-8FI0>HLLOL7Z4I\=0(Z($LRHLUS7GU.2\V&EM4^9])&F7PNW0!74P&
M\S)&>)7<@!V7M"JVVTZ:43+7-NI"@4Q=?V==!U.;0 NN_\J!8$(/Y^DE&/;-
MHXJK;%I6N2P^[<M@-C'N&(3%_7;1"RR24:7+E7(^+GB*]- L'' <*N<RUP;A
M?;ZG!<S#=7ZE%5_)KKPV5Q/;P.(IGAMK/;3G#20R'D\@@V!HTZ*R:UN-7H=E
M@R^?_Q%]^^%8(,7*54XQ<?0>E8:__4WO[M^2\1S\ W8)Z\2^FTSK^HEMGI$5
M8.4TP<HB^^/L6N_-5;MSQLJ+^\Z/J[).OA7DL^,=38 C ;]^.,^K5 <[B7)+
M5N=0W5M#42U<#[-K7@O1G[*HVF0HCB\GFA;M:CKW+Z>6$6?&1?7 4+(ENO/L
M/!<ONDYG3J;713/>-2QN.AY.]0@,#0WTBIE$CLG8.+0@W%<O>X7E;S#^ 4H6
MUC\=S UYC--+2R=F\4=W3C&=S^;7U1-M9K+9%[U#I=,7PG6%]1XOH"@4FE%-
M6-& ?IMKB?QIP6M<"I*:6Z:C>5%[7R[GV="X\\YL.H-UL=TY[__J__B@%_VZ
M!!('X;5NQL:5G=LL_/7OU0\ZL]D,^F'OI_]K-/L%];5JA!_P5[V(I-X]T'WW
MWV<V"&ASLF%#$/]7"?3$  (WDK_Q !J_["2?7NE_C+0VOD,H-!U9 (7*\ZWI
MO!+^E;OP_=\_AE\_&)DPUA0QU]ROR1JNO&Z"!YJOWG_^\>NBU[\)TMMR>/WR
M5E8'#+8^KYK1E<.'*Q:\F&M/+/W*A3?VG?NZH1VN3G6<>F1IY1D7W(J)MV=K
MHW7"V6XGIN I37]_,N!#KV[;HD6S)6)#TP;6 0ZO= %&QQR>)K1TDV0C\#CV
MG8\7-9Q^#\ZYL@U8_<+;*NG )NU *+(*H%0GRT(B3--I8C,=;LW UZI6S4H9
MOZ7>/U"<:\T'Q N<7F4#D-0,LU>B%Q9Z_RHM<P'?>K'.?"&)IWJHJ46;F@R$
M18AN>).63NG@;C!*VQW5].]:;EP7ZY2:Y=6&]+PRO;G5#J&MXU>-0P::%?0H
MT]96]ZI]-OI#>9T-A-57WYN-NHE1OP_QLC7W5#&A]Q!\;,4>K9AI!R#M-R;:
M:#^69\19$-N_[XTC+D3A[]5I]A-.>E@T[G%G#D3POVT_@5,Z"BR:F0GT+FG/
M__SXZ=.7?UISI-?DE&CM0DM#TM.T-QY.KO6#M82PO5K/SO6#ACV;*WT^.2OS
M9T>FY4^BN6"4CL[@K)SVG&LH#3NS3L1%'"N;L5X4D+$.XZBLM5X%)FR4H0F8
MY=;LLW*E3'2!O+Q4;Y6Q*.NP;-E_(,V-2V0 YEDVLIAKQ-7R+?W=3+N8G_^[
MA,;2XMIRX%(0?QO+83GDMB-+8L4:S>L0M\GDAI6$#6X=VJ850WII2@>,X6@3
MF.%,'68E9-T"DEY3OV+1[,&X7UCBQF>THJO^-C9Y M%ORV;78?#828F/-@F>
M\1W+DZHSJ\'(,4WP;)W_C2F6L)+&E@TL2)@E[F\150E'MZW;</>3?KA4Y96W
MP8CU/Z;:%LG*WBI-QM(BQU9=?\?I7 OJZ54V.AOFV4TZ7DQ0:E*SM]+2#L0Z
MW$J=D\[[)Z5E?7@PSVIC"GH-#:XSZ(\J,&2<6^T^U9#)!KI<F:B^+'VE5HN
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M5+)Q_7S#=ND8OM57I/D$X S^IRZA&66:S(=EVJN1,&TO4$F =ANNZ]9<%;!
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M>ZD%,<3?#SY4,'EQ.C3:;@P-C<)*6 >3XAJP#Z ;F_F"8"?HQ_UO?6WO:?.
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M/S&U#9?XWK;+U/WI,X.T8?I%8\>J+9#3](UO7G"#156=X%Y1CTW@FV5YTZ4
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MG P_%U%0N]T%)&X99KHC#U.QT(HP4I<B%<E<T,5H+^&T>,'-32:H::%.)F(
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MJN2FZ8'P-H$[%RKQ8N+CTX>N 0]NB31<E_VQY$IEGXU)KFI<)^8LR3"A7S7
M&FG9$FDY)3X0"920A<=V]A,Y3FW:X&K]KXTTG>E>8,@O#%.FFB"2EW2 575I
MIB"&2""K2-SHK_H![M^D5[&C6SBPJZ-PU$-='&]SQ1K*J!0]@D:VMT2VKP5Q
M"4@MF&$O=RU6AO9?4E^I+#3[7N00-2IQ*\7FLJ]I)D%G@>2@ T2P,-"&!?O]
M.N=%<23%8&.X*.J! ]++4K3;D8J#(%0(61(HWJH!38JI<M:S,HNV204,HLR
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M^R13JK[*T,>GJA9#D@B4C=!LB]!\0C-*PH:0XO6&0AR85,+:K8#Z/*.=IJK
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MYL[9?#;E:'HR9TF3 WBJY<RALY9+ERD%7N%B!GLF=T.00\ EE-O%0^C@U?[
MB$Q7([>D\F>_NK&![\_TJDH@JX?88H![K!24B?,+0-=Q;4%L9^Q=Z#B"4 ->
M5_*%%2+693E:S!*$GTQ;CER@;[YL[9U5XZ:>Z#7K0YQ=KS0$$H&*PQN3!@[Q
MW8)M#S(F<E^)P%Z/BCO7.5BF*E^\S:7< #HS5A]<=+'?,K[V_26GK 3F;+>"
MU"$Q%K8'(<$H"5JGZ^JO7*-,G],7T7QD\)X121]2"2Q4>^ 3UL2:38*(G%DD
MNSH]K8W032 <(Z\R(B\4IM@1:HIHW'::[Y'69EFAJ%[U=!@CF'?MI)[GD81/
M()-/W5X;M&@D'V?M934^4/-^E65HW:YHSM-7TE%C'5<=$!PW!B9^AZOX^Z@_
M@-4EHW\T694QBB]%T F7G"M=PD7:MNU3 U6([9:(_35;AF[.;!E9)D"1! E$
M\9&E@%H2B$XR!Z4I^Z'05$#CM)3DE>[S!NC*0U\A%H@>=YA>>D."BU3LUFG\
MR1YF>03Q]4F.4'T&XJ,TM@O=_O[<']HW9/E%,4,CWBA4<_6VB=FV5&P_9#&X
MR=IPQ$,Y<IV^=1[^^99]Y^Y(@Z$&D(J0G((7SC7&X$,M'(U6^YJP17#E2$4E
M7FW(HLPWV%:@[HA =>B<./K!]1\:Q S"["94X]V[K2AM12D4)5\Q9>6"'3"M
M'0D*CM$K UEKH:N%'-=9MI0,E_#V5KKNB'0=?UX4%1M"L_0<\TQ)-N<B=W!'
M%0O;>PU!@HK@+,:.OU9ZU@TI]GB+%+LU4FQ[ _P8-\!S2T@=!K-4F20UADZU
M-1#&7]VEH<;(ED?M[@C,6XVC4[6*0 7 *LG/,RSVJ:H4<=RM6)8DA\H4LJWI
M^(JD74^.;]M!ZBN3L;5:G5P5*Z7<,)?^4@2M2\C(B'H&S#K+P#D]Y;*7,F(W
M>IY5'7:WX&D88V>L!E33^#)$+7SI)76,M0 62(%FV:A>12 YXN)*8"!J@40X
M"LG9G8!TUY:RP9OR]%Q8&#+WOH:2)BCE;1,\_9Q5=:?SSB;@0HCB &LY$6;K
MU 0H@"#$;<.L81E@TDJCV-5TJTSA;RY)H,I6_A,$80%C1E%R;5VE/"_,WY0
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M]\Q68/9WD#!NG!3&>T1Z&$-H!^;,/<E7EBA^SY'1&N &0%2Z45K9 5L;W]2
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M9329-5!4Y5UKJ&S21%@??[M@]Q@5'FOP;TSIJT4)'($DC=Y+8:85>UO;?IS
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M*O+KRU0>%)2821WP;!EQ)MO;(F@EL-S"1I+(MH.H^&>>#U4V=[T'A.KYKVW
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M31B[ZDU('F51"':98 @@OY#KH+BM-I@L\?E$X=B[:"N7ZYUD@BL/1.&QAN[
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M'F1Q583$,5@T(L\U@H_\7,IU86 X0O\KTF9"O,Q@:L)-;H>=DB[<)09B7J4
M^TC&(&(=,&T?B:1R8O)0Q=_[HH$:(E0S+&UY2_GTD72C':6*2@*A8_#?5WTU
M3 Q..YP=V908$W1"H,IQ3=AX]22AOEZ(K/P.QE(1!K(FMS-\5.].Z7M%@AE^
M$C/IR.DP IA-#_>Y8 -@HC[7OQN=4F4Y;&!;@F^N'># J:T3/ &2G'1AM2Z
M&VZ$W.DA$2Y<ZCZ%3=00[J3J/0\T:&FW9?=9DG^"/B4CIK.H !J5CY8 @Y=J
M9(C10&HU#YP,C5:P=1;&@N$3[F2RB'D%!L5P6.J,MP0(O\;K<#V1UQ2!KR8
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MAI]%?5H<07#8M7ZLXZG&Q.HA3J,1HA9YHKV27Y24#95Q8SP]Y#[B$+W*MAM
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MYX<'@]V!AT><GP-1;)WV/J=WYFW]EGZ&2XDY&)N9UL_H^KNI2;/P8B%:==$
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MTY<=^XW3Z;]02P$"% ,4    " #J.UY-?M+"_.@,  "FA0  $0
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M+FAT;5!+ 0(4 Q0    ( .H[7DU&?/<+RP4  ',:   7              "
M 5Y$ P!I;G-M+3(P,3@P.3,P>&5X,S(Q+FAT;5!+ 0(4 Q0    ( .H[7DT+
M?]Q+QP4  ,P:   7              "  5Y* P!I;G-M+3(P,3@P.3,P>&5X
=,S(R+FAT;5!+!08     "@ * *("  !:4 ,    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
